{"data":[{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":521.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).","enzymes":null,"type":"small molecule","cas-number":"1544739-75-4","sequences":null,"targets":null,"unii":"11612L5SPI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":521.187208896,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-8666","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14937"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":330.355,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).","enzymes":null,"type":"small molecule","cas-number":"91503-79-6","sequences":null,"targets":null,"unii":"I0OU31PUI5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB00682 DB08953 DB01208 DB14652 DB13400 DB14649 DB00887 DB00656 DB06255 DB06679 DB06737 DB00178 DB08814 DB12289 DB06712 DB00540 DB01142 DB09217 DB06696 DB00814 DB11425 DB00562 DB12945 DB14633 DB00177 DB00642 DB08437 DB00232 DB00800 DB13286 DB00495 DB13510 DB13432 DB11921 DB13199 DB06228 DB09307 DB12604 DB00605 DB13691 DB08984 DB11520 DB00321 DB07615 DB12789 DB14506 DB13843 DB09351 DB09026 DB09030 DB01067 DB00806 DB13867 DB08822 DB00421 DB01124 DB00700 DB00798 DB08970 DB13136 DB08932 DB00390 DB00492 DB11201 DB00741 DB11738 DB13411 DB00839 DB01295 DB00278 DB00222 DB01421 DB13208 DB04846 DB09383 DB00905 DB14541 DB13604 DB00543 DB01044 DB09206 DB08807 DB00519 DB09363 DB00959 DB04828 DB00487 DB00684 DB14659 DB01432 DB00547 DB00945 DB13452 DB00820 DB09299 DB06813 DB15861 DB14210 DB12610 DB13496 DB01240 DB00779 DB00467 DB12726 DB06826 DB00324 DB09084 DB08950 DB01165 DB00758 DB00630 DB05095 DB01082 DB00218 DB09015 DB00086 DB00788 DB12661 DB00939 DB01182 DB00685 DB13233 DB12364 DB07767 DB14209 DB11411 DB01059 DB00031 DB13167 DB00775 DB09368 DB00091 DB06271 DB03615 DB00691 DB14217 DB04865 DB00584 DB06725 DB00498 DB00612 DB12545 DB00598 DB00054 DB01109 DB05488 DB01175 DB00710 DB00866 DB14540 DB00180 DB00749 DB00925 DB00266 DB08955 DB13612 DB14207 DB01397 DB08906 DB00214 DB01410 DB13124 DB14055 DB09238 DB00476 DB06695 DB11720 DB08952 DB02304 DB09220 DB13501 DB00715 DB00586 DB14213 DB00784 DB00720 DB00414 DB01347 DB01120 DB01158 DB01626 DB12054 DB00270 DB11095 DB00629 DB13823 DB02224 DB15821 DB09242 DB01234 DB05099 DB01137 DB09477 DB02709 DB06635 DB08994 DB00582 DB13217 DB06605 DB00695 DB00960 DB01283 DB00452 DB01359 DB00635 DB00881 DB13149 DB00316 DB13429 DB01435 DB04884 DB00206 DB00654 DB00870 DB00313 DB00884 DB09154 DB01325 DB09378 DB00606 DB00722 DB01155 DB06763 DB09288 DB08813 DB00936 DB13782 DB06802 DB00999 DB03866 DB15226 DB09218 DB13524 DB06736 DB13407 DB13384 DB03585 DB11404 DB13649 DB00469 DB00955 DB00903 DB01225 DB14059 DB00015 DB01251 DB00394 DB06543 DB00479 DB00861 DB13371 DB09449 DB00594 DB04840 DB13616 DB15880 DB00055 DB11892 DB00559 DB12930 DB08960 DB13346 DB08794 DB00569 DB00176 DB01104 DB00500 DB01170 DB00401 DB00035 DB01418 DB01108 DB00343 DB13312 DB09215 DB00622 DB13114 DB14068 DB12749 DB08996 DB14094 DB00590 DB00803 DB00350 DB00212 DB00978 DB00812 DB13364 DB00930 DB01384 DB00591 DB04729 DB01275 DB12212 DB11512 DB09095 DB00774 DB13775 DB13779 DB00502 DB01207 DB09295 DB01289 DB00692 DB04948 DB01250 DB00252 DB01116 DB11783 DB01047 DB13989 DB12615 DB01244 DB01133 DB01054 DB01016 DB00195 DB13801 DB00384 DB13538 DB01405 DB01342 DB08972 DB13001 DB13246 DB11984 DB14545 DB13367 DB09259 DB15566 DB11443 DB13225 DB08439 DB06294 DB01105 DB13003 DB09236 DB11362 DB06406 DB01050 DB04896 DB01193 DB04905 DB08981 DB06445 DB08931 DB06081 DB04898 DB01166 DB01609 DB09235 DB13261 DB14681 DB00310 DB13374 DB04630 DB06403 DB00528 DB13657 DB01029 DB08836 DB00373 DB00785 DB00215 DB11507 DB13544 DB01180 DB09211 DB00672 DB03410 DB01009 DB00580 DB14509 DB11943 DB01088 DB01242 DB09283 DB04665 DB00436 DB01380 DB11598 DB00797 DB00375 DB06600 DB11491 DB06700 DB00282 DB00208 DB08940 DB08887 DB00335 DB06762 DB01023 DB09237 DB11487 DB13275 DB12771 DB00573 DB06441 DB00374 DB12480 DB14643 DB00457 DB09167 DB04576 DB01151 DB00796 DB08961 DB00554 DB00443 DB00658 DB01138 DB13514 DB00264 DB04626 DB13327 DB11455 DB06779 DB00461 DB13074 DB09204 DB00300 DB09239 DB04932 DB00864 DB00886 DB09212 DB09016 DB14631 DB00808 DB00325 DB04743 DB09289 DB01172 DB00344 DB00261 DB12693 DB01013 DB09260 DB05767 DB14126 DB01018 DB00465 DB11466 DB08971 DB08942 DB15786 DB11312 DB09075 DB13757 DB00994 DB14512 DB02925 DB13211 DB00287 DB12321 DB04832 DB00860 DB12766 DB13401 DB06726 DB13803 DB13527 DB13232 DB06160 DB13166 DB13646 DB13481 DB15972 DB14507 DB09216 DB13929 DB04831 DB00817 DB00966 DB00244 DB02056 DB13435 DB00063 DB07402 DB00029 DB00588 DB13627 DB11774 DB00616 DB12221 DB11529 DB01203 DB00458 DB01119 DB01399 DB00880 DB03322 DB11166 DB14644 DB01149 DB00537 DB09255 DB06754 DB00407 DB11519 DB13675 DB04808 DB09091 DB15565 DB00009 DB13919 DB13540 DB01340 DB00765 DB00399 DB13629 DB11518 DB01324 DB01222 DB13856 DB14539 DB00187 DB13783 DB09258 DB09214 DB00226 DB11785 DB05266 DB00512 DB00827 DB14646 DB00571 DB11642 DB14208 DB12598 DB00482 DB13036 DB08816 DB12093 DB13443 DB00542 DB00393 DB08808 DB04861 DB01419 DB00489 DB13860 DB01349 DB11323 DB01395 DB13772 DB01077 DB00657 DB13575 DB05229 DB04836 DB13824 DB01014 DB11051 DB13347 DB00876 DB12752 DB00563 DB00314 DB00013 DB00975 DB11511 DB06822 DB00963 DB08976 DB13491 DB04812 DB00678 DB06268 DB09279 DB00159 DB01285 DB11770 DB01089 DB12465 DB00686 DB12092 DB01032 DB08819 DB09213 DB14125 DB15959 DB08496 DB09285 DB13532 DB00365 DB00991 DB11079 DB00764 DB01401 DB00795 DB13508 DB00663 DB05254 DB13722 DB12163 DB00275 DB01600 DB06209 DB13223 DB00726 DB12831 DB13530 DB06731 DB05361 DB12445 DB00620 DB01136 DB00712 DB01348 DB00575 DB13314 DB01021 DB13410 DB01424 DB13631 DB15777 DB11454 DB00968 DB04725 DB04263 DB13451 DB04925 DB14669 DB00001 DB00790 DB12399 DB00727 DB01162 DB00946 DB01628 DB01090 DB13406 DB08918 DB14060 DB11660 DB00217 DB01197 DB07477 DB00974 DB00821 DB08951 DB00472 DB00898 DB00006 DB13615 DB08797 DB08991 DB00524 DB14726 DB00687 DB08962 DB01580 DB00533 DB04552 DB01388 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":330.126737255,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flurbiprofen axetil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14938"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Motixafortide is under investigation in clinical trial NCT01838395 (Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed\/Refractory AML Patients).","enzymes":null,"type":"biotech","cas-number":"664334-36-5","sequences":null,"targets":null,"unii":"DA9G065962","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Motixafortide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14939"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":186.167,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).","enzymes":null,"type":"small molecule","cas-number":"110954-19-3","sequences":null,"targets":null,"unii":"R9CHM391D5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":186.06405681,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aspartyl-alanyl-diketopiperazine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14940"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":454.01,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).","enzymes":null,"type":"small molecule","cas-number":"1202400-18-7","sequences":null,"targets":null,"unii":"AKQ3X6FEH0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":453.2394344,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-817399","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14941"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":561.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).","enzymes":null,"type":"small molecule","cas-number":"1478711-48-6","sequences":null,"targets":null,"unii":"W530IRZ40G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":561.114061209,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-986141","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14942"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":440.47,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and\/or Refractory Hematologic Malignancies).","enzymes":null,"type":"small molecule","cas-number":"1210608-43-7","sequences":null,"targets":null,"unii":"9TG5O4V25H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":440.182395866,"volume-of-distribution":null,"route-of-elimination":null,"name":"LGH-447","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14943"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":601.87,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).","enzymes":null,"type":"small molecule","cas-number":"1636938-13-0","sequences":null,"targets":null,"unii":"H8768UL06V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":600.086853,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tarloxotinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14944"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":364.492,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Florbenazine F-18 is under investigation in clinical trial NCT01515384 (A Trial of 18F-AV-133 Positron Emission Tomography (PET)).","enzymes":null,"type":"small molecule","cas-number":"956903-29-0","sequences":null,"targets":null,"unii":"KM31LBX59H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":364.239156561,"volume-of-distribution":null,"route-of-elimination":null,"name":"Florbenazine F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14945"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":635.66,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1613373-33-3","sequences":null,"targets":null,"unii":"TE53TU0WSQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":635.202539433,"volume-of-distribution":null,"route-of-elimination":null,"name":"PCO-371","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14946"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).","enzymes":null,"type":"biotech","cas-number":"1401965-15-8","sequences":null,"targets":null,"unii":"N6SVN735GY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB09085 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bermekimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14947"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":482.536,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1257213-50-5","sequences":null,"targets":null,"unii":"38CTP01B4L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":482.184171945,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-986020","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14948"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":367.449,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-7687 is under investigation in clinical trial NCT01119352 (AZD7687 Multiple Ascending Dose Study).","enzymes":null,"type":"small molecule","cas-number":"1166827-44-6","sequences":null,"targets":null,"unii":"6QTJ9P2NYT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":367.189591677,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-7687","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14949"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":538.555,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).","enzymes":null,"type":"small molecule","cas-number":"1217338-97-0","sequences":null,"targets":null,"unii":"8S38482CST","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":538.181646975,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-929075","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14950"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).","enzymes":null,"type":"small molecule","cas-number":"848779-32-8","sequences":null,"targets":null,"unii":"LJ16641SFT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Topoisomerase 1 (TOP1) inhibitors ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Etirinotecan pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14951"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and\/or ARB Therapy).","enzymes":null,"type":"biotech","cas-number":"946415-13-0","sequences":null,"targets":null,"unii":"QS5F6VTS0O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pamrevlumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14952"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"946062-05-1","sequences":null,"targets":null,"unii":"WC4978T687","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Firtecan pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14953"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PIK3CA is under investigation in clinical trial NCT02957266 (Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"JQ83GG8LT2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"PIK3CA","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14954"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":511.59,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).","enzymes":null,"type":"small molecule","cas-number":"1228111-63-4","sequences":null,"targets":null,"unii":"51M3FB9B9E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":511.277024528,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-04634817","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14955"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Davalintide is under investigation in clinical trial NCT00785408 (Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects).","enzymes":null,"type":"biotech","cas-number":"863919-85-1","sequences":null,"targets":null,"unii":"668U999F9T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Davalintide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14956"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":521.03,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).","enzymes":null,"type":"small molecule","cas-number":"1019112-29-8","sequences":null,"targets":null,"unii":"03TW1410NL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":520.1928987,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-3577","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14957"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1\/gp100).","enzymes":null,"type":"biotech","cas-number":"1622140-49-1","sequences":null,"targets":null,"unii":"0O39RGI33V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Selicrelumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14958"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).","enzymes":null,"type":"biotech","cas-number":"1422268-07-2","sequences":null,"targets":null,"unii":"WX1WTN0Y15","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Opicinumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14959"},{"toxicity":"Subcutaneous doses of somatrogon higher than 0.66 mg\/kg per week have not been studied. Based on existing clinical data of other growth hormone products, short-term overdosage from somatrogon could lead initially to hypoglycemia and subsequently to hyperglycemia. Long-term overdosage could result in signs and symptoms of gigantism or acromegaly consistent with the effects of excess growth hormone. Overdose with somatrogon should be treated with general supportive measures.[L39362]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Somatrogon mimics the physiological actions of endogenous growth hormone, such as cell proliferation, metabolism, and growth. It was also shown to increase the serum concentration of insulin-like growth factor (IGF-1).[L39362]","msds":null,"description":"Somatrogon is a long-acting recombinant human growth hormone. Growth hormone is a peptide hormone secreted by the pituitary gland that plays a crucial role in promoting longitudinal growth during childhood and adolescence and regulating metabolic function in adulthood.[A241515] Recombinant growth hormone therapy for growth hormone deficiency and other conditions has been available since 1985, with daily administration being the standard treatment for many years. More recently, longer-acting forms of growth hormone were developed to improve patient adherence and thus, improve the therapeutic efficacy of treatment.[A241485] Somatrogon was produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology. It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and C-terminus of human growth hormone.[A241515,L39362] The glycosylation and the presence of CTPs in the protein sequence prolongs the half-life of somatrogon and allows its once-weekly dosing.[L39362]\r\n\r\nIn October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug.[L39060] It is available as a once-weekly subcutaneous injection.[L39080]","enzymes":null,"type":"biotech","cas-number":"1663481-09-1","sequences":">Somatrogon amino acid sequence\nSSSSKAPPPSLPSPSRLPGPSDTPILPQFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFE\nEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQF\nLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHN\nDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGFSSSSKAPPPSLPSPSRLPGPS\nDTPILPQSSSSKAPPPSLPSPSRLPGPSDTPILPQ","targets":null,"unii":"6D848RA61B","protein-binding":"There is no information available.","fda-label":null,"clearance":"Following subcutaneous administration of 0.66 mg\/kg\/wk in pediatric patients with growth hormone deficiency, the clearance was 0.0336 L\/h\/kg.[L39362]","atc-codes":"ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Growth hormone is a key hormone that promotes body growth and regulates carbohydrate, protein and lipid metabolism.[A243092] Somatrogon is a hormone replacement therapy that aims to restore deficient levels of growth hormone (GH). Like endogenous growth hormone, somatrogon binds to the GH receptor, which leads to the binding of JAK2 to GH receptor and activation of JAK2. Activation of JAK2 and phosphorylation of both JAK2 and GHR initiates the recruits various signalling proteins and facilitates multiple signalling pathways responsible for growth and metabolism.[A243092] One of the activated signalling pathways is the STAT5b signalling pathway, which is critical for the effect of GH on body height.[L39362]","drug-interactions":"DB01194 DB00682 DB14652 DB00825 DB08953 DB09124 DB09381 DB13456 DB14649 DB12457 DB15091 DB00656 DB09198 DB08980 DB00382 DB09570 DB00204 DB00540 DB06712 DB01142 DB00637 DB12130 DB15035 DB08828 DB04951 DB00814 DB01215 DB13446 DB00338 DB09273 DB12945 DB14633 DB00280 DB05708 DB00642 DB14132 DB01200 DB00495 DB11921 DB01409 DB06228 DB01223 DB00957 DB01306 DB01086 DB06772 DB00962 DB00277 DB00284 DB00557 DB01595 DB09195 DB09022 DB01229 DB08922 DB12235 DB00321 DB00503 DB07615 DB11919 DB00863 DB06148 DB12781 DB00220 DB12952 DB01256 DB01590 DB13843 DB09026 DB09030 DB05316 DB01067 DB00806 DB00490 DB13867 DB04908 DB01124 DB04652 DB04957 DB00700 DB00531 DB00046 DB00912 DB08970 DB12825 DB01065 DB01558 DB00546 DB08932 DB11828 DB01396 DB11901 DB01551 DB13203 DB00741 DB08865 DB00839 DB00222 DB00367 DB01039 DB12329 DB11823 DB00246 DB13208 DB13293 DB09082 DB09383 DB14541 DB01117 DB04878 DB00778 DB09234 DB15102 DB00787 DB00358 DB04356 DB00238 DB00851 DB01708 DB05676 DB06739 DB00959 DB08820 DB00281 DB00268 DB11827 DB01320 DB00136 DB11703 DB13981 DB00834 DB00773 DB13928 DB11723 DB01323 DB01319 DB04828 DB13943 DB11824 DB14659 DB01259 DB09074 DB01624 DB06717 DB04938 DB00440 DB00820 DB01062 DB09299 DB13954 DB01466 DB01309 DB00708 DB14009 DB12332 DB00240 DB00370 DB01216 DB00731 DB00324 DB11742 DB05521 DB11951 DB13488 DB00758 DB05812 DB11739 DB01191 DB01100 DB09101 DB11641 DB04868 DB14723 DB00788 DB08881 DB11575 DB06595 DB00030 DB06119 DB06479 DB00877 DB01182 DB06290 DB00846 DB14018 DB01184 DB00906 DB00402 DB00908 DB00738 DB06616 DB12406 DB09045 DB11898 DB00091 DB05039 DB09227 DB09225 DB11633 DB06292 DB00351 DB00612 DB13158 DB11950 DB09265 DB11689 DB01175 DB11613 DB14064 DB00299 DB14540 DB00180 DB00949 DB06589 DB00253 DB00872 DB01201 DB08870 DB00420 DB00980 DB14538 DB01015 DB08906 DB01410 DB16390 DB14055 DB01583 DB09238 DB00203 DB00169 DB00213 DB06738 DB12001 DB04839 DB06448 DB12015 DB02703 DB00586 DB00715 DB00784 DB13573 DB12629 DB11952 DB00334 DB14019 DB00414 DB01120 DB08873 DB00977 DB00468 DB00924 DB00270 DB00993 DB12010 DB00641 DB13835 DB15328 DB13955 DB00629 DB00307 DB00823 DB06155 DB01234 DB06654 DB11978 DB00706 DB04856 DB12026 DB00582 DB02134 DB01277 DB12935 DB01241 DB06605 DB00674 DB12268 DB00635 DB00304 DB01094 DB01412 DB00363 DB06011 DB00724 DB01536 DB14066 DB00316 DB04871 DB01435 DB09063 DB09183 DB08838 DB04884 DB00294 DB00628 DB15171 DB00297 DB00193 DB12147 DB12500 DB09378 DB09318 DB06237 DB09288 DB04835 DB11567 DB14543 DB00822 DB06203 DB11757 DB01382 DB09053 DB00568 DB13874 DB00831 DB09068 DB15444 DB14678 DB00705 DB13399 DB00617 DB00783 DB00734 DB01195 DB01227 DB05109 DB11094 DB09166 DB08896 DB00624 DB03701 DB00532 DB01097 DB13449 DB00224 DB01251 DB14544 DB00394 DB00604 DB05541 DB14063 DB01118 DB15133 DB12267 DB08867 DB08910 DB00559 DB00471 DB11886 DB16165 DB08794 DB00454 DB00176 DB01104 DB11712 DB11960 DB11718 DB01095 DB00401 DB01357 DB01008 DB11730 DB00921 DB09555 DB01058 DB01192 DB01418 DB11574 DB11637 DB13725 DB09200 DB06207 DB00201 DB00343 DB00496 DB00622 DB06789 DB14068 DB04838 DB00396 DB06446 DB13766 DB11636 DB00590 DB01181 DB06603 DB06713 DB14035 DB01130 DB00690 DB00978 DB13685 DB08893 DB13345 DB00379 DB01114 DB06414 DB01384 DB00591 DB00377 DB04934 DB01026 DB09095 DB14570 DB01248 DB01278 DB00615 DB01134 DB13866 DB09118 DB00661 DB01037 DB01303 DB00717 DB09043 DB09083 DB00404 DB11697 DB04889 DB00502 DB12543 DB00932 DB01289 DB04948 DB00486 DB14881 DB00252 DB06235 DB11853 DB01047 DB01244 DB14761 DB00353 DB05467 DB01016 DB01054 DB13956 DB01056 DB00195 DB01167 DB13953 DB14011 DB00384 DB00619 DB01268 DB01405 DB09317 DB01002 DB05239 DB13385 DB00603 DB06670 DB06685 DB14545 DB00518 DB00956 DB00745 DB15566 DB01411 DB00188 DB09199 DB00564 DB00398 DB05667 DB11750 DB01173 DB11581 DB12531 DB13961 DB08439 DB04833 DB06730 DB08864 DB13634 DB00234 DB06742 DB01105 DB06684 DB06144 DB06777 DB08899 DB09065 DB06655 DB13003 DB09236 DB12471 DB09291 DB04876 DB13944 DB11362 DB01050 DB04896 DB09201 DB01006 DB00843 DB09241 DB04905 DB16098 DB03515 DB01587 DB00412 DB01392 DB11614 DB01232 DB00295 DB08931 DB13950 DB01482 DB01263 DB00442 DB00911 DB00636 DB00755 DB14185 DB00589 DB01166 DB00736 DB01211 DB11780 DB09235 DB01307 DB14681 DB12941 DB06287 DB04630 DB09049 DB00675 DB00904 DB06403 DB00455 DB12537 DB00528 DB12625 DB01611 DB06282 DB08815 DB14542 DB01456 DB09089 DB06016 DB01431 DB04946 DB09230 DB14737 DB00215 DB06626 DB00248 DB01591 DB01601 DB06781 DB13791 DB06152 DB01072 DB06774 DB00672 DB00625 DB06218 DB09048 DB08895 DB08907 DB00751 DB01267 DB00580 DB06786 DB01154 DB01242 DB01254 DB00836 DB01700 DB01380 DB01236 DB01656 DB01420 DB06700 DB00477 DB06480 DB00889 DB06210 DB09330 DB06702 DB06762 DB01023 DB09237 DB06127 DB06234 DB12597 DB11487 DB05115 DB00349 DB00997 DB01394 DB04829 DB12131 DB12417 DB01393 DB00296 DB05294 DB01621 DB14921 DB06652 DB00250 DB01138 DB00443 DB06335 DB14583 DB04845 DB09017 DB11817 DB15233 DB13074 DB00461 DB00813 DB04975 DB16691 DB00433 DB09128 DB11619 DB09239 DB03783 DB00864 DB00865 DB01367 DB04841 DB14975 DB14631 DB00688 DB13592 DB05212 DB05351 DB00808 DB00185 DB04842 DB00934 DB14065 DB04743 DB09289 DB00381 DB00191 DB12278 DB08833 DB01049 DB01196 DB00544 DB00757 DB00261 DB01013 DB08992 DB00317 DB01018 DB06636 DB09143 DB11693 DB08971 DB09223 DB13812 DB01589 DB13179 DB12713 DB15217 DB00990 DB02568 DB15685 DB13728 DB09229 DB16732 DB06176 DB09054 DB14512 DB00747 DB11568 DB00976 DB00969 DB00860 DB00972 DB13602 DB00593 DB12674 DB04076 DB00288 DB13857 DB00497 DB01623 DB00829 DB02489 DB09216 DB01252 DB00163 DB01098 DB00207 DB00539 DB00567 DB11915 DB00197 DB09073 DB15031 DB00588 DB00696 DB11251 DB00333 DB00470 DB11529 DB00286 DB09038 DB00458 DB01221 DB11992 DB11586 DB14644 DB05885 DB12265 DB05154 DB01149 DB01076 DB09262 DB00730 DB00331 DB09090 DB11791 DB13675 DB00697 DB01132 DB01224 DB06077 DB00047 DB15011 DB00740 DB00802 DB00356 DB00499 DB09071 DB00199 DB00759 DB00907 DB01198 DB06697 DB08903 DB00337 DB11986 DB09079 DB08875 DB01036 DB01222 DB14539 DB12161 DB00857 DB00285 DB00309 DB00514 DB11963 DB01264 DB09389 DB12371 DB12483 DB14646 DB00571 DB08882 DB00608 DB08912 DB00444 DB11642 DB12240 DB00574 DB12923 DB00482 DB12474 DB08816 DB09039 DB12093 DB00347 DB00570 DB09297 DB01128 DB02187 DB00744 DB08901 DB06470 DB01028 DB09102 DB00359 DB06710 DB00393 DB04861 DB00320 DB01349 DB04855 DB01667 DB01395 DB00378 DB01260 DB00982 DB00263 DB00530 DB13347 DB00563 DB06708 DB08877 DB00655 DB11737 DB11796 DB00318 DB00491 DB00678 DB11274 DB01276 DB00216 DB04920 DB14568 DB00315 DB06216 DB01285 DB00346 DB12092 DB05482 DB13952 DB00910 DB01544 DB12927 DB09256 DB00439 DB12301 DB01218 DB09231 DB08496 DB13941 DB12515 DB00938 DB00850 DB09232 DB00365 DB11635 DB01087 DB00764 DB12214 DB09371 DB12245 DB00647 DB00663 DB05271 DB16703 DB14027 DB01588 DB14840 DB11967 DB02789 DB01103 DB12412 DB06212 DB06209 DB01261 DB06419 DB13528 DB08883 DB00342 DB00896 DB06267 DB00897 DB09061 DB00227 DB00448 DB00998 DB09240 DB04574 DB04830 DB00620 DB00361 DB00862 DB01190 DB01136 DB00673 DB00909 DB06780 DB11942 DB16236 DB00575 DB00683 DB01424 DB06770 DB13500 DB00243 DB01645 DB06769 DB14669 DB00186 DB11698 DB01159 DB11799 DB12016 DB13609 DB09034 DB00602 DB08827 DB01238 DB01012 DB01628 DB00946 DB01253 DB15149 DB13406 DB09123 DB08918 DB05773 DB08382 DB00425 DB04572 DB06594 DB14634 DB11130 DB13746 DB00762 DB01559 DB12141 DB12926 DB11837 DB00247 DB00918 DB01233 DB00255 DB04825 DB01074 DB13007 DB09290 DB12887 DB00262 DB15822 DB00472 DB09456 DB00898 DB09564 DB00541 DB01115 DB00071 DB00914 DB00533 DB08962 DB00687 DB00701 DB01068 DB01388 DB11273","absorption":"Following subcutaneous administration of 0.66 mg\/kg\/wk in pediatric patients with growth hormone deficiency, C<sub>max<\/sub> of somatrogon was 690 ng\/mL. T<sub>max<\/sub> was 8 hours and the AUC was 21800 ng x h\/mL. Over the dose range of 0.25-0.66 mg\/kg\/week, somatrogon exposure increased in a dose-proportional manner.[L39362]","created":"2019-05-20","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Following subcutaneous administration of 0.66 mg\/kg\/wk in pediatric patients with growth hormone deficiency, the half-life was 28.3 hours. Somatrogon was detected in the circulation for about 6 days after the last dose.[L39362]","monoisotopic-mass":null,"volume-of-distribution":"Following subcutaneous administration of 0.66 mg\/kg\/wk in pediatric patients with growth hormone deficiency, the apparent central volume of distribution (Vc) was 0.812 L\/kg and the apparent peripheral volume of distribution (Vt) was 0.169 L\/kg. Somatrogon does not accumulate after once-weekly administration.[L39362]","route-of-elimination":"There is no information available.","name":"Somatrogon","metabolism":"Somatrogon is expected to undergo protein catabolism, with subsequent reclamation of the amino acids and return to the systemic circulation.[L39362]","reactions":null,"indication":"Somatrogon is indicated for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency).[L39362]","ahfs-codes":null,"updated":"2021-12-07","drugbank-id":"DB14960"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":407.453,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).","enzymes":null,"type":"small molecule","cas-number":"1452539-75-1","sequences":null,"targets":null,"unii":"AIS8N3O50B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":407.186986519,"volume-of-distribution":null,"route-of-elimination":null,"name":"Seltorexant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14961"},{"toxicity":"LD50 and overdose information are not currently available, but effects of an overdose are likely to impact the lungs, heart, and circulatory system, leading to significant toxicity.[L10842]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":"BE0003659 BE0001032 BE0001067 BE0001004 BE0004752 BE0000785","pharmacodynamics":"Trastuzumab demonstrates antitumor activity against certain types of HER2 positive breast cancer, however, clinical trials are still ongoing to confirm its efficacy.[A188982,L10842,L10845]  By exploiting both targeted antibody and cytotoxic effects, trastuzumab deruxtecan can effectively destroy tumors.[A188988] \r\n\r\nThe FDA label warns of a potential risk for neutropenia, interstitial lung disease\/pneumonitis, and left ventricular dysfunction following the use of this drug.[L10842]","msds":null,"description":"Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer.[L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.[A188988] Trastuzumab deruxtecan has been granted FDA approval for specific patients with HER-2 positive breast cancer who have failed other treatments.[L10842]\r\n\r\nPromising results from a clinical trial prompted accelerated FDA approval for this indication on December 20, 2019.[L10845] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca. In May 2022, trastuzumab deruxtecan was fully approved by the FDA.[L10842]","enzymes":"BE0000939 BE0000971 BE0002135 BE0002638 BE0000876","type":"biotech","cas-number":"1826843-81-5","sequences":null,"targets":"BE0000971 BE0000710","unii":"5384HK7574","protein-binding":"The Dxd portion of the drug has a plasma protein binding estimated at 97%.[L10842]","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB14962.pdf?1576876599","clearance":"Trastuzumab deruxtecan is rapidly cleared from systemic circulation.[A188979] Estimated systemic clearance of trastuzumab deruxtecan is 0.42 L\/day, according to a population pharmacokinetic analysis. DXd showed a systemic clearance of about 19.2 L\/h.[L10842]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":"Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, Miyazaki H, Kasuya Y, Ogitani Y, Yamaguchi J, Abe Y2, Honda T2. (2016).Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. _Bioorg Med Chem Lett.,Mar 15;26(6):1542-1545_","mechanism-of-action":"Trastuzumab deruxtecan is a humanized anti-HER2 IgG1 antibody, targeting cancer cause by mutation of the HER2 gene. In addition, the small molecule portion of this drug, deruxtecan (DXd), is a topoisomerase I inhibitor.[A188976,L10842]  It is attached to the antibody by a peptide linker. After trastuzumab deruxtecan binds to HER2 found on malignant cells, it is internalized and linker cleavage occurs through the actions of lysosomal enzymes. After it is released through cleavage, DXd causes targeted DNA damage and apoptosis in cancer cells, due to the ability to cross cell membranes.[A188988,L10842]\r\n\r\nNormally, drugs in this class (antibody-drug conjugates) present a challenge. The monoclonal antibody accurately targets cancer cells, however exert limited killing action. The addition of a cytotoxic agent (a topoisomerase I inhibitor in this case) effectively kills dividing cancer cells, including those in the healthy tissues, leading to various adverse effects.  The peptide linker used to formulate this drug is cleavable, which is unique to other antibody-drug conjugates, allowing for increased efficacy and reduced drug resistance to topoisomerase.[A188988]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB14947 DB09085 DB15441 DB15383 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"The Cmax of trastuzumab deruxtecan at normal therapeutic doses was 122 g\/mL (20%). The AUC of trastuzumab deruxtecan was 735 gday\/mL (31%).[L10842]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"In a pharmacokinetic study, the median elimination half-life of trastuzumab deruxtecan was about 5.8 days.[L10842]","monoisotopic-mass":null,"volume-of-distribution":"The estimated volume of distribution of trastuzumab deruxtecan in the central compartment is 2.77 L, according to a population based pharmacokinetic study.[L10842] Pharmacokinetic studies found that the unchanged drug is distributed in the blood and is not significantly retained in tissues.[A188979]","route-of-elimination":"A pharmacokinetic study revealed that this drug was mainly excreted in the feces. Another study determined that 67% of a dose was excreted in the feces.[A188979,A188988] Unmetabolized DXd was found in the urine during a pharmacokinetic study.[A188979]","name":"Trastuzumab deruxtecan","metabolism":"Trastuzumab deruxtecan is likely broken down into small peptides and amino acids through catabolism,  just as the metabolism of endogenous IgG.[A189009,L10842] Cathepsin B and L enzymes are thought to be involved in the cleavage of the peptide linker that joins the topoisomerase I inhibitor and the antibody.[A188988] In vitro, DXd, the topoisomerase inhibitor portion of the drug, is found to be metabolized by CYP3A4.[L10842]","reactions":"BE0002135 BE0000939 P07711 P07858","indication":"Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.[L10842]\r\n\r\nIt is also indicated to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+\/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.[L10842]\r\n\r\nTrastuzumab deruxtecan is also indicated to treat adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.[L10842]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14962"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Konjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).","enzymes":null,"type":"small molecule","cas-number":"37220-17-0","sequences":null,"targets":null,"unii":"36W3E5TAMG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB00219 DB00887 DB00742 DB08980 DB00540 DB06712 DB00737 DB01142 DB07715 DB13695 DB00387 DB00562 DB15465 DB13505 DB00280 DB13252 DB00232 DB01409 DB09484 DB01337 DB13792 DB00424 DB01209 DB15477 DB00321 DB00810 DB07615 DB00732 DB13738 DB01535 DB00421 DB00463 DB14504 DB01075 DB00700 DB11855 DB09076 DB01148 DB01339 DB01551 DB00246 DB00777 DB00209 DB13636 DB09234 DB00543 DB11057 DB09462 DB11827 DB11228 DB09481 DB00332 DB13468 DB01062 DB01555 DB01466 DB15861 DB00708 DB00245 DB01046 DB13787 DB00581 DB00599 DB15478 DB00835 DB13488 DB13584 DB00670 DB09015 DB14018 DB00908 DB00652 DB08861 DB09227 DB06292 DB14064 DB01175 DB00872 DB09125 DB00819 DB00420 DB13769 DB00214 DB09300 DB00967 DB09238 DB06738 DB09020 DB13284 DB00715 DB00327 DB00237 DB00334 DB06694 DB13542 DB00899 DB00241 DB00270 DB00941 DB13835 DB00915 DB00753 DB00695 DB00312 DB09413 DB01412 DB00363 DB14066 DB08801 DB01638 DB08838 DB00809 DB01231 DB00418 DB01459 DB09414 DB04843 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB11110 DB00999 DB00979 DB00568 DB05246 DB01625 DB00311 DB13454 DB01227 DB13617 DB00903 DB09449 DB14063 DB01118 DB00594 DB01199 DB08960 DB16165 DB00454 DB00505 DB14516 DB11315 DB11960 DB13678 DB00401 DB06283 DB11235 DB00921 DB01192 DB13725 DB00875 DB00343 DB00496 DB00622 DB14502 DB14068 DB04838 DB01450 DB06446 DB13766 DB13606 DB11189 DB15889 DB11113 DB13913 DB01355 DB00774 DB00849 DB00555 DB00661 DB06787 DB01531 DB14881 DB00942 DB01116 DB01244 DB13989 DB01054 DB13801 DB00384 DB13254 DB14500 DB00956 DB13759 DB00572 DB01173 DB13961 DB08162 DB13648 DB09236 DB13486 DB00854 DB11609 DB01354 DB00704 DB00295 DB13950 DB01378 DB12670 DB00340 DB09235 DB08890 DB05710 DB00310 DB09049 DB13666 DB00528 DB14546 DB01377 DB09089 DB09230 DB01591 DB13526 DB00771 DB13791 DB06152 DB08907 DB00517 DB01483 DB12704 DB09272 DB00836 DB00436 DB14684 DB00477 DB06480 DB01239 DB00354 DB06702 DB13448 DB00804 DB01023 DB12942 DB09237 DB00565 DB12131 DB09167 DB01151 DB08961 DB13663 DB09311 DB00725 DB00813 DB00376 DB14499 DB00508 DB01226 DB09239 DB04841 DB08897 DB00721 DB13413 DB00808 DB04842 DB00934 DB14065 DB04743 DB12278 DB00381 DB08992 DB11181 DB08997 DB13170 DB01565 DB09229 DB00747 DB02925 DB00383 DB00653 DB12766 DB13803 DB00593 DB06204 DB00497 DB00483 DB00940 DB04831 DB13295 DB00986 DB13430 DB09472 DB00333 DB12221 DB14627 DB04816 DB09287 DB00458 DB00880 DB05885 DB09262 DB11089 DB00392 DB09090 DB09007 DB12554 DB09219 DB01224 DB12492 DB11365 DB00802 DB14232 DB00907 DB01288 DB00794 DB01433 DB01036 DB01324 DB13844 DB01351 DB01403 DB04834 DB12526 DB00462 DB00514 DB00434 DB00844 DB11059 DB09104 DB12923 DB01352 DB00703 DB12086 DB09338 DB12093 DB01353 DB00347 DB11097 DB09174 DB04823 DB00393 DB13619 DB01496 DB13380 DB01529 DB01395 DB00657 DB00767 DB13850 DB13405 DB04824 DB01174 DB01497 DB00318 DB04920 DB14513 DB13351 DB12092 DB01144 DB14585 DB15959 DB09231 DB00728 DB13532 DB09232 DB01079 DB13708 DB06153 DB13160 DB00366 DB13720 DB00647 DB14503 DB06370 DB01069 DB11107 DB06212 DB09268 DB00342 DB09240 DB01136 DB00909 DB13500 DB01021 DB00306 DB11622 DB13581 DB14482 DB13369 DB01238 DB09023 DB13707 DB01090 DB01336 DB15360 DB01338 DB11130 DB00611 DB13478 DB01135 DB09281 DB04825 DB01081 DB01074 DB00472 DB09401 DB00782 DB13507 DB01115 DB00524 DB01388 DB05034","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Konjac mannan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14963"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1188275-92-4","sequences":null,"targets":null,"unii":"R42YK40U9M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Narnatumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14964"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":706.6078,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).","enzymes":null,"type":"small molecule","cas-number":"1628717-55-4","sequences":null,"targets":null,"unii":"QMH3V8VSPB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":706.226266725,"volume-of-distribution":null,"route-of-elimination":null,"name":"CTT-1057","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14965"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":389.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).","enzymes":null,"type":"small molecule","cas-number":"1401090-53-6","sequences":null,"targets":null,"unii":"BLP1XA3FZA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":389.157326362,"volume-of-distribution":null,"route-of-elimination":null,"name":"Venglustat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14966"},{"toxicity":"Toxicity information regarding margetuximab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as infusion-related reactions. Symptomatic and supportive measures are recommended.[L27986]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Margetuximab is a chimeric IgG1 monoclonal antibody (mAb) directed against the extracellular domain of the human epidermal growth factor receptor 2 (HER2) cell-surface protein. Also, margetuximab has an engineered Fc region that alters its affinity for the CD16A and CD32B effector cell receptors resulting in increased antibody-dependent cell-mediated cytotoxicity (ADCC). To date, the exposure-response and time course pharmacodynamic relationships of margetuximab remain incompletely characterized. Although generally well-tolerated, margetuximab carries a risk of infusion-related reactions, including symptoms such as fever, fatigue, nausea, vomiting, headache, tachycardia, hypotension, and cutaneous manifestations such as a rash or urticaria; infusion reactions may require alterations to the infusion or, in serious reactions, discontinuation.[L27986]","msds":null,"description":"The HER2 oncoprotein, the product of the human _ERBB2_\/mouse _neu_ genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative cancer.[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcRIIIA\/CD16A receptor, whereby low affinity 158F CD16A variants are associated with shorter progression-free survival and worse patient outcomes.[A225756]\r\n\r\nMargetuximab (formerly MGAH22) is an Fc-engineered human\/mouse chimeric anti-HER2 IgG1 monoclonal antibody derived from the same mouse 4D5 clone that [trastuzumab] is derived from and is produced in Chinese Hamster Ovary (CHO) culture.[A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab]. However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC) and increased efficacy compared to [trastuzumab].[A225751, A225756, A225766, A191829, L27986]\r\n\r\nMargextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA\u201E by MacroGenics, Inc.[L27986]","enzymes":null,"type":"biotech","cas-number":"1350624-75-7","sequences":null,"targets":"BE0000511","unii":"K911R84KEW","protein-binding":null,"fda-label":null,"clearance":"Margetuximab has a geometric mean (%CV) clearance of 0.22 (24%) L\/day. Four months following margetuximab discontinuation, the concentration is approximately 3% of the steady-state trough serum concentration.[L27986]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S, Bonvini E: Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi: 10.1186\/bcr3069.","mechanism-of-action":"The HER family of transmembrane receptor tyrosine kinases (RTKs) includes the epidermal growth factor receptor (EGFR\/HER1), HER2, HER3, and HER4 proteins; HER family members are generally involved in cell proliferation, angiogenesis, cell motility and invasiveness, and resistance to apoptosis.[A225751] HER2 is an oncoprotein whose overexpression is observed in breast, gastric, and other cancers.[A225751, A225756] HER2 undergoes both ligand-independent homodimerization and ligand-dependent heterodimerization with other HER family members, followed by RTK phosphorylation and induction of downstream oncogenic signalling pathways. EGFR\/HER2 dimerization promotes EGFR recycling and prolonged signalling while HER2\/HER3 dimerization potently stimulates the downstream PI3K\/AKT pathway; HER2 homodimerization directly activates the RAS\/MAPK pathway and indirectly activates the PI3K\/AKT pathway.[A225751]\r\n\r\nThe prototypical anti-HER2 therapy is [trastuzumab], a monoclonal antibody (mAb) that binds the HER2 extracellular domain. [Trastuzumab] works through several mechanisms: [trastuzumab] binding induces receptor internalization and c-CBL-mediated HER2 degradation; effector cell binding to the Fc region of [trastuzumab] through CD16A results in antibody-mediated cell-dependent cytotoxicity (ADCC); finally, [trastuzumab] binding dampens HER2 activation, phosphorylation, and subsequent downstream oncogenic signalling.[A225751]\r\n\r\nDespite demonstrated clinical efficacy, [trastuzumab] efficacy is dependent on polymorphisms in CD16A. Effector cells such as natural killer (NK) cells and macrophages bind to mAbs through Fc receptors such as CD16A (FcRIIIA), CD32A (FcRIIA), and the inhibitory CD32B (FcRIIB).[A225751, A225756, A225766] CD16A has both high affinity (with valine at position 158; 158V) and low affinity (158F) variants; patients heterozygous or homozygous for the 158F variant have poorer responses to [trastuzumab].[A225751, A225756, A225766] Margetuximab is derived from the same mouse 4D5 clone as [trastuzumab], but with a modified (MGFc0264) Fc region encoding five amino acid substitutions (L235V, F243L, R292P, Y300L, and P396L) to alter Fc receptor binding.[A225756, A191829, L27986] Comparatively, margetuximab exhibits increased binding to both the high affinity (K<sub>D<\/sub> of 89 nM vs 415 nM) and low affinity (K<sub>D<\/sub> of 161 nM vs 1059 nM) CD16A receptors and decreased binding to the inhibitory CD32B receptor (K<sub>D<\/sub> of 437 nM vs 52 nM).[A225756, L27986] This, in turn, increases ADCC and anti-tumour effect, especially in cells expressing lower levels of HER2 and in patients with the lower affinity 158F CD16A variant.[A225756, A225766]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06810 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB04978 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB00385 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB12410 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB11616 DB13976 DB15089 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB12755 DB09342 DB05793 DB06013 DB06049 DB06168 DB11618 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB00445 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB06420 DB13418 DB14947 DB09085 DB15441 DB15383 DB14962 DB15349 DB00997 DB05941 DB11930 DB06050 DB00296 DB06162 DB00694 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB01177 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB13103 DB06304 DB11595 DB09029 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB11617 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"In patients with HER2-positive relapsed or refractory breast cancer, margetuximab administered at the recommended dose results in a steady-state geometric mean (%CV) C<sub>max<\/sub> of 466 (20%) g\/mL and an AUC<sub>0-21d<\/sub> of 4120 (21%) g\\*day\/mL. After a single dose, the C<sub>max<\/sub> and AUC<sub>0-21d<\/sub> increase in a dose-proportional manner from 10 to 18 mg\/kg, which is 0.67 to 1.2 times the recommended dose. The time to steady-state is two months at the recommended dosage, and the accumulation ratio is 1.65 based on the AUC<sub>0-21d<\/sub>. There are no significant effects on margetuximab exposure by altering the infusion time in the range of 30 minutes to 120 minutes.[L27986]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Margetuximab has a geometric mean (%CV) terminal half-life of 19.2 (28%) days.[L27986]","monoisotopic-mass":null,"volume-of-distribution":"Margetuximab has a geometric mean (%CV) volume of distribution of 5.47 (22%) L.[L27986]","route-of-elimination":null,"name":"Margetuximab","metabolism":"Like other monoclonal antibodies, margetuximab is expected to be metabolized into smaller peptides through various proteases and catabolic pathways.[L27986]","reactions":null,"indication":"Margetuximab is an anti-HER2 monoclonal antibody indicated, in combination with chemotherapy, for the treatment of metastatic HER2-positive breast cancer in adult patients who have received two or more prior anti-HER2 regimens with at least one prior regimen for metastatic disease.[L27986]","ahfs-codes":null,"updated":"2021-07-28","drugbank-id":"DB14967"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bacillus calmette-guerin substrain tokyo 172-1 live antigen is under investigation in clinical trial NCT03091660 (S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"267H8I71ZT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bacillus calmette-guerin substrain tokyo 172-1 live antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14968"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":341.314,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).","enzymes":null,"type":"small molecule","cas-number":"938067-78-8","sequences":null,"targets":null,"unii":"406GR1485Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":341.086349609,"volume-of-distribution":null,"route-of-elimination":null,"name":"GTX-758","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14969"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":437.503,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer).","enzymes":null,"type":"small molecule","cas-number":"1637771-14-2","sequences":null,"targets":null,"unii":"3QBL0BLP3D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":437.185175001,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alobresib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14970"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":411.199,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Iomazenil is under investigation in clinical trial NCT01590277 (Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans).","enzymes":null,"type":"small molecule","cas-number":"127985-21-1","sequences":null,"targets":null,"unii":"7DVX185FLQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":411.00799,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iomazenil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14971"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":141.129,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).","enzymes":null,"type":"small molecule","cas-number":"10265-92-6","sequences":null,"targets":null,"unii":"8Z083FM94W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":141.001335707,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methamidophos","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14972"},{"toxicity":"There is no experience regarding human overdosage with abrocitinib.[L39769] In clinical trials, there were no specific toxicities observed when abrocitinib was administered in single oral doses of 800 mg and 400 mg daily for 28 days. An overdose should be responded with symptomatic and supportive treatment, as there is no specific antidote for overdose with abrocitinib.[L39774]","snp-adverse-drug-reactions":null,"average-mass":323.42,"transporters":"BE0003645 BE0001032 BE0003648","pharmacodynamics":"Abrocitinib mediates anti-inflammatory effects by blocking the signalling of pro-inflammatory cytokines implicated in atopic dermatitis.[A244554] It dose-dependently reduces the serum markers of inflammation in atopic dermatitis, including high sensitivity C-reactive protein (hsCRP), interleukin-31 (IL-31), and thymus and activation regulated chemokine (TARC). These changes returned to near baseline within four weeks following drug discontinuation.[L39769] At two weeks of treatment, the mean absolute lymphocyte count increased, which returned to baseline by nine months of treatment. Treatment with abrocitinib was associated with a dose-related increase in B cell counts and a dose-related decrease in NK cell counts: the clinical significance of these changes is unknown.[L39774]\r\n\r\nTreatment with 200 mg abrocitinib once-daily was associated with a transient, dose-dependent decrease in platelet count with the nadir occurring at a median of 24 days. Recovery of platelet count (~40% recovery by 12 weeks) occurred without discontinuation of the treatment.[L39769]","msds":null,"description":"Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function.[L39774] The Janus kinase (JAK)\u20AC\u201Csignal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis. Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options. JAK inhibitors recently attracted more attention as potential treatments for inflammatory disorders, as JAK inhibition is associated with rapid and sustained anti-inflammatory efects.[A244549]\r\n\r\nAbrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.[L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.[L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395]","enzymes":"BE0002638 BE0003536 BE0003549 BE0002793","type":"small molecule","cas-number":"1622902-68-4","sequences":null,"targets":"BE0003493 BE0004145 BE0002408 BE0004146","unii":"73SM5SF3OR","protein-binding":"Approximately 64%, 37% and 29% of circulating abrocitinib and its active metabolites M1 and M2, respectively, are bound to plasma proteins. Abrocitinib and its active metabolites M1 and M2 bind predominantly to albumin and distribute equally between red blood cells and plasma.[L39769]","fda-label":null,"clearance":"There is no information available.","atc-codes":"DERMATOLOGICALS Agents for dermatitis, excluding corticosteroids OTHER DERMATOLOGICAL PREPARATIONS","pdb-entries":false,"food-interactions":"Take at the same time every day. Administer with or without food, as it has no clinically relevant effect on abrocitinib exposures.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Janus kinases (JAKs) are a family consisting of four receptor-associated kinases - JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Upon ligand binding and subsequent dimerization of cytokine and hormone receptors, receptor-associated JAKs are activated and phosphorylated. This allows the binding of Signal Transducers and Activators of Transcription (STATs), which are transcription factors. STAT binds to the receptor, and JAK phosphorylates and activates STAT to create a STAT dimer. The STAT dimer translocates to the nucleus to upregulate the gene transcription of pro-inflammatory cytokines and growth factors implicated in atopic dermatitis.[A183188,A244549] Blocking the JAK-STAT pathway is advantageous, as it is an intracellular signalling pathway where many pro-inflammatory pathways converge.[A244554]\r\n\r\nEach JAK plays a role in the signalling and regulation of different cytokines and immune cells. In atopic dermatitis, JAK1 is the therapeutic target of focus as it is involved in the signalling of the c family of cytokines involved in immune responses and disease pathophysiology, including IL-2, IL-4, IL-7, IL-9, and IL-15.[A244549] Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. Biochemical assays demonstrate that abrocitinib is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold), as well as the broader kinome.[L39769] Similarly, in cellular settings, abrocitinib preferentially inhibited cytokine-induced STAT phosphorylation by signalling pairs involving JAK1, while sparing signalling by JAK2\/JAK2, or JAK2\/TYK2 pairs.[L39774] The relevance of inhibition of specific JAK enzymes to the drug's therapeutic effectiveness is currently unknown.[L39769]","drug-interactions":"DB00328 DB00682 DB13400 DB12457 DB00742 DB09198 DB06737 DB00916 DB08814 DB00540 DB06712 DB01142 DB00970 DB08828 DB12020 DB04951 DB00814 DB00338 DB00177 DB13510 DB03756 DB00495 DB13878 DB06228 DB00395 DB00957 DB01086 DB06772 DB13691 DB13174 DB14033 DB00321 DB00503 DB07615 DB01129 DB01590 DB00665 DB09030 DB01067 DB00806 DB01124 DB01075 DB00531 DB11855 DB12825 DB09076 DB13136 DB01396 DB11901 DB00390 DB08865 DB01039 DB00222 DB00839 DB11823 DB01381 DB00613 DB01117 DB00358 DB00238 DB05676 DB06739 DB11827 DB01320 DB00834 DB00773 DB13943 DB01323 DB01259 DB04818 DB04938 DB00945 DB00440 DB09299 DB13954 DB14009 DB13879 DB12332 DB01240 DB09080 DB14635 DB01274 DB00599 DB11979 DB00731 DB05521 DB11951 DB01281 DB00758 DB09161 DB11739 DB11641 DB14723 DB08881 DB00549 DB11575 DB00788 DB06119 DB00877 DB06290 DB12364 DB08930 DB00908 DB00775 DB06616 DB00738 DB00091 DB05039 DB11633 DB06725 DB06292 DB00612 DB12545 DB00598 DB00054 DB11689 DB01175 DB11613 DB00949 DB06589 DB01201 DB00749 DB08870 DB00266 DB00980 DB00420 DB01015 DB00214 DB05928 DB00983 DB14055 DB09238 DB00022 DB00203 DB00213 DB00476 DB06695 DB00668 DB06738 DB00951 DB12001 DB06448 DB12015 DB12319 DB00715 DB00327 DB00586 DB00784 DB00175 DB11952 DB00334 DB01156 DB00414 DB01120 DB00977 DB00468 DB00641 DB15328 DB13955 DB00307 DB01093 DB11978 DB02709 DB04856 DB12026 DB01241 DB00582 DB06605 DB15463 DB01283 DB00312 DB00304 DB00363 DB11869 DB09183 DB09063 DB00621 DB01435 DB00313 DB12500 DB12147 DB06237 DB09288 DB00936 DB11757 DB00882 DB05246 DB13874 DB00568 DB09068 DB00705 DB00617 DB00783 DB05109 DB01195 DB00469 DB12836 DB08896 DB00624 DB09166 DB00532 DB01097 DB01251 DB00065 DB05541 DB01118 DB15133 DB08904 DB00776 DB08910 DB00559 DB00471 DB12917 DB00176 DB01104 DB05015 DB09296 DB11712 DB01095 DB01357 DB01041 DB00921 DB01058 DB11574 DB01418 DB06207 DB00343 DB00622 DB00196 DB11560 DB12749 DB00396 DB06372 DB11652 DB00590 DB06603 DB01181 DB08893 DB00812 DB06414 DB01355 DB00818 DB06168 DB00615 DB00849 DB09118 DB00661 DB01037 DB16222 DB00502 DB01207 DB00932 DB01289 DB00486 DB00252 DB01045 DB08933 DB11853 DB00763 DB01016 DB13956 DB14011 DB13953 DB00619 DB05239 DB00603 DB06670 DB09078 DB00518 DB00745 DB13367 DB00322 DB11994 DB11800 DB01411 DB00188 DB00564 DB00398 DB00330 DB11581 DB08439 DB06730 DB08864 DB06684 DB08899 DB13944 DB11362 DB01050 DB04905 DB01006 DB00843 DB09241 DB14724 DB00412 DB11614 DB01232 DB00295 DB08931 DB01263 DB00755 DB04956 DB06081 DB00736 DB04898 DB01166 DB08995 DB12941 DB06287 DB09049 DB00675 DB00904 DB06403 DB05889 DB00441 DB01029 DB00373 DB14737 DB11732 DB00215 DB00248 DB06626 DB01601 DB11638 DB01072 DB00672 DB00625 DB06218 DB09048 DB08907 DB01267 DB00580 DB11943 DB01242 DB01254 DB11760 DB00679 DB01483 DB01154 DB01088 DB09283 DB04665 DB00836 DB06480 DB00208 DB06413 DB09330 DB01685 DB08887 DB01023 DB12597 DB12771 DB06441 DB00349 DB01394 DB00997 DB00374 DB09167 DB14921 DB06652 DB00796 DB00250 DB11753 DB01138 DB00554 DB15233 DB13327 DB08860 DB00461 DB06442 DB01220 DB00300 DB09027 DB00752 DB03783 DB04932 DB00446 DB04841 DB11995 DB06273 DB14975 DB14631 DB05351 DB04743 DB00544 DB15093 DB00261 DB00465 DB05767 DB14126 DB11693 DB01043 DB15786 DB01131 DB01589 DB09075 DB01110 DB06176 DB13125 DB09054 DB12321 DB00969 DB14575 DB00972 DB13401 DB00273 DB00051 DB04911 DB00829 DB13929 DB04831 DB01098 DB00966 DB00539 DB01176 DB00063 DB00197 DB00333 DB01177 DB00026 DB00470 DB00458 DB01221 DB11586 DB12265 DB00080 DB04216 DB13675 DB06729 DB09280 DB13919 DB01198 DB06697 DB00794 DB09079 DB00891 DB08875 DB01036 DB09119 DB00857 DB11963 DB13762 DB00514 DB05266 DB01264 DB12371 DB00950 DB12483 DB12455 DB00571 DB08912 DB08882 DB00444 DB12474 DB00482 DB13036 DB08816 DB00347 DB00570 DB08934 DB09297 DB08798 DB15762 DB00744 DB08916 DB01028 DB09036 DB00359 DB00576 DB04861 DB08889 DB01030 DB05229 DB00263 DB15442 DB01007 DB01174 DB00975 DB08877 DB11796 DB06268 DB00678 DB14568 DB04920 DB00216 DB11770 DB12465 DB12092 DB13952 DB01544 DB12070 DB01032 DB00439 DB09213 DB13941 DB08496 DB09029 DB01079 DB04557 DB12245 DB14840 DB06674 DB06370 DB11967 DB06803 DB12163 DB01069 DB00501 DB06212 DB06209 DB01261 DB06419 DB00726 DB06731 DB06174 DB09061 DB15719 DB00448 DB00227 DB12445 DB04574 DB00862 DB00712 DB00909 DB01136 DB01424 DB00243 DB06769 DB01645 DB04725 DB01159 DB01171 DB01628 DB00946 DB15149 DB13406 DB05773 DB01101 DB00425 DB06594 DB12141 DB11837 DB00255 DB13007 DB15822 DB12887 DB00472 DB00541 DB00898 DB00701 DB00533 DB08962 DB00005 DB15982 DB01388","absorption":"Abrocitinib is absorbed with over 91% extent of oral absorption and absolute oral bioavailability of approximately 60%. The peak plasma concentrations of abrocitinib are reached within one hour. Steady-state plasma concentrations of abrocitinib are achieved within 48 hours after once-daily administration. Both C<sub>max<\/sub> and AUC of abrocitinib increased dose proportionally up to 200 mg.[L39769]\r\n\r\nA high-fat meal, high-calorie meal increased AUC by 26% and C<sub>max<\/sub> by 29%, and prolongs T<sub>max<\/sub> by two hours; however, there are ultimately no clinically relevant effect on abrocitinib exposures.[L39769]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The mean elimination half-lives of abrocitinib and its two active metabolites, M1 and M2, range from three to five hours.[L39769]","monoisotopic-mass":323.14159611,"volume-of-distribution":"After intravenous administration, the volume of distribution of abrocitinib was approximately 100 L.[L39769]","route-of-elimination":"Abrocitinib is eliminated primarily by metabolic clearance mechanisms, with less than 1% of the dose being excreted in urine as an unchanged parent drug. The metabolites of abrocitinib are excreted predominantly in urine.[L39769] \r\n\r\nPharmacokinetics data up to and including a single oral dose of 800 mg in healthy adult volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 48 hours.[L39774]","name":"Abrocitinib","metabolism":"Abrocitinib undergoes CYP-mediated oxidative metabolism. CYP2C19 is the predominant enzyme, accounting for about 53% of drug metabolism. CYP2C9 is responsible for 30% of drug metabolism. About 11% and 6% of the drug is metabolized by CYP3A4 and CYP2B6, respectively. In a human radiolabeled study, the parent drug was the most prevalent circulating species. Polar mono-hydroxylated metabolites of abrocitinib - M1 (3-hydroxypropyl; PF-06471658), M2 (2-hydroxypropyl; PF-07055087), and M4 (pyrrolidinone pyrimidine; PF-07054874) - were also identified in the systemic circulation.[L39769,L39774] M2 has a chiral center, thus has an enantiomer M3 (PF-07055090).[A244544] At steady state, M2 and M4 are major metabolites and M1 is a minor metabolite.[L39774]\r\n\r\nM2 has a pharmacological activity comparable to abrocitinib while M1 is less pharmacologically active than abrocitinib. M3 and M4 are inactive metabolites. The pharmacologic activity of abrocitinib is attributable to the unbound exposures of the parent molecule (~60%) as well as M1 (~10%) and M2 (~30%) in the systemic circulation. The sum of unbound exposures of abrocitinib, M1 and M2, each expressed in molar units and adjusted for relative potencies, is referred to as the abrocitinib active moiety.[L39774]","reactions":"BE0003536 P20813 BE0003549 P33261 P11712 P08684 BE0002638 BE0002793","indication":"Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.[L39774] In the US, it is indicated to treat refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.[L39769]\r\n\r\nAbrocitinib is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.[L39769]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14973"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":399.402,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).","enzymes":null,"type":"small molecule","cas-number":"1629869-44-8","sequences":null,"targets":null,"unii":"DFC121MXC3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":399.150681198,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pimodivir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-11","drugbank-id":"DB14974"},{"toxicity":"LD50 information and overdose information is unavailable at this time. Dose-limiting toxicities are unlikely, based on the results of clinical studies.[A188126]","snp-adverse-drug-reactions":null,"average-mass":337.379,"transporters":null,"pharmacodynamics":"Voxelotor modifies hemoglobin to prevent painful and dangerous sickle cell crises that normally lead to organ damage, hospitalization, and sometimes death.[T734] It prevents low hemoglobin, which is normally associated with the destruction of sickled blood cells in sickle cell disease. Voxelotor has led to up to a 40% increase in hemoglobin in clinical trials.[A188123,A188126]","msds":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/msds\/DB14975.pdf?1574959104","description":"Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.[T734]\r\n\r\nVoxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide.[L10403] It was developed by Global Blood Therapeutics, Inc.[L10403] and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]","enzymes":"BE0002638 BE0003536 BE0003549 BE0002793","type":"small molecule","cas-number":"1446321-46-5","sequences":null,"targets":"BE0000130","unii":"3ZO554A4Q8","protein-binding":"The protein binding of voxeletor is 99.8%, according to in vitro studies.[L10397]","fda-label":null,"clearance":"The apparent oral clearance of voxelotor is approximately 6.7 L\/h.[L10397]","atc-codes":"OTHER HEMATOLOGICAL AGENTS BLOOD AND BLOOD FORMING ORGANS Other hematological agents","pdb-entries":null,"food-interactions":"Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of voxelotor. Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of voxelotor. Take with or without food.","state":"solid","synthesis-reference":"Zhe Li, Nathan Guz, Yiyang Shao, Julieana Cocuz, Markus Frieser, George Petros Yiannikouros, Liang Liao.(2017).US10077249B2.Retrieved from: https:\/\/patents.google.com\/patent\/US10077249B2\/en","mechanism-of-action":"Deoxygenated sickle hemoglobin (HbS) polymerization is the causal factor for sickle cell disease.  The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises.[T734] Voxelotor binds irreversibly with the N\u20ACterminal valine of the \u20ACchain of hemoglobin, leading to an allosteric modification of Hb20, which increases the affinity for oxygen. Oxygenated HbS does not polymerize.[A188126,A188129] By directly blocking HbS polymerization, voxelotor can successfully treat sickle cell disease by preventing the formation of abnormally shaped cells, which eventually cause lack of oxygenation and blood flow to organs.[A188123,A188138,T734]","drug-interactions":"DB01873 DB11459 DB00328 DB00682 DB08953 DB12095 DB13456 DB14649 DB09198 DB06737 DB00916 DB09570 DB00204 DB00540 DB06712 DB01142 DB00637 DB15035 DB08828 DB12020 DB04951 DB00814 DB09185 DB12978 DB00338 DB00845 DB00177 DB01200 DB03756 DB00495 DB01223 DB00395 DB00957 DB01086 DB06772 DB13174 DB00277 DB01229 DB14033 DB00321 DB00503 DB07615 DB06148 DB01129 DB00220 DB01590 DB00665 DB01067 DB13867 DB01124 DB01075 DB00531 DB13136 DB11828 DB01127 DB01396 DB11901 DB00741 DB08865 DB01039 DB00222 DB00839 DB11823 DB00246 DB01381 DB00613 DB01117 DB00714 DB05814 DB00778 DB00481 DB00358 DB00238 DB02520 DB05676 DB06739 DB11703 DB08820 DB01320 DB00834 DB00773 DB13943 DB01323 DB01259 DB09074 DB06717 DB04818 DB04938 DB13409 DB00945 DB00440 DB01062 DB08811 DB13954 DB01466 DB14009 DB12332 DB09080 DB00370 DB14635 DB01274 DB00731 DB00599 DB00835 DB11932 DB05521 DB11951 DB01281 DB00758 DB05812 DB11739 DB01100 DB06233 DB09101 DB11641 DB00607 DB04868 DB00788 DB08881 DB00549 DB06595 DB06119 DB00877 DB06290 DB14960 DB01184 DB01059 DB00908 DB00738 DB06616 DB00091 DB09227 DB11633 DB06725 DB06292 DB14973 DB00598 DB01698 DB11689 DB01175 DB11613 DB00949 DB06589 DB00872 DB01201 DB00749 DB08870 DB00819 DB00266 DB00980 DB00420 DB09046 DB01015 DB08906 DB01152 DB00214 DB05928 DB14055 DB00983 DB00022 DB09238 DB00203 DB00213 DB06738 DB00476 DB00668 DB00951 DB12001 DB04839 DB06448 DB12015 DB12319 DB00586 DB00327 DB00784 DB00715 DB02703 DB00334 DB01156 DB14019 DB00648 DB00414 DB01120 DB08873 DB09309 DB00977 DB00468 DB00270 DB12010 DB00641 DB13955 DB00307 DB00753 DB01093 DB01234 DB02709 DB04856 DB01241 DB00582 DB06605 DB01283 DB15463 DB00312 DB00304 DB00363 DB00316 DB04871 DB01435 DB09063 DB00621 DB04884 DB00313 DB00193 DB12500 DB12147 DB06237 DB09288 DB00936 DB11757 DB05246 DB00568 DB13874 DB09068 DB00705 DB00617 DB00783 DB05109 DB01195 DB00469 DB01227 DB06663 DB11198 DB09166 DB08896 DB00624 DB00532 DB01097 DB00224 DB11400 DB01251 DB00604 DB00065 DB05541 DB12532 DB01118 DB15133 DB12267 DB12089 DB08904 DB00776 DB08910 DB03010 DB00559 DB00471 DB12917 DB00454 DB00176 DB01104 DB11383 DB01095 DB12391 DB01357 DB01041 DB01008 DB11730 DB00921 DB01058 DB01418 DB11574 DB00343 DB00622 DB00196 DB11560 DB00396 DB06372 DB00590 DB01181 DB06603 DB11652 DB00780 DB00812 DB00379 DB06414 DB12582 DB01384 DB01355 DB00818 DB11470 DB01275 DB01026 DB06168 DB01248 DB00615 DB00849 DB09118 DB01037 DB00661 DB00502 DB00932 DB01289 DB00486 DB11363 DB00252 DB01045 DB08933 DB00763 DB14761 DB00353 DB01016 DB13956 DB14011 DB01011 DB01167 DB13953 DB06318 DB00619 DB01268 DB01071 DB05239 DB00603 DB06412 DB00518 DB00956 DB00745 DB11672 DB00322 DB11994 DB01411 DB00188 DB00564 DB05667 DB00398 DB00330 DB11581 DB01173 DB08439 DB06730 DB08864 DB09065 DB06684 DB08899 DB07348 DB13944 DB06469 DB01050 DB04896 DB11752 DB04905 DB01006 DB00843 DB14724 DB09241 DB01587 DB00412 DB11614 DB01232 DB13950 DB01263 DB00755 DB04956 DB00736 DB04898 DB01211 DB08995 DB06791 DB09235 DB06287 DB00675 DB00904 DB01029 DB00373 DB00954 DB01369 DB15569 DB14737 DB00215 DB06626 DB00248 DB01601 DB11638 DB01072 DB00672 DB06774 DB06218 DB00625 DB09048 DB00751 DB00580 DB11943 DB01154 DB01483 DB00679 DB01254 DB01242 DB04665 DB01236 DB06700 DB00208 DB06413 DB09330 DB01685 DB01023 DB12597 DB00349 DB00374 DB00997 DB01394 DB11805 DB09167 DB05294 DB01151 DB06652 DB00796 DB14921 DB00250 DB11753 DB01138 DB00443 DB00554 DB05903 DB11405 DB15233 DB04845 DB08860 DB00461 DB04975 DB06442 DB11779 DB00694 DB00752 DB00865 DB03783 DB00864 DB00446 DB04841 DB11995 DB06273 DB14631 DB05351 DB09289 DB00544 DB15093 DB00104 DB13975 DB00465 DB06636 DB09143 DB01043 DB01131 DB01589 DB13179 DB01110 DB06176 DB09054 DB00976 DB13132 DB09308 DB00969 DB14575 DB04832 DB00972 DB00273 DB00051 DB04070 DB13946 DB04911 DB00829 DB11442 DB04831 DB01098 DB00966 DB01176 DB00197 DB09073 DB00588 DB00696 DB00333 DB01177 DB00026 DB00470 DB00458 DB01221 DB11586 DB12265 DB01149 DB00537 DB04216 DB13675 DB06729 DB09280 DB13919 DB00259 DB13338 DB00759 DB00199 DB01198 DB06697 DB00794 DB11986 DB00891 DB08875 DB01036 DB09119 DB00857 DB00309 DB00514 DB13762 DB11963 DB01264 DB12371 DB12483 DB00571 DB11642 DB08912 DB08882 DB00444 DB00574 DB12474 DB00482 DB08816 DB00347 DB00570 DB08798 DB15762 DB01128 DB00744 DB08901 DB06470 DB01028 DB09036 DB00041 DB01406 DB00359 DB00576 DB06710 DB04794 DB04861 DB01030 DB00320 DB04855 DB09099 DB03575 DB00263 DB00530 DB00563 DB01007 DB01174 DB08877 DB06268 DB00678 DB00216 DB14568 DB04920 DB04894 DB05482 DB00435 DB13952 DB11767 DB01544 DB12070 DB01032 DB00439 DB09213 DB13941 DB08496 DB09231 DB09029 DB01085 DB01764 DB01087 DB04557 DB12245 DB00647 DB06674 DB06370 DB06803 DB01069 DB00501 DB06212 DB06209 DB06419 DB08883 DB00726 DB00342 DB00896 DB06458 DB06731 DB06174 DB09061 DB12266 DB00448 DB00227 DB14240 DB04574 DB00361 DB16236 DB00712 DB00909 DB01136 DB00673 DB00575 DB00683 DB01424 DB00243 DB01645 DB04725 DB06587 DB01159 DB09499 DB01171 DB08827 DB01628 DB00946 DB13406 DB00184 DB05773 DB00425 DB01101 DB04572 DB06594 DB01183 DB00762 DB01559 DB11837 DB06342 DB00255 DB01074 DB15822 DB00515 DB00472 DB00541 DB00898 DB00533 DB08962 DB00005 DB00701 DB15982 DB01388","absorption":"Voxelotor is rapidly absorbed after oral administration, with a plasma Tmax of 2 hours.[A188126,L10406] Tmax in the red blood cells ranges from 17-24 hours.[A188126]  The Cmax, on average in whole blood and red blood cells occur 6 and 18 hours after an oral dose, respectively. Consumption of a high fat meal with voxelotor significantly increased exposure to the drug during clinical trials.[L10397] After a daily dose of either 300, 600, or 900 mg for a period of 15 days, when steady-state concentrations were reached, the average RBC Cmax for the respective doses were measured to be 4950, 9610 and 14 000 g*h mL\u20191, respectively.[A188126]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The plasma elimination half-life of voxelotor in sickle cell disease patients is about 35.5 hours, according to the FDA label.[L10397] The mean half-life  in the red blood cell is 60 days. The average plasma half-life of voxelotor was 50 hours in patients with sickle cell disease, compared with 61\u20AC\u201C85 hours in healthy patients, in one clinical study.[A188126]","monoisotopic-mass":337.142641484,"volume-of-distribution":"The apparent volume of distribution of voxelotor in the central compartment is 338L and 72.2L in the plasma.[L10397]","route-of-elimination":"62.6% of the voxelotor dose administered orally as well as its metabolites are found in the feces (with 33.3% as unchanged drug) and 35.5% in urine (with only 0.08% unchanged drug).[A188126,L10397,L10406]","name":"Voxelotor","metabolism":"Voxeletor is heavily metabolized via 2 phases.  Phase I consists of oxidation and reduction, while phase II consists of glucuronidation. Voseletor is oxidized mainly by  CYP3A4, and to a lesser extent by CYP2C19, CYP2B6, and CYP2C9 hepatic cytochrome enzymes.[L10397,L10406]","reactions":null,"indication":"In the US, voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 4 years and older.[L10397] In Europe, it is indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older as monotherapy or in combination with [hydroxyurea].[L41419]","ahfs-codes":null,"updated":"2022-06-01","drugbank-id":"DB14975"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":586.57,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).","enzymes":null,"type":"small molecule","cas-number":"1496510-51-0","sequences":null,"targets":null,"unii":"2158753C7E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":586.141022418,"volume-of-distribution":null,"route-of-elimination":null,"name":"Relacorilant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14976"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":432.79,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).","enzymes":null,"type":"small molecule","cas-number":"1294000-61-5","sequences":null,"targets":null,"unii":"0R1HN52K0N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":432.0446154,"volume-of-distribution":null,"route-of-elimination":null,"name":"Padsevonil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14977"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":568.335,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).","enzymes":null,"type":"small molecule","cas-number":"1258980-67-4","sequences":null,"targets":null,"unii":"7DM27RQ9V0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":568.073362949,"volume-of-distribution":null,"route-of-elimination":null,"name":"MIP-1095 I-131","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14978"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":354.494,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Martinostat is under investigation in clinical trial NCT03721211 (Imaging With [11C]Martinostat in Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"1629052-58-9","sequences":null,"targets":null,"unii":"8JJC99KHGL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":354.230728214,"volume-of-distribution":null,"route-of-elimination":null,"name":"Martinostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14979"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":408.458,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).","enzymes":null,"type":"small molecule","cas-number":"1173900-33-8","sequences":null,"targets":null,"unii":"78G6MP5PZ5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":408.179755269,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-6482","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14980"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":660.0353,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Phytic acid is under investigation in clinical trial NCT01000233 (Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications).","enzymes":null,"type":"small molecule","cas-number":"83-86-3","sequences":null,"targets":null,"unii":"7IGF0S7R8I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":659.861370576,"volume-of-distribution":null,"route-of-elimination":null,"name":"Phytic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-03","drugbank-id":"DB14981"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":432.531,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).","enzymes":null,"type":"small molecule","cas-number":"1313881-70-7","sequences":null,"targets":null,"unii":"T1DQI1B52Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":432.206244797,"volume-of-distribution":null,"route-of-elimination":null,"name":"Miransertib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14982"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":177.17,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1620330-72-4","sequences":null,"targets":null,"unii":"2US4FK1EPV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":177.009578883,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cimlanod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14983"},{"toxicity":"Studies in male mice and rats suggest potential nephrotoxicity. Casimersen was administered weekly to male rats by IV injection for 12 weeks (0, 12, 120, or 960 mg\/kg) or 22 weeks (0, 300, 960, or 2000 mg\/kg) or by subcutaneous injection for 26 weeks (0, 300, 600, or 960 mg\/kg). In the 12-week study, microscopic findings in the kidney (cytoplasmic basophilia and microvacuolation) were observed at the highest dose tested. In the 22- and 26-week studies, renal tubular degeneration was observed at all doses. Male rats administered casimersen (0, 250, 500, 1000, or 2000 mg\/kg) intravenously for 13 weeks also experienced renal tubular degeneration at all tested doses, as well as microscopic changes accompanied by blood urea nitrogen increase at the highest tested dose. A no-effect dose for adverse effects on the kidneys was not identified in any of these studies. Plasma exposure (AUC) at the lowest dose tested in the 26-week study (300 mg\/kg) was approximately two times that in humans at the recommended human dose (RHD) of 30 mg\/kg\/week, while exposure in the rat studies at the lowest dose was approximately four times that in humans.[L32118]\r\n\r\nStudies involving weekly administration in cynomolgus monkeys found similar tubular basophilia and microvacuolation at doses \u203040 mg\/kg, which largely resolved by four weeks following the last dose. This study determined a no observed adverse effect level for repeated intravenous administration of 320 mg\/kg.[A229993]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Casimersen is an antisense phosphorodiamidate morpholino oligonucleotide designed to bind to exon 45 of the _DMD_ pre-mRNA, preventing its inclusion in mature mRNA and allowing the production of an internally truncated dystrophin protein in patients who would normally produce no functional dystrophin. Due to the need for continuous alteration of mRNA splicing and its relatively short half-life, casimersen is administered weekly.[L32118] Although casimersen is associated with mostly mild adverse effects, animal studies suggest a potential for nephrotoxicity, which has also been observed after administration of some oligonucleotides.[A229993, L32118] Measurement of glomerular filtration rate before starting casimersen is advised. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting therapy. They should be measured monthly (urine dipstick) or every three months (serum cystatin C and urine protein-to-creatinine ratio) during treatment. Creatinine levels are not reliable in muscular dystrophy patients and should not be used. Any persistent alteration in kidney function should be further investigated.[L32118]","msds":null,"description":"Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production. Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.[A218171, A218176, A229988]\r\n\r\nThe application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping to produce truncated BMD-like dystrophin proteins, which restore partial muscle function and slow disease progression.[A218171, A218176, A229993, A188574, L32118] Casimersen is a phosphorodiamidate morpholino oligonucleotide (PMO); PMOs are oligonucleotides in which the five-membered ribofuranosyl ring is replaced with a six-membered morpholino ring, and the phosphodiester links between nucleotides are replaced with a phosphorodiamidate linkage.[A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides.[A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. However, the specific mutations, and hence the precise exon skipping, targeted by each is different.\r\n\r\nCasimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent on further verification in confirmatory trials. Casimersen is currently marketed under the tradename AMONDYS 45\u201E by Sarepta Therapeutics, Inc.[L32118]","enzymes":"BE0002638 BE0003536 BE0002362 BE0002793","type":"biotech","cas-number":"1422958-19-7","sequences":null,"targets":"BE0010036","unii":"X8UHF7SX0R","protein-binding":"Casimersen binding to human plasma proteins is not concentration-dependent, ranging from 8.4-31.6%.[L32118]","fda-label":null,"clearance":"Casimersen administered at 30 mg\/kg has a plasma clearance of 180 mL\/hr\/kg.[L32118]","atc-codes":"MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Other drugs for disorders of the musculo-skeletal system","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Diane Elizabeth Frank and Richard K. Bestwick, \"Exon skipping oligomers for muscular dystrophy.\" U.S. Patent US20190262375A1, issued August 29, 2019.","mechanism-of-action":"Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder that results in the absence of functional dystrophin, a large protein comprising an N-terminal actin-binding domain, C-terminal -dystroglycan-binding domain, and 24 internal spectrin-like repeats.[A218171, A218176, A229988] Dystrophin is vital for normal muscle function; the absence of dystrophin leads to muscle membrane damage, extracellular leakage of creatinine kinase, calcium influx, and gradual replacement of normal muscle tissue with fibrous and adipose tissue over time.[A218171, A218176] DMD shows a characteristic disease progression with early functional complaints related to abnormal gait, locomotion, and falls that remain relatively stable until around seven years of age. The disease then progresses rapidly to loss of independent ambulatory function, ventilatory insufficiency, and cardiomyopathy, with death typically occurring in the second or third decade of life.[A218171, A218176, A229988]\r\n\r\nThe human _DMD_ gene contains 79 exons spread over approximately 2.4 million nucleotides on the X chromosome.[A218171] DMD is associated with a variety of underlying mutations, including exon duplications or deletions, as well as point mutations leading to nonsense translation through direct production of an in-frame stop codon, frameshift production of an in-frame stop codon, or aberrant inclusion of an intronic pseudo-exon with the concomitant production of an in-frame stop codon.[A218171, A218176] In all cases, no functional dystrophin protein is produced. Becker muscular dystrophy (BMD) is a related condition with in-frame mutations that result in the production of a truncated but partially functional dystrophin protein. BMD patients, therefore, have milder symptoms, delayed disease progression, and longer life expectancy compared to DMD patients.[A218171, A218176, A229988]\r\n\r\nCasimersen is an antisense phosphorodiamidate morpholino oligonucleotide designed to bind to exon 45 of the _DMD_ pre-mRNA and prevent its inclusion within the mature mRNA before translation.[A229993, L32118] It is estimated that around 8% of DMD patients may benefit from exon 45 skipping, in which the exclusion of this exon results in the production of an internally truncated and at least partly functional dystrophin protein.[A229993, L32118, A188574] Although fibrotic or fatty muscle tissue developed previously cannot be improved, this therapy aims to slow further disease progression through the production of partially functional dystrophin and alleviation of the pathogenic mechanism of muscle tissue necrosis.[A218171, A218176]","drug-interactions":null,"absorption":"DMD patients receiving IV doses of 4-30 mg\/kg\/week revealed exposure in proportion to dose with no accumulation of casimersen in plasma with once-weekly dosing. Following a single IV dose, casimersen C<sub>max<\/sub> was reached by the end of infusion. Inter-subject variability, as measured by the coefficient of variation, ranged from 12-34% for C<sub>max<\/sub> and 16-34% for AUC.[L32118]\r\n\r\nPre-clinical studies in nonhuman primates (cynomolgus monkeys) investigated the pharmacokinetics of once-weekly casimersen administered at doses of 5, 40, and 320 mg\/kg. On days 1 and 78, the 5 mg\/kg dose resulted in a C<sub>max<\/sub> of 19.5  3.43 and 21.6  5.60 g\/mL and an AUC<sub>0-t<\/sub> of 24.9  5.17 and 26.9  7.94 g\\*hr\/mL. The 40 mg\/kg dose resulted in a C<sub>max<\/sub> of 208  35.2 and 242  71.1 g\/mL and an AUC<sub>0-t<\/sub> of 283  68.5 and 320  111 g\\*hr\/mL. Lastly, the 320 mg\/kg dose resulted in a a C<sub>max<\/sub> of 1470  88.1 and 1490  221 g\/mL and an AUC<sub>0-t<\/sub> of 1960  243 and 1930  382 g\\*hr\/mL.[A229993]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Casimersen has an elimination half-life of 3.5  0.4 hours.[L32118]","monoisotopic-mass":null,"volume-of-distribution":"Casimersen administered at 30 mg\/kg had a mean steady-state volume of distribution (%CV) of 367 mL\/kg (28.9%).[L32118]","route-of-elimination":"Casimersen is predominantly (more than 90%) excreted in the urine unchanged with negligible fecal excretion.[L32118]","name":"Casimersen","metabolism":"Casimersen incubated with human hepatic microsomal preparations is metabolically stable, and no metabolites are detected in plasma or urine.[L32118]","reactions":null,"indication":"Casimersen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients confirmed to have a _DMD_ gene mutation amenable to exon 45 skipping. This indication represents an accelerated approval based on observed efficacy; continued approval for this indication may be contingent on the verification of safety and efficacy in a confirmatory trial.[L32118]","ahfs-codes":null,"updated":"2021-10-21","drugbank-id":"DB14984"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":340.339,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Enarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).","enzymes":null,"type":"small molecule","cas-number":"1262132-81-9","sequences":null,"targets":null,"unii":"JSK7TUA223","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":340.117155011,"volume-of-distribution":null,"route-of-elimination":null,"name":"Enarodustat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14985"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":410.92,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Linrodostat is under investigation in clinical trial NCT03247283 (Pharmacokinetics and Metabolism Study in Healthy Male Participants).","enzymes":null,"type":"small molecule","cas-number":"1923833-60-6","sequences":null,"targets":null,"unii":"0A7729F42K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":410.1561193,"volume-of-distribution":null,"route-of-elimination":null,"name":"Linrodostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14986"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":446.451,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Difamilast is under investigation in clinical trial NCT01702181 (A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis).","enzymes":null,"type":"small molecule","cas-number":"937782-05-3","sequences":null,"targets":null,"unii":"T3U32GLJ0F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":446.165328207,"volume-of-distribution":null,"route-of-elimination":null,"name":"Difamilast","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14987"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed\/Refractory Multiple Myeloma).","enzymes":null,"type":"biotech","cas-number":"1186210-24-1","sequences":null,"targets":null,"unii":"EGC16R10V0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dalantercept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14988"},{"toxicity":"The oral LD50 of umbralisib in rats is 3320 mg\/kg.[L31898] Overdose information is not readily available on prescribing information [L31878] or the literature. In any overdose, supportive and symptomatic treatment should be provided as required.","snp-adverse-drug-reactions":null,"average-mass":571.56,"transporters":"BE0001032","pharmacodynamics":"Umbralisib acts against against marginal zone lymphoma by interrupting the PI3K pathway; this is an essential pathway for B-cell receptor signaling responsible for the progression of lymphoma.[A229368,A229373,A229593] In addition, Umbralisib inhibits other pathways involved in specific types of lymphoma, including the casein kinase pathway.[L31878] An overall response rate of 55% was recorded during clinical trials and the rate of 1-year progression free survival from marginal zone lymphoma was 71%.[A229368]\r\n\r\nA relationship between higher umbralisib steady state exposures and higher incidence of adverse reactions, including diarrhea and elevated AST\/ALT was observed during clinical studies. The effect of this drug on QT interval has not been fully characterized.[L31878]","msds":null,"description":"Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression.[A229668]\r\n\r\nOn February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results from clinical trials. It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.[L31863] Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1, distinguishing it from other lymphoma treatments. While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated with a possible increased risk of death outweighing the benefits.[L41930]","enzymes":"BE0002638 BE0000014 BE0002793 BE0002433","type":"small molecule","cas-number":"1532533-67-7","sequences":null,"targets":"BE0000014 BE0003512 BE0002406","unii":"38073MQB2A","protein-binding":"Umbralisib is more than 99.7% protein bound.[L31878]","fda-label":null,"clearance":"The average apparent clearance of umbralisib is 15.5 L\/h.[L31878]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with food. Food increases the bioavailability and concentration of umbralisib.","state":"solid","synthesis-reference":null,"mechanism-of-action":"The PI3K pathway is a  deregulated in malignancies, leading to the overexpression of  p110 isoforms (p110, p110, p110, p110) that induces malignant transformation in cells.[A229593] Umbralisib inhibits several protein kinases, including PI3K and casein kinase CK1. PI3K is expressed in both healthy cells and malignant B-cells. CK1 is believed to be involved in the pathogenesis of malignant cells, including lymphomas.  This results in reduced progression of relapsed or refractory lymphoma.[A229363,L31878] In biochemical assays, umbralisib inhibited a mutated form of ABL1. In vitro, umbralisib inhibits malignant cell proliferation, CXCL12-mediated cell adhesion, and CCL19-mediated cell migration.[A229363,L31878]","drug-interactions":"DB00080 DB00203 DB11800 DB06695 DB00188 DB12457 DB09107 DB00742 DB12001 DB13259 DB11581 DB00175 DB00540 DB11952 DB00970 DB00907 DB11362 DB00814 DB00527 DB00468 DB09079 DB09241 DB00641 DB15328 DB05232 DB01232 DB00295 DB08931 DB11963 DB01263 DB11978 DB13878 DB12026 DB01264 DB06228 DB00950 DB12483 DB12455 DB06605 DB06772 DB13691 DB08882 DB08912 DB01086 DB12941 DB06287 DB09049 DB11869 DB08816 DB06403 DB09183 DB09063 DB05889 DB09297 DB08934 DB00570 DB00441 DB01590 DB00297 DB08916 DB12500 DB11732 DB00248 DB06237 DB06626 DB08889 DB01030 DB01075 DB11855 DB12825 DB09076 DB06774 DB00645 DB08907 DB01267 DB01396 DB00882 DB15442 DB01254 DB11760 DB00390 DB08865 DB00836 DB11796 DB06480 DB12836 DB08896 DB09330 DB09085 DB00358 DB11770 DB00349 DB01394 DB00997 DB12532 DB15133 DB11827 DB00281 DB08910 DB00296 DB00773 DB11753 DB13578 DB01079 DB01161 DB05015 DB09296 DB11712 DB00807 DB00961 DB01220 DB00300 DB09027 DB09345 DB11574 DB14840 DB13328 DB11995 DB11967 DB06207 DB09009 DB09299 DB00721 DB06212 DB13879 DB01261 DB06419 DB14631 DB00750 DB00726 DB00892 DB11979 DB15719 DB00012 DB09342 DB11652 DB06603 DB00862 DB05521 DB11951 DB09161 DB08893 DB14126 DB03255 DB11693 DB11502 DB06770 DB00243 DB06769 DB11641 DB09075 DB08987 DB06176 DB13125 DB09054 DB11575 DB14723 DB08881 DB00877 DB06290 DB13683 DB12364 DB00016 DB15149 DB08930 DB13401 DB16222 DB11148 DB00908 DB05773 DB00932 DB06616 DB00091 DB05039 DB12141 DB11853 DB00612 DB00539 DB15982 DB11689 DB08894 DB11613 DB13007 DB15822 DB12887 DB06589 DB00541 DB01002 DB08870 DB05239 DB06670 DB09078 DB00458 DB01388","absorption":"Umbralisib is rapidly absorbed in the GI tract.[A229363] The Tmax of umbralisib is about 4 hours. After consumption of a high-fat, high calorie meal with umbralisib, the AUC increased by 61% and the Cmax increased by 115%.[L31878]","created":"2019-05-20","groups":"approved investigational withdrawn","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The effective half-life of Umbralisib is about 91 hours.[L31878]","monoisotopic-mass":571.183124142,"volume-of-distribution":"The average apparent central volume of distribution of umbralisib is 312 L.[L31878]","route-of-elimination":"During pharmacokinetic studies, about 81% of the umbralisib dose was recovered in feces (17% unchanged). Approximately 3% was detected in the urine (0.02% unchanged) after a radiolabeled dose of 800 mg in healthy volunteers.[L31878]","name":"Umbralisib","metabolism":"During in vitro studies, umbralisib was metabolized by CYP2C9, CYP3A4, and CYP1A2 enzymes.[L31878]","reactions":null,"indication":"Umbralisib does not have any approved therapeutic indications.","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14989"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bazlitoran is under investigation in clinical trial NCT02092909 (Phase 1\/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia).","enzymes":null,"type":"biotech","cas-number":"1378549-07-5","sequences":null,"targets":null,"unii":"2U46M95B5M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bazlitoran","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14990"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).","enzymes":null,"type":"biotech","cas-number":"875125-19-2","sequences":null,"targets":null,"unii":"79V7Q9VIWQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nomacopan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14991"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pegunigalsidase alfa is under investigation in clinical trial NCT02921620 (Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Nave Fabry Disease).","enzymes":null,"type":"biotech","cas-number":"1644392-61-9","sequences":null,"targets":null,"unii":"8M7V7Q6537","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS ALIMENTARY TRACT AND METABOLISM Enzymes","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pegunigalsidase alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14992"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":583.09,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"1269662-73-8","sequences":null,"targets":null,"unii":"CJN36EQM0H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":582.2146166,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pyrotinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14993"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":399.373,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).","enzymes":null,"type":"small molecule","cas-number":"1807454-59-6","sequences":null,"targets":null,"unii":"1ER2O3UZ4W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":399.119461256,"volume-of-distribution":null,"route-of-elimination":null,"name":"NP-G2-044","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB14995"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Following a single sutimlimab injection, >90% inhibition of the complement pathway was observed, and this inhibition was sustained when concentrations of sutimlimab were \u2030100 mcg\/mL.[L40109]\r\n\r\nAs sutimlimab can impair the complement-mediated immune response, patients requiring therapy should receive all appropriate vaccinations against encapsulated bacteria at least 2 weeks prior to its initiation.[L40109] Patients undergoing treatment with sutimlimab are at a higher risk of serious infections, especially those caused by encapsulated bacteria such as _Neisseria meningitides_ or _Streptococcus pneumoniae_, and should be monitored closely throughout therapy for evidence of developing or ongoing infections.[L40109]","msds":null,"description":"Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4C and are therefore referred to as \"cold agglutinin\".[A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis.[A245159] The most common presenting symptoms in patients with CAD are chronic anemia, acrocyanosis, and Raynaud phenomenon.[A245159]\r\n\r\nTreatment options for patients with CAD are limited. In addition to non-pharmacological strategies, such as counseling patients to keep warm and the use of red blood cell transfusions, approximately 70% of patients require pharmacological treatment.[A245159] Pharmacologic strategies have included the targeting of B-cells with agents like [rituximab], as well as targeting of the complement system with drugs like [eculizumab], an anti-C5 mAb, and [pegcetacoplan], a novel inhibitor of C3.[A245154] Notably, none of these agents are approved for use in the treatment of CAD.\r\n\r\nSutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway.[A245144] It received FDA approval in February 2022, under the brand name Enjamyo (sutimlimab-jome), becoming the first approved therapy for patients with CAD.[L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]","enzymes":null,"type":"biotech","cas-number":"2049079-64-1","sequences":">SUBUNIT_4\nQIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVP\nSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIKRTVAAPSVFIF\nPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST\nLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >SUBUNIT_1\nEVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYY\nLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSSAS\nTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL\nYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFL\nFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV\nVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQ\nVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV\nFSCSVMHEALHNHYTQKSLSLSLGK >SUBUNIT_2\nEVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYY\nLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSSAS\nTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL\nYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFL\nFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV\nVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQ\nVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNV\nFSCSVMHEALHNHYTQKSLSLSLGK >SUBUNIT_3\nQIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVP\nSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIKRTVAAPSVFIF\nPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST\nLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","targets":"BE0001529","unii":"GNWE7KJ995","protein-binding":null,"fda-label":null,"clearance":"At the approved recommended dosage, the clearance of sutimlimab is 0.14 L\/day.[L40109] The clearance of sutimlimab varies at different doses due to target-mediated drug disposition at lower concentrations.[L40109]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS Selective immunosuppressants","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Hemolysis associated with cold agglutinin disease is driven by the activation of the complement system.[A245159] Cold agglutinins transiently bind erythrocytes as they circulate through cooler parts of the body (e.g. the extremities) - as they circulate back to warmer areas, C1q esterase activates C4 and C2, which generates C3 convertase, an enzyme which cleaves C3 into C3a and C3b.[A245159] At this stage, the erythrocytes tagged with C3b can be sequestered by macrophages in the reticuloendothelial system, ultimately leading to extravascular hemolysis.[A245159] Alternatively, C3b may be further cleaved into C3c and C3d - if complement activation continues past the C3 step, the membrane attack complex with C5b-C9 may form, which causes intravascular hemolysis.[A245159]\r\n\r\nSutimlimab is a humanized IgG4 monoclonal antibody targeted at the complement C1s subunit, a serine protease responsible for the activation of the classic complement pathway.[A245144,L40109] By inhibiting the complement cascade at the level of C1s, sutimlimab prevents the deposition of complement opsinins on erythrocytes, thus preventing their eventual hemolysis.","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"When administered at the approved weight-based recommended dosage, the exposure to sutimlimab increases proportionately with increasing dosage.[L40109] Steady-state concentrations are achieved by week 7 of therapy.[L40109]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"At the approved recommended dosage, the terminal elimination half-life of sutimlimab is 21 days.[L40109] The half-life of sutimlimab varies at different doses due to target-mediated drug disposition at lower concentrations.[L40109]","monoisotopic-mass":null,"volume-of-distribution":"At steady-state, the volume of distribution of sutimlimab in patients with cold agglutinin disease was approximately 5.8 L.[L40109]","route-of-elimination":null,"name":"Sutimlimab","metabolism":"As with other therapeutic proteins, sutimlimab likely undergoes catabolism to smaller peptides and amino acids.[L40109]","reactions":null,"indication":"Sutimlimab is indicated to decrease the need for red blood cell transfusion due to hemolysis in adult patients with cold agglutinin disease.[L40109,L44111]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB14996"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).","enzymes":null,"type":"biotech","cas-number":"1202526-59-7","sequences":null,"targets":null,"unii":"QOK1YYH7J2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pateclizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14997"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":357.414,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Olorinab is under investigation in clinical trial NCT03155945 (Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain).","enzymes":null,"type":"small molecule","cas-number":"1268881-20-4","sequences":null,"targets":null,"unii":"581F7DFA9B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":357.180089621,"volume-of-distribution":null,"route-of-elimination":null,"name":"Olorinab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB14998"},{"toxicity":"LD50 information for beta interferon is not readily available in the literature.\r\n\r\nOverdose information\r\n\r\nFollowing an overdose with a very high dose of beta interferon, one patient described in a case report experienced a modest rise in body temperature with diffuse limb and truncal erythema. The symptoms resolved within 24 hours.  Biochemical and hematologic parameters were nonremarkable after the overdose.[A191871] In the case of an overdose, discontinue beta interferon and resume when the patient has returned to baseline function.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Interferon-beta has antiviral and immunomodulatory effects. It reduces demyelination, the main component of Multiple Sclerosis pathophysiology, reducing the clinical frequency of MS attacks and slowing disease progression.[A191751,A191784,L12096]\r\n\r\nIn vitro studies have shown that beta interferon reduces the replication of certain coronaviruses in lung tissue.[A191874] Retrospective studies using combinations of [mycophenolate mofetil] and beta interferon showed improved survival against MERS-CoV, the virus that causes Middle Eastern Respiratory Syndrome (MERS). [A191871]","msds":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/msds\/DB14999.pdf?1583868232","description":"Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992.[L12081] Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.[A191784] \r\n\r\nInterferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.[L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS). It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012]","enzymes":"BE0002433","type":"biotech","cas-number":"74899-71-1","sequences":null,"targets":"BE0000661","unii":"V9GU1EM8SF","protein-binding":null,"fda-label":null,"clearance":"Average serum clearance in a pharmacokinetic study of beta-interferon 1b ranged from 9.4 mL\/min\u20ACkg-1 to 28.9 mL\/min\u20ACkg-1.[L12096] Another study revealed a clearance ranging between 0.3 to 1.4 L\/h\/kg.[A191859]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Part of the pathophysiology of MS is immune cell activation in addition to degradation of the blood\u20AC\u201Cbrain barrier (BBB), resulting in both neural demyelination and axon injury. Immunomodulating drugs such as interferon-beta decrease the inflammation that results in demyelination of nerves.  Binding of interferon-beta to type 1 interferon receptors induces a series of beneficial transcriptional JAK\/STAT pathway changes. This decreases antigen presentation as well as the proliferation of inflammatory T-cells, reducing the inflammation associated with MS. It also changes the expression of cytokine and matrix metalloproteinase (MMP).[A191751,A191814]","drug-interactions":"DB13812 DB02568 DB11919 DB12927 DB15122 DB12531 DB06479 DB13573 DB13634 DB14018 DB01303 DB00806 DB04076 DB02245 DB01667 DB00651 DB12406 DB14029 DB02489 DB09273 DB12926 DB00201 DB06575 DB01033 DB07954 DB13203 DB14132 DB13592 DB00495 DB01482 DB08844 DB02377 DB01223 DB01978 DB02134 DB13449 DB00277 DB04356 DB01412","absorption":"Beta interferon has a bioavailability of about 30% after subcutaneous or intramuscular administration, demonstrating peak serum concentrations within several hours of a dose. Peak interferon beta-1b concentrations are achieved between 1-8 hours post-dose, measuring about 40 IU\/mL.[L12081] After injection, it is absorbed mainly by the lymphatic route.[A191859] Prescribing information for interferon beta-1b indicates a bioavailability of 50%.[L12096] Concentrations of beta interferon are detectable in the circulation 1-2 to days after administration.[A191859]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The mean terminal elimination half-life of interferon-beta varies from 8 minutes to about 4 hours.[A191859,L12081]","monoisotopic-mass":null,"volume-of-distribution":"The average state volume of distribution for beta interferon is 0.25 L\/kg to 2.88 L\/kg.[L12081,L12096] Another reference mentions a volume of distribution of 120 L.[A191859] Beta interferon is distributed throughout the body after extravasation across the vascular wall into the tissue after injection. It likely does not cross the blood-brain barrier, and it is unclear whether beta interferon crosses the placenta.[A191859]","route-of-elimination":"Beta interferon is excreted by hepatic and renal pathways, with renal pathways accountable for about 40% of its clearance.[A191859]","name":"Human interferon beta","metabolism":"Data regarding the metabolism of beta interferon is not readily available in the literature.","reactions":null,"indication":"This drug is indicated to treat relapsing forms of Multiple Sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.[L12081]","ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB14999"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).","enzymes":null,"type":"biotech","cas-number":"1352413-49-0","sequences":null,"targets":null,"unii":"S5HS95L6CN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dianexin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15000"},{"toxicity":"An overdose of eflapegrastim may result in leukocytosis and bone pain.[L43135] In the event of an overdose, the patient should be monitored for adverse effects and general supportive measures should be implemented as necessary.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Eflapegrastim increases absolute neutrophil count (ANC) in a dose-dependent manner in both healthy subjects and cancer patients.[L43135] In rat studies, it was associated with higher serum and bone marrow concentrations than pegfilgrastim, which translated to a significantly shorter duration of neutropenia when eflapegrastim was administered 24 hours post-chemotherapy compared to pegfilgrastim.[A252320]","msds":null,"description":"Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 \u2014C) and severe neutropenia (ANC < 500 cells\/mm<sup>3<\/sup>), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia.[A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality. The primary factor associated with FN risk is the chemotherapy regimen being administered - regimens are classified as either high-, intermediate-, or low-risk for FN, and relevant guidelines recommend the use of pharmacologic prophylaxis against FN in patients receiving high-risk regimens and those receiving intermediate-risk regimens who have \u20301 additional risk factor.[A252320]\r\n\r\nGranulocyte-colony stimulating factors (G-CSFs) - which include [filgrastim] and [pegfilgrastim] - were first used clinically in the 1990s and are the primary means of prophylaxis against chemotherapy-induced neutropenia, including FN.[A252320] They trigger signaling pathways that control the differentiation, proliferation, migration, and survival of neutrophils, thereby helping to restore depressed neutrophil counts.[L43135] \r\n\r\nEflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.[L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer drugs.[L43170]","enzymes":null,"type":"biotech","cas-number":"1384099-30-2","sequences":">SUBUNIT_2\nPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN\nAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP\nQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL\nYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK >SUBUNIT_3\nTPLGPASSLPQSFLLKSLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAP\nLSSCSSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQ\nMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP >SUBUNIT_1\nPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHN\nAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREP\nQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL\nYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK","targets":"BE0000793","unii":"UT99UG9QJX","protein-binding":null,"fda-label":null,"clearance":"The clearance of eflapegrastim-xnst decreased with increasing dose, suggesting target-mediated clearance by neutrophils.[L43135] With repeat dosing clearance appears to increase, potentially due to the subsequent increase in circulating neutrophils.[L43135]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Eflapegrastim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF). Like endogenous G-CSF, eflapegrastim binds to G-CSF receptors on myeloid progenitor cells and neutrophils - this triggers signaling pathways that result in neutrophil differentiation, proliferation, migration, and survival.[L43135]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00531 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB11641 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB13374 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB05168 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB00309 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00570 DB00056 DB11803 DB09036 DB14707 DB12683 DB01030 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB00361 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB00541 DB09312 DB04575","absorption":"The T<sub>max<\/sub> of eflapegrastim is dose-dependent and increases with increasing dose.[A252315] Following administration of the recommended dosage in patients with breast cancer, the median T<sub>max<\/sub> of eflapegrastim-xnst is 25 hours.[L43135]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"In patients with breast cancer, the geometric mean half-life of eflapegrastim-xnst is 36.4 hours.[L43135]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of eflapegrastim-xnst is 1.44 L.[L43135]","route-of-elimination":"Following subcutaneous administration, eflapegrastim is not detectable in the urine.[L43135,A252315]","name":"Eflapegrastim","metabolism":"Eflapegrastim is likely metabolized via endogenous degradation following internalization by cells expressing G-CSF receptors.[L43135]","reactions":null,"indication":"Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[L43135]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15001"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B).","enzymes":null,"type":"biotech","cas-number":"1499251-18-1","sequences":null,"targets":null,"unii":"SV9W47ZLE1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fitusiran","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15002"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":389.411,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1883299-62-4","sequences":null,"targets":null,"unii":"3X8387Q25N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":389.17756465,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06700841","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15003"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"V6AP1D8NNW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MS-1819","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15004"},{"toxicity":"Viltolarsen administered by subcutaneous injection in juvenile male mice resulted in deaths due to renal toxicity at high doses; in animals administered either 240 or 1200 mg\/kg viltolarsen, dose-dependent increases in the incidence and severity of renal tubular effects were observed. Although renal toxicity in humans has not been observed, it is recommended to measure urine dipstick every month and serum cystatin C and urine protein-to-creatinine ratio every three months to detect renal toxicity.[L15526]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Viltolarsen is an antisense phosphorodiamidate morpholino oligonucleotide designed to bind to and disrupt splicing of exon 53 in the human _DMD_ gene, which results in the expression of a partially functional dystrophin protein in patients who otherwise would not produce dystrophin.[A218161, A218166, L15526] Despite a relatively short half-life, the physiological effect of producing relatively stable dystrophin protein allows for effective therapeutic benefit with weekly dosing.[L15526] Viltolarsen may cause renal toxicity, and so kidney function should be monitored in patients. However, due to the alteration of serum creatinine in Duchenne muscular dystrophy patients,[A218171] creatinine should not be used as a marker of renal function.[L15526]","msds":null,"description":"Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by the production of shortened and partially functional dystrophin protein. Although corticosteroids are effective in slowing disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.[A218171, A218176, A218191]\r\n\r\nThe application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping, which retains a productive reading frame and results in the production of truncated BMD-like dystrophin proteins.[A218161, A218166, A218171, A218176, A218181, A218191, L15526] These shortened forms of dystrophin can restore partial muscle function and slow the progression of DMD. Viltolarsen is a phosphorodiamidate morpholino oligonucleotide (PMO); PMOs are oligonucleotides in which the five-membered ribofuranosyl ring is replaced with a six-membered morpholino ring, and the phosphodiester links between nucleotides are replaced with a phosphorodiamidate linkage.[A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides.[A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific for exon 53 skipping.[A218176]\r\n\r\nViltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval is contingent on further verification in confirmatory trials. Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO\u201E.[L15526]","enzymes":null,"type":"biotech","cas-number":"2055732-84-6","sequences":null,"targets":"BE0010012","unii":"SXA7YP6EKX","protein-binding":"Viltolarsen _in vitro_ plasma protein binding is between 39 and 40% and is not concentration-dependent.[A218191, L15526]","fda-label":null,"clearance":"Viltolarsen has a reported plasma clearance of 217 mL\/hr\/kg (22% CV).[L15526] Patients taking 1.25, 5, or 20 mg\/kg viltolarsen weekly for 12 weeks had a total clearance of between 149  21 and 239  97 ml\/hr\/kg.[A218166]","atc-codes":"MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Other drugs for disorders of the musculo-skeletal system","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, Kitagawa H, Komaki H, Takagaki K, Takeda S: NS-065\/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids. 2018 Dec 7;13:442-449. doi: 10.1016\/j.omtn.2018.09.017.","mechanism-of-action":"Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder that results in the absence of functional dystrophin, a large protein comprising an N-terminal actin-binding domain, C-terminal -dystroglycan-binding domain, and 24 internal spectrin-like repeats.[A218171, A218176] Dystrophin is vital for normal muscle function; the absence of dystrophin leads to muscle membrane damage, extracellular leakage of creatinine kinase, calcium influx, and gradual replacement of normal muscle tissue with fibrous and adipose tissue over time. The disease progresses from loss of ambulatory function to ventilatory insufficiency and cardiomyopathy, with death typically occurring in the second or third decade of life.[A218171, A218176, A218181]\r\n\r\nThe human _DMD_ gene contains 79 exons spread over approximately 2.4 million nucleotides on the X chromosome.[A218171] DMD is associated with a variety of underlying mutations, including exon duplications or deletions, as well as point mutations leading to nonsense translation through direct production of an in-frame stop codon, frameshift production of an in-frame stop codon, or aberrant inclusion of an intronic pseudo-exon with the concomitant production of an in-frame stop codon.[A218171, A218176] In all cases, no functional dystrophin protein is produced. Becker muscular dystrophy (BMD) is a related condition with in-frame mutations that result in the production of a truncated but partially functional dystrophin protein. BMD patients, therefore, have milder symptoms, delayed disease progression, and longer life expectancy compared to DMD patients.[A218161,  A218171, A218176, A218181]\r\n\r\nViltolarsen is an antisense phosphorodiamidate morpholino oligonucleotide designed to bind to a specific region in exon 53 of the _DMD_ pre-mRNA and prevent its inclusion within the mature mRNA before translation. In patients with specific mutations, including those with deletions of exons 45-52, 47-52, 48-52, 49-52, 50-52, or solely of exon 52, this results in restoration of the expected reading frame and the production of a BMD-like dystrophin protein.[A218161, A218181, A218186, A218191, L15526] Although fibrotic or fatty muscle tissue developed previously cannot be improved, this therapy aims to slow further disease progression through the production of partially functional dystrophin and alleviation of the pathogenic mechanism of muscle tissue necrosis.[A218171, A218176]","drug-interactions":null,"absorption":"Viltolarsen is administered by intravenous infusion and is assumed to have a bioavailability of 100%.[L15526] In a phase 1 dose-escalation trial of 10 patients given either 1.25, 5, or 20 mg\/kg weekly for 12 weeks, the mean C<sub>max<\/sub> was 6040  300 ng\/mL in the low dose group and 70,200  44,900 ng\/mL in the high dose group on initial dose, with the corresponding final dose values of 5640  2440 and 72,800  26,400 ng\/mL, respectively. Similarly, the AUC<sub>0-t<\/sub> for the initial\/final dose was 8410  1310\/8410  3520 ng\\*hr\/mL for the low dose and 98,900  54,100\/115,000  56,000 ng\\*hr\/mL for the high dose.[A218166] The T<sub>max<\/sub> varied between 0.667  0.289 and 1.00  0.00 hours,[A218166] and viltolarsen has a documented median T<sub>max<\/sub> of approximately one hour.[L15526]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Viltolarsen has a reported elimination half-life of 2.5 hours (8% CV).[L15526] When administered at either 40 or 80 mg\/kg for 24 weeks, viltolarsen elimination half-life was 2.38 and 2.82 hours, respectively.[A218191]","monoisotopic-mass":null,"volume-of-distribution":"Viltolarsen has a steady-state volume of distribution of 300 mL\/kg (14% CV) when given at 80 mg\/kg.[L15526] In patients given either 1.25, 5, or 20 mg\/kg viltolarsen weekly for 12 weeks the volume of distribution was between 183  14 and 264  68 mL\/kg.[A218166]","route-of-elimination":"Viltolarsen is mainly excreted in the urine unchanged;[L15526] in a phase 1\/2 study of 16 Japanese DMD patients, 92.0-93.1% of a single 80 mg\/kg dose of viltolarsen was recovered unchanged in the patient urine within 24 hours of administration.[A218191]","name":"Viltolarsen","metabolism":"Viltolarsen metabolism was not detected in serum or liver-derived microsomes, and it appears not to be metabolized by either DNase I or phosphodiesterase type 1 _in vitro_.[A218191] This lack of metabolism is consistent with what is known regarding the stability of phosphorodiamidate morpholino oligonucleotides to enzymatic cleavage.[A218186]","reactions":null,"indication":"Viltolarsen is indicated for the treatment of Duchenne muscular dystrophy in patients confirmed to have a _DMD_ gene mutation amenable to exon 53 skipping. This indication represents an accelerated approval based on observed efficacy; continued approval for this indication may be contingent on the verification of safety and efficacy in a confirmatory trial.[L15526]","ahfs-codes":null,"updated":"2021-08-05","drugbank-id":"DB15005"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":488.77,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flufenoxuron is under investigation in clinical trial NCT00922870 (Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock).","enzymes":null,"type":"small molecule","cas-number":"101463-69-8","sequences":null,"targets":null,"unii":"OD068OSS0N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":488.0362389,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flufenoxuron","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15006"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":"7C17NQF03M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sevuparin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15007"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2352.8,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I\/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1469735-88-3","sequences":null,"targets":null,"unii":"5YSY733NA3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2351.33253843,"volume-of-distribution":null,"route-of-elimination":null,"name":"GO-203-2C","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15008"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":432.432,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1245603-92-2","sequences":null,"targets":null,"unii":"7E99B9ZM19","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":432.154603158,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-04937319","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15009"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":490.688,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).","enzymes":null,"type":"small molecule","cas-number":"1204317-86-1","sequences":null,"targets":null,"unii":"AF3Z6434KS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":490.31954322,"volume-of-distribution":null,"route-of-elimination":null,"name":"Edasalonexent","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15010"},{"toxicity":"Animal studies have not revealed any mutagenic potential of avacopan and no impairment of fertility at doses up to 1000 mg\/kg\/day. Avacopan is not mutagenic based on the Ames test.[L38919]","snp-adverse-drug-reactions":null,"average-mass":581.656,"transporters":"BE0001032","pharmacodynamics":"Avacopan is a complement 5a receptor (C5aR) antagonist that blocks C5a-induced upregulation of C11b (integrin alpha M) on neutrophils and inhibits C5a-mediated neutrophil activation and migration. Avacopan has been associated with hypersensitivity reactions, including angioedema, and hepatotoxicity, as evidenced by elevated liver transaminases. Likely due to its effect on the complement pathway, avacopan has also been associated with hepatitis B virus reactivation and serious infections, which should be monitored for as appropriate.[L38919]","msds":null,"description":"Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of \"pauci-immune\" systemic small-vessel vasculitis typified by the presence of ANCAs in the serum.[A240249, A240254, A227003] The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and drug-induced AAV. AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN).[A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin fragment C5a and its cognate C5aR receptor in AAV.[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV.[A240269, A240329, L38919]\r\n\r\nAvacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.[L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the two main forms of ANCA-associated vasculitis - in combination with [rituximab] or [cyclophosphamide].[L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650]","enzymes":"BE0002638 BE0003549 BE0002793 BE0002433","type":"small molecule","cas-number":"1346623-17-3","sequences":null,"targets":"BE0010095","unii":"O880NM097T","protein-binding":"Avacopan and its M1 metabolite are more than 99.9% bound to plasma proteins.[L38919]","fda-label":null,"clearance":"Avacopan has an estimated total apparent body clearance (CL\/F) of 16.3 L\/h.[L38919]","atc-codes":null,"pdb-entries":false,"food-interactions":"Take with food.","state":"solid","synthesis-reference":"Christopher Lange, Viengkham Malathong, Venkat Reddy Mali, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Yu Wang, Ju Yang, Penglie Zhang, \"Immunomodulator compounds.\" U.S. Patent US10919852B2, issued May 9, 2019.","mechanism-of-action":"Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is considered a \"pauci-immune\" form of systemic small-vessel vasculitis accompanied by the presence of ANCAs in the serum. The full spectrum of AAV includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and drug-induced AAV. AAV may be associated with necrotizing and crescentic glomerulonephritis (NCGN). Of the various known ANCAs, the major antigens are myeloperoxidase (MPO) and proteinase 3 (PR3\/myeloblastin).[A240249, A240254]\r\n\r\nThe pathophysiology giving rise to AAV is complex, though a working model has been proposed. An initial trigger, such as infection, causes differentiation of naive T cells into T<sub>H<\/sub>17 helper T cells that induce the release from macrophages of pro-inflammatory cytokines (e.g., TNF- and IL-1), which prime neutrophils. Concurrently, the anaphylatoxin C5a is produced through activation of the alternative complement pathway, which also primes neutrophils through binding to the C5a receptor (C5aR; CD88). Primed neutrophils undergo physiological changes, including upregulating the display of ANCA antigens on their surface. Circulating ANCAs bind to displayed ANCA antigens on the surface of neutrophils; simultaneously, the Fc region of these ANCAs is recognized by Fc receptors on other neutrophils, resulting in excessive neutrophil activation. Activated neutrophils form NETs (neutrophil extracellular traps), which induce tissue damage and vasculitis. MPO\/PR3 in NETs induces further ANCA production through dendritic cell- and CD4<sup>+<\/sup> T cell-mediated activation of B cells, further exacerbating the condition.[A240249, A240254]\r\n\r\nA role for complement was not initially considered in AAV due to a lack of excessive complement or immunoglobulin deposition in AAV lesions.[A240254, A240259] However, extensive molecular studies confirmed a significant role for the alternative complement pathway, acting through C3 and C5, in the pathogenesis of AAV.[A240254, A240259, A240264, A240269] The C5a fragment, generated by C5 cleavage, can bind to both the C5aR and C5a-like receptor (C5L2) on the surface of neutrophils; C5aR binding is associated with AAV while C5L2 binding has a protective effect.[A240264, A240269] As the alternative complement pathway is self-sustaining in the absence of down-regulation by specific proteins, it is likely a significant driver of AAV. Furthermore, neutrophils activated by C5a release reactive oxygen species, properdin, and other molecules that stimulate the complement pathway leading to the production of more C5a in a vicious cycle.[A240249, A240254]\r\n\r\nAvacopan (CCX168) is a specific C5aR receptor allosteric antagonist that inhibits C5a-mediated neutrophil activation both _in vitro_ and _in vivo_.[A240269, A240274, A240329] By inhibiting the C5a\/C5aR axis, avacopan should have minimal effects on the formation of the membrane attack complex (which includes C5b) and therefore little effect on the innate immune response in treated patients.[A240254, A240259]","drug-interactions":"DB01149 DB00537 DB08953 DB11672 DB00682 DB12095 DB00564 DB00188 DB05667 DB00398 DB00951 DB12001 DB11581 DB09280 DB06448 DB12015 DB02703 DB09570 DB06712 DB00204 DB09065 DB11952 DB00540 DB08899 DB00637 DB14019 DB00648 DB15035 DB00199 DB09071 DB00794 DB08873 DB04896 DB11986 DB09185 DB12978 DB09079 DB00270 DB01232 DB00309 DB11963 DB01263 DB01234 DB01264 DB12371 DB01223 DB12483 DB00582 DB01211 DB06772 DB08882 DB11642 DB08912 DB00277 DB00444 DB00312 DB00363 DB06287 DB01229 DB00675 DB12235 DB00503 DB09063 DB00570 DB15569 DB15762 DB00220 DB12952 DB01128 DB01590 DB08901 DB01406 DB01431 DB12147 DB09030 DB05316 DB00248 DB06626 DB06237 DB01601 DB00320 DB04855 DB01395 DB00531 DB12825 DB01072 DB00625 DB06218 DB09048 DB11828 DB01396 DB11901 DB00530 DB01242 DB01254 DB13874 DB00563 DB08865 DB15444 DB01174 DB01039 DB08877 DB00705 DB01656 DB00246 DB05109 DB01227 DB06700 DB00477 DB08896 DB09330 DB14568 DB00224 DB00604 DB02520 DB00997 DB01118 DB11703 DB12267 DB01320 DB08910 DB05294 DB11886 DB14921 DB00773 DB09231 DB00454 DB00176 DB01323 DB11753 DB12515 DB01087 DB04845 DB09074 DB01624 DB06717 DB11779 DB01008 DB11730 DB00864 DB09299 DB01418 DB00343 DB14009 DB06212 DB00622 DB00196 DB00342 DB06731 DB09289 DB00227 DB00590 DB01181 DB00361 DB06603 DB11742 DB05521 DB11652 DB11932 DB00673 DB06636 DB13345 DB09143 DB01100 DB00575 DB13179 DB09101 DB01026 DB11641 DB01110 DB04868 DB06176 DB01248 DB09054 DB08881 DB06595 DB00976 DB06119 DB00877 DB09034 DB06290 DB14960 DB09118 DB00661 DB00717 DB04832 DB08827 DB00946 DB00908 DB00502 DB05773 DB00932 DB04572 DB01183 DB06616 DB00091 DB11363 DB09227 DB00252 DB01045 DB11633 DB12141 DB00762 DB01098 DB00763 DB00207 DB00247 DB00567 DB09073 DB12887 DB01167 DB06589 DB00696 DB00872 DB00541 DB01268 DB01201 DB08870 DB05239 DB13385 DB00701 DB09046 DB15982 DB00518 DB11273 DB05154","absorption":"In AAV patients receiving 30 mg avacopan twice daily, avacopan had a C<sub>max<\/sub> of 349  169 ng\/mL and an AUC<sub>0-12hr<\/sub> of 3466  1921 ng\\*h\/mL. On this dosing scheme, steady-state plasma concentrations are reached by 13 weeks with a roughly 4-fold accumulation. Co-administration of 30 mg with a high-fat meal increased the C<sub>max<\/sub> by ~8%, the AUC by ~72%, and delayed the T<sub>max<\/sub> by four hours (from two hours).[L38919]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"A single 30 mg dose of avacopan given with food to healthy subjects resulted in mean elimination half-lives of 97.6 and 55.6 hours for avacopan and its M1 metabolite, respectively.[L38919]","monoisotopic-mass":581.266540031,"volume-of-distribution":"Avacopan has an apparent volume of distribution of 345 L.[L38919]","route-of-elimination":"Avacopan is mainly eliminated in feces, with smaller amounts present in the urine. Following oral administration of the radiolabeled drug, roughly 77% (7% as unchanged avacopan) was recovered in feces while 10% (<0.1% unchanged) was recovered in urine.[L38919]","name":"Avacopan","metabolism":"Avacopan is metabolized primarily by CYP3A4. The major circulating M1 metabolite, a mono-hydroxylated form of avacopan, represents ~12% of drug plasma levels and acts as a C5aR antagonist with similar efficacy to avacopan itself.[L38919]","reactions":null,"indication":"Avacopan is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis; GPA\/MPA) in combination with standard therapy including glucocorticoids. Avacopan does not eliminate the need for glucocorticoids.[L38919]\r\n\r\nIn Europe, avacopan is approved for the treatment of adults with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide.[L40149]","ahfs-codes":null,"updated":"2022-05-01","drugbank-id":"DB15011"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":231.255,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Farampator is under investigation in clinical trial NCT00113022 (Org 24448 to Treat Major Depression).","enzymes":null,"type":"small molecule","cas-number":"211735-76-1","sequences":null,"targets":null,"unii":"7X6P5N8K2L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":231.100776671,"volume-of-distribution":null,"route-of-elimination":null,"name":"Farampator","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15012"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":519.51,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1450833-55-2","sequences":null,"targets":null,"unii":"V9GGV0YCDI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":519.085795601,"volume-of-distribution":null,"route-of-elimination":null,"name":"TAK-243","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15013"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).","enzymes":null,"type":"biotech","cas-number":"1800381-36-5","sequences":null,"targets":null,"unii":"3QG7W0YN2Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gremubamab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15014"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Recombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"T169OM1T8L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Recombinant CD40-ligand","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15015"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":102.9061,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).","enzymes":null,"type":"small molecule","cas-number":"14967-68-1","sequences":null,"targets":null,"unii":"68QTV136DF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":102.906087204,"volume-of-distribution":null,"route-of-elimination":null,"name":"Palladium Pd-103","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15016"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1353485-38-7","sequences":null,"targets":null,"unii":"M6030H73N9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Enoblituzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15017"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).","enzymes":null,"type":"biotech","cas-number":"207623-20-9","sequences":null,"targets":null,"unii":"5V336PV3HG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Agatolimod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15018"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects).","enzymes":null,"type":"biotech","cas-number":"1443994-46-4","sequences":null,"targets":null,"unii":"O1VIU3R1NE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mongersen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15019"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mureletecan is under investigation in clinical trial NCT00004076 (PNU 166148 in Treating Patients With Metastatic Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"246527-99-1","sequences":null,"targets":null,"unii":"TTJ03QI76T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mureletecan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15020"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":372.438,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).","enzymes":null,"type":"small molecule","cas-number":"146062-44-4","sequences":null,"targets":null,"unii":"K824X25AYA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":372.114377828,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leriglitazone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15021"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Apomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)).","enzymes":null,"type":"biotech","cas-number":"1108170-71-3","sequences":null,"targets":null,"unii":"703KLX5LXZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Apomab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15022"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":531.61,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).","enzymes":null,"type":"small molecule","cas-number":"1008116-73-1","sequences":null,"targets":null,"unii":"60BN6CDL0K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":531.174039054,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-791826","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15023"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":364.39,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Apararenone is under investigation in clinical trial NCT02531568 (Drug Interaction Study of Warfarin and MT-3995).","enzymes":null,"type":"small molecule","cas-number":"945966-46-1","sequences":null,"targets":null,"unii":"832663U2NB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":364.089306372,"volume-of-distribution":null,"route-of-elimination":null,"name":"Apararenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15024"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET\/CT).","enzymes":null,"type":"biotech","cas-number":"1011710-99-8","sequences":null,"targets":null,"unii":"P0I0FT82VK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Girentuximab I-124","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15025"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":327.465,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).","enzymes":null,"type":"small molecule","cas-number":"875685-46-4","sequences":null,"targets":null,"unii":"1N19AGY57Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":327.240958547,"volume-of-distribution":null,"route-of-elimination":null,"name":"CXA-10","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15026"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":262.361,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).","enzymes":null,"type":"small molecule","cas-number":"943057-12-3","sequences":null,"targets":null,"unii":"D65H9YE9VU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":262.190594732,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adriforant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15027"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":461.91,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).","enzymes":null,"type":"small molecule","cas-number":"1207253-08-4","sequences":null,"targets":null,"unii":"O812716S9E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":461.1254672,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-1064","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15028"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":457.478,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).","enzymes":null,"type":"small molecule","cas-number":"1627494-13-6","sequences":null,"targets":null,"unii":"AIQ4OWD0RA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":457.181312623,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-8186","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15029"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GTI-2040 is under investigation in clinical trial NCT00084643 (GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"236391-66-5","sequences":null,"targets":null,"unii":"5WY0FWR2CF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"GTI-2040","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15030"},{"toxicity":"There is limited clinical experience with daridorexant overdose. In clinical pharmacology studies, healthy subjects were administered single doses of up to 200 mg, four times the maximum recommended dose. Somnolence, muscle weakness, cataplexy-like symptoms, sleep paralysis, disturbance in attention, fatigue, headache, and constipation were observed in these patients.\r\n\r\nThere is no specific antidote to overdosage of daridorexant. In the event of an overdose, general symptomatic and supportive medical care, along with immediate gastric lavage where appropriate, should be provided in addition to careful monitoring. Dialysis is unlikely to be effective as daridorexant is highly protein-bound.[L39655]","snp-adverse-drug-reactions":null,"average-mass":450.93,"transporters":null,"pharmacodynamics":"Daridorexant binds to and antagonizes the orexin receptors OX1R and OX2R (Ki = 0.47 and 0.93 nM, respectively) equipotentally.[L39655] In clinical trials, daridorexant improved sleep onset and sleep maintenance, and patient-reported total sleep time. Patient-reported daytime sleepiness was also reportedly reduced.[L39660] At a dose four times the maximum recommended dose, daridorexant does not prolong the QTc interval to any clinically relevant extent.[L39655]\r\n\r\nDaridorexant is currently being assessed for a controlled substance schedule in the US. In a human abuse potential study, daridorexant showed some abuse potential at doses higher than the recommended dose (100-150 mg), indicated by similar \u20ACdrug liking\u20AC ratings to zolpidem (30 mg) and suvorexant in recreational sedative drug users.[L39655] However, at clinically relevant concentrations, daridorexant does not bind to abuse-associated CNS targets.[A244225] In animal studies and clinical trials evaluating physical dependence, chronic administration of daridorexant did not produce withdrawal signs or symptoms upon drug discontinuation, indicating that the drug does not produce physical dependence.[L39655]","msds":null,"description":"Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and\/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression. Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported, such as next-morning residual sleepiness, motor incoordination, falls, memory and cognitive impairment. Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an orexin receptor antagonist that improved sleep. Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity.[A244225] \r\n\r\nDaridorexant works on orexin receptors OX1R and OX2R to block the binding of orexins, which are wake-promoting neuropeptides and endogenous ligands to these receptors. Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia.[A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].[A244280] Daridorexant was approved by the European Commission on May 3, 2022 as the first dual orexin receptor antagonist approved in the market.[L41725]","enzymes":"BE0002638","type":"small molecule","cas-number":"1505484-82-1","sequences":null,"targets":"BE0005865 BE0005864","unii":"LMQ24G57E9","protein-binding":"Daridorexant is 99.7% bound to plasma proteins.[L39655]","fda-label":null,"clearance":"There is limited information on clearance.","atc-codes":null,"pdb-entries":false,"food-interactions":"Avoid alcohol. Concomitant use of alcohol with daridorexant may lead to additive impairment of psychomotor performance and risk of CNS depression .","state":"solid","synthesis-reference":null,"mechanism-of-action":"The sleep and wake cycle is regulated by complex interactions between sleep-promoting systems, including inhibitory GABA activity, and wake-promoting systems, including orexins, acetylcholine and monoaminergic systems.[A244280] Orexin, also called hypocretin, is a wake-promoting neuropeptide produced by a small group of neurons in the lateral hypothalamus.[A244280] Orexin stabilizes wakefulness by activating orexin neurons with the highest activity during active wakefulness and minimal activity during sleep.[A244225] Orexin neurons project to other wake-promoting neurons that also express orexin receptors: these include the histaminergic neurons of the tuberomammillary nucleus, noradrenergic neurons of the locus coeruleus, serotoninergic neurons of the dorsal raphe, dopaminergic neurons of the ventral tegmental area, and cholinergic neurons of the basal forebrain and the pedunculopontine and laterodorsal tegmental nuclei.[A244225] These wake-promoting neurons are part of the ascending reticular activating system that operates under a feedback loop in the sleep and wake cycle.[A244290] \r\n\r\nThere are two identified types of orexin (OXA and OXB) that bind to orexin type 1 and 2 receptors (OX1R and OX2R), which are G-protein coupled receptors. OXA binds more preferentially to OX1R, while OX2R shows a dual affinity for OXA and OXB.[A244290] The defined role of each orexin receptor is still unclear; however, there is some evidence suggesting that OX2R regulates sleep and wake, while OX1R have some role in sleep maintenance.[A244280] Daridorexant blocks the binding of wake-promoting neuropeptides OXA and OXB to OX1R and OX2R, thereby suppressing wake drive.[L39655] Daridorexant selectively targets orexin neurons and inhibits downstream neuronal pathways that promote wakefulness; however, it does not affect neuronal pathways that cause side effects commonly seen in positive allosteric GABA-A receptor modulators.[A244225]","drug-interactions":"DB08953 DB14028 DB12095 DB14719 DB12710 DB14649 DB08329 DB00219 DB00656 DB01560 DB13082 DB13259 DB01545 DB13642 DB13841 DB11552 DB00540 DB06712 DB00737 DB01142 DB06554 DB12184 DB11957 DB13875 DB13695 DB13876 DB01215 DB00387 DB09185 DB05542 DB12193 DB09253 DB01247 DB13505 DB00280 DB01200 DB05232 DB01618 DB13799 DB13252 DB06701 DB01409 DB01337 DB09307 DB13522 DB00395 DB00424 DB01086 DB00962 DB00557 DB01209 DB01595 DB09184 DB11859 DB08922 DB13303 DB00321 DB00810 DB00503 DB13354 DB00732 DB06148 DB13754 DB00220 DB13738 DB01246 DB12338 DB00292 DB00490 DB00475 DB01235 DB01535 DB04908 DB00463 DB01075 DB02234 DB11855 DB09076 DB13534 DB01065 DB00546 DB01558 DB01127 DB01148 DB11901 DB01339 DB01551 DB13948 DB08865 DB13411 DB11823 DB00246 DB01577 DB00777 DB15119 DB00209 DB09190 DB13636 DB00714 DB00543 DB08927 DB13572 DB02520 DB13552 DB04017 DB06690 DB00230 DB00281 DB00268 DB01320 DB13554 DB01323 DB00181 DB13219 DB01495 DB01624 DB04818 DB08839 DB00332 DB13468 DB01062 DB01555 DB12404 DB08811 DB12883 DB01466 DB06529 DB00708 DB13496 DB12229 DB09224 DB01622 DB00370 DB00245 DB09249 DB13787 DB00599 DB13541 DB16021 DB08550 DB00835 DB13837 DB11932 DB05521 DB11951 DB13584 DB00670 DB00391 DB01100 DB13396 DB13253 DB09101 DB00623 DB04868 DB01445 DB04888 DB00607 DB12661 DB06595 DB06119 DB11903 DB06290 DB01202 DB13233 DB14960 DB00906 DB00298 DB00908 DB00402 DB09251 DB00372 DB00091 DB00652 DB08861 DB11889 DB13805 DB09227 DB01107 DB09225 DB11633 DB06582 DB04917 DB01245 DB00614 DB13940 DB01175 DB00866 DB00949 DB00872 DB09194 DB01201 DB00819 DB00662 DB00420 DB00980 DB13323 DB13769 DB09046 DB09300 DB00967 DB12576 DB04821 DB00996 DB12177 DB00476 DB06738 DB11868 DB13014 DB00951 DB12958 DB06448 DB02703 DB00715 DB00327 DB00237 DB00334 DB01156 DB14019 DB12110 DB00648 DB13542 DB08873 DB00899 DB00241 DB13414 DB00468 DB01484 DB00924 DB01626 DB00270 DB00941 DB13662 DB00307 DB13817 DB00753 DB06654 DB01234 DB06155 DB11304 DB11664 DB00582 DB13402 DB06512 DB05227 DB00960 DB00312 DB01359 DB00363 DB08801 DB04871 DB12590 DB08810 DB13687 DB04884 DB00206 DB01534 DB00628 DB00418 DB01231 DB01616 DB00313 DB06201 DB04843 DB00297 DB00193 DB13605 DB06237 DB00416 DB01452 DB11555 DB13782 DB00231 DB00633 DB00937 DB05246 DB01625 DB13737 DB11540 DB00831 DB09068 DB12395 DB13384 DB13454 DB00705 DB00450 DB00617 DB00734 DB01227 DB13784 DB09166 DB00532 DB00224 DB11400 DB00754 DB12273 DB00604 DB05541 DB11582 DB01118 DB00842 DB12427 DB01199 DB11376 DB08986 DB00776 DB08059 DB08910 DB09243 DB12930 DB08960 DB14651 DB00559 DB00454 DB00176 DB09117 DB01104 DB00505 DB00985 DB01161 DB11371 DB11315 DB09250 DB04819 DB13678 DB06283 DB01041 DB11235 DB11730 DB00921 DB09345 DB09021 DB01192 DB05607 DB09009 DB00875 DB00343 DB00496 DB00622 DB00196 DB13114 DB01450 DB08996 DB06446 DB11477 DB13221 DB13588 DB13606 DB11652 DB00474 DB13234 DB00780 DB00690 DB13913 DB01114 DB13213 DB06414 DB00818 DB00377 DB01355 DB00323 DB01026 DB00952 DB13025 DB00849 DB01615 DB13993 DB00555 DB00661 DB09118 DB00423 DB01037 DB11686 DB06787 DB00404 DB01531 DB00502 DB13577 DB00932 DB13733 DB04948 DB00486 DB14881 DB01017 DB00252 DB01511 DB01045 DB00942 DB05077 DB09001 DB08933 DB09245 DB00763 DB00801 DB13550 DB12518 DB04953 DB01063 DB14011 DB01167 DB13335 DB12649 DB01002 DB13254 DB13246 DB00956 DB00745 DB11672 DB01954 DB00660 DB13420 DB13759 DB12308 DB15203 DB00564 DB05667 DB09000 DB00572 DB01501 DB11156 DB01173 DB11581 DB13225 DB13352 DB04833 DB00234 DB09065 DB01105 DB06684 DB08899 DB06144 DB01440 DB13648 DB13256 DB04896 DB00854 DB00843 DB01354 DB09241 DB11609 DB13357 DB13437 DB01587 DB01608 DB01392 DB01232 DB00295 DB13099 DB01263 DB13950 DB14185 DB14043 DB00589 DB00340 DB01211 DB05710 DB00748 DB00904 DB01614 DB12105 DB13666 DB06527 DB12537 DB01563 DB06282 DB08815 DB15569 DB01547 DB09089 DB06016 DB04946 DB14737 DB13070 DB13770 DB11732 DB00215 DB00248 DB01591 DB01601 DB01567 DB13745 DB09011 DB00771 DB13791 DB01072 DB00625 DB00645 DB09048 DB06218 DB12989 DB00751 DB01267 DB00202 DB01154 DB00517 DB01242 DB00679 DB01483 DB06109 DB13455 DB14509 DB13457 DB06660 DB14715 DB08872 DB01236 DB06700 DB00477 DB00889 DB01239 DB11543 DB09085 DB00354 DB06702 DB13448 DB06753 DB00804 DB05687 DB13324 DB00189 DB00565 DB00349 DB04829 DB13520 DB00427 DB12131 DB00150 DB09167 DB00484 DB00296 DB01621 DB01151 DB14921 DB11753 DB12327 DB00725 DB13362 DB09017 DB09247 DB00813 DB00376 DB14672 DB00433 DB09128 DB11779 DB13273 DB06442 DB09254 DB00508 DB01226 DB00752 DB01463 DB00865 DB06691 DB13331 DB01367 DB04841 DB04903 DB08897 DB00494 DB09016 DB00721 DB01106 DB13413 DB00750 DB01186 DB00892 DB04842 DB01442 DB00934 DB09289 DB12278 DB00344 DB00042 DB00579 DB01049 DB09014 DB00757 DB12693 DB13403 DB08992 DB06636 DB01018 DB06579 DB13623 DB00805 DB09223 DB13179 DB01589 DB06797 DB08997 DB14718 DB01565 DB00083 DB01110 DB00747 DB00976 DB04820 DB13598 DB00383 DB00653 DB14010 DB00969 DB14575 DB04832 DB00972 DB04599 DB06204 DB00593 DB11148 DB12111 DB00273 DB06716 DB13583 DB00497 DB01121 DB00483 DB01623 DB08954 DB00829 DB09226 DB00940 DB13295 DB00986 DB11549 DB01176 DB00408 DB00588 DB00696 DB00333 DB00470 DB00832 DB00458 DB00953 DB01221 DB01149 DB11556 DB00537 DB09262 DB13523 DB00392 DB09007 DB00697 DB12554 DB09280 DB01224 DB12492 DB06077 DB06678 DB11428 DB00740 DB00802 DB00356 DB14050 DB00199 DB00765 DB00907 DB01198 DB09071 DB00794 DB01509 DB00527 DB00680 DB01433 DB01036 DB09119 DB13844 DB01351 DB01594 DB01403 DB06288 DB04834 DB12526 DB13601 DB00285 DB00462 DB00514 DB04827 DB01264 DB00434 DB00844 DB08882 DB11642 DB08912 DB01219 DB00574 DB00371 DB01352 DB11755 DB12086 DB04872 DB12093 DB01353 DB02207 DB00347 DB13643 DB12401 DB01489 DB09174 DB00228 DB13665 DB15762 DB09248 DB02852 DB01406 DB06470 DB01028 DB13619 DB00320 DB13380 DB04855 DB01529 DB12725 DB03575 DB13690 DB01454 DB00767 DB13850 DB04836 DB13370 DB01007 DB01174 DB01497 DB11675 DB00318 DB01488 DB00216 DB14568 DB00341 DB00315 DB06216 DB13351 DB00405 DB12465 DB12951 DB01189 DB12361 DB01544 DB04165 DB00933 DB06264 DB09231 DB13377 DB01356 DB00728 DB00850 DB00409 DB06153 DB00961 DB01087 DB00807 DB13160 DB14754 DB00366 DB13720 DB09187 DB09246 DB00283 DB05271 DB00647 DB01588 DB06624 DB12163 DB01069 DB09252 DB11699 DB08883 DB00342 DB00726 DB13382 DB00896 DB06458 DB00897 DB01437 DB06731 DB13872 DB09061 DB00227 DB13557 DB00998 DB14240 DB00673 DB00909 DB00575 DB13500 DB00306 DB00683 DB06770 DB12071 DB00186 DB13984 DB00837 DB01159 DB13581 DB00669 DB00413 DB09244 DB09034 DB01171 DB09186 DB13369 DB01238 DB09023 DB01253 DB09286 DB02959 DB08918 DB01336 DB04325 DB08892 DB15360 DB01338 DB00425 DB01183 DB06594 DB04885 DB05562 DB11130 DB00611 DB13478 DB01559 DB12867 DB01135 DB00247 DB00918 DB01233 DB00856 DB01081 DB01178 DB01553 DB01168 DB09290 DB13676 DB00472 DB09072 DB00898 DB00782 DB13507 DB01080 DB01472 DB00701 DB12833 DB01580 DB15982 DB01068","absorption":"Daridorexant reaches peak plasma concentrations within one to two hours. Daridorexant has an absolute bioavailability of 62%. While a high-fat and high-calorie meal delayed the Tmax by 1.3 hours and decreased the Cmax by 16% in healthy subjects, the total exposure (AUC) was not affected.[L39655]","created":"2019-05-20","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal half-life is approximately 8 hours.[L39655]","monoisotopic-mass":450.1571017,"volume-of-distribution":"Daridorexant has a volume of distribution of 31 L. The blood to plasma ratio is 0.64.[L39655] It effectively passes the blood-brain barrier.[A244225]","route-of-elimination":"The primary route of excretion is via feces, accounting for approximately 57% of drug excretion. About 28% of the drug is excreted via urine primarily in the form of metabolites. Trace amounts of the parent drug were found in feces and urine.[L39655]","name":"Daridorexant","metabolism":"Daridorexant undergoes extensive metabolism primarily mediated by CYP3A4 (89%),[L39655] mostly via oxidative transformations.[A244285] Other CYP enzymes individually contribute to less than 3% of metabolic clearance of daridorexant.[L39655]","reactions":null,"indication":"In the US and Europe, daridorexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and\/or sleep maintenance.[L39655] The European prescribing information states that insomnia should be characterized by symptoms that are present for at least 3 months and considerable impact on daytime functioning.[L41720]","ahfs-codes":null,"updated":"2022-06-01","drugbank-id":"DB15031"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb5871 in Patients With Systemic Lupus Erythematosus).","enzymes":null,"type":"biotech","cas-number":"1690307-05-1","sequences":null,"targets":null,"unii":"RM16A4BA8R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Obexelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15032"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":263.275,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flortaucipir is under investigation in clinical trial NCT03507257 (Longitudinal Early-onset Alzheimer's Disease Study Protocol).","enzymes":null,"type":"small molecule","cas-number":"1415379-56-4","sequences":null,"targets":null,"unii":"J09QS3Z3WB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":263.085875497,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flortaucipir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15033"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":658.652,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).","enzymes":null,"type":"small molecule","cas-number":"1198780-38-9","sequences":null,"targets":null,"unii":"43Y934BBZ6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":658.230484489,"volume-of-distribution":null,"route-of-elimination":null,"name":"PRI-724","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15034"},{"toxicity":"There is limited data on zanubrutinib overdose.","snp-adverse-drug-reactions":null,"average-mass":471.561,"transporters":"BE0001032","pharmacodynamics":"Zanubrutinib is an immunomodulating agent that decreases the survival of malignant B cells. It inhibits BTK by binding to its active site. It works to inhibit the proliferation and survival of malignant B cells to reduce the tumour size in mantle cell lymphoma.[L10163]","msds":null,"description":"Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[L10163] Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma that is associated with early relapse, poor clinical outcomes, and long-term survival.[A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, where it promotes the survival and proliferation of malignant B cells.[A187985] Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects.[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.\r\n\r\nZanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.[L10169] It is currently marketed under the trade name BRUKINSA\u201E and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenstrm\u20ACs macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.[L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.[L39025] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukaemia.[L43737]","enzymes":"BE0002638 BE0003549 BE0004866","type":"small molecule","cas-number":"1691249-45-2","sequences":null,"targets":"BE0000511 BE0004772 BE0009416 BE0009413 BE0003493 BE0000767 BE0001284 BE0002408 BE0009403 BE0000842 BE0009385 BE0001341 BE0004742 BE0004731 BE0005539","unii":"AG9MHG098Z","protein-binding":"The plasma protein binding of zanubrutinib is approximately 94%.[L10163]","fda-label":null,"clearance":"The mean (%CV) apparent oral clearance (CL\/F) of zanubrutinib is 182 (37%) L\/h.[L10163]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Bruton's tyrosine kinase (BTK) inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":null,"food-interactions":"Take with or without food. Food does not significantly affect drug concentrations. Take with a full glass of water. Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of zanubrutinib. Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of zanubrutinib. Dose adjustment may be necessary if coadministered.","state":"solid","synthesis-reference":"Guo Y, Liu Y, Hu N, et al. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton\u20ACs Tyrosine Kinase. JOURNAL OF MEDICINAL CHEMISTRY. 62(17):7923-7940. doi:10.1021\/acs.jmedchem.9b00687.","mechanism-of-action":"Bruton's tyrosine kinase (BTK) is a non-receptor kinase and a signalling molecule for the B cell receptors expressed on the peripheral B cell surface.[A187985] The BCR signalling pathway plays a crucial role in normal B-cell development but also the proliferation and survival of malignant B cells in many B cell malignancies, including mantle-cell lymphoma (MCL).[A187985,A187958] Once activated by upstream Src-family kinases, BTK phosphorylates phospholipase-C (PLC), leading to Ca2+ mobilization and activation of NF-B and MAP kinase pathways. These downstream cascades promote the expression of genes involved in B cell proliferation and survival.[A187952] The BCR signalling pathway also induces the anti-apoptotic protein Bcl-xL and regulates the integrin 41 (VLA-4)-mediated adhesion of B cells to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin via BTK. Apart from the direct downstream signal transduction pathway of B cells, BTK is also involved in chemokine receptor, Toll-like receptor (TLR) and Fc receptor signalling pathways.[A187985] \r\n\r\nZanubrutinib inhibits BTK by forming a covalent bond with cysteine 481 residue in the adenosine triphosphate (ATP)\u20AC\u201Cbinding pocket of BTK, which is the enzyme's active site. This binding specificity is commonly seen with other BTK inhibitors. Due to this binding profile, zanubrutinib may also bind with varying affinities to related and unrelated ATP-binding kinases that possess a cysteine residue at this position.[A187958] By blocking the BCR signalling pathway, zanubrutinib inhibits the proliferation, trafficking, chemotaxis, and adhesion of malignant B cells, ultimately leading to reduced tumour size.[L10163] Zanubrutinib was also shown to downregulate programmed death-ligand 1 (PD-1) expression and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) on CD4+ T cells.[A187949]","drug-interactions":"DB01873 DB11459 DB00682 DB14652 DB08953 DB12095 DB13456 DB14649 DB13259 DB00916 DB15673 DB06712 DB00637 DB12130 DB12020 DB00814 DB09185 DB00338 DB14633 DB00845 DB05232 DB11921 DB00957 DB01086 DB01229 DB12235 DB00321 DB00503 DB06148 DB12952 DB00220 DB13843 DB09030 DB05316 DB13867 DB01075 DB00531 DB08970 DB12825 DB00769 DB01127 DB11901 DB08865 DB00741 DB01039 DB11823 DB00246 DB13208 DB01381 DB09383 DB05814 DB00714 DB00778 DB00481 DB00301 DB00238 DB02520 DB05676 DB06739 DB00959 DB08820 DB11703 DB00281 DB01320 DB00136 DB00834 DB13943 DB01323 DB01319 DB13578 DB14659 DB01259 DB09074 DB01624 DB06717 DB04938 DB13409 DB01062 DB09299 DB13954 DB01466 DB14009 DB13879 DB12332 DB00370 DB14635 DB00012 DB00835 DB11932 DB11742 DB13287 DB11951 DB01281 DB00758 DB05521 DB11502 DB01100 DB06233 DB09101 DB00607 DB04868 DB08881 DB00549 DB06595 DB06119 DB06290 DB14960 DB01184 DB00908 DB06616 DB00091 DB09227 DB11633 DB08894 DB11613 DB14540 DB00180 DB00949 DB06589 DB00872 DB01201 DB08870 DB00819 DB09046 DB01015 DB08906 DB01152 DB16390 DB05928 DB09238 DB06738 DB00668 DB09107 DB00951 DB04839 DB06448 DB12015 DB02703 DB00586 DB00715 DB11952 DB01156 DB14019 DB00648 DB08873 DB09309 DB00241 DB00468 DB01333 DB00270 DB12010 DB00641 DB13955 DB00307 DB01093 DB00753 DB01234 DB02709 DB00582 DB15463 DB00312 DB00363 DB00316 DB04871 DB01435 DB09063 DB04884 DB00418 DB00313 DB06201 DB00297 DB00193 DB08905 DB06237 DB11757 DB00568 DB13874 DB09068 DB15444 DB00705 DB06663 DB00624 DB00532 DB00224 DB11400 DB00394 DB00604 DB00065 DB05541 DB12532 DB01118 DB12089 DB08904 DB00776 DB03010 DB00559 DB11886 DB12917 DB00454 DB00176 DB01104 DB01161 DB11383 DB12391 DB01095 DB11730 DB00921 DB09345 DB09009 DB00343 DB00622 DB00196 DB11560 DB06372 DB09342 DB00590 DB01181 DB11652 DB00812 DB13345 DB00379 DB06414 DB01384 DB00591 DB00818 DB11470 DB01275 DB01026 DB09095 DB06168 DB01248 DB00615 DB00849 DB00717 DB01037 DB08909 DB00661 DB09118 DB13683 DB11697 DB00502 DB00932 DB00252 DB01045 DB09001 DB01047 DB00763 DB14761 DB00353 DB01016 DB13956 DB01011 DB06318 DB01167 DB13953 DB00619 DB01071 DB01002 DB05239 DB13385 DB00603 DB14545 DB00518 DB00956 DB00745 DB11672 DB15566 DB05667 DB00564 DB00398 DB00330 DB01173 DB11581 DB08864 DB09065 DB08899 DB07348 DB13003 DB13944 DB06469 DB04896 DB11752 DB04905 DB09241 DB14724 DB01587 DB01232 DB13950 DB01263 DB00636 DB00755 DB04956 DB01609 DB09235 DB06791 DB08995 DB01211 DB14681 DB00675 DB01029 DB01369 DB00954 DB15569 DB01431 DB14737 DB00215 DB01601 DB01072 DB06774 DB06218 DB00625 DB09048 DB00645 DB00751 DB01154 DB01254 DB01483 DB00357 DB00485 DB01380 DB01656 DB01236 DB06700 DB00477 DB00208 DB09330 DB06413 DB01685 DB09085 DB12597 DB11487 DB00349 DB00997 DB11805 DB09167 DB00296 DB01151 DB14921 DB11753 DB01138 DB00443 DB05903 DB11405 DB04975 DB06442 DB11779 DB00694 DB00865 DB00864 DB00446 DB13328 DB06273 DB00721 DB14975 DB14631 DB00750 DB00892 DB00627 DB01013 DB00104 DB06636 DB08971 DB01043 DB01589 DB13179 DB01110 DB08987 DB06176 DB09054 DB14512 DB00976 DB13132 DB09308 DB14575 DB00860 DB04832 DB00016 DB11148 DB00273 DB04070 DB00051 DB04911 DB11442 DB00163 DB01098 DB00207 DB00567 DB00197 DB09073 DB00588 DB00696 DB00333 DB00026 DB00470 DB00458 DB01221 DB11586 DB12265 DB05154 DB01149 DB00537 DB06729 DB09280 DB15011 DB13338 DB00759 DB09071 DB00199 DB00907 DB06697 DB00794 DB00527 DB09079 DB01222 DB09119 DB14539 DB01351 DB00857 DB15434 DB11963 DB01264 DB12371 DB14646 DB11642 DB08912 DB08882 DB00444 DB00574 DB01352 DB08816 DB00570 DB15762 DB01128 DB00041 DB01406 DB06470 DB01028 DB09036 DB06710 DB04794 DB00320 DB04855 DB09099 DB01395 DB03575 DB00530 DB01007 DB01174 DB00678 DB06268 DB14568 DB04920 DB04894 DB01285 DB11767 DB05482 DB13952 DB01544 DB12070 DB01032 DB00439 DB13941 DB09231 DB12515 DB09029 DB01764 DB00961 DB00764 DB01087 DB00807 DB12245 DB00647 DB06674 DB06370 DB01069 DB00501 DB06209 DB06419 DB08883 DB00342 DB06458 DB00400 DB06731 DB06174 DB12266 DB00227 DB09061 DB14240 DB00620 DB16236 DB00673 DB03255 DB00683 DB06770 DB00243 DB01645 DB14669 DB06587 DB01159 DB09034 DB09499 DB08827 DB01628 DB00184 DB04572 DB01183 DB12141 DB00762 DB01559 DB11837 DB00247 DB06342 DB00255 DB01074 DB15822 DB12887 DB00515 DB00472 DB00898 DB00533 DB00701 DB00005 DB15982 DB01388 DB11273","absorption":"Following oral administration of zanubrutinib 160 mg twice daily and 320 mg once daily, the mean (%CV) zanubrutinib steady-state concentrations were 2,295 (37%) ngh\/mL and 2,180 (41%) ngh\/mL, respectively. The mean Cmax (%CV) was 314 (46%) ng\/mL following 160 mg twice daily and 543 (51%) ng\/mL following 320 mg once daily.[L10163] \r\n\r\nThe Cmax and AUC of zanubrutinib increase in a dose-proportional manner and there is minimal systemic accumulation after repeated dosing. The median Tmax is 2 hours.[L10163]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Following administration of a single oral dose of 160 mg or 320 mg of zanubrutinib, the mean half-life is approximately 2 to 4 hours.[L10163]","monoisotopic-mass":471.227039814,"volume-of-distribution":"The geometric mean (%CV) apparent steady-state Vd is 881 (95%) L. The blood-to plasma ratio is about 0.7 to 0.8.[L10163]","route-of-elimination":"Following oral administration of 320 mg radiolabelled zanubrutinib, approximately 87% of the dose was excreted in the feces and about 8% of the dose was recovered in the urine, where less than 1% of the recovered drug comprised of unchanged parent drug.[L10163]","name":"Zanubrutinib","metabolism":"Zanubrutinib is predominantly metabolized by CYP3A4.[L10163] Its metabolites have not been characterized.","reactions":null,"indication":"Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[L10163, L40788]\r\n\r\nIt is used to treat Waldenstrm\u20ACs macroglobulinemia in adults.[L10163, L40788]\r\n\r\nZanubrutinib is also indicated for the treatment of relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen.[L10163, L40788]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15035"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":629.68,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).","enzymes":null,"type":"small molecule","cas-number":"1123837-84-2","sequences":null,"targets":null,"unii":"CWG62Q1VTB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":629.190831934,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sitravatinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15036"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).","enzymes":null,"type":"small molecule","cas-number":"26811-96-1","sequences":null,"targets":null,"unii":"W92NDP347A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Poly(lactic acid)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15037"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":241.334,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).","enzymes":null,"type":"small molecule","cas-number":"86811-09-8","sequences":null,"targets":null,"unii":"9980ST005G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":241.146664236,"volume-of-distribution":null,"route-of-elimination":null,"name":"Litoxetine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15038"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":507.573,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).","enzymes":null,"type":"small molecule","cas-number":"1160521-50-5","sequences":null,"targets":null,"unii":"3GBO34D1BE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":507.218286648,"volume-of-distribution":null,"route-of-elimination":null,"name":"ITI-214","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15039"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":558.563,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).","enzymes":null,"type":"small molecule","cas-number":"1207284-17-0","sequences":null,"targets":null,"unii":"Y6IUM7395Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":558.212592137,"volume-of-distribution":null,"route-of-elimination":null,"name":"TP-271","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15040"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":206.204,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Florilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).","enzymes":null,"type":"small molecule","cas-number":"1196963-74-2","sequences":null,"targets":null,"unii":"92T1Y5X038","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":206.093220602,"volume-of-distribution":null,"route-of-elimination":null,"name":"Florilglutamic acid F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15041"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tavolixizumab is under investigation in clinical trial NCT02318394 (A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1635395-25-3","sequences":null,"targets":null,"unii":"4LU9B48U4D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tavolixizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15042"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).","enzymes":null,"type":"biotech","cas-number":"1924598-82-2","sequences":null,"targets":"BE0003436","unii":"8JXN261VVA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Toripalimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15043"},{"toxicity":"Data regarding overdose of tafasitamab are unavailable. Symptoms of overdosage are likely to be consistent with its adverse effect profile, and may therefore involve significant infusion-related reactions and\/or myelosuppression.[L15292]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Tafasitamab induces a reduction in circulating B-cell counts by binding to a surface antigen, CD19, which is important for their survival.[L15302] Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) experienced a 97% reduction in peripheral blood B-cell counts following 8 days of treatment, with a 100% reduction reached within 16 weeks of treatment.[L15292]\r\n\r\nTafasitamab can cause infusion-related reactions, particularly during the initial cycles of therapy. Symptoms may include chills, flushing, dyspnea, and hypertension. Patients may be administered premedications (such as [acetaminophen], antihistamines, or glucocorticoids) 0.5 - 2 hours prior to infusion to minimize infusion-related reactions.[L15292] Tafasitamab may also cause significant myelosuppression, and subsequent infection, due to its mechanism of action - patients should undergo monitoring throughout therapy for signs of myelosuppression and\/or infection.[L15292]","msds":null,"description":"Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.[L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1\/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.[L15292,A191829]\r\n\r\nThe CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.[L15302] Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes,[L15292] as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL))[L15302] has made it a desirable target in the treatment these B-cell malignancies. Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant).[L15292]\r\n\r\nHaving previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,[A191829] tafasatimab-cxix (Monjuvi) received an accelerated approval on July 31st, 2020, for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants.[L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292]","enzymes":null,"type":"biotech","cas-number":"1422527-84-1","sequences":null,"targets":"BE0003496","unii":"QQA9MLH692","protein-binding":null,"fda-label":null,"clearance":"The clearance of tafasitamab is approximately 0.41 L\/day.[L15292]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":" \u20AC, \u2022\u201C\u2022\u201E \u20AC, \u2039 \u2014, \u2039\u2039\u2014 \u201D\u201E, \u201E . Anti-CD19 antibody preparation. South Korean Patent KR20190021373A. Published March 5, 2019.","mechanism-of-action":"The CD19 surface antigen is a protein expressed on the surface of pre-B and mature B-lymphocytes[L15292] that appears to play a role in enhancing B-cell receptor signaling and is considered integral to their survival.[L15302] These surface proteins are also highly expressed on several B-cell malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and diffuse large B-cell lymphoma (DLBCL).[L15302]\r\n\r\nTafasitamab is a CD19-directed cytolytic monoclonal antibody that, upon binding and blocking the activity of CD19, causes lysis of B-cells. This process is mediated through both direct apoptosis and immune-mediated effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).[L15292]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB09107 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB14947 DB09085 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"Following intravenous administration of tafasitamab 12 mg\/kg on Days 1, 8, 15, and 22 in cycle(s) 1-3 (with an additional dose on Day 4 of cycle 1), mean trough concentrations were 179 ( 53) g\/mL. From cycle 4 onwards, which involve the administration of tafasitamab 12 mg\/kg on Days 1 and 15, mean trough concentrations were 153 ( 68) g\/mL.[L15292]\r\n\r\nThe overall maximum tafasitamab serum concentrations reached were 483 ( 109) g\/mL.[L15292]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal elimination half-life of tafasitamab is approximately 17 days.[L15292]","monoisotopic-mass":null,"volume-of-distribution":"The total volume of distribution of tafasitamab following intravenous injection is approximately 9.3 L.[L15292]","route-of-elimination":"Monoclonal antibodies are typically eliminated via uptake into cells and subsequent catabolism via lysosomal degradation. Due to their large size, they are only eliminated renally under pathologic conditions.[A216712]","name":"Tafasitamab","metabolism":"The biotransformation of tafasitamab has not been elucidated. Most monoclonal antibodies undergo intracellular catabolism via lysosomal degradation to smaller amino acids and peptides.[A19126,A216712]","reactions":null,"indication":"Tafasitamab is indicated, in combination with [lenalidomide], for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified whom are ineligible for autologous stem cell transplant (ASCT).[L15292]","ahfs-codes":null,"updated":"2022-04-01","drugbank-id":"DB15044"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1391727-24-4","sequences":null,"targets":null,"unii":"2N71QUE3NL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ipafricept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15045"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":491.631,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).","enzymes":null,"type":"small molecule","cas-number":"1292290-38-0","sequences":null,"targets":null,"unii":"LAD0ZG7FFO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":491.246043927,"volume-of-distribution":null,"route-of-elimination":null,"name":"LY-2881835","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15046"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":468.54,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).","enzymes":null,"type":"small molecule","cas-number":"1272353-82-8","sequences":null,"targets":null,"unii":"NGB50MQK8N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":468.136845082,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-919373","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15047"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":416.47,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity).","enzymes":null,"type":"small molecule","cas-number":"1291094-73-9","sequences":null,"targets":null,"unii":"57J06X6EI0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":416.183503242,"volume-of-distribution":null,"route-of-elimination":null,"name":"Licogliflozin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15048"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":397.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sucralose is an artificial sweetener used as a sugar substitute.","enzymes":null,"type":"small molecule","cas-number":"56038-13-2","sequences":null,"targets":null,"unii":"96K6UQ3ZD4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":396.0145507,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sucralose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-03","drugbank-id":"DB15049"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":253.2147,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Neopterin is under investigation in clinical trial NCT02974192 (Neopterin Effects on Ischemic Stroke).","enzymes":null,"type":"small molecule","cas-number":"2009-64-5","sequences":null,"targets":null,"unii":"9PLD60N7SO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":253.081103865,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neopterin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-29","drugbank-id":"DB15050"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":422.226,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ethaselen is under investigation in clinical trial NCT02166242 (Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers).","enzymes":null,"type":"small molecule","cas-number":"217798-39-5","sequences":null,"targets":null,"unii":"4Q2EZS1IWG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06210","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":423.922922,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ethaselen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15051"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":381.516,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ansofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).","enzymes":null,"type":"small molecule","cas-number":"916918-80-4","sequences":null,"targets":null,"unii":"A7CGH459FN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":381.230393862,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ansofaxine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15052"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies).","enzymes":null,"type":"biotech","cas-number":"2209911-94-2","sequences":null,"targets":null,"unii":"V860J30J9N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lintuzumab satetraxetan AC-225","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15053"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":424.504,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TAS-117 is under investigation in clinical trial NCT03017521 (K-BASKET, TAS-117, PI3K\/AKT Gene Aberration).","enzymes":null,"type":"small molecule","cas-number":"1402602-94-1","sequences":null,"targets":null,"unii":"QI52W1ZIIB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":424.189926029,"volume-of-distribution":null,"route-of-elimination":null,"name":"TAS-117","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15054"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":455.9,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).","enzymes":null,"type":"small molecule","cas-number":"1235560-28-7","sequences":null,"targets":null,"unii":"0G7D0CQ88I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":455.0881967,"volume-of-distribution":null,"route-of-elimination":null,"name":"ABT-639","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15055"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":422.87,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).","enzymes":null,"type":"small molecule","cas-number":"82657-04-3","sequences":null,"targets":null,"unii":"6B66JED0KN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":422.1260421,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bifenthrin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15056"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":580.482,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).","enzymes":null,"type":"small molecule","cas-number":"840506-29-8","sequences":null,"targets":null,"unii":"XCL1K2T28K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":580.153457169,"volume-of-distribution":null,"route-of-elimination":null,"name":"NUC-1031","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15057"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":274.31,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).","enzymes":null,"type":"small molecule","cas-number":"637003-10-2","sequences":null,"targets":null,"unii":"0F3M7032P5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":274.057612319,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flutemetamol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15058"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":546.19,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).","enzymes":null,"type":"small molecule","cas-number":"1103522-45-7","sequences":null,"targets":null,"unii":"MZI81HV01P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":543.9164,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aprocitentan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15059"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lefitolimod is under investigation in clinical trial NCT03837756 (Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV).","enzymes":null,"type":"biotech","cas-number":"1548439-51-5","sequences":null,"targets":null,"unii":"6SO72A12FN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lefitolimod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15061"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":587.5,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).","enzymes":null,"type":"small molecule","cas-number":"475650-36-3","sequences":null,"targets":null,"unii":"TQ0A9FIV71","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":587.119948237,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inarigivir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15062"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":703.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).","enzymes":null,"type":"small molecule","cas-number":"942123-43-5","sequences":null,"targets":null,"unii":"365052M0DK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":703.167292355,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inarigivir soproxil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15063"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).","enzymes":null,"type":"biotech","cas-number":"1231737-88-4","sequences":null,"targets":null,"unii":"O03W5S19PJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Teprasiran","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15064"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":503.522,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).","enzymes":null,"type":"small molecule","cas-number":"1393124-08-7","sequences":null,"targets":null,"unii":"CGY4I8F278","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":503.203190883,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06291874","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15065"},{"toxicity":"Little information is currently available regarding the toxicity of givosiran. Weekly subcutaneous dosing of up to 30 mg\/kg in both female and male rats resulted in no apparent effects on fertility or reproductive function.[L10202]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Givosiran decreases the rate at which toxic byproducts of heme synthesis are produced in the livers of patients with acute hepatic porphyria, thus preventing their accumulation and associated neuro-, nephro-, and gastrotoxicity.[L10202,A187988] As givosiran works at the transcriptional level, it has a long duration of action and can be administered subcutaneously on a monthly basis. Although givosiran appears to be relatively well-tolerated, hepatic and renal toxicity were noted during clinical trials. Patients receiving therapy with givosiran should undergo routine laboratory monitoring of liver and kidney function.[L10202]","msds":null,"description":"Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway.[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity.[L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases.[A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.","enzymes":null,"type":"biotech","cas-number":"1639325-43-1","sequences":null,"targets":"BE0009790","unii":"ROV204583W","protein-binding":"Plasma protein binding is inversely proportional to givosiran concentration, ranging from 92% at 1 g\/mL to 21% at 50 g\/mL.[L10202] The specific plasma protein to which givosiran is bound is unclear.","fda-label":null,"clearance":"The apparent clearance of givosiran is 35.1 L\/hr.[L10202]","atc-codes":"OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS ALIMENTARY TRACT AND METABOLISM Various alimentary tract and metabolism products","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda, \"Compositions and methods for inhibiting expression of the ALAS1 gene.\" US Patent US10119143B2, issued November, 2018.","mechanism-of-action":"Acute hepatic porphyrias are a class of genetic disorders involving deficiencies in the pathway responsible for heme synthesis in liver hepatocytes.[A187988] The rate-limiting step in heme synthesis is the first enzyme in the pathway, 5-aminolevulinic acid synthase (ALAS1), which is controlled via a negative feedback loop by the presence of heme end-product in the liver.[A187988] Deficiencies in later enzymes in the pathway result in low circulating levels of heme, which in turn stimulates the up-regulation of ALAS1. The overexpression of ALAS1, in combination with downstream enzyme deficiencies, leads to the overproduction and accumulation of toxic heme intermediates which are ultimately responsible for the neurovisceral symptoms characteristic of acute hepatic porphyrias.[L10202,A187988]\r\n\r\nGivosiran is a double-stranded small interfering RNA (siRNA) directed at ALAS1 mRNA in hepatocytes.[L10202] It is covalently bound to a ligand containing three N-acetylgalactosamine (GalNAc) residues that facilitate uptake into hepatocytes via asialoglycoprotein receptors (ASPGRs), which are highly expressed on the cell surface of hepatocytes and are selective for glycoproteins containing GalNAc residues.[F4727] Following endocytosis into hepatocytes, the antisense strand of givosiran is loaded into an enzyme complex called the RNA-induced silencing complex (RISC), which uses the antisense strand to seek out and selectively cleave the complementary mRNA sequence (in this case found between nucleotide 918 and 937 of the ALAS1 mRNA).[F4727] Cleavage of the ALAS1 mRNA results in its degradation, preventing the synthesis of the ALAS1 enzyme and ultimately leading to reduced circulating levels of neurotoxic heme intermediates.","drug-interactions":"DB13821 DB01345 DB00328 DB00682 DB00928 DB00887 DB00742 DB06196 DB00656 DB06255 DB06737 DB00382 DB09570 DB00540 DB00737 DB09205 DB01142 DB09217 DB06823 DB00637 DB01066 DB06230 DB06696 DB04951 DB00814 DB01215 DB11085 DB09185 DB12978 DB00558 DB09209 DB09273 DB12945 DB14006 DB00280 DB05708 DB00642 DB14132 DB08437 DB00800 DB13286 DB13432 DB01409 DB06228 DB09257 DB01223 DB12604 DB00605 DB01086 DB00962 DB09325 DB01327 DB00277 DB09195 DB06796 DB08984 DB08922 DB11520 DB06154 DB00583 DB00321 DB00503 DB11919 DB00863 DB06148 DB01129 DB06211 DB01140 DB06705 DB00665 DB01020 DB09351 DB00292 DB06767 DB06506 DB01067 DB00806 DB00490 DB01124 DB01075 DB06217 DB00798 DB11855 DB00535 DB00631 DB01273 DB09076 DB01065 DB01558 DB08932 DB00853 DB01148 DB09050 DB11901 DB01551 DB00492 DB00390 DB13266 DB13203 DB00839 DB01039 DB01295 DB01421 DB12161 DB01577 DB13293 DB04846 DB09082 DB09111 DB00592 DB00787 DB04356 DB00238 DB00543 DB00851 DB08807 DB05676 DB00230 DB00281 DB00268 DB00773 DB13943 DB04828 DB00181 DB09062 DB09481 DB00684 DB01249 DB01610 DB01624 DB09546 DB11367 DB11114 DB00945 DB09081 DB00440 DB00820 DB09299 DB06402 DB06813 DB13954 DB01466 DB00017 DB00577 DB00274 DB12332 DB01240 DB09224 DB00370 DB00245 DB01274 DB01046 DB13145 DB00731 DB11979 DB09084 DB04817 DB00758 DB01191 DB01100 DB00553 DB00630 DB05095 DB01035 DB01082 DB00871 DB09394 DB00438 DB09132 DB00447 DB00788 DB00939 DB00552 DB06479 DB01182 DB14018 DB01184 DB13167 DB00402 DB00775 DB00908 DB00733 DB00372 DB06262 DB09210 DB00718 DB00738 DB00091 DB12406 DB03615 DB00529 DB09225 DB06725 DB06292 DB00351 DB09496 DB01331 DB12545 DB00612 DB09013 DB09265 DB00598 DB08894 DB11689 DB00710 DB00866 DB00299 DB01175 DB09320 DB06589 DB09194 DB00841 DB00749 DB13595 DB08955 DB13612 DB00420 DB00980 DB01397 DB13461 DB01015 DB01410 DB00983 DB14529 DB00203 DB00213 DB00476 DB01150 DB06695 DB09136 DB01139 DB08952 DB14713 DB00951 DB00789 DB09220 DB02703 DB00586 DB00327 DB00715 DB13667 DB11102 DB00237 DB13573 DB00784 DB00334 DB01156 DB00720 DB11121 DB13504 DB05018 DB00977 DB00468 DB00924 DB01333 DB09133 DB00270 DB00993 DB00641 DB00915 DB13955 DB09488 DB09149 DB00629 DB00165 DB01093 DB01326 DB00007 DB01137 DB09477 DB11127 DB11364 DB12026 DB00706 DB01241 DB13217 DB09103 DB02134 DB01283 DB00695 DB00960 DB00674 DB00452 DB00312 DB00635 DB00781 DB00363 DB01094 DB01412 DB01359 DB01638 DB00316 DB04871 DB00355 DB01435 DB09183 DB00206 DB00294 DB04884 DB00628 DB00418 DB04930 DB00884 DB00297 DB09121 DB00193 DB08905 DB09318 DB00722 DB09288 DB09204 DB00936 DB01416 DB00231 DB04890 DB06203 DB00999 DB00456 DB00633 DB00894 DB11757 DB09053 DB04918 DB11090 DB00568 DB09218 DB13524 DB13874 DB06736 DB13407 DB00831 DB09068 DB03585 DB00705 DB00783 DB13649 DB00432 DB00469 DB00955 DB01195 DB00734 DB00903 DB05109 DB00624 DB14059 DB11136 DB00532 DB15593 DB01097 DB13449 DB01550 DB00479 DB00861 DB13371 DB00988 DB05541 DB00842 DB04840 DB01112 DB08904 DB08910 DB09502 DB00828 DB00569 DB00454 DB00176 DB01104 DB00500 DB11718 DB01095 DB01170 DB00401 DB01438 DB00923 DB00921 DB09555 DB00035 DB08824 DB01058 DB01192 DB01418 DB01111 DB14007 DB00201 DB00343 DB09215 DB01157 DB00496 DB00196 DB11560 DB06735 DB08996 DB00396 DB00430 DB09407 DB08840 DB13178 DB14530 DB00590 DB01181 DB00803 DB00158 DB00780 DB00690 DB00978 DB00833 DB00812 DB00339 DB00379 DB01114 DB08893 DB11098 DB06608 DB00591 DB00377 DB04729 DB01275 DB00323 DB11512 DB12212 DB09095 DB13025 DB01099 DB00811 DB00555 DB00626 DB13499 DB08909 DB00661 DB13884 DB01037 DB01303 DB09118 DB00289 DB00404 DB13775 DB13679 DB09357 DB04889 DB00502 DB01213 DB09295 DB00932 DB00651 DB00692 DB09395 DB01250 DB04948 DB14881 DB00252 DB06235 DB01244 DB09245 DB00763 DB12615 DB00689 DB00493 DB01133 DB04953 DB13956 DB01011 DB00195 DB01056 DB13953 DB00384 DB13538 DB00619 DB01405 DB09317 DB01002 DB01071 DB00603 DB13001 DB00518 DB00956 DB09277 DB04570 DB00290 DB00322 DB00660 DB00264 DB00564 DB00188 DB00398 DB11156 DB00330 DB12531 DB08439 DB13269 DB00713 DB13634 DB01105 DB06684 DB08899 DB06144 DB13944 DB01050 DB04896 DB01193 DB04905 DB00229 DB09163 DB09241 DB00182 DB00843 DB08981 DB01587 DB00412 DB01392 DB11614 DB00597 DB01482 DB09292 DB00442 DB00911 DB11338 DB09418 DB14185 DB00589 DB01166 DB13470 DB00675 DB00200 DB00904 DB13657 DB01611 DB01563 DB06282 DB12107 DB00441 DB11135 DB00373 DB11935 DB00709 DB00480 DB09089 DB01431 DB00699 DB04946 DB01060 DB13156 DB00215 DB06626 DB01591 DB01601 DB14527 DB13544 DB01072 DB00672 DB06774 DB00625 DB01212 DB09048 DB01009 DB08907 DB00751 DB01267 DB00580 DB01576 DB09106 DB11943 DB14509 DB01242 DB01254 DB00679 DB00267 DB08872 DB01169 DB01656 DB11598 DB01420 DB13778 DB06700 DB00477 DB06480 DB00282 DB00014 DB09148 DB00198 DB08940 DB06210 DB01685 DB00208 DB06702 DB00335 DB00804 DB00681 DB00573 DB00349 DB01394 DB09134 DB04829 DB15561 DB09167 DB00296 DB01022 DB14498 DB13682 DB01621 DB13873 DB01151 DB00554 DB01332 DB06335 DB04626 DB00698 DB00190 DB11455 DB11817 DB00364 DB00813 DB00461 DB14499 DB09129 DB11577 DB00433 DB01255 DB09128 DB12007 DB00300 DB09027 DB01048 DB09264 DB03783 DB00864 DB01367 DB04841 DB09212 DB01024 DB08897 DB13638 DB00688 DB13592 DB00808 DB00325 DB00185 DB00319 DB01427 DB00934 DB04743 DB12278 DB01172 DB00716 DB06815 DB00544 DB00757 DB00261 DB01297 DB00465 DB00317 DB14126 DB01018 DB11466 DB08942 DB01043 DB09165 DB09223 DB00805 DB13812 DB02568 DB09075 DB00115 DB11691 DB13757 DB00994 DB04895 DB14010 DB00969 DB00972 DB06726 DB13527 DB04076 DB13232 DB00273 DB13481 DB00900 DB09344 DB13946 DB00497 DB14507 DB01623 DB00829 DB09216 DB02489 DB09156 DB00521 DB00244 DB09472 DB00567 DB11915 DB07402 DB11251 DB13139 DB00333 DB01177 DB09301 DB00369 DB11358 DB04844 DB00958 DB00286 DB01203 DB11989 DB00458 DB01399 DB00953 DB01328 DB01221 DB12783 DB11586 DB12265 DB01149 DB00080 DB00537 DB01004 DB06637 DB09255 DB09262 DB01429 DB00730 DB00331 DB06186 DB09008 DB00437 DB06623 DB04808 DB09091 DB00697 DB09219 DB01224 DB00254 DB13540 DB06678 DB00740 DB11145 DB01001 DB11587 DB00759 DB00356 DB00499 DB09071 DB13629 DB00399 DB00380 DB11518 DB01036 DB01222 DB00303 DB01330 DB01403 DB00995 DB00857 DB00187 DB01210 DB13783 DB09276 DB00285 DB00514 DB11963 DB09214 DB14526 DB11785 DB09137 DB09324 DB00512 DB00571 DB00608 DB11642 DB09329 DB09104 DB00574 DB00482 DB09139 DB09039 DB09338 DB08934 DB13909 DB01228 DB13443 DB13191 DB01205 DB00041 DB09066 DB00744 DB01028 DB08901 DB00359 DB06710 DB08808 DB04861 DB01419 DB13860 DB01030 DB00489 DB01667 DB01077 DB00657 DB11278 DB01454 DB01014 DB00982 DB06590 DB00530 DB12752 DB00563 DB03450 DB00314 DB01413 DB08877 DB08911 DB00655 DB00548 DB00081 DB08976 DB04812 DB00318 DB13987 DB00216 DB04920 DB00159 DB01414 DB00341 DB00315 DB06809 DB06216 DB11770 DB02247 DB08826 DB13868 DB00435 DB13952 DB01214 DB12927 DB00933 DB01032 DB09256 DB12070 DB09213 DB08496 DB01356 DB00279 DB09285 DB00850 DB00409 DB00365 DB01079 DB00991 DB00961 DB01087 DB01329 DB14754 DB01401 DB00795 DB13508 DB08900 DB12245 DB00647 DB05271 DB09173 DB13722 DB01010 DB11967 DB01600 DB00501 DB01069 DB00761 DB09268 DB06209 DB01261 DB11699 DB08883 DB00342 DB00726 DB00897 DB13530 DB06782 DB06800 DB12445 DB00998 DB04574 DB00712 DB00909 DB01136 DB00308 DB13314 DB00683 DB00575 DB01424 DB06770 DB00243 DB01645 DB06769 DB06727 DB00968 DB04263 DB00186 DB00415 DB14528 DB00271 DB00669 DB00413 DB00790 DB09244 DB01171 DB01238 DB01012 DB01628 DB06824 DB00225 DB14060 DB09123 DB08918 DB01101 DB01183 DB11164 DB00425 DB06594 DB11130 DB00235 DB01135 DB12926 DB00743 DB09281 DB13967 DB00821 DB00918 DB01233 DB01415 DB09135 DB09290 DB00515 DB00262 DB08951 DB01428 DB00472 DB01074 DB00898 DB08797 DB08991 DB00760 DB00782 DB13185 DB01115 DB00914 DB00524 DB01472 DB00533 DB00701 DB01580 DB01068 DB04552 DB11328","absorption":"The mean steady-state C<sub>max<\/sub> and AUC<sub>24<\/sub> of givosiran are 321 ng\/mL and 4130 ngh\/mL, respectively, and increase proportionally over the dosing range.[L10202] The T<sub>max<\/sub> following subcutaneous injection is approximately 3 hours.[L10202]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Both givosiran and its active metabolite, AS(N-1)3' givosiran, have an elimination half-life of 6 hours.[L10202]","monoisotopic-mass":null,"volume-of-distribution":"The apparent central volume of distribution is 10.4 L.[L10202] Both givosiran and AS(N-1)3' givosiran distribute primarily to the liver following subcutaneous administration.[L10202]","route-of-elimination":"Approximately 5-14% of the dose recovered in urine is unchanged parent drug, and 4-13% is AS(N-1)3' givosiran.[L10202]","name":"Givosiran","metabolism":"Givosiran is metabolized to shorter oligonucleotides by nuclease enzymes. Its active metabolite, AS(N-1)3' givosiran, carries equal potency to the parent drug and its AUC<sub>0-24<\/sub> comprises approximately 45% of the parent drug AUC at the recommended givosiran dosage.[L10202] _In vitro_ studies suggest that givosiran is not a substrate of the CYP enzyme system.[L10202]","reactions":null,"indication":"Givosiran is indicated for the treatment of adults with acute hepatic porphyria.[L10202]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15066"},{"toxicity":"Data regarding overdose are not readily available.[L16621] However, symptoms are likely to involve injection site reactions and constitutional symptomns.[L16621] Treat patients with symptomatic and supportive care.[L16621]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Volanesorsen is an antisense oligonucleotide that prevents the translation of apoC-III.[A221296,L16621] It has a long duration of action as it has a half life of >2 weeks.[L16621] Patients should be counselled regarding the risk of thrombocytopenia, raised LDL-C levels, renal toxicity, hepatotoxicity, and immunogenicity.[L16621]","msds":null,"description":"Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation.[L16621] It is indicated to treat familial chylomicronemia, a genetic condition that prevents breakdown of triglycerides and chylomicrons.[L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.[L16621]\r\n\r\nVolanesorsen was granted a conditional approval by the European Medicines Agency.[L16621]","enzymes":null,"type":"biotech","cas-number":"915430-78-3","sequences":null,"targets":"BE0008880","unii":"2O4BE0K238","protein-binding":"Volanesorsen is >98% bound to proteins in plasma.[A221296,L16621] Though the exact proteins have not been identified.[A221296]","fda-label":null,"clearance":"The exact rate of clearance of volanesorsen is unknown, however it is rapidly distributed to tissues and very slowly eliminated.[L16621]","atc-codes":"Other lipid modifying agents LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN CARDIOVASCULAR SYSTEM","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation, and preventing translation of apoC-III protein.[L16621] Normally, apoC-III would inhibit triglyceride metabolism and hepatic clearance of chylomicrons.[L16621] Preventing translation of apoC-III allows for metabolism and breakdown of these triglycerides and chylomicrons.[L16621]","drug-interactions":null,"absorption":"Volanesorsen is approximately 80% bioavailable.[L16621] A 285mg dose given weekly reaches a C<sub>max<\/sub> of 8.92 g\/mL, with an AUC of 136 g\\*h\/mL.[L16621]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Volanesorsen has a half life of >2 weeks.[L16621]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution at steady state is 330 L in patients with familial chylomicronemia.[L16621]","route-of-elimination":"Volanesorsen is predominantly eliminated in the urine, though <3% of a dose was recovered within 24 hours.[L16621]","name":"Volanesorsen","metabolism":"Volanesorsen is metabolized by endonucleases and exonucleases in a nonspecific manner.[L16621] The unchanged parent drug is 26% recovered in the urine and pentamer to heptamer sized metabolites account for 55% of urinary recovery.[L16621","reactions":null,"indication":"Volanesorsen is conditionally approved by the EMA as an adjunct to diet in adults with familial chylomicronemia, at high risk for pancreatitis, and who have had an inadequate response to diet and triglyceride lowering therapy.[L16621]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15067"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":517.465,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).","enzymes":null,"type":"small molecule","cas-number":"1188910-76-0","sequences":null,"targets":null,"unii":"78I4VEX88N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":517.157303317,"volume-of-distribution":null,"route-of-elimination":null,"name":"Agerafenib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15068"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).","enzymes":null,"type":"biotech","cas-number":"1058624-46-6","sequences":null,"targets":null,"unii":"K82DG47I0G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pexastimogene devacirepvec","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15069"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GI heptapeptide is under investigation in clinical trial NCT01391208 (Esophageal Protocol for Detection of Neoplasia in the Digestive Tract).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"D33CAJ796A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"GI heptapeptide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15070"},{"toxicity":"Toxicity information regarding omidenepag isopropyl is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as ocular inflammation.[L43503] Symptomatic and supportive measures are recommended. Lifetime studies evaluating the carcinogenic effects of omidenepag isopropyl or omidenepag have not been performed. In rats given omidenepag isopropyl subcutaneously for 26 weeks, nephroblastoma and a spermatic cord tumor were developed at 0.003 mg\/kg\/day (33 times the recommended human ophthalmic dose). At 0.03 mg\/kg\/day (319 times the recommended human ophthalmic dose), rats given omidenepag isopropyl developed mammary adenocarcinoma and pituitary pars distalis adenomas. Based on the results of the _in vitro_ mouse lymphoma forward mutation assay, omidenepag isopropyl (no metabolic activation) was mutagenic and clastogenic. Its active metabolite, omidenepag, was not mutagenic in the _in vivo_ mouse micronucleus and bacterial reverse mutation tests.[L43503]","snp-adverse-drug-reactions":null,"average-mass":520.61,"transporters":null,"pharmacodynamics":"Omidenepag isopropyl is rapidly hydrolyzed to its active metabolite, omidenepag. Omidenepag has a high affinity for the prostaglandin E2 (EP2) receptor and binds strongly with a K<sub>i<\/sub> of 3.6 nM. Omidenepag also has high agonistic activity towards the EP2 receptor, with an EC<sub>50<\/sub> of 8.3 nM, and has no effects over other receptors such as prostaglandin E1 (EP1) receptor and prostaglandin F receptor (FP). Unlike omidenepag, omidenepag isopropyl has weak or no affinity towards prostanoid receptors.[A253263,A253268]\r\n\r\nThe use of omidenepag isopropyl may lead to pigmentation of the iris, periorbital tissue and eyelash. The pigmentation of the iris is likely to be permanent, while the pigmentation of the periorbital tissue and eyelash are reversible in most patients. Patients receiving omidenepag isopropyl may also experience eyelash changes and ocular inflammation. Also, in patients with pseudophakia, the use of omidenepag isopropyl may lead to macular edema.[L43503]","msds":null,"description":"Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.[L43503] Omidenepag isopropyl is quickly metabolized to its active metabolite, omidenepag, a molecule with high selectivity and agonistic activity towards the prostaglandin E2 (EP2) receptor.[A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients achieve adequate IOP reduction with FP agonists and require changes in treatment. The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost].[A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.[L43503]","enzymes":"BE0004740","type":"small molecule","cas-number":"1187451-19-9","sequences":null,"targets":"BE0000368 BE0000064","unii":"G0G0H52U6K","protein-binding":"The protein binding of omidenepag isopropyl is not available. The protein binding of its active metabolite, omidenepag, is 97.8%.[L43508]","fda-label":null,"clearance":"Not available.","atc-codes":"GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS GENITO URINARY SYSTEM AND SEX HORMONES ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Sulfonamides","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Pharmaceutical composition for treating or preventing glaucoma (WO 2010\/113957 A1). World Intellectual Property Organization. https:\/\/patents.google.com\/patent\/WO2010113957A1\/en","mechanism-of-action":"Omidenepag isopropyl is a prodrug of omidenepag, a relatively selective prostaglandin E2 (EP2) receptor agonist that decreases intraocular pressure (IOP). Elevated IOP is associated with glaucomatous field loss risk, and the higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.[L43503]\r\n\r\nThe exact mechanism by which omidenepag lowers IOP is not fully elucidated; however, it has been suggested that by binding to the EP2 receptor, omidenepag causes an increase in aqueous humor outflow through the conventional and uveoscleral pathways.[A253253,A253258]  The EP2 receptor is present in different types of ocular tissues associated with aqueous humor dynamics, such as the ciliary muscle (CM) and trabecular meshwork (TM). The stimulation of EP2 receptors may lead to an increase in intracellular cyclic adenosine monophosphate (cAMP) and result in the relaxation of tissues in the CM and TM.[A253258]","drug-interactions":null,"absorption":"The ophthalmic solution of omidenepag isopropyl is absorbed through the cornea, where it is hydrolyzed into its active metabolite, omidenepag. After the administration of one drop of omidenepag isopropyl 0.0025% eye drops to both eyes for 7 days, plasma concentration in humans reached C<sub>max<\/sub> at 10-15 minutes. There was no evidence of omidenepag isopropyl systemic accumulation, given that systemic exposure was similar between days 1 and 7.[L43503] A study comparing the pharmacokinetic parameters of omidenepag in Japanese and Caucasian healthy subjects did not find significant differences. Japanese and Caucasian healthy subjects had a corresponding C<sub>max<\/sub> of 41.5  20.1 and 27.2  10.2 pg\/mL, and a corresponding AUC<sub>0-8 h<\/sub> of 26.1  5.7 and 15.3  4.7 hpg\/mL (mean  standard deviation).[A253243]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The half-life of omidenepag isopropyl is not available. The mean terminal half-life of its active metabolite, omidenepag, is approximately 30 minutes.[L43508]","monoisotopic-mass":520.18927458,"volume-of-distribution":"Not available.","route-of-elimination":"In rats given 0.03% omidenepag isopropyl in both eyes as a single dose (5 mcL\/eye, 3 mcg\/animal), 89% of the administered dose was excreted 168 hours after ocular instillation. Omidenepag was eliminated in feces (83%) and urine (4%).[L43503]","name":"Omidenepag isopropyl","metabolism":"Omidenepag isopropyl is rapidly metabolized after topical ocular administration by carboxylesterase-1 to its pharmacologically active form, omidenepag. In the liver, omidenepag is further metabolized through oxidation, N-dealkylation, glucuronidation, sulfate conjugation or taurine conjugation.[L43503] CYP3A4 plas an important role in the liver metabolism of omidenepag.[A253243,L43508]","reactions":"BE0004740 Q6LAP9","indication":"Omidenepag isopropyl ophthalmic solution (0.002%) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.[L43503]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15071"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus).","enzymes":null,"type":"biotech","cas-number":"123475-27-4","sequences":null,"targets":null,"unii":"38I1O6L31D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Glucagon-like peptide-1 (GLP-1) analogues BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS DRUGS USED IN DIABETES ALIMENTARY TRACT AND METABOLISM","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Beinaglutide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15072"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.1299,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ribose is under investigation in clinical trial NCT01727479 (Ribose and Sport Performance).","enzymes":null,"type":"small molecule","cas-number":"50-69-1","sequences":null,"targets":null,"unii":"681HV46001","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.05282343,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ribose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15073"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aglatimagene besadenovec is under investigation in clinical trial NCT00638612 (AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)).","enzymes":null,"type":"biotech","cas-number":"1621271-62-2","sequences":null,"targets":null,"unii":"5Z72SSS34W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aglatimagene besadenovec","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15074"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":724.02,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"4-demethyl-4-cholesteryloxycarbonylpenclomedine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).","enzymes":null,"type":"small molecule","cas-number":"942149-56-6","sequences":null,"targets":null,"unii":"1S83F4T2WE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":721.2025975,"volume-of-distribution":null,"route-of-elimination":null,"name":"4-demethyl-4-cholesteryloxycarbonylpenclomedine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15075"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).","enzymes":null,"type":"biotech","cas-number":"1342290-43-0","sequences":null,"targets":null,"unii":"Y9UQ37XT2T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Abrilumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15076"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)).","enzymes":null,"type":"biotech","cas-number":"2055640-93-0","sequences":null,"targets":null,"unii":"DR6P1M58PO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Efinopegdutide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15077"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":466.56,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).","enzymes":null,"type":"small molecule","cas-number":"1443530-05-9","sequences":null,"targets":null,"unii":"98BSN6N516","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":466.178709895,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rogaratinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15078"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":419.38,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Troriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).","enzymes":null,"type":"small molecule","cas-number":"1926203-09-9","sequences":null,"targets":null,"unii":"S7H48S6K7H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":419.087509678,"volume-of-distribution":null,"route-of-elimination":null,"name":"Troriluzole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15079"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":482.531,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).","enzymes":null,"type":"small molecule","cas-number":"1375073-95-2","sequences":null,"targets":null,"unii":"TP732M43NA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":482.25879344,"volume-of-distribution":null,"route-of-elimination":null,"name":"ELX-02","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15080"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"C1357NAP5J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Melanoma antigen recognized by T-cells 1","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15081"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).","enzymes":null,"type":"biotech","cas-number":"1613144-80-1","sequences":null,"targets":null,"unii":"5FJL6W0640","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cabiralizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15082"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).","enzymes":null,"type":"biotech","cas-number":"1629605-31-7","sequences":null,"targets":null,"unii":"516MD5WQ24","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Domagrozumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15083"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":734.839,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).","enzymes":null,"type":"small molecule","cas-number":"859209-84-0","sequences":null,"targets":null,"unii":"5I2GJW5Z2Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":734.366918392,"volume-of-distribution":null,"route-of-elimination":null,"name":"GS-9191","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15084"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":487.391,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).","enzymes":null,"type":"small molecule","cas-number":"1488354-15-9","sequences":null,"targets":null,"unii":"VIR72PP4ZU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":487.099119736,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fulacimstat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15085"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":209.2848,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ocrylate is under investigation in clinical trial NCT01918059 (Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive).","enzymes":null,"type":"small molecule","cas-number":"6701-17-3","sequences":null,"targets":null,"unii":"6C655P1XVG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":209.141578857,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ocrylate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15086"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":180.1559,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Psicose is under investigation in clinical trial NCT02459834 (The Fructose and Allulose Catalytic Effects (FACE) Trial).","enzymes":null,"type":"small molecule","cas-number":"23140-52-5","sequences":null,"targets":null,"unii":"KRF88IOA7T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":180.063388116,"volume-of-distribution":null,"route-of-elimination":null,"name":"Psicose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15087"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).","enzymes":null,"type":"biotech","cas-number":"1803176-05-7","sequences":null,"targets":null,"unii":"5CRY01URYQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Oleclumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15088"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).","enzymes":null,"type":"biotech","cas-number":"1643672-70-1","sequences":null,"targets":null,"unii":"87PZ955YRB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Frovocimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15089"},{"toxicity":"Toxicity information regarding tezepelumab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as opportunistic infections and other conditions related to immunosuppression. Symptomatic and supportive measures are recommended.[L39504]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Tezepelumab is a human monoclonal IgG2 antibody blocking thymic stromal lymphopoietin (TSLP). Tezepelumab treatment in asthmatic patients improves disease markers, including blood and airway submucosal eosinophils and IgE, FeNO, IL-5, and IL-13 levels. Despite an excellent safety profile, tezepelumab may be associated with hypersensitivity reactions and increased risk of infection, especially by parasitic helminths. Patients receiving tezepelumab should not discontinue systemic or inhaled corticosteroids, and any reduction in these drugs should be performed cautiously.[L39504]","msds":null,"description":"Asthma is a heterogeneous chronic obstructive respiratory disease with both \"type 2\" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling.[A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. Blocking the interaction of TSLP with the receptors TSLPR and IL-7R improves asthma-associated biomarkers including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels.[A243764, A243769, A243774] As existing asthma treatments such as [omalizumab], [mepolizumab], [reslizumab], [benralizumab], and [dupilumab] act on specific downstream mediators of the inflammatory response, they are mostly limited to treating T2 asthma.[A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes.[A243764, A243769, A243774]\r\n\r\nTezepelumab is a human monoclonal IgG2 antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen\/AstraZeneca.[L39504]","enzymes":null,"type":"biotech","cas-number":"1572943-04-4","sequences":null,"targets":"BE0010181","unii":"RJ1IW3B4QX","protein-binding":null,"fda-label":null,"clearance":"Tezepelumab has an estimated clearance of 0.17 L\/d (for a 70 kg individual).[L39504]","atc-codes":"OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES RESPIRATORY SYSTEM Other systemic drugs for obstructive airway diseases","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Michael R Comeau, James F Smothers, Bo-Rin P Yoon, Christopher Mehlin, \"Antigen binding proteins capable of binding thymic stromal lymphopoietin.\" U.S. Patent US9284372B2, issued March 15, 2016.","mechanism-of-action":"Asthma is a heterogeneous chronic obstructive respiratory disease characterized by reduced airflow, chronic inflammation, and airway remodelling. Generally, asthma can be divided into \"type 2\" (T2, including allergic and eosinophilic presentations) and T2-low (including neutrophilic and paucigranulocytic presentations) endotypes, each driven by distinct underlying pathways.[A243764, A243769] Thymic stromal lymphopoietin (TSLP) is an innate pleiotropic IL-2-family cytokine distantly related to IL-7; two forms of TSLP exist, with a short isoform (sfTSLP, 60 amino acids long) and a long isoform (lfTSLP, 159 amino acids long). The short isoform appears to be constitutively expressed, especially by lung and gut epithelial cells, while lfTSLP is upregulated in response to proinflammatory stimuli. While the role of sfTSLP is still unclear, lfTSLP has emerged as an upstream alarmin central to the pathophysiology of inflammatory disorders including asthma, atopic rhinitis, chronic obstructive pulmonary disease, eosinophilic esophagitis, and atopic dermatitis.[A243764, A243769, A243774]\r\n\r\nUnder normal conditions, lfTSLP interacts with its cognate receptor TSLPR, and IL-7R in a ternary complex with three contact sites labelled site I (TSLP:TSLPR), site II (TSLP:IL-7R), and site III (TSLPR:IL-7R). The assembly of the ternary complex is stepwise, as TSLP does not interact appreciably with IL-7R until after it has bound TSLPR. Complementary electrostatic surfaces on TSLP and TSLPR mediate initial high affinity formation of a TSLP:TSLPR complex (_K_<sub>D<\/sub> of 32 nM and _k_<sub>a<\/sub> of 1.7 x 10<sup>5<\/sup> M<sup>-1<\/sup>s<sup>-1<\/sup>). This initial binding induces a restructuring of the \u20AC-helical turn in the TSLP A helix and structuring of the AB loop to facilitate binding of TSLP to a hydrophobic patch on IL-7R to form the ternary complex (_K_<sub>D<\/sub> of 29 nM and _k_<sub>a<\/sub> of 1.23 x 10<sup>5<\/sup> M<sup>-1<\/sup>s<sup>-1<\/sup>). The complete ternary complex is stabilized by additional interactions between TSLPR and IL-7R at site III near the transmembrane domain of each receptor.[A243779]\r\n\r\nFormation of the ternary complex activates JAK1\/2, which, through downstream pathways involving STAT3\/5, NF-B, PI3K, and MAPK, induces the expression of Th2 cytokines including IL-4, IL-5, IL-9, and IL-13.[A243764] TSLP can induce Th2 cytokine production by stimulating dendritic cells and ILC2 cells (primarily in T2 asthma). Furthermore, TSLP has been implicated in steroid resistance of ILC2 cells. In neutrophilic asthma, TSLP induces dendritic cells to drive the development of Th17 cells, which secrete IL-17A to recruit neutrophils and drive inflammation. In paucigranulocytic asthma, TSLP mediates cross-talk between mast cells, smooth muscle cells, and fibroblasts. Hence, despite different underlying pathways, TSLP appears to function as a critical upstream driver across asthma endotypes.[A243764, A243769, A243774]\r\n\r\nTezepelumab is a human monoclonal IgG2 antibody that binds to TSLP with a dissociation constant of 15.8 pM.[A243779, L39504] Specifically, the variable heavy chain domain (V<sub>H<\/sub>) complementarity determining regions (CDRs) of tezepelumab bind TSLP at the _AB_-loop region and C-terminal region of the D helix, obstructing the TSLPR binding region while leaving the IL-7R binding region unobstructed. As TSLP is incapable of binding IL-7R prior to its inclusion in the TSLP:TSLPR dimer, tezepelumab effectively blocks the assembly of the ternary complex and resulting downstream signalling.[A243779] Furthermore, unlike existing therapies that act on specific downstream effector molecules, targeting TSLP ensures effective upstream blockade and is expected to be efficacious against multiple asthma endotypes.[A243764, A243769, A243774]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"When administered subcutaneously, tezepelumab reaches C<sub>max<\/sub> in approximately 3-10 days with an estimated absolute bioavailability of 77%, regardless of injection site choice.[L39504]\r\n\r\nTezepelumab displays dose-proportional pharmacokinetics over a range of 2.1-420 mg (0.01-2 times the recommended dose) following a single subcutaneous dose. With a 4-week dosing schedule, tezepelumab achieves steady-state kinetics after 12 weeks with a 1.86-fold C<sub>trough<\/sub> accumulation ratio.[L39504]\r\n\r\nThere are no clinically meaningful changes expected for tezepelumab pharmacokinetics in patients across patient populations, including those with renal or hepatic impairment.[L39504]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Tezepelumab has an elimination half-life of ~26 days.[L39504]","monoisotopic-mass":null,"volume-of-distribution":"Tezepelumab has a central V<sub>d<\/sub> of 3.9 L and a peripheral V<sub>d<\/sub> of 2.2 L (for a 70 kg individual).[L39504]","route-of-elimination":"As a human monoclonal antibody, tezepelumab is eliminated primarily through catabolism; there is no evidence of target-mediated clearance at the therapeutic dose.[L39504]","name":"Tezepelumab","metabolism":"As a human monoclonal antibody, tezepelumab is expected to be degraded by various proteolytic enzymes throughout the body.[L39504]","reactions":null,"indication":"Tezepelumab is indicated as an add-on maintenance treatment for patients aged 12 years and older with severe asthma.[L39504]\r\n\r\nTezepelumab is not indicated for the relief of acute bronchospasm or status asthmaticus.[L39504]","ahfs-codes":null,"updated":"2022-04-01","drugbank-id":"DB15090"},{"toxicity":"There is limited clinical information on the overdose from upacitinib: in clinical trials, once-daily administration of 60 mg in extended-release formulations were well tolerated. In case of an overdose, it is recommended that the patient is monitored for signs and symptoms of adverse reactions and treated with appropriate symptomatic treatment.[L10896]\r\n\r\nThe oral LD<sub>50<\/sub> in rats is 14500 mg\/kg.[L10911]","snp-adverse-drug-reactions":null,"average-mass":380.375,"transporters":"BE0001004 BE0001032 BE0001067","pharmacodynamics":"Upadacitinib is a DMARD that works by inhibiting the Janus Kinases (JAKs), which are essential downstream cell signalling mediators of pro-inflammatory cytokines. It is believed that these pro-inflammatory cytokines play a role in many autoimmune inflammatory conditions, such as rheumatoid arthritis.[A189171] In clinical trials, upadacitinib decreased the activity of pro-inflammatory interleukins, transiently increased the levels of lymphocytes, and insignificantly decreased the levels of immunoglobulins from the baseline.[L10896]","msds":null,"description":"Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.[A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.[A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis.[A189168] To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed.[A189165]\r\n\r\nThe FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.[L10896] In December 2019, it was additionally approved by the European Commission.[L10899] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896]","enzymes":"BE0002638 BE0002363","type":"small molecule","cas-number":"1310726-60-3","sequences":null,"targets":"BE0004145","unii":"4RA0KN46E0","protein-binding":"Upadacitinib is 52% bound to human plasma proteins.[L10896]","fda-label":null,"clearance":"The apparent oral clearance of upadacitinib in healthy volunteers receiving the extended-release formulation was 53.7 L\/h.[A184043]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS Selective immunosuppressants","pdb-entries":null,"food-interactions":"Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of upadacitinib. Take with or without food. Food does not significantly affect drug concentrations.","state":"liquid","synthesis-reference":null,"mechanism-of-action":"Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that involves the interplay of several mediators, including the immune cells (mainly T- and B-lymphocytes) and pro-inflammatory cytokines, such as the tumour necrosis factor (TNF), transforming growth factor (TGF), and interleukin 6 (IL-6).[A189165] The Janus Kinase (JAK) family plays an essential role in the normal physiological functions (such as erythropoiesis), but also the signalling of pro-inflammatory cytokines that are implicated in many immune-mediated diseases.[A189168] The JAK family consists of four isoforms (JAK1, JAK2, JAK3, and Tyrosine Kinase 2) that each interacts with different cytokine receptors and uniquely associates with the intracellular domains of Type I\/II cytokine receptors.[A189168] JAK1 is primarily involved in the signalling transduction pathways of IL-6, IFN and the common  -chain cytokines, including IL-2 and IL-15.[A189180] IL-6 has been closely studied in particular, as it is a major cytokine involved in B- and T-cell differentiation and the acute phase response in inflammation.[A189177]\r\n\r\nUpon interaction of cytokines with their cytokine receptors, the JAKs mediate the JAK-STAT signal transduction pathway in response to receptor activation. JAKs are tyrosine kinases that cause phosphorylation of several proteins, including cytokine receptors and JAKs themselves. Phosphorylation of JAKs promotes the phosphorylation and activation of the signalling molecules called STATs, leading to their nuclear translocation, binding to DNA promoters, and target gene transcription. JAK1-mediated signalling pathways ultimately promote pro-inflammatory events, such as increased proliferation and survival of immune cells, T cell differentiation, and macrophage activation.[A189168] Upadacitinib is a selective JAK1 inhibitor that has a negligible effect on JAK3, leading to an improved drug safety profile.[A189165] Upadacitinib blocks the cellular processes that contribute to the inflammatory conditions in rheumatoid arthritis. In human leukocytes cellular assays, upadacitinib inhibited JAK1\/3-induced phosphorylation of STAT3\/5 mediated by IL-6\/7.[L10896]","drug-interactions":"DB08880 DB00328 DB08953 DB00928 DB15274 DB12095 DB09052 DB15857 DB06712 DB00092 DB00970 DB04951 DB00034 DB09185 DB00642 DB13068 DB00495 DB11921 DB00105 DB00305 DB06772 DB16650 DB01229 DB00503 DB15646 DB12386 DB00220 DB01590 DB13843 DB13867 DB16611 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB01127 DB00853 DB11901 DB08865 DB11044 DB14685 DB10804 DB00246 DB13208 DB15119 DB09082 DB09383 DB00851 DB02520 DB05676 DB10584 DB00959 DB11003 DB01320 DB00773 DB01323 DB09074 DB00008 DB00120 DB00547 DB00428 DB06813 DB10990 DB01033 DB00987 DB00324 DB00276 DB11932 DB10061 DB01204 DB05521 DB00098 DB01281 DB09101 DB05942 DB04868 DB06595 DB00552 DB00877 DB06119 DB06290 DB14960 DB01257 DB11976 DB06616 DB00033 DB01005 DB00091 DB14711 DB09227 DB11633 DB15626 DB14540 DB00180 DB06589 DB00872 DB01201 DB08870 DB10276 DB09046 DB01015 DB08906 DB01410 DB00022 DB13014 DB14919 DB00951 DB05459 DB06448 DB02703 DB00526 DB10283 DB14019 DB00648 DB00601 DB08873 DB17088 DB00270 DB00993 DB00072 DB11988 DB14619 DB00307 DB01234 DB03451 DB00582 DB00635 DB11616 DB14445 DB00312 DB14066 DB10317 DB00363 DB16736 DB11834 DB01206 DB10062 DB09378 DB15656 DB14022 DB06237 DB09122 DB00069 DB12025 DB09053 DB00705 DB05109 DB00432 DB12530 DB01097 DB00224 DB00394 DB00065 DB01816 DB01118 DB08904 DB08059 DB08910 DB12917 DB00176 DB05015 DB11708 DB00550 DB15628 DB01008 DB01041 DB11730 DB09033 DB01108 DB00343 DB00622 DB00196 DB11603 DB06372 DB01280 DB11652 DB01181 DB06603 DB10600 DB10769 DB01384 DB00591 DB10794 DB01026 DB09095 DB06168 DB01248 DB01099 DB09118 DB00661 DB12996 DB00502 DB00932 DB11050 DB08908 DB08879 DB13924 DB00252 DB01045 DB01047 DB00763 DB06662 DB15982 DB06612 DB11569 DB01167 DB00619 DB01268 DB11580 DB00445 DB14545 DB03523 DB11672 DB00290 DB00322 DB02546 DB00188 DB00564 DB05667 DB00398 DB11581 DB09065 DB09077 DB08899 DB13003 DB04896 DB00075 DB14724 DB10343 DB12947 DB00078 DB16648 DB06584 DB01232 DB01263 DB00755 DB04956 DB14443 DB01211 DB00073 DB06643 DB14449 DB14394 DB06287 DB04630 DB01611 DB14783 DB00441 DB10989 DB15569 DB11040 DB00480 DB01601 DB00242 DB14384 DB14620 DB01072 DB00625 DB09048 DB00291 DB06688 DB08895 DB01254 DB00111 DB00068 DB01380 DB15810 DB01169 DB01656 DB06700 DB12991 DB00859 DB11487 DB00997 DB15654 DB14921 DB12612 DB11753 DB00443 DB04845 DB11817 DB11041 DB14385 DB11779 DB05144 DB00694 DB05472 DB00864 DB00446 DB01024 DB06273 DB05325 DB15483 DB00688 DB01196 DB06681 DB00544 DB01013 DB06636 DB11693 DB11466 DB08971 DB12692 DB13179 DB04914 DB01110 DB12568 DB09054 DB14512 DB11038 DB00976 DB01262 DB00860 DB04832 DB15595 DB00051 DB10318 DB10803 DB09073 DB00588 DB00696 DB00095 DB01177 DB14845 DB00026 DB11529 DB00488 DB00958 DB02806 DB01149 DB00537 DB14762 DB09091 DB09280 DB10991 DB10805 DB08868 DB08871 DB00199 DB00794 DB00380 DB00337 DB12902 DB05440 DB16694 DB01222 DB13856 DB14539 DB15434 DB00309 DB01264 DB12371 DB11642 DB08882 DB08912 DB00444 DB06650 DB01073 DB01423 DB00570 DB00056 DB14409 DB15762 DB05259 DB00041 DB08901 DB01406 DB11803 DB09036 DB08889 DB01030 DB04855 DB12617 DB00563 DB01174 DB08877 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB14568 DB06400 DB00011 DB14513 DB01285 DB11767 DB09231 DB09029 DB00764 DB01087 DB00795 DB05260 DB08935 DB16703 DB13241 DB00059 DB15461 DB06674 DB00293 DB13223 DB00342 DB06731 DB10583 DB05258 DB00227 DB00361 DB00620 DB00673 DB06769 DB11627 DB11776 DB12016 DB15253 DB10316 DB05773 DB01101 DB04572 DB01183 DB14219 DB09057 DB00762 DB06343 DB00074 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00701 DB00005 DB10315","absorption":"Upadacitinib displays a dose-proportional pharmacokinetic profile over the therapeutic dose range. Following oral administration, the median time to reach Cmax (Tmax) ranges from 2 to 4 hours. The steady-state plasma concentrations of upadacitinib are reached within 4 days following multiple once-daily administrations, with minimal accumulation.[L10896] Food intake has no clinically relevant effect on the AUC, Cmax, and Cmin of upadacitinib from the extended-release formulation.[A189162]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean terminal elimination half-life of upadacitinib ranged from 8 to 14 hours following administration of the extended-release formulation.[L10896,L10905] In clinical trials, approximately 90% of upadacitinib in the systemic circulation was eliminated within 24 hours of dosing.[L10896]","monoisotopic-mass":380.157243745,"volume-of-distribution":"The volume of distribution of upadacitinib in a patient with rheumatoid arthritis and a body weight of 74 kg is estimated to be  224 L following oral administration of an extended-release formula.[L10905] In a pharmacokinetic study consisting of healthy volunteers receiving the extended-release formulation, the steady-state volume of distribution was 294 L.[A184043] Upadacitinib partitions similarly between plasma and blood cellular components with a blood to plasma ratio of 1.0.[L10896]","route-of-elimination":"Following administration of a single radio-labelled dose from the immediate-release formulation, approximately 53% of the total dose was excreted in the feces where 38% of the excreted dose was an unchanged parent drug. About 43% of the total dose was excreted in the urine, where 24% of that dose was in the unchanged parent drug form.[L10905] Approximately 34% of the total dose of upadacitinib dose was excreted as metabolites.[L10896]","name":"Upadacitinib","metabolism":"Upadacitinib predominantly undergoes CYP3A4-mediated metabolism;[L10896] however, upadacitinib is a nonsensitive substrate of CYP3A4.[A189162] It is also metabolized by CYP2D6 to a lesser extent.[L10896] \r\nIn a human radio-labelled study, about 79% of the total plasma radioactivity accounted for the parent drug, and about 13% of the total plasma radioactivity accounted for the main metabolite produced from mono-oxidation, followed by glucuronidation.[L10896] There are no known active metabolites of upadacitinib.[L10905]","reactions":null,"indication":"Upadacitinib is indicated for the treatment of moderately to severely active **rheumatoid arthritis** or active **psoriatic arthritis** in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as TNF blockers.[L10896, L39474] In Europe, upadacitinib may be used as monotherapy or in combination with [methotrexate] for rheumatoid or psoriatic arthritis.[L39474] \r\n\r\nUpadacitinib is indicated for use in patients 12 years of age and older with refractory, moderate-to-severe **atopic dermatitis** whose disease is inadequately controlled with other systemic therapies or when other therapies are inadvisable.[L10896,L39474]\r\n\r\nUpadacitinib is indicated for the treatment of active **ankylosing spondylitis** or radiographic axial spondyloarthritis in adult patients who have an inadequate response to conventional therapy.[L10896,L39474] It is also indicated to treat non-radiographic axial spondyloarthritis with objective signs of inflammation in adults who have had an inadequate response or intolerance to TNF blocker therapy.[L10896]\r\n\r\nUpadacitinib is also indicated to treat moderately to severely active **ulcerative colitis** in adults who have had an inadequate response or intolerance to either conventional therapy or a biologic agent,[L39474] such as to one or more TNF blockers.[L10896]\r\n\r\nCombining upadacitinib with other JAK inhibitors, biologic DMARDs, or other potent immunosuppressive agents is not recommended.[L10896]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15091"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":379.46,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).","enzymes":null,"type":"small molecule","cas-number":"879409-35-5","sequences":null,"targets":null,"unii":"63J9EQ81YC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":379.189591677,"volume-of-distribution":null,"route-of-elimination":null,"name":"LY-2624803","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15092"},{"toxicity":"Patients experiencing an acute overdose of somapacitan may present with fluid retention.[L15661] Chronic overdose may resemble gigantism or acromegaly.[L15661] Treat patients with symptomatic and supportive measures to minimize the permanent effects.[A219141]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Somapacitan stimulates the growth hormone receptor.[L15661] Somapacitan has a long duration of action as it is given once weekly.[L15661] It has a moderately wide therapeutic window as an acute overdose may cause hypoglycemia followed by hyperglycemia.[L15661] Patients should be counselled regarding the risk of increased mortality in patients with critical illness, risk of neoplasms, glucose intolerance in diabetes mellitus, intracranial hypertension, hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, pancreatitis, lipohypertrophy, and lipoatrophy.[L15661]","msds":null,"description":"Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.[A219146]\r\n\r\nSomapacitan was granted FDA approval on 28 August 2020.[L15666]","enzymes":"BE0000329 BE0003536 BE0010015 BE0002433","type":"biotech","cas-number":"1338578-34-9","sequences":null,"targets":"BE0000075","unii":"8FOJ430U94","protein-binding":"Somapacitan is >99% bound to albumin.[A219096,L15661]","fda-label":null,"clearance":"The apparent maximum rate of saturable elimination is estimated to be 0.268  0.03 mg\/h.[A219126]","atc-codes":"ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Somapacitan binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1).[A219096,L15661] IGF-1 causes growth in bones and muscle tissue.[A219096] Growth hormones more directly cause the fusion of myoblasts and myotubes to cause muscle fibre growth, activate neural stem cells, and induce chondrocyte proliferation.[A219096]","drug-interactions":"DB00682 DB14652 DB09381 DB09198 DB00382 DB01142 DB04951 DB13446 DB00338 DB09273 DB12945 DB14633 DB00280 DB05708 DB00642 DB14132 DB01200 DB11921 DB01223 DB00395 DB01306 DB01086 DB00277 DB00284 DB09022 DB12235 DB00321 DB11919 DB00863 DB06148 DB01129 DB12781 DB00665 DB13843 DB01067 DB00806 DB13867 DB01124 DB00531 DB08970 DB00046 DB00912 DB01065 DB01558 DB13203 DB00839 DB00222 DB11823 DB13208 DB09383 DB04878 DB00787 DB04356 DB00851 DB05676 DB06739 DB00281 DB00268 DB11827 DB01320 DB00834 DB00773 DB13928 DB11723 DB01323 DB11824 DB01259 DB14659 DB13954 DB01309 DB14009 DB12332 DB00370 DB00599 DB00324 DB00731 DB00758 DB01191 DB01100 DB00788 DB00030 DB06119 DB06479 DB01182 DB14018 DB01184 DB00890 DB00738 DB12406 DB09045 DB11898 DB09225 DB14973 DB06292 DB11950 DB00598 DB09265 DB11689 DB01175 DB00299 DB06589 DB00253 DB00980 DB00420 DB01015 DB08906 DB01410 DB00983 DB14055 DB00213 DB00715 DB00586 DB00784 DB13573 DB00334 DB00414 DB09369 DB01120 DB00977 DB00468 DB00924 DB00993 DB13955 DB00629 DB11674 DB12026 DB00582 DB02134 DB01277 DB12935 DB06605 DB15463 DB12268 DB00312 DB00635 DB01094 DB01412 DB00363 DB06011 DB00316 DB04871 DB01435 DB15171 DB00313 DB12500 DB09318 DB09288 DB11567 DB06203 DB11757 DB01382 DB05246 DB00568 DB13874 DB00831 DB09068 DB00783 DB05109 DB01195 DB09166 DB00624 DB00532 DB01097 DB13449 DB01251 DB00394 DB13386 DB08910 DB12487 DB00176 DB01104 DB01357 DB01058 DB01418 DB09200 DB00201 DB00396 DB00590 DB14035 DB00978 DB00379 DB06414 DB01384 DB01355 DB09095 DB01278 DB00849 DB09118 DB00661 DB01037 DB01303 DB09043 DB04889 DB00502 DB01289 DB04948 DB00252 DB06235 DB11478 DB01047 DB01016 DB13956 DB01056 DB00195 DB13953 DB00384 DB00619 DB01268 DB01405 DB09317 DB01002 DB00518 DB00188 DB09199 DB00398 DB11750 DB12531 DB08864 DB13634 DB06684 DB06655 DB13003 DB04876 DB09201 DB09241 DB00412 DB01482 DB00442 DB01166 DB00736 DB11780 DB01307 DB14681 DB00675 DB00904 DB12625 DB00373 DB00215 DB06626 DB09070 DB06774 DB00672 DB06218 DB00625 DB08907 DB01242 DB01483 DB00679 DB01254 DB01700 DB01380 DB13418 DB01656 DB00477 DB00208 DB06210 DB06127 DB11487 DB05115 DB00349 DB12417 DB00296 DB14921 DB00443 DB06335 DB13074 DB00461 DB03783 DB01367 DB04841 DB14975 DB14631 DB05351 DB13592 DB00934 DB00544 DB00261 DB01013 DB15334 DB08971 DB13812 DB01131 DB12713 DB15217 DB02568 DB13728 DB14512 DB11568 DB00969 DB00972 DB04076 DB00288 DB01623 DB00829 DB02489 DB01252 DB00197 DB00588 DB00333 DB00286 DB09038 DB00458 DB11992 DB14644 DB12265 DB15335 DB00730 DB00331 DB13675 DB00697 DB01132 DB00047 DB00740 DB00356 DB00499 DB09071 DB06697 DB00794 DB13143 DB00857 DB13762 DB04573 DB00269 DB14646 DB00571 DB08882 DB00444 DB00574 DB12474 DB00347 DB00744 DB00359 DB04861 DB01667 DB00263 DB00530 DB01174 DB00655 DB00491 DB01276 DB00315 DB06216 DB13952 DB12927 DB09256 DB08496 DB00850 DB00365 DB01087 DB00764 DB12214 DB12245 DB14027 DB11967 DB12412 DB01261 DB08883 DB00726 DB00896 DB09061 DB00448 DB00998 DB00620 DB04574 DB04830 DB01136 DB00909 DB07931 DB00575 DB01424 DB06770 DB01645 DB06769 DB14669 DB11698 DB01171 DB01012 DB01628 DB13406 DB08382 DB00425 DB06594 DB14634 DB12926 DB01233 DB00255 DB09290 DB00262 DB00472 DB09456 DB00898 DB09564 DB01115 DB00071 DB00914 DB00533 DB08962 DB04575","absorption":"A 0.02mg\/kg single dose of somapacitan reaches a C<sub>max<\/sub> of 14.4 ng\/mL, with a T<sub>max<\/sub> of 11.1 hours, and an AUC of 475 ng\\*h\/mL.[A219136] A 0.04mg\/kg single dose of somapacitan reaches a C<sub>max<\/sub> of 19.8 ng\/mL, with a T<sub>max<\/sub> of 25.6 hours, and an AUC of 777 ng\\*h\/mL.[A219136] A 0.08mg\/kg single dose of somapacitan reaches a C<sub>max<\/sub> of 64.2 ng\/mL, with a T<sub>max<\/sub> of 16.6 hours, and an AUC of 2753 ng\\*h\/mL.[A219136] A 0.12mg\/kg single dose of somapacitan reaches a C<sub>max<\/sub> of 142.5 ng\/mL, with a T<sub>max<\/sub> of 22.5 hours, and an AUC of 6382 ng\\*h\/mL.[A219136]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The elimination half life of somapacitan is 2-3 days.[L15661]","monoisotopic-mass":null,"volume-of-distribution":"The approximate volume of distribution of somapacitan is 14.6 L.[L15661]","route-of-elimination":"Somapacitan is approximately 81% eliminated in the urine and 13% in the feces.[L15661]","name":"Somapacitan","metabolism":"Studies in humans and rats show that somapacitan is metabolized through cleavage of the albumin-binding moiety and linker sidechain before further non-specific mechanisms.[A219096,L15661]","reactions":null,"indication":"Somapacitan is indicated as a replacement for growth hormone in adult patients with growth hormone deficiency.[L15661]","ahfs-codes":null,"updated":"2021-08-07","drugbank-id":"DB15093"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Anfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).","enzymes":null,"type":"biotech","cas-number":"1622134-89-7","sequences":null,"targets":null,"unii":"DCG29J773G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anfibatide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15094"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).","enzymes":null,"type":"biotech","cas-number":"193700-51-5","sequences":null,"targets":null,"unii":"WYY7RA43DK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00541 DB05168 DB11641 DB00570 DB00361 DB00531 DB00309 DB13374","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leridistim","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15095"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":368.477,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"18-methoxycoronaridine is under investigation in clinical trial NCT03084952 (Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients).","enzymes":null,"type":"small molecule","cas-number":"308123-60-6","sequences":null,"targets":null,"unii":"KX8NQX91Z8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":368.20999277,"volume-of-distribution":null,"route-of-elimination":null,"name":"18-methoxycoronaridine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15096"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":353.4,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gefapixant is under investigation in clinical trial NCT02397460 (Effect of Gefapixant (AF-219\/MK-7264) on Cough Reflex Sensitivity).","enzymes":null,"type":"small molecule","cas-number":"1015787-98-0","sequences":null,"targets":null,"unii":"6K6L7E3F1L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS COUGH AND COLD PREPARATIONS RESPIRATORY SYSTEM Other cough suppressants","pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":353.115775286,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gefapixant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15097"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":270.289,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Morinidazole is under investigation in clinical trial NCT03380793 (A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis).","enzymes":null,"type":"small molecule","cas-number":"92478-27-8","sequences":null,"targets":null,"unii":"TUPWG40JAL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":270.132805076,"volume-of-distribution":null,"route-of-elimination":null,"name":"Morinidazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15098"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":368.82,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).","enzymes":null,"type":"small molecule","cas-number":"476689-77-7","sequences":null,"targets":null,"unii":"3WGI8FOO62","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":368.0927701,"volume-of-distribution":null,"route-of-elimination":null,"name":"GW-468816","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15099"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.[A241975]\r\n\r\nCusatuzumab is a humanized IgG1 antibody targeted against CD70.[A241045] It is currently being investigated in the Phase 2 CULMINATE trial, in combination with [azacitidine], for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in patients unsuitable for chemotherapy.[A241045,L39120]","enzymes":null,"type":"biotech","cas-number":"1864871-20-4","sequences":null,"targets":"BE0010130","unii":"RR5U4UFJ8L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"CD70 is transiently expressed on activated lymphocytes and mature dendritic cells, where it serves as a ligand for the CD27 receptor.[A241975] The CD70-CD27 interaction results in the downstream activation of the NF-B pathway responsible for cell proliferation and survival. The overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological tumors - elevated urinary concentrations of soluble CD27 (sCD27), a byproduct resulting from the CD70-CD27 interaction, are correlated with a poorer prognosis in patients with non-Hodgkin lymphoma (NHL), Waldenstrm macroglobulinemia, and acute lymphoblastic leukemia (ALL).[A241975] \r\n\r\nCD70 may also be involved in creating a tumor microenvironment that facilitates immune system evasion via the recruitment of regulatory T-cells.[A241975,A241045]\r\n\r\nCusatuzumab is a humanized IgG1 monoclonal antibody targeted against CD70. In binding to CD70, cusatuzumab blocks the CD70-CD27 signaling that results in the proliferation of malignant cells and prevents the formation of sCD27.[L39120] In addition, cusatuzumab may exert some efficacy via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC).[L39120]","drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cusatuzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-11-11","drugbank-id":"DB15100"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin\/Paclitaxel in Chemotherapy nave Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).","enzymes":null,"type":"biotech","cas-number":"918127-53-4","sequences":null,"targets":null,"unii":"237GB6IDKO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tigatuzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15101"},{"toxicity":"There is limited information on the LD<sub>50<\/sub> value and overdose profile of pemigatinib. \r\n\r\nIn animal studies, pemigatinib caused fetal harm and embryo-fetal death in pregnant rats. FDA advises nursing women to avoid breastfeeding when receiving pemigatinib. Physeal and cartilage dysplasia were present in multiple bones of rats and non-human primates with pemigatinib exposures lower than the human exposure at the clinical dose of 13.5 mg.[L13050]","snp-adverse-drug-reactions":null,"average-mass":487.508,"transporters":"BE0001032 BE0001067 BE0003657 BE0003647","pharmacodynamics":"Pemigatinib is a small molecule kinase inhibitor that exerts anti-tumour activity through inhibition of fibroblast growth factor receptors (FGFRs). [A193716] With an IC<sub>50<\/sub> of less than 2 nM, pemigatinib displays potent inhibition of FGFR1, FGFR2, and FGFR3. In mouse xenograft models of human tumours with FGFR1, FGFR2, or FGFR3 alterations, pemigatinib exhibited potent anti-tumour activity by suppressing the growth of xenografted tumour models. It also showed efficacy against a patient-derived xenograft model of cholangiocarcinoma that expressed an oncogenic FGFR2 Transformer-2 beta homolog (TRA2b) fusion protein.[A193716,L13050] Pemigatinib also inhibited FGFR4 _in vitro_, however at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3.[L13050]","msds":null,"description":"Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.[A198984] Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death.[A193716]\r\n\r\nIn April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.[L13068] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.[A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.[L13050]","enzymes":"BE0002638","type":"small molecule","cas-number":"1513857-77-6","sequences":null,"targets":"BE0002133 BE0002131 BE0001203 BE0000748","unii":"Y6BX7BL23K","protein-binding":"The _in vitro_ serum protein binding of pemigatinib was 90.6% at drug concentrations ranging from 1 to 10 M.[L13050]","fda-label":null,"clearance":"Following administration of a single oral dose of 13.5 mg pemigatinib, the geometric mean apparent clearance (CL\/F) was 10.6 L\/h (54% CV).[L13050]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":false,"food-interactions":"Take with or without food. A high-fat or high-calorie meal does not have clinically significant effects on drug concentrations. Take at the same time every day. Avoid grapefruit products. Grapefruit may increase drug levels and adverse effects.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Fibroblast growth factor receptor (FGFR) is a receptor tyrosine kinase involved in activating signalling pathways that promote cell proliferation, survival, and migration, as well as growth arrest and cellular differentiation.[A193716] The initiation of the FGFR signalling pathway requires the binding of its natural ligand, fibroblast growth factor (FGF). Once FGF binds to the extracellular ligand-binding domain of the receptor, FGFRs dimerize and autophosphorylate the tyrosine residue in the intracellular tyrosine-kinase domain, leading to the activation of the tyrosine kinase.[A193719] Downstream cascades involve phosphorylation of multiple intracellular signalling proteins, such as phosphatidylinositol 3 kinase (PI3K)-AKT and RAS\/mitogen-activated protein kinase (MAPK), and phospholipase C, which activates the protein kinase C pathway.[A193716,A193719] FGFR-mediated pathway ultimately promotes cell growth, differentiation, survival, angiogenesis, and organogenesis, depending on cell type. Expressed in different isoforms in various tissues and cell lines, FGFRs are not constitutively active in normal cells.[A193719] However, FGFR1, FGFR2, or FGFR3 alterations in certain tumours can lead to constitutive FGFR activation and aberrant FGFR signalling, supporting the proliferation and survival of malignant cells.[L13050]\r\n\r\nPemigatinib inhibits FGFR1, FGFR2, and FGFR3, blocking their signalling pathways and decreasing cell viability in cancer cell lines with activating FGFR amplification and fusions that resulted in constitutive activation of FGFR signalling.[L13050] Genetic alterations in FGFR1, FGFR2, and FGFR3 (such as amplification, missense, or fusion mutations in the coding region) leading to constitutive activation of FGFR signalling pathways are observed in various tumours.[A193719,A198984] However, alterations in FGFR genes are demonstrated in selected patients and do not always imply oncogene development. Therefore, it is imperative that fusion or rearrangement of FGFRs are demonstrated through tests prior to initiation of drug therapy.[A193716]","drug-interactions":"DB01149 DB00537 DB08953 DB11672 DB12095 DB14649 DB00564 DB09107 DB05667 DB00951 DB13259 DB11581 DB09280 DB06448 DB02703 DB06712 DB09065 DB08899 DB14019 DB00648 DB00199 DB00907 DB00794 DB08873 DB04896 DB00814 DB00527 DB09185 DB00270 DB05232 DB00307 DB01232 DB01263 DB01234 DB01264 DB00582 DB01211 DB01086 DB11642 DB08882 DB08912 DB00312 DB00363 DB00503 DB15569 DB15762 DB00220 DB00297 DB01406 DB06237 DB01601 DB04855 DB01075 DB01072 DB06774 DB00625 DB00645 DB09048 DB01127 DB11901 DB08865 DB01007 DB01174 DB00705 DB00246 DB06700 DB09085 DB14568 DB00224 DB02520 DB12532 DB01118 DB00281 DB01320 DB00296 DB00559 DB14921 DB09231 DB00176 DB01323 DB11753 DB13578 DB01161 DB00961 DB01087 DB00807 DB06442 DB11779 DB11730 DB09345 DB13328 DB09009 DB00343 DB00721 DB00622 DB00196 DB00342 DB00750 DB00892 DB06731 DB00012 DB00227 DB09342 DB11652 DB14240 DB11932 DB05521 DB00673 DB11502 DB03255 DB06636 DB06414 DB06770 DB13179 DB09101 DB01026 DB01110 DB00607 DB04868 DB08987 DB06595 DB00976 DB06119 DB06290 DB14960 DB09118 DB00661 DB13683 DB04832 DB00016 DB11148 DB00502 DB00932 DB01183 DB00091 DB09227 DB00252 DB01045 DB11633 DB08933 DB00763 DB08894 DB01167 DB00696 DB00872 DB01201 DB01002 DB00701 DB09046 DB15982 DB00745","absorption":"Following administration of a single oral dose of 13.5 mg pemigatinib, the median Tmax was 1.13 (0.50-6.00) hours. The steady state was reached within 4 days following repeated once daily dosing, with the median drug accumulation ratio of 1.63 (range 0.63 to 3.28). Steady-state concentration of pemigatinib increased in a dose-proportional manner over the dose range of 1 to 20 mg, which is about 0.07 to 1.5 times the recommended dose. The mean steady-state AUC and Cmax were 2620 nM x h (54% CV) and 236 nM, respectively.[L13050]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Following administration of a single oral dose of 13.5 mg pemigatinib, the geometric mean elimination half-life (t) of pemigatinib was 15.4 (51.6% CV) hours.[L13050]","monoisotopic-mass":487.203110695,"volume-of-distribution":"The apparent volume of distribution was 235 L (60.8% CV) following a single oral dose of 13.5 mg pemigatinib.[L13050]","route-of-elimination":"Following oral administration of a single radiolabeled dose of 11 mg pemigatinib, about 82.4% of the dose was recovered in feces. Of this recovered drug, about 1.4% of the dose was unchanged parent compound. About 12.6% of the dose was recovered in urine, where 1% of the dose was unchanged.[L13050]","name":"Pemigatinib","metabolism":"Pemigatinib is predominantly metabolized by the CYP3A4 enzyme _in vitro_.[L13050] Its specific metabolic pathway and resulting metabolites have not yet been characterized.","reactions":null,"indication":"Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.[L13050]\r\n\r\nIt is also indicated for the treatment of adults with relapsed or refractory myeloid\/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.[L43005]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15102"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).","enzymes":null,"type":"biotech","cas-number":"1714088-51-3","sequences":null,"targets":null,"unii":"976X9VXC3Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Telisotuzumab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15104"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":455.5,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).","enzymes":null,"type":"small molecule","cas-number":"1818339-66-0","sequences":null,"targets":null,"unii":"1Y0Y126GUG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":455.089738166,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06751979","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15105"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":480.59,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).","enzymes":null,"type":"small molecule","cas-number":"1308672-74-3","sequences":null,"targets":null,"unii":"B2K5L1L8S9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":480.19435996,"volume-of-distribution":null,"route-of-elimination":null,"name":"Surufatinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15106"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":182.147,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).","enzymes":null,"type":"small molecule","cas-number":"29702-43-0","sequences":null,"targets":null,"unii":"ZO2JV75L55","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":182.059051617,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fludeoxyglucose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15107"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":604.66,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tipranavir C-14 is under investigation in clinical trial NCT02253797 (Pharmacokinetics of Tipranavir\/Ritonavir and Its Metabolites in Healthy Male Subjects).","enzymes":null,"type":"small molecule","cas-number":"1141509-98-9","sequences":null,"targets":null,"unii":"VU8T5RB4VW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":604.209469822,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tipranavir C-14","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15108"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":499.604,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ingenol disoxate is under investigation in clinical trial NCT02120456 (Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis).","enzymes":null,"type":"small molecule","cas-number":"1383547-60-1","sequences":null,"targets":null,"unii":"3B100VJ4ZW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":499.257002535,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ingenol disoxate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15109"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":532.5182,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).","enzymes":null,"type":"small molecule","cas-number":"1034616-18-6","sequences":null,"targets":null,"unii":"67RM91WDHQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":532.215821385,"volume-of-distribution":null,"route-of-elimination":null,"name":"Onvansertib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15110"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":59.052,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acetic acid C-11 is under investigation in clinical trial NCT01953965 (Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.).","enzymes":null,"type":"small molecule","cas-number":"78887-71-5","sequences":null,"targets":null,"unii":"2A9OM7IPNW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":59.032563187,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acetic acid C-11","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15111"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Somatropin pegol is under investigation in clinical trial NCT00715689 (Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083).","enzymes":null,"type":"biotech","cas-number":"1088845-67-3","sequences":null,"targets":null,"unii":"ZF7544FTQW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00682 DB00730 DB00331 DB00188 DB09199 DB13675 DB00398 DB00697 DB01132 DB09198 DB12531 DB00382 DB00586 DB00715 DB00784 DB13573 DB13634 DB00047 DB01142 DB00334 DB00740 DB06655 DB00356 DB00499 DB09071 DB00414 DB04876 DB04951 DB13956 DB01120 DB00977 DB00468 DB13446 DB00924 DB09273 DB09201 DB00993 DB09241 DB12945 DB00280 DB05708 DB00642 DB13955 DB00629 DB14132 DB00857 DB00412 DB01200 DB01482 DB00442 DB12026 DB01223 DB01166 DB02134 DB01277 DB01306 DB01086 DB11780 DB00571 DB01307 DB08882 DB12935 DB00277 DB00284 DB12268 DB01094 DB00574 DB00363 DB01412 DB06011 DB09022 DB00675 DB00316 DB00904 DB04871 DB01435 DB00321 DB12625 DB11919 DB00863 DB15171 DB06148 DB12781 DB00744 DB01067 DB00806 DB06626 DB00359 DB01124 DB09288 DB11567 DB01667 DB00046 DB00912 DB06203 DB06774 DB11757 DB00625 DB00672 DB01065 DB01382 DB08907 DB01558 DB00263 DB00568 DB00530 DB01242 DB01254 DB13874 DB00831 DB13203 DB01700 DB01380 DB00839 DB00222 DB01656 DB00655 DB00783 DB01195 DB00477 DB00491 DB06210 DB00532 DB04878 DB01276 DB01097 DB00787 DB13449 DB00315 DB06216 DB01251 DB04356 DB06127 DB00851 DB05115 DB05676 DB13952 DB00281 DB00268 DB11827 DB12417 DB12927 DB08910 DB00296 DB09256 DB00834 DB00773 DB13928 DB08496 DB11723 DB00176 DB00850 DB00365 DB06335 DB11824 DB01087 DB12214 DB13074 DB00461 DB12245 DB03783 DB01367 DB01058 DB14027 DB04841 DB01418 DB11967 DB13954 DB09200 DB00201 DB12412 DB01309 DB01261 DB12332 DB13592 DB08883 DB00370 DB00934 DB00731 DB00544 DB00998 DB00261 DB04574 DB04830 DB14035 DB00758 DB00978 DB01136 DB00379 DB01100 DB00575 DB01191 DB01424 DB06770 DB01645 DB06769 DB13812 DB12713 DB15217 DB02568 DB11992 DB11698 DB00788 DB01278 DB00030 DB11568 DB06479 DB01182 DB00969 DB00661 DB01037 DB01303 DB00972 DB01012 DB01184 DB01628 DB09118 DB14018 DB09043 DB13406 DB04076 DB04889 DB00502 DB08382 DB00425 DB00738 DB01289 DB06594 DB04948 DB12406 DB09045 DB01623 DB11898 DB02489 DB06235 DB09225 DB01252 DB06292 DB12926 DB11950 DB09265 DB01233 DB11689 DB00197 DB01016 DB00299 DB09290 DB01056 DB00195 DB00262 DB06589 DB00472 DB00384 DB00619 DB00898 DB13953 DB01405 DB01268 DB01002 DB01115 DB09456 DB00071 DB00914 DB09564 DB00286 DB00420 DB00533 DB00980 DB08962 DB00458 DB01015 DB09038 DB00518 DB12265","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Somatropin pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15112"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).","enzymes":null,"type":"biotech","cas-number":"1417318-27-4","sequences":null,"targets":null,"unii":"6YY8O697VF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Utomilumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15113"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":356.462,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vamorolone is under investigation in clinical trial NCT03439670 (A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)).","enzymes":null,"type":"small molecule","cas-number":"13209-41-1","sequences":null,"targets":null,"unii":"8XP29XMB43","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":356.198759382,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vamorolone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15114"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).","enzymes":null,"type":"biotech","cas-number":"2098636-09-8","sequences":null,"targets":null,"unii":"85TS31SOL3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nimacimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15115"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ramatercept is under investigation in clinical trial NCT00952887 (A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women).","enzymes":null,"type":"biotech","cas-number":"1169766-01-1","sequences":null,"targets":null,"unii":"42HQC6QLEK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ramatercept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15116"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":371.15,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Transfluthrin is under investigation in clinical trial NCT02394522 (Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)).","enzymes":null,"type":"small molecule","cas-number":"118712-89-3","sequences":null,"targets":null,"unii":"QWL3SKA6EG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":370.0150477,"volume-of-distribution":null,"route-of-elimination":null,"name":"Transfluthrin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15117"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).","enzymes":null,"type":"biotech","cas-number":"1496553-00-4","sequences":null,"targets":null,"unii":"TF5MPQ8WGY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zolbetuximab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15118"},{"toxicity":"Ropeginterferon alfa-2b overdose may present with influenza-like symptoms or other adverse reactions. As there is no known antidote, symptomatic and supportive care should be administered in the result of an overdose. Ropeginterferon alfa-2b is not mutagenic in standard assays but has not been tested for carcinogenic potential.[L39170]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Ropeginterferon alfa-2b acts through the interferon-alpha\/beta receptor to initiate downstream JAK\/STAT signalling leading to its therapeutic effects. Like other interferon alfa products, ropeginterferon alfa-2b may cause various toxicities, including endocrine, cardiovascular, pulmonary, ophthalmologic, dental\/periodontal, renal, and dermatological toxicity. In addition, interferon alfa has been associated with hepatotoxicity, including increases in serum ALT, AST, GGT, and bilirubin; ropeginterferon alfa-2b is contraindicated in patients with moderate to severe (Child-Pugh B or C) hepatic impairment. Pancreatitis and colitis, including fatal ulcerative\/hemorrhagic\/ischemic colitis, have occurred in patients treated with interferon alfa. Significant toxicity of any kind may require treatment discontinuation. Interferon alfa treatment has decreased peripheral blood counts, including thrombocytopenia and leukopenia, and altered lipid levels, including hyperlipidemia, hypertriglyceridemia, and dyslipidemia. Hypersensitivity reactions, including anaphylaxis, may occur; ropeginterferon alfa-2b is contraindicated in hypersensitive patients and those with known hypersensitivity to other interferons. Life-threatening or fatal neuropsychiatric reactions may occur, including in patients without prior history; ropeginterferon alfa-2b is contraindicated in patients with a history of severe psychiatric disorders. Finally, ropeginterferon alfa-2b can cause fetal harm and should be used with caution in females of reproductive potential.[L39170]","msds":null,"description":"Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet\/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia.[A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients.[A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN--2b in _Escherichia coli_ that has high tolerability and a long half-life.[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials.[A242010, A242015]\r\n\r\nRopeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]","enzymes":"BE0002363 BE0003336 BE0002433","type":"biotech","cas-number":"1335098-50-4","sequences":null,"targets":"BE0010136","unii":"981TME683S","protein-binding":null,"fda-label":null,"clearance":"Ropeginterferon alfa-2b administered to polycythemia vera patients over a dose range of 100-500 g has a clearance of 1.7-2.5 L\/h.[L39170]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), which also includes essential thrombocytopenia and myelofibrosis.[A242000, A242005] PV is characterized by increased hematocrit and platelet\/leukocyte counts, an increased risk for hemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia. The main driver mutation, _JAK2_ V617F, is present in >95% of PV patients and results in constitutive JAK\/STAT signalling; other exon 12 mutations in _JAK2_ may also result in PV. PV results in clonal hematopoietic stem cells, such that they form endogenous erythroid colonies (EECs) _in vitro_.[A242000]\r\n\r\nInterferon alfa-2b has been used for decades in PV despite the lack of formal approval.[A242005] Although the mechanism of action is unclear, interferon alfa-2b is known to bind the interferon-alpha\/beta receptor (IFNAR) and activate downstream JAK\/STAT signalling.[A242005, L39170] The overall result is a series of anti-proliferative, anti-angiogenic, pro-apoptotic, and immunomodulatory effects, including augmenting T-cell, macrophage, and natural killer cells.[A242005] Interestingly, _in vitro_ studies have revealed that ropeginterferon alfa-2b is specific to some extent for _JAK2_-mutant EECs, a result that is in line with the reduced allelic burden observed in clinical trials.[A242010, A242015] Partial and complete molecular and hematological responses have been achieved with ropeginterferon alfa-2b.[A242015]","drug-interactions":"DB08880 DB00682 DB14719 DB01560 DB13259 DB01545 DB13841 DB15857 DB00970 DB06554 DB12184 DB00092 DB11957 DB13875 DB04951 DB00562 DB01618 DB13799 DB00232 DB11921 DB13199 DB02377 DB06228 DB09307 DB00305 DB06772 DB00962 DB09195 DB01209 DB01595 DB11859 DB00321 DB13354 DB01265 DB15646 DB00292 DB16611 DB01075 DB09076 DB01065 DB00888 DB01551 DB13293 DB04846 DB00787 DB04356 DB00543 DB00851 DB08807 DB05676 DB04017 DB00230 DB00268 DB13554 DB13219 DB00120 DB00428 DB01555 DB01466 DB10990 DB06529 DB12229 DB09224 DB16021 DB13584 DB04888 DB00877 DB01257 DB00906 DB00298 DB09251 DB01005 DB12406 DB13805 DB06271 DB00091 DB00498 DB04917 DB01245 DB00614 DB00266 DB00662 DB00420 DB13323 DB10276 DB01410 DB00967 DB13124 DB00022 DB06738 DB06695 DB11868 DB13014 DB05459 DB02703 DB00327 DB13573 DB00468 DB11988 DB14619 DB00307 DB05099 DB02709 DB03451 DB06512 DB00674 DB11616 DB00363 DB14066 DB16736 DB09183 DB13687 DB00206 DB09154 DB08813 DB00231 DB11757 DB09053 DB05246 DB00831 DB12395 DB13384 DB00705 DB00734 DB01195 DB00604 DB05541 DB00842 DB08986 DB08904 DB15880 DB00471 DB00176 DB05015 DB01041 DB00921 DB01418 DB00343 DB00875 DB01450 DB08996 DB06446 DB13588 DB13606 DB06603 DB00780 DB00978 DB08893 DB00379 DB01355 DB09095 DB01615 DB01303 DB11686 DB13679 DB00502 DB01207 DB08908 DB08879 DB01511 DB01244 DB12518 DB01056 DB13335 DB00619 DB01268 DB01071 DB00445 DB13246 DB00660 DB00322 DB15203 DB09000 DB11156 DB13225 DB15122 DB01173 DB12531 DB13256 DB01193 DB00854 DB01354 DB11609 DB16648 DB01482 DB05710 DB12537 DB06527 DB00441 DB00480 DB11732 DB01601 DB09011 DB14620 DB00771 DB00625 DB03410 DB00645 DB00291 DB06688 DB01576 DB01267 DB14509 DB01242 DB01254 DB00068 DB13457 DB06660 DB15810 DB08872 DB00889 DB00859 DB00565 DB06441 DB00349 DB15654 DB00150 DB01621 DB01151 DB01138 DB00264 DB13327 DB00461 DB14385 DB14672 DB09128 DB01226 DB00865 DB01106 DB00688 DB13592 DB00892 DB04842 DB00579 DB00261 DB01013 DB08992 DB00317 DB09260 DB01018 DB11693 DB15786 DB13812 DB11312 DB09054 DB11038 DB04832 DB00972 DB00860 DB00273 DB00051 DB00497 DB01121 DB09226 DB01176 DB00029 DB00588 DB00696 DB14845 DB11529 DB00488 DB00286 DB02806 DB00880 DB11166 DB12265 DB09255 DB00407 DB00009 DB01224 DB10805 DB00740 DB00802 DB14050 DB00527 DB12902 DB01433 DB16694 DB01222 DB01351 DB01403 DB12161 DB13601 DB00844 DB00608 DB11642 DB00347 DB02852 DB00041 DB06470 DB01028 DB09036 DB04861 DB00320 DB01529 DB03575 DB01454 DB00013 DB01174 DB01497 DB00081 DB00352 DB00087 DB06400 DB01285 DB00405 DB01189 DB12361 DB01544 DB12070 DB00933 DB06264 DB01356 DB09029 DB00409 DB00764 DB09187 DB09173 DB05254 DB00059 DB12163 DB06209 DB13223 DB00342 DB13200 DB12831 DB00897 DB01437 DB06458 DB05361 DB09061 DB04574 DB00361 DB00620 DB06770 DB06727 DB12071 DB00186 DB11627 DB01159 DB11776 DB00001 DB09244 DB01238 DB09023 DB00946 DB02959 DB08892 DB00425 DB04572 DB06594 DB04885 DB13478 DB01559 DB12926 DB07954 DB00974 DB01553 DB00262 DB09072 DB00541 DB00006 DB00005 DB10315 DB01068 DB00328 DB08329 DB15091 DB00656 DB09052 DB00916 DB08814 DB00540 DB01142 DB00034 DB09273 DB00280 DB01200 DB00642 DB13510 DB06701 DB00105 DB01337 DB00395 DB00557 DB08922 DB01229 DB00503 DB07615 DB00863 DB09030 DB00490 DB00463 DB06217 DB00108 DB13534 DB00546 DB00853 DB01339 DB00278 DB14685 DB10804 DB11823 DB09082 DB09190 DB00238 DB00281 DB00773 DB00181 DB04818 DB00945 DB12883 DB12404 DB08811 DB13954 DB13496 DB01622 DB00245 DB12726 DB00599 DB11979 DB13541 DB13837 DB11951 DB00758 DB01191 DB00391 DB13396 DB04868 DB00788 DB12661 DB06119 DB06479 DB01182 DB07767 DB00031 DB00775 DB06616 DB11889 DB14711 DB06292 DB12545 DB01109 DB00866 DB00949 DB08870 DB00819 DB01015 DB04821 DB00983 DB00996 DB12177 DB00601 DB00241 DB00941 DB00641 DB00629 DB13817 DB00753 DB01234 DB08994 DB06605 DB00960 DB00312 DB00635 DB01435 DB12590 DB04884 DB01206 DB00313 DB15656 DB06203 DB00999 DB00633 DB00937 DB00568 DB11540 DB00617 DB01227 DB00432 DB12530 DB13784 DB09166 DB01225 DB12273 DB00065 DB00394 DB11582 DB01816 DB04840 DB00776 DB08059 DB12930 DB14651 DB01104 DB11708 DB11371 DB15628 DB06283 DB09555 DB09033 DB09345 DB05607 DB09009 DB00201 DB00496 DB06735 DB01280 DB00474 DB00690 DB13213 DB10769 DB01384 DB13025 DB01099 DB13993 DB00661 DB01037 DB00423 DB13775 DB01531 DB04889 DB00651 DB11050 DB00252 DB01047 DB00763 DB01405 DB01978 DB11984 DB01954 DB13420 DB00290 DB02546 DB04833 DB06144 DB06406 DB00075 DB00182 DB10343 DB01587 DB00295 DB00442 DB14185 DB00755 DB14443 DB00073 DB06643 DB00675 DB00748 DB12105 DB06282 DB00699 DB00248 DB00242 DB13745 DB14384 DB13791 DB12989 DB01154 DB01088 DB06109 DB09283 DB04665 DB00436 DB01380 DB01169 DB01239 DB11543 DB06702 DB12991 DB00427 DB09167 DB00484 DB04845 DB11817 DB09017 DB13362 DB09247 DB06779 DB13273 DB05144 DB09254 DB00494 DB09016 DB06273 DB05325 DB00750 DB00042 DB01049 DB01196 DB00544 DB13623 DB06579 DB08971 DB09223 DB12568 DB13757 DB01262 DB14010 DB00593 DB12111 DB00829 DB13929 DB10803 DB11549 DB00063 DB15031 DB01177 DB00958 DB01221 DB01149 DB13523 DB00697 DB10991 DB06077 DB06678 DB08868 DB00499 DB00794 DB01509 DB01036 DB00857 DB00285 DB00514 DB09258 DB11785 DB05266 DB04827 DB00434 DB00444 DB00371 DB11755 DB01073 DB09039 DB01423 DB13643 DB00570 DB09174 DB09248 DB08901 DB00489 DB12725 DB01667 DB13690 DB04836 DB00563 DB06822 DB12768 DB05374 DB00018 DB04920 DB00341 DB11770 DB12465 DB12951 DB12092 DB11767 DB08496 DB00850 DB00365 DB13160 DB00366 DB09246 DB13241 DB15461 DB09252 DB11699 DB08883 DB12445 DB01136 DB00306 DB01645 DB06769 DB04925 DB13984 DB01171 DB09186 DB09286 DB01336 DB01338 DB05562 DB00074 DB01135 DB00856 DB01074 DB00515 DB01042 DB12833 DB01297 DB08953 DB15274 DB13400 DB12710 DB13082 DB06679 DB11552 DB01215 DB09185 DB12945 DB09253 DB13068 DB05232 DB08844 DB13522 DB16650 DB13303 DB11919 DB06148 DB13754 DB01590 DB12338 DB13843 DB06506 DB00806 DB00475 DB04908 DB12814 DB13136 DB01558 DB13411 DB01295 DB01577 DB00777 DB09383 DB00714 DB13552 DB10584 DB06690 DB00959 DB01323 DB09074 DB01624 DB01495 DB00008 DB00547 DB01033 DB00708 DB01240 DB00987 DB00370 DB09249 DB13787 DB00731 DB00276 DB08550 DB10061 DB01204 DB01100 DB01035 DB05942 DB00623 DB01202 DB14018 DB13233 DB00402 DB00372 DB11976 DB00738 DB00033 DB00652 DB00598 DB11689 DB01175 DB00299 DB14540 DB00180 DB15626 DB08906 DB12576 DB00203 DB00476 DB12958 DB00586 DB00715 DB01156 DB12110 DB13414 DB00977 DB17088 DB00924 DB00993 DB13662 DB00072 DB06654 DB11304 DB12026 DB13402 DB01359 DB14445 DB10317 DB04871 DB08810 DB01534 DB00628 DB11834 DB06201 DB09378 DB00606 DB14022 DB00416 DB00069 DB01452 DB12025 DB11555 DB13782 DB13874 DB13737 DB09327 DB09068 DB00015 DB13449 DB11400 DB00754 DB06543 DB12427 DB01199 DB11376 DB08960 DB12917 DB08794 DB00454 DB01161 DB11718 DB01095 DB01008 DB01058 DB01108 DB13114 DB00396 DB11603 DB13221 DB14094 DB00590 DB13234 DB10600 DB00377 DB12212 DB00774 DB06168 DB00849 DB09118 DB13577 DB00932 DB13733 DB04948 DB00486 DB06235 DB09001 DB04953 DB01063 DB06612 DB13953 DB00384 DB11580 DB14545 DB00518 DB00956 DB03523 DB09259 DB12308 DB00188 DB01501 DB00234 DB01105 DB04896 DB04905 DB00843 DB09241 DB14724 DB13437 DB01608 DB12947 DB06584 DB13099 DB06081 DB04956 DB01166 DB04898 DB14449 DB14394 DB00904 DB01614 DB14783 DB00373 DB10989 DB00215 DB06626 DB01567 DB02245 DB06218 DB09048 DB08895 DB00202 DB01483 DB00679 DB00111 DB06700 DB00477 DB00208 DB08887 DB00335 DB13324 DB05687 DB13275 DB12612 DB00443 DB09204 DB00433 DB00694 DB00508 DB13331 DB04932 DB00446 DB04841 DB04903 DB15483 DB01186 DB00039 DB04743 DB09289 DB06681 DB13403 DB12692 DB14718 DB04914 DB02568 DB09075 DB14512 DB04820 DB13598 DB00653 DB04599 DB11148 DB13646 DB10318 DB13583 DB13430 DB00408 DB09073 DB00026 DB04844 DB00470 DB00832 DB01203 DB00458 DB00953 DB11556 DB06754 DB00437 DB09091 DB08871 DB00356 DB09071 DB00337 DB05440 DB13856 DB01594 DB04834 DB00187 DB00309 DB12598 DB00482 DB04872 DB00056 DB13665 DB00744 DB11803 DB08808 DB12617 DB13347 DB00318 DB13491 DB01488 DB00011 DB00315 DB06216 DB09256 DB00961 DB00807 DB05260 DB08935 DB05271 DB01588 DB06674 DB13382 DB06731 DB13872 DB10583 DB05258 DB13557 DB00998 DB00909 DB00683 DB00243 DB13451 DB00837 DB00669 DB15253 DB09034 DB01012 DB01628 DB01253 DB10316 DB00184 DB04325 DB15360 DB01101 DB11130 DB00762 DB06343 DB01081 DB01178 DB09290 DB00472 DB00898 DB01472 DB01580 DB00928 DB14028 DB13642 DB00382 DB12289 DB00737 DB00637 DB13876 DB05542 DB01247 DB13505 DB05708 DB14132 DB00495 DB01409 DB01223 DB01086 DB00277 DB09184 DB00732 DB12386 DB01246 DB09351 DB01235 DB01535 DB13867 DB00531 DB02234 DB11855 DB08970 DB00631 DB13948 DB13203 DB11044 DB00246 DB13208 DB00592 DB08927 DB13572 DB11003 DB01320 DB08839 DB06813 DB15861 DB12332 DB01274 DB00324 DB00835 DB00098 DB01281 DB13253 DB01445 DB00086 DB00552 DB12364 DB01184 DB08861 DB01107 DB09225 DB06582 DB00054 DB13940 DB06589 DB09194 DB00980 DB14055 DB08952 DB14919 DB00784 DB00526 DB00237 DB10283 DB00334 DB00899 DB01484 DB01626 DB11095 DB13955 DB00706 DB11664 DB06635 DB02134 DB05227 DB01094 DB01412 DB13149 DB00316 DB00418 DB01616 DB10062 DB00297 DB00193 DB13605 DB09122 DB09288 DB13454 DB00450 DB00783 DB05109 DB00532 DB01097 DB13616 DB08910 DB00055 DB09243 DB00569 DB00985 DB09117 DB00550 DB09250 DB04819 DB09021 DB01192 DB06575 DB12749 DB06372 DB11477 DB01181 DB01114 DB06608 DB00591 DB00818 DB10794 DB00323 DB00952 DB01248 DB00811 DB00555 DB00289 DB12996 DB00404 DB14881 DB13924 DB09245 DB00801 DB06662 DB13550 DB13956 DB00195 DB11569 DB01002 DB13367 DB00564 DB00398 DB13352 DB06294 DB13634 DB06684 DB09077 DB01440 DB13648 DB13003 DB14029 DB01006 DB13357 DB01392 DB00078 DB11614 DB00589 DB06287 DB04630 DB01611 DB01563 DB08815 DB11040 DB01547 DB06016 DB04946 DB13770 DB01591 DB06774 DB00751 DB13455 DB14715 DB01236 DB11598 DB01656 DB06210 DB09085 DB06753 DB00189 DB11487 DB12771 DB04829 DB00997 DB13520 DB12131 DB00296 DB12327 DB11041 DB00813 DB01255 DB00752 DB05472 DB03783 DB00864 DB01463 DB06691 DB01367 DB04977 DB01024 DB00721 DB00185 DB01442 DB00934 DB00344 DB09014 DB00757 DB12693 DB09042 DB05767 DB11466 DB00805 DB01589 DB06797 DB01565 DB00083 DB00115 DB00747 DB12321 DB00969 DB14575 DB06726 DB06204 DB04076 DB15595 DB06716 DB01623 DB00483 DB08954 DB02489 DB13295 DB11915 DB00333 DB00095 DB11586 DB01429 DB14762 DB00730 DB12492 DB11428 DB01198 DB00380 DB00680 DB01324 DB09119 DB14539 DB06288 DB15434 DB11963 DB12371 DB00571 DB01219 DB06650 DB00574 DB01352 DB13036 DB08816 DB12093 DB01353 DB02207 DB01228 DB01489 DB12401 DB00228 DB13443 DB14409 DB15762 DB05259 DB08889 DB01030 DB05229 DB00530 DB13370 DB12752 DB00975 DB08877 DB11675 DB00216 DB14513 DB00686 DB13952 DB04165 DB12927 DB13377 DB00728 DB13532 DB01079 DB06153 DB01087 DB14754 DB00795 DB13508 DB12245 DB00647 DB00283 DB16703 DB11967 DB01069 DB00293 DB00726 DB13530 DB00575 DB01424 DB01021 DB12016 DB08918 DB05773 DB14219 DB09057 DB00611 DB12867 DB00247 DB00918 DB01233 DB01168 DB13676 DB01115 DB00914 DB01080 DB14726 DB00701 DB00533 DB00687 DB09312","absorption":"In patients with polycythemia vera on a two-week dosing interval, the estimated steady-state C<sub>min<\/sub> was 1.4-12 ng\/mL, C<sub>max<\/sub> was 4.4-31 ng\/mL, and AUC was 1011-7809 ng\\*h\/mL. The estimated geometric mean (%CV) of the absorption rate constant if 0.12 day<sup>-1<\/sup> (27%) and the estimated steady-state C<sub>max<\/sub> occurs between 2-5 days.[L39170]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Ropeginterferon alfa-2b administered to polycythemia vera patients over a dose range of 100-500 g has a half-life of approximately seven days.[L39170]","monoisotopic-mass":null,"volume-of-distribution":"Ropeginterferon alfa-2b has an estimated geometric mean apparent volume of distribution (%CV) of 4.8 L (21%) in polycythemia vera patients.[L39170]","route-of-elimination":"Ropeginterferon alfa-2b is expected to be eliminated predominantly by hepatic metabolism.[L15811]","name":"Ropeginterferon alfa-2b","metabolism":"Ropeginterferon alfa-2b is expected to be catabolized by various proteolytic enzymes.[L15811]","reactions":null,"indication":"Ropeginterferon alfa-2b is indicated for the treatment of adult patients with polycythemia vera.[L39170]","ahfs-codes":null,"updated":"2021-12-03","drugbank-id":"DB15119"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":377.488,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).","enzymes":null,"type":"small molecule","cas-number":"720691-69-0","sequences":null,"targets":null,"unii":"4I7U5C459M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06698 DB00852 DB12080 DB14740 DB09480 DB00895 DB00070 DB13108 DB01579 DB06205 DB01255 DB01566 DB01454 DB01509 DB00865 DB01365 DB01484 DB00937 DB01576 DB00182 DB13940 DB01467 DB01442 DB01577 DB00191 DB13703 DB13624 DB00424 DB01556","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":377.210327121,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK-239512","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15120"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":421.35,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).","enzymes":null,"type":"small molecule","cas-number":"1355612-71-3","sequences":null,"targets":null,"unii":"E8I3O45DDU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":421.045644865,"volume-of-distribution":null,"route-of-elimination":null,"name":"AT-001","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15121"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":285.359,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).","enzymes":null,"type":"small molecule","cas-number":"1268605-91-9","sequences":null,"targets":null,"unii":"FLV771E8ZV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01873 DB11459 DB01208 DB14028 DB14719 DB15131 DB13456 DB08329 DB00610 DB01545 DB03374 DB08841 DB06554 DB00034 DB01215 DB09185 DB09273 DB00451 DB13799 DB08941 DB06213 DB00105 DB01337 DB13703 DB06715 DB00962 DB00368 DB01556 DB01595 DB11859 DB06711 DB01102 DB14506 DB01590 DB12338 DB09351 DB00806 DB00475 DB00463 DB06814 DB13341 DB12814 DB00388 DB00546 DB01558 DB00640 DB14999 DB01295 DB01577 DB04846 DB15119 DB09082 DB01044 DB08807 DB00230 DB00389 DB01320 DB15749 DB09480 DB00487 DB00008 DB13409 DB00901 DB12404 DB01064 DB00779 DB09080 DB00467 DB01274 DB01364 DB00599 DB13837 DB13287 DB01165 DB06233 DB13396 DB00871 DB00218 DB00549 DB06119 DB00877 DB01182 DB01202 DB00685 DB01059 DB00906 DB00908 DB06262 DB00033 DB05039 DB01321 DB00723 DB00612 DB00598 DB13940 DB05488 DB00866 DB00949 DB00841 DB00819 DB01152 DB00983 DB00996 DB00022 DB01583 DB12080 DB11868 DB00668 DB08952 DB12100 DB00951 DB00237 DB09309 DB00241 DB00468 DB01484 DB13823 DB01137 DB13624 DB06512 DB00960 DB00312 DB01359 DB00628 DB00418 DB00313 DB06201 DB01155 DB09122 DB00069 DB00231 DB00822 DB01566 DB00937 DB05246 DB00816 DB11404 DB00617 DB09166 DB08985 DB00532 DB00397 DB11400 DB00754 DB00852 DB00988 DB05541 DB11471 DB01118 DB00842 DB12089 DB11892 DB00776 DB03010 DB00176 DB09117 DB11383 DB00550 DB12391 DB01366 DB00060 DB05396 DB00474 DB00449 DB00690 DB00978 DB00379 DB01355 DB11470 DB12212 DB15753 DB00849 DB00555 DB09118 DB13775 DB00404 DB00830 DB01365 DB00252 DB01511 DB09001 DB07637 DB00763 DB13692 DB00801 DB04953 DB06318 DB00195 DB13335 DB11554 DB01405 DB00867 DB08972 DB15203 DB00564 DB11443 DB01407 DB07348 DB01193 DB11752 DB13633 DB14029 DB00182 DB13437 DB01587 DB08931 DB06764 DB09418 DB09352 DB01211 DB13261 DB06287 DB12537 DB06527 DB01363 DB00373 DB00954 DB13644 DB01567 DB09011 DB06152 DB06218 DB01576 DB14509 DB01154 DB01483 DB11943 DB13455 DB00068 DB14715 DB06600 DB11491 DB00208 DB00335 DB00349 DB12131 DB04854 DB04576 DB05903 DB00935 DB11405 DB04845 DB09017 DB00264 DB13362 DB01255 DB09204 DB14672 DB00865 DB04841 DB01467 DB01442 DB00191 DB01408 DB01589 DB13179 DB13757 DB00211 DB09308 DB11475 DB11124 DB00653 DB14575 DB06707 DB06726 DB00593 DB06160 DB00273 DB00051 DB04070 DB14507 DB01121 DB08954 DB09203 DB00829 DB11442 DB00817 DB11549 DB13777 DB13139 DB13627 DB11774 DB00832 DB03322 DB00537 DB00730 DB00437 DB00697 DB14025 DB00740 DB13338 DB14050 DB01001 DB11587 DB00199 DB01288 DB00794 DB01509 DB09119 DB01351 DB01594 DB03604 DB12526 DB00187 DB11785 DB00827 DB00571 DB00574 DB02207 DB13643 DB00347 DB13852 DB01489 DB13443 DB06470 DB13108 DB08808 DB04861 DB00489 DB13772 DB01454 DB12752 DB01174 DB11511 DB00018 DB00011 DB11770 DB01544 DB04165 DB01032 DB00024 DB08957 DB00279 DB00938 DB00365 DB13508 DB13804 DB01588 DB00501 DB06419 DB08883 DB06458 DB13530 DB00897 DB13872 DB12266 DB05258 DB09061 DB01190 DB01136 DB00909 DB00683 DB00186 DB06587 DB00837 DB13064 DB11871 DB01559 DB00221 DB01291 DB06342 DB01553 DB09100 DB01080 DB00533 DB01580 DB01068 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":285.18492425,"volume-of-distribution":null,"route-of-elimination":null,"name":"PCS-499","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15122"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":462.93,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dorzagliatin is under investigation in clinical trial NCT03173391 (Long-term Efficacy and Safety of HMS5552 in T2DM).","enzymes":null,"type":"small molecule","cas-number":"1191995-00-2","sequences":null,"targets":null,"unii":"X59W6980E8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":462.1669977,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dorzagliatin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15123"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":436.91,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).","enzymes":null,"type":"small molecule","cas-number":"1387633-03-5","sequences":null,"targets":null,"unii":"8RAL5N48VT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":436.097204,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-05241328","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15124"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).","enzymes":null,"type":"small molecule","cas-number":"1980787-47-0","sequences":null,"targets":null,"unii":"K7ODU55HT6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Belapectin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15125"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":519.625,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"IMG-7289 is under investigation in clinical trial NCT03136185 (IMG-7289 in Patients With Myelofibrosis).","enzymes":null,"type":"small molecule","cas-number":"1990504-34-1","sequences":null,"targets":null,"unii":"Y2T4ALDEAT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":519.275801526,"volume-of-distribution":null,"route-of-elimination":null,"name":"IMG-7289","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15126"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2.016,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Hydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).","enzymes":null,"type":"small molecule","cas-number":"1333-74-0","sequences":null,"targets":null,"unii":"7YNJ3PO35Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2.015650064,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hydrogen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-10","drugbank-id":"DB15127"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).","enzymes":null,"type":"biotech","cas-number":"1791410-27-9","sequences":null,"targets":null,"unii":"1V8WRH3RVX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Remtolumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15128"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pegadricase is under investigation in clinical trial NCT01021241 (Safety and Efficacy Study of Intravenous Uricase-PEG 20).","enzymes":null,"type":"biotech","cas-number":"1040753-26-1","sequences":null,"targets":null,"unii":"50XB37EKN8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pegadricase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15129"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":211.33,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).","enzymes":null,"type":"small molecule","cas-number":"104632-28-2","sequences":null,"targets":null,"unii":"WI638GUS96","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08922 DB09223 DB11376 DB08815 DB00623 DB04888 DB00933 DB06016 DB01224 DB04946 DB00850 DB00422 DB06077 DB01238 DB00334 DB06144 DB01156 DB01624 DB00502 DB00433 DB09128 DB01623 DB01267 DB09225 DB09226 DB00679 DB00875 DB00831 DB01608 DB01403 DB06288 DB01618 DB01233 DB00408 DB09224 DB00246 DB00450 DB00734 DB01622 DB06701 DB14185 DB00477 DB01239 DB00420 DB06216 DB01100 DB00363","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":211.114318733,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dexpramipexole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15130"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).","enzymes":"BE0002433","type":"biotech","cas-number":"142192-09-4","sequences":null,"targets":null,"unii":"VW75A46X0K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00682 DB00730 DB00188 DB00697 DB00398 DB15122 DB12531 DB00382 DB00586 DB00715 DB13573 DB13634 DB00784 DB01142 DB00334 DB00740 DB00356 DB00499 DB09071 DB04951 DB13956 DB00977 DB00468 DB14029 DB00924 DB09273 DB00993 DB12945 DB09241 DB00280 DB05708 DB00642 DB14132 DB00629 DB13955 DB00857 DB00495 DB01482 DB00442 DB08844 DB12026 DB02377 DB01223 DB01166 DB02134 DB01086 DB00571 DB00277 DB01094 DB01412 DB00363 DB00574 DB00675 DB00316 DB00904 DB04871 DB01435 DB00321 DB11919 DB00863 DB06148 DB00744 DB00806 DB06626 DB09288 DB02245 DB01667 DB06774 DB11757 DB00625 DB01065 DB01558 DB00568 DB00530 DB01254 DB13874 DB01242 DB00831 DB13203 DB01656 DB00783 DB01195 DB00477 DB06210 DB00532 DB01097 DB13449 DB00787 DB00315 DB06216 DB04356 DB00851 DB05676 DB13952 DB00281 DB00268 DB12927 DB08910 DB00296 DB09256 DB00773 DB08496 DB00176 DB00850 DB00365 DB01087 DB00461 DB12245 DB03783 DB01367 DB01058 DB04841 DB01418 DB11967 DB13954 DB00201 DB06575 DB01033 DB13592 DB12332 DB08883 DB00370 DB00934 DB00544 DB00998 DB04574 DB00261 DB00758 DB00978 DB01136 DB00379 DB01191 DB01100 DB00575 DB01424 DB06770 DB01645 DB13812 DB06769 DB02568 DB00788 DB06479 DB01182 DB14018 DB00661 DB00969 DB01303 DB01012 DB01037 DB01184 DB01628 DB09118 DB00972 DB04076 DB04889 DB00502 DB00425 DB00651 DB06594 DB04948 DB12406 DB01623 DB02489 DB06235 DB09225 DB06292 DB12926 DB07954 DB01233 DB11689 DB00299 DB09290 DB01056 DB00195 DB00262 DB06589 DB00472 DB00384 DB00619 DB00898 DB13953 DB01405 DB01002 DB01978 DB01115 DB00286 DB00420 DB00533 DB00980 DB00458 DB00518 DB12265","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Interferon alfa-2c","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15131"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":513.91,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-8165 is under investigation in clinical trial NCT01150812 (Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects).","enzymes":null,"type":"small molecule","cas-number":"1201686-72-7","sequences":null,"targets":null,"unii":"7WO8I5IY24","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":513.132758,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-8165","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15132"},{"toxicity":"There are no data regarding overdosage of tepotinib. Symptoms of overdose are likely to be consistent with tepotinib's adverse effect profile and may therefore involve significant gastrointestinal symptoms, musculoskeletal pain, and laboratory abnormalities.[L31443] Treatment of overdose should involve symptomatic and supportive measures. In the event of overdose, dialysis is unlikely to be of benefit given the high degree of plasma protein binding exhibited by tepotinib.","snp-adverse-drug-reactions":null,"average-mass":492.583,"transporters":"BE0000703 BE0003647 BE0003657 BE0001067 BE0001032 BE0003648 BE0004752","pharmacodynamics":"Tepotinib is a highly-selective inhibitor of MET kinase activity, with an average IC<sub>50<\/sub> of approximately 1.7 nmol\/L.[A228058] It has a moderate duration of action necessitating once-daily administration.[L31443]\r\n\r\nTepotinib has been associated with the development of interstitial lung disease (ILD)\/pneumonitis, which can sometimes be fatal.[L31443] Patients should be monitored closely for signs of new or worsening respiratory symptoms (e.g. dyspnea, cough), and treatment with tepotinib should be immediately withheld if ILD\/pneumonitis is suspected. If no other potential causes of ILD\/pneumonitis are identified, therapy with tepotinib should be suspended indefinitely.[L31443]","msds":null,"description":"Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.[A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma.[A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is overexpressed and\/or mutated.\r\n\r\nTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand name Tepmetko, for the treatment of adult patients with metastatic NSCLC and _MET_ exon 14 skipping alterations.[L31443,L31473] It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an advantage that may aid in easing the pill burden often associated with chemotherapeutic regimens. In February 2022, tepotinib was approved for use in Europe.[L42200]","enzymes":"BE0002638 BE0002887 BE0002793","type":"small molecule","cas-number":"1100598-32-0","sequences":null,"targets":"BE0000915 BE0000327 BE0003580","unii":"1IJV77EI07","protein-binding":"Tepotinib is approximately 98% protein-bound in plasma,[L31443] primarily to serum albumin and alpha-1-acid glycoprotein.[A228038] Plasma protein binding is independent of drug concentration at clinically relevant exposures.[L31443]","fda-label":null,"clearance":"The apparent clearance of tepotinib is 23.8 L\/h.[L31443]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Other protein kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":false,"food-interactions":"Take with food. Co-administration with a meal improves the absorption of tepotinib.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Mesenchymal-epithelial transition factor (MET) is a receptor tyrosine kinase found overexpressed and\/or mutated in a variety of tumor types, thus making it a desirable target in their treatment. MET plays a critical role in the proliferation, survival, invasion, and mobilization of tumor cells, and aberrant MET activation is thought to contribute to the development of more aggressive cancers with poorer prognoses.[A228033] \r\n\r\nTepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping - it inhibits MET phosphorylation and subsequent downstream signaling pathways in order to inhibit tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells.[L31443] Tepotinib has also been observed to down-regulate the expression of epithelial-mesenchymal transition (EMT) promoting genes (e.g. MMP7, COX-2, WNT1, MUC5B, and c-MYC) and upregulate the expression of EMT-suppressing genes (e.g. MUC5AC, MUC6, GSK3, and E-cadherin) in c-MET-amplified gastric cancer cells,[A228033] suggesting that the tumor-suppressing activity of tepotinib is driven, at least in part, by the negative regulation of c-MET-induced EMT. It has also been shown to inhibit melatonin 1B and nischarin at clinically relevant concentrations, though the relevance of this activity in regards to tepotinib's mechanism of action is unclear.[L31443]","drug-interactions":"DB08880 DB00328 DB08953 DB00682 DB12095 DB12457 DB00742 DB13259 DB06737 DB03374 DB00540 DB06712 DB01142 DB00970 DB08828 DB04951 DB00814 DB09185 DB05829 DB00338 DB12035 DB00451 DB00845 DB00177 DB05232 DB00495 DB03756 DB13878 DB06228 DB00957 DB06715 DB01086 DB13691 DB06772 DB00321 DB00503 DB07615 DB00973 DB00220 DB01590 DB09030 DB01067 DB04908 DB01124 DB04690 DB01075 DB00531 DB11855 DB12825 DB00631 DB09076 DB13136 DB11828 DB01127 DB01396 DB11901 DB00390 DB08865 DB00839 DB00222 DB11823 DB00246 DB00481 DB00358 DB00238 DB02520 DB06739 DB00389 DB08820 DB11827 DB00281 DB01320 DB00834 DB00773 DB13943 DB01323 DB13578 DB09421 DB01259 DB04938 DB00945 DB00440 DB09299 DB06813 DB13954 DB00017 DB14009 DB13879 DB12332 DB09080 DB01274 DB00731 DB11979 DB00012 DB11932 DB01204 DB05521 DB11951 DB00758 DB09161 DB11502 DB09101 DB11641 DB04881 DB04868 DB14723 DB08881 DB11575 DB00549 DB00788 DB06595 DB06119 DB00877 DB01182 DB06290 DB14960 DB12364 DB08930 DB00908 DB06616 DB00091 DB05039 DB09227 DB11633 DB14973 DB06292 DB06725 DB00612 DB11689 DB08894 DB11613 DB06589 DB00872 DB01201 DB00749 DB08870 DB00266 DB00420 DB00980 DB09046 DB01015 DB00214 DB00983 DB14055 DB01583 DB00203 DB00476 DB06738 DB06695 DB09107 DB00951 DB12001 DB06448 DB12015 DB02703 DB12629 DB00327 DB00586 DB00784 DB00526 DB00175 DB11952 DB01156 DB14019 DB00648 DB00414 DB04851 DB01120 DB08873 DB00977 DB00468 DB00270 DB00641 DB15328 DB13955 DB00307 DB01234 DB11978 DB12026 DB00582 DB06605 DB01283 DB00312 DB00304 DB00363 DB11869 DB00316 DB09183 DB09063 DB01435 DB00206 DB00313 DB00297 DB12147 DB12500 DB06237 DB09288 DB00936 DB11757 DB00882 DB00568 DB13874 DB09068 DB00705 DB00617 DB00783 DB05109 DB05084 DB00469 DB12836 DB08896 DB00624 DB00532 DB01097 DB00224 DB01251 DB05541 DB12532 DB01118 DB12267 DB08910 DB00559 DB00471 DB00176 DB01104 DB01161 DB05015 DB00550 DB09296 DB11712 DB01095 DB01357 DB01041 DB11730 DB00921 DB09345 DB11574 DB01418 DB09009 DB06207 DB00343 DB00622 DB00196 DB14068 DB11560 DB00396 DB09342 DB11652 DB00590 DB06603 DB01181 DB00158 DB08893 DB00812 DB06414 DB12582 DB00818 DB01355 DB01026 DB09118 DB00661 DB01037 DB13683 DB16222 DB11697 DB00502 DB00932 DB01289 DB00486 DB00252 DB01045 DB11853 DB07637 DB00763 DB01016 DB13956 DB14011 DB01167 DB13953 DB00619 DB01002 DB05239 DB06670 DB12799 DB09078 DB11672 DB11800 DB05667 DB00564 DB00188 DB00398 DB11581 DB08439 DB09065 DB08899 DB07348 DB13944 DB09291 DB06191 DB11362 DB01050 DB04896 DB00843 DB09241 DB00412 DB11614 DB08931 DB01232 DB00295 DB01263 DB14069 DB00755 DB09418 DB14989 DB04898 DB01211 DB08995 DB12941 DB06287 DB09049 DB00675 DB00904 DB06403 DB05889 DB00441 DB01029 DB15569 DB00709 DB13644 DB14737 DB11732 DB00248 DB06626 DB01601 DB00242 DB01072 DB00672 DB06774 DB00625 DB06218 DB09048 DB00645 DB08907 DB01267 DB00580 DB11943 DB01254 DB11760 DB01154 DB04665 DB00836 DB01169 DB06700 DB06480 DB09330 DB09085 DB12597 DB06234 DB00349 DB01394 DB00997 DB00374 DB00457 DB03496 DB00296 DB05294 DB14921 DB12612 DB00796 DB06652 DB00250 DB11753 DB00554 DB04845 DB15233 DB00698 DB08860 DB15263 DB00461 DB01220 DB11779 DB00694 DB00300 DB09027 DB09239 DB03783 DB00864 DB04841 DB13328 DB11995 DB06285 DB13742 DB00721 DB14975 DB00688 DB14631 DB00750 DB00892 DB00544 DB00317 DB00465 DB06636 DB14126 DB11693 DB13179 DB01131 DB12713 DB01589 DB09075 DB01110 DB08987 DB06176 DB13125 DB09054 DB00976 DB00969 DB04832 DB00016 DB00972 DB13401 DB11148 DB12466 DB00829 DB01098 DB00539 DB00408 DB00197 DB09073 DB00696 DB00333 DB01177 DB00470 DB00286 DB00458 DB01221 DB11586 DB01149 DB00080 DB00537 DB00437 DB11791 DB13675 DB09280 DB13919 DB00360 DB00066 DB00740 DB00199 DB00907 DB01198 DB06697 DB00794 DB11986 DB00527 DB09079 DB08875 DB01036 DB03604 DB00857 DB11963 DB00514 DB01264 DB12371 DB12483 DB00950 DB12455 DB11642 DB08882 DB08912 DB00444 DB00482 DB12474 DB08816 DB09039 DB00347 DB00570 DB08934 DB09297 DB15762 DB08901 DB01406 DB08916 DB09102 DB00744 DB01028 DB06240 DB08889 DB01030 DB04855 DB15442 DB00563 DB01174 DB08877 DB11796 DB00678 DB06268 DB09279 DB14568 DB00216 DB11770 DB13952 DB01544 DB00439 DB00024 DB09213 DB09231 DB08496 DB13941 DB00279 DB01079 DB00961 DB01087 DB00807 DB04557 DB00795 DB13804 DB12245 DB16703 DB14840 DB06370 DB11967 DB06803 DB06212 DB06209 DB06419 DB01261 DB00342 DB00726 DB00896 DB06731 DB09061 DB15719 DB00227 DB00448 DB04574 DB00862 DB16236 DB01136 DB00909 DB00673 DB00712 DB03255 DB01424 DB06770 DB00243 DB06769 DB04725 DB01159 DB00669 DB09034 DB00602 DB08827 DB01628 DB00946 DB15149 DB13406 DB05773 DB00425 DB01183 DB01101 DB00762 DB12141 DB15822 DB13007 DB12887 DB00472 DB00541 DB09100 DB00701 DB00533 DB08962 DB15982 DB01388","absorption":"The absolute bioavailability of tepotinib following oral administration is approximately 72%.[L31443,A228038] At the recommended dosage of 450mg once daily, the median T<sub>max<\/sub> is 8 hours and the mean steady-state C<sub>max<\/sub> and AUC<sub>0-24h<\/sub> were 1,291 ng\/mL and 27,438 ngh\/mL, respectively.[L31443]\r\n\r\nCo-administration with a high-fat, high-calorie meal increases the AUC and C<sub>max<\/sub> of tepotinib by approximately 1.6-fold and 2-fold, respectively.[L31443]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530 BE0000925","half-life":"Following oral administration, the half-life of tepotinib is approximately 32 hours.[L31443]","monoisotopic-mass":492.227374166,"volume-of-distribution":"The mean apparent volume of distribution is 1,038L.[L31443]","route-of-elimination":"Following oral administration, approximately 85% of the given dose is excreted in the feces with the remainder excreted in the urine.[L31443] Unchanged parent drug accounts for roughly half of the dose excreted in the feces,[L31443,A228038] with the remainder comprising the demethylated M478 metabolite, a glucuronide metabolite, the racemic M506 metabolite, and some minor oxidative metabolites.[A228038] Unchanged parent drug also accounts for roughly half of the dose excreted in the urine, with the remainder comprising a glucuronide metabolite and a pair of N-oxide diastereomer metabolites.[A228038]","name":"Tepotinib","metabolism":"Tepotinib is metabolized primarily by CYP3A4 and CYP2C8,[L31443] with some apparent contribution by unspecified UGT enzymes.[A228038] The metabolite M506 is the major circulating metabolite, comprising approximately 40.4% of observed drug material in plasma,[L31443] while the M668 glucuronide metabolite has been observed in plasma at much lower quantities (~4% of an orally administered dose).[A228038] A total of 10 phase I and phase II metabolites have been detected following tepotinib administration, most of which are excreted in the feces.[A228038]","reactions":null,"indication":"Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (_MET_) exon 14 skipping alterations.[L31443]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15133"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":246.185,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).","enzymes":null,"type":"small molecule","cas-number":"864084-85-5","sequences":null,"targets":null,"unii":"UG7I3Y42PV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":246.062983101,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluoroazomycin arabinoside F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15134"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).","enzymes":null,"type":"biotech","cas-number":"1178862-65-1","sequences":null,"targets":null,"unii":"1TG15H1XE9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ponezumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15135"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":967.021,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).","enzymes":null,"type":"small molecule","cas-number":"58543-16-1","sequences":null,"targets":null,"unii":"B3FUD0528F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":966.430788514,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rebaudioside A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15136"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":514.98,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).","enzymes":null,"type":"small molecule","cas-number":"852948-13-1","sequences":null,"targets":null,"unii":"3Z11398FNQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":514.1675888,"volume-of-distribution":null,"route-of-elimination":null,"name":"VK-2809","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15137"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":442.482,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).","enzymes":null,"type":"small molecule","cas-number":"1639042-08-2","sequences":null,"targets":null,"unii":"DA9P7LN909","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":442.186812542,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-9496","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15138"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"JEH09DQZ6V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bifunctional epoxide hydrolase 2","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15139"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).","enzymes":null,"type":"biotech","cas-number":"1939126-74-5","sequences":null,"targets":null,"unii":"BNO1JG5MZC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bempegaldesleukin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15140"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":401.554,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Deutivacaftor is under investigation in clinical trial NCT03227471 (A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis).","enzymes":null,"type":"small molecule","cas-number":"1413431-07-8","sequences":null,"targets":null,"unii":"SHA6U5FJZL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":401.266483483,"volume-of-distribution":null,"route-of-elimination":null,"name":"Deutivacaftor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15141"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":361.373,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1817626-54-2","sequences":null,"targets":null,"unii":"S3F315JJXI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":361.143784299,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06650833","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15143"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":425.275,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Altropane I-123 is under investigation in clinical trial NCT01950468 (A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes).","enzymes":null,"type":"small molecule","cas-number":"208517-65-1","sequences":null,"targets":null,"unii":"D20OLL8HWU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":425.061230027,"volume-of-distribution":null,"route-of-elimination":null,"name":"Altropane I-123","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15144"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":439.53,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ziresovir is under investigation in clinical trial NCT03699202 (Anti-RSV Study in Chinese Patients (ASCENT)).","enzymes":null,"type":"small molecule","cas-number":"1422500-60-4","sequences":null,"targets":null,"unii":"XCF42D7AG4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":439.167810859,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ziresovir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15145"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1351.308,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).","enzymes":null,"type":"small molecule","cas-number":"128446-35-5","sequences":null,"targets":null,"unii":"8W6Q67R6NX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1350.542308587,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adrabetadex","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15146"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":415.36,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tinostamustine is under investigation in clinical trial NCT03452930 (Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma).","enzymes":null,"type":"small molecule","cas-number":"1236199-60-2","sequences":null,"targets":null,"unii":"29DKI2H2NY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":414.1589316,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tinostamustine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15147"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).","enzymes":null,"type":"biotech","cas-number":"1229575-09-0","sequences":null,"targets":null,"unii":"IE4X6497XK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lenzilumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15148"},{"toxicity":"There is no information available regarding acute toxicity and overdose of futibatinib.","snp-adverse-drug-reactions":null,"average-mass":418.457,"transporters":"BE0001032 BE0001067","pharmacodynamics":"Futibatinib is an anticancer agent with demonstrated anti-tumour activity in mouse and rat xenograft models of human tumours with activating FGFR genetic alterations.[L43347] Futibatinib is not expected to affect cell lines with no FGFR genomic aberrations.[A253198] It suppresses the growth of tumours in a dose-dependent manner.[A253198]","msds":null,"description":"Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies.[A253193,A253198]\r\n\r\nAs a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.[L43347]","enzymes":"BE0002638 BE0002363 BE0002793","type":"small molecule","cas-number":"1448169-71-8","sequences":null,"targets":"BE0002133 BE0002131 BE0001203 BE0000748","unii":"4B93MGE4AL","protein-binding":"Futibatinib is 95% bound to human plasma protein at 0.2 to 5 mol\/L _in vitro_, primarily to albumin and 1-acid glycoprotein.[L43347]","fda-label":null,"clearance":"The geometric mean (CV%) apparent clearance (CL\/F) is 20 L\/h (23%).[L43347]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":false,"food-interactions":"Take at the same time every day. Take with or without food. A high-fat and high-calorie meal decreases drug exposure, but not to a clinically significant extent.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Fibroblast Growth Factor receptor (FGFR) pathway play a key role in cell proliferation, differentiation, migration, and survival. Notably, FGFR genomic aberrations and aberrant FGFR signalling pathways are observed in some cancers,[A253193,A253198] as constitutive FGFR signalling can support the proliferation and survival of malignant cells.[L43347]\r\n\r\nFutibatinib is a selective, irreversible inhibitor of FGFR 1, 2, 3, and 4 with IC<sub>50<\/sub> values of less than 4 nM.[A253198,L43347] It binds to the FGFR kinase domain by forming a covalent bond with cysteine in the ATP-binding pocket.[A253198] Upon binding to FGFR, futibatinib blocks FGFR phosphorylation and downstream signalling pathways,[L43347] such as the RAS-dependent mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3KCA)\/Akt\/mTOR, phospholipase C (PLC), and JAK\/STAT.[A253223] Futibatinib ultimately decreases cell viability in cancer cell lines with FGFR alterations, including FGFR fusions or rearrangements, amplifications, and mutations.[L43347]","drug-interactions":"DB08953 DB12095 DB14649 DB12457 DB00742 DB00656 DB13259 DB06712 DB00540 DB00970 DB12130 DB00814 DB09185 DB12035 DB00451 DB00845 DB05232 DB13878 DB06228 DB00957 DB01086 DB06772 DB00503 DB00220 DB01590 DB09030 DB04908 DB01075 DB11855 DB12825 DB09076 DB11828 DB01127 DB01396 DB11901 DB00390 DB08865 DB00246 DB00358 DB02520 DB08820 DB11827 DB00281 DB01320 DB00834 DB00773 DB01323 DB13578 DB01259 DB13879 DB00012 DB11979 DB11932 DB05521 DB11951 DB09161 DB11502 DB09101 DB11641 DB04881 DB04868 DB14723 DB08881 DB11575 DB06595 DB06119 DB00877 DB01182 DB06290 DB14960 DB12364 DB08930 DB00908 DB06616 DB00091 DB05039 DB09227 DB11633 DB14973 DB00612 DB08894 DB11689 DB11613 DB06589 DB00872 DB01201 DB08870 DB09046 DB00203 DB06695 DB09107 DB00951 DB12001 DB06448 DB02703 DB00175 DB11952 DB14019 DB00648 DB04851 DB08873 DB00468 DB00270 DB00641 DB15328 DB01234 DB11978 DB12026 DB00582 DB06605 DB00312 DB00363 DB11869 DB09183 DB09063 DB00206 DB00297 DB12147 DB12500 DB06237 DB11757 DB00882 DB13874 DB00705 DB12836 DB08896 DB00224 DB12532 DB01118 DB15133 DB08910 DB00176 DB01161 DB05015 DB09296 DB11712 DB11730 DB09345 DB11574 DB09009 DB06207 DB00343 DB00622 DB00196 DB14068 DB09342 DB11652 DB06603 DB08893 DB12582 DB01026 DB09118 DB00661 DB13683 DB16222 DB11697 DB00502 DB00932 DB00252 DB01045 DB11853 DB00763 DB01167 DB01002 DB05239 DB06670 DB12799 DB09078 DB11672 DB11800 DB00564 DB05667 DB00188 DB00398 DB11581 DB09065 DB08899 DB07348 DB09291 DB06191 DB11362 DB04896 DB09241 DB01232 DB00295 DB08931 DB01263 DB14069 DB14989 DB01211 DB08995 DB12941 DB06287 DB00675 DB06403 DB05889 DB00441 DB15569 DB11732 DB00248 DB06626 DB01601 DB01072 DB06774 DB00625 DB00645 DB09048 DB08907 DB01267 DB01254 DB11760 DB00836 DB01169 DB06700 DB09330 DB09085 DB06234 DB12597 DB00349 DB01394 DB00296 DB05294 DB14921 DB11753 DB04845 DB11779 DB00300 DB09027 DB09239 DB00864 DB13328 DB11995 DB00721 DB14631 DB00750 DB00892 DB06636 DB14126 DB11693 DB13179 DB12713 DB09075 DB01110 DB08987 DB06176 DB13125 DB09054 DB00976 DB00016 DB04832 DB11148 DB12466 DB00539 DB00408 DB09073 DB00696 DB00458 DB11586 DB01149 DB00537 DB00080 DB11791 DB09280 DB00360 DB00199 DB00907 DB00794 DB11986 DB00527 DB09079 DB11963 DB01264 DB12483 DB00950 DB12455 DB08882 DB11642 DB08912 DB08816 DB09039 DB00570 DB08934 DB09297 DB15762 DB08901 DB01406 DB08916 DB09102 DB06240 DB08889 DB01030 DB04855 DB15442 DB01174 DB11796 DB14568 DB11770 DB09231 DB01079 DB00961 DB01087 DB00807 DB16703 DB14840 DB11967 DB06212 DB06419 DB01261 DB00342 DB00726 DB00896 DB06731 DB00227 DB15719 DB00862 DB16236 DB00673 DB00909 DB01136 DB03255 DB06770 DB00243 DB06769 DB09034 DB08827 DB05773 DB01183 DB12141 DB15822 DB13007 DB12887 DB00541 DB00701 DB15982 DB01388","absorption":"T<sub>max<\/sub> ranges from 1.2 to 22.8 hours, with a median value of two hours. In healthy subjects, a high-fat and high-calorie meal (900 to 1000 calories with approximately 50% of total caloric content from fat) decreased futibatinib AUC by 11% and C<sub>max<\/sub> by 42%.[L43347]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530 BE0000925","half-life":"The mean (CV%) elimination half-life (t<sub>1\/2<\/sub>) of futibatinib is 2.9 hours (27%).[L43347]","monoisotopic-mass":418.175338592,"volume-of-distribution":"The geometric mean (CV%) apparent volume of distribution (Vc\/F) is 66 L (18%).[L43347]","route-of-elimination":"Following a single oral dose of 20 mg radiolabeled futibatinib, approximately 91% of the total recovered radioactivity was observed in feces and 9% in urine, with negligible unchanged futibatinib in urine or feces.[L43347]","name":"Futibatinib","metabolism":"_In vitro_, futibatinib is primarily metabolized by CYP3A and to a lesser extent by CYP2C9 and CYP2D6. Unchanged futibatinib is the major drug-related moiety in plasma (accounting for 59% of radioactivity) in healthy subjects.[L43347]","reactions":null,"indication":"Futibatinib is indicated to treat adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.[L43347]\r\n\r\nThis indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).[L43347]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15149"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"WC7168JT17","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fibronectin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15150"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":540.13,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810\/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).","enzymes":null,"type":"small molecule","cas-number":"1349719-98-7","sequences":null,"targets":null,"unii":"TA3QN7788D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":539.2234076,"volume-of-distribution":null,"route-of-elimination":null,"name":"RO-6870810","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15151"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":422.442,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin).","enzymes":null,"type":"small molecule","cas-number":"1019639-33-8","sequences":null,"targets":null,"unii":"9GE48QZN6X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":422.191382581,"volume-of-distribution":null,"route-of-elimination":null,"name":"TMC-649128","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15152"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).","enzymes":null,"type":"biotech","cas-number":"1662664-56-3","sequences":null,"targets":null,"unii":"6U3F28IT58","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dezamizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15153"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).","enzymes":null,"type":"biotech","cas-number":"1792181-33-9","sequences":null,"targets":null,"unii":"Y4U029R8MS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vunakizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15154"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pepinemab is under investigation in clinical trial NCT03769155 (VX15\/2503 With or Without Ipilimumab and\/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).","enzymes":null,"type":"biotech","cas-number":"2097151-87-4","sequences":null,"targets":null,"unii":"BPZ4A29SYE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pepinemab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15155"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":469.56,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).","enzymes":null,"type":"small molecule","cas-number":"1132936-00-5","sequences":null,"targets":null,"unii":"PSQ4R5K1QI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":469.167142155,"volume-of-distribution":null,"route-of-elimination":null,"name":"ABT-072","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15156"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":469.84,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Voruciclib is under investigation in clinical trial NCT03547115 (A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML).","enzymes":null,"type":"small molecule","cas-number":"1000023-04-0","sequences":null,"targets":null,"unii":"W66XP666AM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":469.0903849,"volume-of-distribution":null,"route-of-elimination":null,"name":"Voruciclib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15157"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"50AL13JD55","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BPI-3016","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15158"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men).","enzymes":null,"type":"biotech","cas-number":"1429201-24-0","sequences":null,"targets":null,"unii":"87T4327873","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Trevogrumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15159"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).","enzymes":null,"type":"biotech","cas-number":"1450882-18-4","sequences":null,"targets":null,"unii":"F333OQQ9UV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Asunercept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15160"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":255.32,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pittsburgh Compound B is under investigation in clinical trial NCT01723553 (Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD).","enzymes":null,"type":"small molecule","cas-number":"566170-04-5","sequences":null,"targets":null,"unii":"7P55415B0R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":255.078468006,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pittsburgh Compound B","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15161"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).","enzymes":null,"type":"biotech","cas-number":"1966111-35-2","sequences":null,"targets":null,"unii":"5Z9850I25F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pegilodecakin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15162"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":618.628,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Selatogrel is under investigation in clinical trial NCT03814200 (A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1159500-34-1","sequences":null,"targets":"BE0000110","unii":"6DPK7O4PR7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":618.256699238,"volume-of-distribution":null,"route-of-elimination":null,"name":"Selatogrel","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-05-03","drugbank-id":"DB15163"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Apadamtase alfa is under investigation in clinical trial NCT03922308 (Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)).","enzymes":null,"type":"biotech","cas-number":"2086325-24-6","sequences":null,"targets":null,"unii":"U5SFU33XUX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Apadamtase alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15164"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Avacincaptad pegol is under investigation in clinical trial NCT03362190 (ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)).","enzymes":null,"type":"biotech","cas-number":"1613641-69-2","sequences":null,"targets":null,"unii":"TT0V5JLG5B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Avacincaptad pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15165"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Albuvirtide is under investigation in clinical trial NCT03719664 (Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects).","enzymes":null,"type":"biotech","cas-number":"1417179-66-8","sequences":null,"targets":null,"unii":"MG9PC54E43","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Albuvirtide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15166"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":364.461,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).","enzymes":null,"type":"small molecule","cas-number":"166173-78-0","sequences":null,"targets":null,"unii":"G9FWZ369GX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB12890 DB13520 DB00268 DB00413 DB01238 DB00248 DB01235 DB00320 DB09128 DB12313 DB05271 DB09097 DB01200 DB12161 DB01186 DB00800 DB00245 DB00589 DB12478 DB04844 DB01049 DB13385 DB00714 DB11275 DB11273","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":364.216220965,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fallypride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15167"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":586.85,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis).","enzymes":null,"type":"small molecule","cas-number":"1418274-28-8","sequences":null,"targets":null,"unii":"YUN2306954","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":585.0625039,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cilofexor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15168"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":629.54,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"H3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).","enzymes":null,"type":"small molecule","cas-number":"1702259-66-2","sequences":null,"targets":null,"unii":"4HTE364XIK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":628.208007,"volume-of-distribution":null,"route-of-elimination":null,"name":"H3B-6527","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15169"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":429.524,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).","enzymes":null,"type":"small molecule","cas-number":"1415823-73-2","sequences":null,"targets":"BE0001284","unii":"ZA45457L1K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":429.216475129,"volume-of-distribution":null,"route-of-elimination":null,"name":"Evobrutinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-05-05","drugbank-id":"DB15170"},{"toxicity":"There is limited information regarding the LD<sub>50<\/sub> and overdose of tirzepatide. In case of an overdosage, appropriate supportive treatment should be initiated with a sufficient amount of time for observation and treatment, as tirzepatide has a long half-life.[L41815]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Tirzepatide is a synthetic peptide with glucose-lowering effects. It works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.[A246260,L41815] Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake,[L41815] and reduce body weight in patients with type 2 diabetes.[A246265] Tirzepatide can increase insulin sensitivity.[L41815]\r\n\r\nAs the peptide is conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20, the drug is highly bound to albumin in the plasma, which prolongs its half-life.[A246265]","msds":null,"description":"Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP\/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.[A246260]\r\n\r\nTirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety.[A246260] Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing.[A246265] Tirzepatide was approved by the FDA on May 13, 2022, for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication.[L41820] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]","enzymes":null,"type":"biotech","cas-number":"2023788-19-2","sequences":">Tirzepatide protein sequence\nYXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS","targets":"BE0000857 BE0010190","unii":"OYN3CCI6QE","protein-binding":"Tirzepatide is 99% bound to plasma albumin.[A246260,A246265,L41815]","fda-label":null,"clearance":"The apparent population mean clearance of tirzepatide is 0.061 L\/h.[L41815] The mean steady-state apparent clearance of tirzepatide was  0.056 L\/h.[A246260]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with or without food. Food has no clinically significant effects on drug exposure.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.[A246260] Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.[A246265] However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.[A246260,A246265]\r\n\r\nThe exact mechanism of action of tirzepatide has not been fully elucidated; however, dual agonism at GIP and GLP-1R may contribute to the glycemic and weight control effects of the drug.[A246265] Studies demonstrated that co-administration of GIP and a GLP-1R agonist more significantly increased insulin response and suppressed glucagon secretion compared to separate administration of either hormone alone.[A246270] Tirzepatide binds to GIP and GLP-1R with high affinity.[A246260,A246265] _In vitro_, tirzepatide has a comparable GIP receptor binding affinity to native GIP and five times lower GLP-1R affinity than that of native GLP-1.[A246270] Tirzepatide potently activates the GLP-1R signalling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.[A246260] However, the role of GIPR agonism in the drug's mechanism of action requires further investigation, as the evidence of GIPR agonism on glycemic and weight control in preclinical and clinical studies are conflicting.[A246265]","drug-interactions":"DB00328 DB08953 DB14652 DB01208 DB14649 DB00887 DB09198 DB08980 DB00540 DB06251 DB06712 DB01142 DB11564 DB13875 DB13876 DB00223 DB13446 DB00562 DB00451 DB09253 DB01247 DB14633 DB14006 DB00280 DB01200 DB00232 DB11921 DB09307 DB00957 DB13792 DB01306 DB00284 DB09022 DB12235 DB14033 DB01299 DB00321 DB00503 DB11461 DB07615 DB12781 DB00220 DB01590 DB13843 DB09351 DB01067 DB13867 DB11389 DB01124 DB06719 DB00046 DB00912 DB08970 DB12950 DB00873 DB00741 DB13411 DB00839 DB00222 DB00367 DB01295 DB00246 DB13208 DB04846 DB09383 DB14541 DB04878 DB09234 DB00592 DB00543 DB01044 DB08807 DB04017 DB00230 DB00959 DB11827 DB13981 DB00834 DB13928 DB13943 DB01323 DB01319 DB11723 DB00181 DB00487 DB11824 DB14659 DB00547 DB04818 DB00945 DB13563 DB15861 DB01309 DB13496 DB00779 DB00467 DB00240 DB09249 DB00731 DB00324 DB08550 DB13488 DB01165 DB02901 DB00218 DB04868 DB08881 DB00030 DB00877 DB13310 DB01182 DB06290 DB00846 DB00685 DB13233 DB14960 DB01059 DB09368 DB09251 DB00738 DB09045 DB11898 DB09227 DB06292 DB00351 DB00612 DB13158 DB06718 DB11950 DB00614 DB09265 DB00598 DB05488 DB14064 DB01175 DB00866 DB14540 DB00180 DB00253 DB13169 DB00819 DB13612 DB14538 DB01015 DB08906 DB00214 DB01410 DB09238 DB01583 DB00476 DB00668 DB13284 DB08952 DB00951 DB04839 DB00715 DB00334 DB06694 DB00414 DB00601 DB01298 DB01120 DB00977 DB00468 DB01626 DB00270 DB13835 DB13283 DB13823 DB15821 DB00823 DB06654 DB01234 DB00007 DB01137 DB00706 DB11463 DB01277 DB12935 DB00695 DB00960 DB12268 DB00635 DB00304 DB01359 DB00363 DB06011 DB14066 DB09063 DB00621 DB08838 DB04884 DB00294 DB16220 DB01325 DB09378 DB00606 DB01155 DB00936 DB11567 DB13782 DB14543 DB06150 DB06203 DB00999 DB01382 DB06807 DB08804 DB00568 DB05246 DB00082 DB13384 DB01582 DB11404 DB00311 DB00734 DB00596 DB00783 DB06663 DB13617 DB00903 DB00624 DB00224 DB01251 DB14544 DB00394 DB00861 DB00852 DB14063 DB01118 DB11892 DB12930 DB09243 DB00559 DB00176 DB01104 DB11960 DB09250 DB13726 DB01357 DB00401 DB06283 DB13214 DB13725 DB01108 DB09009 DB09200 DB00343 DB00622 DB13114 DB06789 DB14068 DB04838 DB00196 DB08996 DB00396 DB06446 DB13766 DB13320 DB14035 DB00780 DB01130 DB00978 DB13685 DB15975 DB09543 DB01185 DB01384 DB00591 DB00052 DB09095 DB00774 DB01278 DB00838 DB00717 DB01037 DB00661 DB09043 DB13775 DB13358 DB00502 DB00932 DB01289 DB01250 DB00252 DB01244 DB09245 DB13989 DB01047 DB01016 DB01054 DB00195 DB13538 DB01268 DB01405 DB15112 DB00603 DB08972 DB06412 DB13246 DB14545 DB14026 DB02546 DB06821 DB15566 DB09199 DB06788 DB11443 DB13225 DB11750 DB13961 DB06730 DB12921 DB04707 DB08162 DB06655 DB09236 DB13944 DB13003 DB04876 DB04896 DB01193 DB09201 DB09241 DB00412 DB00166 DB01232 DB13950 DB09235 DB11780 DB06791 DB01307 DB13261 DB14681 DB00310 DB06287 DB04630 DB01294 DB00528 DB12625 DB01611 DB08815 DB01363 DB00373 DB13509 DB09089 DB04946 DB09230 DB00215 DB01601 DB06781 DB13664 DB13791 DB06152 DB01072 DB00672 DB07996 DB08907 DB01267 DB12461 DB06786 DB11943 DB01242 DB11462 DB00836 DB01700 DB00436 DB01380 DB01169 DB01420 DB06600 DB11491 DB00477 DB06700 DB00014 DB00335 DB01023 DB09237 DB06127 DB11487 DB05115 DB14643 DB12131 DB12417 DB09167 DB01621 DB04576 DB01151 DB08961 DB13663 DB00443 DB06335 DB00264 DB09204 DB09128 DB11619 DB09254 DB09239 DB00752 DB00864 DB01367 DB04841 DB09016 DB00721 DB14631 DB00808 DB04842 DB01581 DB14065 DB04743 DB09289 DB00381 DB00191 DB00344 DB00627 DB15093 DB12693 DB01013 DB00104 DB08992 DB13485 DB00805 DB08971 DB00984 DB12713 DB15217 DB09229 DB13728 DB13757 DB14512 DB11568 DB04820 DB02925 DB00653 DB04832 DB00860 DB13803 DB00593 DB06726 DB00288 DB13857 DB06160 DB15972 DB13946 DB01252 DB00817 DB01098 DB00244 DB13430 DB00197 DB00588 DB13627 DB11774 DB11529 DB13699 DB01203 DB09038 DB00458 DB01119 DB11992 DB00880 DB03322 DB05885 DB14644 DB01149 DB00537 DB00331 DB09090 DB13675 DB09091 DB06729 DB01132 DB01224 DB00047 DB14025 DB00664 DB13547 DB00891 DB12051 DB01324 DB01222 DB13856 DB14539 DB01403 DB03604 DB00285 DB11785 DB01264 DB09389 DB00827 DB14646 DB00571 DB08912 DB08882 DB12923 DB00482 DB00703 DB12474 DB12093 DB00347 DB08798 DB13443 DB09248 DB01406 DB00542 DB00359 DB00576 DB06710 DB00393 DB08808 DB04861 DB00489 DB13772 DB01395 DB01260 DB04836 DB01014 DB00263 DB13405 DB13556 DB12752 DB11511 DB13491 DB00491 DB01276 DB04920 DB13773 DB06216 DB01285 DB11770 DB12092 DB00233 DB01144 DB01032 DB00024 DB09231 DB00279 DB13532 DB09232 DB00365 DB13708 DB11079 DB00764 DB09098 DB12214 DB00795 DB13508 DB09371 DB09246 DB00663 DB13580 DB14027 DB06370 DB12412 DB09252 DB01261 DB13223 DB13528 DB00726 DB00896 DB13530 DB12445 DB09240 DB04574 DB04830 DB00620 DB16236 DB09270 DB00909 DB01136 DB13500 DB01021 DB11464 DB15777 DB14669 DB11698 DB00669 DB13248 DB09244 DB01171 DB01238 DB13406 DB09123 DB08918 DB08382 DB13587 DB14634 DB06343 DB04825 DB01074 DB01168 DB00472 DB09456 DB09564 DB01115 DB09100 DB06825 DB00071 DB00914 DB00524 DB08962 DB00687 DB01580 DB01388 DB01297","absorption":"Over the dose range of 1-5 mg, the C<sub>max<\/sub> of tirzepatide ranged from 108 to 397 ng\/mL.[A246260] The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Following subcutaneous administration, the T<sub>max<\/sub> ranged from eight to 72 hours. The steady-state plasma concentrations were achieved following four weeks of once-weekly subcutaneous administration.[L41815]\r\n\r\nAs tirzepatide delays gastric emptying, it has the potential to affect the absorption of concomitantly administered oral medications. The US prescribing information recommends the use of caution when co-administering tirzepatide with other oral medications.[L41815]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The half-life is approximately five days.[A246265,L41815]","monoisotopic-mass":null,"volume-of-distribution":"Following subcutaneous administration, the mean steady-state volume of distribution was 9.5 L.[A246260] The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type 2 diabetes mellitus was approximately 10.3 L.[L41815]","route-of-elimination":"Tirzepatide is primarily excreted via urine and feces, mostly in the form of metabolites. Unchanged parent drug was not detectable in urine and feces.[L41815]","name":"Tirzepatide","metabolism":"Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis.[L41815]","reactions":null,"indication":"Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[L41815,L44376] In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.[L44376]\r\n\r\nThis drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.[L41815]","ahfs-codes":null,"updated":"2022-12-23","drugbank-id":"DB15171"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).","enzymes":null,"type":"biotech","cas-number":"1629620-18-3","sequences":null,"targets":null,"unii":"4L1997J4DF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Suvratoxumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15172"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":410.81,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Jnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).","enzymes":null,"type":"small molecule","cas-number":"1346528-50-4","sequences":null,"targets":null,"unii":"AH2E5UQ11Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":410.0957244,"volume-of-distribution":null,"route-of-elimination":null,"name":"JNJ-42165279","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15173"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ofranergene obadenovec is under investigation in clinical trial NCT01229865 (Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer).","enzymes":null,"type":"biotech","cas-number":"1476737-24-2","sequences":null,"targets":null,"unii":"5Q5PRH05GI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ofranergene obadenovec","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15175"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).","enzymes":null,"type":"biotech","cas-number":"1228538-47-3","sequences":null,"targets":null,"unii":"26F96HRJ3W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Quilizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15176"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":591.65,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VX-659 is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).","enzymes":null,"type":"small molecule","cas-number":"2204245-48-5","sequences":null,"targets":null,"unii":"8C7XEW3K7S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":591.212710193,"volume-of-distribution":null,"route-of-elimination":null,"name":"VX-659","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15177"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX\u201E in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).","enzymes":null,"type":"biotech","cas-number":"1646321-00-7","sequences":null,"targets":null,"unii":"5P637IXG16","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tomuzotuximab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15178"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"alpha-Lactalbumin is under investigation in clinical trial NCT02082418 (Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly).","enzymes":null,"type":"biotech","cas-number":"9051-29-0","sequences":null,"targets":null,"unii":"GOY102QI5I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Lactalbumin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15182"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":468.406,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).","enzymes":null,"type":"small molecule","cas-number":"2091769-17-2","sequences":null,"targets":null,"unii":"1XQ871489P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":468.11987141,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fosmanogepix","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15183"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer).","enzymes":null,"type":"biotech","cas-number":"1587257-96-2","sequences":null,"targets":null,"unii":"SU9AMV39DB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rasdegafusp alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15185"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":382.428,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).","enzymes":null,"type":"small molecule","cas-number":"1382979-44-3","sequences":null,"targets":null,"unii":"P5DKZ70636","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":382.18657198,"volume-of-distribution":null,"route-of-elimination":null,"name":"Paxalisib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15186"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":516.06,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1\/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).","enzymes":null,"type":"small molecule","cas-number":"1341200-45-0","sequences":null,"targets":null,"unii":"14D65TV20J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":515.1870221,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dubermatinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15187"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":962.036,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).","enzymes":null,"type":"small molecule","cas-number":"1088543-62-7","sequences":null,"targets":null,"unii":"9VHD7J6363","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":961.472977149,"volume-of-distribution":null,"route-of-elimination":null,"name":"Livoletide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15188"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":491.99,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).","enzymes":null,"type":"small molecule","cas-number":"202590-98-5","sequences":null,"targets":null,"unii":"X40LKS49S3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":491.1182738,"volume-of-distribution":null,"route-of-elimination":null,"name":"Birabresib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15189"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":458.526,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability and Food Effect).","enzymes":null,"type":"small molecule","cas-number":"1195065-29-2","sequences":null,"targets":null,"unii":"52EG7RFE6Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":458.217872109,"volume-of-distribution":null,"route-of-elimination":null,"name":"GLPG-0259","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15190"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":438.53,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MAX-40279 is under investigation in clinical trial NCT03412292 (MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)).","enzymes":null,"type":"small molecule","cas-number":"2070931-57-4","sequences":null,"targets":null,"unii":"DL772G3NN7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":438.163808722,"volume-of-distribution":null,"route-of-elimination":null,"name":"MAX-40279","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15191"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":372.472,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ABT-288 is under investigation in clinical trial NCT01018875 (Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease).","enzymes":null,"type":"small molecule","cas-number":"948845-91-8","sequences":null,"targets":null,"unii":"5MEI1M3NHH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06698 DB00852 DB12080 DB14740 DB09480 DB00895 DB00070 DB13108 DB01579 DB06205 DB01255 DB01566 DB01454 DB01509 DB00865 DB01365 DB01484 DB00937 DB01576 DB00182 DB13940 DB01467 DB01442 DB01577 DB00191 DB13703 DB13624 DB00424 DB01556","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":372.195011409,"volume-of-distribution":null,"route-of-elimination":null,"name":"ABT-288","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15192"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":691.03,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).","enzymes":null,"type":"small molecule","cas-number":"1392312-45-6","sequences":null,"targets":null,"unii":"4CA9IAU7RJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":690.443029658,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-955176","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15193"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":3728.092,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight\/Obese Subject With Type 2 Diabetes).","enzymes":null,"type":"small molecule","cas-number":"1686108-82-6","sequences":null,"targets":null,"unii":"QL6A9B13HW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":3725.821320382,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cotadutide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15194"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2097.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mibenratide is under investigation in clinical trial NCT01798745 (A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies).","enzymes":null,"type":"small molecule","cas-number":"1239011-83-6","sequences":null,"targets":null,"unii":"P1T1143877","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2095.88400821,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mibenratide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15195"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":388.402,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).","enzymes":null,"type":"small molecule","cas-number":"676128-63-5","sequences":null,"targets":null,"unii":"6NF9HI6D98","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":388.133553966,"volume-of-distribution":null,"route-of-elimination":null,"name":"RSV-604","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15197"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":309.453,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).","enzymes":null,"type":"small molecule","cas-number":"5653-80-5","sequences":null,"targets":null,"unii":"S95RZH8AMH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":309.209264493,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dextromethadone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-08-13","drugbank-id":"DB15198"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":512.708,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).","enzymes":null,"type":"small molecule","cas-number":"1438492-26-2","sequences":null,"targets":null,"unii":"U2R67KV65Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":512.402318834,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ciraparantag","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15199"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"851373-13-2","sequences":null,"targets":null,"unii":"3160WY51LV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bixalomer","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15200"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":380.484,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Norbixin is under investigation in clinical trial NCT03820245 (Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals).","enzymes":null,"type":"small molecule","cas-number":"542-40-5","sequences":null,"targets":null,"unii":"E8M59E17AI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":380.198759382,"volume-of-distribution":null,"route-of-elimination":null,"name":"Norbixin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15201"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":77.045,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).","enzymes":null,"type":"small molecule","cas-number":"7574-44-9","sequences":null,"targets":null,"unii":"74Q3U8O789","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":77.014242004,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluoroacetic acid F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15202"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":278.71,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).","enzymes":null,"type":"small molecule","cas-number":"871824-55-4","sequences":null,"targets":null,"unii":"G1TI012DLT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08953 DB14028 DB14719 DB12710 DB08329 DB00219 DB00656 DB01560 DB13082 DB13259 DB01545 DB13642 DB00916 DB13841 DB11552 DB00540 DB00737 DB01142 DB06554 DB12184 DB11957 DB11447 DB13875 DB13695 DB13876 DB01215 DB00814 DB00387 DB09185 DB05542 DB09273 DB12193 DB09253 DB01247 DB13505 DB00280 DB01200 DB11238 DB14132 DB05232 DB01618 DB13799 DB13252 DB06701 DB01409 DB08844 DB02377 DB01337 DB09307 DB13522 DB01223 DB00395 DB00957 DB00424 DB01086 DB00962 DB00277 DB00557 DB01209 DB01595 DB09184 DB11859 DB08922 DB12235 DB01598 DB13303 DB00810 DB00321 DB13354 DB11919 DB00732 DB06148 DB13754 DB13738 DB01246 DB12338 DB04066 DB00292 DB00490 DB00806 DB00475 DB01235 DB01535 DB04908 DB00463 DB14071 DB01075 DB02234 DB11855 DB09076 DB13534 DB01065 DB00546 DB01558 DB01148 DB01339 DB01551 DB13948 DB13203 DB13411 DB00367 DB11823 DB00246 DB01577 DB00777 DB15119 DB00209 DB09190 DB13636 DB00714 DB00358 DB00543 DB08927 DB13572 DB04356 DB13552 DB04017 DB06690 DB00230 DB00281 DB00268 DB01320 DB13981 DB00834 DB13554 DB01323 DB00181 DB13578 DB13219 DB01495 DB01624 DB01610 DB04818 DB08839 DB00332 DB13468 DB01062 DB01555 DB12883 DB08811 DB13563 DB13954 DB01466 DB12404 DB09299 DB06529 DB01033 DB00708 DB13496 DB12229 DB09224 DB00779 DB01622 DB00370 DB00245 DB09249 DB13787 DB00599 DB13541 DB16021 DB08550 DB00835 DB13837 DB13584 DB11951 DB11502 DB00670 DB00391 DB01100 DB13396 DB13253 DB00623 DB01445 DB04888 DB12661 DB06479 DB13310 DB11903 DB01202 DB13233 DB14018 DB13854 DB00906 DB00908 DB00402 DB09251 DB00372 DB00652 DB08861 DB11889 DB13805 DB12406 DB00091 DB01107 DB09225 DB06582 DB04917 DB00351 DB01245 DB00614 DB13940 DB01175 DB00866 DB00949 DB09194 DB00819 DB00662 DB00420 DB00980 DB13323 DB13769 DB09300 DB00967 DB12576 DB04821 DB00996 DB12177 DB00476 DB06738 DB11868 DB13014 DB12958 DB00951 DB04839 DB00715 DB00327 DB13573 DB02136 DB00237 DB00334 DB01156 DB12110 DB00601 DB13542 DB00899 DB00241 DB13414 DB00468 DB00977 DB01484 DB00924 DB01626 DB00941 DB13662 DB13817 DB00753 DB00823 DB06654 DB06155 DB11664 DB13402 DB02134 DB06512 DB05227 DB00960 DB00312 DB01359 DB00304 DB01412 DB00363 DB08801 DB04871 DB12590 DB08810 DB13687 DB04884 DB00206 DB01534 DB00628 DB00418 DB01231 DB00294 DB01616 DB00313 DB06201 DB04843 DB00297 DB00193 DB13605 DB00416 DB01452 DB12025 DB11555 DB13782 DB00231 DB00822 DB00456 DB00633 DB00937 DB05246 DB01625 DB13737 DB11540 DB00831 DB09068 DB12395 DB13384 DB14678 DB13454 DB00450 DB00617 DB00734 DB00783 DB01227 DB13784 DB09166 DB04682 DB00532 DB00397 DB13449 DB11400 DB00754 DB12273 DB00604 DB05541 DB09449 DB12532 DB11582 DB00842 DB12427 DB01199 DB11376 DB08986 DB08867 DB00776 DB08059 DB08910 DB09243 DB12930 DB08960 DB14651 DB00454 DB00176 DB09117 DB01104 DB00505 DB00985 DB01161 DB11371 DB11315 DB09250 DB04819 DB13678 DB01357 DB06283 DB01041 DB11235 DB00921 DB09555 DB09345 DB09021 DB01192 DB05607 DB09009 DB00201 DB00875 DB06575 DB00496 DB00622 DB13114 DB06789 DB01450 DB08996 DB00396 DB06446 DB11477 DB13221 DB13588 DB13606 DB11636 DB09342 DB00474 DB00719 DB13234 DB06713 DB13685 DB00780 DB00690 DB13913 DB01114 DB13213 DB00818 DB00377 DB01355 DB00323 DB00952 DB13025 DB00849 DB01615 DB13993 DB13866 DB00555 DB00423 DB01037 DB09118 DB01303 DB11686 DB00422 DB00717 DB13683 DB06787 DB00404 DB13679 DB01531 DB13577 DB00502 DB13733 DB00651 DB04948 DB00486 DB14881 DB01017 DB00252 DB01511 DB05077 DB00942 DB09001 DB09245 DB00801 DB13550 DB12518 DB00493 DB04953 DB01063 DB14011 DB13956 DB13335 DB13953 DB12649 DB01002 DB01978 DB00603 DB13254 DB13246 DB01362 DB00956 DB01954 DB13420 DB00660 DB13759 DB12308 DB00564 DB09000 DB00572 DB01501 DB11156 DB01173 DB13225 DB13352 DB12531 DB15122 DB06266 DB04833 DB06730 DB13634 DB00234 DB01105 DB06684 DB06144 DB01440 DB13648 DB00902 DB13944 DB13256 DB04896 DB00854 DB14029 DB00843 DB01354 DB09241 DB11609 DB13357 DB00182 DB13437 DB01587 DB01608 DB01392 DB00295 DB13099 DB01482 DB13950 DB14185 DB14043 DB00589 DB00340 DB05710 DB00748 DB00904 DB01614 DB12105 DB13666 DB06527 DB12537 DB01611 DB01563 DB06282 DB08815 DB01547 DB09089 DB06016 DB04946 DB14737 DB13070 DB13770 DB11732 DB00215 DB00248 DB01591 DB11507 DB01567 DB13745 DB02245 DB09011 DB00771 DB13791 DB06774 DB00625 DB00645 DB06218 DB00291 DB12989 DB01267 DB00751 DB00202 DB01154 DB00517 DB01242 DB00679 DB01483 DB06109 DB13455 DB14509 DB03938 DB13457 DB06660 DB14715 DB08872 DB01236 DB06700 DB00477 DB00889 DB01239 DB11543 DB09085 DB00354 DB06702 DB13448 DB06753 DB00804 DB05687 DB13324 DB00189 DB00565 DB00681 DB00349 DB04829 DB01083 DB13520 DB00427 DB12131 DB00150 DB09167 DB00484 DB00296 DB01621 DB01151 DB05830 DB12327 DB00725 DB14583 DB13362 DB09017 DB09247 DB00813 DB00376 DB14672 DB00433 DB09128 DB13273 DB11619 DB09254 DB00508 DB01226 DB00752 DB01463 DB00865 DB06691 DB13331 DB01367 DB04841 DB13328 DB04903 DB08897 DB00494 DB09016 DB00721 DB06804 DB13592 DB13413 DB01186 DB00750 DB00892 DB04842 DB01442 DB00934 DB09289 DB12278 DB00344 DB00042 DB00579 DB01049 DB09014 DB00757 DB12693 DB13403 DB08992 DB01018 DB06579 DB13623 DB00805 DB09223 DB13812 DB01589 DB06797 DB14718 DB08997 DB01565 DB00083 DB02568 DB08987 DB00747 DB04820 DB13598 DB00383 DB00653 DB14010 DB00969 DB14575 DB04832 DB00972 DB04599 DB06204 DB00593 DB13857 DB04076 DB11148 DB12111 DB00273 DB06716 DB00497 DB01121 DB06793 DB00483 DB01623 DB08954 DB00829 DB02489 DB09226 DB00940 DB13295 DB00986 DB11549 DB01176 DB00408 DB15031 DB00588 DB00696 DB11199 DB00333 DB00470 DB11358 DB00832 DB00458 DB00953 DB01221 DB03313 DB01149 DB11556 DB01004 DB09262 DB13523 DB00392 DB01284 DB09007 DB00697 DB12554 DB01224 DB12492 DB06077 DB06678 DB11428 DB00740 DB00802 DB00356 DB14050 DB09071 DB00765 DB00907 DB01198 DB00794 DB01061 DB01509 DB00527 DB00680 DB01433 DB01036 DB09119 DB13844 DB01351 DB01594 DB01403 DB06288 DB12526 DB04834 DB13601 DB13044 DB00285 DB00462 DB00514 DB04827 DB09389 DB00434 DB00844 DB00608 DB01219 DB00574 DB00371 DB01352 DB11755 DB12474 DB12086 DB04872 DB12093 DB01353 DB02207 DB00347 DB13643 DB12401 DB01489 DB09174 DB00228 DB13665 DB09248 DB02852 DB06470 DB01028 DB01030 DB13619 DB13380 DB00320 DB01529 DB12725 DB01667 DB01395 DB03575 DB13690 DB01454 DB00767 DB13850 DB04836 DB13370 DB01174 DB01497 DB11675 DB00318 DB01488 DB00216 DB00341 DB00315 DB06216 DB13351 DB00405 DB12465 DB12951 DB01189 DB12361 DB01544 DB04165 DB12927 DB00933 DB06264 DB01218 DB13377 DB01356 DB00728 DB00850 DB00409 DB06153 DB00961 DB00807 DB13160 DB14754 DB00366 DB13720 DB09187 DB09371 DB09246 DB00283 DB05271 DB00647 DB01588 DB06624 DB12163 DB01069 DB09252 DB11699 DB13528 DB08883 DB00342 DB00726 DB13382 DB06458 DB00897 DB01437 DB06731 DB13872 DB09061 DB13557 DB00998 DB04574 DB00909 DB03255 DB00683 DB13500 DB00306 DB06770 DB00575 DB14256 DB12071 DB00186 DB13984 DB00837 DB01159 DB13581 DB00669 DB00413 DB09244 DB09034 DB01171 DB09186 DB13369 DB01238 DB01253 DB09023 DB09286 DB02959 DB09123 DB08918 DB01336 DB04325 DB08892 DB15360 DB01338 DB00425 DB06594 DB04885 DB05562 DB11130 DB00611 DB13478 DB01559 DB12867 DB01135 DB12926 DB07954 DB00247 DB00918 DB01233 DB00255 DB01081 DB01178 DB01553 DB01168 DB09290 DB13676 DB00472 DB09072 DB00898 DB00782 DB13507 DB01080 DB01472 DB12833 DB01580 DB01068","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":278.0128057,"volume-of-distribution":null,"route-of-elimination":null,"name":"JNJ-26489112","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15203"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":547.47,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).","enzymes":null,"type":"small molecule","cas-number":"351227-64-0","sequences":null,"targets":null,"unii":"L4Q6O5430L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTIFUNGALS FOR SYSTEMIC USE Antifungals for systemic use DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":547.089083262,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fosravuconazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15204"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":505.619,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Capromorelin is under investigation in clinical trial NCT00527046 (Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults).","enzymes":null,"type":"small molecule","cas-number":"193273-66-4","sequences":null,"targets":null,"unii":"0MQ44VUN84","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":505.268904627,"volume-of-distribution":null,"route-of-elimination":null,"name":"Capromorelin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15205"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":545.91,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).","enzymes":null,"type":"small molecule","cas-number":"1496551-77-9","sequences":null,"targets":null,"unii":"JW31KPS26S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":545.1329942,"volume-of-distribution":null,"route-of-elimination":null,"name":"Uprifosbuvir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15206"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":466.48,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).","enzymes":null,"type":"small molecule","cas-number":"1632006-28-0","sequences":null,"targets":null,"unii":"N62TGJ04A1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":466.117412827,"volume-of-distribution":null,"route-of-elimination":null,"name":"Esaxerenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15207"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":420.52,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin\/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).","enzymes":null,"type":"small molecule","cas-number":"1283095-70-4","sequences":null,"targets":null,"unii":"DQY244459T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":420.168305585,"volume-of-distribution":null,"route-of-elimination":null,"name":"NOP-1A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15208"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":469.57,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).","enzymes":null,"type":"small molecule","cas-number":"719272-79-4","sequences":null,"targets":null,"unii":"9RT16RBU2Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":469.201082881,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-0736","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15209"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Chlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).","enzymes":null,"type":"biotech","cas-number":"163515-35-3","sequences":null,"targets":null,"unii":"06UV5RFW57","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chlorotoxin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15210"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).","enzymes":null,"type":"biotech","cas-number":"1831098-91-9","sequences":null,"targets":null,"unii":"J545GSE96Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Duvortuxizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15211"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":490.556,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).","enzymes":null,"type":"small molecule","cas-number":"848259-27-8","sequences":null,"targets":null,"unii":"17VGG92R23","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":490.210386694,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pemafibrate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15212"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":835.008,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).","enzymes":null,"type":"small molecule","cas-number":"79039-56-8","sequences":null,"targets":null,"unii":"29A0K44SJO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB14055 DB00682 DB08952 DB00951 DB13259 DB00907 DB00814 DB01193 DB00527 DB05232 DB00187 DB11785 DB14443 DB01086 DB00571 DB00960 DB01359 DB12235 DB00373 DB13443 DB00297 DB09351 DB14022 DB08808 DB04861 DB00489 DB01075 DB06774 DB03410 DB00645 DB13136 DB13347 DB12752 DB04665 DB01295 DB12768 DB04846 DB09085 DB00335 DB11770 DB00565 DB13275 DB08807 DB12532 DB00281 DB00296 DB08794 DB08496 DB13578 DB01161 DB00961 DB00807 DB00264 DB09204 DB13508 DB09345 DB01418 DB13328 DB09009 DB01024 DB00721 DB09268 DB00688 DB00750 DB00892 DB13530 DB00581 DB09342 DB00758 DB01136 DB03255 DB11502 DB06770 DB13451 DB12212 DB08987 DB13757 DB01182 DB13683 DB00946 DB06726 DB13775 DB11148 DB00498 DB00612 DB00598 DB00866 DB00195 DB01002 DB00266 DB01203 DB01580 DB03322 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":834.441508832,"volume-of-distribution":null,"route-of-elimination":null,"name":"25-desacetylrifapentine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15213"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":329.528,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).","enzymes":null,"type":"small molecule","cas-number":"1622180-31-7","sequences":null,"targets":null,"unii":"KJ9D084FO4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":329.271864751,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-986104","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15214"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":589.694,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"151276-95-8","sequences":null,"targets":null,"unii":"8VH13L5K20","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":589.322396753,"volume-of-distribution":null,"route-of-elimination":null,"name":"KRN-5500","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15215"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Amylose is under investigation in clinical trial NCT01027325 (Resistant Starch Insulin Sensitivity Trial).","enzymes":null,"type":"small molecule","cas-number":"9005-82-7","sequences":null,"targets":null,"unii":"7TDQ74Y18L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amylose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15216"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).","enzymes":null,"type":"biotech","cas-number":"100040-31-1","sequences":null,"targets":null,"unii":"1O4H75S7H2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB08953 DB14652 DB01208 DB14649 DB00887 DB09198 DB08980 DB00540 DB06251 DB06712 DB01142 DB11564 DB13875 DB13876 DB00223 DB13446 DB00562 DB00451 DB09253 DB01247 DB14633 DB14006 DB00280 DB01200 DB00232 DB11921 DB09307 DB00957 DB13792 DB01306 DB00284 DB09022 DB12235 DB14033 DB01299 DB00321 DB00503 DB11461 DB07615 DB12781 DB00220 DB01590 DB13843 DB09351 DB01067 DB13867 DB11389 DB01124 DB06719 DB00046 DB00912 DB08970 DB12950 DB00873 DB00741 DB13411 DB00839 DB00222 DB00367 DB01295 DB00246 DB13208 DB04846 DB09383 DB14541 DB04878 DB09234 DB00592 DB00543 DB01044 DB08807 DB04017 DB00230 DB00959 DB11827 DB00834 DB13928 DB13943 DB01323 DB01319 DB11723 DB00181 DB00487 DB11824 DB14659 DB00547 DB04818 DB00945 DB15861 DB01309 DB13496 DB00779 DB00467 DB00240 DB09249 DB00731 DB00324 DB08550 DB13488 DB01165 DB02901 DB00218 DB04868 DB08881 DB00030 DB00877 DB01182 DB06290 DB00846 DB00685 DB13233 DB14960 DB01059 DB09368 DB09251 DB00738 DB09045 DB11898 DB09227 DB06292 DB00351 DB00612 DB13158 DB06718 DB11950 DB00614 DB09265 DB00598 DB05488 DB14064 DB01175 DB00866 DB14540 DB00180 DB00253 DB13169 DB00819 DB13612 DB14538 DB01015 DB08906 DB00214 DB01410 DB09238 DB01583 DB00476 DB00668 DB13284 DB08952 DB00951 DB04839 DB00715 DB00334 DB06694 DB00414 DB00601 DB01298 DB01120 DB00977 DB00468 DB01626 DB00270 DB13835 DB13283 DB13823 DB15821 DB00823 DB06654 DB01234 DB00007 DB01137 DB00706 DB11463 DB01277 DB12935 DB00695 DB00960 DB12268 DB00635 DB00304 DB01359 DB00363 DB06011 DB14066 DB09063 DB00621 DB08838 DB04884 DB00294 DB15171 DB16220 DB01325 DB09378 DB00606 DB01155 DB00936 DB11567 DB13782 DB14543 DB06150 DB06203 DB00999 DB01382 DB06807 DB08804 DB00568 DB05246 DB00082 DB13384 DB01582 DB11404 DB00311 DB00734 DB00596 DB00783 DB06663 DB13617 DB00903 DB00624 DB00224 DB01251 DB14544 DB00394 DB00861 DB00852 DB14063 DB01118 DB11892 DB12930 DB09243 DB00559 DB00176 DB01104 DB11960 DB09250 DB13726 DB01357 DB00401 DB06283 DB13214 DB13725 DB01108 DB09009 DB09200 DB00343 DB00622 DB13114 DB06789 DB14068 DB04838 DB00196 DB08996 DB00396 DB06446 DB13766 DB13320 DB14035 DB00780 DB01130 DB00978 DB15975 DB09543 DB01185 DB01384 DB00591 DB00052 DB09095 DB00774 DB01278 DB00838 DB00717 DB01037 DB00661 DB09043 DB13775 DB13358 DB00502 DB00932 DB01289 DB01250 DB00252 DB01244 DB09245 DB13989 DB01047 DB01016 DB01054 DB00195 DB13538 DB01268 DB01405 DB15112 DB00603 DB08972 DB06412 DB13246 DB14545 DB14026 DB02546 DB06821 DB15566 DB09199 DB06788 DB11443 DB13225 DB11750 DB13961 DB12921 DB04707 DB08162 DB06655 DB09236 DB13944 DB13003 DB04876 DB04896 DB01193 DB09201 DB09241 DB00412 DB00166 DB01232 DB13950 DB09235 DB11780 DB06791 DB01307 DB13261 DB14681 DB00310 DB06287 DB04630 DB01294 DB00528 DB12625 DB01611 DB08815 DB01363 DB00373 DB13509 DB09089 DB04946 DB09230 DB00215 DB01601 DB06781 DB13664 DB13791 DB06152 DB01072 DB00672 DB07996 DB08907 DB01267 DB12461 DB06786 DB11943 DB01242 DB11462 DB00836 DB01700 DB00436 DB01380 DB01169 DB01420 DB06600 DB11491 DB00477 DB06700 DB00014 DB00335 DB01023 DB09237 DB06127 DB11487 DB05115 DB14643 DB12131 DB12417 DB09167 DB01621 DB04576 DB01151 DB08961 DB13663 DB00443 DB06335 DB00264 DB09204 DB09128 DB09254 DB09239 DB00752 DB00864 DB01367 DB04841 DB09016 DB00721 DB14631 DB00808 DB04842 DB01581 DB14065 DB04743 DB09289 DB00381 DB00191 DB00344 DB00627 DB15093 DB12693 DB01013 DB00104 DB08992 DB13485 DB00805 DB08971 DB00984 DB12713 DB09229 DB13728 DB13757 DB14512 DB11568 DB04820 DB02925 DB00653 DB04832 DB00860 DB13803 DB00593 DB06726 DB00288 DB06160 DB15972 DB13946 DB01252 DB00817 DB01098 DB00244 DB13430 DB00197 DB00588 DB13627 DB11774 DB11529 DB13699 DB01203 DB09038 DB00458 DB01119 DB11992 DB00880 DB03322 DB05885 DB14644 DB01149 DB00537 DB00331 DB09090 DB13675 DB09091 DB06729 DB01132 DB01224 DB00047 DB14025 DB00664 DB13547 DB00891 DB12051 DB01324 DB01222 DB13856 DB14539 DB01403 DB03604 DB00285 DB11785 DB01264 DB00827 DB14646 DB00571 DB08912 DB08882 DB12923 DB00482 DB00703 DB12093 DB00347 DB08798 DB13443 DB09248 DB01406 DB00542 DB00359 DB00576 DB06710 DB00393 DB08808 DB04861 DB00489 DB13772 DB01395 DB01260 DB04836 DB01014 DB00263 DB13405 DB13556 DB12752 DB11511 DB13491 DB00491 DB01276 DB04920 DB13773 DB06216 DB01285 DB11770 DB12092 DB00233 DB01144 DB01032 DB00024 DB09231 DB00279 DB13532 DB09232 DB00365 DB13708 DB11079 DB00764 DB09098 DB12214 DB00795 DB13508 DB09246 DB00663 DB13580 DB14027 DB06370 DB12412 DB09252 DB01261 DB13223 DB00726 DB00896 DB13530 DB12445 DB09240 DB04574 DB04830 DB00620 DB16236 DB09270 DB00909 DB01136 DB13500 DB01021 DB11464 DB15777 DB14669 DB11698 DB00669 DB13248 DB09244 DB01171 DB01238 DB13406 DB09123 DB08918 DB08382 DB13587 DB14634 DB06343 DB04825 DB01074 DB01168 DB00472 DB09456 DB09564 DB01115 DB09100 DB06825 DB00071 DB00914 DB00524 DB08962 DB00687 DB01580 DB01388 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gastric inhibitory polypeptide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15217"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pozelimab is under investigation in clinical trial NCT03115996 (Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers).","enzymes":null,"type":"biotech","cas-number":"2096328-94-6","sequences":null,"targets":null,"unii":"0JJ21K6L2I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pozelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15218"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":340.387,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).","enzymes":null,"type":"small molecule","cas-number":"1849590-01-7","sequences":null,"targets":null,"unii":"U2H19X4WBV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":340.164773908,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tomivosertib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15219"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":235.335,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).","enzymes":null,"type":"small molecule","cas-number":"1164115-89-2","sequences":null,"targets":null,"unii":"B61N8R7TDH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":235.179695696,"volume-of-distribution":null,"route-of-elimination":null,"name":"Seliforant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15220"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":302.35,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects).","enzymes":null,"type":"small molecule","cas-number":"1612755-71-1","sequences":null,"targets":null,"unii":"3I487UHH95","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":302.083746881,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06260414","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15221"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":644.622,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Nave Subjects With Chronic Hepatitis C Virus Infection).","enzymes":null,"type":"small molecule","cas-number":"1350735-70-4","sequences":null,"targets":null,"unii":"WD5DUG7X38","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":644.235963793,"volume-of-distribution":null,"route-of-elimination":null,"name":"GS-6620","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15222"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed\/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2\/High Risk MDS).","enzymes":null,"type":"biotech","cas-number":"1664355-28-5","sequences":null,"targets":null,"unii":"0AHT0IC02G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flotetuzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15223"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":515.578,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1\/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).","enzymes":null,"type":"small molecule","cas-number":"1263384-43-5","sequences":null,"targets":null,"unii":"5PT0QP06X5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":515.23933583,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lisavanbulin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15224"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).","enzymes":null,"type":"biotech","cas-number":"2055640-86-1","sequences":null,"targets":null,"unii":"Q9J81E7VFM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mitazalimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15225"},{"toxicity":"Overdose may be characterized by nausea, vomiting, inhibition of gastrointestinal tract motility, increased blood pressure, and elevated heart rate. In case of a suspected overdose, serum potassium may decrease so monitoring and correcting of potassium levels may be warranted. A marked increase in blood pressure may be managed by the short-term use of phentolamine mesylate. Appropriate supportive treatment should be initiated.[L39190]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Dasiglucagon works to increase blood glucose levels under normal and hypoglycemic conditions.[A242140] After administration of dasiglucagon in adult patients with type 1 diabetes, the mean glucose increase from baseline at 90 minutes was 168 mg\/dL. In pediatric patients with type 1 diabetes aged seven to 17 years, the mean glucose increase at 60 minutes after administration of dasiglucagon was 162 mg\/dL.[L39190]","msds":null,"description":"Dasiglucagon is a glucagon analog that acts to increase blood sugar levels.[L39190] It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation.[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE.[L39190]\r\n\r\nSevere hypoglycemia is an acute, life-threatening medical condition resulting from a profound drop in blood glucose levels. It is characterized by neurological impairment, with manifestations like loss of consciousness and seizure. Hypoglycemia is a common side effect of antidiabetic treatments, most notably insulin and sulfonylureas. Although it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience severe hypoglycemia a year.[L39195] Even with close monitoring of blood glucose levels, it is not always possible to prevent severe hypoglycemic events in patients with diabetes, and children are particularly at risk for experiencing severe hypoglycemia.[L39200] Treatments for severe hypoglycemia have mostly been limited to intravenous dextrose and different glucagon formulations.[L39195] The approval of dasiglucagon marks the first glucagon analog approved for severe hypoglycemia treatment that does not require administration by a healthcare professional.[L39195]","enzymes":null,"type":"biotech","cas-number":"1544300-84-6","sequences":null,"targets":"BE0000527","unii":"AD4J2O47FQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Dasiglucagon is an analog of glucagon, which is a peptide hormone responsible for increasing blood glucose levels. It has the same mechanism of action as endogenous glucagon by acting as an agonist at glucagon receptors, which are G-coupled receptors expressed throughout the body. Dasiglucagon binds to glucagon receptors in the liver, which activates Gs and Gq, and consequently, adenylate cyclase. Adenyl cyclase increases intracellular cyclic AMP, which stimulates glycogenolysis and glucogenesis in the liver.[A19402,A242145] As glucose is primarily released from liver glycogen stores, hepatic stores of glycogen are crucial for dasiglucagon to exert its antihypoglycemic effects.[L39190]","drug-interactions":"DB00328 DB04899 DB00682 DB13400 DB00887 DB00742 DB00656 DB00610 DB06737 DB00178 DB00540 DB06712 DB09205 DB01142 DB09217 DB08841 DB11792 DB13875 DB13876 DB00814 DB01612 DB00562 DB09273 DB12945 DB09253 DB01247 DB01200 DB00177 DB13510 DB13286 DB00800 DB08941 DB00232 DB13432 DB06701 DB09307 DB13703 DB00605 DB00368 DB01556 DB08984 DB01229 DB00321 DB06711 DB01102 DB06148 DB01020 DB09026 DB00292 DB00490 DB00806 DB01235 DB04908 DB08822 DB00421 DB13341 DB00700 DB00631 DB00388 DB08932 DB00492 DB11201 DB12551 DB11738 DB13411 DB01295 DB00246 DB01577 DB04846 DB00777 DB09082 DB13398 DB00905 DB13604 DB00714 DB00543 DB09206 DB08807 DB04017 DB06690 DB00519 DB09363 DB00268 DB09480 DB04828 DB00181 DB00869 DB01579 DB01624 DB04818 DB00945 DB00901 DB13452 DB00820 DB01064 DB15861 DB00708 DB12610 DB13496 DB01240 DB09080 DB01622 DB00370 DB08925 DB01274 DB01216 DB09249 DB06826 DB01364 DB00599 DB09084 DB08550 DB04817 DB08950 DB05095 DB00871 DB00086 DB00788 DB00939 DB12661 DB01182 DB07767 DB00908 DB13167 DB09251 DB06262 DB00091 DB05039 DB00723 DB00691 DB14217 DB00584 DB09227 DB06725 DB06292 DB00612 DB12545 DB00614 DB00598 DB13940 DB00866 DB00872 DB00841 DB00749 DB00925 DB08955 DB00420 DB13323 DB13612 DB01397 DB14207 DB00214 DB00983 DB09238 DB00203 DB12080 DB13781 DB00668 DB11720 DB08952 DB12100 DB09220 DB00586 DB00784 DB14213 DB00334 DB06694 DB00601 DB01347 DB00899 DB00468 DB01484 DB05395 DB01626 DB01158 DB12054 DB00270 DB12010 DB00629 DB02224 DB00753 DB09242 DB06654 DB09477 DB00706 DB13217 DB13624 DB01283 DB00695 DB00960 DB01359 DB00881 DB00363 DB13429 DB01435 DB08810 DB00206 DB14938 DB00297 DB00606 DB00722 DB06237 DB06763 DB16629 DB09288 DB00936 DB13782 DB00999 DB00633 DB13251 DB00937 DB09218 DB13524 DB00831 DB06736 DB09068 DB13407 DB00816 DB03585 DB12779 DB13384 DB13399 DB00450 DB00734 DB13649 DB00469 DB00903 DB08985 DB14059 DB00397 DB00861 DB00852 DB00988 DB13371 DB01118 DB00594 DB04840 DB01143 DB12930 DB09243 DB00559 DB08960 DB13378 DB00500 DB09250 DB01170 DB00401 DB01366 DB01041 DB00035 DB06706 DB00875 DB00343 DB13312 DB09215 DB00622 DB13114 DB14068 DB08996 DB11477 DB14094 DB00590 DB00350 DB00780 DB00212 DB00812 DB08893 DB13345 DB00818 DB01275 DB00952 DB00323 DB12212 DB00774 DB00422 DB01037 DB00661 DB00289 DB13779 DB13775 DB00830 DB09295 DB14337 DB00692 DB04948 DB01250 DB00486 DB01365 DB01116 DB01244 DB09245 DB11783 DB13692 DB00353 DB01054 DB00195 DB13801 DB00384 DB13538 DB01002 DB13385 DB00867 DB13001 DB13246 DB00572 DB13225 DB08439 DB01407 DB06684 DB09077 DB09236 DB11362 DB01050 DB01193 DB00182 DB09241 DB08981 DB06445 DB01608 DB01392 DB08931 DB00295 DB09292 DB04581 DB06764 DB14185 DB00755 DB00589 DB09235 DB00073 DB00310 DB13374 DB01614 DB06403 DB13657 DB00528 DB08815 DB01363 DB01029 DB00373 DB08836 DB06016 DB00699 DB04946 DB00785 DB00248 DB01591 DB11541 DB13544 DB01180 DB06152 DB01009 DB01576 DB01267 DB08907 DB00580 DB01242 DB01088 DB00679 DB13917 DB00436 DB01236 DB01169 DB00797 DB00477 DB00922 DB08940 DB11543 DB06190 DB00883 DB00335 DB06762 DB01023 DB09237 DB00681 DB00573 DB04829 DB00374 DB13520 DB00457 DB11481 DB09167 DB00484 DB00296 DB01151 DB00796 DB00554 DB00935 DB00264 DB01214 DB00190 DB11455 DB00461 DB00813 DB11632 DB01255 DB09204 DB09128 DB12313 DB09254 DB09239 DB00752 DB00865 DB00886 DB01367 DB09212 DB09016 DB00721 DB01186 DB01467 DB00808 DB00325 DB01442 DB04743 DB09289 DB12278 DB00191 DB00344 DB00381 DB01049 DB00465 DB15456 DB01018 DB01408 DB11466 DB00805 DB08942 DB12846 DB01282 DB15685 DB13757 DB00211 DB04820 DB13598 DB13211 DB14010 DB11124 DB00287 DB12766 DB00561 DB06707 DB13803 DB13527 DB13232 DB13166 DB13481 DB08954 DB09203 DB09216 DB04831 DB00521 DB00966 DB00244 DB15965 DB13435 DB13430 DB13777 DB09517 DB07402 DB00696 DB13139 DB00616 DB01203 DB11373 DB00458 DB01119 DB01399 DB00953 DB09038 DB00880 DB03322 DB01149 DB11556 DB00697 DB01224 DB13919 DB06678 DB11428 DB09112 DB00802 DB01001 DB11587 DB01340 DB00765 DB13629 DB01288 DB01509 DB11518 DB01324 DB01403 DB00187 DB13783 DB09282 DB09214 DB00226 DB11785 DB05266 DB12371 DB00571 DB14208 DB11755 DB00482 DB00703 DB12093 DB13453 DB13852 DB13559 DB13443 DB09248 DB00041 DB01028 DB13108 DB00542 DB00393 DB08808 DB04861 DB01419 DB13860 DB00320 DB04855 DB11323 DB00489 DB13575 DB11278 DB00657 DB12248 DB01454 DB04836 DB01014 DB00876 DB00975 DB09202 DB08976 DB04812 DB14231 DB00678 DB06268 DB09279 DB00216 DB04920 DB00159 DB00315 DB06216 DB11770 DB01089 DB12465 DB00346 DB01189 DB12092 DB12361 DB00435 DB01144 DB12927 DB09213 DB14125 DB08957 DB00938 DB09285 DB13532 DB09232 DB06153 DB00991 DB01126 DB14754 DB01401 DB00795 DB13508 DB09246 DB08935 DB05271 DB13722 DB00275 DB01600 DB02032 DB09252 DB00726 DB06267 DB13530 DB09061 DB12445 DB00998 DB00862 DB00712 DB01136 DB01348 DB00575 DB13314 DB01424 DB01021 DB13410 DB13631 DB00968 DB04725 DB01159 DB00669 DB00790 DB12399 DB00413 DB09244 DB01171 DB00727 DB01238 DB01253 DB01628 DB01162 DB09286 DB01090 DB14060 DB13064 DB11871 DB00217 DB01197 DB05562 DB00221 DB01113 DB00821 DB00247 DB00918 DB01291 DB01168 DB08951 DB08797 DB08991 DB01115 DB01472 DB00524 DB00533 DB01580 DB04552 DB01388 DB11273 DB01297","absorption":"Following subcutaneous administration of 0.6 mg dasiglucagon, the mean peak plasma concentration was 5110 pg\/mL (1510 pmol\/L). T<sub>max<\/sub> was 35 minutes. In pediatric patients with type 1 diabetes, the mean peak plasma concentration of 3920 pg\/mL occurred at around 21 minutes.[L39190] Dasiglucagon has a higher absorption rate than traditional reconstituted glucagon.[A242140]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The half-life was approximately 30 minutes following subcutaneous administration.[L39190] Dasiglucagon has a longer plasma elimination half-life than traditional reconstituted glucagon.[A242140]","monoisotopic-mass":null,"volume-of-distribution":"The mean apparent volume of distribution ranged from 47 L to 57 L after subcutaneous administration.[L39190]","route-of-elimination":null,"name":"Dasiglucagon","metabolism":"Like endogenous glucagon, dasiglucagon undergoes proteolytic degradation pathways in blood, liver, and kidney.[L39190]","reactions":null,"indication":"Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.[L39190]","ahfs-codes":null,"updated":"2021-11-21","drugbank-id":"DB15226"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":454.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).","enzymes":null,"type":"small molecule","cas-number":"1351636-18-4","sequences":null,"targets":"BE0001284","unii":"LXG44NDL2T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":454.175338592,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tirabrutinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15227"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Avidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).","enzymes":null,"type":"biotech","cas-number":"110539-97-4","sequences":null,"targets":null,"unii":"639T22V8VD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Avidin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15228"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":427.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CNV-2197944 is under investigation in clinical trial NCT01893125 (Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy).","enzymes":null,"type":"small molecule","cas-number":"1204535-44-3","sequences":null,"targets":null,"unii":"SSB9S6N20R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":427.117747179,"volume-of-distribution":null,"route-of-elimination":null,"name":"CNV-2197944","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15229"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":401.415,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dithiopyr is under investigation in clinical trial NCT01236781 (Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates).","enzymes":null,"type":"small molecule","cas-number":"97886-45-8","sequences":null,"targets":null,"unii":"2TXF17HAV1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":401.054261166,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dithiopyr","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15230"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":3822.514,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 g\/kg XG-102 Administered to Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1445179-97-4","sequences":null,"targets":null,"unii":"2K30142185","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":3820.237428273,"volume-of-distribution":null,"route-of-elimination":null,"name":"Brimapitide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15231"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":571.58,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1439399-58-2","sequences":null,"targets":null,"unii":"U6CL98GLP4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":571.161343324,"volume-of-distribution":null,"route-of-elimination":null,"name":"Telaglenastat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15232"},{"toxicity":"Data regarding overdoses of avapritinib are not readily available.[L40363]","snp-adverse-drug-reactions":null,"average-mass":498.57,"transporters":"BE0000703 BE0003657 BE0001067 BE0001032 BE0004752","pharmacodynamics":"Avapritinib is a selective kinase inhibitor that negatively modulates the action of cell transporters to resensitize them to other chemotherapies.[L40363] It has a long duration of action as it is given once daily.[L40363] Patients should be counselled regarding the risk of intracranial hemorrhage, CNS effects, and embryo-fetal toxicity.[L40363]","msds":null,"description":"Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib].\r\n\r\nAvapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464]","enzymes":"BE0002638 BE0002793","type":"small molecule","cas-number":"1703793-34-3","sequences":null,"targets":"BE0000453 BE0008625","unii":"513P80B4YJ","protein-binding":"Avapritinib is 98.8% protein bound in serum.[L40363]","fda-label":null,"clearance":"The mean apparent oral clearance of avapritinib is 19.5L\/h.[L40363]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Other protein kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":null,"food-interactions":"Take on an empty stomach. Take more than 1 hour before or 2 hours after a meal. Avoid grapefruit products. Grapefruit inhibits CYP3A metabolism, which may increase the serum concentration of avapritinib. Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of avapritinib.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Avapritinib has a negative modulating effect on the transporters ABCB1 and ABCG2, which mediate the multidrug resistance phenotype of some cancers.[A189327] This modulation may be due to interactions of avapritinib with the drug binding pocket of these transporters.[A189327] Negative modulation of these transporters, resensitizes cancerous cells to treatment with chemotherapeutic agents like [paclitaxel].[A189327]","drug-interactions":"DB00328 DB00682 DB08953 DB12095 DB09198 DB06737 DB03374 DB00916 DB06712 DB01142 DB08828 DB04951 DB00814 DB09185 DB05829 DB00338 DB00451 DB00177 DB03756 DB00495 DB00957 DB06715 DB13174 DB14033 DB00321 DB00503 DB07615 DB00220 DB00665 DB01067 DB01124 DB01075 DB00531 DB13136 DB11901 DB08865 DB01039 DB00222 DB00839 DB11823 DB00246 DB01381 DB00613 DB01117 DB00238 DB02520 DB05676 DB06739 DB00389 DB01320 DB00834 DB13943 DB01323 DB09421 DB04818 DB04938 DB00945 DB00440 DB13954 DB00017 DB14009 DB12332 DB09080 DB01274 DB00731 DB11932 DB05521 DB01281 DB00758 DB09101 DB04868 DB08881 DB00549 DB00788 DB06595 DB06119 DB06290 DB14960 DB00908 DB00091 DB09227 DB11633 DB06725 DB06292 DB14973 DB11689 DB00949 DB00872 DB01201 DB00749 DB00266 DB00420 DB00980 DB09046 DB01015 DB00214 DB00983 DB14055 DB00022 DB09238 DB01583 DB00203 DB00476 DB06738 DB00668 DB00951 DB06448 DB12015 DB12319 DB00715 DB00327 DB00586 DB00784 DB02703 DB12629 DB00334 DB01156 DB14019 DB00648 DB00414 DB01120 DB08873 DB00977 DB00468 DB00270 DB00641 DB13955 DB00307 DB01234 DB04856 DB01241 DB00582 DB01283 DB06605 DB00312 DB00304 DB00363 DB00316 DB01435 DB09063 DB00621 DB00313 DB12147 DB06237 DB09288 DB00936 DB11757 DB00568 DB13874 DB09068 DB00705 DB00617 DB00783 DB05109 DB01195 DB00469 DB05084 DB08896 DB00624 DB00532 DB01097 DB00224 DB01251 DB00065 DB05541 DB01118 DB15133 DB08904 DB00559 DB00471 DB12917 DB00176 DB01104 DB00550 DB01095 DB01357 DB01041 DB11730 DB00921 DB01418 DB00343 DB00622 DB00196 DB11560 DB00396 DB06372 DB00590 DB01181 DB11652 DB00812 DB06414 DB00818 DB01355 DB01026 DB06168 DB09118 DB01037 DB00661 DB00502 DB00932 DB01289 DB00486 DB00252 DB01045 DB07637 DB00763 DB01016 DB13956 DB14011 DB01167 DB13953 DB00619 DB00603 DB00745 DB11672 DB00322 DB11994 DB01411 DB00188 DB00564 DB05667 DB00398 DB00330 DB11581 DB08439 DB08864 DB09065 DB08899 DB13944 DB01050 DB04896 DB00843 DB09241 DB14724 DB00412 DB11614 DB01232 DB01263 DB00755 DB04956 DB09418 DB04898 DB01211 DB08995 DB00675 DB00904 DB01029 DB15569 DB13644 DB14737 DB01601 DB01072 DB00672 DB06218 DB00625 DB09048 DB00580 DB11943 DB01154 DB04665 DB06700 DB00208 DB06413 DB01685 DB01023 DB12597 DB00374 DB14921 DB06652 DB00796 DB00250 DB11753 DB01138 DB00554 DB08860 DB15263 DB00461 DB06442 DB11779 DB00752 DB03783 DB04841 DB11995 DB06285 DB13742 DB06273 DB14975 DB00544 DB00465 DB06636 DB01131 DB01589 DB13179 DB01110 DB00976 DB00969 DB04832 DB00972 DB00051 DB04911 DB00829 DB04831 DB01098 DB01176 DB00197 DB00696 DB00333 DB01177 DB00026 DB00470 DB01221 DB11586 DB01149 DB00537 DB04216 DB13675 DB06729 DB09280 DB13919 DB00066 DB00199 DB01198 DB06697 DB00794 DB00891 DB08875 DB01036 DB00857 DB03604 DB00514 DB11963 DB01264 DB12371 DB08912 DB11642 DB08882 DB00444 DB00482 DB12474 DB08816 DB00347 DB08798 DB15762 DB00744 DB01406 DB01028 DB09036 DB00359 DB00576 DB04855 DB00263 DB01174 DB08877 DB06268 DB00678 DB00216 DB04920 DB14568 DB13952 DB01544 DB01032 DB00439 DB00024 DB09213 DB13941 DB08496 DB09231 DB00279 DB09029 DB01087 DB04557 DB13804 DB12245 DB06674 DB06370 DB06803 DB01069 DB00501 DB06209 DB00342 DB00726 DB06731 DB06174 DB09061 DB00227 DB00448 DB04574 DB00712 DB01136 DB00673 DB01424 DB01645 DB04725 DB01159 DB01628 DB00946 DB13406 DB00425 DB01101 DB01183 DB06594 DB00255 DB15822 DB00472 DB00898 DB09100 DB00533 DB08962 DB00005 DB00701 DB15982","absorption":"A 300mg oral dose of avapritinib reaches a C<sub>max<\/sub> of 813ng\/mL with a T<sub>max<\/sub> of 2.0-4.1h and an AUC of 15400h\\*ng\/mL.[L40363]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The half life of avapritinib is 32-57h.[L40363]","monoisotopic-mass":498.240419072,"volume-of-distribution":"The mean apparent volume of distribution is 1200L.[L40363]","route-of-elimination":"Avapritinib is 70% eliminated in the feces with 11% as the unchanged drug and 18% eliminated in the urine with 0.23% as the unchanged drug.[L40363]","name":"Avapritinib","metabolism":"Avapritinib is metabolized mainly by CYP3A4 and CYP2C9 _in vitro_.[L40363] A 310mg oral dose is recovered as 49% unchanged drug, 35% hydroxy glucuronide metabolite, and 14% oxidatively deaminated metabolite.[L40363]","reactions":null,"indication":"Avapritinib is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.[L40363]\r\n\r\nIt is also used to treat adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia. However, it is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 X 10<sup>9<\/sup> L.[L40363]","ahfs-codes":null,"updated":"2022-04-10","drugbank-id":"DB15233"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Semorinemab is under investigation in clinical trial NCT03289143 (A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease).","enzymes":null,"type":"biotech","cas-number":"2159141-27-0","sequences":null,"targets":null,"unii":"O8DG8VI95O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Semorinemab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15234"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":353.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1382469-39-7","sequences":null,"targets":null,"unii":"6068Z4Y7QI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":353.167416935,"volume-of-distribution":null,"route-of-elimination":null,"name":"Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15235"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":164.157,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fucose is under investigation in clinical trial NCT03354533 (Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II).","enzymes":null,"type":"small molecule","cas-number":"2438-80-4","sequences":null,"targets":null,"unii":"28RYY2IV3F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":164.068473486,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fucose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15236"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":133.122,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"222727-43-7","sequences":null,"targets":null,"unii":"YKG0YF688X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":133.053906665,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluciclovine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15237"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":509.397,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1628732-62-6","sequences":null,"targets":null,"unii":"PD5F4ZXD21","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":509.123478218,"volume-of-distribution":null,"route-of-elimination":null,"name":"Olinciguat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15238"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":354.366,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PTI-428 is under investigation in clinical trial NCT03258424 (Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO as Background Therapy).","enzymes":null,"type":"small molecule","cas-number":"1953130-87-4","sequences":null,"targets":null,"unii":"T2U4ZA62U4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":354.132805076,"volume-of-distribution":null,"route-of-elimination":null,"name":"PTI-428","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15239"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Elezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).","enzymes":null,"type":"biotech","cas-number":"1791416-49-3","sequences":null,"targets":null,"unii":"SK1LVT23A1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Elezanumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15240"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":385.483,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Methylsamidorphan is under investigation in clinical trial NCT01418092 (ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)).","enzymes":null,"type":"small molecule","cas-number":"1119361-12-4","sequences":null,"targets":null,"unii":"8347HC35J6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":385.212183842,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methylsamidorphan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15241"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":527.496,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).","enzymes":null,"type":"small molecule","cas-number":"668455-28-5","sequences":null,"targets":null,"unii":"J17152066B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":527.155571986,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-0533","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15242"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":636.837,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).","enzymes":null,"type":"small molecule","cas-number":"149402-51-7","sequences":null,"targets":null,"unii":"DOB7Y3RSX0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":636.367556042,"volume-of-distribution":null,"route-of-elimination":null,"name":"2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15243"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":641.626,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).","enzymes":null,"type":"small molecule","cas-number":"873438-88-1","sequences":null,"targets":null,"unii":"R048696O9L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":641.277345357,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iopofosine I-131","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15244"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":498.562,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1928707-56-5","sequences":null,"targets":null,"unii":"T34SH2H9HI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB03410 DB13136 DB00682 DB14055 DB00946 DB01418 DB00498 DB13451 DB13347 DB00266 DB04665 DB08794 DB08496 DB13275","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":498.217952296,"volume-of-distribution":null,"route-of-elimination":null,"name":"Olorofim","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15245"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":494.452,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Salvianolic acid A is under investigation in clinical trial NCT03908242 (Phase I Study of Continuous Administration of Salvianolic Acid A Tablet).","enzymes":null,"type":"small molecule","cas-number":"96574-01-5","sequences":null,"targets":null,"unii":"51622542XO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":494.121296908,"volume-of-distribution":null,"route-of-elimination":null,"name":"Salvianolic acid A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15246"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":439.491,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vorolanib is under investigation in clinical trial NCT03904719 (CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)).","enzymes":null,"type":"small molecule","cas-number":"1013920-15-4","sequences":null,"targets":null,"unii":"YP8G3I74EL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":439.20196788,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vorolanib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15247"},{"toxicity":"There are no reports of overdose with bulevirtide. In the case of an overdose, monitor the patient and provide supportive treatment.[L30290]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Bulevirtide prevents Hepatitis D entry into cells. It is effective in the reduction of Hepatitis D virus (HDV) RNA levels and improvement of liver inflammation in cases of Hepatitis D infection.[L30215,L30220,L30260]","msds":null,"description":"Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection.[A226305]  \r\n\r\nBulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.[L30215] In the USA, bulevirtide has been granted Orphan Drug Designation and Breakthrough Therapy Designation.[L30260,L30275] Due to potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon Alfa-2a]) in Patients With CHD. Completion of this clinical trial is anticipated in early 2023.[L30240]","enzymes":null,"type":"biotech","cas-number":"2012558-47-1","sequences":null,"targets":"BE0003644","unii":"WKM56H3TLB","protein-binding":"The plasma protein binding of bulevirtide is >99%,[L30290] and it is primarily bound to albumin.[L30215]","fda-label":null,"clearance":"The clearance after of bulevirtide after subcutaneous administration (CL\/F) in healthy volunteers ranged from 7.98 L\/h (2.02) to 62 L\/h (16.7), depending on the dose administered.[L30215] The clearance of bulevirtide decreases as the dose increases.[L30290]","atc-codes":"ANTIVIRALS FOR SYSTEMIC USE ANTIINFECTIVES FOR SYSTEMIC USE Other antivirals DIRECT ACTING ANTIVIRALS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"The sodium taurocholate co-transporting polypeptide (NTCP) serves to transport bile acids in the sodium salt form to the liver from the portal circulation. It is an important component of enterohepatic circulation. The Hepatitis D virus replicates independently within liver cells but requires the hepatitis B surface antigen in order to propagate. Hepatitis B and D viruses enter hepatocytes through the binding of NTCP (sodium\/taurocholate cotransporting polypeptide) to the Hepatitis B virus preS1 surface protein domain.[L30260] \r\n\r\nBulevirtide binds and subsequently inactivates the hepatitis B (HBV) and HDV receptors on hepatocytes. Bulevirtide blocks the NTCP binding site, subsequently blocking the entry of the viruses into cells. This prevents viral entry and replication, reducing symptoms of Hepatitis D infection.[L30260]","drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":"Human pharmacokinetic data for bulevirtide is limited in the literature. In rats, bulevirtide administered by subcutaneous injection is rapidly absorbed with a Cmax of 4 to 6 hours.[L30215] The estimated bioavailability is 85% in humans, and steady-state concentrations are expected to occur within weeks of initiating treatment.[A226375,L30290] The AUC for bulevirtide after a 2mg subcutaneous dose was found to be approximately 46 ng\/ml.h with a Tmax of 0.5 hours.[L30215]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The half-life of bulevirtide ranges between 4 and 7 hours in healthy adults.[L30290]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of bulevirtide is estimated to be lower than total body water.[L30290] In animals, bulevirtide distributes into the liver, gastrointestinal tract, kidney, and bladder.[L30215]","route-of-elimination":"Elimination through target (NTCP) binding is expected to be the main route of elimination for bulevirtide. In healthy volunteers, bulevirtide was not found to be excreted in the urine.[L30290]","name":"Bulevirtide","metabolism":"To date, metabolism studies have not been conducted on bulevirtide. It is expected to be catabolized by peptidases to smaller peptides and amino acids, with no active metabolites.[L30215,L30290]","reactions":null,"indication":"Bulevirtide is indicated for the treatment of chronic Hepatitis D infection in HDV-RNA positive adult patients with compensated liver disease.[L30215]","ahfs-codes":null,"updated":"2021-10-15","drugbank-id":"DB15248"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":821.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).","enzymes":null,"type":"small molecule","cas-number":"1263814-52-3","sequences":null,"targets":null,"unii":"59LD48P07K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":820.382948581,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-6325","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15249"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":444.93,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).","enzymes":null,"type":"small molecule","cas-number":"698394-73-9","sequences":null,"targets":"BE0002463","unii":"MWI54OUA12","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Vercirnon, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying IBD by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD.","drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":444.091056,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vercirnon","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15250"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":604.713,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Antipain is a serine\/cysteine protease inhibitor originally isolated from various strains of actinomycetes.[A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro-_N_-nitrosoguanidine (MNNG).[A214484, A214487]\r\n\r\nAntipain was used in 2010 to obtain a crystal structure of the _Leishmania major_ oligopeptidase B (OPB), a serine protease that serves as a virulence factor in trypanosomatids.[A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development as anti-trypanosomatid drugs.[A214493, A214496]","enzymes":null,"type":"small molecule","cas-number":"37691-11-5","sequences":null,"targets":null,"unii":"47V479BE6L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":604.344529177,"volume-of-distribution":null,"route-of-elimination":null,"name":"Antipain","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-24","drugbank-id":"DB15251"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).","enzymes":null,"type":"biotech","cas-number":"1476039-58-3","sequences":null,"targets":null,"unii":"GN465U8B72","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nemolizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15252"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).","enzymes":null,"type":"biotech","cas-number":"1453067-91-8","sequences":null,"targets":null,"unii":"AS3AZ5R46K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB08880 DB00328 DB14905 DB00928 DB15274 DB06474 DB09381 DB06647 DB15091 DB11959 DB09052 DB12034 DB11857 DB15857 DB14039 DB12023 DB06305 DB00092 DB00970 DB15898 DB04951 DB14877 DB00034 DB11604 DB12344 DB13886 DB00642 DB13068 DB14811 DB00495 DB11921 DB11884 DB00105 DB11685 DB11746 DB15118 DB00305 DB06772 DB16650 DB14997 DB01229 DB12815 DB12235 DB06602 DB15646 DB12386 DB12053 DB01590 DB13843 DB14012 DB09035 DB13867 DB14891 DB16611 DB13017 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB06599 DB06310 DB00853 DB14864 DB09105 DB11044 DB14685 DB12520 DB10804 DB12396 DB13208 DB05797 DB15119 DB09082 DB09383 DB05656 DB00851 DB06557 DB12274 DB11680 DB13140 DB05676 DB10584 DB00959 DB11003 DB06607 DB15443 DB00773 DB14897 DB09074 DB00008 DB00120 DB00028 DB00547 DB12104 DB15001 DB12261 DB00428 DB12849 DB06813 DB13954 DB12826 DB12844 DB10990 DB01033 DB04962 DB11866 DB12205 DB00987 DB12498 DB11715 DB00324 DB00276 DB10061 DB01204 DB00098 DB01281 DB11621 DB16385 DB00113 DB12246 DB15627 DB05942 DB04868 DB00002 DB04949 DB00552 DB00877 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB06616 DB00033 DB01005 DB12119 DB00091 DB09045 DB14711 DB14952 DB00054 DB05111 DB15626 DB14540 DB00180 DB16225 DB06589 DB12698 DB13073 DB08870 DB11731 DB14776 DB10276 DB01015 DB08906 DB01410 DB11771 DB05304 DB00022 DB12893 DB15090 DB16755 DB13014 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB00526 DB15865 DB12943 DB10283 DB12584 DB15899 DB00601 DB09369 DB00977 DB12891 DB15415 DB05276 DB17088 DB00993 DB11914 DB16170 DB00072 DB11988 DB14619 DB06371 DB00307 DB11674 DB15045 DB01269 DB06550 DB01234 DB16355 DB06322 DB03451 DB00635 DB11616 DB14445 DB13976 DB14066 DB10317 DB15089 DB14967 DB16736 DB13979 DB11834 DB01206 DB05679 DB10062 DB05006 DB09378 DB09318 DB15656 DB14022 DB09122 DB00069 DB12025 DB14843 DB12589 DB06606 DB11756 DB09053 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB05109 DB00432 DB12530 DB01097 DB16265 DB00394 DB00065 DB15718 DB05892 DB13386 DB01816 DB12089 DB09303 DB08904 DB08059 DB08910 DB12487 DB14959 DB12917 DB12845 DB06192 DB05015 DB11708 DB00550 DB15628 DB00043 DB12976 DB09559 DB01357 DB01008 DB01041 DB09033 DB11826 DB01108 DB14004 DB06241 DB00057 DB11603 DB06372 DB00112 DB01280 DB01181 DB06603 DB10600 DB05793 DB10769 DB01384 DB00591 DB10794 DB09095 DB06168 DB06049 DB01248 DB16659 DB01099 DB14996 DB12996 DB16222 DB06043 DB11945 DB11050 DB08908 DB08879 DB13924 DB00076 DB06366 DB09037 DB11478 DB01047 DB00763 DB05550 DB06662 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB00619 DB01268 DB09317 DB14824 DB16376 DB15453 DB11580 DB00445 DB12142 DB14545 DB05555 DB03523 DB14580 DB00290 DB00322 DB16195 DB02546 DB00188 DB00564 DB12189 DB00398 DB00110 DB09077 DB13003 DB15428 DB00075 DB14724 DB05101 DB10343 DB12947 DB00078 DB16648 DB06584 DB00755 DB04956 DB05136 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB14449 DB12560 DB12797 DB14394 DB05496 DB06287 DB04630 DB12157 DB12609 DB05916 DB01611 DB05889 DB06467 DB12102 DB14783 DB00441 DB10989 DB04958 DB11040 DB00480 DB12342 DB01601 DB00242 DB09070 DB12090 DB14988 DB15432 DB14384 DB14620 DB00291 DB06688 DB08895 DB15363 DB01254 DB00111 DB01270 DB00068 DB01380 DB13418 DB15810 DB01169 DB01656 DB14947 DB15441 DB15383 DB12991 DB00859 DB11487 DB14962 DB15349 DB00997 DB15654 DB05941 DB11930 DB06050 DB12612 DB00443 DB04845 DB11817 DB11041 DB06162 DB14385 DB05144 DB00694 DB12489 DB09264 DB05472 DB00864 DB00446 DB01024 DB12773 DB12456 DB06273 DB05325 DB15483 DB12317 DB12413 DB06317 DB14809 DB00688 DB12807 DB01196 DB06681 DB00544 DB01013 DB15334 DB00089 DB11693 DB11466 DB05097 DB08971 DB11840 DB12692 DB04914 DB13375 DB16732 DB12568 DB09054 DB14512 DB11038 DB01262 DB12202 DB13045 DB00860 DB06360 DB15595 DB00051 DB10318 DB14908 DB12820 DB15941 DB10803 DB15113 DB09073 DB00588 DB00095 DB01177 DB14845 DB00026 DB11529 DB05578 DB00488 DB00958 DB00286 DB12701 DB15101 DB02806 DB14778 DB12331 DB14762 DB15335 DB06186 DB15559 DB09091 DB10991 DB10805 DB11850 DB08868 DB08902 DB15409 DB15014 DB08871 DB00380 DB00337 DB12902 DB05440 DB12296 DB13143 DB16694 DB01222 DB16695 DB16394 DB13856 DB14539 DB15225 DB12250 DB15434 DB00309 DB14042 DB04573 DB00269 DB12213 DB12371 DB16077 DB00444 DB12240 DB06650 DB16393 DB01073 DB11646 DB15252 DB01423 DB00570 DB00056 DB14409 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB14707 DB12683 DB08889 DB01030 DB13923 DB16421 DB16151 DB09302 DB12617 DB00563 DB12118 DB08877 DB05915 DB00655 DB14871 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB11657 DB12775 DB06400 DB00011 DB04988 DB14513 DB01285 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB00764 DB00795 DB05260 DB08935 DB05545 DB15076 DB11972 DB13241 DB16703 DB00059 DB06116 DB15461 DB14040 DB06674 DB15900 DB09331 DB00293 DB13223 DB14041 DB13127 DB10583 DB05258 DB15719 DB00361 DB00620 DB04574 DB07931 DB15044 DB06769 DB11608 DB15104 DB11862 DB11627 DB05336 DB11714 DB12152 DB11776 DB12016 DB06324 DB12534 DB04964 DB15336 DB10316 DB11849 DB05773 DB14597 DB01101 DB04572 DB15940 DB14219 DB09057 DB12718 DB00762 DB06343 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00005 DB10315 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bleselumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15253"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":471.46,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"RO-5126766 free base is under investigation in clinical trial NCT03875820 (Phase I Trial of VS-6063 and RO5126766.).","enzymes":null,"type":"small molecule","cas-number":"946128-88-7","sequences":null,"targets":null,"unii":"D0D4252V97","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":471.101268037,"volume-of-distribution":null,"route-of-elimination":null,"name":"RO-5126766 free base","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15254"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":384.391,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).","enzymes":null,"type":"small molecule","cas-number":"1345410-31-2","sequences":null,"targets":null,"unii":"4S0HBYW6QE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":384.15101555,"volume-of-distribution":null,"route-of-elimination":null,"name":"Reldesemtiv","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15256"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":618.53,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)).","enzymes":null,"type":"small molecule","cas-number":"1398568-47-2","sequences":null,"targets":null,"unii":"R3I80TLN7S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":617.1971882,"volume-of-distribution":null,"route-of-elimination":null,"name":"Milademetan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15257"},{"toxicity":"There is currently no data for imlifidase administered at supra-therapeutic doses; therefore, toxicity information is not readily available.[L28001] In cases of overdose, the patient should be carefully monitored and symptomatic treatment should be initiated as needed.[L28001] Although there is no antidote to imlifidase, administration of intravenous IgG may correct depleted IgG levels.[L28001]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Imlifidase is highly specific to all four human IgG subclasses and does not cleave any other immunoglobulins (IgM, IgA, IgE, IgD).[A225836,L28041] The inactivation of human IgG antibodies occurs rapidly and efficiently after administration of imlifidase, with the effect lasting for several weeks.[A226045]","msds":null,"description":"Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large.[A225916] Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.[A225836,A225916]  \r\n\r\nPatients who have developed human leukocyte antigen (HLA) sensitization from prior exposure to blood products, pregnancy, or any other circumstance which may have resulted in exposure to non-self HLA antigens, face additional barriers to transplantation.[A225836,A225921] Highly sensitized individuals carry high levels of anti-HLA antibodies and are at significant risk for antibody-mediated rejection which occurs mainly through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).[A225836] High levels of anti-HLA antibodies also contribute to poor graft survival.[A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft.[A225836,A225921]\r\n\r\nImlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies.[L28001] As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation in highly sensitized patients to proceed.[A225836,L28001]","enzymes":null,"type":"biotech","cas-number":"1947415-68-0","sequences":null,"targets":"BE0010027","unii":"UVJ7NL8S2P","protein-binding":"There is currently no evidence to suggest that imlifidase binds to any other protein besides its primary target - immunoglobulin G (IgG).[L28041] Studies have demonstrated that imlifidase is highly specific for IgG and does not bind to any other human immunoglobulins.[L28041]","fda-label":null,"clearance":"The mean clearance value of imlifidase is reported to be 1.8 mL\/h\/kg.[A225836]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS Selective immunosuppressants","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Imlifidase is a cysteine protease derived from _Streptococcus pyogenes_ which degrades immunoglobulin G (IgG) in a multistep process.[A226040,L28001] In the first step, imlifidase cleaves one of the two IgG heavy chains at the lower hinge leaving the other intact, resulting in a single cleaved IgG molecule. In the second step, the second heavy chain is cleaved yielding one homodimeric Fc fragment and one F(ab\u20AC)<sub>2<\/sub> fragment.[A226040,A226045,L28001] \r\n\r\nThis process removes the ability of the F(ab\u20AC)<sub>2<\/sub> fragments to participate in Fc-mediated functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).[L28001,L28041] Ultimately, by degrading the entire IgG pool, imlifidase reduces donor-specific antibodies (DSA) and allows transplantation to occur.[A225836,L28001]","drug-interactions":"DB16655 DB12331 DB12893 DB14762 DB06474 DB15090 DB06186 DB12189 DB14919 DB00110 DB09052 DB15135 DB12034 DB14039 DB12023 DB12943 DB08902 DB09077 DB15899 DB15898 DB14877 DB12891 DB00075 DB14724 DB05101 DB00072 DB16394 DB11988 DB15434 DB06371 DB14811 DB16405 DB14042 DB01269 DB06550 DB16355 DB11884 DB12213 DB12159 DB11856 DB16258 DB00073 DB06643 DB14997 DB12560 DB12797 DB12240 DB06650 DB13976 DB05496 DB12157 DB16393 DB13979 DB12609 DB15252 DB05889 DB06467 DB00056 DB06602 DB11834 DB12053 DB04958 DB05679 DB14707 DB12683 DB14012 DB09035 DB14843 DB13017 DB13923 DB15432 DB00108 DB12589 DB06606 DB11756 DB06310 DB09302 DB00111 DB14907 DB01270 DB12734 DB14864 DB12530 DB05797 DB14947 DB00087 DB12775 DB05656 DB00065 DB14962 DB15718 DB05892 DB12274 DB13140 DB05941 DB11767 DB06607 DB09303 DB08904 DB14580 DB12917 DB06192 DB11595 DB09029 DB00043 DB09559 DB00028 DB12489 DB08935 DB09264 DB09033 DB06116 DB14040 DB12849 DB06674 DB12826 DB12456 DB06273 DB12844 DB15900 DB09331 DB06317 DB12498 DB00112 DB13127 DB11715 DB15719 DB05097 DB15044 DB16385 DB11862 DB15627 DB11714 DB12152 DB00002 DB13375 DB04949 DB06168 DB11776 DB16732 DB06324 DB14996 DB16222 DB11849 DB06043 DB06360 DB12335 DB05773 DB00051 DB11945 DB14597 DB14908 DB12820 DB15941 DB11976 DB15940 DB12119 DB08879 DB06366 DB09037 DB00074 DB00054 DB05111 DB06342 DB06612 DB15397 DB05595 DB06318 DB15626 DB11569 DB14784 DB00095 DB13073 DB08870 DB11731 DB05578 DB11580 DB14776 DB15101 DB15453 DB11771 DB05555","absorption":"Given that imlifidase is administered intravenously, it is fully absorbed and bioavailable; imlifidase exposure is dose-proportional and predictable.[A225836,L28001] After a dose of 0.25 mg\/kg, the mean Cmax of imlifidase was 5.8 (4.2-8.9) ug\/mL.[L28001] Tmax occurs once infusion is complete or soon after.[A225836] Food is not expected to impact the effectiveness or absorption of imlifidase.[L28001]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean distribution half-life of imlifidase is reported to be 1.8 hours, while the mean elimination half-life is reported to be 89 hours.[A225836]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of imlifidase is reported to be 0.2 L\/kg in the elimination phase.[A225836]","route-of-elimination":null,"name":"Imlifidase","metabolism":"There is currently no imlifidase metabolism data available; however, it is thought to be eliminated via proteolysis.[L28041]","reactions":null,"indication":"Imlifidase is indicated for desensitization of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.[L28001] The treatment is reserved for patients unlikely to receive a transplant under the available kidney allocation system including prioritization programs for highly sensitized patients.[L28001]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15258"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":581.772,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).","enzymes":null,"type":"small molecule","cas-number":"630112-41-3","sequences":null,"targets":null,"unii":"SJ5A8151JO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":581.405654894,"volume-of-distribution":null,"route-of-elimination":null,"name":"VB-201","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15259"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjgren's Syndrome).","enzymes":null,"type":"biotech","cas-number":"2031153-61-2","sequences":null,"targets":null,"unii":"0628T707D0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iscalimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15260"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":474.815,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Butafenacil is under investigation in clinical trial NCT03760328 (Effect of Upper Airway Stimulation in Patients With Obstructive Sleep Apnea).","enzymes":null,"type":"small molecule","cas-number":"134605-64-4","sequences":null,"targets":null,"unii":"7Z141CCP2R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":474.08054864,"volume-of-distribution":null,"route-of-elimination":null,"name":"Butafenacil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15261"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1310460-85-5","sequences":null,"targets":null,"unii":"B37J680LX0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Futuximab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15262"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Thyrotropin is under investigation in clinical trial NCT01348191 (Detection of Thyrotrophin Receptor in Human Myometrium).","enzymes":null,"type":"biotech","cas-number":"9002-71-5","sequences":null,"targets":null,"unii":"02KSI6Z9AK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"DIAGNOSTIC AGENTS VARIOUS OTHER DIAGNOSTIC AGENTS Tests for thyreoidea function","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01149 DB04849 DB08953 DB11800 DB00476 DB12080 DB00668 DB11791 DB13675 DB00398 DB00656 DB13225 DB00610 DB00715 DB01407 DB00540 DB00047 DB01105 DB01142 DB02424 DB08841 DB00414 DB11564 DB06469 DB01288 DB01120 DB04896 DB01509 DB05575 DB01193 DB11986 DB11085 DB01484 DB12978 DB09079 DB08875 DB00182 DB12010 DB11963 DB08941 DB06764 DB13703 DB09307 DB13624 DB01306 DB16650 DB01307 DB00368 DB01556 DB12235 DB00321 DB09063 DB06711 DB04884 DB13852 DB08901 DB00041 DB08916 DB12147 DB12500 DB00215 DB13108 DB11973 DB06626 DB01067 DB01124 DB11567 DB13341 DB13782 DB05465 DB01566 DB00046 DB01454 DB06152 DB04836 DB00672 DB00388 DB09053 DB00937 DB01576 DB11828 DB00530 DB01254 DB01242 DB12752 DB08865 DB13411 DB00816 DB08877 DB00222 DB00839 DB13384 DB11737 DB01577 DB06700 DB04846 DB08896 DB09330 DB08985 DB00397 DB01251 DB00543 DB05115 DB00852 DB00988 DB11805 DB00233 DB15133 DB11703 DB12267 DB06302 DB12930 DB09167 DB05294 DB09480 DB11886 DB14651 DB01151 DB00176 DB01104 DB00935 DB00850 DB15233 DB01259 DB12323 DB01255 DB01366 DB05424 DB00865 DB12307 DB01064 DB09016 DB01309 DB13496 DB13114 DB01467 DB00726 DB08996 DB01442 DB06731 DB01364 DB00191 DB02567 DB00344 DB05258 DB00227 DB09289 DB11652 DB12693 DB00317 DB03758 DB01645 DB04879 DB00871 DB08399 DB15685 DB04868 DB13757 DB08881 DB14723 DB00211 DB06595 DB00030 DB11568 DB11124 DB13233 DB04832 DB06707 DB11832 DB13406 DB08918 DB13064 DB11697 DB00830 DB06616 DB01289 DB11363 DB01365 DB09203 DB00723 DB00829 DB12141 DB13692 DB00598 DB13777 DB13940 DB12048 DB11689 DB01175 DB01233 DB01016 DB02058 DB06589 DB00472 DB09456 DB00619 DB00841 DB01268 DB09564 DB00071 DB00609 DB00867 DB08962 DB13246 DB09078 DB11904 DB00458 DB05928","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thyrotropin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15263"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":187.283,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes \/ Flushes) Associated With Menopause).","enzymes":null,"type":"small molecule","cas-number":"313651-33-1","sequences":null,"targets":null,"unii":"61SA6645RL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":187.15722892,"volume-of-distribution":null,"route-of-elimination":null,"name":"PD-0299685","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15264"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":422.577,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"USL-311 is under investigation in clinical trial NCT02765165 (Phase 1\/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed\/Recurrent Glioblastoma Multiforme (GBM)).","enzymes":null,"type":"small molecule","cas-number":"1373268-67-7","sequences":null,"targets":null,"unii":"2BTG5MX2Q2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":422.279409739,"volume-of-distribution":null,"route-of-elimination":null,"name":"USL-311","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15265"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":506.29,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tovorafenib (TAK-580) is under investigation in clinical trial NCT02723006 (Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma).","enzymes":null,"type":"small molecule","cas-number":"1096708-71-2","sequences":null,"targets":null,"unii":"ZN90E4027M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":505.0102337,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tovorafenib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15266"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lesinidase alfa is under investigation in clinical trial NCT02324049 (Safety, Pharmacokinetics, and Pharmacodynamics\/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)).","enzymes":null,"type":"biotech","cas-number":"1522433-40-4","sequences":null,"targets":null,"unii":"61A4G0P3IB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lesinidase alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15267"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":485.433,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Afabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus).","enzymes":null,"type":"small molecule","cas-number":"1518800-35-5","sequences":null,"targets":null,"unii":"DMM8663H2R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":485.135187123,"volume-of-distribution":null,"route-of-elimination":null,"name":"Afabicin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15268"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":512.05,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ALK-4290 is under investigation in clinical trial NCT03558061 (Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration).","enzymes":null,"type":"small molecule","cas-number":"1251528-23-0","sequences":null,"targets":null,"unii":"R0T9LLR4TN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":511.2350177,"volume-of-distribution":null,"route-of-elimination":null,"name":"ALK-4290","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15269"},{"toxicity":"There are no data regarding overdosage with efgartigimod alfa.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Efgartigimod alfa exerts its pharmacologic effect by reducing circulating levels of the autoantibody responsible for myasthenia gravis symptoms. It is administered as a once-weekly intravenous infusion, given for 4 weeks per treatment cycle, with the option to initiate additional treatment cycles as clinically indicated after at least 50 days have passed following the previous cycle.[L39496]\r\n\r\nBecause efgartigimod alfa reduces circulating IgG levels, patients undergoing therapy may be at greater risk of infection due to a depressed immune response.[L39496] It should not be initiated in patients with an active infection, and consideration should be given to holding therapy in patients who develop a serious infection during a treatment cycle.","msds":null,"description":"Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction.[A243759] The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors and a reduction in electrical nerve impulses.[A243759,A243784]\r\n\r\nEfgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of myasthenia gravis (MG).[L39496] IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a process which significantly extends their half-life, by evading lysosomal degradation via binding with FcRn.[L39509] By antagonizing this interaction, efgartimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against AChRs.\r\n\r\nEfgartimod alfa was granted FDA approval on December 17, 2021 [L39501] and European Commission approval on August 11, 2022.[L43190]","enzymes":null,"type":"biotech","cas-number":"1821402-21-4","sequences":">SUBUNIT_2\nDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVD\nGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK\nGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS\nDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGK >SUBUNIT_1\nDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVD\nGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK\nGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS\nDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGK","targets":"BE0010182","unii":"961YV2O515","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction of the skeletal muscles.[A243759] While the pathophysiologic mechanisms of MG differ depending on the subtype in question, all forms involve the production of IgG autoantibodies to some endogenous protein. One of the most commonly implicated proteins against which autoantibodies are produced are acetylcholine receptors (AChRs), which undergo degradation via the membrane attack complex (MAC) secondary to their interaction with AChR-specific autoantibodies.[A243759] The destruction of AChRs prevents regular transmission of electrical impulses across the neuromuscular junction, which ultimately leads to the characteristic muscular weakness - especially of the eyes, throat, and extremities - observed in patients with MG.\r\n\r\nImmunoglobulin G, as opposed to other immunoglobulins, undergoes a recycling phase in the vascular endothelium that dramatically extends its half-life.[L39509] In the case of pathogenic IgGs causing MG, this may facilitate an increased ability to impair neuromuscular transmission. This recycling involves IgG binding to the neonatal Fc receptor (FcRn), which rescues IgG from lysosomal degradation.[L39509]\r\n\r\nEfgartigimod alfa is a human IgG1 antibody fragment that binds to FcRn, thus preventing IgG recycling and subsequently reducing the amount of circulating IgG, including the autoantibodies responsible for MG.[L39496,L39509]","drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB12386 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":null,"created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal elimination half-life of efgartigimod alfa ranges from 80 to 120 hours.[L39496]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of efgartigimod alfa ranges from 15 to 20 liters.[L39496]","route-of-elimination":"After a single intravenous dose of efgartigimod alfa 10 mg\/kg in healthy subjects, less than 0.1% of the administered dose was recovered in the urine.[L39496]","name":"Efgartigimod alfa","metabolism":"As with other therapeutic proteins, efgartigimod alfa is likely metabolized to smaller peptides and amino acids via proteolytic enzymes.[L39496]","reactions":null,"indication":"Efgartigimod alfa is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive.[L39496,L43185]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15270"},{"toxicity":"Data regarding the toxicity of crizanlizumab is not readily available.[L10097]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Crizanlizumab is a P-selectin inhibitor that prevents interactions between endothelial cells, platelets, red blood cells, and leukocytes.[L10097] It has a long duration of action as it is given every 4 weeks.[L10097] Patients should be counselled regarding the risk of infusion reactions as well as crizanlizumab's interference with platelet counts using EDTA tubes.[L10097]","msds":null,"description":"Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.[T734]\r\n\r\nCurrently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.[A187904] Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug between patients.[A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019.[L10097]","enzymes":null,"type":"biotech","cas-number":"1690318-25-2","sequences":null,"targets":"BE0001159","unii":"L7451S9126","protein-binding":"Monoclonal antibodies are generally not protein bound[A31470,A177074].","fda-label":null,"clearance":"Given a 5mg\/kg dose of crizanlizumab, the clearance rate is 11.7ml\/hr in healthy subjects.[L10097]","atc-codes":"OTHER HEMATOLOGICAL AGENTS BLOOD AND BLOOD FORMING ORGANS Other hematological agents","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Crizanlizumab binds to P-selectin on endothelial cells and platelets, preventing their interaction with P-selectin glycoprotein ligand 1 on endothelial cells, platelets, red blood cells, and leukocytes.[A187910,L10097] By preventing this interaction, components of the blood are less likely to come together, causing a vaso-occlusive crisis in patients with sickle cell diseases.[A187910,L10097] The median per year incidence of vaso-occlusive crises was 1.04 in the high-dose crizanlizumab group, 2.00 in the low-dose crizanlizumab group, and 2.08 in the placebo group.[A187901]","drug-interactions":null,"absorption":"Crizanlizumab reaches a C<sub>max<\/sub> of 0.16mg\/mL with an AUC of 34.6mg\\*hr\/mL.[L10097]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Given a 5mg\/kg dose of crizanlizumab, the mean terminal elimination half life of crizanlizumab is 10.6 days in healthy subjects and 7.6 days in patients with sickle cell disease.[L10097]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of crizanlizumab is 4.26L.[L10097]","route-of-elimination":"Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins.[A31470,A177074] Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.[A40006]","name":"Crizanlizumab","metabolism":"Crizanlizumab is expected to be metabolized into smaller peptides and amino acids.[L10097]","reactions":null,"indication":"Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are \u203016 years old.[L10097]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15271"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2309.574,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Edratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).","enzymes":null,"type":"small molecule","cas-number":"433922-67-9","sequences":null,"targets":null,"unii":"38PLP07BKC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2308.106537266,"volume-of-distribution":null,"route-of-elimination":null,"name":"Edratide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15272"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":501.51,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1061353-68-1","sequences":null,"targets":null,"unii":"L2BD0MW4OL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":501.198774206,"volume-of-distribution":null,"route-of-elimination":null,"name":"VS-4718","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15273"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pertussis vaccine is under investigation in clinical trial NCT01698346 (Pertussis (Tdap) Vaccination in Pregnancy).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"2QNL82089R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01410 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB04845 DB11817 DB00764 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB06603 DB01204 DB01013 DB00620 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00515 DB00262 DB11569 DB06589 DB00588 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00180 DB00445 DB00005 DB00687 DB08906 DB02806 DB03523","absorption":null,"created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pertussis vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-01-24","drugbank-id":"DB15274"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":407.378,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GDC-0077 is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"2060571-02-8","sequences":null,"targets":null,"unii":"L4C1UY2NYH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":407.140510438,"volume-of-distribution":null,"route-of-elimination":null,"name":"GDC-0077","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15275"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).","enzymes":null,"type":"biotech","cas-number":"182253-77-6","sequences":null,"targets":null,"unii":"54XUF2TZ7G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"PR1 leukemia peptide vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15276"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).","enzymes":null,"type":"biotech","cas-number":"1807954-17-1","sequences":null,"targets":null,"unii":"6IRE1TI49I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gedivumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15277"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).","enzymes":null,"type":"biotech","cas-number":"1600492-21-4","sequences":null,"targets":null,"unii":"J5LT149M79","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Marzeptacog alfa (activated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15278"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":242.322,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CB-103 is under investigation in clinical trial NCT03422679 (Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies).","enzymes":null,"type":"small molecule","cas-number":"218457-67-1","sequences":null,"targets":null,"unii":"Q5BB91JL0V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":242.141913208,"volume-of-distribution":null,"route-of-elimination":null,"name":"CB-103","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15279"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).","enzymes":null,"type":"biotech","cas-number":"1648796-29-5","sequences":null,"targets":null,"unii":"8961SFA7R3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gimsilumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15280"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":440.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1453848-26-4","sequences":null,"targets":null,"unii":"R6AXV96CRH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":440.1163797,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ravoxertinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15281"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":427.503,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).","enzymes":null,"type":"small molecule","cas-number":"160388-43-2","sequences":null,"targets":null,"unii":"3I798OGQ8B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":427.202436701,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluorofuranylnorprogesterone F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15282"},{"toxicity":"There is limited information regarding the LD<sub>50<\/sub> and overdose of tebentafusp.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Tebentafusp is novel immunotherapy that causes cytotoxicity of cancer cells. Tebentafusp increased the serum levels of cytokines (IFN-, TNF, IL-2, IL-6, IL-10 and IL-1RA) and chemokines (CXCL9, CXCL10, CXCL11, hepatocyte growth factor, and monocyte chemoattractant protein-1) during the first three doses. The levels of cytokines and chemokines peaked between eight to 24 hours after treatment, and levels returned to baseline before subsequent doses. In subsequent treatment cycles, cytokine elevation occurred in fewer patients with lesser intensity than the first three doses. Tebentafusp also reduced lymphocyte counts after the first three doses, which returned to baseline before subsequent doses.[L39985] In phase III clinical trials, patients treated with tebentafusp showed a better overall survival rate compared to [pembrolizumab], [ipilimumab], or [dacarbazine].[L39995]","msds":null,"description":"Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager.[L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic T cells to lyse the cells, such as melanocytes.[A244815,A244910]\r\n\r\nUveal melanoma is a rare ocular tumour with often poor prognosis and limited treatment options. Even after surgical ablation or removal of the ocular tumour, almost 50% of patients with uveal melanoma develop metastatic disease.[A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. This approval marks the first bispecific T cell engager to be approved by the FDA to treat a solid tumour and being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA.[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]","enzymes":null,"type":"biotech","cas-number":"1874157-95-5","sequences":">Subunit 2\nAQQGEEDPQALSIQEGENATMNCSYKTSINNLQWYRQNSGRGLVHLILIRSNEREKHSGR\nLRVTLDTSKKSSSLLITASRAADTASYFCATDGSTPMQFGKGTRLSVIANIQKPDPAVYQ\nLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDF\nACANAFNNSIIPEDT >Subunit 1\nAIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPS\nRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGSGGG\nGSGGGGSGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVA\nLINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYF\nDVWGQGTLVTVSSGGGGSDGGITQSPKYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQG\nLRLIYYSWAQGDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASSWGAPYEQY\nFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGK\nEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWT\nQDRAKPVTQIVSAEAWGRAD","targets":"BE0010187","unii":"N658GY6L3E","protein-binding":"There is no information available.","fda-label":null,"clearance":"The geometric mean clearance (%CV) of tebentafusp is 16.4 L\/d (24.5%).[L39985]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Glycoprotein 100 (gp100) is a transmembrane glycoprotein highly expressed in melanoma cells and weakly expressed by normal melanocytes or other tissues. Gp100 is presented as a human leukocyte antigen (HLA)-peptide complex on the cell surface. Gp100 has a particularly high affinity for the HLA-A subtype HLA-A*02:01.[A244815,A244910] HLAs are part of a protein complex that normally regulates immune function: natural T cell responses are initiated by the interaction between the T-cell receptor (TCR) and its peptide antigen, such as gp100, presented by HLA on the surface of a target cell.[A244915]\r\n\r\nTebentafusp is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. It consists of a TCR targeting domain - or a TCR arm - fused to a single-chain variable fragment (scFv) anti-CD3 effector domain.[A244815] The TCR arm binds to a gp100 peptide bound to HLA-A on the uveal melanoma tumour cell surface. The anti-CD3 effector domain of tebentafusp engages and activates CD3+ T cells to inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumour cells.[L39985] The anti-CD3 fragment of the drug has a lower affinity, so the T cells are not stimulated unless tebentafusp has detected gp100.[A244910] \r\n\r\nTebentafusp is only effective in HLA-A*02:01-positive patients.[L39985,A244910]","drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":"After a single dose administration, C<sub>max<\/sub> and AUC<sub>0-7d<\/sub> increased dose-proportionally from 20 to 68 mg (0.3 to 1 times the approved recommended dose). Following administration of the approved recommended dosage in patients with metastatic uveal melanoma, the steady-state geometric mean (% CV) C<sub>max<\/sub> of tebentafusp was 13 ng\/mL (34.6%) and AUC<sub>0-7d<\/sub> was 4.6 ng.day\/mL (23%) with no accumulation.[L39985]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The median terminal half-life is 7.5 hours, with a range of 6.8 to 7.5 hours.[L39985]","monoisotopic-mass":null,"volume-of-distribution":"The geometric mean (%CV) steady-state volume of distribution is 7.56 L (24%).[L39985]","route-of-elimination":"There is no information available.","name":"Tebentafusp","metabolism":"Tebentafusp is expected to be catabolized into small peptides and amino acids.[L39985]","reactions":null,"indication":"Tebentafusp is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.[L39985]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15283"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":349.43,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sulopenem is under investigation in clinical trial NCT03357614 (Sulopenem Followed by Sulopenem-etzadroxil\/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults).","enzymes":null,"type":"small molecule","cas-number":"120788-07-0","sequences":null,"targets":null,"unii":"XX514BJ1XW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":349.011236109,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sulopenem","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15284"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients).","enzymes":null,"type":"biotech","cas-number":"1350667-54-7","sequences":null,"targets":null,"unii":"0493WH50VT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"ARC-19499","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15285"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":287.12,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"2095732-06-0","sequences":null,"targets":null,"unii":"IFD73D535A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":287.165251,"volume-of-distribution":null,"route-of-elimination":null,"name":"CB-1158","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15286"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":542.53,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1400699-64-0","sequences":null,"targets":null,"unii":"KIB8V5UR7D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":542.112327447,"volume-of-distribution":null,"route-of-elimination":null,"name":"Elismetrep","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15287"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":311.35,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).","enzymes":null,"type":"small molecule","cas-number":"760173-05-5","sequences":null,"targets":null,"unii":"9X96V6DBU4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":311.090389615,"volume-of-distribution":null,"route-of-elimination":null,"name":"Etamicastat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15288"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":152.237,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Perillyl alcohol is under investigation in clinical trial NCT02704858 (Safety and Efficacy Study in Recurrent Grade IV Glioma).","enzymes":null,"type":"small molecule","cas-number":"18457-55-1","sequences":null,"targets":null,"unii":"3UL4QIY642","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":152.120115135,"volume-of-distribution":null,"route-of-elimination":null,"name":"Perillyl alcohol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15289"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pegteograstim is under investigation in clinical trial NCT02787876 (Pegteograstim in Children With Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1329602-23-4","sequences":null,"targets":null,"unii":"71V0XKJ0WZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Colony stimulating factors IMMUNOSTIMULANTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00541 DB05168 DB11641 DB00570 DB00361 DB00531 DB00309 DB13374","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pegteograstim","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15290"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":572.613,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).","enzymes":null,"type":"small molecule","cas-number":"1643368-58-4","sequences":null,"targets":null,"unii":"PJX9GH268R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":572.223511788,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-986142","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15291"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":421.52,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Foliglurax is under investigation in clinical trial NCT02639221 (A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects).","enzymes":null,"type":"small molecule","cas-number":"1883329-53-0","sequences":null,"targets":null,"unii":"FR50CP1D6W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":421.146012787,"volume-of-distribution":null,"route-of-elimination":null,"name":"Foliglurax","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15292"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":319.39,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Epalrestat is under investigation in clinical trial NCT03244358 (Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer).","enzymes":null,"type":"small molecule","cas-number":"82159-09-9","sequences":null,"targets":null,"unii":"424DV0807X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":319.033685631,"volume-of-distribution":null,"route-of-elimination":null,"name":"Epalrestat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15293"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":462.55,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SB-1578 is under investigation in clinical trial NCT01235871 (A Single and Multiple-Dose Study of SB1578).","enzymes":null,"type":"small molecule","cas-number":"937273-04-6","sequences":null,"targets":null,"unii":"4T71DC0G0A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":462.226705462,"volume-of-distribution":null,"route-of-elimination":null,"name":"SB-1578","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15294"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":415.428,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).","enzymes":null,"type":"small molecule","cas-number":"1639417-53-0","sequences":null,"targets":null,"unii":"2261HH611H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":415.144453003,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tenalisib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15295"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":212.211,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"D-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET\/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations).","enzymes":null,"type":"small molecule","cas-number":"870452-26-9","sequences":null,"targets":null,"unii":"58HVN5SR99","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":212.082655917,"volume-of-distribution":null,"route-of-elimination":null,"name":"D-fluoromethyltyrosine F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15296"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":603.54,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1252637-35-6","sequences":null,"targets":null,"unii":"A26QO95U37","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":603.137494393,"volume-of-distribution":null,"route-of-elimination":null,"name":"Petesicatib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-08-13","drugbank-id":"DB15297"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ontamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).","enzymes":null,"type":"biotech","cas-number":"2098790-40-8","sequences":null,"targets":null,"unii":"6LGI7RV4PB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ontamalimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15298"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":568.55,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1352066-68-2","sequences":null,"targets":null,"unii":"7R7G6EH5UL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":567.1612998,"volume-of-distribution":null,"route-of-elimination":null,"name":"Navtemadlin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-08-13","drugbank-id":"DB15299"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":326.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).","enzymes":null,"type":"small molecule","cas-number":"1435-55-8","sequences":null,"targets":null,"unii":"8P68XPY4HG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Antiarrhythmics, class Ia CARDIOVASCULAR SYSTEM ANTIARRHYTHMICS, CLASS I AND III CARDIAC THERAPY","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01429 DB00825 DB09238 DB09090 DB08952 DB13863 DB00572 DB08980 DB13961 DB09220 DB00204 DB06712 DB08868 DB08162 DB06694 DB09236 DB01078 DB01193 DB01158 DB00680 DB00270 DB12712 DB13835 DB00280 DB00187 DB13950 DB11785 DB06200 DB13652 DB00424 DB09235 DB13691 DB00571 DB12923 DB14066 DB09039 DB12093 DB00528 DB00347 DB07615 DB08838 DB01228 DB00373 DB09089 DB09230 DB00393 DB08808 DB04861 DB13651 DB00489 DB04957 DB04855 DB06217 DB13791 DB06152 DB01396 DB00568 DB05246 DB00640 DB00390 DB13645 DB12704 DB00836 DB01195 DB04846 DB00922 DB13546 DB00678 DB09234 DB04920 DB00335 DB01023 DB11770 DB01426 DB12092 DB14063 DB01118 DB12131 DB00281 DB09231 DB13635 DB09232 DB13653 DB00264 DB01214 DB11960 DB00401 DB06283 DB09239 DB04841 DB13725 DB00343 DB00622 DB11699 DB09224 DB14068 DB04838 DB04842 DB13718 DB06446 DB13766 DB04743 DB14065 DB00381 DB09240 DB13488 DB01136 DB00909 DB08992 DB00379 DB00308 DB13500 DB06727 DB01035 DB12212 DB09229 DB12016 DB01182 DB00653 DB00555 DB00661 DB13240 DB12766 DB13401 DB13555 DB00593 DB13775 DB00908 DB13358 DB06468 DB13746 DB09227 DB15366 DB00521 DB01244 DB00612 DB00511 DB04825 DB14064 DB01054 DB00866 DB01074 DB01056 DB00195 DB01115 DB14207 DB01203 DB01580 DB12286 DB01388 DB03322 DB05885 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":326.199428085,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hydroquinidine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-09-25","drugbank-id":"DB15300"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).","enzymes":null,"type":"biotech","cas-number":"2223113-32-2","sequences":null,"targets":null,"unii":"YVK735A3PU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bevifimod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15301"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":166.148,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"70763-62-1","sequences":null,"targets":null,"unii":"W39886N0ZG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":166.064136997,"volume-of-distribution":null,"route-of-elimination":null,"name":"2-fluorofucose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15302"},{"toxicity":"Toxicity information regarding faricimab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as conjunctival hemorrhage. Symptomatic and supportive measures are recommended. Due to its mechanism of action, faricimab may pose a risk to reproductive capacity.[L40026]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Faricimab is a bispecific antibody (bsAb) based on human IgG<sub>1<\/sub> comprising two different heavy and two different light chains capable of simultaneously binding to both VEGF-A and Ang-2.[A225995, A226005, A226010] Faricimab suppresses endothelial proliferation, neovascularization, and vascular permeability, which are associated with the increased retinal thickness observed in nAMD and DME. In four phase 3 studies in nAMD and DME, faricimab reduced central subfield thickness through the first year in all treatment arms.[L40026]\r\n\r\nAs with other medications administered intravitreally, faricimab carries a risk of transient increases in intraocular pressure, endophthalmitis, and retinal detachment. Proper injection techniques should always be observed, and patients monitored carefully following injection. Low risk of arterial thromboembolic events, defined as nonfatal stroke or myocardial infarction and vascular death, has been documented with faricimab.[L40026]","msds":null,"description":"Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely target VEGF-A. However, another set of factors, the Tie\/Ang axis, comprising the transmembrane Tie-2 receptor and its soluble ligands Ang-1 and Ang-2, has been shown to play critical roles in mediating VEGF-A-induced NV.[A225985, A225990, A225995] Faricimab is an IgG<sub>1<\/sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic efficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy.[A225985, A225990, A225995, A226000, A226005, A226010]\r\n\r\nFaricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.[L40026] It received subsequent approval for the same indications in Canada in May 2022.[L42305] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended faricimab be granted marketing authorization for the treatment of neovascular age-related macular degeneration and diabetic macular edema.[L43085]","enzymes":null,"type":"biotech","cas-number":"1607793-29-2","sequences":null,"targets":"BE0000163 BE0010028","unii":"QC4F7FKK7I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252\/emmm.201505889.","mechanism-of-action":"The retina is largely avascular to facilitate effective photoreceptor function; rather, the retina is fed by both retinal and choroidal capillary networks, pathologies of which result in retinal and choroidal vascular diseases such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO).[A225985, A225990, A225995] One of the underlying causes of retinal vascular diseases (RVDs) is retinal neovascularization (NV), the aberrant growth of new vasculature, usually due to sustained retinal ischemia and mediated primarily by vascular endothelial growth factor A (VEGF-A).[A225985, A225990, A225995] VEGF-A is a VEGF family member, which also includes VEGF-B, -C, and -D, whose members signal through the VEGF receptors (VEGFRs) VEGFR-1, -2, and -3 to mediate endothelial and lymphatic growth.[A225990] Extensive work in animal models of RVD has demonstrated that VEGF-A is necessary but not sufficient in many cases to mediate NV, suggesting that additional factors may be required in deep retinal capillary beds.[A225985] One such factor has been identified as the angiopoietins Ang-1 and Ang-2 and their cellular receptor Tie-2; Ang-1 is a full Tie-2 agonist whose binding results in Tie-2 phosphorylation and downstream signalling, whereas Ang-2 is a Tie-2 partial agonist\/antagonist that inhibits Tie-2 phosphorylation. Ang-1 generally has a protective effect, making endothelial cells less responsive to VEGF-A, while Ang-2 increases VEGF-A-dependent NV and stimulates pericyte apoptosis and breakdown of both the blood-brain and blood-retinal barriers; Ang-2 is upregulated in retinal vascular development and retinal ischemia.[A225985, A225990, A225995, A226000]\r\n\r\nFaricimab is a bispecific antibody (bsAb) based on human IgG<sub>1<\/sub> comprising two different heavy and two different light chains capable of simultaneously binding to both VEGF-A and Ang-2 produced using the \"CrossMab\" platform.[A225995, A226005, A226010] Faricimab binds VEGF-A and Ang-2 with binding affinities (K<sub>D<\/sub>) of approximately 3 and 22 nM, respectively; importantly, faricimab does not detectably bind Ang-1.[A225995] Also, the faricimab Fc region has been modified to reduce binding to FcR and FcRn receptors. The former virtually eliminates immune-mediated functions such as antibody- and complement-dependent cytotoxicity and antibody-dependent phagocytosis, whereas the latter increases faricimab systemic clearance by reducing FcRn-mediated IgG recycling.[A225995] Thus, faricimab works by depleting both VEGF-A and Ang-2 to prevent retinal NV in the privileged ophthalmic environment.[A225995]","drug-interactions":null,"absorption":"Faricimab unbound plasma C<sub>max<\/sub> are estimated to be 0.23  0.07 and 0.22  0.07 g\/mL in nAMD and DME patients, respectively; these plasma levels are achieved approximately two days post-dose (T<sub>max<\/sub>). Following repeated intravitreal administration on a q8w schedule, mean plasma trough free faricimab concentrations are predicted to be 0.002-0.003 g\/mL. No accumulation is expected in either the vitreal fluid or plasma.[L40026]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Faricimab has an estimated mean apparent systemic half-life of 7.5 days.[L40026]","monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":"Faricimab elimination has not been fully characterized; faricimab may be excreted renally following its breakdown into smaller peptides and amino acids through cellular catabolism.[L40026]","name":"Faricimab","metabolism":"Faricimab metabolism has not been fully characterized; as an antibody, faricimab is expected to be catabolized like endogenous immunoglobulins.[L40026]","reactions":null,"indication":"Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).[L40026]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15303"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"iota-Carrageenan is under investigation in clinical trial NCT01944631 (Iota-Carrageenan Nasal Spray in Common Cold).","enzymes":null,"type":"small molecule","cas-number":"9062-07-1","sequences":null,"targets":null,"unii":"3582R1F52W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"iota-Carrageenan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15304"},{"toxicity":"Data regarding overdose of risdiplam are unavailable. Symptoms of overdose are likely to be consistent with risdiplam's adverse effect profile, and may therefore involve significant fever, diarrhea, and skin reactions.[L15336]","snp-adverse-drug-reactions":null,"average-mass":401.474,"transporters":"BE0001067 BE0001032 BE0004752 BE0003657","pharmacodynamics":"Risdiplam helps to alleviate symptoms of spinal muscular atrophy by stimulating the production of a critical protein in which these patients are deficient. Early trials with risdiplam demonstrated up to a 2-fold increase in SMN protein concentration in SMA patients after 12 weeks of therapy.[A192756]","msds":null,"description":"Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA).[L12615] It increases systemic SMN protein concentrations by improving the efficiency of _SMN2_ gene transcription. This mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene therapy [onasemnogene abeparvovec], whereas risdiplam offers the ease of oral bioavailability.[L15351,A216871]\r\n\r\nRisdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).[L15331,L15336] Set to be substantially cheaper than other available SMA therapies,[L15351] risdiplam appears to provide a novel and relatively accessible treatment option for patients with SMA regardless of severity or type.","enzymes":"BE0003609 BE0004866 BE0003612 BE0002638 BE0003543 BE0003606 BE0003683","type":"small molecule","cas-number":"1825352-65-5","sequences":null,"targets":null,"unii":"76RS4S2ET1","protein-binding":"Risdiplam is approximately 89% protein-bound in plasma, primarily to serum albumin.[L15336]","fda-label":null,"clearance":"For a 14.9kg patient, the apparent clearance of risdiplam is 6.3 L\/kg.[L15336]","atc-codes":"MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Other drugs for disorders of the musculo-skeletal system","pdb-entries":null,"food-interactions":"Take after a meal. Take at the same time every day.","state":"solid","synthesis-reference":"Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, Jablonski P, Jacobsen B, Khwaja O, Kletzl H, Ko CP, Kustermann S, Marquet A, Metzger F, Mueller B, Naryshkin NA, Paushkin SV, Pinard E, Poirier A, Reutlinger M, Weetall M, Zeller A, Zhao X, Mueller L: Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). J Med Chem. 2018 Aug 9;61(15):6501-6517. doi: 10.1021\/acs.jmedchem.8b00741. Epub 2018 Jul 25.","mechanism-of-action":"Spinal muscular atrophy (SMA) is a severe and progressive congenital neuromuscular disease resulting from mutations in the survival of motor neuron 1 (_SMN1_) gene responsible for making SMN proteins.[A192759] Clinical features of SMA include degeneration of motor neurons in the spinal cord which ultimately leads to muscular atrophy and, in some cases, loss of physical strength.[A192750] SMN proteins are expressed ubiquitously throughout the body and are thought to hold diverse intracellular roles in DNA repair, cell signaling, endocytosis, and autophagy.[A192750] A secondary _SMN_ gene (_SMN2_) can also produce SMN proteins, but a small nucleotide substitution in its sequence results in the exclusion of exon 7 during splicing in approximately 85% of the transcripts - this means that only ~15% of the SMN proteins produced by _SMN2_ are functional,[A192750] which is insufficient to compensate for the deficits caused by _SMN1_ mutations. Emerging evidence suggests that many cells and tissues are selectively vulnerable to reduced SMN concentrations, making this protein a desirable target in the treatment of SMA.[A192750]\r\n\r\nRisdiplam is an mRNA splicing modifier for _SMN2_ that increases the inclusion of exon 7 during splicing, which ultimately increases the amount of functional SMN protein produced by _SMN2_.[A192759] It does so by binding to two sites in _SMN2_ pre-mRNA: the 5' splice site (5'ss) of intron 7 and the exonic splicing enhancer 2 (ESE2) of exon 7.[A216871]","drug-interactions":"DB00537 DB01004 DB01035 DB00331 DB12001 DB00536 DB11817 DB14754 DB01030 DB01333 DB12377 DB00567 DB01195 DB08837 DB01137 DB08840 DB04574 DB01203 DB00787 DB00879","absorption":"The T<sub>max<\/sub> following oral administration is approximately 1-4 hours.[A192759,L15336] Following once-daily administration with a morning meal (or after breastfeeding), risdiplam reaches steady-state in approximately 7-14 days.[L15336] The pharmacokinetics of risdiplam were found to be approximately linear between all studied dosages in patients with SMA.[L15336]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The terminal elimination half-life of risdiplam is approximately 50 hours in healthy adults.[L15336]","monoisotopic-mass":401.196408389,"volume-of-distribution":"Following oral administration, risdiplam distributes well into the central nervous system and peripheral tissues.[A192750] The apparent volume of distribution at steady-state is 6.3 L\/kg.[L15336]","route-of-elimination":"Following the oral administration of 18mg risdiplam, approximately 53% of the dose was excreted in the feces and 28% was excreted in the urine.[L15336] Unchanged parent drug comprised 14% of the dose excreted in feces and 8% of the dose excreted in urine.[L15336]","name":"Risdiplam","metabolism":"The metabolism of risdiplam is mediated primarily by flavin monooxygenases 1 and 3 (FMO1 and FMO3), with some involvement of CYP1A1, CYP2J2, CYP3A4, and CYP3A7.[L15336] Parent drug comprises approximately 83% of circulating drug material.[L15336]\r\n\r\nA pharmacologically-inactive metabolite, M1, has been identified as the major circulating metabolite - this M1 metabolite has been observed _in vitro_ to inhibit MATE1 and MATE2-K transporters, similar to the parent drug.[L15336]","reactions":null,"indication":"Risdiplam is indicated for the treatment of spinal muscular atrophy (SMA).[L41935]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15305"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b\/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies).","enzymes":null,"type":"biotech","cas-number":"1715924-11-0","sequences":null,"targets":null,"unii":"AKV2GM43DD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MEDI-6469","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15306"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":367.4,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).","enzymes":null,"type":"small molecule","cas-number":"1200493-78-2","sequences":null,"targets":null,"unii":"2834W8D6GK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":367.090309428,"volume-of-distribution":null,"route-of-elimination":null,"name":"Atabecestat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15307"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":388.434,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).","enzymes":null,"type":"small molecule","cas-number":"308362-25-6","sequences":null,"targets":null,"unii":"06DX01190R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":388.143644539,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ridinilazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15308"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":399.433,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).","enzymes":null,"type":"small molecule","cas-number":"1352608-82-2","sequences":null,"targets":null,"unii":"6T4O391P5Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":399.160771771,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vactosertib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15310"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"916851-14-4","sequences":null,"targets":null,"unii":"C2BXC3OWPA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Davanat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15311"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).","enzymes":null,"type":"biotech","cas-number":"2066544-85-0","sequences":null,"targets":null,"unii":"1LTT6HMX9N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Orilanolimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15312"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).","enzymes":null,"type":"biotech","cas-number":"946032-08-2","sequences":null,"targets":null,"unii":"227R1C272Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"DAS-181","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-07-03","drugbank-id":"DB15313"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2433.96,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).","enzymes":null,"type":"small molecule","cas-number":"926277-68-1","sequences":null,"targets":null,"unii":"96C1EBE9CG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2432.362709634,"volume-of-distribution":null,"route-of-elimination":null,"name":"Modimelanotide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15314"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":782.899,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Coblopasvir is under investigation in clinical trial NCT03416491 (Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C).","enzymes":null,"type":"small molecule","cas-number":"1312608-46-0","sequences":null,"targets":null,"unii":"67XWL3R65W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTIINFECTIVES FOR SYSTEMIC USE Antivirals for treatment of HCV infections ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":782.375160602,"volume-of-distribution":null,"route-of-elimination":null,"name":"Coblopasvir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15315"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":359.28,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Florasulam is under investigation in clinical trial NCT01193465 (Temperature and Humidity Among Different Anesthesia Work-station).","enzymes":null,"type":"small molecule","cas-number":"145701-23-1","sequences":null,"targets":null,"unii":"00A64ZX8NB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":359.029994801,"volume-of-distribution":null,"route-of-elimination":null,"name":"Florasulam","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15316"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":337.423,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Posiphen is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen in Subjects With Early Alzheimer's Disease).","enzymes":null,"type":"small molecule","cas-number":"116839-68-0","sequences":null,"targets":null,"unii":"Z0O4TJ588O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB09262 DB14652 DB00392 DB13759 DB15566 DB14649 DB00219 DB09091 DB09007 DB08952 DB11640 DB00572 DB12554 DB01173 DB01224 DB00715 DB00237 DB00540 DB00737 DB09205 DB01142 DB00334 DB01019 DB13648 DB13003 DB00907 DB13542 DB01288 DB00794 DB13695 DB00241 DB01193 DB00387 DB01036 DB01354 DB00941 DB01222 DB14633 DB13505 DB00280 DB00915 DB01351 DB13844 DB05708 DB13856 DB01403 DB14539 DB12526 DB00187 DB04834 DB13252 DB00462 DB00514 DB15821 DB00753 DB11921 DB07720 DB01234 DB01409 DB11785 DB00340 DB05137 DB01337 DB00434 DB14646 DB00424 DB00571 DB00960 DB05710 DB14545 DB00312 DB01359 DB00635 DB14681 DB00363 DB01352 DB08801 DB04630 DB12086 DB13666 DB00321 DB00810 DB01353 DB08838 DB04250 DB00732 DB00418 DB01231 DB00373 DB13443 DB00411 DB13738 DB09089 DB04843 DB13843 DB00193 DB09351 DB15357 DB09378 DB01591 DB13867 DB08808 DB04861 DB00463 DB09288 DB00416 DB13619 DB01496 DB13380 DB00489 DB03128 DB01075 DB00657 DB00771 DB11855 DB08970 DB00767 DB09076 DB13850 DB01273 DB05152 DB00202 DB01148 DB00517 DB01483 DB01625 DB01339 DB12752 DB00741 DB01174 DB00975 DB01380 DB01295 DB00246 DB13208 DB01227 DB00477 DB04846 DB13491 DB00777 DB01239 DB09383 DB00209 DB00354 DB06702 DB13636 DB14541 DB04920 DB00335 DB13448 DB00804 DB01285 DB00543 DB11770 DB00394 DB13351 DB11487 DB00565 DB08807 DB14643 DB01199 DB00959 DB09167 DB01151 DB08960 DB00505 DB00443 DB01085 DB00728 DB01161 DB00725 DB06153 DB11315 DB00264 DB14659 DB00764 DB00366 DB00376 DB13678 DB13720 DB09204 DB13508 DB11235 DB00547 DB00332 DB00508 DB00663 DB01226 DB13468 DB01062 DB01108 DB08897 DB01069 DB00721 DB06709 DB00496 DB00622 DB14631 DB13223 DB13413 DB00342 DB03322 DB00892 DB00245 DB00185 DB00934 DB13530 DB01364 DB12278 DB00599 DB00324 DB00835 DB00620 DB01013 DB13584 DB01136 DB08893 DB00670 DB01408 DB13913 DB13500 DB00306 DB08971 DB01384 DB00591 DB01355 DB15777 DB08997 DB14669 DB12212 DB09095 DB13581 DB13757 DB04365 DB00747 DB14512 DB14644 DB00849 DB00383 DB01182 DB13369 DB00555 DB01238 DB09023 DB00860 DB06726 DB00868 DB00908 DB01090 DB06787 DB13775 DB00184 DB01336 DB09368 DB15972 DB01338 DB00483 DB00762 DB00942 DB01116 DB00940 DB01135 DB00986 DB01047 DB00612 DB13295 DB00598 DB05875 DB01175 DB00866 DB14540 DB00180 DB00195 DB00588 DB00472 DB00333 DB00782 DB13507 DB11529 DB13254 DB00420 DB00687 DB13769 DB01203 DB00458 DB01580 DB08906 DB01410 DB09300 DB00967 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":337.179026993,"volume-of-distribution":null,"route-of-elimination":null,"name":"Posiphen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15317"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":144.242,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Neodymium is under investigation in clinical trial NCT03525522 (Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus).","enzymes":null,"type":"small molecule","cas-number":"7440-00-8","sequences":null,"targets":null,"unii":"2I87U3734A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":141.907718643,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neodymium","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15318"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":620.67,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).","enzymes":null,"type":"small molecule","cas-number":"1071470-72-8","sequences":null,"targets":null,"unii":"009954O7PB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":620.152317809,"volume-of-distribution":null,"route-of-elimination":null,"name":"VM4-037","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15319"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":495.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).","enzymes":null,"type":"small molecule","cas-number":"914382-60-8","sequences":null,"targets":null,"unii":"ZAU91150SB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB02546 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":495.273321303,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tefinostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15321"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed\/Refractory Cutaneous T-cell Lymphomas (CTCL)).","enzymes":null,"type":"biotech","cas-number":"2187368-16-5","sequences":null,"targets":null,"unii":"N8O7MY0VNS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lacutamab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15322"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":357.389,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus\").","enzymes":null,"type":"small molecule","cas-number":"865759-25-7","sequences":null,"targets":null,"unii":"Q836OWG55H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":357.160103067,"volume-of-distribution":null,"route-of-elimination":null,"name":"Trelagliptin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15323"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":354.438,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ORM-13070 C-11 is under investigation in clinical trial NCT00735774 (Suitability of 11C-ORM-13070 as a PET Tracer).","enzymes":null,"type":"small molecule","cas-number":"1227170-74-2","sequences":null,"targets":null,"unii":"Y61S1UFN4Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":354.201025495,"volume-of-distribution":null,"route-of-elimination":null,"name":"ORM-13070 C-11","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15324"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":500.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ONO-8539 is under investigation in clinical trial NCT01707901 (A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease).","enzymes":null,"type":"small molecule","cas-number":"459842-29-6","sequences":null,"targets":null,"unii":"94W010PZ1Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":500.143964358,"volume-of-distribution":null,"route-of-elimination":null,"name":"ONO-8539","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15325"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":251.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).","enzymes":null,"type":"small molecule","cas-number":"950834-06-7","sequences":null,"targets":null,"unii":"T7Q0XY74OK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":250.992214742,"volume-of-distribution":null,"route-of-elimination":null,"name":"CXL-1020","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15326"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":487.539,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).[L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).[L17388]\r\n\r\nAbivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.[L17388,L17393] The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.[L17398]","enzymes":null,"type":"small molecule","cas-number":"1557267-42-1","sequences":null,"targets":"BE0001284 BE0000767","unii":"CER0OPG92L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":487.213201268,"volume-of-distribution":null,"route-of-elimination":null,"name":"Abivertinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15327"},{"toxicity":"As clinical experience with ubrogepant is limited, detailed toxicity information is not readily available. Prescribing information for ubrogepant recommends a monitoring period of at least 24 hours following overdose based on its 5 to 7 hour half-life.[L10926]","snp-adverse-drug-reactions":null,"average-mass":549.554,"transporters":"BE0003659 BE0003647 BE0001032 BE0001066 BE0001067 BE0001004","pharmacodynamics":"Ubrogepant acutely treats migraine headache pain by blocking the activity of a key transmitter involved in migraine pathogenesis.[L10926] Exposure to ubrogepant can be significantly increased in patients with severe hepatic or renal insufficiency - dose adjustments are required for these patients in order to avoid excessive exposure, and ubrogepant is not recommended in patients with end-stage renal disease.[L10926]","msds":null,"description":"Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.[L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as \"gepants\", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors.[A189195] Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.[L43987]\r\n\r\nCompared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages.[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease.[A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition.","enzymes":"BE0003536 BE0002887 BE0002198 BE0003541 BE0002363 BE0002638 BE0002793","type":"small molecule","cas-number":"1374248-77-7","sequences":null,"targets":"BE0009009","unii":"AD0O8X2QJR","protein-binding":"Ubrogepant is 87% protein-bound _in vitro_, although the specific proteins to which ubrogepant binds have not been elucidated.[L10926]","fda-label":null,"clearance":"The apparent oral clearance of ubrogepant is approximately 87 L\/h.[L10926]","atc-codes":"ANTIMIGRAINE PREPARATIONS Calcitonin gene-related peptide (CGRP) antagonists ANALGESICS NERVOUS SYSTEM","pdb-entries":null,"food-interactions":"Take with or without food. Co-administration with food slightly alters pharmacokinetics, but not to a clinically significant extent. Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of ubrogepant.","state":"solid","synthesis-reference":"Leonardo R. Allain, et. al., \"Formulations for CGRP receptor antagonists.\" Australian Patent AU2014318741B2, published December 06, 2018.","mechanism-of-action":"The currently accepted theory of migraine pathophysiology considers dysfunction of the central nervous system, in particular the trigeminal ganglion, to be the root cause behind the condition.[A189207] Activation of the trigeminal ganglion triggers the stimulation of trigeminal afferents that project to the spinal cord and synapse on various pain-sensing intra- and extracranial structures, such as the dura mater. Pain signals are then further transmitted via second-order ascending neurons to the brainstem, hypothalamus, and thalamic nuclei, and from there to several cortical regions (e.g. auditory, visual, motor cortices).[A189207] The trigeminal ganglion appears to amplify and perpetuate the migraine headache pain through the activation of perivascular fibers and the release of molecules involved in pain generation, such as calcitonin gene-related peptide (CGRP).[A189207]\r\n\r\nThe -isoform of CGRP, expressed in primary sensory neurons, is a potent vasodilator and has been implicated in migraine pathogenesis - CGRP levels are acutely elevated during migraine attacks, return to normal following treatment with triptan medications, and intravenous infusions of CGRP have been shown to trigger migraine-like headaches in migraine patients. In addition to its vasodilatory properties, CGRP appears to be a pronociceptive factor that modulates neuronal excitability to facilitate pain responses.[A189213]\r\n\r\nUbrogepant is a potent antagonist of the calcitonin gene-related peptide receptor[L10926] - it competes with CGRP for occupancy at these receptors, preventing the actions of CGRP and its ability to amplify and perpetuate migraine headache pain, ultimately terminating the headache.[A189213]","drug-interactions":"DB08880 DB08953 DB00682 DB12095 DB14649 DB12457 DB00742 DB00540 DB06712 DB00970 DB08828 DB12020 DB09185 DB00338 DB12035 DB00845 DB13878 DB06228 DB00957 DB06772 DB00503 DB01129 DB00220 DB01590 DB09030 DB04908 DB11855 DB12825 DB09076 DB11828 DB01127 DB01396 DB11901 DB00390 DB08865 DB11823 DB00246 DB01381 DB00778 DB00358 DB02520 DB08820 DB11827 DB11703 DB01320 DB00834 DB00773 DB01323 DB01259 DB09074 DB06717 DB01051 DB03467 DB13954 DB13879 DB12332 DB00370 DB11979 DB11932 DB05521 DB11951 DB09161 DB09101 DB11641 DB04881 DB00607 DB04868 DB14723 DB08881 DB11575 DB06595 DB06119 DB00877 DB01182 DB06290 DB14960 DB12364 DB08930 DB00908 DB06616 DB00091 DB05039 DB09227 DB11633 DB14973 DB00612 DB11689 DB11613 DB00949 DB06589 DB00872 DB01201 DB08870 DB09046 DB05928 DB09238 DB00203 DB00213 DB06695 DB00951 DB12001 DB04839 DB06448 DB12015 DB02703 DB00175 DB11952 DB14019 DB00648 DB04851 DB08873 DB00468 DB00270 DB12010 DB00641 DB13955 DB00307 DB06654 DB01234 DB11978 DB12026 DB00582 DB06605 DB00312 DB01094 DB00363 DB11869 DB00316 DB09183 DB09063 DB04884 DB00206 DB06201 DB12500 DB12147 DB06237 DB11757 DB00882 DB13874 DB00705 DB00783 DB06663 DB12836 DB08896 DB00224 DB00394 DB01118 DB15133 DB12267 DB08910 DB00559 DB00176 DB05015 DB09296 DB11712 DB11730 DB00921 DB11574 DB06207 DB00201 DB00343 DB00622 DB00196 DB11560 DB14068 DB00396 DB11652 DB06603 DB08893 DB06414 DB12582 DB00818 DB01026 DB00615 DB09118 DB00661 DB08909 DB16222 DB11697 DB00502 DB00932 DB11363 DB00252 DB01045 DB11853 DB08933 DB00763 DB14761 DB01016 DB14011 DB13956 DB01167 DB13953 DB00619 DB01268 DB05239 DB04847 DB06670 DB09078 DB12799 DB00745 DB11672 DB11800 DB00188 DB05667 DB00564 DB00398 DB00330 DB11581 DB01173 DB08864 DB09065 DB08899 DB07348 DB09291 DB06191 DB11362 DB04896 DB09241 DB01232 DB00295 DB08931 DB01263 DB14069 DB14989 DB01211 DB08995 DB06791 DB12941 DB06287 DB00675 DB06403 DB05889 DB00441 DB01369 DB15569 DB11732 DB00215 DB00248 DB06626 DB01601 DB01072 DB00625 DB09048 DB08907 DB01267 DB11760 DB01254 DB00836 DB01169 DB06700 DB06413 DB06210 DB01685 DB09330 DB12597 DB06234 DB00349 DB01394 DB04854 DB05294 DB14921 DB11753 DB04845 DB06442 DB11779 DB00300 DB09027 DB09239 DB00864 DB11995 DB06273 DB14631 DB00317 DB14126 DB06636 DB11693 DB13179 DB12713 DB09075 DB01110 DB06176 DB13125 DB09054 DB00976 DB04832 DB00273 DB12466 DB04911 DB04540 DB00966 DB00539 DB00408 DB09073 DB00696 DB00458 DB11586 DB01149 DB00080 DB00537 DB04216 DB11791 DB09280 DB00360 DB00199 DB00794 DB11986 DB09079 DB09119 DB02115 DB00285 DB11963 DB01264 DB00950 DB12483 DB12455 DB11642 DB08882 DB08912 DB08816 DB09039 DB00570 DB08934 DB09297 DB04348 DB15762 DB01128 DB08901 DB01406 DB08916 DB09102 DB09036 DB04794 DB06240 DB08889 DB01030 DB04855 DB09099 DB15442 DB00530 DB01007 DB01174 DB00655 DB11796 DB14568 DB04920 DB04894 DB11770 DB11767 DB13952 DB12070 DB11644 DB09231 DB13941 DB01079 DB01764 DB01087 DB00795 DB16703 DB14840 DB11967 DB00501 DB06212 DB01261 DB06419 DB00342 DB00726 DB00896 DB06731 DB09061 DB15719 DB00227 DB00448 DB14240 DB00862 DB16236 DB00673 DB00909 DB01136 DB00243 DB06769 DB01645 DB09034 DB08827 DB15149 DB05773 DB01183 DB13055 DB12141 DB11837 DB00255 DB15822 DB13007 DB12887 DB00472 DB00541 DB00898 DB00701 DB15982 DB01388","absorption":"Following oral administration, T<sub>max<\/sub> occurs between 0.7 and 1.5 h.[A189213,L10926] When administered with a high-fat meal, T<sub>max<\/sub> is delayed by approximately 2 hours and C<sub>max<\/sub> was reduced by 22% with no significant changes to the AUC.[L10926] Ubrogepant exhibits dose-proportional pharmacokinetics throughout the entirety of its recommended dosing range.[L10926]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Ubrogepant has an elimination half-life of 5-7 hours.[L10926]","monoisotopic-mass":549.198774206,"volume-of-distribution":"The apparent central volume of distribution following oral administration is approximately 350 L.[L10926]","route-of-elimination":"The main route of elimination is fecal\/biliary, while renal excretion is comparatively minor - following administration of a single oral dose to healthy subjects, approximately 42% of the dose was recovered unchanged in the feces and 6% was recovered unchanged in the urine.[L10926]","name":"Ubrogepant","metabolism":"Ubrogepant is eliminated primarily via metabolism, the majority of which is mediated by CYP3A4.[L10926] Two circulating glucuronide conjugates, along with unchanged parent drug, were found to be the most abundant circulating components in human plasma. The glucuronide metabolites reportedly carry 6000-fold less activity at CGRP receptors and are therefore considered to be pharmacologically inert.[L10926]","reactions":null,"indication":"Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.[L10926,L43987]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15328"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nattokinase is under investigation in clinical trial NCT00749801 (Efficacy and Safety of Geneferm Nattokinase).","enzymes":null,"type":"biotech","cas-number":"133876-92-3","sequences":null,"targets":null,"unii":"H81695M5OP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nattokinase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15329"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)).","enzymes":null,"type":"biotech","cas-number":"1296818-77-3","sequences":null,"targets":null,"unii":"WX8293WGLC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nesvacumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15330"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vocimagene amiretrorepvec is under investigation in clinical trial NCT02576665 (A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)).","enzymes":null,"type":"biotech","cas-number":"1300724-82-6","sequences":null,"targets":null,"unii":"DC4WO3WA4Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vocimagene amiretrorepvec","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15331"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Radavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).","enzymes":null,"type":"biotech","cas-number":"1228284-45-4","sequences":null,"targets":null,"unii":"9P30PF804H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Radavirsen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15332"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":371.432,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-1386 is under investigation in clinical trial NCT00945178 (Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"942937-80-6","sequences":null,"targets":null,"unii":"210323T9CP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":371.180918699,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-1386","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15333"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":284.267,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).","enzymes":null,"type":"small molecule","cas-number":"491-80-5","sequences":null,"targets":null,"unii":"U13J6U390T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB00682 DB06474 DB06647 DB11959 DB09052 DB13259 DB06679 DB12034 DB11857 DB08814 DB14039 DB12023 DB12289 DB00540 DB06305 DB09217 DB01142 DB11564 DB15898 DB14877 DB00814 DB11604 DB12344 DB00451 DB13886 DB05232 DB14811 DB11921 DB11884 DB11685 DB13199 DB11746 DB15118 DB06228 DB09307 DB01306 DB01086 DB14997 DB12815 DB00321 DB00503 DB06602 DB12053 DB13843 DB09030 DB00070 DB14012 DB01067 DB09035 DB01124 DB14891 DB13017 DB01075 DB00108 DB00046 DB06599 DB13136 DB06310 DB00741 DB14864 DB09105 DB13411 DB00839 DB00222 DB00278 DB12520 DB12396 DB13208 DB05797 DB09383 DB00543 DB05656 DB06557 DB12274 DB11680 DB01708 DB13140 DB06607 DB15443 DB00959 DB00268 DB00281 DB14897 DB13578 DB00028 DB12104 DB04938 DB15001 DB12261 DB12849 DB12826 DB12844 DB04962 DB01309 DB11866 DB12205 DB13496 DB01240 DB09130 DB12498 DB12726 DB11715 DB00012 DB08830 DB00098 DB11502 DB11621 DB16385 DB00113 DB05095 DB12246 DB15627 DB00086 DB00002 DB04949 DB00030 DB13535 DB12364 DB07767 DB01257 DB00031 DB12335 DB04901 DB11976 DB12119 DB09045 DB06271 DB00498 DB14952 DB05111 DB00054 DB01109 DB08894 DB15626 DB00180 DB16225 DB12698 DB13073 DB00749 DB08870 DB11731 DB01217 DB14776 DB00266 DB11771 DB13124 DB05304 DB14055 DB12893 DB01583 DB15090 DB06695 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB00414 DB15899 DB01120 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11095 DB11988 DB06371 DB15045 DB01269 DB06550 DB01234 DB05099 DB16355 DB06322 DB06635 DB08994 DB06605 DB01283 DB00635 DB13976 DB15089 DB13149 DB14967 DB13979 DB09183 DB11834 DB16220 DB05679 DB05006 DB00297 DB09154 DB09378 DB08813 DB14843 DB11567 DB13782 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB06736 DB15022 DB15277 DB13384 DB15172 DB11597 DB12530 DB01225 DB16265 DB00015 DB01251 DB00065 DB06543 DB15718 DB05892 DB12532 DB12089 DB09303 DB08904 DB13616 DB00055 DB15880 DB12930 DB14959 DB12917 DB12845 DB00569 DB06192 DB08794 DB01161 DB00043 DB09296 DB15628 DB12976 DB09559 DB01041 DB09033 DB09345 DB11826 DB01418 DB01108 DB14004 DB09009 DB06241 DB13114 DB08996 DB00057 DB00112 DB09342 DB14094 DB05793 DB01384 DB00052 DB06049 DB06168 DB16659 DB00555 DB13683 DB14996 DB16222 DB06043 DB14483 DB11945 DB09295 DB01289 DB08879 DB00076 DB06366 DB09037 DB05550 DB12169 DB06612 DB01016 DB15397 DB05595 DB06318 DB11569 DB14784 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB13246 DB11984 DB14580 DB05555 DB09259 DB16195 DB12189 DB00110 DB13225 DB08439 DB06294 DB09077 DB06205 DB13003 DB06406 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB04898 DB06101 DB00073 DB06643 DB01307 DB12560 DB12797 DB14681 DB05496 DB12157 DB04630 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB00480 DB12342 DB14988 DB12090 DB15432 DB00672 DB06774 DB03410 DB00645 DB15363 DB00580 DB01242 DB00111 DB01270 DB04665 DB01380 DB11598 DB14947 DB09085 DB15441 DB15383 DB13275 DB14962 DB15349 DB06441 DB05115 DB05941 DB11930 DB06050 DB09167 DB00296 DB01151 DB00443 DB06162 DB11455 DB06779 DB00461 DB12489 DB09264 DB04932 DB13328 DB12773 DB12456 DB06273 DB12413 DB09016 DB12317 DB00721 DB06317 DB14809 DB12807 DB00750 DB00892 DB04743 DB09289 DB00344 DB15093 DB00089 DB09260 DB05097 DB11840 DB11312 DB00990 DB09075 DB13375 DB16732 DB08987 DB11568 DB12202 DB13045 DB00860 DB00016 DB11148 DB06360 DB14485 DB13646 DB00051 DB14908 DB12820 DB15941 DB15113 DB00029 DB00095 DB11529 DB05578 DB15101 DB12701 DB14486 DB00458 DB14778 DB11166 DB12331 DB09255 DB14762 DB06754 DB00407 DB06186 DB15559 DB13675 DB00009 DB11850 DB00047 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB16695 DB01222 DB16394 DB15225 DB12250 DB03604 DB15434 DB14042 DB09258 DB12213 DB16077 DB12240 DB06650 DB12598 DB16393 DB00482 DB08816 DB11646 DB15252 DB09297 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB05229 DB04836 DB16151 DB09302 DB13347 DB00013 DB12118 DB00975 DB05915 DB14871 DB06822 DB00081 DB00087 DB11657 DB12775 DB04988 DB14513 DB01285 DB05996 DB00686 DB11767 DB14740 DB05139 DB00024 DB06304 DB08496 DB11595 DB00279 DB09029 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB05254 DB00126 DB14040 DB06674 DB15900 DB09331 DB06209 DB14041 DB00726 DB12831 DB13127 DB05361 DB15719 DB00620 DB03255 DB15044 DB06770 DB11608 DB15104 DB11862 DB13451 DB04925 DB05336 DB11714 DB12152 DB14482 DB11776 DB00001 DB12399 DB15253 DB06324 DB12534 DB04964 DB15336 DB00946 DB01628 DB11849 DB13406 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB00974 DB13037 DB00821 DB06342 DB05405 DB12077 DB09456 DB00006 DB09564 DB09100 DB00071 DB09312 DB14726 DB00533 DB08962 DB00687 DB04552","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":284.068473486,"volume-of-distribution":null,"route-of-elimination":null,"name":"Biochanin A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15334"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":268.268,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Formononetin is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).","enzymes":null,"type":"small molecule","cas-number":"485-72-3","sequences":null,"targets":null,"unii":"295DQC67BJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB00682 DB06474 DB06647 DB11959 DB09052 DB06679 DB12034 DB11857 DB08814 DB14039 DB12023 DB12289 DB00540 DB06305 DB09217 DB01142 DB11564 DB15898 DB14877 DB00814 DB11604 DB12344 DB00451 DB13886 DB14811 DB11921 DB11884 DB11685 DB13199 DB11746 DB15118 DB06228 DB09307 DB01306 DB14997 DB12815 DB00321 DB00503 DB06602 DB12053 DB13843 DB09030 DB00070 DB14012 DB01067 DB09035 DB01124 DB14891 DB13017 DB00108 DB00046 DB06599 DB13136 DB06310 DB00741 DB14864 DB09105 DB13411 DB00839 DB00222 DB00278 DB12520 DB12396 DB13208 DB05797 DB09383 DB00543 DB05656 DB06557 DB12274 DB11680 DB01708 DB13140 DB06607 DB15443 DB00959 DB00268 DB14897 DB00028 DB12104 DB04938 DB15001 DB12261 DB12849 DB12826 DB12844 DB04962 DB01309 DB11866 DB12205 DB13496 DB01240 DB09130 DB12498 DB12726 DB11715 DB08830 DB00098 DB11621 DB16385 DB00113 DB05095 DB12246 DB15627 DB00086 DB00002 DB04949 DB00030 DB13535 DB12364 DB07767 DB01257 DB00031 DB12335 DB04901 DB11976 DB12119 DB09045 DB06271 DB00498 DB14952 DB05111 DB00054 DB01109 DB15626 DB00180 DB16225 DB12698 DB13073 DB00749 DB08870 DB11731 DB01217 DB14776 DB00266 DB11771 DB13124 DB05304 DB14055 DB12893 DB01583 DB15090 DB06695 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB00414 DB15899 DB01120 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11095 DB11988 DB06371 DB15045 DB01269 DB06550 DB01234 DB05099 DB16355 DB06322 DB06635 DB08994 DB06605 DB01283 DB00635 DB13976 DB15089 DB13149 DB14967 DB13979 DB09183 DB11834 DB16220 DB05679 DB05006 DB09154 DB09378 DB08813 DB14843 DB11567 DB13782 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB06736 DB15022 DB15277 DB13384 DB15172 DB11597 DB12530 DB01225 DB16265 DB00015 DB01251 DB00065 DB06543 DB15718 DB05892 DB12089 DB09303 DB08904 DB13616 DB00055 DB15880 DB12930 DB14959 DB12917 DB12845 DB00569 DB06192 DB08794 DB00043 DB09296 DB15628 DB12976 DB09559 DB01041 DB09033 DB11826 DB01418 DB01108 DB14004 DB06241 DB13114 DB08996 DB00057 DB00112 DB14094 DB05793 DB01384 DB00052 DB06049 DB06168 DB16659 DB00555 DB14996 DB16222 DB06043 DB14483 DB11945 DB09295 DB01289 DB08879 DB00076 DB06366 DB09037 DB05550 DB12169 DB06612 DB01016 DB15397 DB05595 DB06318 DB11569 DB14784 DB14824 DB16376 DB15453 DB11580 DB12142 DB13246 DB11984 DB14580 DB05555 DB09259 DB16195 DB12189 DB00110 DB13225 DB08439 DB06294 DB09077 DB06205 DB13003 DB06406 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB04898 DB06101 DB00073 DB06643 DB01307 DB12560 DB12797 DB14681 DB05496 DB12157 DB04630 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB00480 DB12342 DB14988 DB12090 DB15432 DB00672 DB03410 DB15363 DB00580 DB01242 DB00111 DB01270 DB04665 DB01380 DB11598 DB14947 DB15441 DB15383 DB13275 DB14962 DB15349 DB06441 DB05115 DB05941 DB11930 DB06050 DB09167 DB01151 DB00443 DB06162 DB11455 DB06779 DB00461 DB12489 DB09264 DB04932 DB12773 DB12456 DB06273 DB12413 DB09016 DB12317 DB06317 DB14809 DB12807 DB04743 DB09289 DB00344 DB15093 DB00089 DB09260 DB05097 DB11840 DB11312 DB00990 DB09075 DB13375 DB16732 DB11568 DB12202 DB13045 DB00860 DB06360 DB14485 DB13646 DB00051 DB14908 DB12820 DB15941 DB15113 DB00029 DB00095 DB11529 DB05578 DB15101 DB12701 DB14486 DB00458 DB14778 DB11166 DB12331 DB09255 DB14762 DB06754 DB00407 DB06186 DB15559 DB13675 DB00009 DB11850 DB00047 DB08902 DB15409 DB15014 DB12296 DB16695 DB01222 DB16394 DB15225 DB12250 DB03604 DB15434 DB14042 DB09258 DB12213 DB16077 DB12240 DB06650 DB12598 DB16393 DB00482 DB08816 DB11646 DB15252 DB09297 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB05229 DB04836 DB16151 DB09302 DB13347 DB00013 DB12118 DB00975 DB05915 DB14871 DB06822 DB00081 DB00087 DB11657 DB12775 DB04988 DB14513 DB01285 DB05996 DB00686 DB11767 DB14740 DB05139 DB00024 DB06304 DB08496 DB11595 DB00279 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB05254 DB00126 DB14040 DB06674 DB15900 DB09331 DB06209 DB14041 DB00726 DB12831 DB13127 DB05361 DB15719 DB00620 DB15044 DB11608 DB15104 DB11862 DB13451 DB04925 DB05336 DB11714 DB12152 DB14482 DB11776 DB00001 DB12399 DB15253 DB06324 DB12534 DB04964 DB15336 DB00946 DB01628 DB11849 DB13406 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB00974 DB13037 DB00821 DB06342 DB05405 DB12077 DB09456 DB00006 DB09564 DB09100 DB00071 DB09312 DB14726 DB00533 DB08962 DB00687 DB04552","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":268.073558866,"volume-of-distribution":null,"route-of-elimination":null,"name":"Formononetin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15335"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).","enzymes":null,"type":"biotech","cas-number":"1815583-32-4","sequences":null,"targets":null,"unii":"ML78ZA3RNC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Valanafusp alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15336"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":366.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).","enzymes":null,"type":"small molecule","cas-number":"204386-76-5","sequences":null,"targets":null,"unii":"9DL0X410PY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":366.136176378,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rovatirelin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15338"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":163.2163,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Methcathinone is under investigation in clinical trial NCT02617862 (PCI Imaging System in Pediatric Ophthalmology).","enzymes":null,"type":"small molecule","cas-number":"5650-44-2","sequences":null,"targets":null,"unii":"386QA522QG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":163.099714043,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methcathinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15339"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1060.14,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).","enzymes":null,"type":"small molecule","cas-number":"1025066-50-5","sequences":null,"targets":null,"unii":"RWY5U5KZV3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1059.421912843,"volume-of-distribution":null,"route-of-elimination":null,"name":"EC-0652","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15340"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":881.12,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).","enzymes":null,"type":"small molecule","cas-number":"311768-81-7","sequences":null,"targets":null,"unii":"464OXX39Y6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":880.487396398,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dinalbuphine sebacate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15341"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa).","enzymes":null,"type":"biotech","cas-number":"885053-97-4","sequences":null,"targets":null,"unii":"62B4OXU259","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Panobacumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15342"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":501.08,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":"C0WUS7XXE9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":500.2455228,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tuspetinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15343"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":118.1311,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"beta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).","enzymes":null,"type":"small molecule","cas-number":"625-08-1","sequences":null,"targets":null,"unii":"3F752311CD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":118.062994186,"volume-of-distribution":null,"route-of-elimination":null,"name":"beta-Hydroxyisovaleric acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15344"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":451.502,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.).","enzymes":null,"type":"small molecule","cas-number":"944406-54-6","sequences":null,"targets":null,"unii":"U9T63BZ3AS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":451.20196788,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK-945237","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15345"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":378.428,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).","enzymes":null,"type":"small molecule","cas-number":"1445847-37-9","sequences":null,"targets":null,"unii":"K9WR6LRA5D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":378.157957196,"volume-of-distribution":null,"route-of-elimination":null,"name":"GLPG-1205","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15346"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":370.428,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1912445-55-6","sequences":null,"targets":"BE0001284","unii":"7LBRZUYSHU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":370.18050416,"volume-of-distribution":null,"route-of-elimination":null,"name":"Branebrutinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-05-05","drugbank-id":"DB15347"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":321.343,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).","enzymes":null,"type":"small molecule","cas-number":"1227056-84-9","sequences":null,"targets":null,"unii":"19997EZ42I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":321.134048693,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ampreloxetine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15348"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).","enzymes":null,"type":"biotech","cas-number":"1418200-58-4","sequences":null,"targets":null,"unii":"2X3CKG601L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sofituzumab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15349"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":180.1559,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"D-chiro-Inositol is under investigation in clinical trial NCT03201601 (Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome).","enzymes":null,"type":"small molecule","cas-number":"643-12-9","sequences":null,"targets":null,"unii":"6R79WV4R10","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":180.063388116,"volume-of-distribution":null,"route-of-elimination":null,"name":"D-chiro-Inositol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15350"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1179.385,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dihematoporphyrin ether is under investigation in clinical trial NCT00118222 (High Light and Low Light Dose PDT in Glioma).","enzymes":null,"type":"small molecule","cas-number":"97067-70-4","sequences":null,"targets":null,"unii":"625J2HS54G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB15575 DB00721 DB05232 DB08894 DB00750 DB00892 DB00755 DB00012 DB01002 DB09342 DB09085 DB01086 DB00460 DB00707 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1178.547705235,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dihematoporphyrin ether","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15351"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).","enzymes":null,"type":"biotech","cas-number":"1165741-01-4","sequences":null,"targets":null,"unii":"699619YVTQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vorsetuzumab mafodotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15352"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":324.31,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nacubactam is under investigation in clinical trial NCT03174795 (A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection).","enzymes":null,"type":"small molecule","cas-number":"1452458-86-4","sequences":null,"targets":null,"unii":"832O37V7MZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":324.073970045,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nacubactam","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15353"},{"toxicity":"There are no data regarding overdosage with evinacumab. Symptoms of overdose are likely to be consistent with evinacumab's adverse effect profile and may therefore include significant infusion reactions or dizziness.[L31833] Patients experiencing an overdose should be treated with symptomatic and supportive measures.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Evinacumab exerts its hypolipidemic and antiatherogenic effects via decreasing circulating levels of triglycerides, HDL-C, and LDL-C, apolipoprotein B, and total cholesterol.[L31833] It is has a relatively long duration of action that allows for its administration via intravenous injection once-monthly.[L31833]\r\n\r\nAnimal studies have demonstrated embryo-fetal toxicity - administration to pregnant rabbits during organogenesis resulted in increases in fetal malformations at concentrations lower than those used in humans. For this reason, patients receiving therapy with evinacumab should obtain a pregnancy test prior to beginning therapy and use effective contraception throughout the duration of therapy and for 5 months following the administration of the last dose.[L31833]","msds":null,"description":"Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with cardiovascular risk, and it was these observations that provided a rationale for the development of a therapy targeted against ANGPTL3.[A229278]\r\n\r\nIn February 2021, evinacumab became the first-and-only inhibitor of ANGPTL3 to receive FDA approval after it was granted approval for the adjunctive treatment of homozygous familial hypercholesterolemia (HoFH) under the brand name \"Evkeeza\".[L31838] Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.","enzymes":null,"type":"biotech","cas-number":"1446419-85-7","sequences":null,"targets":"BE0010034","unii":"T8B2ORP1DW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Other lipid modifying agents LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN CARDIOVASCULAR SYSTEM","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Angiopoetin-like proteins (ANGPTL) are a diverse group of proteins involved in a number of physiological processes, including the regulation of lipoprotein metabolism. Loss-of-function mutations in _ANGPTL3_ and _ANGPTL4_ have been shown to result in hypolipidemia and a reduced risk of coronary artery disease, while increased levels of these proteins appear to be associated with cardiovascular risk.[A229273,A229318] While these observations have made ANGPTLs as a class a desirable target in the treatment of hyperlipidemic disorders,[A229273] ANGPTL3 is the first to be pharmacologically targeted for the purposes of lipid-lowering therapy.[A229318] ANGPTL3 is expressed primarily in the liver and acts as an endogenous inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL) which are responsible, in part, for metabolizing triglycerides (TG) and HDL-C, respectively.[L31833]\r\n\r\nEvinacumab is monoclonal antibody that binds to and inhibits ANGPTL3, with the resulting disinhibition of LPL and EL reducing the levels of circulating TG and HDL-C. While the mechanism through which evinacumab reduces LDL-C is not entirely clear, this effect is independent of LDL receptor density and is therefore most likely due to the promotion of VLDL processing and upstream clearance of LDL formation.[L31833]","drug-interactions":null,"absorption":"Following the recommended dosing regimen (15 mg\/kg intravenously every 4 weeks), steady-state concentrations are reached after four doses. According to population pharmacokinetic modeling, the mean steady-state trough concentration is approximately 241 mg\/L and the C<sub>max<\/sub> at the end of infusion is approximately 689 mg\/L.[L31833]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The elimination half-life of evinacumab is a function of its serum concentration and is therefore variable.[L31833] This is because evinacumab is eliminated by two parallel pathways: at higher concentrations it is eliminated primarily through a non-saturable proteolytic pathway, while at lower concentrations its elimination occurs primarily via a saturable target-mediated pathway.[L31833]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of evinacumab was estimated to be 4.8 L via population pharmacokinetic analysis.[L31833]","route-of-elimination":"Monoclonal antibodies are typically eliminated via uptake into cells and subsequent catabolism via lysosomal degradation. Due to their large size, they are only eliminated renally under pathologic conditions.[A216712]","name":"Evinacumab","metabolism":"The biotransformation of evinacumab has not been characterized.[L31833] Monoclonal antibodies as a class are typically degraded via catabolic pathways into smaller peptides and amino acids.[A216712]","reactions":null,"indication":"Evinacumab is indicated, as an adjunct with other lipid-lowering therapies, for the treatment of familial homozygous hypercholesterolemia (HoFH) in patients 12 years of age and older.[L31833]","ahfs-codes":null,"updated":"2021-07-02","drugbank-id":"DB15354"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1875.21,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).","enzymes":null,"type":"small molecule","cas-number":"952295-80-6","sequences":null,"targets":null,"unii":"YI2S0GUQ2C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1873.919211945,"volume-of-distribution":null,"route-of-elimination":null,"name":"PL-3994","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15355"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":556.659,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.).","enzymes":null,"type":"small molecule","cas-number":"182821-33-6","sequences":null,"targets":null,"unii":"3613ZP748K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":556.257336887,"volume-of-distribution":null,"route-of-elimination":null,"name":"SLV-334","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15356"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":281.42,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Xanomeline is under investigation in clinical trial NCT02831231 (Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium).","enzymes":null,"type":"small molecule","cas-number":"131986-45-3","sequences":null,"targets":null,"unii":"9ORI6L73CJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00392 DB04808 DB08952 DB01400 DB13503 DB00677 DB00382 DB13540 DB00989 DB06696 DB01193 DB00527 DB00843 DB00941 DB02365 DB11397 DB12482 DB08437 DB00187 DB11785 DB01337 DB12604 DB00571 DB00960 DB00674 DB00452 DB01359 DB11520 DB00373 DB05386 DB13443 DB09351 DB04864 DB08808 DB04861 DB00489 DB00798 DB13694 DB06774 DB00888 DB11473 DB12752 DB00314 DB00082 DB01295 DB01421 DB00477 DB04846 DB01381 DB15317 DB00955 DB02845 DB00335 DB00358 DB11770 DB00479 DB08807 DB01199 DB00264 DB06692 DB00684 DB04626 DB09204 DB13508 DB00508 DB01010 DB01064 DB00721 DB13668 DB00545 DB13530 DB14031 DB01172 DB11390 DB00803 DB11412 DB01136 DB01408 DB00391 DB01043 DB00805 DB00585 DB01035 DB01082 DB00871 DB04729 DB04263 DB12212 DB11512 DB13757 DB06756 DB00994 DB00711 DB01182 DB06726 DB13775 DB04892 DB01338 DB00981 DB04572 DB13058 DB00944 DB01122 DB00483 DB03615 DB12615 DB00612 DB01245 DB00598 DB01233 DB00866 DB09271 DB00515 DB00195 DB13495 DB01203 DB01580 DB01221 DB03322 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":281.156183547,"volume-of-distribution":null,"route-of-elimination":null,"name":"Xanomeline","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15357"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":440.79,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"JNJ-54175446 is under investigation in clinical trial NCT02933762 (A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma).","enzymes":null,"type":"small molecule","cas-number":"1627902-21-9","sequences":null,"targets":null,"unii":"32524GLF40","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":440.0775494,"volume-of-distribution":null,"route-of-elimination":null,"name":"JNJ-54175446","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15358"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":354.3964,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Xanthohumol is under investigation in clinical trial NCT01367431 (Xanthohumol and Metabolic Syndrome).","enzymes":null,"type":"small molecule","cas-number":"6754-58-1","sequences":null,"targets":null,"unii":"T4467YT1NT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":354.146723814,"volume-of-distribution":null,"route-of-elimination":null,"name":"Xanthohumol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15359"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":393.515,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Carfentanil, C-11 is under investigation in clinical trial NCT01899170 (Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain).","enzymes":null,"type":"small molecule","cas-number":"98598-83-5","sequences":null,"targets":null,"unii":"UVI40IC2GN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB08953 DB14028 DB14719 DB12710 DB08329 DB00219 DB00887 DB00742 DB00656 DB01560 DB13082 DB13642 DB01545 DB13841 DB11552 DB00540 DB00737 DB01142 DB07715 DB06554 DB12184 DB11957 DB06230 DB13875 DB13695 DB13876 DB01215 DB00387 DB09185 DB00562 DB15465 DB05542 DB12193 DB01548 DB09253 DB01247 DB13505 DB00280 DB01200 DB05232 DB01618 DB13799 DB13252 DB00232 DB06701 DB01409 DB09484 DB13703 DB01337 DB09307 DB13522 DB00395 DB13792 DB00424 DB01086 DB00962 DB00557 DB01209 DB01556 DB09184 DB11859 DB01595 DB08922 DB15477 DB13303 DB00810 DB00321 DB13354 DB06711 DB00732 DB06148 DB13754 DB13738 DB01246 DB12338 DB00292 DB00490 DB01235 DB01535 DB04908 DB00475 DB00463 DB14504 DB00421 DB01075 DB02234 DB00700 DB11855 DB09076 DB13534 DB01065 DB00546 DB01558 DB01148 DB01339 DB01551 DB13948 DB13411 DB11823 DB00246 DB01577 DB00777 DB15119 DB00209 DB09190 DB13636 DB00714 DB00543 DB08927 DB13572 DB11057 DB09462 DB13552 DB04017 DB06690 DB00230 DB00281 DB00268 DB11827 DB01320 DB09480 DB13554 DB01323 DB00181 DB11228 DB13219 DB09481 DB01579 DB01495 DB01624 DB04818 DB08839 DB00332 DB13468 DB01555 DB01062 DB12883 DB08811 DB12404 DB01466 DB06529 DB15861 DB00708 DB13496 DB12229 DB09224 DB11490 DB01622 DB00370 DB00245 DB09249 DB01046 DB13787 DB00581 DB00599 DB13541 DB16021 DB15478 DB08550 DB13180 DB00835 DB13837 DB13584 DB11951 DB00758 DB00670 DB00391 DB01100 DB13396 DB13253 DB09015 DB00623 DB01445 DB04888 DB12661 DB11903 DB01202 DB13233 DB14018 DB00906 DB00908 DB00402 DB09251 DB00372 DB08861 DB00652 DB11889 DB13805 DB01107 DB09225 DB06582 DB09409 DB06292 DB04917 DB01245 DB00614 DB13940 DB01175 DB00866 DB00949 DB09194 DB00872 DB09125 DB00819 DB00662 DB00420 DB00980 DB13323 DB13769 DB00214 DB09300 DB00967 DB12576 DB04821 DB00996 DB12177 DB00476 DB06738 DB12080 DB11868 DB09020 DB13284 DB13014 DB12958 DB00715 DB00327 DB00237 DB00334 DB01156 DB12110 DB00601 DB13542 DB00899 DB00241 DB13414 DB00468 DB01484 DB00924 DB01626 DB00941 DB13662 DB00915 DB13817 DB00753 DB06654 DB06155 DB11664 DB12013 DB13402 DB13624 DB06512 DB05227 DB00960 DB00695 DB00312 DB01359 DB09413 DB01412 DB00363 DB08801 DB01638 DB04871 DB12590 DB08810 DB08838 DB04884 DB00206 DB01534 DB13687 DB00418 DB01231 DB00628 DB01459 DB01616 DB00313 DB09414 DB06201 DB04843 DB00297 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB11555 DB13782 DB00231 DB01566 DB11110 DB00999 DB00633 DB00937 DB05246 DB01625 DB13737 DB14963 DB11540 DB00831 DB09068 DB00082 DB12395 DB13384 DB13454 DB00311 DB00450 DB00617 DB00734 DB01227 DB13617 DB13784 DB00903 DB09166 DB00532 DB11400 DB00754 DB12273 DB00604 DB00852 DB05541 DB09449 DB11582 DB00842 DB12427 DB01199 DB11376 DB00594 DB08986 DB00776 DB08059 DB08910 DB12930 DB09243 DB08960 DB14651 DB16165 DB00454 DB00176 DB09117 DB01104 DB00505 DB00985 DB14516 DB01161 DB11371 DB11315 DB09250 DB04819 DB13678 DB06283 DB01041 DB11235 DB00921 DB09345 DB00035 DB09021 DB01192 DB05607 DB09009 DB00875 DB00496 DB00622 DB14502 DB13114 DB01450 DB08996 DB06446 DB11477 DB13221 DB13588 DB13606 DB11189 DB15889 DB00474 DB11113 DB13234 DB00780 DB00690 DB13913 DB01114 DB13213 DB01355 DB00377 DB00818 DB00323 DB00952 DB00774 DB13025 DB00849 DB01615 DB13993 DB00555 DB00423 DB09118 DB01037 DB11686 DB06787 DB00404 DB01531 DB13577 DB00502 DB12543 DB13733 DB04948 DB00486 DB14881 DB01365 DB01017 DB00252 DB01511 DB05077 DB00942 DB01116 DB09001 DB09245 DB09483 DB13989 DB00801 DB13550 DB12518 DB04953 DB01063 DB14011 DB13801 DB13335 DB00384 DB12649 DB01002 DB13254 DB14500 DB13246 DB00956 DB13420 DB01954 DB00660 DB13759 DB12308 DB15203 DB00564 DB09000 DB00572 DB01501 DB11156 DB01173 DB13225 DB13352 DB04833 DB00234 DB01105 DB06684 DB06144 DB13648 DB01440 DB13486 DB13256 DB04896 DB00854 DB00843 DB11609 DB00182 DB01354 DB13357 DB09241 DB13437 DB01587 DB01608 DB00704 DB01392 DB00295 DB13099 DB13950 DB01378 DB14185 DB14043 DB00589 DB00340 DB12670 DB09235 DB08890 DB05710 DB00310 DB09049 DB00748 DB00904 DB01614 DB12105 DB13666 DB06527 DB12537 DB01563 DB06282 DB08815 DB14546 DB01377 DB01547 DB09089 DB06016 DB04946 DB14737 DB13070 DB13770 DB11732 DB00215 DB00248 DB01591 DB01567 DB13745 DB13526 DB09011 DB00771 DB13791 DB00625 DB00645 DB06218 DB01576 DB01267 DB12989 DB00202 DB00751 DB08907 DB01154 DB00517 DB01483 DB00679 DB01242 DB06109 DB13455 DB14509 DB12704 DB09272 DB13457 DB06660 DB00436 DB14715 DB08872 DB01236 DB14684 DB06700 DB00477 DB06480 DB00889 DB01239 DB11543 DB09085 DB00354 DB06702 DB13448 DB06753 DB00804 DB05687 DB13324 DB00189 DB12942 DB00565 DB04829 DB00349 DB13520 DB00427 DB12131 DB00150 DB09167 DB00484 DB00296 DB01621 DB01151 DB08961 DB13663 DB12327 DB09311 DB00725 DB13362 DB09017 DB09247 DB00813 DB00376 DB01255 DB00433 DB09128 DB13273 DB14499 DB14672 DB09254 DB00508 DB01226 DB01463 DB06691 DB00865 DB13331 DB00752 DB01367 DB04841 DB04903 DB08897 DB00494 DB09016 DB00721 DB13413 DB01186 DB01467 DB00750 DB00892 DB04842 DB00808 DB01442 DB00934 DB09289 DB12278 DB00191 DB00344 DB00042 DB00579 DB01049 DB09014 DB00757 DB12693 DB13403 DB08992 DB01018 DB06579 DB13623 DB00805 DB09223 DB01589 DB06797 DB14718 DB08997 DB13170 DB01565 DB00083 DB11691 DB00747 DB04820 DB13598 DB00383 DB00653 DB14010 DB02925 DB00969 DB14575 DB04832 DB00972 DB12766 DB04599 DB06204 DB00593 DB13803 DB12111 DB00273 DB06716 DB00497 DB01121 DB00483 DB01623 DB08954 DB00829 DB09226 DB00940 DB04831 DB12341 DB13295 DB00986 DB13430 DB00504 DB11549 DB01176 DB09472 DB00408 DB15031 DB00588 DB00696 DB00333 DB00470 DB14627 DB12221 DB00832 DB04816 DB09287 DB00458 DB00953 DB01221 DB00880 DB01149 DB11556 DB09262 DB13523 DB00392 DB11089 DB09007 DB00697 DB12554 DB09219 DB01224 DB12492 DB06077 DB11365 DB06678 DB11428 DB00740 DB00802 DB00356 DB14050 DB09071 DB00765 DB00907 DB01198 DB14232 DB01288 DB00794 DB01509 DB00527 DB00680 DB01433 DB01036 DB01324 DB09119 DB13844 DB01351 DB01594 DB01403 DB06288 DB12526 DB04834 DB13601 DB00285 DB00462 DB00514 DB04827 DB00434 DB00844 DB11059 DB01219 DB09104 DB00574 DB01352 DB00371 DB11755 DB00703 DB12086 DB08816 DB04872 DB12093 DB09338 DB01353 DB02207 DB00347 DB13643 DB11097 DB12401 DB13665 DB09174 DB00228 DB01489 DB09248 DB02852 DB06470 DB01028 DB13108 DB04823 DB13619 DB01496 DB01529 DB13380 DB00320 DB12725 DB01395 DB00657 DB03575 DB13690 DB01454 DB00767 DB13850 DB04836 DB13405 DB13370 DB04824 DB01174 DB01497 DB11675 DB00318 DB01488 DB06274 DB00216 DB13996 DB00341 DB14513 DB00315 DB06216 DB13351 DB00405 DB12465 DB12951 DB01189 DB12361 DB01544 DB04165 DB01144 DB00933 DB06264 DB14585 DB15959 DB13377 DB01356 DB00728 DB00850 DB00409 DB01079 DB13532 DB13708 DB06153 DB00961 DB13160 DB14754 DB00366 DB13720 DB09187 DB09246 DB00647 DB05271 DB00283 DB14503 DB01588 DB06624 DB06370 DB12163 DB01069 DB09252 DB11107 DB09268 DB06212 DB11699 DB08883 DB00342 DB13382 DB00726 DB06458 DB00897 DB01437 DB06731 DB13872 DB09061 DB06800 DB13557 DB00998 DB00909 DB00683 DB13500 DB00306 DB06770 DB01021 DB00575 DB12071 DB00186 DB13984 DB11622 DB00837 DB01159 DB13581 DB00669 DB14482 DB00413 DB09244 DB09034 DB01171 DB09186 DB13369 DB01238 DB09023 DB01253 DB13707 DB09286 DB12585 DB01090 DB02959 DB08918 DB01336 DB04325 DB08892 DB01338 DB00425 DB01183 DB06594 DB04885 DB11130 DB05562 DB00611 DB13478 DB12867 DB01559 DB01135 DB09281 DB00247 DB00918 DB01233 DB01081 DB01178 DB01553 DB01168 DB09290 DB13676 DB00472 DB09072 DB00898 DB09401 DB00782 DB13507 DB01080 DB01472 DB00524 DB12833 DB01580 DB01068 DB05034","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":393.237076652,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carfentanil, C-11","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15360"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":200.9708,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).","enzymes":null,"type":"small molecule","cas-number":"15064-65-0","sequences":null,"targets":null,"unii":"H91Z8HBK1B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":200.97080377,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thallium Tl-201","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15361"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":470.46,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I\/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).","enzymes":null,"type":"small molecule","cas-number":"2135600-76-7","sequences":null,"targets":null,"unii":"0Y175XGX4P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":470.07996469,"volume-of-distribution":null,"route-of-elimination":null,"name":"LSZ-102","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15362"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).","enzymes":null,"type":"biotech","cas-number":"1509928-04-4","sequences":null,"targets":null,"unii":"XLR461MD3M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Istiratumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15363"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).","enzymes":null,"type":"biotech","cas-number":"2089039-22-3","sequences":null,"targets":null,"unii":"P5T1E46W5D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pegbelfermin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15365"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1565.841,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).","enzymes":null,"type":"small molecule","cas-number":"1187852-48-7","sequences":null,"targets":null,"unii":"C79B5A73C4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01429 DB00825 DB09238 DB09090 DB09107 DB08952 DB13863 DB00572 DB13259 DB08980 DB13961 DB09220 DB00204 DB06712 DB15300 DB08162 DB06694 DB09236 DB00907 DB01078 DB00814 DB01193 DB00527 DB01158 DB00680 DB00270 DB12712 DB13835 DB00280 DB05232 DB00187 DB13950 DB11785 DB06200 DB13652 DB00424 DB09235 DB13691 DB00571 DB01086 DB12923 DB14066 DB12093 DB00528 DB00347 DB07615 DB08838 DB01228 DB00373 DB09089 DB00297 DB09230 DB00393 DB08808 DB13651 DB04861 DB00489 DB04957 DB04855 DB01075 DB06217 DB13791 DB06152 DB06774 DB00645 DB01396 DB00568 DB05246 DB00640 DB00390 DB13645 DB12704 DB00836 DB01195 DB04846 DB00922 DB13546 DB00678 DB09085 DB09234 DB04920 DB00335 DB01023 DB11770 DB01426 DB12092 DB14063 DB01118 DB12532 DB12131 DB00281 DB00296 DB09231 DB13635 DB13578 DB09232 DB01161 DB13653 DB00961 DB00807 DB00264 DB01214 DB11960 DB00401 DB06283 DB09239 DB09345 DB04841 DB13328 DB13725 DB09009 DB00343 DB00721 DB00622 DB11699 DB09224 DB14068 DB00750 DB04838 DB04842 DB13718 DB00892 DB06446 DB13766 DB04743 DB14065 DB00381 DB00012 DB09342 DB09240 DB13488 DB08992 DB00909 DB01136 DB03255 DB11502 DB00379 DB00308 DB13500 DB06770 DB06727 DB01035 DB12212 DB09229 DB08987 DB01182 DB00653 DB00555 DB13240 DB00661 DB12766 DB00016 DB13683 DB13401 DB13555 DB00593 DB13775 DB00908 DB11148 DB13358 DB06468 DB13746 DB09227 DB00521 DB01244 DB00612 DB00511 DB04825 DB14064 DB08894 DB01054 DB01074 DB00866 DB01056 DB00195 DB01115 DB01002 DB14207 DB12286 DB01203 DB01580 DB01388 DB03322 DB05885 DB01297","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1564.872561595,"volume-of-distribution":null,"route-of-elimination":null,"name":"SOR-C13","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15366"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":527.6,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).","enzymes":null,"type":"small molecule","cas-number":"1162264-07-4","sequences":null,"targets":null,"unii":"6FHZ595FNM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":527.233268009,"volume-of-distribution":null,"route-of-elimination":null,"name":"LY-2623091","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15367"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).","enzymes":null,"type":"biotech","cas-number":"943976-23-6","sequences":null,"targets":null,"unii":"2L271110ED","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Yttrium Y-90 clivatuzumab tetraxetan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15368"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).","enzymes":null,"type":"biotech","cas-number":"1146887-67-3","sequences":null,"targets":null,"unii":"0N3FY8225K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aganirsen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15369"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Balixafortide is under investigation in clinical trial NCT03786094 (Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer).","enzymes":null,"type":"biotech","cas-number":"1051366-32-5","sequences":null,"targets":null,"unii":"PRC974M49B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Balixafortide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15370"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":837.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).","enzymes":null,"type":"small molecule","cas-number":"1193902-95-2","sequences":null,"targets":null,"unii":"7YM030A71C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":836.377863201,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-2748","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15371"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1139.6,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"JNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).","enzymes":null,"type":"small molecule","cas-number":"303983-00-8","sequences":null,"targets":null,"unii":"3I8JKL1CHB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1138.66735234,"volume-of-distribution":null,"route-of-elimination":null,"name":"JNJ-27548547","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15372"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).","enzymes":null,"type":"small molecule","cas-number":"1185986-76-8","sequences":null,"targets":null,"unii":"MDU8BQ474H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tilmanocept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-21","drugbank-id":"DB15373"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":59.9338,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cobalt Co-60 is under investigation in clinical trial NCT02891083 (Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer).","enzymes":null,"type":"small molecule","cas-number":"10198-40-0","sequences":null,"targets":null,"unii":"5C8182XDPZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":59.933822196,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cobalt Co-60","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15374"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).","enzymes":null,"type":"biotech","cas-number":"1673565-40-6","sequences":null,"targets":null,"unii":"835UH424TU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tozuleristide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15375"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).","enzymes":null,"type":"biotech","cas-number":"1788032-39-2","sequences":null,"targets":null,"unii":"09FZ7Q0PQZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gosuranemab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15376"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":365.45,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1226895-20-0","sequences":null,"targets":null,"unii":"3096O7WP53","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":365.10856465,"volume-of-distribution":null,"route-of-elimination":null,"name":"ATB-346","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15377"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and\/or Refractory Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"2039148-04-2","sequences":null,"targets":null,"unii":"QXN20J93AH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vopratelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15378"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1467.468,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C).","enzymes":null,"type":"small molecule","cas-number":"128446-35-5","sequences":null,"targets":null,"unii":"1I96OHX6EK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1466.626038213,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hydroxypropyl betadex","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15379"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":345.449,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Flutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques).","enzymes":null,"type":"small molecule","cas-number":"1274863-98-7","sequences":null,"targets":null,"unii":"M96ARL6373","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":345.208190784,"volume-of-distribution":null,"route-of-elimination":null,"name":"Flutriciclamide F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15380"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":512.778,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists).","enzymes":null,"type":"small molecule","cas-number":"1182-68-9","sequences":null,"targets":null,"unii":"12V8PA4WCH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01083","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":512.365430786,"volume-of-distribution":null,"route-of-elimination":null,"name":"Menaquinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15381"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":550.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1116743-46-4","sequences":null,"targets":null,"unii":"XH93U6NIJE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":550.136942524,"volume-of-distribution":null,"route-of-elimination":null,"name":"SAR-125844","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15382"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).","enzymes":null,"type":"biotech","cas-number":"1036730-42-3","sequences":null,"targets":null,"unii":"B932PAQ1BQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB14947 DB09085 DB15441 DB14962 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pidilizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15383"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":896.01,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Simotaxel is under investigation in clinical trial NCT00088647 (Study Evaluating MST-997 in Advanced Malignant Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"791635-59-1","sequences":null,"targets":null,"unii":"E1M30YOE59","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":895.344891313,"volume-of-distribution":null,"route-of-elimination":null,"name":"Simotaxel","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15384"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":481.552,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acebilustat is under investigation in clinical trial NCT01748838 (Phase 1 Study Assessing the Safety and Tolerability of CTX-4430).","enzymes":null,"type":"small molecule","cas-number":"943764-99-6","sequences":null,"targets":null,"unii":"J64RI4D29U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":481.200156361,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acebilustat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15385"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).","enzymes":null,"type":"biotech","cas-number":"1188450-53-4","sequences":null,"targets":null,"unii":"QWZ40O5W6K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"ALT-801","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15386"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).","enzymes":null,"type":"biotech","cas-number":"1918149-01-5","sequences":null,"targets":null,"unii":"NW9K8C1JN3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bintrafusp alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15387"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"3GFS72WN4M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anti-GD2 monoclonal antibody 3F8","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15388"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).","enzymes":null,"type":"biotech","cas-number":"136279-32-8","sequences":null,"targets":null,"unii":"H5ZRB188EI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Teceleukin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15389"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Efizonerimod alfa is under investigation in clinical trial NCT02221960 (A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1635395-27-5","sequences":null,"targets":null,"unii":"1MH7C2X8KE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Efizonerimod alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15390"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":437.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).","enzymes":null,"type":"small molecule","cas-number":"1388651-30-6","sequences":null,"targets":null,"unii":"RXJ96XL94H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":437.113330503,"volume-of-distribution":null,"route-of-elimination":null,"name":"Elenbecestat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15391"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":132.9055,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cesium is under investigation in clinical trial NCT02794675 (Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer).","enzymes":null,"type":"small molecule","cas-number":"7440-46-2","sequences":null,"targets":null,"unii":"1KSV9V4Y4I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":132.90544687,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cesium","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15392"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":409.83,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine\/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).","enzymes":null,"type":"small molecule","cas-number":"332012-40-5","sequences":null,"targets":null,"unii":"18P7197Q7J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":409.0941671,"volume-of-distribution":null,"route-of-elimination":null,"name":"Telatinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15393"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":416.6795,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"gamma-Tocopherol is under investigation in clinical trial NCT00836368 (In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics).","enzymes":null,"type":"small molecule","cas-number":"54-28-4","sequences":null,"targets":null,"unii":"8EF1Z1238F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01083","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":416.36543078,"volume-of-distribution":null,"route-of-elimination":null,"name":"gamma-Tocopherol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15394"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06863135 is under investigation in clinical trial NCT03269136 (Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse\/ Refractory Multiple Myeloma).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"L0HR9A577V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06863135","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15395"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":532.571,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).","enzymes":null,"type":"small molecule","cas-number":"1416241-23-0","sequences":null,"targets":null,"unii":"I8C3R768IZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":532.219844002,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vamotinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15396"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).","enzymes":null,"type":"biotech","cas-number":"946415-70-9","sequences":null,"targets":null,"unii":"I0TG4Z02RN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"GMA-161","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15397"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":308.4125,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dihydrocapsiate is under investigation in clinical trial NCT00999297 (Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate).","enzymes":null,"type":"small molecule","cas-number":"205687-03-2","sequences":null,"targets":null,"unii":"W2F7769AEU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":308.198759384,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dihydrocapsiate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15398"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":461.4948,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux in Subjects With Advanced or Metastatic Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1001350-96-4","sequences":null,"targets":"BE0000858 BE0000033","unii":"W9E3353E8J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":461.20878464,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-754807","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-03-13","drugbank-id":"DB15399"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).","enzymes":null,"type":"biotech","cas-number":"1401812-88-1","sequences":null,"targets":null,"unii":"7IUT83FK6S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lifastuzumab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15400"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":580.418,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Danicopan is under investigation in clinical trial NCT03459443 (A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)).","enzymes":null,"type":"small molecule","cas-number":"1903768-17-1","sequences":null,"targets":null,"unii":"JM8C1SFX0U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":579.102979,"volume-of-distribution":null,"route-of-elimination":null,"name":"Danicopan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15401"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).","enzymes":null,"type":"biotech","cas-number":"339986-90-2","sequences":null,"targets":null,"unii":"4ON7FF680U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tucotuzumab celmoleukin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15402"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":588.71,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ziritaxestat is under investigation in clinical trial NCT03798366 (A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis).","enzymes":null,"type":"small molecule","cas-number":"1628260-79-6","sequences":null,"targets":null,"unii":"I02418V13W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":588.243121672,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ziritaxestat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15403"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Heparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass).","enzymes":null,"type":"small molecule","cas-number":"9005-49-6","sequences":null,"targets":null,"unii":"P776JQ4R2F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Heparin, bovine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15404"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":226.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"FET F-18 is under investigation in clinical trial NCT01756352 (FET-PET for Evaluation of Response of Recurrent GBM to Avastin).","enzymes":null,"type":"small molecule","cas-number":"178433-03-9","sequences":null,"targets":null,"unii":"1326R5J1IA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":226.098305982,"volume-of-distribution":null,"route-of-elimination":null,"name":"FET F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15405"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":485.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GLPG-0974 is under investigation in clinical trial NCT01721980 (Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects).","enzymes":null,"type":"small molecule","cas-number":"1391076-61-1","sequences":null,"targets":"BE0010131","unii":"X7REK61AIS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":484.1223562,"volume-of-distribution":null,"route-of-elimination":null,"name":"GLPG-0974","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-06-30","drugbank-id":"DB15406"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":401.405,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acalisib is under investigation in clinical trial NCT01705847 (A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies).","enzymes":null,"type":"small molecule","cas-number":"870281-34-8","sequences":null,"targets":null,"unii":"OVW60IDW1D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":401.140036326,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acalisib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15407"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":349.77,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).","enzymes":null,"type":"small molecule","cas-number":"1009820-21-6","sequences":null,"targets":null,"unii":"C6RWP0N0L2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":349.06180435,"volume-of-distribution":null,"route-of-elimination":null,"name":"Silmitasertib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15408"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).","enzymes":null,"type":"biotech","cas-number":"1629760-29-7","sequences":null,"targets":null,"unii":"VM4G5D1A60","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ladiratuzumab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15409"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":341.451,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"(S)-Propafenone is under investigation in clinical trial NCT02710669 (New Formulations of Propafenone to Treat Atrial Fibrillation).","enzymes":null,"type":"small molecule","cas-number":"107381-32-8","sequences":null,"targets":null,"unii":"N0BQN4E2YT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":341.199093733,"volume-of-distribution":null,"route-of-elimination":null,"name":"(S)-Propafenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15410"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":314.341,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ABP-700 is under investigation in clinical trial NCT02800590 (Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy).","enzymes":null,"type":"small molecule","cas-number":"1446482-29-6","sequences":null,"targets":null,"unii":"LZ0835OW2M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":314.126657068,"volume-of-distribution":null,"route-of-elimination":null,"name":"ABP-700","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15411"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":268.313,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).","enzymes":null,"type":"small molecule","cas-number":"1632032-53-1","sequences":null,"targets":null,"unii":"0C1JUU9S0L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":268.142307132,"volume-of-distribution":null,"route-of-elimination":null,"name":"LB-100","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15412"},{"toxicity":"There is limited information on the overdosage profile of pafolacianine.","snp-adverse-drug-reactions":null,"average-mass":1326.49,"transporters":"BE0003659 BE0001066 BE0001004","pharmacodynamics":"Tumor to background ratios changed with different mass doses studied. High tumor to background ratio was observed with 0.025 mg\/kg dose. Pafolacianine exposure-response relationships and the time course of pharmacodynamic responses are unknown.[L39332]","msds":null,"description":"Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption of 776 nm. It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.[L39332] The longer wavelength allows for deeper penetration of the fluorescent light through tissues for better imaging and detection of tumours. Pafolacianine targets the folate receptor alpha (FR) which is upregulated in numerous epithelial malignancies.[A242572]\r\n\r\nOn November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.[L39332] It is currently under investigation for use in FR-positive pituitary adenoma, lung cancer,[A242577] and renal-cell carcinoma, which is thought to be the second-highest folate receptor-expressing cancer.[A242572]","enzymes":null,"type":"small molecule","cas-number":"1628423-76-6","sequences":null,"targets":"BE0003405","unii":"F7BD3Z4X8L","protein-binding":"Plasma protein binding of pafolacianine is 93.7%. No notable partitioning into red blood cells was observed.[L39332]","fda-label":null,"clearance":"The mean plasma clearance is 28.6  4.97 L\/hr.[L39332]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Pafolacianine is consists of folic acid linked by its -carboxyl and a short spacer to an indocyanine green-related near-infrared dye called SO456. It is used for intraoperative fluorescence for tumour identification and surgical resection. It targets the folate receptor alpha (FR), which is often overexpressed in various cancers including ovarian cancer.[A242567] Pafolacianine binds to FR-expressing cancer cells with an affinity of ~1 nM and is internalized via receptor-mediated endocytosis to be concentrated in FR-positive cancer tissues.[L39332] Pafolacianine absorbs light and in the near-infrared (NIR) region within a range of 760 nm to 785 nm with a peak absorption of 776 nm and, upon excitation, emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.[L39332]","drug-interactions":"DB11256 DB02067 DB04789 DB00158 DB00650 DB11596 DB08898 DB00116 DB02031 DB03256","absorption":"The mean C<sub>max<\/sub> of pafolacianine was 59.1  5.94 ng\/mL and AUC<sub>inf<\/sub> was 63.6  12.6 ng x hr\/mL.[L39332]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The elimination half-life of pafolacianine is 0.44  0.23 hours.[L39332]","monoisotopic-mass":1325.353776429,"volume-of-distribution":"The mean volume of distribution (V<sub>z<\/sub>) is 17.1  5.99 L, indicating distribution into tissues.[L39332] During intraoperative molecular imaging for surgically resectable pulmonary adenocarcinoma, pafolacianine accumulated in nearly 70% of squamous cell carcinomas.[A242577]","route-of-elimination":"Following a single intravenous infusion of radiolabeled pafolacianine sodium, approximately 35% of the dose was recovered in urine (19.1%) and in feces (15.8%) after approximately 3-5 weeks.[L39332]","name":"Pafolacianine","metabolism":"The metabolism of pafolacianine is unknown; however, pafolacianine is not metabolized by cytochrome P450 (CYP) enzymes.[L39332]","reactions":null,"indication":"Pafolacianine is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.[L39332]","ahfs-codes":null,"updated":"2021-12-17","drugbank-id":"DB15413"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":467.85,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).","enzymes":null,"type":"small molecule","cas-number":"1130115-44-4","sequences":null,"targets":null,"unii":"41XGO0VS1U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":467.1051328,"volume-of-distribution":null,"route-of-elimination":null,"name":"CM-4307","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15414"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).","enzymes":null,"type":"biotech","cas-number":"1449294-76-1","sequences":null,"targets":null,"unii":"P45C2W27DU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tomaralimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15415"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":554.85,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).","enzymes":null,"type":"small molecule","cas-number":"1268244-88-7","sequences":null,"targets":null,"unii":"378SU5NO8S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":553.0614413,"volume-of-distribution":null,"route-of-elimination":null,"name":"PX-102","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15416"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Recanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).","enzymes":null,"type":"biotech","cas-number":"1667762-62-0","sequences":null,"targets":null,"unii":"9QBH807006","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Recanaclotide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15417"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":399.378,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD-9977 is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers).","enzymes":null,"type":"small molecule","cas-number":"1850385-64-6","sequences":null,"targets":null,"unii":"6C9UKZ0CYE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":399.123048855,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD-9977","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15418"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":394.41,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).","enzymes":null,"type":"small molecule","cas-number":"1256448-47-1","sequences":null,"targets":null,"unii":"YTL7A418KQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB02546 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":394.155352039,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nanatinostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15419"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN Expanded Access Program Prevention of Surgical\/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).","enzymes":null,"type":"biotech","cas-number":"9013-55-2","sequences":null,"targets":null,"unii":"Y42G5XID5M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Coagulation factor XIa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15420"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).","enzymes":null,"type":"biotech","cas-number":"2050478-92-5","sequences":null,"targets":null,"unii":"LYK98WP91F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cetrelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15421"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1023.315,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ILS-920 is under investigation in clinical trial NCT00827190 (Study Evaluating Single Ascending Doses Of ILS-920).","enzymes":null,"type":"small molecule","cas-number":"892494-07-4","sequences":null,"targets":null,"unii":"F2D5P81X82","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1022.607905457,"volume-of-distribution":null,"route-of-elimination":null,"name":"ILS-920","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15422"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1317.664,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Disaccharide tripeptide glycerol dipalmitoyl is under investigation in clinical trial NCT00003667 (Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma).","enzymes":null,"type":"small molecule","cas-number":"130114-83-9","sequences":null,"targets":null,"unii":"6PHSP9EORV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1316.819354779,"volume-of-distribution":null,"route-of-elimination":null,"name":"Disaccharide tripeptide glycerol dipalmitoyl","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15423"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":356.39,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET\/MR in Patients Selected for Ablation Therapy).","enzymes":null,"type":"small molecule","cas-number":"863644-14-8","sequences":null,"targets":null,"unii":"BHG7KQ27XV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":356.122826697,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bfpet F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15424"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":397.527,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed\/Refractory CLL).","enzymes":null,"type":"small molecule","cas-number":"1070790-89-4","sequences":null,"targets":null,"unii":"YET2XNU791","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":397.259008646,"volume-of-distribution":null,"route-of-elimination":null,"name":"CYC-065","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15425"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":745.25,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).","enzymes":null,"type":"small molecule","cas-number":"865200-20-0","sequences":null,"targets":null,"unii":"1W10Q5H7WD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":744.203641,"volume-of-distribution":null,"route-of-elimination":null,"name":"Giripladib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15426"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":372.091,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fialuridine is under investigation in clinical trial NCT01337466 (Biodistribution and Dosimetry Evaluation of [124I]FIAU).","enzymes":null,"type":"small molecule","cas-number":"69123-98-4","sequences":null,"targets":null,"unii":"53T7IN77LC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":371.96184,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fialuridine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15427"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1205533-60-3","sequences":null,"targets":null,"unii":"7SF22186WT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vesencumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15428"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":92.117,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Thioglycolic acid is under investigation in clinical trial NCT03238105 (Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light).","enzymes":null,"type":"small molecule","cas-number":"68-11-1","sequences":null,"targets":null,"unii":"7857H94KHM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":91.993200062,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thioglycolic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15429"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).","enzymes":null,"type":"biotech","cas-number":"1512559-37-3","sequences":null,"targets":null,"unii":"5F1CN52GFM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Elgemtumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15430"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":449.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"M-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).","enzymes":null,"type":"small molecule","cas-number":"1379545-95-5","sequences":null,"targets":null,"unii":"0DXG50I4WD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":449.1230224,"volume-of-distribution":null,"route-of-elimination":null,"name":"M-2698","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15431"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).","enzymes":null,"type":"biotech","cas-number":"1313706-14-7","sequences":null,"targets":null,"unii":"6KA1906BLC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pinatuzumab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15432"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0P93LDFNTU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AVI-7537","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15433"},{"toxicity":"In case of a mosunetuzumab overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be instituted.[L42230] Patients experiencing an overdose are at an increased risk of severe adverse effects such as cytokine release syndrome (CRS), febrile neutropenia, neutropenia and pneumonia.[A249320,L42230] \r\n\r\nPreclinical single- and repeat-dose toxicity studies of up to 26 weeks in duration found that transient CRS was developed mostly after the first dose of mosunetuzumab. Findings suggest that this effect is pharmacologically-mediated and reversible.[L42230] The effect of mosunetuzumab on male and female reproductive organs was evaluated in sexually mature cynomolgus monkeys given an intravenous infusion dose equivalent to the one recommended in patients. Up to 26 weeks, mosunetuzumab did not have an effect on male or female reproductive organs.[L42230] Preclinical studies evaluating the effect of mosunetuzumab on developmental toxicity have not been conducted. Due to the low placental transfer of antibodies during the first trimester, mosunetuzumab is not expected to have a teratogenic effect. However, it can lead to a higher risk of opportunistic infections, which may cause fetal loss.[L42230]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Mosunetuzumab is an anti-CD20\/CD3 bispecific antibody that leads to B-cell depletion (CD19 B-cell counts < 0.07 x 109\/L) and hypogammaglobulinemia (IgG levels < 500 mg\/dL).[L42230] In patients with aggressive non-Hodgkin's lymphoma (NHL) treated with mosunetuzumab, the overall response rate (ORR) was 37.4%, and the complete remission (CR) rate was 19.5%, while patients with indolent NHL treated with mosunetuzumab had an ORR of 62.7% and a CR rate of 43.3%.[A249335] The response to mosunetuzumab in a high-risk group of patients with progression of follicular lymphoma within 24 months after initiating frontline treatment (n=29) was also beneficial; the ORR was 75.9% and the CR rate was 55.2%.[A249335] \r\n\r\nPatients treated with mosunetuzumab may develop cytokine release syndrome (CRS), including life-threatening reactions. CRS mainly occurred on days 1 and 15 of cycle 1. To avoid CRS, patients should receive corticosteroids, antipyretics and antihistamines prior to mosunetuzumab therapy.[L42230] Serious infections such as pneumonia, bacteremia, and sepsis or septic shock have been reported in patients treated with mosunetuzumab, and caution should be exercised in patients with a history of recurring or chronic infections. Tumour flare and tumour lysis syndrome (TLS) have also been reported in patients treated with mosunetuzumab.[L42230]","msds":null,"description":"Mosunetuzumab is a humanized anti-CD20\/CD3 bispecific antibody.[L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells.[A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy. However, patients with certain types of B-cell lymphoma, such as follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence after treatment.[A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel] and [tisagenlecleucel], it is an \u20ACoff-the-shelf\u20AC alternative, readily available to patients.[L42245] In June 2022, the European Medicines Agency approved mosunetuzumab for the treatment of adult patients with relapsed or refractory (R\/R) FL who have received at least two prior systemic therapies.[L42245]","enzymes":null,"type":"biotech","cas-number":"1905409-39-3","sequences":">CD20 Light Chain\nDIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSR\nFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIKRTVAAPSVFIFPPS\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL\nSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC >CD20 Heavy Chain\nEVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSY\nNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTV\nSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ\nSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL\nGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ\nYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR\nEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS\nRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >CD3E Heavy Chain\nEVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKY\nNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSSA\nSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG\nLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP\nSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGS\nTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM\nTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQ\nQGNVFSCSVMHEALHNHYTQKSLSLSPGK >CD3E Light Chain\nDIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTR\nESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIKRTVAAPSV\nFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL\nSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","targets":"BE0000274 BE0000066","unii":"LDJ89SS0YG","protein-binding":"Mosunetuzumab is a bispecific antibody; therefore, protein binding studies were not carried out.[L42230]","fda-label":null,"clearance":"The mean steady-state plateau clearance (CL<sub>ss<\/sub>) of mosunetuzumab is 1.08 L\/day, and its baseline clearance (CL<sub>base<\/sub>) is 0.584 L\/day.","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Ast, O., et al. (2018). Bispecific T cell activating antigen binding molecules (U.S. Patent No. 9,914,776 B2). U.S. Patent and Trademark Office. https:\/\/patentimages.storage.googleapis.com\/e5\/93\/68\/6ded0d607c0070\/US9914776.pdf","mechanism-of-action":"Mosunetuzumab is a full-length, humanized anti-CD20\/CD3 bispecific antibody that targets CD20-expressing B-cells.[A249320,L42230] Unlike B-cell-targeting monoclonal antibodies, such as [rituximab], mosunetuzumab can recognize and bind two different targets, CD20 on cancer B-cells and CD3 on T-cells in a 1:1 ratio.[A249320,A249335] Mosunetuzumab is a conditional agonist; the targeted killing of CD20-expressing B-cells is observed only when this drug is simultaneously bound to CD20 on B-cells and CD3 on T-cells. Mosunetuzumab recruits T-cells and leads to their activation by promoting the formation of an immunologic synapse between a target B-cell and a cytotoxic T-cell. The activation of T-cells leads to the directed release of perforin and granzymes through the immunologic synapsis, which ultimately induces B-cell lysis and cell death.[L42230]","drug-interactions":"DB05209 DB08880 DB00328 DB14905 DB00928 DB00682 DB15274 DB13400 DB09381 DB06474 DB06647 DB15091 DB11959 DB09052 DB13259 DB06679 DB12034 DB11857 DB15857 DB08814 DB14039 DB12023 DB12289 DB00204 DB00540 DB09570 DB06305 DB00092 DB00970 DB00637 DB15035 DB15898 DB04951 DB14877 DB00034 DB00814 DB11604 DB12344 DB00562 DB12978 DB13886 DB00642 DB13068 DB05232 DB14811 DB13510 DB00495 DB00232 DB11921 DB11884 DB00105 DB11685 DB13199 DB11746 DB15118 DB06228 DB01223 DB00305 DB01086 DB06772 DB16650 DB14997 DB00277 DB01229 DB12815 DB12235 DB00321 DB07615 DB06602 DB15646 DB12386 DB12053 DB01590 DB13843 DB09030 DB14012 DB00806 DB09035 DB13867 DB14891 DB16611 DB13017 DB01075 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB06599 DB13136 DB11828 DB06310 DB00853 DB01396 DB08865 DB14864 DB09105 DB11044 DB14685 DB12520 DB10804 DB12396 DB00278 DB13208 DB05797 DB15119 DB09082 DB09383 DB00543 DB05656 DB00851 DB06557 DB12274 DB11680 DB13140 DB05676 DB10584 DB00959 DB11003 DB06607 DB15443 DB11703 DB01320 DB00281 DB00773 DB14897 DB13578 DB09074 DB00008 DB00120 DB00028 DB00547 DB12104 DB15001 DB00945 DB12261 DB00428 DB12849 DB06813 DB13954 DB12826 DB12844 DB10990 DB01033 DB04962 DB15861 DB11866 DB12205 DB01240 DB00987 DB12498 DB12726 DB11715 DB00599 DB00012 DB00324 DB00276 DB10061 DB01204 DB00098 DB01281 DB00758 DB11502 DB11621 DB01100 DB16385 DB00113 DB01035 DB12246 DB11641 DB15627 DB05942 DB04868 DB00002 DB00086 DB04949 DB08881 DB06595 DB00552 DB00877 DB13535 DB12364 DB07767 DB01257 DB00031 DB00908 DB00775 DB12335 DB00890 DB04901 DB11976 DB06616 DB00033 DB01005 DB12119 DB00091 DB09045 DB06271 DB14711 DB00498 DB12545 DB14952 DB00054 DB05111 DB01109 DB08894 DB15626 DB14540 DB00180 DB16225 DB06589 DB00872 DB12698 DB13073 DB08870 DB11731 DB14776 DB00266 DB10276 DB01015 DB08906 DB01410 DB11771 DB13124 DB05304 DB14055 DB00022 DB12893 DB15090 DB06695 DB09107 DB16755 DB13014 DB05437 DB14919 DB15135 DB12001 DB05459 DB12015 DB14211 DB12363 DB00526 DB15865 DB12943 DB10283 DB12584 DB15899 DB00601 DB09369 DB00977 DB05276 DB12891 DB15415 DB17088 DB00993 DB11914 DB16170 DB00072 DB11095 DB11988 DB14619 DB06371 DB00307 DB11674 DB15045 DB01269 DB06550 DB01234 DB16355 DB02709 DB06322 DB05099 DB06635 DB03451 DB08994 DB06605 DB00635 DB11616 DB14445 DB13976 DB14066 DB00363 DB10317 DB14967 DB15089 DB13149 DB16736 DB13979 DB09063 DB11834 DB01206 DB05679 DB10062 DB05006 DB00297 DB09154 DB12147 DB09378 DB09318 DB00606 DB15656 DB14022 DB09122 DB00069 DB08813 DB12025 DB14843 DB12589 DB00999 DB06606 DB11756 DB09053 DB15160 DB14907 DB13874 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB05109 DB00432 DB12530 DB01227 DB01195 DB08896 DB01225 DB01097 DB16265 DB00015 DB00394 DB00065 DB06543 DB15718 DB05892 DB13386 DB01816 DB01118 DB12532 DB12267 DB12089 DB09303 DB08904 DB13616 DB08059 DB08910 DB00055 DB15880 DB12487 DB14959 DB12917 DB12845 DB00569 DB06192 DB08794 DB01161 DB05015 DB11708 DB00550 DB15628 DB00043 DB12976 DB09559 DB01357 DB01008 DB01041 DB11730 DB09033 DB09345 DB11826 DB01418 DB01108 DB14004 DB09009 DB00875 DB06241 DB12749 DB00057 DB11603 DB06372 DB00112 DB01280 DB09342 DB14094 DB01181 DB06603 DB10600 DB05793 DB10769 DB01384 DB00591 DB10794 DB09095 DB06168 DB06049 DB01248 DB00774 DB16659 DB01099 DB13683 DB14996 DB12996 DB16222 DB06043 DB01207 DB11945 DB11050 DB08908 DB11363 DB08879 DB13924 DB00076 DB06366 DB09037 DB00252 DB11478 DB01047 DB00763 DB05550 DB06662 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB00619 DB01268 DB09317 DB14824 DB16376 DB15453 DB11580 DB05239 DB01002 DB00445 DB12142 DB11984 DB14545 DB05555 DB03523 DB13367 DB14580 DB00290 DB00322 DB16195 DB02546 DB09259 DB00188 DB00564 DB12189 DB00398 DB00110 DB11581 DB06294 DB09077 DB13003 DB06406 DB15428 DB00075 DB04905 DB14724 DB05101 DB10343 DB12947 DB00078 DB16648 DB06584 DB00755 DB04956 DB06081 DB05136 DB12159 DB14443 DB01166 DB11856 DB04898 DB06101 DB00073 DB06643 DB14449 DB12560 DB12797 DB14394 DB05496 DB06287 DB04630 DB12157 DB00675 DB12609 DB05916 DB01611 DB05889 DB06467 DB12102 DB14783 DB00441 DB10989 DB04958 DB11040 DB00480 DB00248 DB12342 DB06626 DB01601 DB00242 DB09070 DB12090 DB14988 DB15432 DB14384 DB14620 DB06774 DB03410 DB00645 DB00291 DB08895 DB06688 DB15363 DB01254 DB00111 DB01088 DB09283 DB01270 DB01242 DB00068 DB04665 DB00436 DB01380 DB13418 DB15810 DB01169 DB01656 DB11598 DB00208 DB14947 DB09330 DB09085 DB08887 DB15441 DB15383 DB12991 DB00859 DB11487 DB13275 DB12771 DB14962 DB06441 DB15349 DB00997 DB15654 DB05941 DB11930 DB06050 DB09167 DB00296 DB05294 DB01151 DB12612 DB01138 DB00443 DB04845 DB11817 DB11041 DB13327 DB06162 DB06779 DB14385 DB05144 DB00694 DB12489 DB09264 DB05472 DB04932 DB00864 DB00446 DB13328 DB01024 DB12773 DB12456 DB06273 DB05325 DB15483 DB12317 DB12413 DB06317 DB14809 DB00721 DB00688 DB12807 DB00750 DB00892 DB00039 DB04743 DB09289 DB01196 DB06681 DB00544 DB00261 DB01013 DB15334 DB00089 DB09260 DB05767 DB09042 DB11693 DB09143 DB11466 DB05097 DB08971 DB15786 DB12692 DB11840 DB11312 DB04914 DB09075 DB13375 DB16732 DB12568 DB00115 DB06176 DB09054 DB14512 DB11038 DB08987 DB01262 DB12202 DB13045 DB12321 DB00860 DB00016 DB11148 DB15595 DB06360 DB13646 DB00051 DB10318 DB14908 DB12820 DB15941 DB10803 DB13929 DB15113 DB13430 DB00063 DB09073 DB00588 DB00029 DB00696 DB00095 DB01177 DB14845 DB00026 DB11529 DB05578 DB00488 DB00958 DB00286 DB12701 DB15101 DB00458 DB02806 DB14778 DB11166 DB00880 DB12331 DB09255 DB14762 DB15335 DB06754 DB00407 DB06186 DB15559 DB00437 DB09091 DB00697 DB00009 DB10991 DB10805 DB11850 DB08868 DB08902 DB15409 DB15014 DB08871 DB00907 DB00380 DB00337 DB12902 DB05440 DB11986 DB00527 DB12296 DB08875 DB13143 DB16694 DB01324 DB01222 DB16695 DB16394 DB13856 DB14539 DB15225 DB12250 DB00309 DB14042 DB11963 DB09258 DB04573 DB00269 DB05266 DB12213 DB12371 DB12483 DB16077 DB08912 DB00444 DB12240 DB06650 DB12598 DB16393 DB01073 DB13036 DB08816 DB11646 DB15252 DB01423 DB00570 DB00056 DB14409 DB01128 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB14707 DB12683 DB08889 DB01030 DB00320 DB04855 DB00489 DB13923 DB16421 DB05229 DB16151 DB09302 DB12617 DB13347 DB00530 DB00563 DB00013 DB01174 DB00975 DB08877 DB05915 DB12118 DB00655 DB14871 DB06822 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB11657 DB12775 DB14568 DB06400 DB00011 DB04988 DB14513 DB01285 DB05996 DB12465 DB00686 DB12092 DB11767 DB13952 DB05139 DB09256 DB06304 DB08496 DB11595 DB09029 DB15258 DB13532 DB00961 DB00764 DB00807 DB00795 DB05260 DB08935 DB05545 DB15076 DB11972 DB13241 DB16703 DB00059 DB06116 DB05254 DB15461 DB14040 DB06674 DB12163 DB15900 DB09331 DB00293 DB06212 DB06209 DB13223 DB14041 DB00726 DB13200 DB12831 DB13127 DB10583 DB05361 DB05258 DB15719 DB12445 DB00361 DB00620 DB04574 DB03255 DB07931 DB15044 DB01021 DB00575 DB06770 DB06769 DB11608 DB15104 DB11862 DB11627 DB04925 DB05336 DB11714 DB12152 DB13451 DB11776 DB12016 DB00001 DB15253 DB08827 DB06324 DB12534 DB04964 DB10316 DB15336 DB00946 DB11849 DB05773 DB14597 DB01101 DB04572 DB15940 DB14219 DB09057 DB12718 DB00762 DB06343 DB00074 DB00974 DB13037 DB06342 DB00255 DB05405 DB12077 DB01168 DB00515 DB00262 DB00541 DB01042 DB00006 DB09312 DB00687 DB14726 DB00005 DB10315 DB04575","absorption":"Between 0.05 and 60 mg, mosunetuzumab follows a dose-proportional pharmacokinetic profile. The population pharmacokinetics of intravenous mosunetuzumab are described with a two-compartment pharmacokinetic model with time-dependent clearance.[L42230] After two cycles of mosunetuzumab (42 days, given by intravenous infusion), patients reached a C<sub>max<\/sub> of 17.9 g\/mL at the end of dose of Cycle 2 Day 1. The average AUC of two cycles of mosunetuzumab was 126 g\u2039\u2026day\/mL.[L42230]  In patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated with mosunetuzumab, serum concentration reached the C<sub>max<\/sub> at the end of the intravenous infusion and declined in a bi-exponential fashion.[L42230] \r\n\r\nMosunetuzumab is expected to have a bioavailability close to 100% when given intravenously. In clinical trials, mosunetuzumab administered subcutaneously had a slow absorption rate and high bioavailability (>75%).[A249335] The pharmacokinetics of mosunetuzumab was similar in Asian and non-Asian subjects. Compared to males, the steady-state clearance of mosunetuzumab in females is marginally lower (approximately 13%), and dose adjustment based on gender is not required.[L42230]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Mosunetuzumab has a terminal half-life of 16.1 days,[L42230] and an apparent half-life between 6 and 11 days.[A249320]","monoisotopic-mass":null,"volume-of-distribution":"The estimated central volume of distribution for mosunetuzumab administered via intravenous infusion is 5.49 L.[L42230]","route-of-elimination":"Since mosunetuzumab is an immunoglobulin G (IgG) antibody, it is expected to be mainly eliminated via intracellular catabolism. Hepatic or renal impairment is not expected to influence the elimination of mosunetuzumab.[L42230]","name":"Mosunetuzumab","metabolism":"Mosunetuzumab is a protein therapeutic; it is expected to be degraded into small peptides and amino acids via catabolic pathways.[L42230]","reactions":null,"indication":"Mosunetuzumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.[L42230]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15434"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":495.627,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).","enzymes":null,"type":"small molecule","cas-number":"1800340-40-2","sequences":null,"targets":null,"unii":"X8BW0MQ5PI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":495.263425323,"volume-of-distribution":null,"route-of-elimination":null,"name":"BMS-986158","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15435"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":437.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Glucoraphanin is under investigation in clinical trial NCT01879878 (Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]).","enzymes":null,"type":"small molecule","cas-number":"1432982-77-8","sequences":null,"targets":null,"unii":"Q86A197713","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":437.048409467,"volume-of-distribution":null,"route-of-elimination":null,"name":"Glucoraphanin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15436"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":601.606,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rocacetrapib is under investigation in clinical trial NCT02156544 (Study to Investigate the Safety\/Tolerability and Pharmacokinetics\/Pharmacodynamics of CKD-519).","enzymes":null,"type":"small molecule","cas-number":"1402796-27-3","sequences":null,"targets":null,"unii":"K9SP3L3YQP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":601.2426911,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rocacetrapib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15437"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Artemin is under investigation in clinical trial NCT01842126 (Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)).","enzymes":null,"type":"biotech","cas-number":"309758-71-2","sequences":null,"targets":null,"unii":"ST1KS15P0T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Artemin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15438"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":316.376,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1402837-78-8","sequences":null,"targets":null,"unii":"926SHL95NC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":316.158706087,"volume-of-distribution":null,"route-of-elimination":null,"name":"Navoximod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15439"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":403.523,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK-3117391 is under investigation in clinical trial NCT02965599 (Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis).","enzymes":null,"type":"small molecule","cas-number":"1018673-42-1","sequences":null,"targets":null,"unii":"CKA3P0O1VI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":403.247106555,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK-3117391","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15440"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjgren's Syndrome).","enzymes":null,"type":"biotech","cas-number":"1421830-13-8","sequences":null,"targets":null,"unii":"LCT264LTYE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lulizumab pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15441"},{"toxicity":"Data regarding overdoses of trilaciclib are not readily available.[L31828] For grade 3 or worse injection site reactions, acute drug hypersensitivity reactions, and interstitial lung disease; or any other grade 4 toxicities; permanently discontinue trilacilib.[L31828]","snp-adverse-drug-reactions":null,"average-mass":446.559,"transporters":"BE0003647 BE0003657 BE0001067 BE0001032 BE0004752","pharmacodynamics":"Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.[L31828] It has a short duration of action of approximately 16 hours, and a narrow therapeutic index.[A229313,L31828] Patients should be counselled regarding the risk of injection site reactions, hypersensitivity, and interstitial lung disease.[L31828]","msds":null,"description":"Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.[A229313]\r\n\r\nTrilaciclib was granted FDA approval on 12 February 2021.[L31823]","enzymes":"BE0002433","type":"small molecule","cas-number":"1374743-00-6","sequences":null,"targets":"BE0002207 BE0001072 BE0002212 BE0001913 BE0000890 BE0002216","unii":"U6072DO9XG","protein-binding":"Data regarding the protein binding of trilaciclib are not readily available.[L31828]","fda-label":null,"clearance":"The clearance of trilaciclib is 158 L\/h.[L31828]","atc-codes":"ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment VARIOUS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Trilaciclib is inhibits cyclin-dependant kinase 4 (CDK4) at a concentration of 1 nmol\/L and cyclin-dependent kinase 5 (CDK5) at 4 nmol\/L.[A229313,L31828] Inhibition of CDK2, CDK5, and CDK7 is over 1000-fold less at these concentrations and inhibition of CDK9 is 50-fold less.[A229313]\r\n\r\nCDK4 and CDK5 are expressed in hematopoietic stem cells and progenitor cells.[A229293] They are capable of phosphorylating and inactivating the retinoblastoma protien; a tumor suppressor.[A229313,A229323] When trilaciclib is given to patients with retinoblastoma protein-null small cell lung cancer, it does not interfere with the intended chemotherapy induced cytotoxicity of cancer cells.[A229313] Inhibition of CDK4 and CDK5 leads to a reversible pause in the cell cycle in the G1 phase for approximately 16 hours.[A229313] The temporary cell cycle arrest prevents chemotherapy induced DNA damage in healthy cells, reducing the activity of caspases 3 and 7, which reduces apoptosis of healthy cells.[A229313]\r\n\r\nOther studies have shown inhibitors of CDK4 and CDK6 enhance T-cell activation, upregulating major histocompatibility complex (MHC) class I and II, and stabilize programmed death-ligand 1 (PD-L1).[A229293] Together these activities increase T-cell activity, increase antigen presentation, and sensitize cells to immune checkpoint inhibitors.[A229293]","drug-interactions":"DB08880 DB00682 DB14649 DB12457 DB00742 DB00382 DB00540 DB00204 DB01142 DB00970 DB08828 DB05381 DB04951 DB00338 DB12035 DB09273 DB12945 DB00845 DB14006 DB00280 DB05708 DB00642 DB14132 DB13878 DB06228 DB01223 DB00957 DB01086 DB06772 DB00277 DB00368 DB00321 DB00503 DB11919 DB00863 DB06148 DB01129 DB00220 DB01590 DB09030 DB00806 DB04908 DB11855 DB00798 DB12825 DB01273 DB09076 DB00631 DB01065 DB01558 DB11828 DB01396 DB11901 DB00390 DB08865 DB13203 DB00787 DB00358 DB04356 DB00851 DB05676 DB08820 DB00281 DB11827 DB00268 DB00834 DB00773 DB01259 DB01051 DB03467 DB13954 DB13879 DB12332 DB00370 DB11979 DB05521 DB11951 DB00758 DB09161 DB01191 DB01100 DB01035 DB11641 DB04881 DB04868 DB14723 DB08881 DB00788 DB11575 DB06479 DB00877 DB01182 DB06290 DB14018 DB12364 DB01184 DB08930 DB00908 DB06616 DB00091 DB12406 DB05039 DB09225 DB11633 DB14973 DB06292 DB00612 DB11689 DB11613 DB00299 DB06589 DB00872 DB08870 DB00420 DB00980 DB05928 DB00203 DB00213 DB06695 DB00668 DB12001 DB06448 DB02703 DB00586 DB00715 DB00784 DB13573 DB00526 DB00175 DB11952 DB00334 DB04851 DB00977 DB00468 DB00924 DB01333 DB00993 DB12010 DB00641 DB00915 DB15328 DB13955 DB00629 DB06654 DB01234 DB11978 DB01137 DB12026 DB02134 DB06605 DB01094 DB01412 DB00363 DB11869 DB00316 DB04871 DB09183 DB01435 DB09063 DB00122 DB00206 DB08838 DB12500 DB12147 DB06237 DB09288 DB11757 DB00568 DB00882 DB13874 DB00831 DB00783 DB01195 DB12836 DB08896 DB00532 DB01097 DB13449 DB00394 DB00988 DB01118 DB15133 DB12267 DB08910 DB00176 DB05015 DB09296 DB11712 DB00921 DB01058 DB01418 DB11574 DB06207 DB00201 DB00196 DB14068 DB00396 DB08840 DB11652 DB06603 DB00978 DB08893 DB00379 DB01026 DB09118 DB00661 DB01037 DB01303 DB16222 DB11697 DB04889 DB00502 DB00932 DB04948 DB11363 DB06235 DB11853 DB14011 DB01056 DB00195 DB01167 DB13953 DB13956 DB00384 DB00619 DB01268 DB01405 DB01002 DB05239 DB04847 DB06670 DB12799 DB09078 DB00518 DB11672 DB11800 DB05667 DB00188 DB00398 DB11581 DB12531 DB08864 DB13634 DB09065 DB07348 DB09291 DB06191 DB11362 DB09241 DB01232 DB00295 DB08931 DB01482 DB01263 DB14069 DB00442 DB14989 DB01166 DB01211 DB08995 DB00879 DB12941 DB06287 DB00675 DB00904 DB06403 DB05889 DB00441 DB15569 DB00709 DB11732 DB06626 DB00248 DB01601 DB06774 DB00625 DB09048 DB08907 DB01267 DB01242 DB01254 DB11760 DB00836 DB01169 DB01656 DB00477 DB06210 DB09330 DB01685 DB12597 DB06234 DB00349 DB01394 DB00457 DB04854 DB00296 DB05294 DB09343 DB11753 DB04845 DB11817 DB00461 DB00300 DB09027 DB09239 DB03783 DB00864 DB01367 DB04841 DB11995 DB14631 DB13592 DB00934 DB00544 DB00261 DB00317 DB06636 DB14126 DB11693 DB01043 DB13812 DB12713 DB02568 DB09075 DB06176 DB13125 DB09054 DB00969 DB00972 DB04076 DB12466 DB01623 DB02489 DB04540 DB00966 DB00539 DB00567 DB00408 DB09073 DB00286 DB01203 DB00458 DB11586 DB12265 DB00537 DB01004 DB00080 DB06637 DB04216 DB00730 DB00331 DB11791 DB00697 DB09280 DB00360 DB00536 DB00740 DB00356 DB00499 DB00199 DB09071 DB11986 DB09079 DB00857 DB02115 DB00285 DB11963 DB01264 DB12483 DB00950 DB12455 DB00571 DB11642 DB08912 DB08882 DB12598 DB00574 DB08816 DB09039 DB09297 DB00570 DB08934 DB04348 DB08901 DB00744 DB08916 DB09102 DB06240 DB08889 DB01030 DB04855 DB01667 DB00530 DB12377 DB11796 DB00315 DB06216 DB11770 DB13952 DB12070 DB12927 DB09256 DB11644 DB08496 DB00850 DB01079 DB00365 DB01087 DB14754 DB00795 DB12245 DB16703 DB14840 DB11967 DB06212 DB06419 DB01261 DB08883 DB00726 DB09061 DB15719 DB00448 DB00998 DB04574 DB00862 DB16236 DB01136 DB00909 DB00575 DB01424 DB06770 DB00243 DB01645 DB06769 DB00413 DB09034 DB08827 DB01012 DB01628 DB15149 DB05773 DB00425 DB06594 DB13055 DB12141 DB12926 DB01233 DB00255 DB15822 DB13007 DB09290 DB12887 DB00262 DB00515 DB00472 DB00541 DB00898 DB01115 DB00533 DB15982 DB01388","absorption":"C<sub>max<\/sub> and AUC of trilaciclib increase proportionally with dose.[A229328,L31828]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean terminal half life of trilaciblib is approximately 14 h.[L31828]","monoisotopic-mass":446.254257618,"volume-of-distribution":"The volume of distribution of trilaciclib at steady state is 1130 L.[L31828]","route-of-elimination":"79.1% of a radiolabelled dose is recovered in the feces, 7% as the unchanged parent compound.[L31828] 14% of a radiolabelled dose is recovered in the urine, 2% as the unchanged parent compound.[L31828]","name":"Trilaciclib","metabolism":"Data regarding the metabolism of trilaciclib are not readily available, however it is expected to be extensively metabolised.[L31828]","reactions":null,"indication":"Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.[L31828]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15442"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).","enzymes":null,"type":"biotech","cas-number":"2131168-99-3","sequences":null,"targets":null,"unii":"PL21OR4LXE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lorukafusp alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15443"},{"toxicity":"As elexacaftor is currently only available in the combination product Trikafta<sup>TM<\/sup> (ivacaftor\/tezacaftor\/elexacaftor), data regarding overdose of elexacaftor on its own is unavailable.[L9395] Treatment of Trikafta<sup>TM<\/sup> overdose should consist of general supportive and symptomatic treatment, including monitoring of vital signs and close observation of the affected patient.","snp-adverse-drug-reactions":null,"average-mass":597.66,"transporters":"BE0003659 BE0001004 BE0001032","pharmacodynamics":"As a CFTR corrector, elexacaftor works to increase the amount of mature CFTR proteins present on the surface of cells.[L9395] When used in combination with CFTR potentiators, which enhance the function of cell-surface CFTR proteins, drugs like elexacaftor help to improve a variety of multi-organ cystic fibrosis symptoms, including lung function, nutritional status, and overall quality of life.[A187361] Trikafta<sup>TM<\/sup>, the triple combination product containing elexacaftor, may cause elevations in liver transaminases. Liver function testing should be conducted prior to beginning Trikafta, every 3 months for the first year of treatment, and annually thereafter.[L9395]","msds":null,"description":"Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM<\/sup>.[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor.[A187361] While dual corrector\/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for the _F508del-CFTR_ gene.[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or produces proteins unresponsive to ivacaftor or tezacaftor.[A187361] The triple combination product Trikafta<sup>TM<\/sup>, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- _or_ heterozygous for the _F508del-CFTR_  gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients.","enzymes":"BE0002887 BE0003536 BE0003549 BE0002363 BE0002362 BE0002638 BE0002793 BE0002433","type":"small molecule","cas-number":"2216712-66-0","sequences":null,"targets":"BE0001195","unii":"RRN67GMB0V","protein-binding":"Elexacaftor is >99% protein bound in plasma, primarily to albumin.[L9395]","fda-label":null,"clearance":"The mean apparent clearance of elexacaftor is 1.18 L\/h.[L9395]","atc-codes":"Other respiratory system products OTHER RESPIRATORY SYSTEM PRODUCTS RESPIRATORY SYSTEM","pdb-entries":false,"food-interactions":"Take with a high fat meal. Examples include food prepared with eggs, cheeses, nuts, oils, and butter. Avoid St. John's Wort. This herb induces CYP3A metabolism and may reduce serum levels of elexacaftor. Avoid grapefruit products. Co-administration of grapefruit can inhibit elexacaftor metabolism and increase serum concentrations.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Cystic fibrosis (CF) is the result of a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.[A187373] The CFTR proteins produced by this gene are transmembrane ion channels that move sodium and chloride across cell membranes - water follows the flow of chloride ions to the cell surface, which consequently helps to hydrate the surface of the cell and thin the secretions (i.e. mucous) around the cell.[A187373] Mutations in the CFTR gene produce CFTR proteins of insufficient quantity and\/or function, leading to defective ion transport and a build-up of thick mucous throughout the body that causes multi-organ disease involving the pulmonary, gastrointestinal, and pancreatic systems (amongst others). The most common CFTR mutation, the _F508del_ mutation, is estimated to account for 70[A187373] to 90%[A187361,A187355] of all CFTR mutations and results in severe processing and trafficking defects of the CFTR protein.[A187358]\r\n\r\nElexacaftor is a CFTR corrector that modulates CFTR proteins to facilitate trafficking to the cell surface for incorporation into the cell membrane.[L9395] The end result is an increase in the number of mature CFTR proteins present at the cell surface and, therefore, improved ion transport and CF symptomatology. Elexacaftor is used in combination with tezacaftor, another CFTR corrector with a different mechanism of action, and ivacaftor, a CFTR potentiator that improves the function of CFTR proteins on the cell surface - this multi-faceted, triple-drug approach confers a synergistic effect beyond that seen in typical corrector\/potentiator dual therapy regimens.[L9395,A187361]","drug-interactions":"DB01873 DB11459 DB00682 DB14652 DB08953 DB12095 DB14649 DB13456 DB00656 DB00916 DB09570 DB00204 DB00540 DB06712 DB00637 DB12130 DB15035 DB12020 DB09185 DB12978 DB00338 DB14633 DB00845 DB00177 DB11921 DB06228 DB01223 DB00957 DB06772 DB00962 DB00277 DB00557 DB01229 DB12235 DB00321 DB00503 DB00973 DB12952 DB00220 DB01590 DB13843 DB09030 DB05316 DB00490 DB13867 DB04957 DB00700 DB00531 DB08970 DB00912 DB12825 DB11855 DB00769 DB11828 DB01127 DB01396 DB11901 DB00390 DB00741 DB08865 DB01039 DB00367 DB11823 DB00246 DB13208 DB01381 DB09383 DB14541 DB05814 DB00714 DB00778 DB00481 DB00301 DB00238 DB02520 DB05676 DB06739 DB00959 DB11703 DB00281 DB01320 DB00136 DB00834 DB00773 DB13943 DB01323 DB01319 DB14659 DB01259 DB09074 DB01624 DB06717 DB13409 DB02659 DB00820 DB01062 DB09299 DB13954 DB14009 DB13879 DB12332 DB00370 DB14635 DB01216 DB00731 DB11979 DB11932 DB11742 DB13287 DB11951 DB01281 DB00758 DB05521 DB11739 DB01100 DB06233 DB09101 DB11641 DB00607 DB04868 DB00917 DB11575 DB00549 DB08881 DB06595 DB06119 DB00877 DB06290 DB14960 DB09142 DB01184 DB00908 DB06616 DB00738 DB00091 DB09227 DB00584 DB11633 DB11689 DB14540 DB00180 DB00949 DB06589 DB00872 DB01201 DB08870 DB00819 DB06199 DB09046 DB01015 DB08906 DB01152 DB00214 DB16390 DB05928 DB01583 DB09238 DB00203 DB00668 DB00951 DB12001 DB04839 DB06448 DB12015 DB02703 DB00175 DB11952 DB14019 DB00648 DB08873 DB09309 DB00241 DB00977 DB00468 DB01333 DB11936 DB00270 DB12010 DB00641 DB13955 DB00307 DB01093 DB01234 DB02709 DB04856 DB12026 DB00582 DB06605 DB00312 DB00363 DB00316 DB09063 DB04884 DB00206 DB00418 DB00313 DB06201 DB12147 DB08905 DB06237 DB00822 DB11757 DB09053 DB06721 DB13874 DB09068 DB00705 DB00783 DB05109 DB01227 DB00734 DB06663 DB08896 DB00624 DB00224 DB11400 DB00394 DB00604 DB00065 DB01118 DB12267 DB12089 DB08904 DB00776 DB08910 DB00559 DB03010 DB11886 DB12917 DB00454 DB00176 DB11383 DB01053 DB01095 DB12391 DB00401 DB01008 DB01041 DB11730 DB01092 DB00921 DB01058 DB01418 DB11574 DB08884 DB00343 DB00622 DB06789 DB11560 DB00196 DB00396 DB06372 DB00590 DB01181 DB06603 DB11652 DB00812 DB13345 DB01114 DB06414 DB01384 DB00591 DB00818 DB11470 DB01275 DB01026 DB09095 DB06168 DB01248 DB08862 DB00615 DB00849 DB00717 DB00661 DB08909 DB09118 DB00404 DB11697 DB00502 DB00932 DB11363 DB00252 DB01045 DB09001 DB01047 DB11853 DB08933 DB14761 DB00763 DB00353 DB01016 DB01054 DB13956 DB01011 DB06318 DB14011 DB13953 DB01167 DB00619 DB01268 DB01071 DB05239 DB13385 DB00603 DB00520 DB14545 DB00518 DB00745 DB11672 DB15566 DB00188 DB05667 DB00564 DB00398 DB00330 DB01173 DB11581 DB06730 DB08864 DB09065 DB08899 DB07348 DB13003 DB13944 DB06469 DB11362 DB04896 DB11752 DB04905 DB16098 DB09241 DB14724 DB01587 DB01232 DB13950 DB01263 DB14185 DB00636 DB00755 DB04956 DB01166 DB01609 DB09235 DB06791 DB08995 DB01211 DB14681 DB06287 DB00675 DB00904 DB06403 DB00528 DB01029 DB14542 DB08836 DB01369 DB00954 DB15569 DB01431 DB04946 DB00215 DB00248 DB06626 DB01601 DB01072 DB06774 DB06218 DB00625 DB09048 DB01267 DB01154 DB01242 DB01483 DB01254 DB09272 DB00357 DB00485 DB01380 DB01656 DB06700 DB00477 DB09330 DB06413 DB01685 DB09237 DB01023 DB00859 DB12597 DB11487 DB00349 DB00997 DB11805 DB05294 DB01151 DB06652 DB14921 DB00250 DB11753 DB01138 DB00443 DB05903 DB06335 DB11405 DB04845 DB08860 DB06442 DB11779 DB00694 DB00864 DB00446 DB06273 DB00688 DB14631 DB09289 DB00627 DB01013 DB00104 DB00317 DB06636 DB09143 DB08971 DB13179 DB01110 DB06176 DB09054 DB14512 DB00976 DB09308 DB14575 DB00860 DB00972 DB04832 DB00273 DB04070 DB00051 DB00497 DB04911 DB00829 DB11442 DB00163 DB01098 DB00207 DB00244 DB00567 DB11915 DB00197 DB09073 DB00588 DB13139 DB00696 DB00333 DB00026 DB00286 DB11586 DB12265 DB05154 DB01149 DB01076 DB09280 DB01224 DB15011 DB13338 DB00802 DB00499 DB00759 DB09071 DB00199 DB06697 DB00794 DB11986 DB09079 DB01222 DB09119 DB14539 DB01351 DB12161 DB00857 DB00309 DB11963 DB00514 DB09137 DB01264 DB12371 DB00950 DB14646 DB12483 DB00571 DB11642 DB08912 DB00608 DB00444 DB08882 DB01352 DB08816 DB09297 DB00570 DB04348 DB15762 DB01128 DB12151 DB00041 DB08901 DB09102 DB01406 DB09036 DB04794 DB00320 DB04855 DB09099 DB01395 DB00530 DB00563 DB01007 DB01174 DB08877 DB11737 DB00678 DB06268 DB09279 DB14568 DB04920 DB04894 DB01285 DB11767 DB05482 DB13952 DB12070 DB01032 DB00439 DB09256 DB12301 DB01218 DB13941 DB09231 DB12515 DB00279 DB00938 DB09029 DB01764 DB00764 DB01126 DB01087 DB12245 DB00647 DB06674 DB06370 DB00501 DB01103 DB06212 DB06419 DB08883 DB00342 DB00896 DB06458 DB06267 DB00897 DB00400 DB06731 DB06174 DB12266 DB15719 DB09061 DB00227 DB14240 DB00620 DB00361 DB00862 DB01190 DB16236 DB00673 DB00909 DB00683 DB00575 DB00243 DB01645 DB14669 DB06587 DB00669 DB12016 DB09034 DB08827 DB01238 DB01628 DB00946 DB05773 DB04572 DB01183 DB00762 DB12141 DB11837 DB00247 DB06342 DB00255 DB15822 DB12887 DB00472 DB00541 DB00898 DB01115 DB00533 DB00701 DB00005 DB15982 DB01388 DB11273","absorption":"The absolute oral bioavailability of elexacaftor is approximately 80%. The steady-state AUC<sub>0-24h<\/sub> and C<sub>max<\/sub> following once daily dosing with elexacaftor 200mg are 162 mcgh\/mL and 8.7 mcg\/mL, respectively, and the median T<sub>max<\/sub> is 6 hours.[L9395] The AUC of elexacaftor is increased 1.9-2.5-fold following a moderate-fat meal - for this reason, it is recommended to give Trikafta<sup>TM<\/sup> with fat-containing food.[L9395]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The mean terminal half-life of elexacaftor is approximately 24.7 hours.[L9395]","monoisotopic-mass":597.234508266,"volume-of-distribution":"The apparent volume of distribution of elexacaftor is 53.7 L.[L9395]","route-of-elimination":"Approximately 87.3% of an administered radio-labeled dose of elexacaftor was found in the feces, mostly as metabolites, while only 0.23% of that same dose was found excreted in the urine.[L9395]","name":"Elexacaftor","metabolism":"The metabolism of elexacaftor is extensive and primarily catalyzed via CYP3A4\/5.[L9395] Its main active metabolite, M23-ELX, carries a similar potency as the parent drug.[L9395] The precise metabolic pathway of elexacaftor has not yet been elucidated in published research.","reactions":null,"indication":"Elexacaftor, in combination with [ivacaftor] and [tezacaftor] as the combination product Trikafta<sup>TM<\/sup>, is indicated for the treatment of cystic fibrosis (CF) in patients 12 years of age and older who have at least one _F508del_ mutation in the CTFR gene.[L9395]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15444"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":305.071,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Iodohippuric acid is under investigation in clinical trial NCT02599844 (Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults).","enzymes":null,"type":"small molecule","cas-number":"147-58-0","sequences":null,"targets":null,"unii":"3Y68K91A3M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00391","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":304.95489,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iodohippuric acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15445"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":355.365,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).","enzymes":null,"type":"small molecule","cas-number":"717824-30-1","sequences":null,"targets":null,"unii":"8Y1PJ3VG81","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":355.121986227,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vidofludimus","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15446"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":206.285,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Setogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alstrm Syndrome).","enzymes":null,"type":"small molecule","cas-number":"1002101-19-0","sequences":null,"targets":null,"unii":"879OVM0Y1S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":206.13067982,"volume-of-distribution":null,"route-of-elimination":null,"name":"Setogepram","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15447"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":385.427,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).","enzymes":null,"type":"small molecule","cas-number":"836683-15-9","sequences":null,"targets":null,"unii":"2F16KW647L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":385.153874872,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acumapimod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15448"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":467.95,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +\/- Lenalidomide for Smoldering MM).","enzymes":null,"type":"small molecule","cas-number":"1316215-12-9","sequences":null,"targets":null,"unii":"441P620G3P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":467.1724174,"volume-of-distribution":null,"route-of-elimination":null,"name":"Citarinostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15449"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":428.463,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-05105679 is under investigation in clinical trial NCT01393652 (Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679).","enzymes":null,"type":"small molecule","cas-number":"1398583-31-7","sequences":null,"targets":null,"unii":"F2B10OFV7Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":428.153620707,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-05105679","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15450"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SOBI-003 is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZS87P77DQC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"SOBI-003","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15451"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Technetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"E6G32D6WP9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Technetium Tc-99m epratuzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15452"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).","enzymes":null,"type":"biotech","cas-number":"1607824-64-5","sequences":null,"targets":null,"unii":"WE1X5A83B9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Naratuximab emtansine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15453"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cenersen is under investigation in clinical trial NCT02243124 (A Study of Aezea (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)).","enzymes":null,"type":"biotech","cas-number":"415168-49-9","sequences":null,"targets":null,"unii":"K6KJ8AZ05F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cenersen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15455"},{"toxicity":"Data regarding overdosage with vericiguat are unavailable. Doses of up to 15mg once daily (50% greater than the recommended maintenance dose) have been studied and found to be well-tolerated. Symptoms of overdose are likely to be consistent with the adverse effect profile of vericiguat and may therefore involve significant hypotension for which symptomatic and supportive measures should be provided. Dialysis is unlikely to be of benefit in vericiguat overdose given its high degree of protein binding.[L31153]","snp-adverse-drug-reactions":null,"average-mass":426.388,"transporters":"BE0001032 BE0001067","pharmacodynamics":"By directly stimulating the increased production of intracellular cyclic guanosine monophosphate (cGMP), vericiguat causes the relaxation of vascular smooth muscle and vasodilation.[L31153] Vericiguat has a relatively long half-life (~30h) that allows for once-daily dosing.[L31153]\r\n\r\nAnimal reproduction studies have demonstrated the potential for embryo-fetal toxicity when vericiguat is administered to pregnant females - defects in major vessel and heart formation, as well as spontaneous abortions\/resorptions, were observed when vericiguat was administered to pregnant rabbits during organogenesis.[L31153] The possibility of pregnancy should be excluded prior to beginning therapy with vericiguat, and adequate contraception should be used throughout therapy and for one month following cessation of treatment.[L31153]","msds":null,"description":"Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations.[L31153] A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst other cell types) that catalyze the synthesis of cyclic guanosine monophosphate (cGMP) in response to activation by nitric oxide (NO).[A227458,A227488] Cyclic GMP acts as a second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated deficiencies in its production (primarily due to insufficient NO bioavailability) in the pathogenesis of various cardiovascular diseases.[A227458] As a direct stimulator of sGC, vericiguat mitigates the need for a functional NO-sGC-cGMP axis and thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC activity in heart failure.[L31178]\r\n\r\nVericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.[L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.","enzymes":"BE0003538 BE0003541","type":"small molecule","cas-number":"1350653-20-1","sequences":null,"targets":"BE0010029","unii":"LV66ADM269","protein-binding":"Vericiguat is extensively (~98%) protein-bound in plasma, primarily to serum albumin.[L31153]","fda-label":null,"clearance":"Vericiguat is a low-clearance drug, with an observed plasma clearance of 1.6 L\/h in healthy volunteers and 1.3 L\/h in patients with systolic heart failure.[L31153,A227478]","atc-codes":"Other vasodilators used in cardiac diseases CARDIOVASCULAR SYSTEM VASODILATORS USED IN CARDIAC DISEASES CARDIAC THERAPY","pdb-entries":null,"food-interactions":"Take with food. Administration with food has been shown to reduce pharmacokinetic variability and significantly improve absorption.","state":"solid","synthesis-reference":"Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trubel H, Sandner P, Stasch JP: Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021\/acs.jmedchem.7b00449. Epub 2017 Jun 12.","mechanism-of-action":"Heart failure (HF) involves, amongst other morphologic and physiologic changes, the impaired synthesis of nitric oxide (NO) and decreased activity of soluble guanylate cyclase (sGC). Functioning normally, NO binds to sGC and stimulates the synthesis of intracellular cyclic guanosine monophosphate (cGMP),[A227488] a second messenger involved in the maintenance of vascular tone, as well as cardiac contractility and remodeling. Defects in this pathway are thought to contribute to the myocardial and vascular dysfunction associated with heart failure and are therefore a desirable target in its treatment.[L31153,A227458]\r\n\r\nVericiguat directly stimulates sGC by binding to a target site on its beta-subunit,[A227488] bypassing the need for NO-mediated activation, and in doing so causes an increase in the production of intracellular cGMP that results in vascular smooth muscle relaxation and vasodilation.[L31153]","drug-interactions":"DB04899 DB13400 DB00887 DB00742 DB00178 DB06712 DB11792 DB13875 DB13876 DB01612 DB09273 DB12945 DB09253 DB01247 DB00177 DB01200 DB00232 DB00800 DB08941 DB01229 DB01020 DB09026 DB01235 DB00421 DB08822 DB00700 DB00631 DB08932 DB00492 DB11738 DB01295 DB04846 DB13604 DB00714 DB09206 DB04017 DB00519 DB09363 DB00268 DB01320 DB04818 DB13452 DB00820 DB15861 DB00708 DB01240 DB09249 DB00599 DB08550 DB08950 DB00086 DB12661 DB07767 DB09251 DB00691 DB14217 DB09227 DB00584 DB11633 DB06292 DB00612 DB00614 DB00598 DB00866 DB00872 DB00925 DB14207 DB00214 DB09238 DB00203 DB00476 DB11720 DB08952 DB09220 DB00784 DB14213 DB00237 DB00334 DB00601 DB01347 DB00899 DB00241 DB01158 DB01626 DB12054 DB00270 DB12010 DB00629 DB00753 DB09242 DB06654 DB00706 DB09477 DB00695 DB00960 DB00312 DB01359 DB00881 DB00363 DB13429 DB00206 DB00418 DB00297 DB00606 DB00722 DB06237 DB00999 DB00633 DB15226 DB00734 DB00903 DB08896 DB00861 DB01118 DB00594 DB04840 DB01143 DB09243 DB00559 DB08960 DB09250 DB01170 DB00401 DB01041 DB00343 DB13312 DB00622 DB14068 DB14094 DB00590 DB00474 DB00350 DB00780 DB00212 DB01355 DB00818 DB01275 DB00323 DB12212 DB00774 DB00849 DB01037 DB00661 DB13779 DB00692 DB04948 DB00486 DB00252 DB01045 DB01116 DB09001 DB01244 DB09245 DB11783 DB01054 DB00195 DB13801 DB00384 DB01002 DB00398 DB09077 DB09236 DB11362 DB01193 DB09241 DB06445 DB08931 DB00295 DB09292 DB14185 DB00755 DB09235 DB01609 DB00310 DB13374 DB06403 DB00528 DB01029 DB00373 DB08836 DB00785 DB01180 DB08907 DB01154 DB01088 DB01483 DB00679 DB01242 DB00436 DB01169 DB01236 DB00797 DB00477 DB00922 DB06210 DB00883 DB00335 DB06762 DB01023 DB09237 DB00681 DB00374 DB00457 DB00296 DB00796 DB00264 DB11632 DB09204 DB09254 DB09239 DB00752 DB01367 DB00886 DB00721 DB00808 DB00325 DB00381 DB01018 DB00805 DB01282 DB13757 DB04820 DB13211 DB12766 DB13803 DB13166 DB04831 DB00966 DB13435 DB09517 DB00616 DB01203 DB09038 DB00458 DB01119 DB00880 DB03322 DB00697 DB01224 DB13919 DB09112 DB01340 DB00765 DB00794 DB01324 DB01351 DB00187 DB00226 DB05266 DB00571 DB14208 DB00703 DB12093 DB13443 DB09248 DB00041 DB00542 DB00393 DB08808 DB04861 DB00489 DB13575 DB00657 DB00876 DB01174 DB00975 DB00678 DB06268 DB09279 DB04920 DB11770 DB01089 DB12465 DB01189 DB12092 DB00435 DB01144 DB14125 DB13532 DB09232 DB13508 DB09246 DB08935 DB05271 DB00275 DB09252 DB06267 DB09061 DB00862 DB01136 DB01348 DB00575 DB01021 DB13410 DB13631 DB00968 DB01159 DB00413 DB00790 DB13609 DB09244 DB01171 DB00727 DB01238 DB01162 DB09286 DB01090 DB00217 DB01197 DB01113 DB01168 DB00898 DB01115 DB00524 DB01580 DB04552 DB01388 DB01297","absorption":"Following the administration of 10mg of vericiguat by mouth once daily, the average steady-state C<sub>max<\/sub> and AUC in patients with heart failure is 350 mcg\/L and 6,680 mcg\u20ACh\/L, respectively, with a T<sub>max<\/sub> of 1 hour.[L31153] The absolute bioavailability of orally-administered vericiguat is approximately 93% when taken with food - co-administration with meals has been shown to reduce pharmacokinetic variability, increase T<sub>max<\/sub> to roughly 4 hours, and increase C<sub>max<\/sub> and AUC by 41% and 44%, respectively.[L31153]","created":"2019-05-20","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"In patients with heart failure, the half-life of vericiguat is 30 hours.[L31153]","monoisotopic-mass":426.136428113,"volume-of-distribution":"In healthy subjects the steady-state volume of distribution of vericiguat is approximately 44 liters.[L31153]","route-of-elimination":"Following the oral administration of radiolabeled vericiguat, approximately 53% of the administered radioactivity was recovered in the urine and 45% in the feces.[L31153] A human mass balance study found that the portion recovered in the urine comprised approximately 40.8% N-glucuronide metabolite, 7.7% other metabolites, and 9% unchanged parent drug, while virtually the entire portion recovered in the feces comprised unchanged vericiguat.[A227478]","name":"Vericiguat","metabolism":"Vericiguat is primarily metabolized via phase II conjugation reactions, with CYP-mediated oxidative metabolism comprising a small (<5%) portion of its overall biotransformation. The major inactive metabolite, vericiguat N-glucuronide (M1), is formed by UGT1A9 and, to a lesser extent, UGT1A1.[L31153] Other identified metabolites include a denbenzylated compound[A227458] and an M15 metabolite thought to be the result of oxidative metabolism,[A227478] although these metabolites are poorly characterized.","reactions":null,"indication":"Vericiguat is indicated in adults with symptomatic, chronic heart failure and an ejection fraction of <45% to reduce the risk of cardiovascular death and heart failure-related hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics.[L31153]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15456"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":257.32,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).","enzymes":null,"type":"small molecule","cas-number":"1226795-18-1","sequences":null,"targets":null,"unii":"I8WEG59XVM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":257.065232203,"volume-of-distribution":null,"route-of-elimination":null,"name":"Snubh-nm-333 F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15457"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":131.1729,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women).","enzymes":null,"type":"small molecule","cas-number":"327-57-1","sequences":null,"targets":null,"unii":"832C8OV84S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":131.094628665,"volume-of-distribution":null,"route-of-elimination":null,"name":"Norleucine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15458"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":476.548,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects with osteoarthritis).","enzymes":null,"type":"small molecule","cas-number":"920289-29-8","sequences":null,"targets":null,"unii":"WO23I2827Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":476.211135585,"volume-of-distribution":null,"route-of-elimination":null,"name":"AGG-523","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15460"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Yersinia pestis 195\/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"G10832YT0L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01410 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB04845 DB11817 DB00764 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB06603 DB01204 DB01013 DB00620 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00515 DB00262 DB11569 DB06589 DB00588 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00180 DB00445 DB00005 DB00687 DB08906 DB02806 DB03523","absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Yersinia pestis 195\/p antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15461"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":658.92,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects. In vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. Fucoxanthin regulates lipids metabolism, the effect most likely mediated by AMK-activated protein kinase. A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.","enzymes":null,"type":"small molecule","cas-number":"3351-86-8","sequences":null,"targets":null,"unii":"06O0TC0VSM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-05-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":658.423339588,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fucoxanthin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB15462"},{"toxicity":"Data regarding overdosage with belzutifan is lacking. There is no specific treatment available for belzutifan overdose - if a patient is suspected to have overdosed, immediately withhold belzutifan and institute standard supportive care. Grade 3 hypoxia has been observed at doses of 120mg twice daily and Grade 4 thrombocytopenia has been observed at doses of 240mg once daily (twice the recommended dose).[L35995]","snp-adverse-drug-reactions":null,"average-mass":383.34,"transporters":"BE0003659 BE0001004 BE0001032 BE0004752","pharmacodynamics":"Belzutifan exerts its therapeutic effects by inhibiting a transcription factor necessary for the growth of solid tumors associated with VHL disease.[L35995] It is taken once daily at approximately the same time each day, with or without food. Both severe anemia and hypoxia have been observed following therapy with belzutifan, and patients should be monitored closely before and during therapy to ensure patients can be managed as clinically indicated. There are no data regarding the use of erythropoiesis-stimulating agents for the treatment of belzutifan-induced anemia, and as such these therapies should be avoided.[L35995]\r\n\r\nBelzutifan may cause embryo-fetal toxicity when administered to pregnant women. Female patients and male patients with female partners of reproductive potential should ensure that an effective form of contraception is used throughout therapy and for one week after the last dose - as belzutifan appears to decrease the efficacy of systemic hormonal contraceptives, patients should be advised to use an additional method of contraception (e.g. condoms) to eliminate the possibility of pregnancy during therapy.[L35995]","msds":null,"description":"Belzutifan is an inhibitor of hypoxia-inducible factor 2 (HIF-2) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers.[L35995] The HIF-2 protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.[L36105] Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2 molecule which allowed for compounds to bind and inhibit these proteins. This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired by Merck in 2019).[L36105]\r\n\r\nBelzutifan inhibits the complexation of HIF-2 with another transcription factor, HIF-1, a necessary step in its activation - by preventing the formation of this complex, belzutifan can slow or stop the growth of VHL-associated tumors. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021.[L36000]","enzymes":"BE0002638 BE0003536 BE0003680","type":"small molecule","cas-number":"1672668-24-4","sequences":null,"targets":"BE0009679","unii":"7K28NB895L","protein-binding":"Plasma protein-binding is approximately 45%, although data regarding the specific proteins to which belzutifan binds are unavailable.[L35995]","fda-label":null,"clearance":"The mean clearance of belzutifan following oral administration is 7.3 L\/h.[L35995]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Other antineoplastic agents","pdb-entries":false,"food-interactions":"Take with or without food. The administration of food with belzutifan has no clinically meaningful effect on its disposition.","state":"solid","synthesis-reference":"Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD, Czerwinski RM, Du X, Ged EL, Han G, Tan H, Wong T, Xie S, Josey JA, Wallace EM: 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a Hypoxia-Inducible Factor 2alpha (HIF-2alpha) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019 Aug 8;62(15):6876-6893. doi: 10.1021\/acs.jmedchem.9b00719. Epub 2019 Jul 8.","mechanism-of-action":"Hypoxia-inducible factor 2 (HIF-2) is a transcription factor which aids in oxygen sensing by regulating genes that promote adaptation to hypoxia.[L35995] In healthy patients, when oxygen levels are normal, HIF-2 is broken down via ubiquitin-proteasomal degradation by von-Hippel Lindau (VHL) proteins. In the presence of hypoxia, HIF-2 translocates into cell nuclei and forms a transcriptional complex with hypoxia-inducible factor 1 (HIF-1) - this complex then induces the expression of downstream genes associated with cellular proliferation and angiogenesis.[L35995] \r\n\r\nPatients with von-Hippel Lindau (VHL) disease lack functional VHL proteins, leading to an accumulation of HIF-2, and this accumulation is what drives the growth of VHL-associated tumors. Belzutifan is an inhibitor of HIF-2 that prevents its complexation with HIF-1 in conditions of hypoxia or impaired VHL protein function, thereby reducing the expression of HIF-2 target genes and slowing\/stopping the growth of VHL-associated tumors.[L35995]","drug-interactions":"DB00328 DB00682 DB09198 DB13259 DB09570 DB06712 DB00204 DB00540 DB01142 DB00637 DB15035 DB08828 DB12020 DB04951 DB00814 DB12978 DB00338 DB05232 DB01223 DB00395 DB00957 DB01086 DB06772 DB00277 DB01229 DB00321 DB00503 DB01129 DB01590 DB00665 DB04066 DB01075 DB00531 DB11828 DB01396 DB11901 DB08865 DB01039 DB00367 DB11823 DB05676 DB06739 DB11703 DB00281 DB01320 DB13981 DB00834 DB00773 DB01323 DB13578 DB01259 DB09074 DB13563 DB13954 DB14009 DB12332 DB14635 DB00599 DB00012 DB11979 DB11739 DB01281 DB00758 DB05812 DB11502 DB01100 DB11641 DB04868 DB08881 DB00549 DB06595 DB06119 DB00877 DB13310 DB00908 DB06616 DB00738 DB00091 DB11633 DB14973 DB00351 DB00598 DB08894 DB01175 DB11689 DB00949 DB06589 DB00872 DB01201 DB08870 DB00980 DB05928 DB00983 DB14055 DB09238 DB00203 DB00213 DB09107 DB00951 DB12001 DB04839 DB06448 DB12015 DB12319 DB00715 DB00334 DB01120 DB00977 DB00468 DB01093 DB00823 DB06654 DB00582 DB01241 DB06605 DB00312 DB00304 DB00363 DB01435 DB09063 DB00294 DB00313 DB00297 DB12147 DB12500 DB12025 DB05246 DB13874 DB09068 DB14678 DB00705 DB00783 DB05109 DB01227 DB04682 DB08896 DB00624 DB09166 DB00532 DB00065 DB12532 DB01118 DB12267 DB08867 DB00776 DB08910 DB08904 DB12917 DB00176 DB01104 DB01161 DB01095 DB01357 DB01041 DB01008 DB11730 DB00921 DB09345 DB01058 DB01418 DB09009 DB00622 DB00196 DB06789 DB00396 DB06372 DB11636 DB09342 DB00590 DB01181 DB06603 DB06713 DB13685 DB00780 DB06414 DB01355 DB01026 DB00052 DB06168 DB01248 DB00615 DB00849 DB13866 DB09118 DB00717 DB00661 DB13683 DB00932 DB11363 DB00252 DB01045 DB08933 DB00763 DB01016 DB13956 DB13953 DB00619 DB01268 DB01002 DB05239 DB00603 DB00518 DB00745 DB00188 DB00564 DB00398 DB00330 DB11581 DB06266 DB06730 DB08864 DB06684 DB08899 DB13944 DB01006 DB09241 DB14724 DB04956 DB00736 DB06287 DB00675 DB00373 DB00215 DB00248 DB06626 DB11507 DB11638 DB06774 DB00625 DB06218 DB00645 DB01242 DB01254 DB00679 DB01483 DB00208 DB06413 DB09330 DB01685 DB09085 DB12597 DB09120 DB00349 DB00997 DB09167 DB00296 DB05294 DB14921 DB11753 DB05830 DB14583 DB04845 DB06442 DB11619 DB00752 DB00864 DB00446 DB13328 DB06273 DB00721 DB14975 DB06804 DB05351 DB00750 DB00892 DB09289 DB15093 DB09143 DB01043 DB01131 DB01110 DB08987 DB06176 DB09054 DB14575 DB00016 DB00972 DB11148 DB13857 DB00273 DB00051 DB04911 DB00829 DB00966 DB09073 DB00696 DB00333 DB00026 DB00470 DB00458 DB12265 DB04216 DB09280 DB00259 DB14025 DB00907 DB06697 DB00794 DB11986 DB00527 DB09119 DB13044 DB00309 DB11963 DB13762 DB12371 DB09389 DB12483 DB00571 DB08912 DB00444 DB12474 DB00347 DB00570 DB15762 DB01128 DB08901 DB09036 DB04861 DB00320 DB04855 DB01395 DB00530 DB00563 DB01007 DB01174 DB08877 DB00678 DB06268 DB14568 DB04920 DB12070 DB01032 DB13941 DB08496 DB09029 DB00961 DB00807 DB09371 DB12245 DB06674 DB00501 DB06212 DB13528 DB06731 DB09061 DB00448 DB00361 DB04574 DB00673 DB00909 DB03255 DB00575 DB01424 DB06770 DB01171 DB08827 DB01628 DB00946 DB09123 DB05773 DB04572 DB00425 DB00762 DB11837 DB00255 DB00472 DB00541 DB00898 DB00701 DB00005","absorption":"In patients with VHL disease-associated renal cell carcinoma, the mean C<sub>max<\/sub> and AUC<sub>0-24h<\/sub> at steady-state - which was achieved after approximately three days of therapy - were 1.3 g\/mL and 16.7 g\u20AChr\/mL, respectively.[L35995] The median T<sub>max<\/sub> is one to two hours following oral administration.[L35995]\r\n\r\nThe administration of belzutifan with food has a negligible effect on drug disposition - when given alongside a high-calorie, high-fat meal, the T<sub>max<\/sub> was delayed by approximately 2 hours with no other clinically meaningful effects observed.[L35995]","created":"2019-05-21","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean elimination half-life of belzutifan is 14 hours.[L35995]","monoisotopic-mass":383.043913533,"volume-of-distribution":"The steady-state volume of distribution of belzutifan following oral administration is approximately 130 L.[L35995]","route-of-elimination":null,"name":"Belzutifan","metabolism":"Belzutifan is primarily metabolized by UGT2B17 and CYP2C19, and to a lesser extent by CYP3A4.[L35995]","reactions":null,"indication":"Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), who do not require immediate surgery.[L35995]","ahfs-codes":null,"updated":"2021-08-28","drugbank-id":"DB15463"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":228.2002,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.[A179494]","enzymes":null,"type":"small molecule","cas-number":"1143-70-0","sequences":null,"targets":null,"unii":"ILJ8NEF6DT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-06-18","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":228.042258744,"volume-of-distribution":null,"route-of-elimination":null,"name":"Urolithin A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15464"},{"toxicity":"Overdosage with benzhydrocodone presents as opioid intoxication including respiratory depression, somnolence, coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death.[L4894]\r\n\r\nIn case of oversdosage the foremost priority is the maintenance of a patent and protected airway with the provision of assisted ventilation if necessary. Supportive measures such as IV fluids, supplemental oxygen, and vasopressors may be used to manage circulatory shock.[L4894] Advanced life support may be necessary in the case of cardiac arrest or arrhythmias. Opioid antagonists such as [naloxone] may be used to reverse the respiratory and circulatory effects of hydrocodone. Emergency monitoring is still required after naloxone administration as the opioid effects may reappear. Additionally, if used in an opioid tolerant patient, naloxone may produce opioid withdrawal symptoms.","snp-adverse-drug-reactions":null,"average-mass":403.478,"transporters":null,"pharmacodynamics":"Benzhydrocodone is rapidly metabolized to [hydrocodone] which acts on the central nervous system to produce analgesia. The action of hydrocodone in the brain can also produce euphoria, leading to addiction.","msds":null,"description":"Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.[A182177] Benzhydrocodone is indicated for use in the short-term management of pain. It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]","enzymes":null,"type":"small molecule","cas-number":"1259440-61-3","sequences":null,"targets":null,"unii":"75MS0AAZ9I","protein-binding":null,"fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15465.pdf?1564593506","clearance":"The apparent clearance of the hydrocodone metabolite is 64.4 L\/h.[A182150]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with or without food. Co-administration with food slightly alters pharmacokinetics, but not to a clinically significant extent. Avoid alcohol. Ingesting alcohol may increase the CNS depressive effects of benzhydrocodone. Apadaz also contains acetaminophen, which, when combined with alcohol, may increase the risk of hepatotoxicity.","state":"solid","synthesis-reference":"U.S. Patent 2018 \/ 0055836 A1.","mechanism-of-action":"Benzyhydrocodone is not reported to have pharmacological activity of its own and it not present in the plasma at detectable concentrations. Its active metabolite, [hydrocodone] is a mu-opioid receptor agonist.","drug-interactions":"DB01345 DB08953 DB14028 DB14719 DB12710 DB00219 DB00887 DB00742 DB00656 DB01545 DB13642 DB00540 DB00737 DB01142 DB07715 DB06230 DB13695 DB01215 DB00387 DB00562 DB01548 DB13505 DB00280 DB13252 DB00232 DB01409 DB09484 DB13703 DB01337 DB00395 DB13792 DB00424 DB01556 DB01209 DB01595 DB15477 DB13303 DB00321 DB00810 DB13354 DB06711 DB00732 DB13754 DB13738 DB01246 DB00475 DB01535 DB00421 DB00463 DB14504 DB01075 DB00700 DB11855 DB09076 DB00546 DB01558 DB01148 DB01339 DB01551 DB00246 DB01577 DB00777 DB00209 DB13636 DB00543 DB11057 DB09462 DB00230 DB11827 DB09480 DB00181 DB11228 DB09481 DB01579 DB00332 DB13468 DB01555 DB01062 DB12404 DB01466 DB15861 DB00708 DB11490 DB01622 DB00245 DB01046 DB13787 DB00581 DB00599 DB15478 DB13180 DB00835 DB13837 DB13584 DB00758 DB00670 DB09015 DB00623 DB13233 DB14018 DB00908 DB00402 DB00372 DB08861 DB00652 DB09409 DB06292 DB13940 DB01175 DB00872 DB09125 DB00819 DB00420 DB13769 DB00214 DB09300 DB00967 DB00476 DB06738 DB12080 DB09020 DB13284 DB00715 DB00327 DB00237 DB00334 DB13542 DB00899 DB00241 DB13414 DB00468 DB01484 DB00924 DB00941 DB00915 DB00753 DB12013 DB13624 DB00695 DB00312 DB09413 DB01412 DB00363 DB08801 DB01638 DB08838 DB04884 DB00628 DB00418 DB01231 DB01459 DB09414 DB04843 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB00231 DB01566 DB11110 DB00999 DB00937 DB01625 DB14963 DB11540 DB00831 DB00082 DB13454 DB00311 DB01227 DB13617 DB13784 DB00903 DB09166 DB00852 DB09449 DB11582 DB00842 DB00594 DB01199 DB08960 DB14651 DB16165 DB00454 DB00176 DB01104 DB00505 DB14516 DB11315 DB13678 DB11235 DB00921 DB00035 DB01192 DB00496 DB00622 DB14502 DB01450 DB11477 DB13606 DB11189 DB15889 DB11113 DB00690 DB13913 DB13213 DB01355 DB00774 DB00849 DB01615 DB00555 DB00423 DB06787 DB00404 DB01531 DB12543 DB14881 DB01365 DB01511 DB00942 DB01116 DB09483 DB13989 DB00801 DB01063 DB13801 DB13335 DB00384 DB13254 DB14500 DB00956 DB13420 DB00660 DB13759 DB09000 DB00572 DB01173 DB04833 DB01105 DB13648 DB13486 DB04896 DB00854 DB00843 DB11609 DB00182 DB01354 DB09241 DB13357 DB13437 DB01587 DB01608 DB00704 DB00295 DB01378 DB12670 DB00340 DB09235 DB08890 DB05710 DB00310 DB09049 DB01614 DB12537 DB13666 DB14546 DB01377 DB09089 DB00215 DB01591 DB01567 DB13745 DB13526 DB00771 DB01576 DB08907 DB00202 DB00517 DB01483 DB00679 DB12704 DB09272 DB00436 DB14715 DB14684 DB06700 DB00477 DB06480 DB01239 DB00354 DB06702 DB13448 DB00804 DB05687 DB12942 DB13324 DB00565 DB00349 DB09167 DB01621 DB01151 DB08961 DB13663 DB09311 DB00725 DB09017 DB00813 DB00376 DB01255 DB00433 DB14499 DB14672 DB00508 DB01226 DB00865 DB08897 DB00721 DB13413 DB01467 DB00808 DB01442 DB00934 DB12278 DB00191 DB00042 DB12693 DB08992 DB01589 DB08997 DB13170 DB01565 DB00083 DB11691 DB00747 DB02925 DB00383 DB00653 DB04832 DB12766 DB06204 DB13803 DB00497 DB00483 DB00829 DB00940 DB04831 DB12341 DB13295 DB00986 DB13430 DB00504 DB09472 DB00333 DB14627 DB12221 DB04816 DB09287 DB00458 DB00880 DB01149 DB09262 DB11089 DB00392 DB09007 DB00697 DB12554 DB09219 DB01224 DB12492 DB11365 DB00802 DB00356 DB14232 DB00907 DB01288 DB00794 DB01509 DB00680 DB01433 DB01036 DB01324 DB13844 DB01351 DB01594 DB01403 DB04834 DB12526 DB00462 DB00514 DB00434 DB00844 DB11059 DB01219 DB09104 DB01352 DB00371 DB00703 DB12086 DB08816 DB09338 DB01353 DB13643 DB11097 DB01489 DB09174 DB13108 DB04823 DB13619 DB01496 DB01529 DB13380 DB01395 DB00657 DB01454 DB00767 DB13850 DB13405 DB04824 DB01174 DB01497 DB00318 DB06274 DB13996 DB14513 DB13351 DB01544 DB01144 DB00933 DB06264 DB14585 DB15959 DB00728 DB00850 DB01079 DB13532 DB13708 DB06153 DB13160 DB00366 DB13720 DB00647 DB14503 DB01588 DB06370 DB01069 DB11107 DB09268 DB06212 DB00342 DB13382 DB00897 DB06731 DB13872 DB06800 DB00909 DB00683 DB13500 DB00306 DB01021 DB00575 DB00186 DB11622 DB13581 DB14482 DB13369 DB01238 DB09023 DB13707 DB12585 DB01090 DB08918 DB01336 DB08892 DB15360 DB01338 DB01183 DB11130 DB00611 DB13478 DB01559 DB01135 DB09281 DB01233 DB01081 DB01553 DB01178 DB00472 DB09401 DB00898 DB00782 DB13507 DB00524 DB01068 DB05034","absorption":"The absorption profile of benzhydrocodone meets the FDA bioequivalence requirements for similar hydrocodone immediate-release products.[L4894] Benzhydrocodone itself is rapidly metabolized by intestinal enzymes to the active metabolite, hydrocodone, with no detectable benzhydrocodone reaching circulation. Single oral doses of 6.67 mg benzhydrocodone produces a Cmax of 19.18 ng\/mL with a Tmax of 1.25 h and an AUC of 125.73 h*ng\/mL. Administration with food may slightly delay absorption but has no significant effect on AUC.","created":"2019-07-31","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The hydrocodone metabolite has a half life of elimination of 4.5 h.[L4894]","monoisotopic-mass":403.178358289,"volume-of-distribution":"The hydrocodone metabolite of benzhydrocodone has an apparent volume of distribution of 714 L.[A182150]","route-of-elimination":"The hydrocodone metabolite is eliminated through a mix of metabolism and renal excretion.[L4894,A182150]","name":"Benzhydrocodone","metabolism":"Benzhydrocodone is rapidly metabolized to hydrocodone by intestinal enzymes.[L4894] Hydrocodone undergoes oxidative metabolism by CYP3A4 and CYP2D6 which contribute to N-demethylation and O-demethylation respectively.[L4894,A14920] The dealkylated metabolites undergo further 6-ketoreduction to the 6-- and 6--hydroxy metabolites as well as glucuronide conjugation.[A182114]","reactions":null,"indication":"Benzyhydrocodone is indicated, in combination with [acetaminophen], for the short-term management of acute pain requiring opioid therapy.[L4894]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15465"},{"toxicity":"Tallimustine is associated with myelotoxicity severe enough to stop its development.[A182036,A182039]","snp-adverse-drug-reactions":null,"average-mass":697.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of -halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity\/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]","enzymes":null,"type":"small molecule","cas-number":"115308-98-0","sequences":null,"targets":"BE0004796","unii":"71193OXG6S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":"Cozzi P: The discovery of a new potential anticancer drug: a case history. Farmaco. 2003 Mar;58(3):213-20. doi: 10.1016\/S0014-827X(03)00014-4.","mechanism-of-action":"Tallimustine binds to the minor groove of DNA while avoiding targets like glutathione.[A182039] Currently, the mechanism of DNA minor groove binding agents is poorly understood.[A182048] Though, they may act by directly inhibiting the interaction of protein and DNA.[A182048]","drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2019-08-01","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":696.2454551,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tallimustine","metabolism":null,"reactions":null,"indication":"Tallimustine was being investigated for its use in treating tumors.[A182036,A182039] Derivatives of tallimustine with similar DNA binding ability and reduced myelotoxicity are being investigated for their antitumor activity.[A182039]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15466"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":250.294,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"104-28-9","sequences":null,"targets":null,"unii":"5437O7N5BH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-13","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":250.12050906,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cinoxate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15467"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":766.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"154702-15-5","sequences":null,"targets":null,"unii":"2UTZ0QC864","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-13","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":765.457768028,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iscotrizinol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15468"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":823.092,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"88122-99-0","sequences":null,"targets":null,"unii":"XQN8R9SAK4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-13","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":822.504383869,"volume-of-distribution":null,"route-of-elimination":null,"name":"Octyl triazone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15469"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"195189-17-4","sequences":null,"targets":null,"unii":"235435CH6L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Minretumomab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15470"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"According to Zymeworks, \"ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumor activity in preclinical models of breast and gastric cancers.\"[L8219]","enzymes":null,"type":"biotech","cas-number":"2169946-15-8","sequences":null,"targets":null,"unii":"Z20OC92TDI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-28","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zanidatamab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15471"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"According to Zymeworks, \"ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload.\"[L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies, and other HER2 expressing solid tumors.","enzymes":null,"type":"biotech","cas-number":"2329698-82-8","sequences":null,"targets":null,"unii":"HKH2GV9PVO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-28","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zanidatamab zovodotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15472"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemagglutinin-strain B (Victoria-like)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15473"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemagglutinin-strain B (Yamagata-like)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15474"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemagglutinin-strain A(H3N2)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-11-30","drugbank-id":"DB15475"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemagglutinin-strain A(H1N1)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-11-30","drugbank-id":"DB15476"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":418.398,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"8015-61-0","sequences":null,"targets":null,"unii":"W41H6S09F4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB00219 DB00887 DB00742 DB08980 DB00540 DB06712 DB00737 DB01142 DB07715 DB13695 DB00387 DB00562 DB15465 DB13505 DB00280 DB13252 DB00232 DB01409 DB09484 DB01337 DB13792 DB00424 DB01209 DB00321 DB00810 DB07615 DB00732 DB13738 DB01535 DB00421 DB00463 DB14504 DB01075 DB00700 DB11855 DB09076 DB01148 DB01339 DB01551 DB00246 DB00777 DB00209 DB13636 DB09234 DB00543 DB11057 DB09462 DB11827 DB11228 DB09481 DB00332 DB13468 DB01062 DB01555 DB01466 DB15861 DB00708 DB00245 DB01046 DB13787 DB00581 DB00599 DB00835 DB13488 DB13584 DB00670 DB09015 DB14018 DB00908 DB00652 DB08861 DB09227 DB06292 DB14064 DB01175 DB00872 DB09125 DB00819 DB00420 DB13769 DB00214 DB09300 DB00967 DB09238 DB06738 DB09020 DB13284 DB00715 DB00327 DB00237 DB00334 DB06694 DB13542 DB00899 DB00241 DB00270 DB00941 DB13835 DB00915 DB00753 DB00695 DB00312 DB09413 DB01412 DB00363 DB14066 DB08801 DB01638 DB08838 DB00418 DB01231 DB00809 DB01459 DB09414 DB04843 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB11110 DB00999 DB00979 DB00568 DB05246 DB01625 DB14963 DB00311 DB13454 DB01227 DB13617 DB00903 DB09449 DB14063 DB01118 DB00594 DB01199 DB08960 DB16165 DB00454 DB00505 DB14516 DB11315 DB11960 DB13678 DB00401 DB06283 DB11235 DB00921 DB01192 DB13725 DB00875 DB00343 DB00496 DB00622 DB14502 DB14068 DB04838 DB01450 DB06446 DB13766 DB13606 DB11189 DB15889 DB11113 DB01355 DB00774 DB00849 DB00555 DB00661 DB06787 DB01531 DB14881 DB00942 DB01116 DB01244 DB13989 DB01054 DB13801 DB00384 DB13254 DB14500 DB00956 DB13759 DB00572 DB01173 DB13961 DB08162 DB13648 DB09236 DB13486 DB00854 DB11609 DB01354 DB00704 DB00295 DB13950 DB01378 DB12670 DB00340 DB09235 DB08890 DB05710 DB00310 DB09049 DB13666 DB00528 DB14546 DB01377 DB09089 DB09230 DB01591 DB13526 DB00771 DB13791 DB06152 DB08907 DB00517 DB01483 DB12704 DB09272 DB00836 DB00436 DB14684 DB00477 DB06480 DB01239 DB00354 DB06702 DB13448 DB00804 DB01023 DB12942 DB09237 DB00565 DB12131 DB09167 DB01151 DB08961 DB13663 DB09311 DB00725 DB00813 DB00376 DB14499 DB00508 DB01226 DB09239 DB04841 DB08897 DB00721 DB13413 DB00808 DB04842 DB00934 DB14065 DB04743 DB12278 DB00381 DB08992 DB11181 DB08997 DB13170 DB01565 DB09229 DB00747 DB02925 DB00383 DB00653 DB12766 DB13803 DB00593 DB06204 DB00497 DB00483 DB00940 DB04831 DB13295 DB00986 DB13430 DB09472 DB00333 DB12221 DB14627 DB04816 DB09287 DB00458 DB00880 DB05885 DB09262 DB11089 DB00392 DB09090 DB09007 DB12554 DB09219 DB01224 DB12492 DB11365 DB00802 DB14232 DB00907 DB01288 DB00794 DB01433 DB01036 DB01324 DB13844 DB01351 DB01403 DB04834 DB12526 DB00462 DB00514 DB00434 DB00844 DB11059 DB09104 DB12923 DB01352 DB00703 DB12086 DB09338 DB12093 DB01353 DB00347 DB11097 DB09174 DB04823 DB00393 DB13619 DB01496 DB13380 DB01529 DB01395 DB00657 DB00767 DB13850 DB13405 DB01174 DB01497 DB00318 DB04920 DB14513 DB13351 DB12092 DB01144 DB14585 DB15959 DB09231 DB00728 DB13532 DB09232 DB01079 DB13708 DB06153 DB13160 DB00366 DB13720 DB00647 DB14503 DB06370 DB01069 DB11107 DB06212 DB09268 DB00342 DB09240 DB01136 DB00909 DB13500 DB01021 DB00306 DB11622 DB13581 DB14482 DB13369 DB01238 DB09023 DB13707 DB01090 DB01336 DB15360 DB01338 DB11130 DB00611 DB13478 DB01135 DB09281 DB04825 DB01081 DB01074 DB00472 DB09401 DB00782 DB13507 DB01115 DB00524 DB01388 DB05034","absorption":null,"created":"2019-08-30","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":418.126382288,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alloin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15477"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8015-89-2","sequences":null,"targets":null,"unii":"4VBP01X99F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB00219 DB00887 DB00742 DB08980 DB00540 DB06712 DB00737 DB01142 DB07715 DB13695 DB00387 DB00562 DB15465 DB13505 DB00280 DB13252 DB00232 DB01409 DB09484 DB01337 DB13792 DB00424 DB01209 DB00321 DB00810 DB07615 DB00732 DB13738 DB01535 DB00421 DB00463 DB14504 DB01075 DB00700 DB11855 DB09076 DB01148 DB01339 DB01551 DB00246 DB00777 DB00209 DB13636 DB09234 DB00543 DB11057 DB09462 DB11827 DB11228 DB09481 DB00332 DB13468 DB01062 DB01555 DB01466 DB15861 DB00708 DB00245 DB01046 DB13787 DB00581 DB00599 DB00835 DB13488 DB13584 DB00670 DB09015 DB14018 DB00908 DB00652 DB08861 DB09227 DB06292 DB14064 DB01175 DB00872 DB09125 DB00819 DB00420 DB13769 DB00214 DB09300 DB00967 DB09238 DB06738 DB13284 DB00715 DB00327 DB00237 DB00334 DB06694 DB13542 DB00899 DB00241 DB00270 DB00941 DB13835 DB00915 DB00753 DB00695 DB00312 DB09413 DB01412 DB00363 DB14066 DB08801 DB01638 DB08838 DB00418 DB01231 DB00809 DB01459 DB09414 DB04843 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB11110 DB00999 DB00979 DB00568 DB05246 DB01625 DB14963 DB00311 DB13454 DB01227 DB13617 DB00903 DB09449 DB14063 DB01118 DB00594 DB01199 DB08960 DB16165 DB00454 DB00505 DB14516 DB11315 DB11960 DB13678 DB00401 DB06283 DB11235 DB00921 DB01192 DB13725 DB00875 DB00343 DB00496 DB00622 DB14502 DB14068 DB04838 DB01450 DB06446 DB13766 DB13606 DB11189 DB11113 DB13913 DB01355 DB00774 DB00849 DB00555 DB00661 DB06787 DB01531 DB14881 DB00942 DB01116 DB01244 DB13989 DB01054 DB13801 DB00384 DB13254 DB14500 DB00956 DB13759 DB00572 DB01173 DB13961 DB08162 DB13648 DB09236 DB13486 DB00854 DB11609 DB01354 DB00704 DB00295 DB13950 DB01378 DB12670 DB00340 DB09235 DB08890 DB05710 DB00310 DB09049 DB13666 DB00528 DB14546 DB01377 DB09089 DB09230 DB01591 DB13526 DB00771 DB13791 DB06152 DB08907 DB00517 DB01483 DB12704 DB09272 DB00836 DB00436 DB14684 DB00477 DB06480 DB01239 DB00354 DB06702 DB13448 DB00804 DB01023 DB12942 DB09237 DB00565 DB12131 DB09167 DB01151 DB08961 DB13663 DB09311 DB00725 DB00813 DB00376 DB14499 DB00508 DB01226 DB09239 DB04841 DB08897 DB00721 DB13413 DB00808 DB04842 DB00934 DB14065 DB04743 DB12278 DB00381 DB08992 DB11181 DB08997 DB13170 DB01565 DB09229 DB00747 DB02925 DB00383 DB12766 DB13803 DB00593 DB06204 DB00497 DB00483 DB00940 DB04831 DB13295 DB00986 DB13430 DB09472 DB00333 DB12221 DB14627 DB09287 DB00458 DB00880 DB05885 DB09262 DB11089 DB00392 DB09090 DB09007 DB12554 DB09219 DB01224 DB12492 DB00802 DB14232 DB00907 DB01288 DB00794 DB01433 DB01036 DB01324 DB13844 DB01351 DB01403 DB04834 DB12526 DB00462 DB00514 DB00434 DB00844 DB11059 DB09104 DB12923 DB01352 DB00703 DB12086 DB09338 DB12093 DB01353 DB00347 DB11097 DB09174 DB04823 DB00393 DB13619 DB01496 DB13380 DB01529 DB01395 DB00657 DB00767 DB13850 DB13405 DB01174 DB01497 DB00318 DB04920 DB14513 DB13351 DB12092 DB01144 DB14585 DB15959 DB09231 DB00728 DB13532 DB09232 DB01079 DB13708 DB06153 DB13160 DB00366 DB13720 DB00647 DB14503 DB06370 DB01069 DB11107 DB06212 DB09268 DB00342 DB09240 DB01136 DB00909 DB13500 DB01021 DB00306 DB11622 DB13581 DB14482 DB13369 DB01238 DB09023 DB13707 DB01090 DB01336 DB15360 DB01338 DB11130 DB00611 DB13478 DB01135 DB09281 DB04825 DB01081 DB01074 DB00472 DB09401 DB00782 DB13507 DB01115 DB00524 DB01388 DB05034","absorption":null,"created":"2019-08-30","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Frangula purshiana bark","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-02","drugbank-id":"DB15478"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":143.68,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"10119-31-0","sequences":null,"targets":null,"unii":"R7EF6G80G1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":141.87629,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zirconium chloride hydroxide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15479"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":152.149,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"102-29-4","sequences":null,"targets":null,"unii":"YL6O37RD1S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":152.047344118,"volume-of-distribution":null,"route-of-elimination":null,"name":"Resorcinol monoacetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15480"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8009-00-5","sequences":null,"targets":null,"unii":"BN5IO4652Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fish liver oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15481"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemagglutinin-strain B","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15482"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).[L42660,L42670]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"TU8J357395","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Vaccination with Modified Vaccinia Ankara elicits humoral and cellular immune responses to orthopoxviruses, thereby providing host protection against future orthopoxvirus infections.[L41155]","drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01410 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB04845 DB11817 DB00764 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB06603 DB01204 DB01013 DB00620 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00515 DB00262 DB11569 DB06589 DB00588 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00180 DB00445 DB00005 DB00687 DB08906 DB02806 DB03523","absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Modified vaccinia ankara","metabolism":null,"reactions":null,"indication":"Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.[L41155] In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.[L42670]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15483"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-11","drugbank-id":"DB15484"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vibrio cholerae Inaba 48 classical biotype, heat inactivated","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-11","drugbank-id":"DB15485"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vibrio cholerae Ogawa 50 classical biotype, heat inactivated","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-11","drugbank-id":"DB15486"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-08-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vibrio cholerae Ogawa 50 classical biotype, formalin inactivated","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-11","drugbank-id":"DB15487"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":786.733,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis, acute colitis, wound treatment, and hepatitis.[A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592]","enzymes":"BE0002089","type":"small molecule","cas-number":"82854-37-3","sequences":null,"targets":"BE0003383 BE0000132","unii":"I04O1DT48T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"The neuroprotective effects are thought to be mediated via effects on mitogen-activated protein kinase, nuclear factor kappa-B, caspases 3 and 8, as well as CHOP pathways.[A184577]","drug-interactions":"DB01420 DB04216 DB00323 DB02105 DB00494 DB11632","absorption":"Animal studies suggest an oral bioavailability of 0.83%.[A184577]","created":"2019-09-04","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":786.258243881,"volume-of-distribution":null,"route-of-elimination":null,"name":"Echinacoside","metabolism":"The metabolism of echinacoside has been investigated in rats and is thought to involve catechol O-methyltransferase as well as unspecified UDP-gluc- uronosyltransferases and sulfotransferases.[A184595] A study of echinacoside's metabolism by human intestinal flora identified 13 metabolites which are produced independantly of human metabolism.[A184598]","reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15488"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":363.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions.[A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].[A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910]","enzymes":"BE0002638","type":"small molecule","cas-number":"31868-18-5","sequences":null,"targets":"BE0008668 BE0004797","unii":"S5969B6237","protein-binding":"Mexazolam is >90% protein bound in plasma.[A184910]","fda-label":null,"clearance":null,"atc-codes":"Benzodiazepine derivatives PSYCHOLEPTICS NERVOUS SYSTEM ANXIOLYTICS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Mexazolam is a benzodiazepine that binds to benzodiazepine-type receptors, inhibiting gamma-aminobutyric acid.[A184910]","drug-interactions":"DB06711 DB01392","absorption":"The active metabolite chloronordiazepam has a T<sub>max<\/sub> of 1-2h.[A184910]","created":"2019-09-04","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Mexazolam follows a 2 compartment model with a first half life of 1.4h and a second half life of 76h.[A184910]","monoisotopic-mass":362.05888318,"volume-of-distribution":null,"route-of-elimination":"Mexazolam is mainly eliminated in the bile and feces, with <10% eliminated as metabolites in the urine.[A184910] >50% of a dose of mexazolam is eliminated as the metabolite chloroxazepam.[A184910]","name":"Mexazolam","metabolism":"Mexazolam is rapidly metabolized to the active metabolites chloronordiazepam and chloroxazepam.[A184910]","reactions":null,"indication":"Mexazolam is indicated for the treatment of anxiety with or without psychoneurotic conditions.[A184910]","ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15489"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":409.574,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1632051-40-1","sequences":null,"targets":null,"unii":"7ZW49N180B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-09-05","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":409.272927379,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zuranolone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15490"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":328.8,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"24143-17-7","sequences":null,"targets":null,"unii":"1V2WI2NA1C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-09-06","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":328.0978555,"volume-of-distribution":null,"route-of-elimination":null,"name":"Oxazolam","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15491"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":340.845,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"84226-12-0","sequences":null,"targets":null,"unii":"J8M468HBH4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB12890 DB13520 DB00268 DB00413 DB01238 DB00248 DB01235 DB00320 DB09128 DB12313 DB05271 DB09097 DB01200 DB12161 DB01186 DB00800 DB00245 DB00589 DB12478 DB04844 DB01049 DB13385 DB00714 DB11275 DB11273","absorption":null,"created":"2019-09-11","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":340.155370383,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eticlopride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15492"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":360.43,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.","enzymes":null,"type":"small molecule","cas-number":"14513-15-6","sequences":null,"targets":"BE0002461 BE0003362 BE0009759","unii":"8S2PHY4FNC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Cambinol inhibits the NAD-dependant deacetylases SIRT1 and SIRT2, members of a protein family known as sirtuins.[A185690,L8570]\r\n\r\nInhibiting SIRT1 and SIRT2 while cells are under stress increases acetylation of p53, Ku70, and Foxo3a.[A185690,L8570] This inhibition sensitizes cells to the action of drugs like [etoposide] and [paclitaxel], not just other drugs that damage DNA.[A185690] Although the mechanism of this sensitizing is not defined, it is not dependent on p53, Ku70, or Foxo3a.[A185690] The independent mechanism suggests the existence of more molecular targets.[A185690]\r\n\r\nCambinol is noncompetitive against NAD and competitive against H-4 peptide, substrates of SIRT2.[A185690] Inhibiting SIRT2 increases the acetylation of tubulin.[A185690]\r\n\r\nCambinol also increases the acetylation of BCL6, a protein necessary for oncogenesis.[A185690]\r\n\r\nCambinol is also a weak inhibitor of SIRT5.[L8570]","drug-interactions":null,"absorption":null,"created":"2019-09-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":360.093248937,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cambinol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15493"},{"toxicity":"The LD<sub>50<\/sub> of this medication is not readily available.[L8597]\r\n\r\nIn the event of an overdose, give patients plenty of fluids and diuretics if necessary to encourage frequent urination.[L8597] If possible, an estimation of radioactive dose should be performed.[L8597]","snp-adverse-drug-reactions":null,"average-mass":1486.55,"transporters":null,"pharmacodynamics":"Edotreotide gallium Ga-68 binds to somatostatin receptors where it emits beta particle radiation for detection by positron emission tomography.[L8597] The duration of action is short as it has short radioactive and biological half lives.[A185867,L8603] Patients should hydrate before and after the administration of this medication to encourage frequent urination and rapid clearance.[L8597]","msds":null,"description":"Edotreotide gallium Ga-68 is an 8 amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).[L8603] Edotreotide gallium Ga-68 is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography.[L8597] [Dotatate gallium Ga-68] is used for a similar indication.[A185852] Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.[A185852]\r\n\r\nEdotreotide gallium Ga-68 was granted FDA approval on 21 August 2019.[L8597]","enzymes":null,"type":"small molecule","cas-number":"2101630-92-4","sequences":null,"targets":"BE0003529 BE0003528 BE0000452 BE0002147","unii":"Y68179SY2L","protein-binding":"Data suggests edotreotide gallium-Ga 68 may bind to proteins in serum.[A185873] The extent of serum protein binding and which proteins it binds to are not described in the literature.","fda-label":null,"clearance":"Data regarding the clearance of this medication is not readily available.[L8597]","atc-codes":"DIAGNOSTIC RADIOPHARMACEUTICALS VARIOUS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Edotreotide gallium Ga-68 binds to somatostatin receptors, with higher affinity for somatostatin receptor type 2, where it emits beta particle radiation for detection by positron emission tomography (PET).[L8597]","drug-interactions":"DB06663 DB06791 DB09099 DB00104 DB04894","absorption":"Edotreotide gallium Ga-68 reaches 80% activity in tumors within 30 minutes,[A185867] and reaches its highest activity in tumors 7020min post injection.[L8603] Edotreotide is mostly taken up into the spleen, followed by kidneys, liver, pituitary, thyroid, and adrenal gland.[A185861,A185867,L8603] Accumulation in non-tumor tissue reaches a maximum within 40 minutes.[A185867]","created":"2019-09-17","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Edotreotide gallium Ga-68 has a radioactive half life of 68 minutes.[A185867,L8603] Edotreotide gallium Ga-68 has two half lives, 2.00.3min and 487min for its removal from blood.[A185867,L8603]","monoisotopic-mass":1485.520052927,"volume-of-distribution":"Data regarding the volume of distribution of this medication is not readily available.[L8597]","route-of-elimination":"16% of a Edotreotide gallium Ga-68 dose is eliminated in the urine within 2h.[A185849,L8597] It is expected that Edotreotide gallium Ga-68 is exclusively eliminated in the urine.[A185849,L8597] In animal studies, edotreotide Y-90 was >80% eliminated in the urine within 24h, with 95.63.4% being unmetabolized.[A185861,L8603] <1% of a dose is detected in the feces.[A185870]","name":"Edotreotide gallium Ga-68","metabolism":"Edotreotide gallium Ga-68 is largely unmetabolized.[L8603] 4 hours post injection there are no metabolites or degradation products detectable in serum.[A185867]","reactions":null,"indication":"Edotreotide gallium Ga-68 is a radioactive diagnostic compound used in positron emission tomography (PET) for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adults.[L8597]","ahfs-codes":null,"updated":"2021-08-06","drugbank-id":"DB15494"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":505.567,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides.[A186760] Rocaglamides are secondary metabolites of the plant genus _Aglaia_, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties.[A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.[A186760] Rocaglamide and a number of its derivatives (e.g. [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of certain chemotherapy-resistant cancers.[A186781,A186784,A186799,A186766]","enzymes":null,"type":"small molecule","cas-number":"84573-16-0","sequences":null,"targets":"BE0009786 BE0009007","unii":"FRG4N852F7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Rocaglamide\u20ACs anti-tumor activity is driven primarily via inhibition of protein synthesis in tumor cells.[A186760] Inhibition of protein synthesis is accomplished via inhibition of prohibitin 1 (PHB1) and prohibitin 2 (PHB2)[A186763] - these proteins are necessary in the proliferation of cancer cells and are implicated in the Ras-mediated CRaf-MEK-ERK signaling pathway responsible for phosphorylating eIF4E, a key factor in the initiation of protein synthesis.[A186763,A186760] The rocaglamide derivative silvestrol has also been observed to act directly on eIF4A, another translation initiation factor of the eIF4F complex ultimately responsible for initiation of protein synthesis.[A186766]\r\n\r\nInhibition of protein synthesis has a number of downstream effects. Many of the proteins that are down-regulated in response to protein synthesis inhibition in tumor cells are short-lived proteins responsible for regulation of the cell cycle, such as Cdc25A.[A186760] Cdc25A is an oncogene that can become overexpressed in certain cancers and lead to unchecked cell growth.[A186772] In addition to inhibiting its synthesis via the mechanism described above, rocaglamide promotes degradation of Cdc25A via activation of the ATM\/ATR-Chk1\/Chk2 checkpoint pathway[A186775]. This pathway is normally activated in response to DNA damage and serves to reduce the expression of proteins responsible for cell cycle progression, thereby inhibiting proliferation of damaged (i.e. tumour) cells. Rocaglamide\u20ACs inhibition of protein synthesis also appears to prevent the actions of the transcription factor heat shock factor 1 (HSF1), leading to an increased expression of thioredoxin-interacting protein (TXNIP) which is negatively regulated by HSF1.[A186778] TXNIP is a negative regulator of cell glucose uptake, and its increased expression blocks glucose uptake and consequently impairs the proliferation of malignant cells.[A186778]\r\n\r\nRocaglamide also appears to induce apoptosis in tumor cells via activation of the pro-apoptotic proteins p38 and JNK and inhibition of the anti-apoptotic Mcl-1 protein.[A186760] Similarly, it has been studied as an adjuvant in TRAIL-resistant cancers due to its ability to inhibit the synthesis of c-FLIP and IAP\/XIAP - these anti-apoptotic proteins can become elevated in certain cancers, preventing the induction of apoptosis and resulting in resistance to TRAIL-based therapies.[A186781,A186784]","drug-interactions":null,"absorption":null,"created":"2019-09-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":505.210052342,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rocaglamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15495"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":477.513,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as \"rocaglamides\" derived from plants of the genus _Aglaia_.[A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas.[A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears to carry the most potent anti-tumour activity.[A186802,A186805]","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":"BE0009786 BE0009007","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Little research has been conducted specifically regarding didesmethylrocaglamide, but its mechanism of action is likely to be congruent with the rest of the rocaglamide class.\r\n\r\nDidesmethylrocaglamide\u20ACs anti-tumor activity, similar to other rocaglamide derivatives, is driven primarily via inhibition of protein synthesis in tumor cells.[A186760] Inhibition of protein synthesis is accomplished via inhibition of prohibitin 1 (PHB1) and prohibitin 2 (PHB2)[A186763] - these proteins are necessary in the proliferation of cancer cells and are implicated in the Ras-mediated CRaf-MEK-ERK signaling pathway responsible for phosphorylating eIF4E, a key factor in the initiation of protein synthesis.[A186763,A186760] There is also some evidence that rocaglamides can act directly on eIF4A, another translation initiation factor of the eIF4F complex ultimately responsible for initiation of protein synthesis.[A186766]\r\n\r\nInhibition of protein synthesis has a number of downstream effects. Many of the proteins that are down-regulated in response to protein synthesis inhibition in tumor cells are short-lived proteins responsible for regulation of the cell cycle, such as Cdc25A.[A186760] Cdc25A is an oncogene that can become overexpressed in certain cancers and lead to unchecked cell growth.[A186772] In addition to inhibiting its synthesis via the mechanism described above, rocaglamides promote degradation of Cdc25A via activation of the ATM\/ATR-Chk1\/Chk2 checkpoint pathway[A186775]. This pathway is normally activated in response to DNA damage and serves to reduce the expression of proteins responsible for cell cycle progression, thereby inhibiting proliferation of damaged (i.e. tumour) cells. Inhibition of protein synthesis also appears to prevent the actions of the transcription factor heat shock factor 1 (HSF1), leading to an increased expression of thioredoxin-interacting protein (TXNIP) which is negatively regulated by HSF1.[A186778] TXNIP is a negative regulator of cell glucose uptake, and its increased expression blocks glucose uptake and consequently impairs the proliferation of malignant cells.[A186778]\r\n\r\nRocaglamides also appear to induce apoptosis in tumor cells via activation of the pro-apoptotic proteins p38 and JNK and inhibition of the anti-apoptotic Mcl-1 protein.[A186760] Similarly, they have been studied as an adjuvant in TRAIL-resistant cancers due to their ability to inhibit the synthesis of c-FLIP and IAP\/XIAP - these anti-apoptotic proteins can become elevated in certain cancers, preventing the induction of apoptosis and resulting in resistance to TRAIL-based therapies.[A186781,A186784]","drug-interactions":null,"absorption":null,"created":"2019-09-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":477.178752213,"volume-of-distribution":null,"route-of-elimination":null,"name":"Didesmethylrocaglamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15496"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-09-26","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Smallpox and Monkeypox Vaccine, Live, Non-replicating","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15497"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":446.559,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent.[A187123] Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.[A187120]  An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative breast cancer, and demonstrated promising synergistic effects.[A187123]","enzymes":null,"type":"small molecule","cas-number":"1578245-44-9","sequences":null,"targets":"BE0003791","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Mps1 is a protein kinase that is expressed in normal proliferating tissues and in certain actively dividing tumors. It acts during mitosis (cell division) and plays a crucial role in the alignment of chromosomes in cancer cells.[A187120,L9049]  Checkpoint activities by Mps1 normally inhibit the advancement of cancer cells from metaphase to anaphase until structural integrity and alignment occur. BOS172722 binds to Mps1, inhibiting its regulatory checkpoint activities.[A187141] This inhibition causes accelerated cell division with increased missegregation errors that ultimately reduce the viability of malignant cells.[A187120,L9049]","drug-interactions":null,"absorption":null,"created":"2019-10-06","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":446.254257618,"volume-of-distribution":null,"route-of-elimination":null,"name":"BOS172722","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15498"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":445.54,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed\/refractory Peripheral T-cell Lymphoma (PTCL)).","enzymes":null,"type":"small molecule","cas-number":"1198300-79-6","sequences":null,"targets":null,"unii":"D1LXQ45S1O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":445.189608931,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cerdulatinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15499"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0QK4U2V88L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Brisbane\/02\/2018 IVR-190 (H1N1) antigen (propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15500"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"AL8G7D406D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Kansas\/14\/2017 X-327 (H3N2) antigen (propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15501"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Baccharis sarothroides whole allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"C94X53K2GW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Baccharis sarothroides whole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15502"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Amaranthus hybridus pollen allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"EK7F0414PI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amaranthus hybridus pollen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15503"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acacia dealbata pollen allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"L16Z5HLP8V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acacia dealbata pollen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15504"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Idaho\/07\/2018 (H1N1) antigen (MDCK cell derived, propiolactone inactivated","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15505"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"Z5EJE3EP8T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Indiana\/08\/2018 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15506"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"G4VX46P9M6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Singapore\/INFTT-16-0610\/2016 antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":"In combination with other influenza virus subtypes A and types B strains, this Influenza B viral strain is used for active immunization of adults and children aged 6 months or older for the prevention of influenza disease caused by influenza virus subtypes A and types B.[L41345]","ahfs-codes":null,"updated":"2022-04-01","drugbank-id":"DB15507"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"CA1YT4NE3M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Iowa\/06\/2017 antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15508"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Alnus serrulata pollen allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"390VZ1D0L5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alnus serrulata pollen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15509"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Prosopis velutina seed allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"R0120Z3YIC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Prosopis velutina seed","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15510"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gibberella fujikuroi allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"815V716OR2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gibberella fujikuroi","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15511"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mucor circinelloides f. circinelloides allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"48Z8OUT98B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mucor circinelloides f. circinelloides","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15512"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"05UZ60BGC7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Switzerland\/3330\/2017 (H1N1) live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15513"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"481B6U9IO3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Kansas\/14\/2017 (H3N2) live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15514"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"XW4JB03TI5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Brisbane\/02\/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15515"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"3NZW5ND3D6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Kansas\/14\/2017 X-327 (H3N2) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15516"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"DC4ELG1BFZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Brisbane\/02\/2018 (H1N1) recombinant hemagglutinin antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15517"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"I282A48KKK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Kansas\/14\/2017 (H3N2) recombinant hemagglutinin antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15518"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"Y8O4RY7EEM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Brisbane\/02\/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15519"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"IBB8KGB0WJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Kansas\/14\/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15520"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"75KB2HPX5H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cyd dengue virus serotype 1 live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15521"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"FH5SVG7GLC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cyd dengue virus serotype 2 live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15522"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"RHT2Q37FYG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cyd dengue virus serotype 3 live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15523"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"RS26HP5ND2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cyd dengue virus serotype 4 live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15524"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mucor circinelloides f. lusitanicus allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0J0X819B3C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mucor circinelloides f. lusitanicus","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15525"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Eurotium amstelodami allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"D932NLL87Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eurotium amstelodami","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15526"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":986.294,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"851536-75-9","sequences":null,"targets":null,"unii":"U36PGF65JH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":985.612656485,"volume-of-distribution":null,"route-of-elimination":null,"name":"Umirolimus","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15527"},{"toxicity":"The LD<sub>50<\/sub> and information on overdose have not been evaluated with onasemnogene abeparvovec. In mice toxicology studies, dose-dependent cardiac and hepatic toxicities were observed following intravenous administration. Cardiac toxicity was characterized by mononuclear cell inflammation accompanied by edema, slight to mild fibrosis, and scattered myocardial cell degeneration\/regeneration, as well as atrial thrombosis and dilation. Hepatotoxicity was characterized by hepatocellular hypertrophy, Kupffer cell activation, perinuclear vacuolation, and scattered hepatocellular necrosis.[L9194]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Onasemnogene abeparvovec is a gene therapy that restores the levels of SMN protein in the spinal cord to promote the survival and function of motor neurons. Acute serious liver injury and elevated aminotransferases were observed with the treatment of onasemnogene abeparvovec in clinical trials.[L9194]","msds":null,"description":"Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene.[L9194] SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness.[A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.\r\n\r\nDeveloped by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma, which is available as a single-dose intravenous infusion.[L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA.[A187253]","enzymes":null,"type":"biotech","cas-number":"1922968-73-7","sequences":null,"targets":null,"unii":"MLU3LU3EVV","protein-binding":"There is limited pharmacokinetic information on onasemnogene abeparvovec.","fda-label":null,"clearance":"There is limited pharmacokinetic information on onasemnogene abeparvovec.","atc-codes":"MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Other drugs for disorders of the musculo-skeletal system","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Spinal muscular atrophy is a genetic disorder caused by mutations in the SMN gene, which encodes the SMN protein. SMN protein is found ubiquitously but it is highly expressed in the spinal cord where it is responsible for the survival and maintenance of specialized nerve cells called motor neurons.[L9209] SMN1 and SMN2 genes encode the SMN protein but many mutations in the SMN1 gene have been found to cause spinal muscular atrophy,[A187256,L9209] as SMN1 is the primary gene responsible for functional production of SMN protein.[A187250] A common mutation that causes spinal muscular atrophy involves a bi-allelic deletion of exon 7 in the SMN1 gene.[A187256] The number of copies of the SMN2 gene varies among individuals: while higher number of SMN2 gene copies may protect against SMN protein deficiency caused by SMN1 gene mutations,[L9209] it is generally proposed that the bi-allelic mutation in the SMN1 gene cannot be compensated by the SMN2 gene.[A187256] The mutation results in insufficient SMN protein expression and inefficient assembly of the machinery needed to process pre-mRNA for motor neuron development and survival. Spinal muscular atrophy involves a progressive degeneration and loss of lower motor neurons, leading to muscle weakness and atrophy.[A187250,L9194]\r\n\r\nOnasemnogene abeparvovec is gene therapy that consists of a recombinant self-complementary adeno-associated virus serotype 9 (AAV9) as a gene delivery vector, which contains a transgene encoding the human survival motor neuron (SMN) protein.[A187250,L9194] AAV9 is commonly used in gene therapy applications because it is capable of crossing the blood-brain barrier and transducing neurons in the CNS.[A187259] After administration, this viral vector is shed and a copy of the gene encoding the human SMN protein is delivered, leading to cell transduction and expression of the SMN protein.[L9194]","drug-interactions":"DB10805 DB12768 DB12978 DB15561 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":"There is limited pharmacokinetic information on onasemnogene abeparvovec.","created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"There is limited pharmacokinetic information on onasemnogene abeparvovec.","monoisotopic-mass":null,"volume-of-distribution":"There is limited pharmacokinetic information on onasemnogene abeparvovec. When biodistribution was evaluated in autopsy studies, the highest levels of vector DNA were found in the liver. Vector DNA was also detected in the spleen, heart, pancreas, inguinal lymph node, skeletal muscles, peripheral nerves, kidney, lung, intestines, spinal cord, brain, and thymus.[L9194]","route-of-elimination":"There is limited pharmacokinetic information on onasemnogene abeparvovec.","name":"Onasemnogene abeparvovec","metabolism":"There is limited pharmacokinetic information on onasemnogene abeparvovec. The viral vector and the survival motor neuron (SMN) protein are expected to undergo normal nonspecific cellular degradation.","reactions":null,"indication":"Onasemnogene abeparvovec is indicated for the treatment of pediatric patients less than 2 years of age (neonatal and infant patients) with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.[L9194]","ahfs-codes":null,"updated":"2022-06-03","drugbank-id":"DB15528"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leucanthemum vulgare pollen allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"H9E0IX4MOX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leucanthemum vulgare pollen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15529"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Trifolium pratense pollen allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"3SNK70F46Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Trifolium pratense pollen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15530"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"1190590-38-5","sequences":null,"targets":null,"unii":"0N1VMU8G9W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Silk sericin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15531"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":975.132,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"34540-22-2","sequences":null,"targets":null,"unii":"CQ2F5O6YIY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":974.508644912,"volume-of-distribution":null,"route-of-elimination":null,"name":"Madecassoside","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15532"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":136.141,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7778-18-9","sequences":null,"targets":null,"unii":"E934B3V59H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":135.914320333,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium sulfate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15533"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":385.416,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Colchiceine is one of several metabolites of the anti-gout medication [colchicine].[A192714]","enzymes":null,"type":"small molecule","cas-number":"477-27-0","sequences":null,"targets":"BE0001340 BE0000143","unii":"HJ30158L57","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-09","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":null,"monoisotopic-mass":385.152537465,"volume-of-distribution":null,"route-of-elimination":null,"name":"Colchiceine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15534"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":98.999,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7758-89-6","sequences":null,"targets":null,"unii":"C955P95064","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":97.898453786,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cuprous chloride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15535"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":162.204,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7705-08-0","sequences":null,"targets":null,"unii":"U38V3ZVV3V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":160.841500254,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ferric chloride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-03-03","drugbank-id":"DB15536"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"9000-20-8","sequences":null,"targets":null,"unii":"72T9EZC2VX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eucalyptus gum","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15537"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sea scallop allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"BY65V9YV1I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sea scallop","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15538"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Northern brown shrimp allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"TJH4LL437H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Northern brown shrimp","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15539"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rainbow trout allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"P4M52SZ8L6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rainbow trout","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15540"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Yellowfin tuna allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"12ZC3K09X7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Yellowfin tuna","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15541"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Atlantic mackerel allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"HO615U86UJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Atlantic mackerel","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15542"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pacific ocean perch allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"81369ZC3RW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pacific ocean perch","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15543"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Myristica fragrans fruit allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"GOO22BTU71","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Myristica fragrans fruit","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15544"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pisum sativum whole allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"J21YE3W98E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pisum sativum whole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15545"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Skim milk allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"6A001Y4M5A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Skim milk","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15546"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Black sea bass allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0YJW8KYT51","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Black sea bass","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15547"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Channel catfish allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"FIX499R7DR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Channel catfish","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15548"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Atlantic halibut allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"7E34E106BO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Atlantic halibut","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15549"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":423.79,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pradefovir is a prodrug of [adefovir].","enzymes":null,"type":"small molecule","cas-number":"625095-60-5","sequences":null,"targets":null,"unii":"GZE85Q9Q61","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-13","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":423.0863188,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pradefovir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15550"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":299.71,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leptazoline A is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline B], [Leptazoline C], and [Leptazoline D].","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":299.0560503,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leptazoline A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15551"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":388.8,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leptazoline B is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline C], and [Leptazoline D].","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":388.1037287,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leptazoline B","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15552"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":265.265,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leptazoline C is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline B], and [Leptazoline D].","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":265.095022587,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leptazoline C","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15553"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":354.359,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Leptazoline D is a polar oxazoline from the Cyanobacterium Leptolyngbya sp. Also see [Leptazoline A], [Leptazoline B], and [Leptazoline C].","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":354.142701056,"volume-of-distribution":null,"route-of-elimination":null,"name":"Leptazoline D","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15554"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":156.376,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"869-06-7","sequences":null,"targets":null,"unii":"LA9X9UJA2Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-16","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":155.99091493,"volume-of-distribution":null,"route-of-elimination":null,"name":"Magnesium malate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-01","drugbank-id":"DB15555"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":405.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"955009-96-8","sequences":null,"targets":null,"unii":"H3472PJ7YA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":404.004551,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc glycinate citrate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15556"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":430.673,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"24-Homo-1,25-dihydroxyvitamin D3 is a novel [vitamin D] analogue.","enzymes":null,"type":"small molecule","cas-number":"103656-40-2","sequences":null,"targets":null,"unii":"F35KTH803S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":430.344695341,"volume-of-distribution":null,"route-of-elimination":null,"name":"24-Homo-1,25-dihydroxyvitamin D3","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15557"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Imalumab is under investigation in clinical trial NCT02540356 (Phase 1\/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).","enzymes":null,"type":"biotech","cas-number":"1430205-07-4","sequences":null,"targets":null,"unii":"22F97PC79G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Imalumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15558"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab\/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).","enzymes":null,"type":"biotech","cas-number":"1969309-56-5","sequences":null,"targets":null,"unii":"AE72RB1W1X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2019-10-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zenocutuzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15559"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).","enzymes":null,"type":"biotech","cas-number":"202011-67-4","sequences":null,"targets":null,"unii":"48OB405WWC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Reloxaliase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15560"},{"toxicity":"There are no reports of valoctocogene roxaparvovec accidental infusions or high dose volumes. If considered necessary, the treatment of a valoctocogene roxaparvovec overdose should be symptomatic and supportive. Receiving higher doses than recommended may result in higher factor VIII activity levels, associated with an increased risk of thrombotic events.[L43282]\r\n\r\nAt doses up to 2\u201410<sup>14<\/sup> vg\/kg, CD1 mice given valoctocogene roxaparvovec did not show any signs of toxicity, except for a pattern of hemorrhages, necrosis and fibrosis in the heart, lungs, epididymis and thymus. These effects were consistent with a coagulopathy likely caused by the formation of SQ form of human coagulation factor VIII (hFVIII-SQ) antibodies that cross-reacted with the murine factor VIII protein.[L43282] Vector integration was detected in the liver samples of non-human primates (n=12), which may lead to a higher risk of malignancies. Reproductive and developmental toxicity studies have not been performed. Since the majority of the patient population are males, germline transmission was evaluated in pups sired by male mice dosed with valoctocogene roxaparvovec. No germline transmission was detected.[L43282]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"The pharmacodynamic effects of valoctocogene roxaparvovec were evaluated by measuring the activity of circulating factor VIII. Adult males with severe hemophilia A were given a single intravenous infusion of 6\u201410<sup>13<\/sup> vg\/kg valoctocogene roxaparvovec, and their factor VIII activity levels were tracked at least for 6 months. Within 5 months post-infusion, 95% of patients had factor VIII activity levels equal to or higher than 5 IU\/dL. Long-term data (5 years follow-up) are available from 7 patients treated with valoctocogene roxaparvovec, and they all continued to show a clinically meaningful response to treatment.[L43282] The presence of pre-existing anti-adeno-associated virus serotype 5 (AAV5) antibodies has a significant effect on valoctocogene roxaparvovec efficiency; therefore, it should not be used in patients with detectable anti-AAV5 antibodies.[A252812]\r\n\r\nShortly after valoctocogene roxaparvovec infusion, patients may experience infusion-related side effects. Also, due to the increased production of active factor VIII, patients may have an increased possibility of unwanted blood clot formation. Since there is a possibility that valoctocogene roxaparvovec inserts into body cells other than liver cells, its use may contribute to a higher risk of malignancy.[L43282]","msds":null,"description":"Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).[L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.[L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for the treatment of severe hemophilia A. It is not approved for use in the United States.[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding.[A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and measurable steady-state levels of coagulation factor VIII.[A252807]","enzymes":null,"type":"biotech","cas-number":"1819334-78-5","sequences":null,"targets":null,"unii":"681K1JDI8M","protein-binding":null,"fda-label":null,"clearance":"The maximum time to clearance of valoctocogene roxaparvovec was 8 weeks for urine, 26 weeks for saliva, and 88 weeks for stool. The maximum time to clearance of vector DNA in semen is 36 weeks. The maximum time to clearance of encapsidated and potentially infectious vector DNA in semen was 12 weeks.[L43282]","atc-codes":null,"pdb-entries":null,"food-interactions":"Avoid alcohol. It is recommended that patients abstain from consuming alcohol for at least one year after administration of this medicinal product and, thereafter limit alcohol use.","state":"liquid","synthesis-reference":null,"mechanism-of-action":"Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-specific promoter;[A252797,L43282] and is used to treat hemophilia A, a condition characterized by the deficient activity of coagulation factor VIII.[A252802] After valoctocogene roxaparvovec is infused into patients, the AAV5 vector delivers a B-domain deleted SQ form of a recombinant human factor VIII (hFVIII-SQ) to cells. This working copy of coagulation factor VIII is then expressed in the liver, producing an active form of factor VIII that is then released into the bloodstream. This leads to bleeding normalization and a lower risk of bleeding episodes. The long-term production of hFVIII-SQ is supported following valoctocogene roxaparvovec infusion.[L43282]","drug-interactions":"DB08880 DB01026 DB05889 DB00056 DB14783 DB00188 DB15685 DB00559 DB01248 DB00951 DB09054 DB00313 DB08901 DB08827 DB00459 DB01259 DB04835 DB00008 DB05773 DB15066 DB05528 DB00932 DB00625 DB00982 DB12978 DB01045 DB15528 DB00563 DB01157 DB08886 DB06589 DB00105 DB01268 DB08896 DB00445 DB01219 DB00339 DB00238","absorption":"The total amount of vector DNA in tissues, blood, and shedding matrices was evaluated in patients treated with valoctocogene roxaparvovec. A quantitative polymerase chain reaction (qPCR) assay was used in order to measure transgene DNA and fragments of degraded DNA. Vector DNA was detected in blood and shedding matrices, with peak concentrations between 1 and 9 days after valoctocogene roxaparvovec administration. Blood, saliva, semen, stool, and urine showed the highest vector DNA concentrations.[L43282] The highest concentration detected in blood was 2\u201410<sup>11<\/sup> vg\/mL, and the highest concentration detected in any shedding matrix was 1\u201410<sup>10<\/sup> vg\/mL. Levels declined steadily after reaching the highest transgene DNA concentration.[L43282]","created":"2019-10-17","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":"Clinical studies have shown that valoctocogene roxaparvovec is eliminated through urine (all patients), saliva (99% of patients) and feces (84% of patients).[L43282]","name":"Valoctocogene roxaparvovec","metabolism":"As a gene therapy medicinal product, valoctocogene roxaparvovec is expected to be metabolized by nucleases throughout the body.","reactions":null,"indication":"Valoctocogene roxaparvovec is indicated for the treatment of severe hemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).[L43282]","ahfs-codes":null,"updated":"2022-12-23","drugbank-id":"DB15561"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0B3AM58J28","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-22","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/North carolina\/04\/2016 (H3N2) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15562"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"HW5XP554J1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-22","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Iowa\/06\/2017 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15563"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\n\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0JXM8X6ZW8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-22","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Singapore\/INFTT-16-0610\/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15564"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":389.4455,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"endosome","enzymes":null,"type":"small molecule","cas-number":"90139-06-3","sequences":null,"targets":"BE0000221","unii":"WBL76FH528","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB10713 DB01345 DB00537 DB00328 DB09259 DB06754 DB14026 DB00407 DB00331 DB00887 DB00437 DB00697 DB06196 DB10716 DB06737 DB00009 DB09220 DB08439 DB00586 DB13919 DB00784 DB06294 DB00047 DB06251 DB10963 DB09217 DB10962 DB11564 DB04876 DB13629 DB01050 DB01347 DB00814 DB11518 DB00562 DB14492 DB00993 DB01324 DB08981 DB14006 DB00177 DB09276 DB13286 DB02224 DB13783 DB00232 DB09258 DB09292 DB09214 DB13432 DB09418 DB00605 DB13217 DB06715 DB01283 DB00695 DB01306 DB08882 DB01307 DB12268 DB00893 DB09413 DB10370 DB00310 DB06011 DB06287 DB00482 DB08984 DB01294 DB01435 DB13657 DB12625 DB04884 DB14938 DB01029 DB13509 DB14506 DB09414 DB01590 DB10379 DB09026 DB01325 DB06763 DB08822 DB00421 DB01419 DB08813 DB00936 DB09288 DB13860 DB01349 DB11323 DB11567 DB01395 DB00700 DB10353 DB10494 DB13544 DB00999 DB06203 DB10966 DB00046 DB01014 DB06807 DB01009 DB08907 DB00580 DB11090 DB14509 DB09218 DB13524 DB00876 DB13620 DB10394 DB06736 DB13407 DB11201 DB00436 DB03585 DB06822 DB13649 DB00469 DB08976 DB04812 DB10964 DB00903 DB01225 DB08940 DB14059 DB00678 DB09279 DB10389 DB00159 DB13735 DB06127 DB09087 DB05115 DB00573 DB00861 DB13371 DB09449 DB10949 DB00594 DB00233 DB10489 DB11827 DB10403 DB12417 DB13977 DB14498 DB09213 DB00796 DB15959 DB11723 DB04828 DB08961 DB00554 DB09285 DB13532 DB10395 DB10717 DB06335 DB00991 DB00500 DB06692 DB06792 DB11455 DB06779 DB00461 DB01401 DB00795 DB14499 DB10404 DB00945 DB00440 DB13722 DB09212 DB10836 DB00275 DB01600 DB12412 DB01309 DB09215 DB00761 DB06212 DB12610 DB01261 DB11107 DB10714 DB00808 DB04743 DB10719 DB10366 DB12445 DB09084 DB10879 DB00712 DB00465 DB09260 DB00812 DB11466 DB13314 DB01424 DB08942 DB01021 DB09543 DB11098 DB05095 DB04725 DB11992 DB09015 DB00774 DB00788 DB00939 DB12399 DB00030 DB11568 DB00877 DB02925 DB01592 DB11153 DB00016 DB01628 DB13167 DB13527 DB14060 DB13232 DB13481 DB08382 DB09295 DB14507 DB01250 DB06271 DB09216 DB06725 DB06292 DB00966 DB00244 DB13989 DB12545 DB09483 DB11950 DB13967 DB00821 DB01109 DB10715 DB07402 DB08951 DB00384 DB13538 DB09456 DB09125 DB08797 DB00749 DB08991 DB01342 DB12221 DB00071 DB09564 DB08955 DB13612 DB00533 DB13001 DB01397 DB09038 DB00524 DB14500 DB01399 DB04552 DB00214 DB00880 DB10365","absorption":null,"created":"2019-10-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":389.195070989,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cilazaprilat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15565"},{"toxicity":"The oral LD<sub>50<\/sub> of prednisolone acetate in mice is 1680 mg\/kg.[L9476] Patients experiencing an overdose of oral prednisolone acetate may experience an increased severity in the adverse effects of corticosteroids.[L9449] Overdose of oral prednisolone acetate may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.[L9449] Chronic overdosage may be treated by dose reduction or treating patients on alternate days.[L9449] An overdose by the ophthalmic route is not expected to cause problems.[L9449]","snp-adverse-drug-reactions":null,"average-mass":402.4807,"transporters":"BE0003642 BE0001032","pharmacodynamics":"Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisolone acetate has a short duration of action as the half life is 2-3 hours.[L9449] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]","msds":null,"description":"Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449]\r\n\r\nPrednisolone acetate was granted FDA approval in 1955.[L9449]","enzymes":"BE0002638","type":"small molecule","cas-number":"52-21-1","sequences":null,"targets":"BE0000794","unii":"8B2807733D","protein-binding":"The active metabolite, prednisolone, is 70-90% protein bound in plasma.[L9449]","fda-label":null,"clearance":"Data regarding the clearance of prednisolone acetate is not readily available.[L9452,L9455,L9476]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with food. Food reduces gastrointestinal irritation. Avoid excessive or chronic alcohol consumption. Alcohol may cause gastric irritation.","state":"solid","synthesis-reference":null,"mechanism-of-action":"The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]\r\n\r\nGlucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]\r\n\r\nLower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]","drug-interactions":"DB00328 DB00682 DB08953 DB01208 DB12095 DB16002 DB06272 DB00887 DB09198 DB06737 DB00382 DB09570 DB00204 DB00540 DB06712 DB09217 DB00637 DB15035 DB11564 DB01078 DB00814 DB13446 DB09185 DB12978 DB00562 DB09273 DB13249 DB00280 DB11397 DB01200 DB00232 DB13286 DB13432 DB01337 DB13947 DB01223 DB00957 DB00605 DB01306 DB06772 DB13691 DB00277 DB00284 DB00368 DB08984 DB01229 DB09022 DB12235 DB00503 DB01554 DB00732 DB01102 DB12781 DB12952 DB00220 DB01256 DB01590 DB04066 DB09030 DB05316 DB00070 DB01067 DB13537 DB06814 DB01124 DB00531 DB00046 DB00912 DB12825 DB00888 DB13136 DB11828 DB01396 DB01339 DB11901 DB00390 DB11201 DB08865 DB01039 DB00222 DB00367 DB00839 DB00246 DB04846 DB01381 DB08735 DB09082 DB04878 DB09067 DB00358 DB06117 DB02520 DB01044 DB04891 DB11703 DB11827 DB01320 DB00136 DB13981 DB00834 DB00773 DB13928 DB13943 DB04828 DB11723 DB01323 DB00487 DB11824 DB09481 DB09074 DB01624 DB06717 DB01432 DB00945 DB00901 DB09299 DB13563 DB13954 DB01064 DB15861 DB01309 DB14009 DB12610 DB00779 DB09080 DB00467 DB01274 DB01364 DB00731 DB09084 DB11932 DB11742 DB11412 DB13584 DB05521 DB01165 DB00391 DB01100 DB02901 DB05095 DB01035 DB00871 DB01471 DB00218 DB11641 DB09101 DB04868 DB08619 DB00788 DB08881 DB00939 DB06595 DB00030 DB06119 DB01541 DB13310 DB00877 DB06290 DB14960 DB00685 DB01059 DB13167 DB00908 DB00402 DB06262 DB04892 DB06616 DB00738 DB13058 DB00091 DB09045 DB05039 DB01122 DB11898 DB09227 DB11633 DB06725 DB00498 DB06292 DB00351 DB12545 DB01245 DB06718 DB11950 DB00511 DB09265 DB05488 DB06589 DB00872 DB13280 DB00841 DB13169 DB01201 DB00749 DB13595 DB08870 DB00266 DB13612 DB08955 DB01397 DB09046 DB01015 DB00214 DB00983 DB14055 DB00169 DB00668 DB12100 DB00951 DB12001 DB13467 DB04839 DB06448 DB09220 DB12015 DB02703 DB00586 DB00784 DB11952 DB14019 DB00648 DB00414 DB00989 DB01120 DB08873 DB00977 DB00468 DB00270 DB00941 DB13097 DB02365 DB13823 DB02224 DB00823 DB01234 DB01137 DB00582 DB13217 DB01277 DB12935 DB01283 DB00695 DB00674 DB12268 DB00312 DB00304 DB01536 DB06011 DB00363 DB01435 DB09063 DB00621 DB01390 DB00294 DB14938 DB15171 DB06819 DB00193 DB12147 DB01325 DB08905 DB00606 DB01155 DB06237 DB00416 DB09288 DB12025 DB00936 DB11567 DB06203 DB00999 DB01382 DB09269 DB08804 DB09218 DB13524 DB13874 DB06736 DB13407 DB00146 DB15444 DB00082 DB00816 DB03585 DB14678 DB11404 DB00705 DB00783 DB13649 DB01227 DB00469 DB13710 DB05109 DB11094 DB00903 DB04682 DB08896 DB06410 DB14059 DB00624 DB00397 DB00224 DB01251 DB01434 DB00604 DB00861 DB13371 DB01118 DB01199 DB12267 DB08867 DB11892 DB08910 DB11886 DB08794 DB00454 DB00176 DB00153 DB00500 DB01357 DB01366 DB01008 DB11730 DB01418 DB01108 DB09200 DB05107 DB00343 DB13668 DB09215 DB00622 DB06789 DB00196 DB00396 DB00545 DB11636 DB00590 DB01181 DB06713 DB06603 DB11652 DB13685 DB14035 DB00978 DB00812 DB16820 DB13345 DB01185 DB00585 DB01026 DB00774 DB01248 DB01278 DB13866 DB00717 DB00661 DB08909 DB09118 DB09043 DB09357 DB00502 DB13829 DB09295 DB01289 DB00932 DB01250 DB11363 DB14881 DB00252 DB01045 DB01524 DB13322 DB13989 DB00763 DB01016 DB13956 DB01167 DB13953 DB13538 DB01268 DB01405 DB05239 DB13385 DB00603 DB00867 DB08972 DB06412 DB13001 DB05804 DB16001 DB00518 DB11672 DB11800 DB00188 DB00564 DB09199 DB00398 DB05667 DB11443 DB11156 DB13503 DB06266 DB00677 DB11581 DB08439 DB06730 DB01407 DB09065 DB08899 DB13648 DB06655 DB06205 DB13944 DB13486 DB04876 DB01050 DB04896 DB09201 DB00843 DB08981 DB00412 DB01232 DB01263 DB14185 DB13958 DB01609 DB11780 DB01211 DB01307 DB13261 DB00310 DB06287 DB00675 DB13657 DB12625 DB01363 DB01377 DB15569 DB05386 DB01456 DB16003 DB01431 DB06250 DB01436 DB13650 DB00248 DB06626 DB01601 DB11507 DB01564 DB13544 DB13694 DB01072 DB06774 DB07768 DB03410 DB06218 DB09048 DB00672 DB01009 DB12461 DB12989 DB08907 DB00580 DB11473 DB00202 DB11943 DB01242 DB01254 DB04665 DB01700 DB00357 DB00436 DB01656 DB01420 DB06600 DB00477 DB11491 DB06700 DB08940 DB09330 DB02845 DB06127 DB00565 DB00681 DB13275 DB05115 DB00573 DB00997 DB12417 DB05294 DB04576 DB14921 DB08961 DB11753 DB05830 DB00554 DB06335 DB14583 DB04845 DB06692 DB11455 DB00461 DB11619 DB11779 DB00508 DB01226 DB13626 DB00864 DB09212 DB00721 DB06709 DB00808 DB04743 DB09289 DB14031 DB00381 DB11390 DB01481 DB00465 DB06636 DB01408 DB03793 DB09143 DB11466 DB08942 DB00805 DB01043 DB00984 DB13179 DB12713 DB15217 DB00083 DB01110 DB06176 DB06756 DB09054 DB11568 DB00711 DB02925 DB00976 DB11124 DB04832 DB13401 DB13857 DB13527 DB13232 DB06160 DB13481 DB13946 DB05295 DB06724 DB00944 DB00483 DB09216 DB01252 DB00817 DB11429 DB13295 DB01098 DB00244 DB00207 DB13430 DB00567 DB00197 DB07402 DB09073 DB12194 DB13139 DB13627 DB00696 DB11774 DB09038 DB01399 DB01221 DB11992 DB00880 DB05154 DB01149 DB00537 DB01070 DB00392 DB00331 DB13675 DB01400 DB01132 DB09280 DB06077 DB00047 DB01001 DB11587 DB09071 DB00199 DB13629 DB01288 DB00794 DB11986 DB00527 DB11518 DB09079 DB01324 DB12482 DB12526 DB04834 DB13044 DB13783 DB00309 DB11963 DB09214 DB06194 DB04796 DB09389 DB12371 DB12483 DB00827 DB01264 DB11642 DB08912 DB08882 DB00444 DB09104 DB12474 DB00482 DB01521 DB00570 DB15762 DB01128 DB08901 DB01406 DB00359 DB04864 DB14517 DB06710 DB01419 DB13860 DB00320 DB04855 DB11323 DB01395 DB13772 DB01014 DB06723 DB00263 DB00530 DB13347 DB00563 DB01174 DB08877 DB11511 DB08976 DB04812 DB15317 DB00625 DB00491 DB14568 DB01276 DB00159 DB15614 DB14740 DB00910 DB08938 DB09213 DB08957 DB08496 DB15959 DB12515 DB00938 DB09231 DB09285 DB00728 DB13532 DB00365 DB00991 DB01087 DB12214 DB01401 DB00795 DB01485 DB09371 DB14027 DB13722 DB01010 DB01600 DB12412 DB16625 DB06212 DB01261 DB13528 DB08883 DB00342 DB06731 DB00227 DB12445 DB04574 DB00361 DB04830 DB00712 DB00673 DB00575 DB13314 DB01424 DB01021 DB00243 DB04725 DB13451 DB11698 DB12399 DB09034 DB08827 DB01238 DB01628 DB00946 DB13406 DB09123 DB14060 DB01336 DB08918 DB11871 DB05773 DB08382 DB01338 DB13587 DB00981 DB04572 DB00425 DB01183 DB04258 DB12141 DB00762 DB01135 DB00221 DB09281 DB00821 DB01291 DB00247 DB01233 DB00255 DB12887 DB00515 DB08736 DB08951 DB00541 DB09456 DB13495 DB09564 DB08797 DB08991 DB00071 DB00914 DB00524 DB00533 DB08962 DB00701 DB15982 DB01068 DB04552 DB11273","absorption":"Prednisolone acetate oral suspension given at a dose equivalent to 15mg prednisolone has a C<sub>max<\/sub> of 321.1ng\/hr, a T<sub>max<\/sub>of 1-2 hours, and an AUC of 1999.4ng\\*hr\/mL.[L9449] The absorption pharmacokinetics of prednisolone acetate are not significantly different from a comparable dose of prednisolone.[L9449]","created":"2019-10-23","groups":"vet_approved approved","pathways":null,"snp-effects":null,"carriers":"BE0000530 BE0000209","half-life":"Oral prednisolone acetate has a plasma half life of 2-3 hours.[L9449]","monoisotopic-mass":402.204238692,"volume-of-distribution":"The volume of distribution of the active metabolite, prednisolone, is 0.22\/0.7L\/kg.[L9449]","route-of-elimination":"Prednisolone acetate is predominantly excreted in the urine.[L9449]","name":"Prednisolone acetate","metabolism":"Prednisolone acetate undergoes ester hydrolysis to [prednisolone].[A187421] After this step, the drug undergoes the normal metabolism of prednisolone.\r\n\r\nPrednisolone can be reversibly metabolized to [prednisone] which is then metabolized to 17,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20-dihydro-prednisone (M-V), 6hydroxy-prednisone (M-XII), 6-hydroxy-prednisone (M-XIII), or 20-dihydro-prednisone (M-IV).[A187403] 20-dihydro-prednisone is metabolized to 17,20,21-trihydroxy-5-pregn-1-en-3,11-dione(M-XVIII).[A187403] Prednisolone is metabolized to \u201D6-prednisolone (M-XI), 20-dihydro-prednisolone (M-III), 20-dihydro-prednisolone (M-II), 6hydroxy-prednisolone (M-VII), or 6hydroxy-prednisolone(M-VI).[A187403] 6hydroxy-prednisolone is metabolized to 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-X).[A187403] 6hydroxy-prednisolone is metabolized to 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6,11,17,21-tetrahydroxy-5-pregn-1-en-3,20-dione (M-XIV).[A187403] MVIII is metabolized to 6,11,17,20,21-pentahydroxy-5-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6,11,17,20,21-pentahydroxy-5-pregn-1-en-3-one (M-XVI) and then to MXIV.[A187403] These metabolites and their glucuronide conjugates are excreted predominantly in the urine.[A187403,L9449]","reactions":null,"indication":"Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions.[L9449] Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.[L9449]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15566"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https:\/\/pacylex.com). Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.[L9470]","enzymes":null,"type":"small molecule","cas-number":"1215011-08-7","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-10-28","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"PCLX-001","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15567"},{"toxicity":"Toxicity information regarding adagrasib is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as hepatotoxicity, gastrointestinal adverse reactions and QTc interval prolongation.[L44361] Symptomatic and supportive measures are recommended. \r\n\r\nThe carcinogenicity of adagrasib has not been evaluated. In an _in vitro_ bacterial reverse mutation (Ames) assay, adagrasib was not mutagenic. An _in vitro_ chromosomal aberration assay and an _in vivo_ micronucleus assay in rats showed that it was not genotoxic. Studies evaluating the effects of adagrasib on fertility have not been performed. The oral administration of adagrasib to rats for up to 13 weeks induced phospholipidosis at doses higher than 150 mg\/kg (approximately 2 times the human exposure at the recommended dose based on AUC). The presence of phospholipidosis led to the increased vacuolation of multiple organs.[L44361]","snp-adverse-drug-reactions":null,"average-mass":604.13,"transporters":"BE0001032","pharmacodynamics":"The exposure-response relationship and pharmacodynamic response time course of adagrasib have not been elucidated. The use of adagrasib can cause QTc interval prolongation. The increase in QTc is concentration-dependent. In patients given 600 mg of adagrasib twice daily, the mean QTcF change from baseline (\u201DQTcF) was 18 ms at the mean steady-state maximum concentration.[L44361] The use of adagrasib can also lead to severe gastrointestinal adverse reactions, hepatotoxicity and interstitial lung disease\/pneumonitis.[L44361]","msds":null,"description":"Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding pocket.[A187559] Adagrasib targets KRAS<sup>G12C<\/sup>, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling.[A254052] In a phase I\/IB clinical study that included patients with KRAS<sup>G12C<\/sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. The phase II of the same study showed that in patients with KRAS<sup>G12C<\/sup>-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals.[A254052,A254057,A254946]\r\n\r\nIn February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C<\/sup>\u20AC\u201Cpositive NSCLC.[L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C<\/sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.[L44361,L44366] Adagrasib joins [sotorasib] as another KRAS<sup>G12C<\/sup> inhibitor approved by the FDA.[A254062]","enzymes":"BE0002887 BE0003549 BE0002363 BE0002638 BE0002793 BE0002433","type":"small molecule","cas-number":"2326521-71-3","sequences":null,"targets":"BE0004071","unii":"8EOO6HQF8Y","protein-binding":"_In vitro_, adagrasib has a human plasma protein binding of 98%.[L44361]","fda-label":null,"clearance":"Adagrasib has an apparent oral clearance (CL\/F) of 37 L\/h.[L44361]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with or without food. High-fat and high-calorie meals do not have a clinically significant effect on adagrasib pharmacokinetics.","state":"solid","synthesis-reference":"Fell, Jay B et al. \u20ACIdentification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.\u20AC Journal of medicinal chemistry vol. 63,13 (2020): 6679-6693. doi:10.1021\/acs.jmedchem.9b02052","mechanism-of-action":"In normal cells, KRAS is activated by binding to guanosine triphosphate (GTP), and this promotes the activation of the MAP kinase pathway and intracellular signal transduction. When GTP is hydrolyzed to guanosine diphosphate (GDP), KRAS is inactivated. This mechanism works as an \"on\"\/\"off\" system that regulates cell growth. The substitution of Gly12 by cysteine in KRAS (KRAS<sup>G12C<\/sup>) impairs GTP hydrolysis, and maintains KRAS in its active form. Therefore, the presence of this mutation leads to uncontrolled cellular proliferation and growth, as well as malignant transformation.[A187559] Adagrasib is a covalent inhibitor of KRAS<sup>G12C<\/sup> that irreversibly and selectively binds and locks KRAS<sup>G12C<\/sup> in its inactive, guanosine diphosphate\u20AC\u201Cbound state.[A254052] Therefore, the use of adagrasib inhibits tumor cell growth and viability in cancers with  KRAS<sup>G12C<\/sup> mutations with minimal off-target activity.[L44361]","drug-interactions":"DB01149 DB01076 DB11672 DB14055 DB00203 DB00564 DB09107 DB05667 DB00656 DB13259 DB11581 DB09280 DB06448 DB01224 DB08864 DB00540 DB09065 DB08899 DB00648 DB00802 DB00907 DB00794 DB00814 DB08873 DB11986 DB00527 DB01036 DB01222 DB00641 DB05232 DB01232 DB00285 DB00514 DB01263 DB01234 DB01264 DB06228 DB00582 DB01211 DB01086 DB00571 DB11642 DB00312 DB00557 DB00482 DB09049 DB09039 DB08816 DB00503 DB08815 DB01228 DB00220 DB00297 DB01590 DB01406 DB00193 DB00490 DB06237 DB01601 DB04861 DB01124 DB04835 DB04855 DB01075 DB00700 DB12825 DB01072 DB06774 DB00645 DB00625 DB09053 DB01127 DB11901 DB01254 DB01174 DB00222 DB00705 DB00246 DB09085 DB00216 DB00224 DB01023 DB02520 DB01394 DB12532 DB01118 DB00281 DB01320 DB00296 DB01151 DB01323 DB11753 DB13578 DB00850 DB01161 DB00961 DB00807 DB00264 DB00401 DB11779 DB11730 DB09345 DB00864 DB00820 DB13328 DB11637 DB09009 DB00721 DB00496 DB06212 DB00750 DB00342 DB00726 DB00892 DB00896 DB00897 DB00012 DB00227 DB09342 DB00862 DB05521 DB11742 DB11951 DB00673 DB11502 DB03255 DB01100 DB00683 DB06770 DB13179 DB09101 DB01026 DB04868 DB08987 DB12016 DB06595 DB00976 DB00877 DB01182 DB13683 DB09118 DB08827 DB00016 DB00289 DB11148 DB00404 DB09083 DB00502 DB00932 DB01183 DB00252 DB01045 DB11633 DB00763 DB08894 DB01167 DB00472 DB00696 DB00872 DB01201 DB01002 DB00701 DB00458 DB16390 DB12265","absorption":"The AUC and C<sub>max<\/sub> of adagrasib increase in a dose-proportional manner between 400 mg and 600 mg (0.67 to 1 times the approved recommended dose). At the recommended dose, adagrasib reached steady-state within 8 days, with a 6-fold accumulation. The T<sub>max<\/sub> of adagrasib is approximately 6 hours. The administration of a high-fat and high-calorie meal (900-1000 calories, 50% from fat) did not have a clinically significant effect on the pharmacokinetics of adagrasib.[L44361] Adagrasib has high oral bioavailability and is able to penetrate the central nervous system.[A254941]","created":"2019-11-01","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Adagrasib has a terminal elimination half-life of 23 hours.[L44361]","monoisotopic-mass":603.2524793,"volume-of-distribution":"Adagrasib has an apparent volume of distribution of 942 L.[L44361]","route-of-elimination":"Adagrasib is eliminated through feces and urine. In patients given a single dose of radiolabeled adagrasib, 75% of the dose was recovered in feces (14% as unchanged), while 4.5% was recovered in urine (2% as unchanged).[L44361]","name":"Adagrasib","metabolism":"Following single-dose administration, adagrasib is mainly metabolized by CYP3A4. However, since adagrasib inhibits CYP3A4 following multiple dosing, other enzymes such as CYP2C8, CYP1A2, CYP2B6, CYP2C9, and CYP2D6 contribute to its metabolism at steady-state.[L44361]","reactions":null,"indication":"Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.[L44361]\r\n\r\nThis indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).[L44361]","ahfs-codes":null,"updated":"2022-12-17","drugbank-id":"DB15568"},{"toxicity":"Data regarding overdoses of sotorasib are not readily available. However, in clinical trials, signs of dose limiting toxicity were not found.[A235168] Patients experiencing an overdose may experience and increased risk and severity of adverse effects such as diarrhea, nausea, vomiting, fatigue, and elevated aminotransferase.[A235168]","snp-adverse-drug-reactions":null,"average-mass":560.606,"transporters":"BE0001067 BE0001032","pharmacodynamics":"Sotorasib is indicated in the treatment of adults with KRAS G12C mutant non small cell lung cancer.[L34288] It has a moderate duration of action as it is given daily.[L34288] Patients should be counselled regarding the risks of hepatotoxicity, interstitial lung disease and pneumonitis; and to avoid breastfeeding during treatment and up to 1 week after the last dose.[L34288]","msds":null,"description":"Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.[A187547] The drug [MRTX849] is also currently being developed and has the same target.[A187547]\r\n\r\nSotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 10, 2022.[L39675]","enzymes":"BE0004866 BE0002887 BE0003549 BE0002793","type":"small molecule","cas-number":"2252403-56-6","sequences":null,"targets":"BE0004071","unii":"2B2VM6UC8G","protein-binding":"Sotorasib is 89% protein bound in plasma.[L34288]","fda-label":null,"clearance":"Sotorasib has an apparent clearance at steady state of 26.2 L\/h.[L34288]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS ANTINEOPLASTIC AGENTS Other antineoplastic agents","pdb-entries":null,"food-interactions":"Avoid antacids. If coadministration cannot be avoided, take sotorasib 4 hours before or 10 hours after antacids. Take with or without food. Taking sotorasib with a high fat, high calorie meal increases total exposure to sotorasib by 25%.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Normally GTP binds to KRAS, activating the protein and promoting effectors to the MAP kinase pathway.[A187556] GTP is hydrolyzed to GDP, and KRAS is inactivated.[A187559] KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form.[A187559]\r\n\r\nSotorasib binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form.[A187547] The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects.[L34288] This mutation is present in 13% of non small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors.[A187547]","drug-interactions":"DB01194 DB08880 DB08953 DB00825 DB13760 DB00682 DB09124 DB09381 DB13456 DB14649 DB12457 DB15091 DB00656 DB00742 DB09198 DB13259 DB08980 DB09570 DB06712 DB00204 DB00540 DB01142 DB00637 DB00970 DB12130 DB08805 DB15035 DB08828 DB00814 DB01215 DB12978 DB00338 DB13249 DB00280 DB01200 DB05232 DB00495 DB11921 DB13878 DB01409 DB06228 DB01223 DB00957 DB01086 DB06772 DB13691 DB00962 DB00277 DB00557 DB01595 DB09195 DB08922 DB01229 DB12235 DB00321 DB00503 DB07615 DB00973 DB11919 DB00863 DB06148 DB01129 DB00220 DB12781 DB01256 DB12952 DB01590 DB09026 DB09030 DB05316 DB00490 DB13867 DB04908 DB04652 DB04957 DB04690 DB00700 DB00531 DB01075 DB08970 DB00912 DB12825 DB11855 DB09076 DB00631 DB00546 DB11828 DB08932 DB01396 DB11901 DB01551 DB00390 DB00741 DB08865 DB01039 DB12329 DB00367 DB11823 DB00246 DB13208 DB13293 DB09082 DB09383 DB14541 DB01117 DB09234 DB00778 DB15102 DB00481 DB00358 DB00238 DB01708 DB05676 DB06739 DB00959 DB08820 DB00281 DB11703 DB11827 DB01320 DB00136 DB13981 DB00834 DB00773 DB13943 DB01323 DB01319 DB04828 DB13578 DB09481 DB01259 DB09074 DB01624 DB06717 DB04938 DB00440 DB00820 DB01062 DB09299 DB13954 DB06813 DB01466 DB00708 DB14009 DB13879 DB12332 DB00240 DB00370 DB01216 DB00731 DB00324 DB11979 DB00012 DB11742 DB05521 DB11951 DB13488 DB00758 DB05812 DB09161 DB11502 DB11739 DB01204 DB01100 DB09101 DB11641 DB04868 DB14723 DB11575 DB08881 DB06595 DB06119 DB00877 DB01182 DB06290 DB00846 DB12364 DB01184 DB08930 DB00906 DB00402 DB00908 DB06616 DB00091 DB05039 DB09227 DB09225 DB11633 DB06292 DB00351 DB00612 DB13158 DB11689 DB01175 DB11613 DB14064 DB08894 DB14540 DB00180 DB00949 DB06589 DB00253 DB00872 DB13280 DB01201 DB13595 DB08870 DB00420 DB00980 DB14538 DB08906 DB01410 DB16390 DB14055 DB01583 DB09238 DB00203 DB00169 DB00213 DB06738 DB06695 DB09107 DB12001 DB04839 DB06448 DB12015 DB02703 DB00586 DB00715 DB12629 DB00526 DB00175 DB11952 DB00334 DB14019 DB00648 DB08873 DB00977 DB00468 DB00924 DB00270 DB12010 DB00641 DB13835 DB15328 DB13955 DB00307 DB13209 DB00823 DB06155 DB01234 DB06654 DB11978 DB00706 DB04856 DB12026 DB00582 DB01241 DB06605 DB00674 DB00312 DB00304 DB00635 DB00724 DB00363 DB01536 DB14066 DB11869 DB00316 DB04871 DB01435 DB01390 DB09183 DB09063 DB08838 DB04884 DB00294 DB00628 DB00297 DB00193 DB12500 DB12147 DB09378 DB09318 DB06237 DB09288 DB04835 DB14543 DB00822 DB06203 DB11757 DB09053 DB11964 DB00568 DB00882 DB13874 DB09068 DB15444 DB14678 DB00705 DB13399 DB00617 DB00734 DB00783 DB01227 DB05109 DB11094 DB09166 DB08896 DB00624 DB03701 DB12836 DB12770 DB01097 DB00224 DB14544 DB00394 DB00604 DB05541 DB14063 DB12532 DB01118 DB15133 DB12267 DB08867 DB08910 DB00559 DB00471 DB11886 DB16165 DB08794 DB00454 DB00176 DB01104 DB01161 DB05015 DB11712 DB09296 DB11960 DB11718 DB01095 DB00401 DB01357 DB01008 DB11730 DB00921 DB09555 DB09345 DB01058 DB01192 DB11574 DB11637 DB13725 DB01418 DB09200 DB06207 DB09009 DB00343 DB00496 DB00622 DB06789 DB14068 DB04838 DB00396 DB06446 DB13766 DB11636 DB09342 DB00590 DB06713 DB01181 DB06603 DB11652 DB13685 DB01130 DB00690 DB00158 DB08893 DB13345 DB00379 DB01114 DB06414 DB00585 DB00591 DB01384 DB00377 DB04934 DB01026 DB09095 DB14570 DB01248 DB00615 DB01134 DB13866 DB00717 DB00661 DB01037 DB09118 DB13683 DB16222 DB09083 DB00404 DB11697 DB00502 DB12543 DB13829 DB00932 DB00486 DB14881 DB11363 DB00252 DB01045 DB13322 DB11853 DB01047 DB01244 DB14761 DB00353 DB05467 DB01016 DB01054 DB13956 DB14011 DB01167 DB13953 DB00619 DB01268 DB09317 DB01002 DB05239 DB13385 DB00603 DB06670 DB09078 DB06685 DB14545 DB00518 DB00956 DB00745 DB15566 DB11800 DB01411 DB00564 DB09199 DB00188 DB00398 DB05667 DB11750 DB01173 DB11581 DB13961 DB08439 DB04833 DB06730 DB08864 DB00234 DB06742 DB01105 DB06684 DB08899 DB06144 DB06777 DB09065 DB12471 DB13486 DB09236 DB13944 DB09291 DB11362 DB01050 DB04896 DB12884 DB04905 DB01006 DB00843 DB09201 DB09241 DB16098 DB03515 DB01587 DB00412 DB01392 DB11614 DB01232 DB00295 DB08931 DB13950 DB01263 DB00911 DB00636 DB00755 DB14185 DB00589 DB00736 DB01166 DB01211 DB09235 DB12941 DB06287 DB04630 DB09049 DB00675 DB00904 DB06403 DB00455 DB12537 DB00528 DB01611 DB06282 DB05889 DB08815 DB01377 DB14542 DB00441 DB00709 DB01456 DB09089 DB06016 DB01431 DB04946 DB09230 DB11732 DB14737 DB00215 DB13650 DB00248 DB06626 DB01591 DB01601 DB00242 DB06781 DB13791 DB06152 DB01072 DB06774 DB00625 DB06218 DB09048 DB00645 DB08895 DB06786 DB00751 DB01267 DB00580 DB08907 DB01154 DB01242 DB01254 DB11760 DB11943 DB00836 DB01380 DB01236 DB01656 DB01420 DB06700 DB00477 DB06480 DB00889 DB09330 DB09085 DB06702 DB08806 DB06762 DB01023 DB09237 DB12597 DB06234 DB11487 DB00349 DB01394 DB04829 DB00997 DB00457 DB03496 DB12131 DB01393 DB00296 DB05294 DB01621 DB14921 DB06652 DB12612 DB00250 DB11753 DB01138 DB00443 DB06335 DB14583 DB15233 DB09017 DB04845 DB11817 DB00698 DB13074 DB00813 DB08860 DB04975 DB16691 DB00433 DB09128 DB11619 DB01220 DB00694 DB00300 DB09027 DB09239 DB13626 DB00865 DB03783 DB00864 DB04841 DB13328 DB11995 DB00721 DB14975 DB00688 DB05212 DB05351 DB14631 DB00750 DB00808 DB00185 DB04842 DB00892 DB14065 DB04743 DB09289 DB00381 DB00191 DB12278 DB08833 DB01049 DB01196 DB00544 DB00757 DB01013 DB08992 DB00317 DB01018 DB06636 DB11693 DB09143 DB14126 DB08971 DB09223 DB01589 DB13179 DB00990 DB15685 DB09075 DB09229 DB16732 DB08987 DB06176 DB13125 DB09054 DB00747 DB14512 DB00976 DB00969 DB00860 DB00972 DB13602 DB00016 DB13401 DB00593 DB11148 DB12674 DB00288 DB13857 DB00497 DB06724 DB00829 DB09216 DB00940 DB00163 DB01098 DB00207 DB00539 DB00567 DB11915 DB15031 DB09073 DB00588 DB11251 DB00696 DB00333 DB00470 DB11529 DB00286 DB00458 DB01221 DB11586 DB05885 DB12265 DB05154 DB01149 DB01076 DB00080 DB09262 DB09090 DB11791 DB00437 DB01132 DB09280 DB01224 DB06077 DB15011 DB00740 DB00802 DB00356 DB00499 DB00199 DB00759 DB00907 DB01198 DB08903 DB06697 DB00794 DB09071 DB00337 DB11986 DB00527 DB01370 DB09079 DB08875 DB01036 DB01222 DB14539 DB12161 DB00857 DB00285 DB00514 DB13762 DB00309 DB11963 DB01264 DB09389 DB12371 DB12483 DB00950 DB12455 DB00571 DB00608 DB08882 DB11642 DB00444 DB08912 DB12240 DB09104 DB12923 DB00482 DB12474 DB08816 DB09039 DB12093 DB00347 DB09297 DB00570 DB08934 DB01128 DB02187 DB00744 DB08901 DB06470 DB01028 DB09102 DB08916 DB00359 DB14517 DB00393 DB06710 DB04861 DB08889 DB01030 DB00320 DB01349 DB04855 DB01395 DB00378 DB01260 DB00982 DB06723 DB15442 DB00530 DB13347 DB00563 DB06708 DB01174 DB08877 DB11737 DB11796 DB00318 DB00678 DB11274 DB09279 DB00216 DB04920 DB14568 DB06216 DB01285 DB11770 DB00346 DB12092 DB05482 DB13952 DB00910 DB01544 DB08938 DB00439 DB12301 DB01218 DB09231 DB08496 DB13941 DB12515 DB00938 DB09232 DB00365 DB01079 DB00961 DB11635 DB00764 DB01087 DB00807 DB00795 DB09371 DB12245 DB00647 DB00663 DB05271 DB00927 DB16703 DB01588 DB14840 DB11967 DB02789 DB01069 DB00501 DB01103 DB06212 DB06209 DB01261 DB06419 DB13528 DB00342 DB08883 DB00726 DB00896 DB06267 DB00897 DB09061 DB00227 DB00448 DB15719 DB09240 DB00620 DB01190 DB00862 DB04574 DB00361 DB16236 DB00673 DB00909 DB01136 DB06780 DB11942 DB03255 DB00683 DB13500 DB01424 DB00575 DB06770 DB00243 DB06769 DB14669 DB00186 DB01159 DB11799 DB00669 DB12016 DB13609 DB09034 DB00602 DB08827 DB01238 DB01012 DB01253 DB01628 DB00946 DB15149 DB09123 DB08918 DB05773 DB00425 DB04572 DB11130 DB13746 DB12141 DB01559 DB00762 DB11837 DB09281 DB00247 DB00918 DB01233 DB00255 DB04825 DB01074 DB13007 DB12887 DB15822 DB00541 DB00898 DB01115 DB00533 DB00687 DB00701 DB15982 DB01068 DB01388 DB11273","absorption":"A 960 mg once daily dose of sotorasib reaches a C<sub>max<\/sub> of 7.50 g\/mL, with a median T<sub>max<\/sub> of 2.0 hours, and an AUC<sub>0-24h<\/sub> of 65.3 h\\*g\/mL.[A235168]","created":"2019-11-01","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Sotorasib has a terminal elimination half life of 5.5  1.8 hours.[A235168,L34288]","monoisotopic-mass":560.234745176,"volume-of-distribution":"The volume of distribution of sotorasib is 211 L.[L34288]","route-of-elimination":"Sotorasib is 74% eliminated in the feces and 6% eliminated in the urine.[L34288] 53% of the dose recovered in the feces and 1% of the dose recovered in the urine is in the form of the unchanged parent compound.[L34288]","name":"Sotorasib","metabolism":"Sotorasib is predominantly metabolized through conjugation or by CYP3As.[L34288]","reactions":null,"indication":"Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy.[L34288]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15569"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.[L9875]","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":"BE0009787","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"FLX475","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15570"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":318.457,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"109430-12-8","sequences":null,"targets":null,"unii":"78P2ZC128S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-18","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":318.219494826,"volume-of-distribution":null,"route-of-elimination":null,"name":"(12R)-12-hydroxyeicosapentaenoic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15571"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CTX001 is being developed by CRISPR Therapeutics and Vertex. It is an autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells in clinical trials for the treatment of severe sickle cell disease and severe beta-thalassemia.[L10139]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-19","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CTX001","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15572"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":136.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"80-56-8","sequences":null,"targets":null,"unii":"JPF3YI7O34","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-28","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":136.125200515,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Pinene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15573"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":136.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"127-91-3","sequences":null,"targets":null,"unii":"4MS8VHZ1HJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-28","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":136.125200515,"volume-of-distribution":null,"route-of-elimination":null,"name":"beta-Pinene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15574"},{"toxicity":"There is no information regarding the LD<sub>50<\/sub> of padeliporfin.\r\n\r\nThere is limited clinical information on padeliporfin overdose. In clinical studies, healthy subjects were exposed to doses up to 15 mg\/kg of padeliporfin di-potassium (corresponding to 13.73 mg\/kg of padeliporfin) without light activation and 23 patients have been treated with 6 mg\/kg of padeliporfin di-potassium (corresponding to 5.49 mg\/kg of padeliporfin) without significant safety issues. However, prolonged photosensitization is possible and precautions against light exposure should be maintained for an additional 24 hours. An overdose of the laser light may increase the risk of undesirable extraprostatic necrosis.[L39794]","snp-adverse-drug-reactions":null,"average-mass":840.26,"transporters":"BE0003659 BE0001004","pharmacodynamics":"Padeliporfin mediates tumour-specific cytotoxicity. It works to destroy target cells through the release of reactive oxygen species in response to an exposure to laser light radiation delivered at a specific wavelength. Padeliporfin causes vascular shutdown and activation of an immune response in the target tissue.[A244559] In preclinical studies in animal models, padeliporfin-mediated photosensitization caused occlusion of the full tumour vasculature in a few minutes of treatment.[A244699] \r\n\r\nPadeliporfin remains confined within the circulation even at high doses with minimal extravasation: reactive oxygen species generated upon laser activation are contained in the vasculature and do not directly kill tumour cells.[A244559]","msds":null,"description":"Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.[A244559] Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland.[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]","enzymes":null,"type":"small molecule","cas-number":"759457-82-4","sequences":null,"targets":null,"unii":"EEO29FZT86","protein-binding":"Padeliporfin di-potassium is 99% bound to human plasma proteins.[L39794] Padeliporfin binds to high-density proteins, including serum albumin, but binds poorly to low-level density lipoproteins and high-density lipoproteins.[A244699]","fda-label":null,"clearance":"Following administration of 1.25-15 mg\/kg of padeliporfin di-potassium in healthy men, clearance of padeliporfin di-potassium ranged from 0.0245 to 0.088 L\/h\/kg. In patients with localised prostate cancer treated with 4 mg\/kg and 2 mg\/kg of padeliporfin di-potassium, clearance was 0.04 L\/h\/kg and 0.06 L\/h\/kg, respectively.[L39794]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS OTHER ANTINEOPLASTIC AGENTS Sensitizers used in photodynamic\/radiation therapy ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. VTP involves the process of light activation of photosensitizer localized in the target tissue, which produces reactive oxygen species that work to destroy target cells.[A244559,A244699]\r\n\r\nPadeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a photochemical reaction that generates oxygen radicals (hydroxyl radical, superoxide radical), thereby causing local hypoxia of the target tissue. Nitric oxide radicals are also released, resulting in transient arterial vasodilatation that triggers the release of the vasoconstrictor, endothelin-1. Rapid consumption of the nitric oxide radicals by oxygen radicals leads to the formation of reactive nitrogen species (RNS) including peroxynitrite, in parallel to arterial constriction.[L39794] \r\n\r\nImpaired deformability enhances erythrocyte aggregability and formation of blood clots at the interface of the arterial supply of the target tissue, leading to occlusion of the tumour vasculature, or \"vascular shutdown.\" This effect is enhanced by RNS-induced endothelial cell apoptosis and initiation of self-propagated tumour cells necrosis through peroxidation of their membrane.[L39794]","drug-interactions":"DB14055 DB00682 DB16183 DB06754 DB09255 DB09259 DB00407 DB13400 DB06695 DB09000 DB02285 DB06679 DB00009 DB06294 DB15351 DB08814 DB12289 DB00140 DB06406 DB04905 DB09241 DB11095 DB00845 DB01403 DB00755 DB13510 DB09258 DB05099 DB01137 DB13199 DB02709 DB05266 DB06228 DB06081 DB00434 DB06635 DB04898 DB08994 DB01166 DB06605 DB08912 DB12598 DB13149 DB13036 DB08816 DB07615 DB09154 DB09030 DB00806 DB08813 DB11812 DB05229 DB04619 DB03410 DB13136 DB01088 DB13347 DB09283 DB04665 DB00013 DB00975 DB06261 DB00278 DB11598 DB06822 DB00208 DB01225 DB08887 DB09536 DB00015 DB00707 DB06543 DB00855 DB13275 DB12465 DB06441 DB00686 DB12771 DB12092 DB04854 DB13616 DB15880 DB00055 DB08794 DB00569 DB08496 DB12216 DB01138 DB05296 DB00264 DB09261 DB13327 DB06779 DB00945 DB04932 DB05254 DB01418 DB12163 DB01600 DB01878 DB06209 DB01240 DB12749 DB12726 DB12831 DB04743 DB05361 DB14094 DB12445 DB00261 DB00460 DB00758 DB09260 DB05767 DB16628 DB15786 DB00553 DB11312 DB06659 DB13451 DB04925 DB09075 DB05428 DB04868 DB00086 DB11268 DB08881 DB00001 DB11630 DB12321 DB12364 DB07767 DB00946 DB00031 DB00775 DB13646 DB01207 DB00992 DB04571 DB06271 DB13929 DB00498 DB12545 DB00974 DB00821 DB00054 DB01109 DB00063 DB00029 DB00006 DB00266 DB14726 DB11984 DB11166 DB13124 DB13367","absorption":"After intravenous bolus injection at a dose of 6 mg\/kg into healthy mice, the C<sub>max<\/sub> of padeliporfin was about 52 mg\/L, with a T<sub>max<\/sub> of two minutes.[A244699]","created":"2019-11-29","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The estimated half-life is 1.19 hrs  0.08 at 4 mg\/kg of padeliporfin di-potassium.[L39794]","monoisotopic-mass":839.181629,"volume-of-distribution":"In healthy men receiving 1.25 to 15 mg\/kg of padeliporfin di-potassium, the mean volume of distribution (V<sub>d<\/sub>) ranged from 0.064 to 0.279 L\/kg. In patients with localized prostate cancer treated with 2 and 4 mg\/kg of padeliporfin di-potassium, the mean V<sub>d<\/sub> ranged from 0.09 to 0.10 L\/kg.[L39794] Upon administration, padeliporfin remain confined within the circulation even at high doses, with minimal extravasation to other tissues.[A244699]","route-of-elimination":"In healthy subjects, urinary excretion of padeliporfin was very low, accounting for less than 0.2% of the dose. Fecal elimination is a suspected predominant route of elimination.[L39794]","name":"Padeliporfin","metabolism":"In human liver microsomes and S9 fractions, padeliporfin underwent minimal metabolism. No metabolites of padeliporfin have been identified yet as a radiolabeled study has not been performed.[L39794]","reactions":null,"indication":"Padeliporfin is indicated for the treatment of adults with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate with a life expectancy greater than or equal to 10 years. Patients must meet the following criteria: clinical stage T1c or T2a; Gleason Score \u2030 6, based on high-resolution biopsy strategies; PSA \u2030 10 ng\/mL; and 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with \u2030 50 % cancer involvement in any one core or a PSA density \u2030 0.15 ng\/mL\/cm<sup>3<\/sup>.[L39794]","ahfs-codes":null,"updated":"2022-01-20","drugbank-id":"DB15575"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":166.1739,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"118-61-6","sequences":null,"targets":null,"unii":"555U6TZ2MV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-29","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":166.062994186,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ethyl salicylate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15576"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":341.487,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Desfesoterodine is a metabolite of [tolterodine].","enzymes":null,"type":"small molecule","cas-number":"207679-81-0","sequences":null,"targets":null,"unii":"YU871O78GR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Drugs for urinary frequency and incontinence UROLOGICALS GENITO URINARY SYSTEM AND SEX HORMONES","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-11-29","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":341.235479241,"volume-of-distribution":null,"route-of-elimination":null,"name":"Desfesoterodine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15578"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":296.366,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"35825-57-1","sequences":null,"targets":null,"unii":"5E9SXT166N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":296.141244504,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cryptotanshinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15579"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":292.76,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"38083-17-9","sequences":null,"targets":null,"unii":"9N42CW7I54","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":292.0978555,"volume-of-distribution":null,"route-of-elimination":null,"name":"Climbazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15580"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":254.2375,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"480-40-0","sequences":null,"targets":null,"unii":"3CN01F5ZJ5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":254.057908808,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chrysin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15581"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1101.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Echinomycin is a cytotoxic polypeptide quinoxaline antibiotic isolated from _Streptomyces echinatus_ that binds to DNA and inhibits RNA synthesis.","enzymes":null,"type":"small molecule","cas-number":"512-64-1","sequences":null,"targets":null,"unii":"TG824J6RQT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1100.420807897,"volume-of-distribution":null,"route-of-elimination":null,"name":"Echinomycin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15582"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":506.21,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluazuron is a benzoyl phenylurea compound.","enzymes":null,"type":"small molecule","cas-number":"86811-58-7","sequences":null,"targets":null,"unii":"VB0PV6I7L6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":505.0019374,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluazuron","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15583"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":286.2363,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"491-70-3","sequences":null,"targets":null,"unii":"KUX1ZNC9J2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":286.047738052,"volume-of-distribution":null,"route-of-elimination":null,"name":"Luteolin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15584"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":445.647,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ORG-31710 is a progestational hormone antagonist.","enzymes":null,"type":"small molecule","cas-number":"118968-41-5","sequences":null,"targets":null,"unii":"X2V3MG6PE8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":445.2980795,"volume-of-distribution":null,"route-of-elimination":null,"name":"ORG-31710","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15585"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":154.1201,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"149-29-1","sequences":null,"targets":null,"unii":"95X2BV4W8R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":154.02660868,"volume-of-distribution":null,"route-of-elimination":null,"name":"Patulin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15586"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":667.87,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Antimony potassium tartrate is a schistosomicide possibly useful against other parasites. It has irritant emetic properties and may cause lethal cardiac toxicity among other adverse effects.","enzymes":null,"type":"small molecule","cas-number":"28300-74-5","sequences":null,"targets":null,"unii":"DL6OZ476V3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":665.737,"volume-of-distribution":null,"route-of-elimination":null,"name":"Antimony potassium tartrate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15587"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":456.711,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"cytoplasm","enzymes":null,"type":"small molecule","cas-number":"77-52-1","sequences":null,"targets":"BE0000394 BE0001076","unii":"P3M2575F3F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":456.360345406,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ursolic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-06-27","drugbank-id":"DB15588"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":194.2271,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zingerone is a pungent component of ginger.","enzymes":null,"type":"small molecule","cas-number":"122-48-5","sequences":null,"targets":null,"unii":"4MMW850892","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":194.094294314,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zingerone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15589"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":396.395,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"beta-Apopicropodophyllin is a component of the freshwater plant _Micranthemum umbrosum_.","enzymes":null,"type":"small molecule","cas-number":"477-52-1","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":396.120902984,"volume-of-distribution":null,"route-of-elimination":null,"name":"beta-Apopicropodophyllin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15590"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"85637-73-6","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Atrial natriuretic peptide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15591"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cucurbita pepo subsp. ovifera whole allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"2NS91NJI8N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-12","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cucurbita pepo subsp. ovifera whole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15592"},{"toxicity":"No overdose information is available, however, renal toxicity has been seen with the administration of antisense oligomers, sometimes resulting in fatal glomerulonephritis.[L10755,L10758] In the case of an overdose, it is advisable to provide supportive care and monitor renal function. LD50 information is currently unavailable for this drug.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Golodirsen masks genetic mutations that result in a cascade of events which treat Duchenne Muscular Dystrophy in about 8% of patients. Golodirsen indirectly induces the production of dystrophin, an important protein for muscle function.[A188577,L10755,L10764] It is not yet confirmed whether motor function is improved by golodirsen, however, clinical trials are underway to examine its clinical benefits.[L10755]  \r\n\r\n**A note on nephrotoxicity**\r\n\r\nThough clinical trials have not yet confirmed that golodirsen is nephrotoxic, other morpholino antisense oligonucleotides have been known to cause nephrotoxicity. Ensure to monitor renal function during golodirsen therapy.[L10755]","msds":null,"description":"Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications.[A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation.[L10773]\r\n\r\nGolodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of DMD. Continued approval of this drug will depend on the results of clinical trials that confirm its clinical benefit.[L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755]","enzymes":null,"type":"biotech","cas-number":"1422959-91-8","sequences":null,"targets":"BE0009794","unii":"033072U4MZ","protein-binding":"The protein binding of golodirsen ranges from 33 to 39%.[L10758]","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15593.pdf?1576535162","clearance":"This drug is rapidly cleared from the systemic circulation, like other members of its drug class.[A188595,A188598] The total clearance of eteplirsen, a drug from the same class, was 339 mL\/h\/kg after regular doses of 30 mg\/kg\/week. The clearance of golodirsen is likely similar.[A188598]","atc-codes":"MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Other drugs for disorders of the musculo-skeletal system","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"The hallmark of Duchenne Muscular Dystrophy is the absence of the important muscle stabilizing protein, dystrophin, that is caused by a deletion mutation on the DMD (dystrophin) gene.[T756] This results in the production of a non-functional protein.[L10764] Lack of dystrophin protein leads to progressive muscle weakness and degeneration.[A179449] \r\n\r\nGolodirsen binds to exon 53 of dystrophin pre-mRNA on the DMD gene, excluding this protein coding unit during mRNA processing.[L10758,L10764] The exclusion (or skipping) of exon 53 by golodirsen has the end result of changing out-of-frame mRNA to in-frame mRNA, inducing the production of dystrophin. The production of an imperfect dystrophin protein induced by golodirsen likely leads to a less severe condition, Becker Muscular Dystrophy (BMD), characterized by the production of a truncated dystrophin protein.[A188730,L10758] Patients with BMD generally can expect a longer lifespan and improved quality of life.[A188727,L10758]","drug-interactions":"DB13821 DB01345 DB00328 DB00682 DB00928 DB00887 DB00742 DB06196 DB06737 DB09570 DB09205 DB01142 DB09217 DB06823 DB01066 DB06230 DB06696 DB00814 DB01215 DB11085 DB09185 DB00562 DB00558 DB09209 DB14006 DB00280 DB00642 DB08437 DB00800 DB13286 DB00232 DB13432 DB01409 DB06228 DB09257 DB12604 DB00605 DB13792 DB00962 DB09325 DB01327 DB09195 DB06796 DB08984 DB11520 DB06154 DB00583 DB00321 DB00863 DB01129 DB06211 DB01140 DB06705 DB00665 DB01020 DB00292 DB06767 DB00490 DB00806 DB01067 DB00421 DB01124 DB00700 DB00798 DB00535 DB00631 DB01273 DB01558 DB08932 DB00853 DB01148 DB09050 DB11901 DB00492 DB00390 DB13266 DB00839 DB01039 DB01421 DB13293 DB01577 DB09082 DB09111 DB00787 DB00851 DB05676 DB00230 DB11827 DB13943 DB04828 DB00181 DB09062 DB09481 DB00684 DB01249 DB01610 DB09546 DB11367 DB11114 DB00945 DB09081 DB00440 DB00820 DB09299 DB06402 DB06813 DB13954 DB00017 DB00577 DB00274 DB15861 DB01240 DB09224 DB00245 DB01274 DB01046 DB13145 DB00731 DB09084 DB04817 DB00553 DB05095 DB01035 DB01082 DB00871 DB09394 DB00438 DB09132 DB09015 DB00447 DB00788 DB00939 DB00552 DB14018 DB13167 DB00402 DB00775 DB00908 DB00733 DB00372 DB06262 DB09210 DB00718 DB00738 DB00091 DB03615 DB00529 DB06725 DB06292 DB00351 DB09496 DB01331 DB12545 DB00612 DB00598 DB09265 DB08894 DB09320 DB09194 DB00872 DB00841 DB09125 DB00749 DB13595 DB00819 DB08955 DB13612 DB00980 DB01397 DB13461 DB01015 DB00214 DB14529 DB00213 DB00476 DB01150 DB06695 DB09136 DB13284 DB01139 DB14713 DB00951 DB00789 DB09220 DB00586 DB00327 DB00784 DB13667 DB11102 DB00237 DB01156 DB11121 DB13504 DB05018 DB01333 DB09133 DB00270 DB00993 DB00915 DB13955 DB09488 DB09149 DB00165 DB01093 DB01326 DB00007 DB00706 DB01137 DB09477 DB11127 DB11364 DB01241 DB13217 DB09103 DB01283 DB00695 DB00960 DB00452 DB00312 DB00635 DB01359 DB00363 DB01412 DB01638 DB00316 DB04871 DB01435 DB00355 DB00206 DB00294 DB00628 DB00418 DB04930 DB09121 DB00193 DB08905 DB09318 DB00606 DB01325 DB00722 DB09288 DB00936 DB01416 DB00231 DB04890 DB06203 DB00999 DB00456 DB00633 DB00894 DB04918 DB11090 DB09218 DB13524 DB06736 DB13407 DB09068 DB03585 DB00311 DB00783 DB13649 DB00432 DB00469 DB00955 DB13617 DB00903 DB00624 DB14059 DB11136 DB01550 DB00479 DB00861 DB13371 DB00988 DB05541 DB00842 DB00594 DB01112 DB08904 DB08910 DB16165 DB09502 DB00828 DB00569 DB00454 DB00176 DB00500 DB01170 DB00401 DB01438 DB00923 DB00035 DB08824 DB01111 DB14007 DB09215 DB01157 DB00196 DB11560 DB08996 DB00430 DB09407 DB08840 DB13178 DB14530 DB01181 DB00803 DB00158 DB00780 DB00690 DB00833 DB00812 DB00339 DB08893 DB11098 DB00591 DB00377 DB04729 DB01275 DB00323 DB11512 DB09095 DB00774 DB13025 DB01099 DB00811 DB00555 DB00626 DB13499 DB00661 DB08909 DB09118 DB13884 DB00289 DB00404 DB09357 DB00502 DB01213 DB09295 DB00651 DB00692 DB04948 DB01250 DB09395 DB09245 DB00763 DB12615 DB00689 DB13989 DB00493 DB01133 DB04953 DB13956 DB01011 DB13801 DB00384 DB13538 DB09317 DB01002 DB00603 DB13001 DB14500 DB09277 DB04570 DB00290 DB00322 DB00660 DB00564 DB00398 DB11156 DB00330 DB08439 DB13269 DB00713 DB01105 DB08899 DB13944 DB01050 DB04896 DB00229 DB09163 DB00182 DB09241 DB08981 DB01587 DB00412 DB00597 DB09292 DB00911 DB11338 DB09418 DB12670 DB01166 DB13470 DB09235 DB00310 DB00200 DB13657 DB01563 DB06282 DB12107 DB00441 DB11135 DB00373 DB11935 DB00709 DB00480 DB09089 DB01431 DB01060 DB13156 DB01601 DB14527 DB13544 DB01072 DB00672 DB01212 DB01009 DB08907 DB01267 DB00580 DB09106 DB11943 DB01242 DB14509 DB12704 DB00267 DB00436 DB08872 DB01169 DB01656 DB11598 DB01420 DB13778 DB06700 DB00477 DB06480 DB00282 DB00014 DB09148 DB00198 DB08940 DB00208 DB01685 DB06702 DB00804 DB00681 DB00573 DB00349 DB01394 DB09134 DB00296 DB01022 DB14498 DB13682 DB01151 DB13873 DB08961 DB13663 DB00554 DB01332 DB06335 DB04626 DB00264 DB00190 DB11455 DB00698 DB00461 DB00364 DB11817 DB09204 DB09129 DB11577 DB14499 DB00813 DB12007 DB00300 DB09027 DB01048 DB09264 DB00864 DB01367 DB09212 DB01024 DB08897 DB13638 DB00688 DB00808 DB00185 DB00325 DB00319 DB00934 DB01427 DB04743 DB12278 DB01172 DB00716 DB06815 DB00465 DB14126 DB01018 DB11466 DB08942 DB01043 DB09165 DB09223 DB09075 DB00115 DB11691 DB00994 DB02925 DB04895 DB12766 DB13803 DB13527 DB13232 DB00273 DB13481 DB00900 DB09344 DB13946 DB14507 DB00829 DB09216 DB09156 DB04831 DB00244 DB13430 DB09472 DB00567 DB11915 DB07402 DB11251 DB13139 DB00333 DB09301 DB00369 DB11358 DB12221 DB00958 DB00286 DB01203 DB11989 DB00458 DB01399 DB00953 DB01328 DB01221 DB12783 DB00880 DB01149 DB00080 DB00537 DB01004 DB06637 DB09255 DB09262 DB00730 DB00331 DB06186 DB09008 DB00437 DB06623 DB04808 DB09091 DB09219 DB01224 DB00254 DB13540 DB11145 DB01001 DB00356 DB15066 DB00499 DB00759 DB09071 DB13629 DB11587 DB00380 DB11518 DB01036 DB01324 DB01222 DB00303 DB01330 DB12161 DB00995 DB13783 DB00285 DB09276 DB09214 DB14526 DB09137 DB09324 DB00512 DB00571 DB00608 DB11642 DB09329 DB09104 DB00482 DB00703 DB09139 DB09338 DB08934 DB13909 DB13191 DB01205 DB00041 DB09066 DB00359 DB06710 DB01419 DB13860 DB01030 DB01395 DB00657 DB11278 DB01014 DB00982 DB06590 DB13405 DB00563 DB03450 DB00314 DB01413 DB08877 DB08911 DB00548 DB00081 DB08976 DB04812 DB13987 DB04920 DB00159 DB01414 DB00341 DB06809 DB02247 DB08826 DB13868 DB00435 DB13952 DB01144 DB01032 DB09256 DB09213 DB15959 DB01356 DB00279 DB09285 DB13532 DB13708 DB00991 DB00961 DB01329 DB14754 DB01401 DB00795 DB08900 DB13722 DB01010 DB06370 DB01600 DB00501 DB01069 DB00761 DB09268 DB06209 DB01261 DB11699 DB06212 DB00897 DB06782 DB06800 DB12445 DB04574 DB00712 DB00909 DB00683 DB13314 DB01424 DB00308 DB01021 DB00243 DB00968 DB04263 DB00186 DB00415 DB14528 DB00271 DB00669 DB00413 DB00790 DB09244 DB01628 DB06824 DB00225 DB14060 DB08918 DB09123 DB01101 DB01183 DB11164 DB11130 DB00235 DB01135 DB00743 DB09281 DB13967 DB00821 DB00918 DB01233 DB01415 DB09135 DB00515 DB00262 DB08951 DB01428 DB09401 DB08797 DB08991 DB00760 DB00782 DB01115 DB13185 DB00524 DB00533 DB01068 DB04552 DB05034 DB11328","absorption":"This drug is given by the intravenous route, and is likely rapidly absorbed into the circulation.[L10758] Pharmacokinetic studies for eteplirsen determined that Cmax occur within 1.1 to 1.2 hours of infusion initiation, after the administration of doses ranging from 0.5 mg\/kg\/week to 50 mg\/kg\/week.[A188598]","created":"2019-12-16","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"In a pharmacokinetic study, the elimination half-life of golodirsen was 3.4 hours with a standard deviation of 0.6 hours.[L10758]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution at steady-state is approximately 668 mL\/kg at 30 mL\/kg dose of golodirsen.[L10758]","route-of-elimination":"Golodirsen is excreted primarily as unchanged drug in the urine.[L10758]","name":"Golodirsen","metabolism":"Golodirsen is not extensively metabolized. There were no metabolites detected in plasma or urine during a pharmacokinetic study.[L10758]","reactions":null,"indication":"Golodirsen is indicated to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that would benefit from exon 53 skipping. Continued FDA approval of this drug is contingent upon the results of clinical trials to confirm its benefit.[L10755,L10758]","ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB15593"},{"toxicity":"The intraperitoneal TDLO in rats is 100 mg\/kg.[L10839] No overdose information is available at this time.[L10830] When compared to other ophthalmological dyes, brilliant blue G appears to have a comparable safety profile.[A188880] Ensure to remove the dye immediately after staining.[L10830]","snp-adverse-drug-reactions":null,"average-mass":854.02,"transporters":null,"pharmacodynamics":"Brilliant Blue G aids in ophthalmologic surgery by rendering it easier to identify the internal limiting membrane (ILM) for surgical removal.[L10830]","msds":null,"description":"Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.[A188841,A188844] This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy. Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]","enzymes":null,"type":"small molecule","cas-number":"6104-58-1","sequences":null,"targets":"BE0009797","unii":"M1ZRX790SI","protein-binding":null,"fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15594.pdf?1576874923","clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"The internal limiting membrane (ILM) is a thin and translucent structure that demarcates the transition from the retina from the vitreous body of the eye. It acts as a scaffold on which excessive tissue can grow, which results in visual distortion when it is projected onto the neighbouring retina. This causes visual loss and\/or distortion.[A188853] \r\n\r\nAn epiretinal membrane (also known as ERM) is a fibrous type of tissue that can be found on the inner surface of the retina and occurs idiopathically, and in some cases, retinal detachment and inflammation. It is often found on the surface of the internal limiting membrane (ILM), causing visual loss and distortion.[A188853] The above condition as well as the associated macular pucker[A188871] or traction maculopathy[A188874] can affect the ILM, contributing to visual complications. The removal of the ILM with or without vitrectomy is often a simple solution to these conditions.\r\n\r\nBrilliant Blue G specifically stains the internal limiting membrane (ILM) in the eye without staining the epiretinal membrane or the retina, allowing for easier surgical removal. The mechanism of its specific staining that is limited to the ILM is currently not fully understood.[L10830]","drug-interactions":null,"absorption":"Due to the fact that this drug is administered by intravitreal injection and subsequently removed after staining, it is not expected to be significantly absorbed systemically.[L10830]","created":"2019-12-20","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":853.28313753,"volume-of-distribution":"This drug is administered via intravitreal injection and likely distributes only to parts of the eye.[L10830]","route-of-elimination":"This dye is removed in a clinical setting after the surgical procedure in which it was used.[L10830]","name":"Brilliant blue G","metabolism":null,"reactions":null,"indication":"This drug is indicated for selectively staining the internal limiting membrane (ILM).[L10830]","ahfs-codes":null,"updated":"2021-08-05","drugbank-id":"DB15594"},{"toxicity":"There is limited information on the overdose and LD<sub>50<\/sub> of Ebola Zaire vaccine.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Ebola Zaire vaccine protects against the Ebola virus infection and disease by introducing a protein produced by the _Zaire ebolavirus_ and initiating the body's normal immune responses against the virus. In clinical trials consisting of subjects receiving the Ebola virus vaccine, the vaccine virus RNA was detected in the plasma samples of most subjects within the first week after intramuscular injection.[L10854]","msds":null,"description":"Ebola virus vaccine is a vaccine used to prevent Ebola virus disease caused by _Zaire ebolavirus_ in adults, prevent outbreaks, and reduce the extent of the virus spreading in case of outbreaks.[L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. It is highly contagious: human to human transmission occurs from contact with body fluids from infected patients.[A189024] It is characterized by fever, headache, myalgia, and gastrointestinal symptoms. These may be accompanied by hypotension and respiratory, kidney and liver failure, as well as internal and external bleeding.[A188994,A188997] In the _Filoviridae_ family, there are five unique Ebolavirus species that are each named after the geographical region where it was first identified. The mortality rate of the Zaire species is about 80%.[A188997]\r\n\r\nConfirmed outbreaks of Ebola virus disease have been documented since the 1970s, mostly in Sub-Saharan Africa, where Ebola first appeared in 1976 near the Ebola River in Zaire (presently referred to as the Democratic Republic of the Congo) and Sudan.[A188994] Between 2014 and 2016, Ebola outbreaks occurred in West Africa, leading to more than 11,310 total deaths during this time in Guinea, Liberia, and Sierra Leone.[A188997] In 2016, this epidemic was exhausted after these countries were declared Ebola-free by 2016, and the World Health Organization (WHO) lifted the Public Health Emergency of International Concern (PHEIC) status on the West Africa Ebola outbreak.[L10884]\r\n\r\nThe first live, attenuated Ebola virus vaccine was developed by a team of Canadian researchers at Canada\u20ACs National Microbiology Laboratory and was later patented by the Canadian government.[L10866] In non-human primate clinical trials, the vaccine was effective in inducing an immune response against the Ebola viruses.[A189018] This vaccine was later sold to NewLink Genetics, a biotech company that held the license to the vaccine from 2010 to 2014, although the vaccine was not marketed.[L10866] In 2014, Merck Inc. signed a licensing agreement with NewLink for further development and marketing. Ervebo, the marketed Ebola virus vaccine by Merck, was first approved by the European Commission in November 2019 after the European Medicines Agency recommended it be licensed. In December 2019, Ervebo was approved by the FDA in the United States. Ervebo consists of an envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain) fused into a vesicular stomatitis virus (VSV) backbone.[L10854] By introducing the relatively inactive viral protein to the patient, the patient\u20ACs immune system learns to recognize and attack the virus if he or she is exposed to it in the future.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":"There is limited pharmacokinetic information on Ebola virus vaccine.","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15595.pdf?1576877522","clearance":"There is limited pharmacokinetic information on Ebola virus vaccine.","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Ebola virus disease occurs when the virus comes into contact with the host tissue and invades the tissue by breaking in the mucosa or skin. Exposure can occur through animal-to-human or human-to-human transmission from blood and other bodily fluids of the virus-infected animal or human.[A189024] The viral genome then replicates inside the cell, causing gene modulation in host cells - including monocytes, macrophages, and dendritic cells - and promote cell apoptosis, releasing the viral particles to extracellular tissue.[A188997] The virus can further disseminate the infection by migrating to the regional lymph nodes, liver, and spleen to cause lymphadenopathy, hepatocellular necrosis, and lymphopenia.[A188997,A189024] Ebola virus can cause dysregulation of the host immune system by inducing the host expression and release of pro-inflammatory mediators, including interferons, interleukins (IL-2, IL- 6, IL-8, and IL-10), and tumour necrosis factor  (TNF-).[A189024] These inflammatory processes promote endothelial activation and reduced vascular integrity. Furthermore, the release of tissue factors and increased nitric oxide levels lead to disseminated intravascular coagulation (DIC) and hypotension seen in the Ebola virus disease, respectively.[A188997,A189024] The incubation period after the Ebola virus infection is 1-21 days.[A189024]\r\n\r\nBy introducing the attenuated viral protein to the patient, the Ebola Zaire vaccine elicits strong cellular and antibody responses against the virus. The vaccine produces a long-term immunity and protects the patient from Ebola virus infection and disease when he or she is exposed to  _Zaire ebolavirus_  in the future.[A39899] However, the relative contributions of innate, humoral and cell-mediated immunity to protection from Zaire ebolavirus is not fully understood.[L10854]","drug-interactions":"DB05209 DB08880 DB00328 DB14905 DB00928 DB06474 DB06647 DB15091 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB00092 DB00970 DB15898 DB04951 DB14877 DB00034 DB11604 DB12344 DB13886 DB00642 DB13068 DB14811 DB00495 DB11921 DB11884 DB00105 DB11685 DB11746 DB15118 DB00305 DB06772 DB16650 DB14997 DB00277 DB01229 DB12815 DB06602 DB15646 DB12053 DB01590 DB13843 DB14012 DB09035 DB13867 DB14891 DB13017 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB06599 DB06310 DB00853 DB00741 DB14864 DB09105 DB12520 DB10804 DB12396 DB13208 DB05797 DB15119 DB09082 DB09383 DB05656 DB00851 DB06557 DB12274 DB11680 DB13140 DB05676 DB00959 DB11003 DB06607 DB15443 DB00773 DB14897 DB09074 DB00008 DB00120 DB00028 DB00547 DB12104 DB15001 DB12261 DB00428 DB12849 DB06813 DB12826 DB12844 DB01033 DB04962 DB11866 DB12205 DB12498 DB11715 DB00324 DB00276 DB01204 DB01281 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB04868 DB00002 DB04949 DB00552 DB00877 DB13535 DB01257 DB12335 DB04901 DB11976 DB06616 DB00033 DB01005 DB12119 DB00091 DB09045 DB14952 DB00054 DB05111 DB15626 DB14540 DB00180 DB16225 DB06589 DB12698 DB13073 DB08870 DB11731 DB14776 DB08906 DB01410 DB11771 DB05304 DB00022 DB12893 DB15090 DB16755 DB13014 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB00526 DB15865 DB12943 DB12584 DB15899 DB00601 DB05276 DB12891 DB15415 DB00993 DB11914 DB16170 DB00072 DB11988 DB06371 DB00307 DB15045 DB01269 DB06550 DB01234 DB16355 DB06322 DB03451 DB00635 DB11616 DB13976 DB14066 DB10317 DB15089 DB14967 DB13979 DB11834 DB01206 DB05679 DB05006 DB09378 DB09122 DB00069 DB12025 DB14843 DB12589 DB06606 DB11756 DB09053 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB05109 DB00432 DB12530 DB01097 DB16265 DB00394 DB00065 DB15718 DB05892 DB01816 DB12089 DB09303 DB08904 DB08059 DB08910 DB14959 DB12917 DB12845 DB06192 DB05015 DB11708 DB00550 DB00043 DB15628 DB12976 DB09559 DB01008 DB01041 DB09033 DB11826 DB01108 DB14004 DB06241 DB00057 DB00112 DB06372 DB01280 DB01181 DB06603 DB05793 DB01384 DB00591 DB09095 DB06049 DB06168 DB01248 DB16659 DB01099 DB14996 DB12996 DB16222 DB06043 DB11945 DB08908 DB08879 DB00076 DB06366 DB09037 DB01047 DB00763 DB05550 DB06662 DB12169 DB06612 DB15397 DB05595 DB06318 DB11569 DB14784 DB00619 DB01268 DB14824 DB16376 DB15453 DB11580 DB00445 DB12142 DB14545 DB05555 DB03523 DB14580 DB00290 DB00322 DB16195 DB02546 DB00188 DB00564 DB12189 DB00398 DB00110 DB09077 DB13003 DB15428 DB00075 DB14724 DB05101 DB10343 DB12947 DB00078 DB16648 DB00755 DB04956 DB05136 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB14681 DB05496 DB06287 DB04630 DB12157 DB12609 DB05916 DB01611 DB05889 DB06467 DB12102 DB14783 DB00441 DB04958 DB00480 DB12342 DB00242 DB14988 DB12090 DB15432 DB00291 DB08895 DB15363 DB01254 DB00111 DB01270 DB00068 DB01380 DB01169 DB14947 DB15441 DB15383 DB12991 DB00859 DB11487 DB14962 DB15349 DB00997 DB05941 DB11930 DB06050 DB12612 DB00443 DB04845 DB11817 DB06162 DB00694 DB12489 DB09264 DB05472 DB00864 DB00446 DB01024 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB00688 DB12807 DB01196 DB06681 DB00544 DB01013 DB00089 DB11693 DB11466 DB05097 DB08971 DB11840 DB12692 DB13375 DB16732 DB09054 DB14512 DB01262 DB12202 DB13045 DB00860 DB06360 DB10318 DB00051 DB14908 DB12820 DB15941 DB15113 DB09073 DB00588 DB00095 DB01177 DB14845 DB00026 DB11529 DB05578 DB00488 DB00958 DB12701 DB15101 DB02806 DB14778 DB12331 DB14762 DB06186 DB15559 DB09091 DB10805 DB11850 DB08868 DB08902 DB15409 DB15014 DB08871 DB00380 DB12902 DB12296 DB16694 DB01222 DB16695 DB16394 DB13856 DB14539 DB15225 DB12250 DB15434 DB00309 DB14042 DB12213 DB12371 DB16077 DB00444 DB12240 DB06650 DB16393 DB01073 DB11646 DB15252 DB01423 DB00570 DB00056 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB14707 DB12683 DB08889 DB01030 DB13923 DB16421 DB16151 DB09302 DB12617 DB00563 DB12118 DB08877 DB05915 DB14871 DB12768 DB00081 DB00018 DB00352 DB13491 DB00087 DB11657 DB12775 DB00011 DB04988 DB01285 DB05996 DB11767 DB05139 DB06304 DB11595 DB09029 DB00764 DB00795 DB05260 DB05545 DB08935 DB00663 DB11972 DB13241 DB15076 DB16703 DB00059 DB06116 DB14040 DB06674 DB15900 DB09331 DB00293 DB13223 DB14041 DB13127 DB05258 DB15719 DB00361 DB00620 DB15044 DB06769 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB12016 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB01101 DB04572 DB15940 DB14219 DB09057 DB12718 DB00762 DB06343 DB00074 DB13037 DB06342 DB05405 DB12077 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00005","absorption":"There is limited pharmacokinetic information on Ebola virus vaccine.","created":"2019-12-20","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"There is limited pharmacokinetic information on Ebola virus vaccine.","monoisotopic-mass":null,"volume-of-distribution":"There is limited pharmacokinetic information on Ebola virus vaccine.","route-of-elimination":"Although there is limited information on the main route of elimination of Ebola virus vaccine, vaccine virus RNA was detected in the in the urine or saliva samples of the subjects in clinical trials who received intramuscular injections.[L10854]","name":"Ebola Zaire vaccine (live, attenuated)","metabolism":"As with other live attenuated vaccines, Ebola virus vaccine is speculated to undergo nonspecific cellular degradation.","reactions":null,"indication":"Ebola Zaire vaccine is indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by _Zaire Ebolavirus_.[L10857]","ahfs-codes":null,"updated":"2021-02-13","drugbank-id":"DB15595"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":327.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"58-37-7","sequences":null,"targets":null,"unii":"S9SDD93U5U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-23","groups":"experimental vet_approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":327.176918991,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aminopromazine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15596"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":296.414,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"60-46-8","sequences":null,"targets":null,"unii":"IP1B47L61M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2019-12-23","groups":"experimental vet_approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":296.188863401,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aminopentamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15597"},{"toxicity":"Data regarding overdoses of ferric maltol are not readily available, however toxicity is expected with acute ingestion of 20mg\/kg and 200-250mg\/kg is potentially fatal.[L10974] Patients experiencing an overdose may present with nausea, vomiting, abdominal pain, diarrhea, hypoperfusion, metabolic acidosis, and systemic toxicity.[L10974] Overdoses should be treated with symptomatic and supportive measures which may include the use of desferroxamine.[L11010] Hemodialysis will not remove iron but will remove the iron-desferroxamine complex.[L11010]","snp-adverse-drug-reactions":null,"average-mass":431.154,"transporters":"BE0008685 BE0001155","pharmacodynamics":"Ferric maltol is used to provide supplemental iron to patients with an iron deficiency.[L10974] It has a wide therapeutic index as patients generally take 30mg twice daily, while concentrations of 20mg\/kg may produce toxicity.[L10974] Patients should be counselled regarding the risk of inflammatory bowel disease flares, iron overload, and accidental ingestion in children.[L10974]","msds":null,"description":"Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate.[A189288] Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.[A189291]\r\n\r\nFerric maltol was granted FDA Approval on 25 July 2019.[L10974]","enzymes":"BE0004694","type":"small molecule","cas-number":"33725-54-1","sequences":null,"targets":"BE0008685 BE0001155","unii":"MA10QYF1Z0","protein-binding":"Data regarding the protein binding of ferric maltol is not readily available.[L10974,L11010]","fda-label":null,"clearance":"Data regarding the clearance of ferric maltol is not readily available.[L10974,L11010]","atc-codes":"BLOOD AND BLOOD FORMING ORGANS IRON PREPARATIONS ANTIANEMIC PREPARATIONS Iron trivalent, oral preparations","pdb-entries":null,"food-interactions":"Take on an empty stomach.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Ferric maltol dissociates as the iron atom is donated to unknown iron uptake mechanisms, possibly beta 3 integrin or divalent metal transporter 1,[A189306] in the ileum and duodenum.[A189294] Once the iron is in circulation, it then associates with transferrin and ferritin.[L10974]","drug-interactions":"DB00537 DB01208 DB13760 DB00213 DB00564 DB11443 DB06255 DB00254 DB01142 DB00334 DB08805 DB13486 DB00720 DB00759 DB00399 DB13264 DB12884 DB05143 DB00338 DB12035 DB00451 DB13249 DB02423 DB00166 DB13823 DB13762 DB14048 DB15617 DB01137 DB00827 DB00736 DB12455 DB13261 DB09413 DB09104 DB13995 DB07841 DB09139 DB01390 DB01377 DB00863 DB01129 DB09414 DB00884 DB01155 DB13650 DB14517 DB01235 DB09147 DB14481 DB11348 DB14523 DB13772 DB01077 DB00535 DB00751 DB06723 DB11943 DB00453 DB00085 DB11404 DB11511 DB06600 DB11491 DB00282 DB06210 DB08806 DB12770 DB06216 DB00859 DB01044 DB09449 DB08826 DB11892 DB01320 DB08938 DB04576 DB00365 DB00487 DB09481 DB00190 DB13626 DB00927 DB00618 DB00501 DB01069 DB00256 DB05351 DB00779 DB00467 DB06782 DB00595 DB11493 DB00448 DB11739 DB01165 DB00978 DB00585 DB00630 DB00968 DB00218 DB04160 DB00931 DB00685 DB02552 DB08930 DB06824 DB01059 DB06160 DB13829 DB02369 DB06724 DB01017 DB00252 DB00940 DB00817 DB13322 DB09281 DB01133 DB05488 DB00710 DB00197 DB13627 DB13280 DB11774 DB01405 DB13595 DB08972","absorption":"Ferric maltol dissociates in the gastrointestinal tract, leading to a T<sub>max<\/sub> of 1.5-3.0 hours for iron concentrations.[A189306,L10974] Mean serum iron increases by 146mol\/L in iron deficient patients following a single dose.[A189288] a 60mg dose is approximately 14% bioavailable.[A189300] 60 minutes after injection of radiolabelled ferric maltol, 11+2% of the dose is present in the bone marrow, 181% is present in the liver, and 2.61% is in the urine.[A189297] Maltol has an AUC of 0.022-0.205h\\*g\/mL and maltol glucuronide has an AUC of 9.83-30.9h\\*g\/mL.[L11010]","created":"2019-12-23","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Maltol has a half life of 0.7h.[L11010]","monoisotopic-mass":431.006543,"volume-of-distribution":"Data regarding the volume of distribution of ferric maltol is not readily available.[L10974,L11010]","route-of-elimination":"39.8-60% of an oral dose of ferric maltol is excreted in the urine as a glucuronide conjugate.[L10974] Iron and ferric maltol are not excreted in the urine and unabsorbed ferric maltol is eliminated in the feces.[A189306]","name":"Ferric maltol","metabolism":"_In vitro_, ferric maltol metabolism is predominantly glucuronidation of maltol by UGT1A6 and sulfation.[L10974]","reactions":"BE0004694 P19224","indication":"Ferric maltol is indicated to treat iron deficiency in adults.[L10974]","ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15598"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"endolysosome lumen","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":"BE0003417","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-01","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MIV-711","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15599"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":194.234,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability.[L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and Pitt Hopkins Syndromes. It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.[L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]","enzymes":null,"type":"small molecule","cas-number":"847952-38-9","sequences":null,"targets":null,"unii":"2T1HU6069S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Insulin-like growth factor 1 (IGF-1) is a hormone secreted by glia and neurons of the CNS that plays an important role in normal brain development and response to pathologies.[L11106] It is broken down into two separate molecules in the brain, both of which have synthetic analogues in development. [Glypromate], or GPE, comprises the last three peptides of IGF-1 and acts on glial cells, in contrast to its parent compound which tends to act on neurons - a synthetic analogue, [trofinetide], is currently under development by Neuren Pharmaceuticals for the treatment of traumatic brain injury, Rett Syndrome, and Fragile X Syndrome.[L11106] Glypromate is further cleaved into cyclic glycine-proline (cGP), which serves a number of diverse roles including the regulation of IGF-1 bioavailability, and of which NNZ-2591 is a synthetic analogue.[L11106]\r\n\r\nWhile the specific actions of NNZ-2591 will likely become clearer following clinical trials, IGF-1 and its derivatives are known to facilitate brain development and normal functioning by regulating responses to disease, stress, injury through a number of signaling pathways.[L11106] For this reason, any therapeutic benefit observed with NNZ-2591 is likely to be the result of many diverse effects rather than action on a specific target.[L11106]","drug-interactions":null,"absorption":null,"created":"2020-01-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":194.105527699,"volume-of-distribution":null,"route-of-elimination":null,"name":"NNZ-2591","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15601"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cashew fruit extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"4A10JR4E7E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cashew fruit","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15602"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Coffea arabica seed, roasted allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"9H58JRT35E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Coffea arabica seed, roasted","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15603"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lactuca sativa whole allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"C0K52765EZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lactuca sativa whole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15604"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Field mushroom allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"19988ORO24","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Field mushroom","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15605"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"White mustard seed allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"25VR943RPP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"White mustard seed","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15606"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"68607-88-5","sequences":null,"targets":null,"unii":"1394NXB9L6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hydrolyzed soy protein","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15607"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Theobroma cacao, whole, allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"EB048G1S9J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Theobroma cacao whole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15608"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":398.446,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"JPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria, and favourable preclinical pharmacokinetics including a lengthy plasma elimination half-life.[A189444]","enzymes":null,"type":"small molecule","cas-number":"1609655-35-7","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":398.198126117,"volume-of-distribution":null,"route-of-elimination":null,"name":"JPC-3210","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15609"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":220.151,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"82971-90-2","sequences":null,"targets":null,"unii":"SQP4E8O29W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":220.045961962,"volume-of-distribution":null,"route-of-elimination":null,"name":"(4-(trifluoromethoxy)phenyl)urea","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15610"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Muskmelon allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZV095H5633","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Muskmelon","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15611"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"American hazelnut allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"IUP4S55D8S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"American hazelnut","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15612"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Musa acuminata fruit allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"T6ENY6RV6W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-10","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Musa acuminata fruit","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15613"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":384.648,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1173-13-3","sequences":null,"targets":null,"unii":"HDA46400N5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB14652 DB01070 DB15566 DB00169 DB14649 DB06272 DB09091 DB13467 DB13486 DB13003 DB01078 DB00562 DB13249 DB01324 DB13097 DB01222 DB14633 DB13856 DB14539 DB00232 DB15821 DB11921 DB01234 DB14515 DB06194 DB04796 DB14646 DB13691 DB14545 DB00635 DB09104 DB14681 DB00310 DB04630 DB13749 DB01164 DB11093 DB13843 DB01406 DB12147 DB09378 DB01325 DB00606 DB01436 DB13537 DB13867 DB11348 DB13590 DB13231 DB11110 DB13365 DB00999 DB08970 DB06723 DB01396 DB00390 DB00741 DB00146 DB00436 DB01380 DB13359 DB14684 DB13208 DB00375 DB13491 DB14514 DB11094 DB06410 DB09383 DB14541 DB14513 DB01285 DB11057 DB00394 DB06117 DB11487 DB01083 DB04891 DB14643 DB00959 DB00910 DB01320 DB00136 DB08938 DB00443 DB13532 DB00658 DB13786 DB00153 DB09481 DB00764 DB14659 DB00364 DB01432 DB00547 DB01092 DB00663 DB01108 DB00326 DB15861 DB14631 DB13223 DB14577 DB00808 DB13307 DB09407 DB00324 DB00620 DB01373 DB01013 DB13800 DB00930 DB01021 DB08971 DB01384 DB00591 DB15777 DB14669 DB09095 DB00774 DB14512 DB09511 DB14644 DB13142 DB12843 DB00653 DB13240 DB13756 DB00860 DB13401 DB09368 DB09357 DB11126 DB15972 DB05295 DB04258 DB00252 DB00258 DB13322 DB01047 DB13989 DB13430 DB00511 DB09281 DB14540 DB00180 DB00588 DB11529 DB00524 DB00687 DB01397 DB08906 DB01410 DB00880","absorption":null,"created":"2020-01-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":384.339216037,"volume-of-distribution":null,"route-of-elimination":null,"name":"Previtamin D(3)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15614"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"557II4LLC3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fennel","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15615"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-01-23","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"REC-994","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15616"},{"toxicity":"LD50 information for ferric derisomaltose is not readily available in the literature, however, the LD50 for iron sucrose (another form of intravenous iron) was 140 mg\/kg in male rats.[L11635] An overdose with ferric derisomaltose may lead to accumulation of stored iron, causing hemosiderosis.[L11620] Symptoms may include abdominal pain, weakness, and lethargy, among others.[A190588] Serum ferritin should be monitored. Employ supportive treatment including chelating agents.[L11581,L11620]","snp-adverse-drug-reactions":null,"average-mass":562.297,"transporters":"BE0004850","pharmacodynamics":"Ferric derisomaltase increases the reticulocyte count and ultimately increases hemoglobin, treating iron deficiency anemia and its various symptoms.[A32524,A190528] Parenteral iron, such as ferric derisomaltose, may cause false elevations in serum bilirubin levels and falsely reduced serum calcium.[L11617,L11620]","msds":null,"description":"Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non life-threatening, iron deficiency may considerably affect quality of life.[A190528]\r\n\r\nFerric derisomaltose is a form of iron used in the treatment of iron deficiency. This drug is a complex of iron (III) hydroxide and derisomaltose. The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.[L11581,L11587] Clinical trials show that it is non-inferior to [iron sucrose], another form of iron that is often administered in iron deficiency, and less likely to cause serious hypersensitivity that is associated with other forms of injectable iron.[A190519,A188021]","enzymes":null,"type":"small molecule","cas-number":"1345510-43-1","sequences":null,"targets":"BE0004850 BE0000130","unii":"AHU547PI9H","protein-binding":"Iron binds to transferrin, the transport molecule responsible for transporting iron to erythroid precursor cells for the production of hemoglobin.[A32524,L11581]","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15617.pdf?1580749879","clearance":"Intravenous iron is cleared from the plasma.[A190582] Ferric derisomaltose is not eliminated via the kidneys, as the size of the complex is large and cannot be excreted via the nephron.[L11617]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Christensen TS, Andreasen HB.(2019)._WO2019048674A1_. Retrieved from: https:\/\/patents.google.com\/patent\/WO2019048674A1\/en","mechanism-of-action":"This drug is a complex made of iron (III) hydroxide and derisomaltose, which is an iron carbohydrate oligosaccharide that works to releases iron. The released iron then binds to the transport protein, transferrin, and is taken to erythroid precursor cells[A190528] for incorporation into the hemoglobin molecule.[L11581,L11617]","drug-interactions":"DB11417 DB14520 DB09507 DB11210 DB11171 DB14489 DB01592 DB09501 DB15763 DB09147 DB14695 DB14488 DB14491 DB13423 DB09146 DB13949 DB06783 DB09508 DB12821 DB13257 DB13381 DB00893 DB15598","absorption":"After a single 1000 mg dose, the Cmax and AUC of serum iron were 408 g\/mL and 17730 g.h \/mL, respectively. Serum ferritin concentrations reach their peak about 7 days after a single dose of intravenous ferric derisomaltose.[L11581]\r\n\r\n\r\nA note on concomitant oral iron\r\n\r\nThe absorption of oral iron is decreased when administered with intravenous iron. The administration of oral iron should be delayed until at least 5 days after the last ferric derisomaltose injection.[L11617]","created":"2020-02-03","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The plasma-half live of intravenous iron is about 1-4 days.[L11617]","monoisotopic-mass":562.117975,"volume-of-distribution":"Ferric derisomaltose or released iron that was released is found in cells of the reticuloendothelial system (RES). It is found to be highly concentrated in the liver and spleen.[L11617] The volume of distribution of other forms of intravenous iron is 3L, on average, in a 70 kg adult.[A32524] Though the specific volume of distribution of ferric derisomaltose is not readily available in the literature, it is likely similar to other intravenous forms of iron.[A32524]","route-of-elimination":"Renal elimination was not a significant route of elimination in single-dose pharmacokinetic studies. Iron can often accumulate in the body leading to iron overload followed by toxic effects.[A190582] Small amounts of ferric derisomaltose are excreted in the urine and feces.[L11617]","name":"Ferric derisomaltose","metabolism":"Iron in the circulation is taken up by the plasma by cells of the RES. This binds proteins that form hemosiderin or ferritin, as well transferrin. Following this step, the bound iron replenishes low hemoglobin (Hb) and iron.[L11617]","reactions":null,"indication":"This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron preparations or insufficient clinical response to orally administered iron.  Ferric derisomaltase is also indicated for patients with non-hemodialysis dependent chronic kidney disease.[L11581] In Australia and United Kingdom, ferric derisomaltase is indicated for cases in which rapid delivery of iron is required.[L11617,L11620]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15617"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.221,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5Z,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-02-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.104465071,"volume-of-distribution":null,"route-of-elimination":null,"name":"(5E,7E,9)-decatrien-2-one","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15618"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.221,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-02-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.104465071,"volume-of-distribution":null,"route-of-elimination":null,"name":"(5Z,7E,9)-decatrien-2-one","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15619"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"VEH9U90EHX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Washington\/02\/2019 antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15620"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"9G0XU62HKP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/South Australia\/34\/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15621"},{"toxicity":"The intraperitoneal LD<sub>50<\/sub> of triazavirin in mice is 1400120mg\/kg in mice and the intragastric LD<sub>50<\/sub> is 220096mg\/kg.[A191706]\r\n\r\nPatients experiencing an overdose may present with nausea, vomiting, dyspepsia, and stomach pain.[L12165] Treat overdose with symptomatic and supportive treatment, which may include discontinuation of treatment.[L12165]","snp-adverse-drug-reactions":null,"average-mass":228.19,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.[A191709,A191625,A191916] It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.[L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625]","enzymes":null,"type":"small molecule","cas-number":"123606-06-4","sequences":null,"targets":null,"unii":"F2HTG1MH2D","protein-binding":"Data regarding the protein binding of triazavirin is not readily available.","fda-label":null,"clearance":"In rabbits, intragastric triazavirin has a clearance of 37.011.2L\/h\\*kg while intravenous triazavirin has a clearance of 14.03.7L\/h\\*kg.[A191706]\r\n\r\nThe clearance of triazavirin is 246mL\/min.[L12165]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take with or without food.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Triazavirin is a guanosine nucleotide analog that inhibits RNA synthesis.[A191916,L12165]","drug-interactions":null,"absorption":"In rabbits, intragastric triazavirin reaches a C<sub>max<\/sub> of 1.10.1mg\/L, with a T<sub>max<\/sub> of 0.400.16h, and an AUC of 3.100.8mg\\*h\/L.[A191706] In rabbits, intravenous triazavirin has an AUC of 1.20.3mg\\*h\/L.[A191706]\r\n\r\nIn humans, triazavirin reaches a C<sub>max<\/sub> of 4.8g\/mL, with a T<sub>max<\/sub> of 1-1.5h, and an AUC of 12.8gg\/h\\*mL.[L12165]","created":"2020-03-04","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":"In rabbits, intragastric triazavirin has a half life of 1.10.1h while intravenous triazavirin has a half life of 0.500.09h.[A191706]\r\n\r\nThe half life of triazavirin is 1-1.5h.[L12165]","monoisotopic-mass":228.006559187,"volume-of-distribution":"In rabbits, intragastric triazavirin has a volume of distribution of 83.519.2L\/kg while intravenous triazavirin has a volume of distribution of 1.20.3L\/kg.[A191706]","route-of-elimination":"Data regarding the route of elimination of triazavirin is not readily available.","name":"Triazavirin","metabolism":"Data regarding the metabolism of triazavirin is not readily available.","reactions":null,"indication":"Triazavirin was developed in Russia as a potential treatment of Influenza A and B infections.[A191706]","ahfs-codes":null,"updated":"2020-07-01","drugbank-id":"DB15622"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":755.987,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir].[L12045] It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for both treatment-naive and PI-experienced patients.[L12045,A191643]\r\n\r\nTMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]","enzymes":null,"type":"small molecule","cas-number":"1000287-05-7","sequences":null,"targets":"BE0000664","unii":"0151W500HP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00585 DB13760 DB01118 DB01390 DB11003 DB00213 DB00604 DB00863 DB01377 DB00564 DB08938 DB00559 DB14409 DB01129 DB01323 DB10805 DB16746 DB13650 DB14517 DB09481 DB00404 DB08860 DB08805 DB13486 DB10318 DB00531 DB13829 DB11050 DB06724 DB12884 DB00927 DB13626 DB01370 DB00338 DB06723 DB00940 DB13249 DB13322 DB10343 DB00501 DB09281 DB16648 DB05351 DB14685 DB10804 DB13762 DB13209 DB14048 DB12768 DB13280 DB01201 DB14443 DB00448 DB00736 DB13595 DB10532 DB01211 DB00582 DB08806 DB12770 DB11739 DB09104 DB10317","absorption":null,"created":"2020-03-04","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":755.338640455,"volume-of-distribution":null,"route-of-elimination":null,"name":"TMC-310911","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15623"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":261.29,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"cytoplasm","enzymes":null,"type":"small molecule","cas-number":"40045-50-9","sequences":null,"targets":"BE0009865","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-04","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":260.944887879,"volume-of-distribution":null,"route-of-elimination":null,"name":"Halicin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15624"},{"toxicity":"There is no information available regarding the LD<sub>50<\/sub>, acute toxicity profile, and overdose of spesolimab.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Spesolimab works to reduce inflammation in GPP in a rapid and sustained manner by blocking inflammatory pathways.[A252225] In clinical trials, spesolimab reduced pustules and improved other disease measures in patients with GPP, irrespective of _IL36RN_ gene mutation status.[A252220]","msds":null,"description":"Spesolimab is an interleukin-36 (IL-36) receptor antagonist. It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares. Spesolimab works by inhibiting the inflammatory signaling pathway of IL-36,[L43090] which is often overexpressed and aberrantly overactive in generalized pustular psoriasis.[A252220, A252225] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended spesolimab be granted marketing authorization for the treatment of flares in adult patients with generalised pustular psoriasis.[L43782]","enzymes":null,"type":"biotech","cas-number":"2097104-58-8","sequences":null,"targets":"BE0010198","unii":"5IB2J79MCX","protein-binding":"There is no information available.","fda-label":null,"clearance":"In the linear dose range (0.3 to 20 mg\/kg), based on the population PK model, spesolimab-sbzo clearance (95% CI) in a typical GPP patient without anti-drug antibodies, weighing 70 kg was 0.184 (0.175, 0.194) L\/day.[L43090]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interleukin inhibitors IMMUNOSUPPRESSANTS","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Pustular psoriasis is a type of psoriasis, a chronic and recurrent immune-mediated multisystem disorder. Based on the characteristics and distribution of pustules, the disorder has different phenotypes, such as GPP. While the pathophysiology of psoriasis is not fully understood, some pro-inflammatory cytokines involved in innate and adaptive immune systems have been implicated as key mediators of psoriatic disease.[A252210] Interleukin (IL)-36 is one of those cytokines whereby unregulated activation and expression of IL-36 - often due to _IL36RN_ gene mutations - can result in pathological autoinflammatory responses in pustular psoriasis.[A252210, A252220, A252225] IL-36 is expressed in epithelial and immune cells and has three members, IL-36, IL-36, and IL-36, that bind to a receptor complex to activate pro-inflammatory and pro-fibrotic downstream signalling pathways, such as increased expression and actions of pro-inflammatory cells and factors. The heterodimeric receptor complex IL-36R comprises an IL-1RL2 subunit - to which IL-36 binds - and an IL-1RAcP co-receptor.[A252210]\r\n\r\nThe exact mechanism of action of spesolimab in managing psoriatic flares is unclear; however, it is believed to ameliorate inflammation by inhibiting IL-36 signalling. Spesolimab binds to the IL-36R receptor complex, preventing the binding of IL-36 downstream activation of receptor signalling pathways.[L43090]","drug-interactions":"DB05209 DB08880 DB00328 DB14905 DB00928 DB15274 DB06474 DB09381 DB06647 DB15091 DB11959 DB09052 DB12034 DB11857 DB15857 DB14039 DB12023 DB06305 DB00092 DB00970 DB15898 DB04951 DB14877 DB00034 DB11604 DB12344 DB13886 DB00642 DB13068 DB14811 DB00495 DB11921 DB11884 DB00105 DB11685 DB11746 DB15118 DB00305 DB06772 DB16650 DB14997 DB01229 DB12815 DB12235 DB06602 DB15646 DB12386 DB12053 DB01590 DB13843 DB14012 DB09035 DB13867 DB14891 DB16611 DB13017 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB06599 DB06310 DB00853 DB14864 DB09105 DB11044 DB14685 DB12520 DB10804 DB12396 DB13208 DB05797 DB15119 DB09082 DB09383 DB05656 DB00851 DB06557 DB12274 DB11680 DB13140 DB05676 DB10584 DB00959 DB11003 DB06607 DB15443 DB00773 DB14897 DB09074 DB00008 DB00120 DB00028 DB00547 DB12104 DB15001 DB12261 DB00428 DB12849 DB06813 DB13954 DB12826 DB12844 DB10990 DB01033 DB04962 DB11866 DB12205 DB00987 DB12498 DB11715 DB00324 DB00276 DB10061 DB01204 DB00098 DB01281 DB11621 DB16385 DB00113 DB12246 DB15627 DB05942 DB04868 DB00002 DB04949 DB00552 DB00877 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB06616 DB00033 DB01005 DB12119 DB00091 DB09045 DB14711 DB14952 DB00054 DB05111 DB14540 DB00180 DB16225 DB06589 DB12698 DB13073 DB08870 DB11731 DB14776 DB10276 DB01015 DB08906 DB01410 DB11771 DB05304 DB00022 DB12893 DB15090 DB16755 DB13014 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB00526 DB15865 DB12943 DB10283 DB12584 DB15899 DB00601 DB09369 DB00977 DB05276 DB12891 DB15415 DB17088 DB00993 DB11914 DB16170 DB00072 DB11988 DB14619 DB06371 DB00307 DB11674 DB15045 DB01269 DB06550 DB01234 DB16355 DB06322 DB03451 DB00635 DB11616 DB14445 DB13976 DB14066 DB10317 DB15089 DB14967 DB16736 DB13979 DB11834 DB01206 DB05679 DB10062 DB05006 DB09378 DB09318 DB15656 DB14022 DB09122 DB00069 DB12025 DB14843 DB12589 DB06606 DB11756 DB09053 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB05109 DB00432 DB12530 DB01097 DB16265 DB00394 DB00065 DB15718 DB05892 DB13386 DB01816 DB12089 DB09303 DB08904 DB08059 DB08910 DB12487 DB14959 DB12917 DB12845 DB06192 DB05015 DB11708 DB00550 DB15628 DB00043 DB12976 DB09559 DB01357 DB01008 DB01041 DB09033 DB11826 DB01108 DB14004 DB06241 DB00057 DB11603 DB06372 DB00112 DB01280 DB01181 DB06603 DB10600 DB05793 DB10769 DB01384 DB00591 DB10794 DB09095 DB06168 DB06049 DB01248 DB16659 DB01099 DB14996 DB12996 DB16222 DB06043 DB11945 DB11050 DB08908 DB08879 DB13924 DB00076 DB06366 DB09037 DB11478 DB01047 DB00763 DB05550 DB06662 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB00619 DB01268 DB09317 DB14824 DB16376 DB15453 DB11580 DB00445 DB12142 DB14545 DB05555 DB03523 DB14580 DB00290 DB00322 DB16195 DB02546 DB00188 DB00564 DB12189 DB00398 DB00110 DB09077 DB13003 DB15428 DB00075 DB14724 DB05101 DB10343 DB12947 DB00078 DB16648 DB06584 DB00755 DB04956 DB05136 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB14449 DB12560 DB12797 DB14394 DB05496 DB06287 DB04630 DB12157 DB12609 DB05916 DB01611 DB05889 DB06467 DB12102 DB14783 DB00441 DB10989 DB04958 DB11040 DB00480 DB12342 DB01601 DB00242 DB09070 DB12090 DB14988 DB15432 DB14384 DB14620 DB00291 DB08895 DB06688 DB15363 DB01254 DB00111 DB01270 DB00068 DB01380 DB13418 DB15810 DB01169 DB01656 DB14947 DB15441 DB15383 DB12991 DB00859 DB11487 DB14962 DB15349 DB00997 DB15654 DB05941 DB11930 DB06050 DB12612 DB00443 DB04845 DB11817 DB11041 DB06162 DB14385 DB05144 DB00694 DB12489 DB09264 DB05472 DB00864 DB00446 DB01024 DB12773 DB12456 DB06273 DB05325 DB15483 DB12317 DB12413 DB06317 DB14809 DB00688 DB12807 DB01196 DB06681 DB00544 DB01013 DB15334 DB00089 DB11693 DB11466 DB05097 DB08971 DB11840 DB12692 DB04914 DB13375 DB16732 DB12568 DB09054 DB14512 DB11038 DB01262 DB12202 DB13045 DB00860 DB15595 DB06360 DB00051 DB10318 DB14908 DB12820 DB15941 DB10803 DB15113 DB09073 DB00588 DB00095 DB01177 DB14845 DB00026 DB11529 DB05578 DB00488 DB00958 DB00286 DB12701 DB15101 DB02806 DB14778 DB12331 DB14762 DB15335 DB06186 DB15559 DB09091 DB10991 DB10805 DB11850 DB08868 DB08902 DB15409 DB15014 DB08871 DB00380 DB00337 DB12902 DB05440 DB12296 DB13143 DB16694 DB01222 DB16695 DB16394 DB13856 DB14539 DB15225 DB12250 DB15434 DB00309 DB14042 DB04573 DB00269 DB12213 DB12371 DB16077 DB00444 DB12240 DB06650 DB16393 DB01073 DB11646 DB15252 DB01423 DB00570 DB00056 DB14409 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB14707 DB12683 DB08889 DB01030 DB13923 DB16421 DB16151 DB09302 DB12617 DB00563 DB12118 DB08877 DB05915 DB00655 DB14871 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB11657 DB12775 DB06400 DB00011 DB04988 DB14513 DB01285 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB00764 DB00795 DB05260 DB08935 DB05545 DB15076 DB11972 DB13241 DB16703 DB00059 DB06116 DB15461 DB14040 DB06674 DB15900 DB09331 DB00293 DB13223 DB14041 DB13127 DB10583 DB05258 DB15719 DB00361 DB00620 DB04574 DB07931 DB15044 DB06769 DB11608 DB15104 DB11862 DB11627 DB05336 DB11714 DB12152 DB11776 DB12016 DB15253 DB06324 DB12534 DB04964 DB10316 DB15336 DB11849 DB05773 DB14597 DB01101 DB04572 DB15940 DB14219 DB09057 DB12718 DB00762 DB06343 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00005 DB10315 DB04575","absorption":"A population pharmacokinetic model was developed based on data collected from healthy subjects, patients with GPP, and patients with other diseases. After a single intravenous dose of 900 mg of spesolimab, the population PK model-estimated AUC<sub>0-<\/sub> (95% CI) and C<sub>max<\/sub> (95% CI) in a typical anti-drug antibody (ADA)-negative patient with GPP were 4750 (4510, 4970) mcg x day\/mL and 238 (218, 256) mcg\/mL, respectively.[L43090]","created":"2020-03-07","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal half-life is 25.5 (24.4, 26.3) days.[L43090]","monoisotopic-mass":null,"volume-of-distribution":"Based on the population pharmacokinetic analysis, the typical total volume of distribution at steady state was 6.4 L.[L43090]","route-of-elimination":"There is no information available.","name":"Spesolimab","metabolism":"The metabolic pathway of spesolimab-sbzo has not been characterized. As a humanized IgG1 monoclonal antibody, spesolimab-sbzo is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.[L43090]","reactions":null,"indication":"Spesolimab is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.[L43090]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15626"},{"toxicity":"There are no data regarding overdose with dostarlimab. Symptoms of overdosage are likely to be consistent with the adverse effect profile of dostarlimab and may therefore involve significant immune-mediated reactions.[L33320]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Dostarlimab is an immunotherapy that facilitates the body's endogenous anti-tumor immune response in the treatment cancer.[L33320] It is administered over a span of 30 minutes via intravenous infusion every three to six weeks depending on the cycle.[L33320]\r\n\r\nAgents that interfere with the PD-1\/PD-L1 pathway, including dostarlimab, remove an important immune system inhibitory response and may therefore induce immune-mediated adverse reactions which can be severe or fatal. These reactions can occur in any organ system and can occur at any time after starting therapy, and while they most often manifest during therapy they may also appear after discontinuing the causative agent. Patients receiving therapy with dostarlimab should be monitored closely for evidence of an underlying immune-mediated reaction and evaluated and treated promptly if an immune-mediated reaction is suspected.[L33320]","msds":null,"description":"Dostarlimab is an IgG<sub>4<\/sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt to destroy the cancerous cells.[A234379] Agents acting on the PD-1 pathway, such as [nivolumab] and [pembrolizumab], facilitate endogenous immune-mediated anti-tumor activity and may therefore be used to treat a wide variety of cancers, including those of the skin, lung, kidneys, and liver. \r\n\r\nIn April 2021, dostarlimab was granted an accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer experiencing disease progression despite treatment with platinum-containing chemotherapy regimens.[L33340] As this accelerated approval was granted only for the treatment of dMMR endometrial cancers, it was approved alongside a companion diagnostic device - the VENTANA MMR RxDx Panel - for use in selecting appropriate patients for treatment.[L33340]\r\n\r\nDostarlimab is currently under investigation for the treatment of rectal cancers with mismatch repair deficiency. A prospective phase II study in patients with mismatch repair-deficient locally advanced rectal cancer resulted in all twelve patients exhibiting a complete clinical response.[A248905]","enzymes":null,"type":"biotech","cas-number":"2022215-59-2","sequences":">Heavy Chain\nEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYY\nQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSSASTK\nGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS\nLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFP\nPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVS\nVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVS\nLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFS\nCSVMHEALHNHYTQKSLSLSLGK >Light Chain\nDIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPS\nRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","targets":"BE0003436","unii":"P0GVQ9A4S5","protein-binding":null,"fda-label":null,"clearance":"At steady-state, the mean clearance of dostarlimab is 0.007 L\/h.[L33320]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS PD-1\/PDL-1 (Programmed cell death protein 1\/death ligand 1) inhibitors MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Approximately 13-30% of recurrent endometrial cancers involve microsatellite instability (MSI) or mismatch repair deficiency (dMMR).[A234379,A234389] The mutations resulting in dMMR endometrial cancers are primarily somatic in nature (~90%), although 5-10% of cases involve germline mutations.[A234389] Cancers that have mutations resulting in dMMR can upregulate the expression of programmed death receptor-1 (PD-1) ligands 1 and 2 (PD-L1 and -L2) - PD-1 is found on T-cells and, when activated, inhibits their proliferation and the production of cytokines.[L33320] The binding of these ligands to PD-1 thereby functions as an immune checkpoint that downregulates the anti-tumor immune response.[A234379] \r\n\r\nDostarlimab is a monoclonal antibody targeted against PD-1 - it binds to the receptor and prevents interactions with PD-L1 and PD-L2, thus allowing the anti-tumor immune response to proceed unimpeded.[L33320]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB14947 DB09085 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"During the first cycle, and administered at 500mg intravenously every 3 weeks, the mean C<sub>max<\/sub> and AUC<sub>0-tau<\/sub> of dostarlimab-gxly are 171 mcg\/mL and 35,730 mcg.h\/mL, respectively. When administered at 1000mg every 6 weeks, the mean C<sub>max<\/sub> and AUC<sub>0-tau<\/sub> are 309 mcg\/mL and 95,820 mcg.h\/mL, respectively.[L33320]","created":"2020-03-07","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean terminal elimination half-life of dostarlimab is 25.4 days.[L33320]","monoisotopic-mass":null,"volume-of-distribution":"At steady-state, the mean volume of distribution of dostarlimab is 5.3L.[L33320]","route-of-elimination":null,"name":"Dostarlimab","metabolism":"The metabolism of dostarlimab has not been characterized, but it is expected to be degraded via catabolic pathways into smaller peptides and amino acids.[L33320,A216712]","reactions":null,"indication":"Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.[L33320]","ahfs-codes":null,"updated":"2022-06-09","drugbank-id":"DB15627"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]","enzymes":null,"type":"biotech","cas-number":"152981-31-2","sequences":null,"targets":"BE0000658","unii":"GO90DFK14U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Inolimomab is a murine monoclonal antibody targeting CD-25, also known as the alpha subunit of the interleukin-2 receptor. [L39010] The binding of this antibody to CD-25 blocks the signaling of interleukin-2, preventing clonal expansion of T-cells. The resulting immunosuppressive effect appears to provide a similar benefit in patients with steroid-resistant graft vs host disease to anti-thymocyte globulin.[A241380]","drug-interactions":"DB05209 DB08880 DB00328 DB14905 DB00928 DB15274 DB06474 DB09381 DB06647 DB15091 DB11959 DB09052 DB12034 DB11857 DB15857 DB14039 DB12023 DB06305 DB00092 DB00970 DB15898 DB04951 DB14877 DB00034 DB11604 DB12344 DB13886 DB00642 DB13068 DB14811 DB00495 DB11921 DB11884 DB00105 DB11685 DB11746 DB15118 DB00305 DB06772 DB16650 DB14997 DB01229 DB12815 DB12235 DB06602 DB15646 DB12386 DB12053 DB01590 DB13843 DB14012 DB09035 DB13867 DB14891 DB16611 DB13017 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB06599 DB06310 DB00853 DB14864 DB09105 DB11044 DB14685 DB12520 DB10804 DB12396 DB13208 DB05797 DB15119 DB09082 DB09383 DB05656 DB00851 DB06557 DB12274 DB11680 DB13140 DB05676 DB10584 DB00959 DB11003 DB06607 DB15443 DB00773 DB14897 DB09074 DB00008 DB00120 DB00028 DB00547 DB12104 DB15001 DB12261 DB00428 DB12849 DB06813 DB13954 DB12826 DB12844 DB10990 DB01033 DB04962 DB11866 DB12205 DB00987 DB12498 DB11715 DB00324 DB00276 DB10061 DB01204 DB00098 DB01281 DB11621 DB16385 DB00113 DB12246 DB15627 DB05942 DB04868 DB00002 DB04949 DB00552 DB00877 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB06616 DB00033 DB01005 DB12119 DB00091 DB09045 DB14711 DB14952 DB00054 DB05111 DB15626 DB14540 DB00180 DB16225 DB06589 DB12698 DB13073 DB08870 DB11731 DB14776 DB10276 DB01015 DB08906 DB01410 DB11771 DB05304 DB00022 DB12893 DB15090 DB16755 DB13014 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB00526 DB15865 DB12943 DB10283 DB12584 DB15899 DB00601 DB09369 DB00977 DB05276 DB12891 DB15415 DB17088 DB00993 DB11914 DB16170 DB00072 DB11988 DB14619 DB06371 DB00307 DB11674 DB15045 DB01269 DB06550 DB01234 DB16355 DB06322 DB03451 DB00635 DB11616 DB14445 DB13976 DB14066 DB10317 DB15089 DB14967 DB16736 DB13979 DB11834 DB01206 DB05679 DB10062 DB05006 DB09378 DB09318 DB15656 DB14022 DB09122 DB00069 DB12025 DB14843 DB12589 DB06606 DB11756 DB09053 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB05109 DB00432 DB12530 DB01097 DB16265 DB00394 DB00065 DB15718 DB05892 DB13386 DB01816 DB12089 DB09303 DB08904 DB08059 DB08910 DB12487 DB14959 DB12917 DB12845 DB06192 DB05015 DB11708 DB00550 DB00043 DB12976 DB09559 DB01357 DB01008 DB01041 DB09033 DB11826 DB01108 DB14004 DB06241 DB00057 DB11603 DB06372 DB00112 DB01280 DB01181 DB06603 DB10600 DB05793 DB10769 DB01384 DB00591 DB10794 DB09095 DB06168 DB06049 DB01248 DB16659 DB01099 DB14996 DB12996 DB16222 DB06043 DB11945 DB11050 DB08908 DB08879 DB13924 DB00076 DB06366 DB09037 DB11478 DB01047 DB00763 DB05550 DB06662 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB00619 DB01268 DB09317 DB14824 DB16376 DB15453 DB11580 DB00445 DB12142 DB14545 DB05555 DB03523 DB14580 DB00290 DB00322 DB16195 DB02546 DB00188 DB00564 DB12189 DB00398 DB00110 DB09077 DB13003 DB15428 DB00075 DB14724 DB05101 DB10343 DB12947 DB00078 DB16648 DB06584 DB00755 DB04956 DB05136 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB14449 DB12560 DB12797 DB14394 DB05496 DB06287 DB04630 DB12157 DB12609 DB05916 DB01611 DB05889 DB06467 DB12102 DB14783 DB00441 DB10989 DB04958 DB11040 DB00480 DB12342 DB01601 DB00242 DB09070 DB12090 DB14988 DB15432 DB14384 DB14620 DB00291 DB06688 DB08895 DB15363 DB01254 DB00111 DB01270 DB00068 DB01380 DB13418 DB15810 DB01169 DB01656 DB14947 DB15441 DB15383 DB12991 DB00859 DB11487 DB14962 DB15349 DB00997 DB15654 DB05941 DB11930 DB06050 DB12612 DB00443 DB04845 DB11817 DB11041 DB06162 DB14385 DB05144 DB00694 DB12489 DB09264 DB05472 DB00864 DB00446 DB01024 DB12773 DB12456 DB06273 DB05325 DB15483 DB12317 DB12413 DB06317 DB14809 DB00688 DB12807 DB01196 DB06681 DB00544 DB01013 DB15334 DB00089 DB11693 DB11466 DB05097 DB08971 DB11840 DB12692 DB04914 DB13375 DB16732 DB12568 DB09054 DB14512 DB11038 DB01262 DB12202 DB13045 DB00860 DB06360 DB15595 DB00051 DB10318 DB14908 DB12820 DB15941 DB10803 DB15113 DB09073 DB00588 DB00095 DB01177 DB14845 DB00026 DB11529 DB05578 DB00488 DB00958 DB00286 DB12701 DB15101 DB02806 DB14778 DB12331 DB14762 DB15335 DB06186 DB15559 DB09091 DB10991 DB10805 DB11850 DB08868 DB08902 DB15409 DB15014 DB08871 DB00380 DB00337 DB12902 DB05440 DB12296 DB13143 DB16694 DB01222 DB16695 DB16394 DB13856 DB14539 DB15225 DB12250 DB15434 DB00309 DB14042 DB04573 DB00269 DB12213 DB12371 DB16077 DB00444 DB12240 DB06650 DB16393 DB01073 DB11646 DB15252 DB01423 DB00570 DB00056 DB14409 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB14707 DB12683 DB08889 DB01030 DB13923 DB16421 DB16151 DB09302 DB12617 DB00563 DB12118 DB08877 DB05915 DB00655 DB14871 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB11657 DB12775 DB06400 DB00011 DB04988 DB14513 DB01285 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB00764 DB00795 DB05260 DB08935 DB05545 DB15076 DB11972 DB13241 DB16703 DB00059 DB06116 DB15461 DB14040 DB06674 DB15900 DB09331 DB00293 DB13223 DB14041 DB13127 DB10583 DB05258 DB15719 DB00361 DB00620 DB04574 DB07931 DB15044 DB06769 DB11608 DB15104 DB11862 DB11627 DB05336 DB11714 DB12152 DB11776 DB12016 DB15253 DB06324 DB12534 DB04964 DB15336 DB10316 DB11849 DB05773 DB14597 DB01101 DB04572 DB15940 DB14219 DB09057 DB12718 DB00762 DB06343 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00005 DB10315 DB04575","absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inolimomab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-11-08","drugbank-id":"DB15628"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Garadacimab is under investigation in clinical trial NCT04281524 (A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line).","enzymes":null,"type":"biotech","cas-number":"2162134-62-3","sequences":null,"targets":null,"unii":"32W6AJL0DY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Garadacimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15629"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":459.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).","enzymes":null,"type":"small molecule","cas-number":"1642581-63-2","sequences":null,"targets":null,"unii":"7JTT036WGX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":459.122591997,"volume-of-distribution":null,"route-of-elimination":null,"name":"Glumetinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15630"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).","enzymes":null,"type":"biotech","cas-number":"187348-17-0","sequences":null,"targets":null,"unii":"31Z82G8ME1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Edodekin alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15631"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).","enzymes":null,"type":"biotech","cas-number":"2148321-69-9","sequences":null,"targets":null,"unii":"FE7L22H028","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zalifrelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15632"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pabinafusp alfa is under investigation in clinical trial NCT03568175 (A Study of JR-141 in Patients With Mucopolysaccharidosis II).","enzymes":null,"type":"biotech","cas-number":"2140211-48-7","sequences":null,"targets":null,"unii":"TRF8S0U6ON","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pabinafusp alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15633"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Temelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).","enzymes":null,"type":"biotech","cas-number":"1393641-34-3","sequences":null,"targets":null,"unii":"T32CR1A69R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Temelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15634"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CD276 (B7-H3) is a B7\/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.[A191829]\r\n\r\nOmburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System\/leptomeningeal Metastases).","enzymes":null,"type":"biotech","cas-number":"1895083-75-6","sequences":null,"targets":"BE0010140","unii":"XQL6783S5T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"CD276 (also known as B7-H3) is a member of the B7\/CD28 immunoglobulin superfamily with possible co-stimulatory and co-inhibitory roles in T cell-mediated immunity.[A242487] Despite low to absent expression on most healthy cells, CD276 is frequently highly expressed among solid human tumours.[A242487, A242492] Omburtamab, a murine anti-B7-H3 antibody, and its humanized forms bind to the CD276 FG loop thought to be important in co-inhibitory functions.[A242487, A191829] Omburtamab also facilitates direct antibody-directed cellular cytotoxicity (ADCC) of CD276-expressing tumour cells.[A242487] Recent experiments using chimeric antigen receptor (CAR) T cells and bispecific killer cell engager (BiKE)-redirected natural killer cells demonstrated efficacy against NSCLC _in vitro_ and _in vivo_.[A242492] Hence, targeting CD276 appears to be an appealing option for overcoming immunotherapy blockade in solid tumours.","drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Omburtamab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-11-27","drugbank-id":"DB15635"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":3562.229,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zilucoplan is under investigation in clinical trial NCT04225871 (Open-label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis).","enzymes":null,"type":"small molecule","cas-number":"1841136-73-9","sequences":null,"targets":"BE0000855","unii":"YG391PK0CC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":3559.969439148,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zilucoplan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-06-17","drugbank-id":"DB15636"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":472.404,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).","enzymes":null,"type":"small molecule","cas-number":"1358715-18-0","sequences":null,"targets":null,"unii":"TWF0ML1CK8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":472.127086431,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluzoparib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15637"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":420.469,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).","enzymes":null,"type":"small molecule","cas-number":"1802148-05-5","sequences":null,"targets":null,"unii":"25CG88L0BB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":420.179755269,"volume-of-distribution":null,"route-of-elimination":null,"name":"Brensocatib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15638"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":463.473,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AMG-337 is under investigation in clinical trial NCT03147976 (QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1173699-31-4","sequences":null,"targets":null,"unii":"08WG8S0L8D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":463.176815759,"volume-of-distribution":null,"route-of-elimination":null,"name":"AMG-337","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15639"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":408.454,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CDC-801 is under investigation in clinical trial NCT00006097 (Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia).","enzymes":null,"type":"small molecule","cas-number":"192819-27-5","sequences":null,"targets":null,"unii":"95HB56U8P8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-08","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":408.168521881,"volume-of-distribution":null,"route-of-elimination":null,"name":"CDC-801","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15640"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":387.523,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity give it theoretical advantages over tamoxifen in the treatment of human breast cancer. Short-term toxicity was generally mild, and similar to that seen with other antiestrogens. Droloxifene appears active and tolerable. It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. Droloxifene may have an effect on bone and breast tissue because it induces apoptosis. Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.[L34184]","enzymes":null,"type":"small molecule","cas-number":"82413-20-5","sequences":null,"targets":null,"unii":"0M67U6Z98F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":null,"created":"2020-03-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":387.219829178,"volume-of-distribution":null,"route-of-elimination":null,"name":"Droloxifene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB15641"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":314.309,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).","enzymes":null,"type":"small molecule","cas-number":"1154028-82-6","sequences":null,"targets":null,"unii":"9JH486CZ13","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-13","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":314.123971723,"volume-of-distribution":null,"route-of-elimination":null,"name":"Molidustat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15642"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":129.207,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).[A192426]","enzymes":null,"type":"small molecule","cas-number":"23435-23-6","sequences":null,"targets":"BE0000982","unii":"K93WMR7E2S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption.[A184781] This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation.[A184781] N-(2-Aminoethyl)-1-aziridineethanamine may inhibit ACE2, preventing these actions from occurring.[A192426]\r\n\r\nN-(2-Aminoethyl)-1-aziridineethanamine binding to ACE2 may lead to a conformational change in ACE2, shifting the residues that would bind SARS-CoV S-glycoprotein, preventing viral attachment and entry.[A192426]","drug-interactions":null,"absorption":null,"created":"2020-03-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":129.126597495,"volume-of-distribution":null,"route-of-elimination":null,"name":"N-(2-Aminoethyl)-1-aziridineethanamine","metabolism":null,"reactions":null,"indication":"This experimental drug was being researched for its use in the treatment of cardiovascular disease and SARS-CoV infections.[A192426]","ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15643"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":306.317,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ochromycinone is under investigation in clinical trial NCT01047943 (STA-21 Topical Efficacy on Psoriasis).","enzymes":null,"type":"small molecule","cas-number":"28882-53-3","sequences":null,"targets":null,"unii":"CKZ6P7I25M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-23","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":306.089208931,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ochromycinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15644"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":320.251,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).","enzymes":null,"type":"small molecule","cas-number":"27200-12-0","sequences":null,"targets":null,"unii":"KD8QND6427","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-23","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":320.05321736,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dihydromyricetin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15645"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":764.78,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee).","enzymes":null,"type":"small molecule","cas-number":"869939-83-3","sequences":null,"targets":null,"unii":"0WL827Z7AE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08880 DB00328 DB00928 DB15274 DB15091 DB09052 DB15857 DB00092 DB00970 DB04951 DB00034 DB00642 DB13068 DB00495 DB11921 DB00105 DB00305 DB06772 DB16650 DB01229 DB12386 DB01590 DB13843 DB13867 DB16611 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00853 DB11044 DB14685 DB10804 DB13208 DB15119 DB09082 DB09383 DB00851 DB05676 DB10584 DB00959 DB11003 DB00773 DB09074 DB00008 DB00120 DB00547 DB00428 DB06813 DB10990 DB01033 DB00987 DB00324 DB00276 DB10061 DB01204 DB00098 DB01281 DB05942 DB04868 DB00552 DB00877 DB01257 DB11976 DB06616 DB00033 DB01005 DB00091 DB14711 DB15626 DB14540 DB00180 DB06589 DB08870 DB10276 DB01015 DB08906 DB01410 DB00022 DB13014 DB14919 DB05459 DB00526 DB10283 DB00601 DB17088 DB00993 DB00072 DB11988 DB14619 DB00307 DB01234 DB03451 DB00635 DB11616 DB14445 DB14066 DB10317 DB16736 DB11834 DB01206 DB10062 DB09378 DB15656 DB14022 DB09122 DB00069 DB12025 DB09053 DB05109 DB00432 DB12530 DB01097 DB00394 DB00065 DB01816 DB08904 DB08059 DB08910 DB12917 DB05015 DB11708 DB00550 DB15628 DB01008 DB01041 DB09033 DB01108 DB11603 DB06372 DB01280 DB01181 DB06603 DB10600 DB10769 DB01384 DB00591 DB10794 DB09095 DB06168 DB01248 DB01099 DB12996 DB11050 DB08908 DB08879 DB13924 DB01047 DB00763 DB06662 DB06612 DB11569 DB00619 DB01268 DB11580 DB00445 DB14545 DB03523 DB00290 DB00322 DB02546 DB00188 DB00564 DB00398 DB09077 DB13003 DB00075 DB14724 DB10343 DB12947 DB00078 DB16648 DB06584 DB00755 DB04956 DB14443 DB00073 DB06643 DB14449 DB14394 DB06287 DB04630 DB01611 DB14783 DB00441 DB10989 DB11040 DB00480 DB01601 DB00242 DB14384 DB14620 DB00291 DB06688 DB08895 DB01254 DB00111 DB00068 DB01380 DB15810 DB01169 DB01656 DB12991 DB00859 DB11487 DB00997 DB15654 DB12612 DB00443 DB04845 DB11817 DB11041 DB14385 DB05144 DB00694 DB05472 DB00864 DB00446 DB01024 DB06273 DB05325 DB15483 DB00688 DB01196 DB06681 DB00544 DB01013 DB11693 DB11466 DB08971 DB12692 DB04914 DB12568 DB09054 DB14512 DB11038 DB01262 DB00860 DB15595 DB00051 DB10318 DB10803 DB09073 DB00588 DB00095 DB01177 DB14845 DB00026 DB11529 DB00488 DB00958 DB02806 DB14762 DB09091 DB10991 DB10805 DB08868 DB08871 DB00380 DB00337 DB12902 DB05440 DB16694 DB01222 DB13856 DB14539 DB15434 DB00309 DB12371 DB00444 DB06650 DB01073 DB01423 DB00570 DB00056 DB14409 DB15762 DB05259 DB00041 DB08901 DB11803 DB09036 DB08889 DB01030 DB12617 DB00563 DB08877 DB12768 DB00081 DB05374 DB00018 DB00352 DB13491 DB00087 DB06400 DB00011 DB14513 DB01285 DB11767 DB09029 DB00764 DB00795 DB05260 DB08935 DB16703 DB13241 DB00059 DB15461 DB06674 DB00293 DB13223 DB10583 DB05258 DB00361 DB00620 DB06769 DB11627 DB11776 DB12016 DB15253 DB10316 DB05773 DB01101 DB04572 DB14219 DB09057 DB00762 DB06343 DB00074 DB01168 DB00515 DB00262 DB00541 DB01042 DB09312 DB00687 DB00005 DB10315","absorption":null,"created":"2020-03-23","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":763.2805863,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fasitibant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15646"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":396.84,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ketodarolutamide, a nonsteroidal antiandrogen (NSAA), is the major active metabolite of [darolutamide].","enzymes":null,"type":"small molecule","cas-number":"1297537-33-7","sequences":null,"targets":"BE0000132","unii":"9EPS75QMTL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":396.1101515,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ketodarolutamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15647"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":56.077,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1305-78-8","sequences":null,"targets":null,"unii":"C7X2M0VVNH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-29","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":55.9575055,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium oxide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15648"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"9007-20-9","sequences":null,"targets":null,"unii":"0A5MM307FC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-29","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carbomer","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15649"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Efpeglenatide is under investigation in clinical trial NCT03713684 (Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)).","enzymes":null,"type":"biotech","cas-number":"1296200-77-5","sequences":null,"targets":"BE0000857","unii":"3M1V5Z2270","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-31","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Efpeglenatide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-06-17","drugbank-id":"DB15650"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":618.864,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).","enzymes":null,"type":"small molecule","cas-number":"195156-77-5","sequences":null,"targets":null,"unii":"506LI1B3A3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-31","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":618.446868992,"volume-of-distribution":null,"route-of-elimination":null,"name":"Valomaciclovir stearate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15651"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":762.912,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).","enzymes":null,"type":"small molecule","cas-number":"1242087-93-9","sequences":null,"targets":null,"unii":"AL3G001BI8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-31","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":762.385331362,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ravidasvir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15652"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":293.258,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Islatravir is under investigation in clinical trial NCT04233216 (Doravirine\/islatravir (DOR\/ISL) in Heavily Treatment-experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)).","enzymes":null,"type":"small molecule","cas-number":"865363-93-5","sequences":null,"targets":null,"unii":"QPQ082R25D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-03-31","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":293.092417429,"volume-of-distribution":null,"route-of-elimination":null,"name":"Islatravir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15653"},{"toxicity":"There is limited information on clinical toxicity.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"The Moderna COVID-19 Vaccine contains nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus. It has the potential to elicit a highly S-protein specific antiviral response.[A225811] In clinical trials, the Moderna COVID-19 Vaccine demonstrated vaccine efficacy of 94.1%; however, the manufacturing company emphasizes that the vaccine may not protect all vaccine recipients against COVID-19, as some vaccinated patients still contracted the virus.[L28026]","msds":null,"description":"The Moderna COVID-19 Vaccine (mRNA-1273) is a novel mRNA-based vaccine encapsulated in a lipid nanoparticle that encodes for a full-length pre-fusion stabilized spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the novel coronavirus, SARS-CoV-2, leading to a respiratory illness alongside other complications. COVID-19 has high interpatient variability in symptoms, ranging from mild symptoms to severe illness.[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29).[L12660] This trial was later followed by phase II and III trials, where the Moderna COVID-19 Vaccine demonstrated vaccine efficacy of 94.1%.[L28026]\r\n\r\nOn December 18, 2020, the FDA first issued an emergency use authorization (EUA) for the Moderna COVID-19 Vaccine as the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in patients aged 18 years and older, after the EUA issued for the [Pfizer-BioNTech Covid-19 Vaccine] on December 11, 2020. The Moderna COVID-19 Vaccine is administered as a series of two intramuscular injections, one month (28 days) apart. In clinical trials, there were no differences in the safety profiles between younger and older (65 years of age and older) study participants.[L28026] On December 23, 2020, Health Canada issued an expedited authorization for the Moderna COVID-19 Vaccine.[L28143] \r\n\r\nIn November 2021, Health Canada and the EMA authorized the use of the Moderna COVID-19 vaccine as a booster shot to be given at least six months following the primary vaccination series and at half (50 mcg) of its regular strength.[L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older.[L39217] The Moderna COVID-19 Vaccine was fully approved by the FDA on January 31, 2022 [L40079] and Health Canada expanded the use of the Moderna COVID-19 Vaccine to include individuals aged six to 11.[L39307] The Moderna COVID-19 vaccine is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"EPK39PL4R4","protein-binding":"There is limited pharmacokinetic information.","fda-label":null,"clearance":"There is limited pharmacokinetic information.","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"The Moderna COVID-19 Vaccine is a vaccine that contains synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in Lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2.[A215497] The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell.[A225811] Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to the protection against SARS-CoV-2.[L28026]","drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01410 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB04845 DB11817 DB00764 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB06603 DB01204 DB01013 DB00620 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00515 DB00262 DB11569 DB06589 DB00588 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00180 DB00445 DB00005 DB00687 DB08906 DB02806 DB03523","absorption":"There is limited pharmacokinetic information.","created":"2020-04-01","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"There is limited pharmacokinetic information.","monoisotopic-mass":null,"volume-of-distribution":"There is limited pharmacokinetic information.","route-of-elimination":"There is limited pharmacokinetic information.","name":"Moderna COVID-19 Vaccine","metabolism":"There is limited pharmacokinetic information.","reactions":null,"indication":"The Moderna COVID-19 Vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older in the US and Europe,[L3927, L40074] and in individuals 6 months of age and older in Canada.[L39307] In the US, under the emergency use authorization, the Moderna COVID-19 Vaccine is used for the prevention of COVID-19 in children 6 months of age and older.[L42770]\r\n\r\nIt is administered in two doses, one month (28 days) apart.[L28026] A booster dose of the vaccine, to be given at least 6 months following the initial vaccine series, is approved for use in all patients 18 years of age and older in Canada and the US.[L39160, L39217, L39277] The Moderna COVID-19 vaccine is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350]\r\n\r\nA new bivalent formulation of the Moderna vaccine which includes davesomeran was approved in November 2022 by Health Canada and in August 2022 by the FDA against the BA.4 and BA.5 omicron variants.[L43862,","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15654"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)[L12675] with an expected completion in December 2020. The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination.[L12678]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"5AHC3V2UQS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-01","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ad5-nCoV","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15655"},{"toxicity":"There are no direct data regarding overdosage with this vaccine - in the event of overdosage, prescribing information recommends supportive and symptomatic treatment.[L32649]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"The AstraZeneca COVID-19 Vaccine comprises two intramuscularly-administered doses given 4 to 12 weeks apart. Vaccine efficacy in the prevention of all COVID-19 cases has been estimated as ~67%, while efficacy in the prevention of serious COVID-19 (including hospitalizations and death) is 100%.[L32679] Exploratory analyses revealed a vaccine efficacy that appeared to increase with increasing dosing interval between the first and second doses[L32679] - up to 80% when administered \u203012 weeks apart - though the significance and validity of this observation is currently unclear.\r\n\r\nIn November 2021, Health Canada released a public advisory regarding a rare risk of immune thrombocytopenia associated with the AstraZeneca COVID-19 vaccine (Vaxzevria) - patients are advised to seek immediate medical treatment if they experience any of the following after vaccination: unexplained bleeding, unexplained bruising, small purple spots beyond the site of vaccination, shortness of breath, chest pain, leg pain and\/or swelling, and persistent abdominal pain.[L39185]","msds":null,"description":"The AstraZeneca COVID-19 Vaccine (previously known as ChAdOx1 nCoV-19 or AZD1222) is one of several vaccines developed in 2020 for the prevention of COVID-19 caused by SARS-CoV-2.[L12669,L32649] The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for vaccines against another human coronavirus, Middle Eastern respiratory syndrome coronavirus (MERS-CoV).[A192822,L12672] The ChAdOx1 nCoV-19 vaccine, produced in a partnership between The University of Oxford's Jenner Institute and Italian pharmaceutical manufacturer Advent Srl, consists of a replication-deficient adenovirus capable of producing the spike (S) protein of SARS-CoV-2, allowing for the formation of endogenous antibodies against these proteins and, consequently, against SARS-CoV-2.[L12672] The University of Oxford struck a development and distribution deal with AstraZeneca in May 2020[L32659] which paved the way for the vaccine's subsequent approval and usage in dozens of regions across the globe, including Canada, Mexico, the UK, the EU, and Australia, amongst others.[L32649,L32664]\r\n\r\nIn March 2021, several EU member countries halted the administration of AstraZeneca's COVID-19 Vaccine due to signals of an increased risk of blood clots associated with thrombocytopenia, including the development of cerebral venous sinus thrombosis (CVST). Upon review, the European Medicines Agency (EMA) determined that the vaccine was not associated with a higher overall risk of blood clots, but that it may be associated with very rare instances of blood clots in association with thrombocytopenia - a causal link with the vaccine has not been proven, but is possible and requires further analysis. Despite these concerns, the EMA concluded its review by reiterating that the benefits of the vaccine in the prevention of COVID-19 - a condition which itself leads to blood clots - continue to outweigh the risks associated with its administration.[L32674]\r\n\r\nA phase I\/II single-blinded, randomized, placebo-controlled trial to investigate the safety, efficacy, and immunogenicity of the vaccine began in April 2020 with an expected completion date of October 2021.[L12669] The trial is taking place in the UK, where the vaccine will be administered intramuscularly to healthy adult volunteers between the ages of 18 and 55.[L12669]","enzymes":null,"type":"biotech","cas-number":"2420395-83-9","sequences":null,"targets":null,"unii":"B5S3K2V0G8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The AstraZeneca COVID-19 Vaccine is a replication-deficient (i.e. inactivated) chimpanzee adenovirus vector - specifically the ChAdOx1 vector - encoding a trimeric pre-fusion form of the SARS-CoV-2 spike (S) protein.[L32649] Following intramuscular administration these spike proteins are expressed locally, allowing the immune system to mount a neutralizing antibody\/cellular immune response. This initial exposure and priming of the immune system subsequently provides protection against future infection.","drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB02806 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB00764 DB04845 DB11817 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB11569 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB00620 DB01013 DB01204 DB06603 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00588 DB00180 DB00262 DB00515 DB06589 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00687 DB00445 DB00005 DB08906 DB01410 DB03523","absorption":null,"created":"2020-04-01","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AstraZeneca COVID-19 Vaccine","metabolism":null,"reactions":null,"indication":"The AstraZeneca COVID-19 Vaccine is indicated for the active immunization of individuals 18 years of age and older for the prevention of COVID-19.[L32649]","ahfs-codes":null,"updated":"2021-12-17","drugbank-id":"DB15656"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1134.11,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ala-geninthiocin is a novel thiopeptide antibacterial compound derived from marine _Streptomyces_ species.[A192840] It has exhibited potent _in vitro_ activity against gram-positive bacteria including _Staphylococcus aureus_, _Bacillus subtilis_, _Mycobacterium smegmatis_, and _Micrococcus luteus_.[A192840]","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB06770 DB14055 DB00682 DB12235 DB12532 DB13451 DB00281 DB08987 DB00296 DB13259 DB08794 DB08496 DB00297 DB13578 DB13683 DB01161 DB14022 DB00946 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB03410 DB00527 DB00645 DB13136 DB09345 DB01418 DB13328 DB00498 DB09009 DB13347 DB00721 DB04665 DB09268 DB05232 DB00750 DB00892 DB12768 DB00581 DB01002 DB14443 DB09085 DB09342 DB00266 DB01086 DB11502 DB03255 DB00565 DB13275","absorption":null,"created":"2020-04-01","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1133.340977176,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ala-geninthiocin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15657"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":156.61,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1124-04-5","sequences":null,"targets":null,"unii":"601F79M480","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":156.0341926,"volume-of-distribution":null,"route-of-elimination":null,"name":"2-chloro-4,5-dimethylphenol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15658"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":310.029,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"514-12-5","sequences":null,"targets":null,"unii":"F89Z8SAG3O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":307.941141,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha,alpha-Dibromo-D-camphor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15659"},{"toxicity":"Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an _in vitro_ IC<sub>50<\/sub> of 0.3M and a CC<sub>50<\/sub> of >10M.[A193014]","snp-adverse-drug-reactions":null,"average-mass":259.218,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.[A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and the human coronavirus HCoV-NL63 _in vitro_.[A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.[A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5\u20AC-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.[A193011] In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.[A193026] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014] The prodrug of N4-hydroxycytidine, [EIDD-2801], is also being investigated for its broad spectrum activity against the coronavirus family of viruses.[A193014]","enzymes":null,"type":"small molecule","cas-number":"3258-02-4","sequences":null,"targets":null,"unii":"C3D11PV2O4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"N4-hydroxycytidine is phosphorylated in tissue to the active 5\u20AC-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe.[A193011,A193029] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014]","drug-interactions":null,"absorption":"N4-hydroxycytidine is orally bioavailable in mice[A193011] but poorly bioavailable in non-human primates.[A193026]","created":"2020-04-07","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":259.080435151,"volume-of-distribution":null,"route-of-elimination":null,"name":"N4-Hydroxycytidine","metabolism":"N4-hydroxycytidine distributes into tissues where it is is phosphorylated to the 5'-triphosphate form.[A193026]","reactions":null,"indication":"N4-hydroxycytidine and its prodrug [EIDD-2801] is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.[A193014, A193029]","ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15660"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":329.309,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine].[A193014,A193026] With improved oral bioavailability in non-human primates, it is hydrolyzed _in vivo_, and distributes into tissues where it becomes the active 5\u20AC-triphosphate form.[A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe.[A193029] Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.[A193014] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014]\r\n\r\nMolnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to COVID-19 in adults.[L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]","enzymes":null,"type":"small molecule","cas-number":"2349386-89-4","sequences":null,"targets":null,"unii":"YA84KI1VEW","protein-binding":"Molnupiravir and the active metabolite, N4-hydroxycytidine, are not protein bound in plasma.[L39055]","fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":"Take with or without food. A high fat meal reduces the maximum concentration of the active metabolite by 35% and does not significantly affect the area under the curve.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Molnupiravir is hydrolyzed _in vivo_ to N4-hydroxycytidine, which is phosphorylated in tissue to the active 5\u20AC-triphosphate form, and incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe.[A193014,A193029] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.[A193014]","drug-interactions":null,"absorption":"After an 800 mg oral dose of molnupiravir every 12 hours, the active compound (N4-hydroxycytidine) reaches a C<sub>max<\/sub> of 2970 ng\/mL, with a T<sub>max<\/sub> of 1.5 hours, and an AUC<sub>0-12h<\/sub> of 8360 h\\*ng\/mL.[L39055]","created":"2020-04-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The half life of the active metabolite, N4-hydroxycytidine, is 3.3 hours.[L39055]","monoisotopic-mass":329.122299964,"volume-of-distribution":null,"route-of-elimination":"\u20303% of an oral molnupiravir dose is eliminated in the urine as the active metabolite N4-hydroxycytidine.[L39055]","name":"Molnupiravir","metabolism":"Molnupiravir is hydrolyzed to [N4-hydroxycytidine], which distributes into tissues.[A193026] Once inside cells, N4-hydroxycytidine is phosphorylated to the 5'-triphosphate form.[A193026]","reactions":null,"indication":"[N4-hydroxycytidine] and its prodrug molnupiravir are being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.[A193014, A193029]\r\n\r\nMolnupiravir is approved in the UK for reducing the risk of hospitalization and death in mild to moderate COVID-19 cases for patients at increased risk of severe disease (eg. with obesity, diabetes mellitus, heart disease, or are over 60 years old).[L39050,L39055]\r\n\r\nIn the US, molnupiravir is authorized for emergency use for the treatment of high-risk adults With mild to moderate COVID-19.[L39588]","ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB15661"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":288.472,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1561-06-4","sequences":null,"targets":null,"unii":"S4JE3R143V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":288.266445019,"volume-of-distribution":null,"route-of-elimination":null,"name":"Myristyl glyceryl ether","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15662"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8016-20-4","sequences":null,"targets":null,"unii":"YR377U58W9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Grapefruit oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15663"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":173.215,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"83-69-2","sequences":null,"targets":null,"unii":"HEE4JPA7DF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-13","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":173.084063978,"volume-of-distribution":null,"route-of-elimination":null,"name":"Vitamin K7","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15664"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":183.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia.  Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine\u20AC\u201Cassociated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A).[A193506] \r\n\r\nSEP-363856 was developed by Sunovion pharmaceuticals.[L12891] An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia. Negative symptoms of schizophrenia are more difficult to treat and may include flattened affect, anhedonia,  and social withdrawal. Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug.[A193506]","enzymes":null,"type":"small molecule","cas-number":"1310426-33-5","sequences":null,"targets":"BE0001044 BE0000291","unii":"3K6270MG59","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":183.071785217,"volume-of-distribution":null,"route-of-elimination":null,"name":"SEP-363856","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15665"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":281.0909,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"55406-53-6","sequences":null,"targets":null,"unii":"603P14DHEB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-17","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":280.991272053,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iodopropynyl butylcarbamate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15666"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"1M5Y26M37U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-18","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bacillus amyloliquefaciens","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15667"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":231.7358,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"20667-12-3","sequences":null,"targets":null,"unii":"897WUN6G6T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":229.805100662,"volume-of-distribution":null,"route-of-elimination":null,"name":"Silver oxide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15668"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":358.4,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fezolinetant is under investigation in clinical trial NCT04234204 (A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause).","enzymes":null,"type":"small molecule","cas-number":"1629229-37-3","sequences":null,"targets":null,"unii":"83VNE45KXX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":358.101208464,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fezolinetant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15669"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":460.542,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gusacitinib is under investigation in clinical trial NCT02550678 (A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma).","enzymes":null,"type":"small molecule","cas-number":"1425381-60-7","sequences":null,"targets":null,"unii":"4801QYW816","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":460.233522174,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gusacitinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15670"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":299.227,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"441785-25-7","sequences":null,"targets":null,"unii":"4PLG22CQUU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":299.078340949,"volume-of-distribution":null,"route-of-elimination":null,"name":"Besifovir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15671"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":500.92,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).","enzymes":null,"type":"small molecule","cas-number":"1383450-81-4","sequences":null,"targets":null,"unii":"NQ99E8OH3P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":500.0896739,"volume-of-distribution":null,"route-of-elimination":null,"name":"Rilematovir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15672"},{"toxicity":"There is limited information available regarding the acute toxicity and overdose of lenacapavir. If overdose occurs the patient must be monitored for signs or symptoms of adverse reactions. Treatment of overdose with lenacapavir consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. As lenacapavir is highly protein bound, it is unlikely to be significantly removed by dialysis.[L42990]","snp-adverse-drug-reactions":null,"average-mass":968.28,"transporters":"BE0001032","pharmacodynamics":"Lenacapavir is an antiviral drug with an extended pharmacokinetic profile. Lenacapavir works against the HIV-1 virus by inhibiting viral replication: it interferes with a number of essential steps of the viral lifecycle, including viral uptake, assembly, and release.[L42990] Single subcutaneous doses \u2030100 mg in healthy volunteers resulted in plasma concentrations exceeding the 95% effective concentration (EC<sub>95<\/sub>) for \u203012 weeks while doses \u2030300 mg exceeded the EC<sub>95<\/sub> for \u203024 weeks. In treatment-naive HIV-1-infected patients, a single subcutaneous dose of 20-450 mg resulted in a mean maximum log<sub>10<\/sub>-transformed reduction in plasma HIV-1 RNA of 1.35-2.20 by the ninth-day post-injection.[A244175]","msds":null,"description":"HIV\/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens.[A244170, A244175] Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy _in vitro_, little to no cross-resistance with existing antiretroviral agents, and extended pharmacokinetics with subcutaneous dosing.[A244170, A244175, A244180, A244190]\r\n\r\nLenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection.[L42995] On December 22, 2022, it was also approved by the FDA.[L44473]","enzymes":"BE0002638 BE0003541","type":"small molecule","cas-number":"2189684-44-2","sequences":null,"targets":"BE0001594","unii":"A9A0O6FB4H","protein-binding":"_In vitro_, lenacapavir is approximately 99.8% bound to plasma proteins.[L42990]","fda-label":null,"clearance":"Lenacapavir clearance was 3.62 L\/h in heavily treatment experienced patients with HIV-1 infection.[L42990]","atc-codes":"ANTIVIRALS FOR SYSTEMIC USE ANTIINFECTIVES FOR SYSTEMIC USE Other antivirals DIRECT ACTING ANTIVIRALS","pdb-entries":false,"food-interactions":"Take with or without food. Oral lenacapavir should be taken orally with or without food, as food has negligible effects on drug absorption.","state":"solid","synthesis-reference":null,"mechanism-of-action":"HIV-1 co-opts various host factors during its replicative cycle, including during host cell entry, nuclear integration, replication, and virion assembly. Following the initial fusion with the host cell membrane, the viral capsid is released into the host cell cytoplasm. The capsid comprises approximately 250 hexamers and exactly 12 pentamers, each composed of monomeric capsid proteins (CA). Each CA monomer has an N-terminal and C-terminal domain (NTD\/CTD) and offers an interaction surface for host cell machinery. Several important protein-protein interaction interfaces occur between CA monomers in the assembled multimers; the binding constants of these proteins are substantially lower for assembled multimers than individual capsid monomers.[A244170]\r\n\r\nTo facilitate HIV-1 genomic integration, the capsid must cross the nuclear envelope, for which it utilizes the nuclear pore complex (NPC). Two host proteins shown to be essential for capsid nuclear entry that directly bind to the capsid are cleavage and polyadenylation specificity factor subunit 6 (CPSF6) and nucleoporin 153 (Nup153, an NPC protein present on the nucleoplasmic face of the complex).[A244170] Both proteins bind the same phenylalanine-glycine binding pocket between the NTD and CTD of neighbouring CA monomers in multimeric CA assemblies.[A244170, A244175, A244180, A244185]\r\n\r\nLenacapavir contains a difluorobenzyl ring that occupies the same binding pocket as CPSF6\/Nup153, overlapping with the benzyl group of F321 in CPSF6 and F1417 in Nup153 in the overlayed structures.[A244170, A244175, A244180, A244185] Crystal structures of lenacapavir bound to CA hexamers reveal that six lenacapavir molecules bind to each hexamer, establishing extensive hydrophobic interactions, two cation-\u20AC interactions, and seven hydrogen bonds, contacting ~2,000 \u201E<sup>2<\/sup> of buried protein surface area.[A244175, A244180] Strong binding of lenacapavir, therefore competitively interrupts capsid interactions with CPSF6 and Nup153. _In vitro_ HIV-1 replication inhibition experiments in a variety of cell lines show EC<sub>50<\/sub> values of ~12-314 pM, with greater efficacy against early steps over later steps.[A244175, A244180] At very low concentrations (0.5 nM), lenacapavir inhibits viral nuclear entry, while at higher concentrations (5-50 nM), it additionally inhibits viral DNA synthesis and reverse transcription.[A244180] As CPSF6 and Nup153 are essential for nuclear entry, it is likely that lenacapavir binding inhibits these interactions and blocks capsid nuclear entry.\r\n\r\nLenacapavir may have additional effects beyond blocking interactions with host cell factors. Lenacapavir increases the rate and extent of CA assembly, dramatically extends the lifetime of assembled CA structures, even at high salt concentrations, and alters assembled capsid morphology.[A244175, A244180] The stabilizing concentration is ~1:1, closely mimicking the observed binding stoichiometry to isolated CA hexamers. Further analysis suggests that lenacapavir binding alters intra- and inter-hexamer interactions, altering the structure and stability of the resulting assemblies.[A244180]\r\n\r\nSerial passage of HIV-1 in increasing concentrations of lenacapavir resulted in the appearance of major resistance mutations Q67H and N74D, which remain sensitive to other antiretroviral drugs. Extended passage resulted in the additional mutations L56I, M66I, K70N, N74S, and T107N. All identified resistance mutations map to the lenacapavir binding site, and all but the Q67H variant show reduced replication capacity _in vitro_.[A244175] Additional studies have shown no lenacapavir resistance in variants associated with resistance to other antiretrovirals or naturally occurring polymorphisms, suggesting a very low potential for cross-resistance in combination therapy.[A244190]","drug-interactions":"DB00682 DB14649 DB00564 DB00188 DB00398 DB00656 DB12001 DB11581 DB09280 DB12015 DB10805 DB09570 DB00204 DB00540 DB08899 DB00637 DB12130 DB00648 DB15035 DB00794 DB11986 DB00977 DB12978 DB00451 DB10343 DB16648 DB00307 DB00495 DB00309 DB11963 DB01234 DB01223 DB12371 DB14443 DB12483 DB06772 DB08912 DB00444 DB00277 DB00312 DB00304 DB10317 DB06287 DB01229 DB00675 DB00503 DB09063 DB00570 DB14409 DB00220 DB01128 DB01590 DB08901 DB12147 DB00248 DB06626 DB00320 DB04855 DB00531 DB00625 DB11828 DB01396 DB11901 DB00530 DB01242 DB01254 DB13874 DB00563 DB08865 DB01174 DB08877 DB14685 DB10804 DB01420 DB12768 DB01227 DB05109 DB08896 DB09330 DB14568 DB00997 DB01118 DB11003 DB11703 DB12267 DB01320 DB08910 DB05294 DB00559 DB00834 DB00773 DB01323 DB11753 DB04845 DB09074 DB06442 DB01008 DB11730 DB00864 DB01418 DB06212 DB14631 DB00896 DB09289 DB14240 DB01181 DB00361 DB06603 DB16236 DB09143 DB01100 DB00575 DB06414 DB11641 DB00607 DB04868 DB06176 DB01248 DB08881 DB09054 DB06595 DB00877 DB00555 DB08827 DB00946 DB00908 DB05773 DB10318 DB00932 DB04572 DB06616 DB11050 DB00091 DB11363 DB00252 DB01045 DB00762 DB09073 DB06589 DB00696 DB00541 DB00872 DB01268 DB01201 DB08870 DB05239 DB00745","absorption":"Following subcutaneous administration, lenacapavir is slowly released but completely absorbed, with peak plasma concentrations occurring at 84 days post-dose. Absolute bioavailability following oral administration is low, approximately 6 to 10%. T<sub>max<\/sub> after oral administration is about four hours. The mean steady-state C<sub>max<\/sub> (%CV) is 97.2 (70.3) ng\/ mL following oral and subcutaneous administration.[L42990]\r\n\r\nAccording to population pharmacokinetics analysis, lenacapavir exposures (AUC<sub>tau<\/sub>, C<sub>max<\/sub> and C<sub>trough<\/sub>) were 29% to 84% higher in heavily treatment-experienced patients with an HIV-1 infection compared to subjects without an HIV-1 infection. A low-fat meal had negligible effects on drug absorption.[L42990]","created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The median half-life ranged from 10 to 12 days following following oral administration, and 8 to 12 weeks following subcutaneous administration.[L42990]","monoisotopic-mass":967.1435188,"volume-of-distribution":"The steady state volume of distribution was 976 L in heavily treatment-experienced patients with an HIV-1 infection.[L42990]","route-of-elimination":"Following a single intravenous dose of radiolabelled-lenacapavir in healthy subjects, 76% of the total radioactivity was recovered from feces and less than 1% from urine. Unchanged lenacapavir was the predominant moiety in plasma (69%) and feces (33%).[L42990]","name":"Lenacapavir","metabolism":"Metabolism played a lesser role in lenacapavir elimination. It undergoes CYP3A4- and UGT1A1-mediated oxidation, N-dealkylation, hydrogenation, amide hydrolysis, glucuronidation, hexose conjugation, pentose conjugation, and glutathione conjugation. The metabolites of lenacapavir have not been fully characterized. No single circulating metabolite accounted for >10% of plasma drug-related exposure.[L42990]","reactions":null,"indication":"Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults who are experiencing a failure of their current antiretroviral regimen due to resistance, intolerance, or safety considerations.[L42990,L44468]","ahfs-codes":null,"updated":"2022-12-31","drugbank-id":"DB15673"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":446.45,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).","enzymes":null,"type":"small molecule","cas-number":"1903763-82-5","sequences":null,"targets":null,"unii":"KE63TTO7WK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":446.172973996,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sisunatovir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15674"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":483.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Baloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).","enzymes":null,"type":"small molecule","cas-number":"1985605-59-1","sequences":null,"targets":null,"unii":"4G86Y4JT3F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":null,"created":"2020-04-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":483.106433604,"volume-of-distribution":null,"route-of-elimination":null,"name":"Baloxavir","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15675"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"2148321-77-9","sequences":null,"targets":null,"unii":"1Q2QT5M7EO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Balstilimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15676"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"133029-32-0","sequences":null,"targets":null,"unii":"DT9D8Z79ET","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Polyaminopropyl biguanide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15677"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":406.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1322-14-1","sequences":null,"targets":null,"unii":"77YW1RTU8V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-27","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":406.2396006,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium undecylenate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15678"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":162.0769,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"142-03-0","sequences":null,"targets":null,"unii":"FGL8577C9S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-04-28","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":162.010886775,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aluminum subacetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15679"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"T4GYX3110D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15680"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZT89E5A103","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15681"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"4WAN8PQK15","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15682"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"L77OK410KW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-01","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15683"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":227.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"84-58-2","sequences":null,"targets":null,"unii":"1H5KD39UH7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-06","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":225.9336826,"volume-of-distribution":null,"route-of-elimination":null,"name":"2,3-dichloro-5,6-dicyanobenzoquinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15684"},{"toxicity":"Toxicity information regarding selpercatinib is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as hepatotoxicity, hypertension, prolonged QT interval, and hemorrhaging. Symptomatic and supportive measures are recommended.[L13604]","snp-adverse-drug-reactions":null,"average-mass":525.613,"transporters":"BE0001032 BE0001067 BE0003657","pharmacodynamics":"Selpercatinib exerts anti-tumour activity in specific cancers through inhibition of mutated forms of RET tyrosine kinases.[A202046, A202055, L13604] Due to its increased specificity for RET over other tyrosine kinases, selpercatinib is thought to have an improved safety profile compared to other multi-kinase inhibitors.[A202049] Despite this, selpercatinib treatment is associated with hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, risk of impaired wound healing, and embryo-fetal toxicity; some patients may also exhibit hypersensitivity to selpercatinib.[L13604]","msds":null,"description":"Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604]\r\n\r\nAlthough selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO\u201E by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission.","enzymes":"BE0002638 BE0002887 BE0004866","type":"small molecule","cas-number":"2152628-33-4","sequences":null,"targets":"BE0000029 BE0002411 BE0000748 BE0002133 BE0002131 BE0000023","unii":"CEGM9YBNGD","protein-binding":"Selpercatinib displays 97% _in vitro_ protein binding independent of concentration and a blood-plasma concentration ratio of 0.7.[L13604]","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15685.pdf?1589299944","clearance":"Selpercatinib has an apparent clearance of 6L\/h; the clearance increases with increasing body weight.[L13604]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Other protein kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":null,"food-interactions":"Take with or without food. Patients on proton pump inhibitors should take selpercatinib with food.","state":"solid","synthesis-reference":"Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang. \"Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile.\" Patent WO2019075092A1, issued April 18, 2019.","mechanism-of-action":"Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development.[A202061, A202055] Constitutive RET activation is primarily achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain, such as _KIF5B-RET_ and _CCDC6-RET_, resulting in constitutive dimerization and subsequent autophosphorylation.[A202055, A202049, A202073] Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[A202046]\r\n\r\nSelpercatinib is a direct RET kinase inhibitor, exhibiting IC<sub>50<\/sub> values between 0.92 and 67.8 nM depending on the exact _RET_ genotype.[L13604] Information based on natural as well as induced resistance mutations and molecular modelling suggests that selpercatinib directly inhibits RET autophosphorylation by competing with ATP for binding. Various single amino acid mutations at position 810 inhibit selpercatinib binding without significantly altering ATP binding, potentially leading to treatment failures.[A202052]\r\n\r\nSelpercatinib is also reported to inhibit other tyrosine kinase receptors, including VEGFR1, VEGFR3, FGFR1, FGFR2, and FGFR3, at clinically relevant concentrations. The significance of these effects is not well studied.[L13604]","drug-interactions":"DB00328 DB08953 DB13760 DB12095 DB13400 DB14649 DB00656 DB00610 DB09198 DB13259 DB06737 DB03374 DB00178 DB00540 DB06712 DB09205 DB01142 DB09217 DB08841 DB12130 DB08805 DB13875 DB00814 DB09185 DB05829 DB12978 DB00338 DB09273 DB00451 DB12945 DB13249 DB09253 DB01247 DB00845 DB00177 DB01200 DB05232 DB00800 DB13286 DB13510 DB08941 DB00495 DB13432 DB06701 DB09307 DB13703 DB00605 DB00957 DB06715 DB01086 DB06772 DB00277 DB00368 DB00557 DB01556 DB08984 DB01229 DB08922 DB00321 DB06711 DB00503 DB00863 DB01102 DB06148 DB01129 DB12781 DB00220 DB09026 DB00292 DB00490 DB04908 DB08822 DB01124 DB13341 DB00700 DB00531 DB01075 DB00912 DB12825 DB00388 DB00769 DB08932 DB11901 DB00492 DB00741 DB08865 DB12551 DB11738 DB13411 DB01295 DB11823 DB00246 DB01577 DB04846 DB00777 DB09082 DB13398 DB00613 DB13604 DB00714 DB00787 DB00543 DB00301 DB02520 DB09206 DB01708 DB04017 DB00519 DB09363 DB06690 DB00389 DB06739 DB00959 DB11703 DB01320 DB00136 DB00281 DB09480 DB00834 DB00773 DB13943 DB04828 DB01323 DB13578 DB09421 DB09481 DB01579 DB01259 DB01624 DB06717 DB04818 DB00945 DB13452 DB00901 DB00820 DB00799 DB13954 DB01064 DB00017 DB15861 DB00708 DB12610 DB13496 DB13879 DB01240 DB09080 DB01622 DB00370 DB08925 DB01274 DB01216 DB09249 DB01364 DB00599 DB11979 DB00012 DB09084 DB11932 DB05521 DB11951 DB08950 DB04817 DB11502 DB05095 DB01035 DB00871 DB09101 DB00607 DB04868 DB08881 DB00788 DB00549 DB12661 DB00939 DB06595 DB06119 DB01182 DB06290 DB14960 DB07767 DB01184 DB13167 DB00402 DB00908 DB09251 DB06262 DB00091 DB05039 DB00691 DB14217 DB00723 DB00584 DB09227 DB06725 DB11633 DB00612 DB12545 DB00614 DB00598 DB13940 DB11689 DB08894 DB11613 DB00866 DB14540 DB00180 DB00949 DB06589 DB00872 DB13280 DB00841 DB01201 DB00749 DB13595 DB00925 DB01217 DB08955 DB00420 DB13323 DB14207 DB01397 DB13612 DB09046 DB14538 DB00214 DB16390 DB00983 DB14055 DB09238 DB01583 DB00257 DB12080 DB13781 DB00213 DB00668 DB11720 DB06738 DB09107 DB08952 DB12100 DB00951 DB12001 DB06448 DB09220 DB12015 DB02703 DB12629 DB00586 DB14213 DB00784 DB00715 DB00334 DB14019 DB00648 DB06694 DB00601 DB01347 DB08873 DB00899 DB00241 DB00977 DB00468 DB01158 DB01484 DB01626 DB12054 DB05395 DB01333 DB00270 DB00641 DB13955 DB00629 DB00307 DB02224 DB13209 DB09242 DB00753 DB06654 DB01234 DB08502 DB01137 DB09477 DB11978 DB12026 DB00582 DB13217 DB13624 DB01283 DB00695 DB00960 DB06605 DB00312 DB01359 DB00881 DB00363 DB00316 DB13429 DB01435 DB01390 DB09183 DB08810 DB00206 DB00418 DB06201 DB00297 DB08905 DB00606 DB00722 DB06237 DB06763 DB16629 DB09288 DB00936 DB13782 DB14543 DB00999 DB00633 DB11757 DB13251 DB00937 DB15226 DB11964 DB09218 DB13524 DB13874 DB00831 DB06736 DB13407 DB09068 DB06510 DB00082 DB00816 DB03585 DB12779 DB13384 DB13399 DB00705 DB00450 DB00617 DB00734 DB13649 DB01195 DB00469 DB05084 DB00783 DB00624 DB08985 DB14059 DB00532 DB12770 DB00397 DB00224 DB14544 DB00754 DB00394 DB00604 DB00861 DB00852 DB00988 DB13371 DB12532 DB01118 DB04840 DB12267 DB12930 DB00776 DB09243 DB00559 DB08960 DB13378 DB00471 DB16165 DB00176 DB01161 DB00550 DB00500 DB09296 DB09250 DB01095 DB01170 DB00401 DB01366 DB01357 DB01041 DB11730 DB00921 DB09345 DB00035 DB06706 DB11637 DB09200 DB09009 DB00875 DB00343 DB13312 DB09215 DB00622 DB13114 DB14068 DB11560 DB00196 DB08996 DB00396 DB11477 DB08840 DB09342 DB14094 DB00590 DB11652 DB01181 DB00719 DB00350 DB00212 DB00780 DB01130 DB08893 DB00812 DB13345 DB06414 DB12582 DB00585 DB00591 DB00818 DB01275 DB00952 DB01026 DB12212 DB00774 DB00615 DB00849 DB09118 DB00422 DB08909 DB01037 DB00661 DB13683 DB00289 DB13779 DB00502 DB00830 DB09295 DB13829 DB00932 DB00692 DB04948 DB01250 DB01365 DB00252 DB01045 DB01116 DB13322 DB09001 DB01244 DB11783 DB09245 DB07637 DB13692 DB00763 DB00353 DB14761 DB01054 DB13956 DB01011 DB00195 DB13801 DB13953 DB01167 DB13538 DB00619 DB01002 DB04847 DB13385 DB00603 DB00867 DB13001 DB06670 DB13246 DB14545 DB00745 DB11672 DB00564 DB09199 DB05667 DB00398 DB00572 DB13225 DB11581 DB08439 DB08864 DB01407 DB09065 DB06684 DB08899 DB09236 DB13486 DB13944 DB11362 DB01050 DB04896 DB01193 DB12884 DB04905 DB09201 DB00182 DB09241 DB08981 DB06445 DB01608 DB00412 DB01392 DB08931 DB00295 DB01232 DB01263 DB04581 DB06764 DB14185 DB09418 DB00589 DB00636 DB00755 DB00736 DB09235 DB01609 DB01211 DB00879 DB00310 DB13374 DB00675 DB01614 DB06403 DB00528 DB13657 DB01611 DB08815 DB01363 DB01377 DB01029 DB00373 DB08836 DB15569 DB13644 DB06016 DB00699 DB04946 DB00785 DB13650 DB00248 DB01591 DB01601 DB11541 DB13544 DB01180 DB06152 DB01072 DB06774 DB00625 DB00645 DB09048 DB01009 DB01576 DB01267 DB00751 DB00580 DB11943 DB01242 DB01483 DB00679 DB13917 DB00836 DB00436 DB00357 DB00485 DB01236 DB00797 DB06700 DB00477 DB08940 DB11543 DB06413 DB06210 DB09085 DB06190 DB08806 DB00335 DB06762 DB01023 DB09237 DB00573 DB00374 DB04829 DB00349 DB13520 DB00457 DB15561 DB11481 DB09167 DB00296 DB01151 DB12612 DB00796 DB14921 DB00250 DB11753 DB01138 DB00443 DB00935 DB00554 DB00264 DB08860 DB11455 DB15263 DB00461 DB00813 DB01255 DB06442 DB09128 DB12313 DB01220 DB11779 DB09254 DB00694 DB09239 DB00752 DB13626 DB00865 DB00886 DB01367 DB13328 DB09212 DB06285 DB13742 DB09016 DB06273 DB00721 DB00688 DB05351 DB01186 DB00750 DB01467 DB00808 DB00325 DB00892 DB01442 DB04743 DB09289 DB00381 DB00191 DB00344 DB12278 DB01049 DB00544 DB01586 DB00465 DB01018 DB01408 DB06636 DB11466 DB00805 DB08942 DB12846 DB13179 DB01110 DB08987 DB13757 DB09054 DB00211 DB00976 DB13211 DB04820 DB13598 DB14010 DB11124 DB14575 DB12766 DB00860 DB00972 DB04832 DB00561 DB06707 DB13803 DB00016 DB11148 DB13527 DB13232 DB00273 DB13166 DB13481 DB13946 DB06724 DB04911 DB08954 DB09203 DB09216 DB04831 DB00940 DB00966 DB00244 DB13435 DB15965 DB13777 DB00567 DB00197 DB07402 DB13139 DB00696 DB00333 DB10534 DB00616 DB01203 DB11373 DB00458 DB01119 DB01399 DB00953 DB01221 DB00880 DB03322 DB11586 DB12265 DB01149 DB11556 DB01076 DB01004 DB00537 DB00331 DB11791 DB01132 DB09280 DB01224 DB13919 DB00066 DB06678 DB11428 DB00536 DB00802 DB01001 DB11587 DB01340 DB00765 DB00199 DB13629 DB01198 DB01288 DB00794 DB06697 DB00907 DB01509 DB11986 DB00527 DB11518 DB01370 DB01324 DB01222 DB09119 DB14539 DB01351 DB01403 DB03604 DB00857 DB00187 DB13783 DB13762 DB09214 DB00226 DB11785 DB01264 DB12371 DB00571 DB11642 DB08912 DB00608 DB08882 DB14208 DB09104 DB11755 DB01352 DB00482 DB12093 DB13453 DB00239 DB00347 DB00570 DB13852 DB13559 DB13443 DB15762 DB09248 DB08901 DB01406 DB01028 DB09036 DB13108 DB00542 DB00359 DB14517 DB00393 DB08808 DB04861 DB01419 DB13860 DB00320 DB01030 DB04855 DB13575 DB00657 DB11278 DB12248 DB01454 DB01260 DB04836 DB05229 DB01014 DB06723 DB00530 DB00876 DB12377 DB01174 DB09202 DB08911 DB11737 DB08976 DB04812 DB00678 DB06268 DB14231 DB00216 DB04920 DB14568 DB00159 DB00315 DB06216 DB01285 DB11770 DB01089 DB12465 DB12092 DB01189 DB12361 DB11767 DB13952 DB12927 DB08938 DB00024 DB00439 DB01032 DB09213 DB14125 DB01218 DB09256 DB08957 DB08496 DB09231 DB00938 DB00279 DB09285 DB13532 DB06153 DB00991 DB00961 DB01087 DB01126 DB00807 DB14754 DB01401 DB00795 DB13508 DB13804 DB09246 DB05271 DB00927 DB13722 DB00275 DB01600 DB00501 DB01069 DB02032 DB09252 DB01261 DB00342 DB00726 DB08883 DB00400 DB06731 DB09061 DB00227 DB00448 DB12445 DB00998 DB04574 DB01190 DB01136 DB00712 DB01348 DB00673 DB03255 DB00575 DB13314 DB01021 DB13410 DB01424 DB06770 DB00243 DB13631 DB01645 DB00968 DB04725 DB01159 DB00669 DB12016 DB00790 DB09244 DB01171 DB00727 DB01238 DB01253 DB01162 DB01628 DB00946 DB01090 DB14060 DB08918 DB13064 DB11871 DB00217 DB01183 DB01197 DB05562 DB13746 DB11837 DB00221 DB09281 DB00821 DB00247 DB01291 DB00856 DB00918 DB00255 DB15822 DB08951 DB00472 DB00898 DB08797 DB08991 DB09100 DB01115 DB00524 DB01472 DB00533 DB00701 DB01580 DB15982 DB04552 DB01388 DB11273 DB01297","absorption":"In patients with locally advanced or metastatic solid tumours receiving 160 mg of selpercatinib twice daily, steady-state was achieved after approximately 7 days, with a C<sub>max<\/sub> of 2,980 (CV 53%) and AUC<sub>0-24h<\/sub> of 51,600 (CV 58%). The absolute bioavailability is between 60 and 82% (mean 73%), and the median t<sub>max<\/sub> is two hours. Food has no apparent effect on the AUC or C<sub>max<\/sub> of selpercatinib. Patients with hepatic impairment display a concomitant increase in AUC<sub>0-INF<\/sub> for mild (7%), moderate (32%), and severe (77%) impairment.[L13604]","created":"2020-05-12","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Selpercatinib has a half-life of 32 hours in healthy individuals.[L13604]","monoisotopic-mass":525.248837886,"volume-of-distribution":"Selpercatinib has an apparent volume of distribution of 191 L; the volume of distribution increases with increasing body weight.[L13604]","route-of-elimination":"Selpercatinib administered as a single 160 mg dose in healthy individuals was primarily recovered in feces (69%, 14% unchanged) and urine (24%, 12% unchanged).[L13604]","name":"Selpercatinib","metabolism":"Selpercatinib is predominantly metabolized in the liver by CYP3A4.[L13604]","reactions":null,"indication":"Selpercatinib is approved to treat: \r\n\r\n- adult with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion.[L43267] In Europe, patients should require systemic therapy following prior treatment with immunotherapy and\/or platinum-based chemotherapy.[L41895] \r\n- adults and children 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy [L43267] In Europe, patients should have been previously treated with [sorafenib] and\/or [lenvatinib].[L41895]\r\n- adults and children 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with [cabozantinib] and\/or [vandetanib] [L41895]\r\n- adults and children 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) [L43267]\r\n- adults with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options [L43267]\r\n\r\nSelpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.[L13604]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15685"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":291.267,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.[L13775] _In vitro_ studies of GS-441524 have determined it has a higher EC<sub>50<\/sub> than remdesivir against a number of viruses, meaning GS-441524 is less potent.[A203057,A203057] GS-441524 continues to be studied in the treatment of Feline Infectious Peritonitis Virus, a coronavirus that only infects cats.[A198840]","enzymes":null,"type":"small molecule","cas-number":"1191237-69-0","sequences":null,"targets":"BE0009862 BE0003801","unii":"1BQK176DT6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"GS-441524 is phosphorylated 3 times to form the active nucleoside triphosphate, which is incorporated into the genome of virions, terminating its replication.[A203057]","drug-interactions":"DB10805 DB12768 DB11003 DB14443 DB10343 DB11050 DB10318 DB14409 DB16648 DB14685 DB10804 DB10317","absorption":"GS-441524 has been found to transport poorly into cells compared to remdesivir.[A203057,A203072,A191427]","created":"2020-05-19","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":291.096753919,"volume-of-distribution":null,"route-of-elimination":null,"name":"GS-441524","metabolism":"GS-441524 is phosphorylated 3 times to form the active nucleoside triphosphate.[A203057]","reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-12","drugbank-id":"DB15686"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1623.85,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Tridecactide, also known as alpha-corticotropin 1-13, is a deacetylated and deaminated alpha-melanocyte stimulating hormone, which may have antipyretic, anti-inflammatory, and antimicrobial effects.[A203210] Tridecactide, along with [metenkefalin], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]","enzymes":null,"type":"small molecule","cas-number":"22006-64-0","sequences":null,"targets":null,"unii":"T7PQK27HTI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-19","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1622.766382447,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tridecactide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15687"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":638.817,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Zavegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. If FDA approved, it will join other previously-approved \"-gepant\" drugs [rimegepant] and [ubrogepant] as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective.\r\n\r\nOn April 15th, 2020, a phase 2 clinical trial (NCT04346615: Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen)[L13868] began to investigate the use of intranasally administered zavegepant to combat the acute respiratory distress syndrome (ARDS) sometimes seen in patients with COVID-19. Acute lung injury activates the release of CGRP, which plays a role in the development of ARDS - CGRP antagonists, then, may help to blunt the significant inflammation associated with COVID-19.[L13886] The clinical trial is expected to complete in September 2020.[L13868]","enzymes":null,"type":"small molecule","cas-number":"1337918-83-8","sequences":null,"targets":"BE0009009","unii":"ODU3ZAZ94J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":638.369287373,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zavegepant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-05-06","drugbank-id":"DB15688"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Azoximer bromide is under investigation in clinical trial NCT04381377 (Efficacy and Safety of Polyoxidonium in Hospitalized Patients With Coronavirus Disease COVID-19).","enzymes":null,"type":"small molecule","cas-number":"892497-01-7","sequences":null,"targets":null,"unii":"90G53638ZD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-05-25","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Azoximer bromide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15689"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":289.381,"transporters":null,"pharmacodynamics":"Fluoroestradiol F-18 is an analog of estradiol that emits small amounts of radioactivity, allowing it to be detected using PET. Following intravenous administration, it accumulates in cancerous tissues expressing estrogen receptors, thus allowing for visualization of these lesions.[L14096] Fluoroestradiol has a relatively short duration of action - at 2 hours post-injection circulating levels are <5% those at peak concentration.\r\n\r\nThe uptake of fluoroestradiol F-18 is not specific to breast cancer cells and make occur in any tumor cell expressing estrogen receptors, including those arising from the uterus or ovaries.[L14096]","msds":null,"description":"Fluoroestradiol F-18 is an imaging agent used with positron emission tomography (PET) to detect estrogen receptor-positive breast cancer lesions.[L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression\/regression, it may also be used to assess for heterogeneity in ER expression across metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies.[A203912]\r\n\r\nFluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.[L14117] It is expected to be available in late 2020\/early 2021.[L14117]","enzymes":null,"type":"small molecule","cas-number":"94153-53-4","sequences":null,"targets":"BE0000792 BE0000123","unii":"T32277KB09","protein-binding":"Following intravenous administration, approximately 95% of fluoroestradiol F-18 is protein-bound[L14096] to both albumin and sex hormone-binding globulin.[A203912]","fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15690.pdf?1590760036","clearance":"Fluoroestradiol F-18 is rapidly cleared from the blood by the liver.[A203912]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ: Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984 Nov;25(11):1212-21.","mechanism-of-action":"Estrogen receptor (ER)-positive breast cancers are a subset of breast cancers in which the cancerous tissue expresses estrogen receptors - these receptors provide a useful target for imaging and treatment agents. Fluoroestradiol F-18 is a fluorinated analog of estradiol that binds to estrogen receptors, allowing for PET imaging of lesions.[L14096]\r\n\r\nFollowing exposure in an ER-positive breast cancer cell line (MCF-7), it was found that fluoroestradiol F-18 bound with a Kd of 0.13  0.02 nM, a B<sub>max<\/sub> of 1901  89 fmol\/mg, and a IC50 = 0.085 nM.[L14096]","drug-interactions":"DB00947 DB00675 DB04938 DB04468 DB00882 DB06202 DB00539 DB13472 DB00481 DB06401 DB13310 DB06735","absorption":null,"created":"2020-05-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":"BE0000530 BE0000685","half-life":null,"monoisotopic-mass":289.170742648,"volume-of-distribution":"As fluoroestradiol and its metabolites undergo enterohepatic circulation,[A203912] it is found primarily distributed within the hepatobiliary system.[L14096] It also distributes to the intestines, heart wall, blood, kidney, uterus, and bladder.[L14096]","route-of-elimination":"Elimination is primarily via urinary and biliary excretion.[L14096] Unbound metabolites comprising mainly glucuronide and sulfate conjugates are secreted in the bile, reabsorbed via enterohepatic circulation, and then renally excreted.[A203912]","name":"Fluoroestradiol F-18","metabolism":"Fluoroestradiol F-18 is highly extracted and metabolized by the liver - at 2 hours post-administration, only 10% of the total activity is attributable to unmetabolized parent drug.[A203912] The majority of generated metabolites are products of glucuronide or sulfate conjugation.[A204023]","reactions":null,"indication":"Fluoroestradiol F-18 is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.[L14096]","ahfs-codes":null,"updated":"2020-10-06","drugbank-id":"DB15690"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19.  This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune  mice in addition to blood samples from patients who have recovered from COVID-19.  These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.[L14303] Two upcoming publications in the journal, _Science_, will provide additional information about preclinical research with the Anti-SARS-COV-2 REGN-COV2 antibody cocktail.[L14306]\r\n\r\nClinical trials for this drug started on June 11, 2020. Regeneron's clinical trial will study the effects of this drug on hospitalized COVID-19 patients, symptomatic COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection, including contacts of an infected individual.[L14303]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":"BE0010022","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-06-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anti-SARS-CoV-2 REGN-COV2","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-12","drugbank-id":"DB15691"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2.[L14333] This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for single patients through an emergency IND (eIND; 21 CFR 312.310).[L14333]\r\n\r\nAlthough there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest that convalescent plasma transfusion in COVID-19 patients is safe.[A214316]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"YM6LN8TU2V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-06-16","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"COVID-19 convalescent plasma","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-17","drugbank-id":"DB15692"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.[A214475] Early _in vitro_ studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.[A214475, A214478] Follow up studies in both BALB\/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.[A214475]\r\n\r\nA Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.[L14372] A Phase 1\/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.[L14375]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-06-23","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"INO-4800","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-06-24","drugbank-id":"DB15693"},{"toxicity":"Cedazuridine administered orally to mice in 7 days on\/21 days off cycles for a total of 91 days in doses of 100, 300, or 1000 mg\/kg produced abnormal effects only at the 1000 mg\/kg dose, which is roughly 108 times the recommended dose in humans. These effects included abnormal histology of the testes, epididymis, and ovaries, as well as decreased sperm count; these effects were reversible following cedazuridine removal.","snp-adverse-drug-reactions":null,"average-mass":268.217,"transporters":null,"pharmacodynamics":"Cedazuridine is a cytidine deaminase inhibitor that is co-administered with hypomethylating agents such as [decitabine] in order to increase their oral bioavailability.[A215107, A215112, A215117, A215127] In combination with hypomethylating agents, cedazuridine may cause myelosuppression and embryo-fetal toxicity and should be administered with appropriate monitoring.[L14897]","msds":null,"description":"Myelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated.[A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.[A215127, L14897] Although effective, these compounds are rapidly metabolized by cytidine deaminase (CDA) prior to reaching systemic circulation when administered orally, necessitating intramuscular or intravenous administration routes.[A215107, A215112, A215117, A215127] Cedazuridine is a fluorinated tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of hypomethylating agents.[A215107, A215112, A215117, A215127, L14897]\r\n\r\nCedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by Astex Pharmaceuticals Inc under the name INQOVI.[L14897]","enzymes":null,"type":"small molecule","cas-number":"1141397-80-9","sequences":null,"targets":"BE0002443","unii":"39IS23Q1EW","protein-binding":"Neither [decitabine] nor cedazuridine display extensive plasma protein binding. The bound fraction of [decitabine] between doses of 17 and 342 ng\/mL was between 4 and 6%, while that of cedazuridine for doses between 1000 ng\/mL and 50000 ng\/mL was between 34 and 38%.[L14897]","fda-label":null,"clearance":"Cedazuridine has an apparent steady-state clearance of 30.3 L\/hours, with a coefficient of variation of 46%.[L14897]","atc-codes":null,"pdb-entries":null,"food-interactions":"Take on an empty stomach. Avoid consuming food for both two hours before and after each dose.","state":"solid","synthesis-reference":"Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, Redkar S, Slusher BB, Tsukamoto T: Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27;57(6):2582-8. doi: 10.1021\/jm401856k. Epub 2014 Feb 24.","mechanism-of-action":"Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematopoietic neoplasms arising from a variety of underlying mutations that manifest in peripheral cytopenias and may eventually progress to secondary acute myeloid leukemia (sAML). There are over 45 genes commonly mutated in MDS patients, including those involved in DNA methylation and repair, histone modification, RNA splicing, transcription, signal transduction, and cellular adhesion. It is hypothesized that initial clonal founder mutations give rise to progressive acquisition of secondary mutations and facilitate disease progression to sAML.[A215082, A215092, A215097]\r\n\r\nHypomethylating agents such as [decitabine] are metabolized into triphosphate derivatives that are subsequently incorporated into DNA. Once incorporated, these agents inhibit the activity of DNA methylases such as DNMT1, leading to progressive DNA hypomethylation and eventual activation of tumour suppression genes and apoptotic pathways.[A215127, L14897] However, hypomethylating agents given orally are vulnerable to first-pass metabolism by cytidine deaminase, and hence typically have to be administered through intramuscular or intravenous routes.[A215107, A215112, A215117, A215127] Co-administration with cedazuridine, which is an efficient inhibitor of cytidine deaminase,[A215107, L14897] drastically increases the oral bioavailability of [decitabine], allowing for combination oral therapy.[A215107, A215112, A215117, A215127, L14897]","drug-interactions":"DB00441 DB01101 DB00987 DB00928","absorption":"Cedazuridine (100 mg) taken orally with [decitabine] (35 mg) once daily for five days resulted in a day 1 AUC and steady-state AUC (coefficient of variation) of 103 (55%) and 178 (53%) ng\\*hr\/mL for [decitabine] and 2950 (49%) and 3291 (45%) ng\\*hr\/mL for cedazuridine, respectively. Overall, the 5-day cumulative AUC for [decitabine] was 851 (50%). Similarly, the C<sub>max<\/sub> for [decitabine] and cedazuridine was 145 (55%) and 371 (52%) ng\/mL, respectively. The median T<sub>max<\/sub> for [decitabine] was 1 hr (range 0.3 to 3.0 hrs) and for cedazuridine was 3 hrs (range 1.5 to 6.1 hrs).[L14897]\r\n\r\nThe bioavailability of [decitabine], as assessed by comparing the AUC of oral [decitabine] co-administered with cedazuridine to intravenous [decitabine] alone, was 60% on day 1 (90% CI of 55-65%). The corresponding values on day 5 and considering the cumulative day 5 dose were 106% (90% CI: 98, 114) and 99% (90% CI: 93, 106). Hence, the oral bioavailability of [decitabine] approaches 100% over the 5-day treatment cycle.[L14897]","created":"2020-07-09","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Cedazuridine has a steady-state half-life of 6.7 hours, with a coefficient of variation of 19%.[L14897]","monoisotopic-mass":268.087077885,"volume-of-distribution":"The apparent volume of distribution (and coefficient of variation) of [decitabine] and cedazuridine at steady state was 417 (54%) and 296 (51%), respectively.[L14897]","route-of-elimination":"Roughly 46% of cedazuridine is found in urine, 21% of which is unchanged, and 51% is found in feces, 27% of which is unchanged.[L14897]","name":"Cedazuridine","metabolism":"The metabolism of cedazuridine is not well-established. Cedazuridine is known to be converted to an epimer that is roughly 10-fold less effective in inhibiting cytidine deaminase and is subsequently degraded through unknown pathways.[A215107, L14897]","reactions":null,"indication":"Cedazuridine, in combination with decitabine, is indicated for the treatment of myelodysplastic syndromes (MDS), including MDS with refractory anemia, MDS with refractory anemia and ringed sideroblasts, MDS with refractory anemia and excess blasts, MDS scoring intermediate-1, intermediate-2, or high-risk on the International Prognostic Scoring System (IPSS), and chronic myelomonocytic leukemia (CMML).[L14897]","ahfs-codes":null,"updated":"2021-08-19","drugbank-id":"DB15694"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BNT162b1 is one of four advanced mRNA-based vaccines being developed through \"Project Lightspeed,\" a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a \"foldon\" trimerization domain derived from T4 fibritin to increase immunogenicity.[L15012] The modRNA is formulated in lipid nanoparticles for delivery via intramuscular injection.[L15007, L15012] Early results from a phase 1\/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in [COVID-19 convalescent plasma] 28 days after initial immunization of either 10 or 30g of BNT162b1, with further improvements following a second dose.[L15012]\r\n\r\nBNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"JV8KBX6XZG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-13","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BNT162b1 SARS-CoV-2 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-07-16","drugbank-id":"DB15695"},{"toxicity":"Overdose data regarding Comirnaty are not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as injection site reactions, headache, arthralgia, myalgia, fatigue, chills, and pyrexia.[L26671, L26676] Symptomatic and supportive measures are recommended.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the SARS-CoV-2 spike (S) protein, translated and expressed in cells in vaccinated individuals to produce the S protein antigen against which an immune response is mounted. As with all vaccines, protection cannot be guaranteed in all recipients, and full protection may not occur until at least seven days following the second dose.[L26671, L26676] \r\n\r\nIn U.S. clinical trials, the vaccine was 95% effective in preventing COVID-19; eight COVID-19 cases occurred in the vaccine group and 162 cases occurred in the placebo group. Of the total 170 COVID-19 cases, one case in the vaccine group and three cases in the placebo group were considered to be severe infections.[A225386,L26956] The clinical study C4591001 assessed the clinical efficacy of Comirnaty as a booster shot: in this study, adult subjects who were given a booster shot approximately six months after the second dose displayed antibody levels that were 3-fold higher after the booster dose relative to levels after the second dose.[L39115]","msds":null,"description":"The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through \"Project Lightspeed,\" a joint program between Pfizer and BioNTech.[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein. It is designed to induce immunity against SARS-CoV-2, the virus responsible for causing COVID-19.[L15002] The modRNA is formulated in lipid nanoparticles for administration via intramuscular injection in two doses, three weeks apart.[A225386,L15007]\r\n\r\nComirnaty is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020.[L15027]  On December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) based on 95% efficacy in clinical trials and a similar safety profile to other viral vaccines over a span of approximately 2 months.[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2.[L26996] Full FDA approval was granted on August 23, 2021.[L36025]\r\n\r\nCurrently, sufficient data are not available to determine the longevity of protection against COVID-19, nor direct evidence that the vaccine prevents the transmission of the SARS-CoV-2 virus from one individual to another.[L26956]  Fact sheets for caregivers, recipients, and healthcare providers are now available.[L26966,L26976] In November 2021, Health Canada [L39115] and the EMA [L39272] approved the vaccine to be administered as a booster dose approximately six months after the second dose. Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350]","enzymes":null,"type":"biotech","cas-number":"2417899-77-3","sequences":null,"targets":null,"unii":"5085ZFP6SJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Comirnaty contains nucleoside modified mRNA (modRNA) encapsulated in lipid nanoparticles that deliver the modRNA into host cells. The lipid nanoparticle formulation facilitates the delivery of the RNA into human cells.[L26996] Once inside these cells, the modRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein antigen, which is subsequently recognized by the host immune system. Comirnaty has been shown to elicit both neutralizing antibody and cellular immune responses to the S protein, which helps protect against subsequent SARS-CoV-2 infection.[L26671, L26676]","drug-interactions":null,"absorption":null,"created":"2020-07-13","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tozinameran","metabolism":null,"reactions":null,"indication":"Comirnaty is fully approved by the FDA and Health Canada for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged five years and older.[L36030,L39020,L39221] A third booster shot is also approved by Health Canada for individuals five years and older and by the FDA for individuals 16 or older, to be given more than 6 months after their second immunization.[L39115,L39272,L39449] The interchangeability of Comirnaty with COVID-19 vaccines from other manufacturers to complete the primary vaccination course or the booster dose (third dose) has not been established.[L39272] Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350] In the US, under the emergency use authorization, Comirnaty is used for the prevention of COVID-19 in children 6 months of age and older.[L42770]\r\n\r\nComirnaty is also available as an Omicron BA.4\/BA.5 bivalent-adapted booster.[L44421]\r\n\r\nThis vaccine should only be administered where appropriate medical treatment for immediate allergic reactions are immediately available in the case of an acute anaphylactic reaction after vaccine administration.[L26996,L26671,L26676,L36030] Comirnaty administration should be postponed in any individual suffering from an acute febrile illness. Immunocompromised individuals maybe have a weaker immune response to Comirnaty.[L36030]","ahfs-codes":null,"updated":"2022-12-23","drugbank-id":"DB15696"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BNT162a1 is one of four advanced mRNA-based vaccines being developed through \"Project Lightspeed,\" a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007]\r\n\r\nBNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-13","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BNT162a1 SARS-CoV-2 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-07-16","drugbank-id":"DB15697"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BNT162c2 is one of four advanced mRNA-based vaccines being developed through \"Project Lightspeed,\" a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007]\r\n\r\nBNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-13","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BNT162c2 SARS-CoV-2 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-07-16","drugbank-id":"DB15698"},{"toxicity":"Toxicity information regarding brexucabtagene autoleucel is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects such as severe infections, severe and prolonged cytopenia, hypogammaglobulinemia, cytokine release syndrome, and neurological toxicities.[A216188, L15148] Symptomatic and supportive measures are recommended.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Brexucabtagene autoleucel is an autologous T cell immunotherapy employing a CD19-directed chimeric antigen receptor (CAR) to direct modified T cells to bind to and subsequently destroy cancerous B cells.[L15148] Like other CAR T cell therapies, brexucabtagene autoleucel has a durable response; in the single-arm ZUMA-2 trial, the median time to peak CAR T cell levels was 15 days, and 60% of assayed patients had detectable levels of CAR T cells at 24 months following the single infusion.[A216148]\r\n\r\nAs brexucabtagene autoleucel recognizes both normal and cancerous B cells, adverse effects related to B cell depletion are expected, including severe and prolonged cytopenia, severe infections, neurological effects, hypogammaglobulinemia, and the potential to develop secondary malignancies. Patients should be advised not to drive or operate heavy machinery for eight weeks following infusion. Hypersensitivity reactions may occur during infusion.[L15148]","msds":null,"description":"Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy have few treatment options.[A216153, A216158]\r\n\r\nMore recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells. These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen.[A216188] Similar to [axicabtagene ciloleucel], brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3-derived co-stimulatory domains.[A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR T cell preparation.[L15148]\r\n\r\nBrexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under the tradename TECARTUS.[L15148]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":"BE0003496","unii":"4MD2J2T8SJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":"Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, and Jonathan Belk. \"Chimeric antigen receptors and CAR-T cells and methods of use.\" U.S. Patent US2019065776, issued June 18, 2020.","mechanism-of-action":"Mantle cell lymphoma (MCL) is a heterogeneous sub-category of B cell non-Hodgkin's lymphoma typified by overexpression of cyclin D1 and SOX-11 as well as mutations in numerous genes including _TP53_; overall, these changes lead to increased cell growth, apoptosis inhibition, and cell-adhesion-mediated drug resistance.[A216153, A216158] Based on the 2016 World Health Organization guidelines, MCL can be generally subdivided into aggressive nodal and indolent leukemic non-nodal subtypes.[A216153, A216158] Bruton's tyrosine kinase (BTK) inhibitors can be used following a relapse of front-line therapy, but patients who relapse after BTK inhibitor therapy have a poor prognosis.[A216148]\r\n\r\nChimeric antigen receptors (CARs) are synthetic immunoreceptors that can be introduced into T cells _ex vivo_ using viral transduction and that allow for major histocompatibility complex (MHC)-independent direction of T cells to any cell possessing the complementary antigen.[A216163] Brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3-derived co-stimulatory domains.[L15148] Brexucabtagene autoleucel is prepared from the patient's own peripheral blood mononuclear cells using a leukapheresis methodology that excludes CD19-expressing tumour cells to avoid potential activation and exhaustion of CAR T cells during manufacturing.[A216148] Collected cells are activated with anti-CD3 and anti-CD28 antibodies along with IL-2, transduced with a replication-incompetent retroviral vector, and subsequently expanded prior to infusion.[L15148]\r\n\r\nOnce infused into the patient, the CAR T cells bind to CD19 antigens on the surface of both normal and cancerous B cells, leading to CAR T cell activation and expansion. Activated CAR T cells secrete cytokines and chemokines including, but not limited to, IL-6, IL-8, IL-10, IL-15, TNF-, IFN-, and soluble IL-2 (sIL2R), leading to tumour cell lysis and anti-tumour activity.[A216168, L15148]","drug-interactions":"DB06770 DB12532 DB00281 DB09107 DB08987 DB00296 DB13259 DB00297 DB13578 DB13683 DB00016 DB01161 DB00961 DB00807 DB11148 DB00907 DB01075 DB00814 DB06774 DB00527 DB00645 DB09345 DB13328 DB09009 DB00721 DB05232 DB08894 DB00750 DB00892 DB00012 DB01002 DB09342 DB09085 DB01086 DB11502 DB03255","absorption":"Patients in the ZUMA-2 clinical trial received a target dose of 2 x 10<sup>6<\/sup> CAR T cells\/kg, which expanded to a variable degree among responders and non-responders; peak levels were reached within the first seven to 15 days following infusion.[A216148, L15148] Median peak CAR T cell levels were 102.4 cells\/L (range 0.2 to 2589.5) in responders and 12.0 cells\/L (range 0.2 to 1354.0) in non-responders. The corresponding median AUC<sub>0-28<\/sub> for responders and non-responders was 1487.0 cells\/L\\*day (range 3.8 to 2.77E+04) and 169.5 cells\/L\\*day (range 1.8 to 1.17E+04), respectively.[L15148]\r\n\r\nThese values were also assessed based on the co-administration of immunosuppressive therapy. Patients receiving neither corticosteroids nor tocilizumab had a peak of 24.7 cells\/L with an AUC<sub>0-28<\/sub> of 360.4 cells\/L\\*day, patients receiving only corticosteroids had a peak of 24.2 cells\/L and an AUC<sub>0-28<\/sub> of 367.8 cells\/L\\*day, and patients receiving only tocilizumab had a peak of 86.5 cells\/L and an AUC<sub>0-28<\/sub> of 1188.9 cells\/L\\*day. The highest counts were in patients receiving both corticosteroids and tocilizumab, with a peak of 167.2 cells\/L and an AUC<sub>0-28<\/sub> of 1996.0 cells\/L\\*day.[L15148]\r\n\r\nFinally, separating patients into those < 65 years of age of \u2030 65 years of age, patients in the lower age group had a median peak of 112.5 cells\/L and a median AUC<sub>0-28<\/sub> of 1640.2 cells\/L\\*day. Older patients had a median peak count of 74.1 cells\/L and a median AUC<sub>0-28<\/sub> of 876.5 cells\/L\\*day.[L15148]","created":"2020-07-27","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Brexucabtagene autoleucel","metabolism":null,"reactions":null,"indication":"Brexucabtagene autoleucel is a modified autologous chimeric antigen receptor (CAR) T cell immunotherapy indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adult patients.[L15148] It is additionally indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[L15148]\r\n\r\nBrexucabtagene autoleucel has been granted accelerated approval based on results from a single-arm, open-label, multicentre clinical trial; continued approval may be contingent on confirmatory trials.[L15148]","ahfs-codes":null,"updated":"2022-06-03","drugbank-id":"DB15699"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"03BDM2QO92","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hawaii\/70\/2019 (H1N1) recombinant hemagglutinin antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15700"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"8Y5GN9YN6E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Minnesota\/41\/2019 (H3N2) recombinant hemagglutinin antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15701"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"L7ZT1J7AEZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Washington\/02\/2019 recombinant hemagglutinin antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-07-22","drugbank-id":"DB15702"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"NY1FF92M1E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Guangdong-Maonan\/SWL1536\/2019 CNIC-1909 (H1N1) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15703"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"P8ORN3UOM6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hong Kong\/2671\/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-15","drugbank-id":"DB15704"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"2J002Y0B0W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Victoria\/2454\/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15705"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"INT614PB1A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Victoria\/705\/2018 BVR-11 antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15706"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"EZQ32TF2AS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Nebraska\/14\/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15707"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"5MIR93VLG8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Delaware\/39\/2019 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15708"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZBC2SPA9BZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Darwin\/7\/2019 antigen (MDCK cell derived, propiolactone inactivated)","metabolism":null,"reactions":null,"indication":"In combination with other influenza virus subtypes A and types B strains, this Influenza B viral strain is used for active immunization of adults and children aged 6 months or older for the prevention of influenza disease caused by influenza virus subtypes A and types B.[L41345]","ahfs-codes":null,"updated":"2022-04-01","drugbank-id":"DB15709"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ID0WP86XC3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hong Kong\/2671\/2019 NIB-121 (H3N2) antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15710"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"YTL6A60F5I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Victoria\/2454\/2019 IVR-207 (H1N1) antigen (propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15711"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"OAT4H11ZT6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hong Kong\/2671\/2019 IVR-208 (H3N2) antigen (propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15712"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"KKA9J8NJL5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Victoria\/705\/2018 BVR-11 antigen (propiolactone inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15713"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"K8A11W1ZVV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Guangdong-Maonan\/SWL1536\/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15714"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"08R56E092Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hong Kong\/2671\/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15715"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"0LS66T074T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-07-30","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Washington\/02\/2019 antigen (UV, formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-01","drugbank-id":"DB15716"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]","enzymes":null,"type":"biotech","cas-number":"906068-56-2","sequences":null,"targets":null,"unii":"POO0DOD3AS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-02","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Theralizumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-03","drugbank-id":"DB15717"},{"toxicity":"Bamlanivimab has been administered at doses of 7000 mg (ten times the authorized dose) during phase 2 clinical trials without any observed dose-limiting toxicity. In the event of an overdose, the recommended treatment is symptomatic and supportive measures; there is no antidote for bamlanivimab overdose.[L20979]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Bamlanivimab is a recombinant human IgG1 monoclonal antibody directed against the spike (S) surface protein of SARS-CoV-2. Patients in a phase 2 trial were administered up to 7000 mg (ten times the authorized dose) with no increase in treatment-related adverse effects and a flat exposure-response relationship over ranges of 700-7000 mg. Despite generally mild adverse effects noted in the phase 2 trial, there is a risk of serious infusion-related hypersensitivity reactions with bamlanivimab, including anaphylaxis, which may necessitate slowing the infusion rate or discontinuing treatment entirely.[L20979]","msds":null,"description":"Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1 mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.[A224039, L15311, L15316, L20979] \r\n\r\nAbCellera initially discovered bamlanivimab in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and subsequently further developed it in collaboration with Eli Lilly and Company. Bamlanivimab consists of two identical light chains of 214 amino acids and two identical heavy chains of 455 amino acids each; the Fc region is unmodified.[L20979] Bamlanivimab is produced in Chinese Hamster Ovary (CHO) cells.[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.[A224044, L20974] It is set to enter phase 3 clinical trials.[L15316, L15321] \r\n\r\nUnder the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.[L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]","enzymes":null,"type":"biotech","cas-number":"2423943-37-5","sequences":null,"targets":"BE0010022","unii":"45I6OFJ8QH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Bamlanivimab is a neutralizing recombinant human IgG1 monoclonal antibody directed against the spike (S) surface protein of SARS-CoV-2 derived from screening antigen-specific B-cells from a convalescent COVID-19 patient.[A224039, L20979] X-ray crystallography and cryo-EM structural determination suggest that bamlanivimab binds the receptor-binding domain (RBD) of the S protein at a position overlapping the ACE2 binding site and which is accessible in both the up and down conformations of the RBD.[A224039] Specifically, bamlanivimab binds to the S protein with a K<sub>D<\/sub> of 0.071 nM and blocks S protein-ACE2 interactions with an IC<sub>50<\/sub> value of 0.025 g\/mL.[L20979]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB14685 DB12520 DB10804 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB11003 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB10317 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB11050 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB10343 DB00078 DB16648 DB05136 DB04956 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB10318 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB10805 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB14409 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB12768 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-08-06","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bamlanivimab","metabolism":"As a monoclonal antibody, it is expected that bamlanivimab will be degraded by proteases in various locations throughout the body. Bamlanivimab is not metabolized by cytochrome P450 enzymes, making drug interactions unlikely.[L20979]","reactions":null,"indication":"Bamlanivimab is not currently approved for any indication by the FDA.[L20974]\r\n\r\nBamlanivimab is authorized under an Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19 in patients aged 12 years and older weighing at least 40 kg who are at high risk for progressing to severe COVID-19 and\/or hospitalization due to COVID-19. Patients should have confirmed COVID-19, with identification of SARS-CoV-2 viral load by an approved test.[L20974, L20979]\r\n\r\nUnder this EUA, bamlanivimab is not authorized in patients who are hospitalized due to COVID-19, who require oxygen due to COVID-19, or in patients on oxygen therapy for non-COVID-19-related comorbidity who require an increased oxygen flow rate due to COVID-19.[L20974, L20979]\r\n\r\nBamlanivimab in combination with etesevimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. This combination regimen is also used for post-exposure prophylaxis of COVID-19 in unvaccinated or immunocompromised adults and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death.[L40184]","ahfs-codes":null,"updated":"2022-06-03","drugbank-id":"DB15718"},{"toxicity":"Data regarding overdose is not readily available.[L15326] However, keratopathy was seen in 71% of patients.[A216756,A216761,A216766,L15326]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":"BE0000703 BE0003659 BE0001032 BE0001069 BE0001061 BE0001004 BE0000785","pharmacodynamics":"Belantamab mafodotin treats multiple myeloma through antibody dependant cell mediated cytotoxicity as well as G2\/M cell cycle arrest.[A216771] It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks.[L15326] Patients should be counselled regarding the risk of keratopathy.[L15326]","msds":null,"description":"Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).[A216756]\r\n\r\nBelantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the US marketing authorization in November 2022. In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.[L44236]","enzymes":null,"type":"biotech","cas-number":"2050232-20-5","sequences":null,"targets":"BE0010010","unii":"DB1041CXDG","protein-binding":"Monoclonal antibodies are generally not protein bound[A31470,A177074].","fda-label":null,"clearance":"The clearance of belantamab mafodotin was 0.9 L\/day after the first dose and 0.7 L\/day at steady state.[L15326]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF).[A216756] Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity.[A216771]\r\n\r\nBCMA is uniquely expressed on CD138-positive myeloma cells.[A216756] Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells.[A216756] Belantamab mafodotin binds to BCMA, is internalised into cells, and releases MMAF.[A216756]\r\n\r\nThe MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.[A216771]","drug-interactions":"DB05209 DB14905 DB08880 DB00328 DB06474 DB09381 DB14649 DB12457 DB06647 DB11959 DB00742 DB09052 DB09198 DB12034 DB11857 DB14039 DB12023 DB00540 DB06305 DB00637 DB00970 DB15898 DB14877 DB11604 DB12344 DB12978 DB12035 DB00451 DB00845 DB13886 DB00177 DB14811 DB13878 DB11884 DB11685 DB11746 DB15118 DB06228 DB00957 DB06772 DB14997 DB12815 DB01229 DB12235 DB00583 DB00503 DB00973 DB06602 DB12053 DB00220 DB01590 DB09030 DB14012 DB01067 DB09035 DB13867 DB04908 DB03619 DB00421 DB14891 DB13017 DB00108 DB11855 DB00912 DB12825 DB09076 DB06599 DB11828 DB06310 DB01396 DB11901 DB00390 DB08865 DB14864 DB09105 DB01039 DB00222 DB12520 DB12396 DB05797 DB00778 DB00358 DB00301 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB08820 DB15443 DB11827 DB00834 DB00773 DB14897 DB01259 DB01051 DB00028 DB12104 DB15001 DB02659 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB13879 DB12498 DB11715 DB11979 DB05521 DB11951 DB00098 DB01165 DB09161 DB11621 DB16385 DB00113 DB12246 DB11641 DB15627 DB04881 DB04868 DB00002 DB04949 DB08881 DB00788 DB11575 DB14723 DB00877 DB13535 DB01182 DB06290 DB12364 DB08930 DB01257 DB00908 DB12335 DB00890 DB04901 DB11976 DB06616 DB12119 DB00091 DB09045 DB05039 DB11633 DB14973 DB00612 DB14952 DB00054 DB05111 DB11689 DB11613 DB15626 DB16225 DB06589 DB00872 DB12698 DB13073 DB11731 DB08870 DB14776 DB01015 DB08906 DB11771 DB05928 DB05304 DB12893 DB00203 DB15090 DB00213 DB06695 DB16755 DB05437 DB14919 DB15135 DB12001 DB06448 DB05459 DB02703 DB14211 DB00586 DB12319 DB12363 DB15865 DB00175 DB12943 DB12584 DB11952 DB15899 DB04851 DB09369 DB00977 DB12891 DB00468 DB15415 DB05276 DB11936 DB00270 DB11914 DB16170 DB12712 DB00072 DB00641 DB15328 DB11988 DB13955 DB01892 DB06371 DB11674 DB15045 DB01269 DB06550 DB01234 DB11978 DB16355 DB06322 DB12026 DB01241 DB06605 DB13976 DB15089 DB11869 DB14967 DB13979 DB09183 DB09063 DB00206 DB11834 DB05679 DB05006 DB12500 DB12147 DB09318 DB06237 DB14843 DB00822 DB12589 DB06606 DB11757 DB11756 DB15160 DB00646 DB00882 DB13874 DB14907 DB12734 DB15444 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB12836 DB08896 DB16265 DB00224 DB00394 DB00065 DB15718 DB05892 DB13386 DB01118 DB15133 DB12089 DB09303 DB08904 DB08910 DB00559 DB12487 DB14959 DB12917 DB12845 DB06192 DB00176 DB05015 DB00043 DB09296 DB15628 DB11712 DB12976 DB09559 DB01095 DB01357 DB01092 DB09033 DB11826 DB11574 DB14004 DB06207 DB00622 DB06241 DB00196 DB14068 DB00396 DB00057 DB00112 DB11652 DB06603 DB08893 DB05793 DB00833 DB13345 DB01026 DB06049 DB06168 DB08862 DB16659 DB09118 DB00661 DB14996 DB16222 DB06043 DB11697 DB11945 DB00932 DB08879 DB00076 DB06366 DB09037 DB01045 DB11478 DB11853 DB05550 DB14761 DB12169 DB06612 DB01016 DB15397 DB05595 DB13956 DB06318 DB01054 DB01167 DB13953 DB11569 DB14784 DB04850 DB00619 DB09317 DB14824 DB16376 DB15453 DB11580 DB05804 DB05239 DB04847 DB06670 DB12142 DB00520 DB09078 DB12799 DB05555 DB14580 DB11672 DB16195 DB11800 DB05667 DB12189 DB00188 DB00398 DB00110 DB00572 DB11581 DB08864 DB09065 DB09077 DB07348 DB09291 DB06191 DB11362 DB15428 DB00075 DB09241 DB05101 DB14724 DB00412 DB00078 DB01232 DB00295 DB08931 DB01263 DB09292 DB14069 DB00911 DB05136 DB04956 DB06081 DB14989 DB12159 DB11856 DB01211 DB08995 DB00073 DB06101 DB06643 DB12560 DB12797 DB12941 DB05496 DB06287 DB12157 DB00675 DB12609 DB00455 DB05916 DB06403 DB05889 DB06467 DB12102 DB00441 DB15569 DB04958 DB11732 DB06626 DB12342 DB00248 DB01601 DB00345 DB09070 DB14988 DB12090 DB15432 DB02123 DB01072 DB00625 DB09048 DB08907 DB01267 DB15363 DB01254 DB00111 DB11760 DB01270 DB09272 DB00836 DB13418 DB01169 DB00477 DB14947 DB06210 DB09330 DB15441 DB15383 DB00335 DB01023 DB12597 DB06234 DB09374 DB14962 DB15349 DB00349 DB00693 DB00997 DB05941 DB01394 DB11930 DB06050 DB01393 DB05294 DB11753 DB01138 DB04845 DB06162 DB08860 DB00698 DB00694 DB12489 DB09027 DB09239 DB09264 DB00300 DB00864 DB11995 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB14631 DB12807 DB01586 DB15334 DB00089 DB06636 DB14126 DB11693 DB05097 DB11840 DB06151 DB12713 DB09075 DB13375 DB16732 DB06176 DB13125 DB09054 DB00976 DB12202 DB13045 DB14057 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB12466 DB05016 DB15113 DB01098 DB00966 DB00539 DB00408 DB00197 DB09073 DB00588 DB00095 DB14845 DB05578 DB15101 DB00286 DB12701 DB00458 DB11586 DB14778 DB01149 DB01076 DB12331 DB00080 DB15335 DB14762 DB04216 DB06186 DB15559 DB11791 DB09280 DB13919 DB00360 DB11850 DB08902 DB15409 DB15014 DB00199 DB11986 DB12296 DB09079 DB13143 DB16695 DB01222 DB09298 DB15225 DB16394 DB12250 DB15434 DB11963 DB14042 DB04573 DB00269 DB12213 DB01264 DB12483 DB00950 DB12455 DB16077 DB06749 DB11642 DB08882 DB08912 DB12240 DB06650 DB16393 DB00482 DB08816 DB09039 DB11646 DB15252 DB00570 DB00056 DB09297 DB04348 DB08934 DB08901 DB08916 DB09102 DB09036 DB11803 DB14707 DB12683 DB06240 DB08889 DB01030 DB04855 DB13923 DB16421 DB16151 DB09302 DB13751 DB15442 DB01174 DB12118 DB00975 DB05915 DB00655 DB14871 DB11796 DB00081 DB00087 DB11657 DB00678 DB12775 DB04988 DB11770 DB05996 DB11767 DB13952 DB05139 DB12070 DB00439 DB06304 DB11595 DB09029 DB15258 DB01079 DB00795 DB05545 DB08935 DB15076 DB16703 DB11972 DB06116 DB14040 DB14840 DB06674 DB11967 DB00275 DB00501 DB15900 DB09331 DB06212 DB06419 DB01261 DB14041 DB00342 DB00726 DB13127 DB00227 DB04574 DB00862 DB16236 DB01136 DB00909 DB11942 DB07931 DB15044 DB00243 DB01645 DB11608 DB06769 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB09034 DB08827 DB00602 DB06324 DB12534 DB04964 DB15336 DB15149 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00762 DB12141 DB00074 DB13037 DB06342 DB05405 DB12077 DB00255 DB15822 DB13007 DB12887 DB00541 DB01115 DB09312 DB00701 DB15982 DB04575 DB01388","absorption":"Belantamab mafodotin at a dose of 2.5mg\/kg reaches a C<sub>max<\/sub> of 42 g\/mL, with a T<sub>max<\/sub> of 0.78 hours, and an AUC of 4666 g\\*h\/mL.[L15326]","created":"2020-08-06","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal half life of belantamab mafodotin was 12 days after the first dose and 14 days at steady state.[L15326]","monoisotopic-mass":null,"volume-of-distribution":"The mean steady state volume of distribution of belantamab mafodotin was 11 L.[L15326]","route-of-elimination":"Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins.[A31470,A177074] Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.[A40006]","name":"Belantamab mafodotin","metabolism":"Monoclonal antibodies are expected to be metabolized to smaller peptides and amino acids.[L15326] MMAF is expected to be metabolized by oxidation and demethylation, however further data is not readily available.[A216781,A216776]","reactions":null,"indication":"Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.[L15326]","ahfs-codes":null,"updated":"2022-12-08","drugbank-id":"DB15719"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":375.56,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"60388-02-5","sequences":null,"targets":null,"unii":"Z722242H10","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":373.947705,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc orotate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15720"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Natural Killer (NK) cells originate and differentiate from hematopoietic stem cells through various signalling pathways involving cytokines and interleukins. These cells arise from CD34+ lymphoid progenitors and comprise 10-15% of all lymphocytes in human peripheral blood. Once completely differentiated, NK cells lack B (CD19-) and T(CD3-) lymphocyte markers and carry their unique CD56+ status instead. The two maturate variants of NK cells are CD56dim and CD56bright, which exert cytotoxicity through release of toxic chemicals and cytokine secretion, respectively. NK Cells express features of innate immune responses, and respond to all molecules that appear to be foreign to the body. \r\n\r\nThe most standard and utilized source of NK cells is directly from the peripheral blood of a donor through leukapheresis: a technique where immune cells are separated from red blood cells. Generally, the number of NK cells collected in the peripheral blood mononuclear cell (PBMC) is too low for sufficient potency, and ex vivo expansion is performed. Expansion involves the use of feeder cell line systems or bioreactors to enhance the number of NK cells with desired cytotoxicity. These cells are also purified using cell-separation systems and processing.\r\n\r\nOther techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy. It is also possible to culture UCB CD34+ hematopoietic stem cells (HSCs) under stimulation of IL-2, IL-15, and stem cell factor (SCF) in a system to develop NK cells. \r\n\r\nInduced pluripotent stem cells (iPSCs) and human embryonic stem cells (HESCs) are also used to generate NK cells through a two-step culture method resulting in CD34+ cells.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"IZR558KO53","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The predominant targets of NK cells are \u20ACstressed\u20AC cells with downregulated expression of class I MHC (MHC-I), a common mechanism used by malignant or virus-infected cells to evade recognition by the body\u20ACs immune system. In response to encountering these cells, NK cells release two types of proteins, perforins and granzyme B, which attack the target cell\u20ACs membrane, damage its organelles, and trigger apoptosis. NK Cell immunotherapy is an emerging anti-cancer strategy, as these cells are able to exert effects without activating the graft-versus-host disease cascade. In addition, their broad mechanism allows for generally safe administration of NK cells that are not immunologically matched to a patient.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Natural Killer Cell","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15721"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+\/CD3-.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"CYNK-001 has the potential to inhibit viral infection by killing host cells through indirect immune responses. CYNK-001 expresses NKG2D and DNAM-1 receptors in addition to cytotoxicity receptors NKp30, NKp44, and NKp46. These receptors bind to the ligands and antigens expressed on infected cells, and initiate the release of perforin and granzyme B from the NK cell to induce cell death. In addition to being investigated for the treatment of acute myeloid leukemia, multiple myeloma, and glioblastoma multiforme, CYNK-001 is also being investigated for treating COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CYNK-001","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15722"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The use of umbilical cord blood (UCB) for therapies is advantageous because of its ease of access, non-invasive collection procedures, and more plasticity for multi-differentiation. UCB contains a large source of hematopoietic stem cells (HSCs) that are capable of self-renewal, have increased sensitivity to various factors, and are able to generate erythroid and myeloid progenitor colonies. Specifically, the proliferation capacity of human umbilical cord blood mononuclear progenitor cells (HUCBC) are much higher than similar cells in bone marrow. From the UCB, mononuclear cells are isolated and cultured in medium, expanded, and differentiated into the desired cell type. \r\n\r\nHUCBC CD34+ cells are cultured with various cytokines and interleukins to give rise to various cell types, from red blood cells, to  B-, T-,  and Natural Killer Cells. The content of these cells depends and changes based on the gestational age. Because HUCBC are largely immature, do not express class II HLA antigens, and do not produce as many cytokines and immunoglobulins as adult lymphocytes, transplantation with these cells means low levels of cytotoxicity and immunological reactions.\r\n\r\nCord blood transplants have been used to treat conditions from aplastic anemia, B-thalassemia, X-linked lymphoproliferative syndrome, Hunter\u20ACs syndrome, acute lymphoid leukemia, chronic myeloid leukemia, to neuroblastoma. This highlights the adaptive nature of these cells.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The mononuclear cells originating from the hematopoietic stem cells in the umbilical cord blood are shown to have a higher immune tolerance in donors after transplants due to their immaturity and lack of class II HLA antigens. These cells are transplanted to treat various diseases, including hematological, oncological, cardiovascular, and even neurological-based pathologies. Currently, this type of therapy is being explored for the treatment of COVID-19 related effects.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Umbilical Cord Blood Hematopoietic Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15723"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs\u20AC differentiation potential, the growth factors and cytokines these cells secrete are also implicated. When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are thought to reduce inflammation and associated damage. Thus, the media in which they are cultured is believed to also have therapeutic potential. \r\n \r\nAfter the human umbilical cord mononuclear cells are extracted from the umbilical cord, they are expanded and cultured in Dulbecco\u20ACs modified Eagle\u20ACs medium. Then, the medium is filtered and separated from the HUCBCs.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Mononuclear umbilical cord cells have the ability to secrete cytokines, growth factors, interleukins,and chemokines. As many of these factors can have anti-inflammatory, angiogenic, and neuroprotective effects, it is thought that the conditioned media may exert some therapeutic potential related to these effects.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Human umbilical cord blood mononuclear cell-conditioned medium","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15724"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Natural killer (NK) cells can be incubated with \u20ACfeeder cells\u20AC expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"IL-15 is a key cytokine in NK cell development and function; the IL-15 receptor (IL-15R) is constitutively expressed in both the CD56<sup>bright<\/sup>  and CD56<sup>dim<\/sup>  matured NK cells. Activation of the IL-15R involves 3 downstream pathways: JAK1\/3\/STAT3\/5, P13K\/Akt\/mTOR, and Ras\/Raf\/MEK\/ERK. It was shown that \u20ACpriming\u20AC NK-cells with IL-15 markedly enhanced anti-tumor responses which included cytotoxicity, degranulation, and cytokine production.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"IL15-NK Cell","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-10-07","drugbank-id":"DB15725"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Stem cells obtained from amniotic fluid, the umbilical cord (UC), and placenta are gaining in popularity. Stem cells from the umbilical cord offer several advantages, including: non-invasive collection procedures, more hearty and steady growth than bone-marrow derived stem cells (they can maintain a steady doubling time (DT) over up to 10 passages), higher differentiation capability, and faster self-renewal. These cells express low levels of major histo-compability complex (MHC) class I, and generally lack MHC class II and its co-stimulatory ligands like CD40, CD80, and CD86. Thus, they are characterized with low immunogenicity. The umbilical cord, which starts developing in the fifth week of gestation, contains different compartments where stem cells originate: the cord lining, Wharton\u20ACs jelly, and perivascular region. \r\n\r\nUC mesenchymal cells derived from Wharton\u20ACs jelly are the most studied and offer more stable and better osteogenic and adipogenic differentiation potentials. The cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the \u20ACstandard\u20AC thus far. The explant method requires manual mincing of the tissue fragments and results in an inconsistent number of extracted MSCs. In contrast, the enzymatic digestion method uses enzymes to break down the non-required cell fragments, and results in more consistent cell numbers. Regardless of extraction method, the cells are usually expanded in vitro in laboratories using culture systems and bioreactors. \r\n\r\nThe cord lining of the UC is generally isolated with the explant method -- resulting in two kinds of MSCs: cord lining mesenchymal stem cells (CLMC), which are used to aid in burn and diabetic ulcer wound healing, and cord lining epithelial stem cells (CLEC), which are used for persistent corneal epithelial defects and skin improvements.\r\n\r\nCurrently many companies are creating their own version of these stem cells, one of which is by Aspire, who are creating a version named ACT-20.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"General theories of therapeutic action postulate that HUCMSCs can replace damaged cells, inhibit immunological functions through paracrine actions, and promote proliferation of endogenous stem cells through cell-cell communication. HUCMScs are thought to alter immune function through inhibition of Natural Killer Cell, T-cell, and B-cell proliferation along with redirecting monocytes and dendritic cells to less mature states. HUCMSCs are currently investigated for specific cell-based therapies, as they can be differentiated and engrafted for various disease states with low immunogenicity. Such applications include neurodegenerative diseases, spinal cord injury, stroke, and even liver disease. Certain factors secreted by HUCMSCs, such as oxidative stress pathways, are also thought to inhibit tumor growth and even lymphoma cell growth.  These therapies are currently being considered for the treatment of COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Human Umbilical Cord Mesenchymal Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15726"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF. Chimeric antigen receptors (CARs) are artificial receptors consisting of an antibody-derived antigen binding domain and transmembrane and signaling domains from T-cell receptor signalling moieties. First used with autologous human T cells (CAR-T) as cancer immunotherapies, these receptors are now being engineered onto natural killer (NK) cells due to lower potential for graft-versus-host disease and cytokine release syndrome. The IL-15 superagonist increases the activity of NK cells and improves their target cytotoxicity. The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity. The transmembrane NKG2D and intracellular 2B4 domains are required for optimal NK signalling and subsequent cell-mediated cytotoxicity. The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"NK cells modified by CARs play a role in targeted immunotherapy without subsequent cytokine release syndrome or neurotoxicity as these effects are mediated through GM-CSF neutralization. The NKG2D-ACE2 CAR-NK cells secreting super IL15 superagonist and GM-CSF neutralizing scFv is thought to act synergistically to target and kill cells infected with SARS-Cov-2 without widespread cytokine release and inflammation.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"NKG2D-ACE2 CAR-NK Cell","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15727"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties. \r\n\r\nOnce MSCs are isolated from the tissue through extraction procedures, they are cultured in the Dulbecco\u20ACs Modified Eagle\u20ACs Medium (DMEM) to separate soluble factors into the liquid.\r\n\r\nMany companies are creating their own version of this medium. One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The factors contained in the CM are thought to hold differentiation and therapeutic function, additionally, they may also intensify the positive effects of cell-based therapies. Some of the growth factors and cytokines found include IL-6, VEGF, angiogenin, and IGF-1. Through these factors, the conditioned medium exerts numerous effects, including accelerated wound healing, anti-photo aging, and induced differentiation.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15728"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient\u20ACs own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro. \r\n\r\nThese AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"3ME9TTI5QB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"AMSCs have been shown to secrete several growth factors and hyaluronic acid (HA) which balance collagen, with hepatocyte growth factor (HGF) being a major part of those secreted. HGF secreted by AMSCs has been shown, in culture, to attenuate collagen production and fibroblast proliferation. AMSCs also have the ability to produce elastic fibers, something that typically does not appear in a scar environment.\r\n\r\nIn some studies, adipose mesenchymal stem cells have demonstrated anti-inflammatory and chondroprotective properties. Currently, the exact mechanism behind AMSCs is unknown. However, a possible mechanism consists of activation of the cells due to inflammation, with the activated cells then modulating inflammation and cartilage remodeling by prostaglandin E2. The effects for AMSCs seem to also possibly be dose-dependent.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB15729"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are obtained from either the fetal side, which hold chorionic plate-derived MSCs, or the maternal side, which contributes decidual parietalis-dreived MSCs. Although pMSCs have multi-lineage differentiation potential, the fetal-side pMSCs have greater expansion capacity, proliferation and differentiation potential than maternal-side pMSCs. It was also found that fetal-side pMSCs express different surface markers.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"DPX6XLD4X1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"All pMSCs contain therapeutic potential and have been used in medical treatment already as they are an ideal candidate for allogeneic transplantation due to their immunomodulatory properties and low immunogenicity. MSCs secrete growth factors and cytokines during angiogenesis, anti-fibrotic processes, chemotaxis, hematopoiesis induction, immunomodulation, and inhibition of apoptosis, with different levels of secretion between fetal- vs. maternal-side pMSCs. Fetal-side pMSCs secrete a higher level of HGF and VCAM-1 and hold potential in angiogenic therapy, while maternal-side pMSCs have the potential for treatment of critical limb ischemia as they secrete VEGF and Ang-1.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Placental Mesenchymal Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15730"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ORBCEL-C\u201E is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord. The isolated cells are expanded in culture and are able to be used allogenically -- meaning that one donor\u20ACs cells can be given to other unrelated patients. These cells are CD362 enriched umbilical cord-derived mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis.  \r\n\r\nRegarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The mesenchymal stem cells (MSCs) of ORBCEL-C\u201E act through release of factors which reduce inflammatory responses, promote blood vessel formation, and have the ability to demonstrate immunomodulatory effects. \r\n\r\nAllogeneic UC-MSCs are also being investigated in orthopedic applications for cartilage and bone regeneration; these UC-MSCs are a valuable allogeneic source of cells as these cells are from a discarded material with virtually unlimited availability. Specifically to orthopedics, UC-MSCs have potential for treatment of chondral and osteochondral lesions, and bone defects as a universal off-the-shelf product.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15731"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute myeloid leukemia, B-cell lymphoma, and solid tumors in combination with other compounds. It is also a potential therapy for COVID-19.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"FT516 contains engineered NK cells expressing CD16, which are activated through binding of the Fc portion of IgG antibodies. When activated, these NK Cells destroy antibody-coated target cells while also secreting additional cytokines and recruiting T-cells. The mechanism, referred to as antibody-dependent cellular cytotoxicity (ADCC), depends on the stable and effective expression of CD16 on the NK cells.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"FT516","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15732"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Lactobacillus is a common bacteria found in the gut with Lactobacillus coryniformis K8 being originally isolated from artisan goat cheese.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Lactobacillus coryniformis has immunomodulatory activity. Administration of a Lc K8 probiotic prior to the influenza vaccine in adults over the age of 65 showed a higher percentage of vaccine responders and a significantly lower incidence of respiratory symptoms associated with respiratory infections.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lactobacillus coryniformis K8","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-13","drugbank-id":"DB15733"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection. These IMRCs are differentiated from human embryonic stem cells that are expanded and then harvested. These cells are currently being investigated against lung injury and fibrosis -- conditions which are outcomes of lung disorders including COVID-19. \r\nIMRCs are similar to MSCs in terms of their capacity for self-renewal and tri-lineage differentiation. However, the difference comes with IMRCs displaying a higher quality of consistency, having stronger immunomodulatory and anti-fibrotic functions, and being stronger in potential treatment of lung injury and fibrosis.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"IMRCs are different from cells such as the umbilical cord mesenchymal stem cells in gene expression profile; thus, this results in IMRCs possessing qualities such as higher expression levels of proliferative, immunomodulatory, and anti-fibrotic genes. Additionally, they have the ability to modulate immunity and regulate extracellular matrix production.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Human Embryonic Stem Cell-derived M Cell","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15734"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs. In some cases, the cells are created from blood samples of patients who have recovered from viral infections.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Administration of VSTs can provide physiological protection against specific infections, especially for patients who are immunocompromised and depleted of T-cells. VSTs are used as an immunotherapy against many infections, including Epstein-Barr virus, adenovirus, BK virus, and human herpesvirus type 6. This type of treatment is also being investigated as a therapy against SARS-Cov-2.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Virus Specific T-Cell","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15735"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.","enzymes":null,"type":"biotech","cas-number":"2416824-55-8","sequences":null,"targets":null,"unii":"FA2I4Z873U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alunacedase alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15736"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dental pulp is a soft, connective tissue present in the dental crown of both third molar and first premolar teeth. Dental pulp stem cells (DPSCs) exhibit fibro-blast like plasticity and adherent properties. They are harvested through surgical extraction of wisdom teeth from adults; this procedure is favoured as it is non-invasive, easily accessible, and allows for an alternate use of teeth that are usually discarded. DPSCs can remain stable in media once extracted, and have a high proliferation and regeneration capacity. \r\n\r\nDPSCs have multiple properties, and express surface antigens like CD90, CD29, and CD105 but not CD14 or CD45. They also express specific pluripotency markers like MYC and SOX2 which can be absent in other MSCs. These cells have innate neurogenic potential as their origins are traced to the embryonic neural crest; there is potential for these cells to create neurons and glial cells. In addition, they are able to differentiate into chondrocytes, adipocytes, and odontoblasts under appropriate conditions.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"DPCSs exert many functions, including tissue development, homeostasis, and tissue repair. They are able to secrete pro-angiogenic and anti-apoptotic factors, and are implicated in the treatment of conditions like osteoarthritis, myocardial infarction, and Alzheimer\u20ACs disorder. DPSCs are currently being used to address the cellular effects of infection with COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dental Mesenchymal Pulp Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-02","drugbank-id":"DB15737"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Stem cells are self-renewing and proliferate without differentiation, with the two major groups being embryonic stem cells (ESCs) and adult stem cells (ASC). Differentiation occurs under different conditions into different cell types. ESCs are from the inner cell mass of blastocysts while ASCs are deposited into adult tissues with restricted differentiation potency but also a lack of tumorigenicity.\r\nMenstrual blood-derived stem cells (MenSCs) are mesenchymal-like ASCs which are non-invasively derived from menstrual blood from the shed endometrium of a human female. These cells possess a high rate of proliferation and multi-lineage differentiation potency. \r\n\r\nMenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method. Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Mesenchymal stem cells have applications in research, therapeutic, and regenerative purposes. Similarly, MenSCs have previously demonstrated their ability to differentiate into adipocytes, cardiomyocytes, chondrocytes,  hepatocytes, osteocytes, and pancreatic cells. Additionally, MenSCs express both pluripotency markers and mesenchymal stem cell-specific markers as well, making them potentially useful for research on differentiation and in regenerative medicine.\r\nMenSCs have also been shown to both induce and inhibit proliferation of natural killer (NK) cells, with inhibition occurring if the MenSCs were pre-treated with IFN-\/IL-1. Additionally, MenSCs can inhibit optimal maturation of monocyte-derived dendritic cells, and depending on the cell concentration, either stimulate or inhibit an allogeneic mixed lymphocyte reaction.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Human Menstrual Blood-derived Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15738"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mesenchymoangioblast (MCA)-derived mesenchymal stem cells (MSCs) originate from the mesoderm and are a common precursor for endothelial cells. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue. \r\n\r\nThe MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability. These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"CYP-001 is a mesenchymal stem cell (MSC) product that is created from induced pluripotent stem cells. It was developed to treat steroid-resistant acute graft-versus-host disease (GvHD), and for preclinical models of asthma, limb ischemia, cytokine release syndrome, among others. As a regenerative medicine, CYP-001 is being used as a therapeutic to treat patients with COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mesenchymoangioblast-derived mesenchymal stem cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15739"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high potential for regenerative medicine. In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps. OM-MSCs are also immunomodulatory and have potential for treating immunological diseases. \r\nCurrently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"OM-MSCs\u20AC immunomodulating activities are partially related to CD4+ T-lymphocytes, B-lymphocytes, macrophages, and dendritic cells. OM-MSCs were also found to suppress cytotoxic functions of CD8 + cytotoxic lymphocytes and natural killer cells. \r\nPotential applications include in the field of experimental neurology to employ it for treatment of different types of lesions and neurodegenerative diseases of the central nervous system, hippocampal lesions, regeneration of peripheral nerves and cranial nerves, and for spinal cord trauma. There are also potentials for immunosuppression for autoimmune diseases and regenerative promotion for myocardial tissue after infarction and also against ischemic tissues.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15740"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"B38-CAP is structured as a carboxypeptidase and derived from _Paenibacillus sp._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels. It is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Angiotensin Converting Enzyme 2 (ACE2) is a recently discovered enzyme that degrades Angiotensin II (known as Ang 1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release, attenuating tissue injury, including ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the depelatory effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Recombinant Bacterial ACE2 Receptors-like Enzyme","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15741"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without tissue matching or concurrent immunosuppressive agents. The cells for creation of the product are isolated from a qualified donor and expanded on a large scale and then frozen until use. After administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"WNR9FH307P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"MultiStem\u20ACs main focus is immunological, with MAPCs mainly acting by producing factors regulating the immune system, protecting damaged and injured cells, and also promoting tissue repair and healing. The MAPCs in MultiStem have the ability to express a range of therapeutically relevant proteins and factors with the potential to reduce inflammation, protect damaged or injured tissue, and enhance the formation of new blood vessels in areas of ischemic injury. Immune-wise, it acts to rebalance the immune system, with studies by the company showing that the therapy acts by reducing inflammation (with reduced inflammatory cytokine levels) and lessening activation and migration of the peripheral immune system to the site of injury.  Additionally, this therapy potentially may have therapeutic effects through decreasing activation of the peripheral immune response to the initial injury which then results in reduction of inflammation and thereby means less secondary tissue damage and scarring while also allowing for accelerated repair processes. These cells have also been shown to lessen adverse results of inflammation while reparative immune cells are activated. In summary, there occurs simultaneous upregulation of reparative immune responses and downregulation of proinflammatory processes. \r\n\r\nOutside of immunological applications, MAPCs are also being investigated for ischemic injury treatment and cardiovascular repair. Compared to MSCs, MAPCs have a stronger angiogenic protein release profile while also inducing more extensively developed vasculature in a study. Additionally, MAPCs also hold potential in being a functional cell source for orthopedic applications and to also promote tissue regeneration and healing. Evidence exists that MAPCs can differentiate into cells of mesenchymal lineages which includes bones, bone marrow, cartilage, fat, muscles, and tendon -- giving reason behind the investigating of MAPCs for treatment of bone and cartilage disease. MAPCs, compared to MSCs, also seem to have greater inclination for endothelial differentiation.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MultiStem","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15742"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Mesenchymal stem cells (MSCs) exert their therapeutic effects through multiple modalities, including paracrine factors such as exosomes. Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication. Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. Various bioactive molecules (including lipids, proteins, mRNAs, and tRNAs) are used to enrich exosomes. While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins. These products originate from multiple cellular types, including immunocytes, tumor cells, and mesenchymal stem cells (MSCs) originating from various tissues. \r\n\r\nExosomes from MSCs carry cytokines and growth factors, like TGFB1, IL-6, IL-10, and hepatocyte growth factor (HGF); all are shown to be immunomodulatory. These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis and tissue repair.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Exosomes are a novel cell-therapy currently investigated for the treatment of liver, kidney, cardiovascular, and neurological disease. They are messengers in intercellular communication through their ability to secrete bioactive lipids, proteins, and RNAs to target sites. As they can carry unique proteins and cytokines, exosomes are involved in both physiological and pathological processes. Therapeutically, MSC-derived exosomes can restore tissue homeostasis, and enable tissue recovery, repair, and regeneration.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Stem-cell derived exosome vesicle products","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-20","drugbank-id":"DB15743"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and IL-15). The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZM7OCV7H6H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Cardiosphere-derived cell exosomes can reduce cardiac scar size, improve myocardial function, and attenuate damaging remodeling that occurs from infections. CAP-1002 was formulated as an intravenous infusion of cardiosphere-derived cells and is currently being investigated as a treatment for critically ill COVID-19 patients.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CAP-1002","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15744"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn\u20ACs disease, and ulcerative colitis. Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic purification system combined with repeated centrifugation and suspension. Fecal particles, parasite eggs, fungus and other potentially harmful things are removed. The resulting suspension is shown to decrease FMT-related adverse events.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"WMT delivers a precise dose of enriched microbiota through intraperitoneal injection, oral capsule, nasogastric tube, nasojeunal tube, or anal enema. The transplantation of the materials within the WMT is thought to recolonize the gut bacteria and aid in treating patient pathology associated with disease like Crohn\u20ACs, and ulcerative colitis. WMT is being investigated as a rescue therapy for critically ill patients with COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Washed Microbiota Transplantation","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15745"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"pGSN also enhances bacterial uptake and death by macrophages. It has positive effects on the immune system as it boosts clearing of pathogens and modulates inflammatory reactions; often pGSN is consumed in both serious infectious and non-infectious conditions. Its physiological effects thus make it a potential candidate for severe acute respiratory syndrome (ARDS) associated with COVID-19, as administration of recombinant protein is thought to supplement depleted levels of pGSN.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Recombinant Human Plasma Gelsolin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15746"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19. Rabbit polyclonal antibodies are derived from the rabbit, a common animal host for polyclonal production. The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. Different antibodies have different mechanisms of action depending on their target. Current applications of antibodies include, but are not limited to, targeting cancer, inflammatory diseases, organ transplantation, cardiovascular disease, infection, respiratory disease, and ophthalmologic disease.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"No information available thus far on the MoA for CoviGlobulin.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CoviGlobulin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15747"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus evade the host immune system through selectively blocking and activating different receptors, preferentially inhibiting acute Th1-associated inflammation while also upregulating Th2 associated immune response.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"This protein has the ability to bind to chemokine receptors (including both HIV coreceptors) and cell surface glycosaminoglycans. At the chemokine receptors, vMIP acts as an antagonist at CCR1, CCR2, CCR5, and CXCR4 while it is an agonist at CCR3 and CCR8. Due to its antagonistic action at CCR5 and CXCR4, vMIP is able to block HIV cell entry through these coreceptors while also inhibiting inflammation of monocytes and Th1 type T cells -- both major targets for HIV-1 and thus vMIP has potential to act as an HIV inhibitor. Glycosaminoglycans, on the other hand, are important as the binding to glycosaminoglycans may be essential for the protein to carry out its natural function in vivo. \r\n\r\nvMIP is angiogenic -- its pro-angiogenic capabilities in mature and progenitor endothelial cells gives it potential for use in organ transplantations. It is also selectively chemotactic for Th2 lymphocytes. Overall, the major role of vMIP-II is regulation of immune responses.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Viral Macrophage-Inflammatory Protein","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15748"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Significant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-\/ receptor 1(IFNAR1) and IFNAR2.","drug-interactions":"DB13812 DB02568 DB11919 DB12927 DB15122 DB12531 DB06479 DB13573 DB13634 DB14018 DB01303 DB00806 DB04076 DB02245 DB01667 DB00651 DB12406 DB14029 DB02489 DB09273 DB12926 DB00201 DB06575 DB01033 DB07954 DB13203 DB14132 DB13592 DB00495 DB01482 DB08844 DB02377 DB01223 DB01978 DB02134 DB13449 DB00277 DB04356 DB01412","absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Interferon Kappa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15749"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages. The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected in mucous layers over the tissue.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"TFF2 acts as a regulator of mucosal tissue repair and is a part of epithelial defences, promoting restitution. TFF2 is upregulated in gastric tissue with Helicobacter infections and gastric tissues with inflammatory conditions; its anti-inflammatory actions allow it to down-regulate gastric and colonic inflammation. It has also been proposed that TFF2 is involved with some aspect of immune function. Although there are reports of a number of potential biological roles for TFF, currently, the exact mechanism of action is yet to be elucidated as cell surface receptors for TFFs have not yet been identified. However, a study proposes TFF2 to have a role in the negative regulation of interleukin 1 (IL-1) receptor-mediated signalling.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Trefoil Factor 2","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15750"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"MRx-4DP0004 is an immunomodulatory therapy with anti-viral activity that simultaneously downregulates molecules associated with hyper-inflammatory responses. It reduces neutrophilic and eosinophilic infiltration in the lungs, in addition to a reduction in peribronchiolar and perivascular immunopathology without the side effects associated with immunosuppressants. A study of MRx-4DP0004 also demonstrated specifics of the biotherapeutic increasing lung D4+CD44+ cells and CD4+FoxP3+ cells, decreasing activated CD11b+ dendritic cells, and reducing pro-inflammatory cytokines and chemokines involved in neutrophil migration. MRx-4DP0004 is currently being investigated for severe asthma management, however, the specific mechanism of action is currently unknown.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MRx-4DP0004","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15751"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"RSIFN-co has immunomodulation, antiviral, and antineoplastic activities. It binds to IFN-specific cell surface receptors and causes transcription and translation of genes that have protein products with antiviral, antiproliferative, anticancer, and immunomodulating effects. It is currently being investigated for viral diseases and cancer.","drug-interactions":null,"absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Recombinant Super-Compound Interferon","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-13","drugbank-id":"DB15752"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"P050J5FWC5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interferons IMMUNOSTIMULANTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Interferon gamma signals as an antiparallel homodimeric glycoprotein, acting at the complex of interferon gamma receptor 1 (IFNGR1) and IFNGR2 after direct binding to IFNGR1. It activates the JAK\/STAT, MAPK, and PI3-Kinase pathways. In addition, Interferon gamma activates macrophages, mediates antiviral and antibacterial immunity, regulates Th1\/Th2 balance, and controls cellular proliferation and apoptosis.  It is currently being investigated as an antitumor drug, and a therapy for juvenile rheumatoid arthritis, chemoresistant pulmonary tuberculosis, idiopathic pulmonary fibrosis, and atypical pulmonary mycobacteriosis.\r\n\r\nThis cytokine has been found to have effects such as promotion of host response in antitumor immunity, playing roles in all three phases (elimination, equilibrium, and escape) of cancer immunoediting, directly influencing antiproliferation, apoptosis, and antiangiogenesis on tumor cells, and indirectly influencing antitumor immunity. However, currently there is no approved indication report of using interferon gamma in cancer treatment, indicating that interferon has not yet reached a stage of being a clinically-useful antitumor drug. \r\n\r\nInterferon gamma, when administered in combination with interferon alpha-2-beta as part of the HerberFERON therapy, is found to have synergistic effects, with the potential for more favorable pharmacodynamics than either alone. This synergy between interferon alpha and gamma include antiproliferative effects on several cancers.","drug-interactions":"DB13812 DB02568 DB11919 DB12927 DB15122 DB12531 DB06479 DB13573 DB13634 DB14018 DB01303 DB00806 DB04076 DB02245 DB01667 DB00651 DB12406 DB14029 DB02489 DB09273 DB12926 DB00201 DB06575 DB01033 DB07954 DB13203 DB14132 DB13592 DB00495 DB01482 DB08844 DB02377 DB01223 DB01978 DB02134 DB13449 DB00277 DB04356 DB01412","absorption":null,"created":"2020-08-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Interferon Gamma","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-10-07","drugbank-id":"DB15753"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"JAA7BS0D8Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-15","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hawaii\/66\/2019 (H1N1) live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-16","drugbank-id":"DB15756"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"ZD4U7FM04M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-15","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza A virus A\/Hong Kong\/2671\/2019 (H3N2) live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-16","drugbank-id":"DB15757"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"J7LDT2B7CD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-15","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Washington\/02\/2019 live (attenuated) antigen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-16","drugbank-id":"DB15758"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":275.264,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"13182-89-3","sequences":null,"targets":null,"unii":"A355C835XC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-17","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":275.090605911,"volume-of-distribution":null,"route-of-elimination":null,"name":"Metronidazole benzoate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15759"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":154.99,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"10124-43-3","sequences":null,"targets":null,"unii":"H7965X29HX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-17","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":154.884924,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cobaltous sulfate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15760"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":347.38,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"69388-79-0","sequences":null,"targets":null,"unii":"2X0WTA96KX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-18","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":347.103873194,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sulbactam pivoxil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15761"},{"toxicity":"There is no data regarding overdose of satralizumab. No serious adverse effects were noted in healthy adults receiving a single dose of 240mg subcutaneously in clinical trials.[L15546] Patients experiencing a suspected overdose should be treated with symptomatic and supportive measures as clinically indicated.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Enspryng, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] utilizes a novel \"recycling antibody technology\" whereby the association of satralizumab to IL-6 receptors occurs in a pH-dependent manner.[A218551] Satralizumab-bound IL-6 receptors are taken up into cells and transported into endosomes, a relatively acidic environment in comparison to plasma (pH 5.5-6.0 vs. pH 7.4) - this decrease in pH allows satralizumab to dissociate from the IL-6 receptor and be recycled back into the plasma, where it can bind to another IL-6 receptor and repeat the process.[A218551] \r\n\r\nSatralizumab has been associated with an increased risk of infection, including serious and potentially fatal infections. It should not be administered to patients with active infections, including localized infections, until the infection resolves, and is contraindicated for use in patients with active hepatitis B or tuberculosis.[L15536]","msds":null,"description":"Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework.[L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions in the optic nerve, spinal cord, brainstem, and cerebrum.[A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators into the CNS.[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses.\r\n\r\nEnspryng, a satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with \"recycling antibody technology\" whereby the association of satralizumab to IL-6 receptors occurs in a pH-dependent manner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again. This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination.\r\n\r\nSatralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.[A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after [eculizumab] in June 2019 and [inebilizumab] in June 2020).","enzymes":null,"type":"biotech","cas-number":"1535963-91-7","sequences":null,"targets":"BE0002859","unii":"YB18NF020M","protein-binding":null,"fda-label":"\/\/s3-us-west-2.amazonaws.com\/drugbank\/fda_labels\/DB15762.pdf?1597780665","clearance":"The total clearance of satralizumab is concentration-dependent and is estimated to be 0.0601-0.0679 L\/day.[L15536,L15546] The inter-compartmental clearance was 0.336 L\/day.[L15536]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Interleukin inhibitors IMMUNOSUPPRESSANTS","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Interleukin-6 (IL-6) is a pro-inflammatory cytokine[A218546] which has been implicated in the pathogenesis of NMOSD.[A218551] The inflammatory cascade triggered by IL-6 signaling is thought to result in the differentiation of T-cells into pro-inflammatory TH17 cells[A218551] and the differentiation of B-cells into plasmablasts producing AQP4 autoantibodies.[A218551,A218546] IL-6 may also play a role in increasing the permeability of the blood-brain barrier, thereby allowing penetration of autoantibodies and pro-inflammatory mediators into the central nervous system.[A218551,A218546]\r\n\r\nSatralizumab is a humanized monoclonal antibody targeted against human IL-6 receptors.[L15536] It binds to soluble and membrane-bound IL-6 receptors and prevents the signaling cascade, and subsequent pro-inflammatory effects, associated with its binding to endogenous IL-6.","drug-interactions":"DB01194 DB00328 DB00682 DB00825 DB08953 DB00928 DB08880 DB09124 DB15274 DB09381 DB13456 DB14649 DB12457 DB15091 DB00656 DB09198 DB09052 DB08980 DB06737 DB00382 DB15857 DB09570 DB00204 DB00540 DB06712 DB01142 DB00637 DB00092 DB12130 DB00970 DB15035 DB08828 DB04951 DB00034 DB00814 DB01215 DB00338 DB09273 DB12945 DB00280 DB01200 DB00642 DB05708 DB14132 DB00177 DB13068 DB00495 DB03756 DB11921 DB01409 DB00105 DB06228 DB01223 DB00395 DB00957 DB00305 DB01086 DB06772 DB16650 DB00962 DB00277 DB00557 DB01595 DB09195 DB01229 DB08922 DB12235 DB00321 DB00503 DB07615 DB11919 DB15646 DB00863 DB12386 DB06148 DB12781 DB00220 DB12952 DB01256 DB01590 DB00665 DB01129 DB13843 DB09026 DB09030 DB05316 DB00490 DB00806 DB01067 DB13867 DB04908 DB01124 DB04652 DB04957 DB16611 DB00700 DB00531 DB01075 DB08970 DB00912 DB12825 DB00108 DB00631 DB12814 DB01065 DB13136 DB00888 DB00546 DB11828 DB08932 DB01558 DB01396 DB00853 DB11901 DB01551 DB00741 DB08865 DB13203 DB01039 DB12329 DB00367 DB00222 DB00839 DB11823 DB00246 DB13208 DB13293 DB10804 DB11044 DB14685 DB15119 DB09082 DB09383 DB14541 DB01117 DB09234 DB00778 DB15102 DB00787 DB00358 DB04356 DB00238 DB14445 DB00851 DB01708 DB05676 DB06739 DB10584 DB00959 DB08820 DB00281 DB11703 DB00268 DB01320 DB00136 DB11003 DB13981 DB00834 DB00773 DB13943 DB01323 DB01319 DB04828 DB01259 DB09074 DB01624 DB06717 DB00008 DB00120 DB00547 DB04938 DB00945 DB00428 DB00440 DB00820 DB01062 DB09299 DB13954 DB06813 DB01466 DB10990 DB01033 DB00708 DB14009 DB12332 DB09080 DB00987 DB00240 DB00370 DB01274 DB01216 DB00731 DB00324 DB00599 DB00276 DB10061 DB11742 DB05521 DB11951 DB13488 DB00758 DB05812 DB00098 DB01204 DB01281 DB01191 DB01100 DB09101 DB11641 DB05942 DB04868 DB14723 DB08881 DB11575 DB00788 DB00549 DB06595 DB06119 DB00877 DB06479 DB00552 DB01182 DB06290 DB00846 DB14018 DB01184 DB01257 DB00906 DB00402 DB00908 DB11976 DB06616 DB00738 DB00033 DB01005 DB00091 DB12406 DB05039 DB14711 DB09227 DB09225 DB11633 DB06725 DB06292 DB14973 DB00351 DB00612 DB13158 DB00598 DB11689 DB01175 DB11613 DB14064 DB00299 DB14540 DB00180 DB00949 DB15626 DB06589 DB00253 DB00872 DB01201 DB00749 DB08870 DB00266 DB00420 DB00980 DB14538 DB10276 DB01015 DB08906 DB01410 DB00214 DB16390 DB14055 DB00983 DB01583 DB09238 DB00022 DB00203 DB00169 DB00213 DB06738 DB00476 DB13014 DB14919 DB12001 DB04839 DB06448 DB05459 DB12015 DB02703 DB00586 DB00715 DB12629 DB13573 DB00327 DB00784 DB00526 DB11952 DB10283 DB00334 DB01156 DB14019 DB00414 DB00601 DB01120 DB08873 DB00977 DB00468 DB17088 DB00924 DB00270 DB00993 DB00072 DB12010 DB00641 DB13835 DB15328 DB11988 DB13955 DB00629 DB14619 DB00307 DB00823 DB06155 DB01234 DB06654 DB11978 DB00706 DB04856 DB12026 DB03451 DB00582 DB01241 DB02134 DB06605 DB01283 DB15463 DB00674 DB00635 DB00304 DB00724 DB01536 DB00363 DB14066 DB01094 DB01412 DB00312 DB11616 DB00316 DB10317 DB16736 DB04871 DB01435 DB09063 DB09183 DB08838 DB04884 DB00294 DB11834 DB00628 DB01206 DB00870 DB00313 DB10062 DB00297 DB00193 DB12147 DB12500 DB09378 DB09318 DB15656 DB14022 DB06237 DB09122 DB00069 DB09288 DB04835 DB00936 DB12025 DB14543 DB00822 DB06203 DB11757 DB09053 DB00568 DB05246 DB13874 DB11041 DB00831 DB09068 DB15444 DB14678 DB00705 DB13399 DB00617 DB00734 DB00783 DB01227 DB05109 DB01195 DB00469 DB00432 DB11094 DB12530 DB09166 DB08896 DB00624 DB03701 DB00532 DB01097 DB00224 DB13449 DB14544 DB01251 DB00394 DB00604 DB00065 DB05541 DB14063 DB01816 DB01118 DB15133 DB12267 DB08867 DB08904 DB08910 DB08059 DB00559 DB00471 DB11886 DB16165 DB12917 DB08794 DB00454 DB00176 DB01104 DB05015 DB11708 DB11712 DB00550 DB15628 DB11960 DB11718 DB01095 DB00401 DB01357 DB01008 DB11730 DB01041 DB00921 DB09555 DB09033 DB01058 DB01192 DB01418 DB11574 DB11637 DB13725 DB09200 DB06207 DB01108 DB00201 DB00343 DB00496 DB00622 DB06789 DB14068 DB11560 DB04838 DB00396 DB06446 DB13766 DB06372 DB11603 DB01280 DB11636 DB00590 DB01181 DB06603 DB06713 DB13685 DB01130 DB00690 DB00978 DB08893 DB00812 DB13345 DB00379 DB01114 DB10600 DB06414 DB10769 DB01384 DB00591 DB00818 DB00377 DB01355 DB10794 DB04934 DB01026 DB09095 DB14570 DB06168 DB01248 DB00615 DB00849 DB01099 DB01134 DB13866 DB00717 DB00661 DB01037 DB01303 DB09118 DB12996 DB09083 DB00404 DB11697 DB04889 DB00502 DB12543 DB00932 DB01289 DB04948 DB00486 DB11050 DB14881 DB08908 DB08879 DB13924 DB00252 DB06235 DB11853 DB01047 DB01244 DB00763 DB14761 DB06662 DB00353 DB05467 DB06612 DB01016 DB01054 DB13956 DB14011 DB00195 DB01167 DB13953 DB01056 DB00384 DB00619 DB01268 DB11569 DB01405 DB09317 DB01002 DB05239 DB13385 DB00603 DB11580 DB06670 DB00445 DB06685 DB14545 DB00518 DB00956 DB00745 DB03523 DB00290 DB00322 DB02546 DB15566 DB01411 DB00188 DB00564 DB09199 DB00398 DB05667 DB11750 DB01173 DB11581 DB13961 DB12531 DB08439 DB04833 DB06730 DB08864 DB13634 DB00234 DB06742 DB01105 DB06684 DB06144 DB06777 DB08899 DB09065 DB09077 DB12471 DB09236 DB13944 DB13003 DB09291 DB11362 DB01050 DB04896 DB00075 DB04905 DB01006 DB00843 DB09201 DB09241 DB16098 DB14724 DB10343 DB03515 DB01587 DB00412 DB01392 DB00078 DB11614 DB12947 DB01232 DB00295 DB08931 DB06584 DB13950 DB01263 DB01482 DB16648 DB00442 DB00911 DB00636 DB00755 DB14185 DB00589 DB04956 DB14443 DB00736 DB01166 DB04898 DB01211 DB09235 DB06643 DB00073 DB14449 DB14394 DB12941 DB06287 DB04630 DB09049 DB00675 DB00904 DB06403 DB00455 DB12537 DB00528 DB01611 DB06282 DB08815 DB14783 DB14542 DB01029 DB00441 DB00373 DB10989 DB01456 DB11040 DB00480 DB09089 DB06016 DB01431 DB04946 DB09230 DB14737 DB00215 DB00248 DB06626 DB01591 DB01601 DB00242 DB06781 DB14384 DB14620 DB13791 DB06152 DB01072 DB06774 DB00672 DB00625 DB06218 DB09048 DB00291 DB08895 DB06786 DB00751 DB01267 DB00580 DB08907 DB06688 DB01154 DB01242 DB01254 DB00679 DB01483 DB00111 DB00068 DB04665 DB00836 DB01380 DB15810 DB01236 DB01656 DB01169 DB01420 DB06700 DB00477 DB06480 DB00889 DB00208 DB09330 DB06210 DB06702 DB12991 DB06762 DB01023 DB09237 DB12597 DB06234 DB00859 DB11487 DB00349 DB00997 DB01394 DB04829 DB00374 DB15654 DB12131 DB01393 DB00296 DB05294 DB01621 DB14921 DB06652 DB00796 DB12612 DB00250 DB01138 DB00443 DB00554 DB06335 DB14583 DB04845 DB09017 DB11817 DB15233 DB08860 DB13074 DB00813 DB00461 DB04975 DB16691 DB00433 DB09128 DB11619 DB14385 DB05144 DB00694 DB09239 DB05472 DB00865 DB00864 DB03783 DB01367 DB00446 DB04841 DB01024 DB06273 DB05325 DB15483 DB14975 DB00688 DB05212 DB05351 DB14631 DB13592 DB00808 DB00185 DB04842 DB14065 DB00934 DB04743 DB09289 DB00381 DB00191 DB12278 DB08833 DB01049 DB01196 DB00544 DB00757 DB06681 DB00261 DB01013 DB08992 DB00317 DB00465 DB01018 DB06636 DB09143 DB11693 DB11466 DB08971 DB09223 DB12692 DB13812 DB01589 DB13179 DB01131 DB04914 DB00990 DB15685 DB02568 DB09229 DB16732 DB12568 DB06176 DB09054 DB14512 DB00747 DB11038 DB00976 DB01262 DB00969 DB00860 DB00972 DB13602 DB00593 DB12674 DB00288 DB13857 DB04076 DB15595 DB00051 DB10318 DB00497 DB01623 DB00829 DB09216 DB02489 DB10803 DB00163 DB01098 DB00207 DB00539 DB00567 DB11915 DB00197 DB09073 DB15031 DB00588 DB00696 DB11251 DB00333 DB00095 DB01177 DB14845 DB00026 DB00470 DB11529 DB00488 DB00958 DB00286 DB00458 DB01221 DB11586 DB02806 DB05885 DB12265 DB05154 DB01149 DB01076 DB09262 DB14762 DB00730 DB09090 DB11791 DB13675 DB09091 DB00697 DB01132 DB01224 DB10991 DB13919 DB10805 DB06077 DB15011 DB08868 DB00740 DB08871 DB00802 DB00356 DB00499 DB00199 DB00759 DB00907 DB01198 DB08903 DB06697 DB09071 DB00794 DB00337 DB11986 DB00380 DB12902 DB05440 DB09079 DB08875 DB01036 DB16694 DB01222 DB13856 DB14539 DB12161 DB00857 DB15434 DB00285 DB00309 DB00514 DB11963 DB13762 DB01264 DB09389 DB12371 DB12483 DB00571 DB00608 DB08882 DB08912 DB00444 DB11642 DB12240 DB06650 DB00574 DB12923 DB00482 DB12474 DB01073 DB08816 DB09039 DB12093 DB01423 DB00347 DB00570 DB09297 DB00056 DB14409 DB01128 DB05259 DB02187 DB00744 DB08901 DB06470 DB01028 DB09102 DB00041 DB09036 DB11803 DB00359 DB06710 DB00393 DB04861 DB08889 DB01030 DB00320 DB01349 DB04855 DB01667 DB01395 DB00378 DB01260 DB00982 DB00530 DB12617 DB13347 DB00563 DB06708 DB01174 DB08877 DB11737 DB00655 DB11796 DB00081 DB05374 DB00318 DB00018 DB00352 DB13491 DB12768 DB00678 DB06268 DB00087 DB11274 DB00216 DB04920 DB14568 DB06400 DB00011 DB14513 DB00315 DB06216 DB01285 DB00346 DB12092 DB05482 DB11767 DB13952 DB00910 DB01544 DB12927 DB09256 DB00439 DB09213 DB12301 DB01218 DB09231 DB08496 DB13941 DB12515 DB00938 DB09029 DB00850 DB09232 DB00365 DB11635 DB00764 DB01087 DB04557 DB00795 DB09371 DB05260 DB12245 DB08935 DB00647 DB00663 DB05271 DB16703 DB13241 DB00059 DB15461 DB01588 DB14840 DB06674 DB06370 DB11967 DB06803 DB02789 DB01103 DB11739 DB01168 DB00293 DB06212 DB06209 DB01261 DB06419 DB13528 DB00342 DB08883 DB00726 DB00896 DB13223 DB06267 DB00897 DB10583 DB09061 DB00227 DB00448 DB05258 DB09240 DB00998 DB01190 DB00361 DB00620 DB00862 DB04574 DB16236 DB00673 DB00909 DB01136 DB06780 DB11942 DB00712 DB00575 DB00683 DB01424 DB13500 DB06770 DB00243 DB01645 DB06769 DB04725 DB14669 DB00186 DB11627 DB01159 DB11799 DB12016 DB11776 DB13609 DB15253 DB09034 DB01171 DB00602 DB08827 DB01238 DB01012 DB01253 DB00946 DB01628 DB10316 DB15149 DB13406 DB09123 DB08918 DB05773 DB00425 DB04572 DB01101 DB06594 DB14219 DB09057 DB11130 DB13746 DB00762 DB01559 DB12141 DB00074 DB06343 DB12926 DB11837 DB00247 DB00918 DB01233 DB00255 DB04825 DB01074 DB13007 DB12887 DB15822 DB00262 DB09290 DB00515 DB00472 DB00541 DB00898 DB01042 DB01115 DB09312 DB00533 DB00687 DB00701 DB08962 DB00005 DB10315 DB01068 DB01388 DB11273","absorption":"The C<sub>max<\/sub> and AUC at steady-state, achieved after an 8-week loading period, were approximately 31.5 mcg\/mL and 737 mcg.mL\/day, respectively.[L15536] Average C<sub>trough<\/sub> concentrations were approximately 19 mcg\/mL.[L15546] The bioavailability of satralizumab following subcutaneous injection has been reported to be between 78.5% and 85%.[L15536,L15546]","created":"2020-08-18","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The terminal half-life of satralizumab is approximately 30 days (range 22-37 days).[L15536]","monoisotopic-mass":null,"volume-of-distribution":"Satralizumab is subject to biphasic distribution - the estimated volume of distribution for the central and peripheral compartments are 3.46 L and 2.07 L, respectively.[L15546]","route-of-elimination":"Monoclonal antibodies are typically eliminated via uptake into cells and subsequent catabolism via lysosomal degradation. Due to their large size, they are only eliminated renally under pathologic conditions.[A216712]","name":"Satralizumab","metabolism":"While the metabolism of satralizumab has not been studied directly,[L15536] monoclonal antibodies as a class are principally cleared by catabolism.[L15536,A216712]","reactions":null,"indication":"Satralizumab is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.[L15536] In Canada, it is also used in adolescent patients for the same indication.[L15546]","ahfs-codes":null,"updated":"2022-06-03","drugbank-id":"DB15762"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":449.163,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"53858-86-9","sequences":null,"targets":null,"unii":"UM5219H89V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00537 DB01208 DB13760 DB00213 DB11443 DB06255 DB00254 DB01142 DB00334 DB08805 DB13486 DB00720 DB00759 DB00399 DB13264 DB12884 DB05143 DB00338 DB12035 DB00451 DB13249 DB02423 DB00166 DB13823 DB13762 DB14048 DB15617 DB01137 DB00827 DB00736 DB12455 DB13261 DB09413 DB09104 DB13995 DB07841 DB09139 DB01390 DB01377 DB00863 DB01129 DB09414 DB00884 DB01155 DB13650 DB14517 DB01235 DB09147 DB14481 DB11348 DB14523 DB13772 DB01077 DB00535 DB00751 DB06723 DB11943 DB00453 DB00085 DB11404 DB11511 DB06600 DB11491 DB00282 DB06210 DB08806 DB12770 DB06216 DB00859 DB01044 DB09449 DB08826 DB11892 DB08938 DB04576 DB00365 DB00487 DB09481 DB00190 DB13626 DB00927 DB00618 DB00501 DB01069 DB00256 DB05351 DB00779 DB00467 DB06782 DB00595 DB11493 DB00448 DB11739 DB01165 DB00978 DB00585 DB00630 DB00968 DB00218 DB04160 DB00931 DB00685 DB02552 DB08930 DB06824 DB01059 DB06160 DB13829 DB02369 DB06724 DB01017 DB00940 DB00817 DB13322 DB09281 DB01133 DB05488 DB00710 DB13627 DB13280 DB11774 DB01405 DB13595 DB08972","absorption":null,"created":"2020-08-19","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":449.059366,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iron polymaltose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15763"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":213.236,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"94-44-0","sequences":null,"targets":null,"unii":"S497LCF9C9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-19","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":213.078978598,"volume-of-distribution":null,"route-of-elimination":null,"name":"Benzyl nicotinate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15764"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"external side of plasma membrane","enzymes":null,"type":"biotech","cas-number":"2072873-06-2","sequences":null,"targets":"BE0003436","unii":"8FU7FQ8UPK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sintilimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15765"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"external side of plasma membrane","enzymes":null,"type":"biotech","cas-number":"2079108-44-2","sequences":null,"targets":"BE0003436","unii":"2Y3T5IF01Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS PD-1\/PDL-1 (Programmed cell death protein 1\/death ligand 1) inhibitors MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES ANTINEOPLASTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Retifanlimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15766"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"external side of plasma membrane","enzymes":null,"type":"biotech","cas-number":"1422184-00-6","sequences":null,"targets":"BE0003436","unii":"SKF3JJJ5QA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AMP-224","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15767"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"external side of plasma membrane","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":"BE0003436","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MEDI0680","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15768"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"endomembrane system","enzymes":null,"type":"biotech","cas-number":"2102192-68-5","sequences":null,"targets":"BE0003441","unii":"ES1M06M6QH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Envafolimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15769"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"endomembrane system","enzymes":null,"type":"biotech","cas-number":"2216751-26-5","sequences":null,"targets":"BE0003441","unii":"PNW7GBB44P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cosibelimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15770"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"endomembrane system","enzymes":null,"type":"biotech","cas-number":"1353563-85-5","sequences":null,"targets":"BE0003441","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AUNP-12","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15771"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CA-170 is a selective, small molecule inhibitor of PD-L1.","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":"BE0003441","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CA-170","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15772"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":"BE0003441","unii":"P9XVH8H2HF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-20","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"anti-OX40 antibody BMS 986178","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15773"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1131.269,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"26339-90-2","sequences":null,"targets":null,"unii":"QYK0D6H79O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1130.550903649,"volume-of-distribution":null,"route-of-elimination":null,"name":"beta-Escin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15774"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":448.603,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"24356-94-3","sequences":null,"targets":null,"unii":"OL7KC2O3OT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB14055 DB00682 DB09255 DB06754 DB09259 DB00407 DB06695 DB06679 DB00009 DB06294 DB08814 DB00254 DB12289 DB00047 DB11564 DB00759 DB06406 DB13264 DB12035 DB11095 DB09258 DB05099 DB13199 DB06228 DB06635 DB04898 DB08994 DB12455 DB01306 DB06605 DB01307 DB12598 DB13149 DB08816 DB09154 DB09030 DB08813 DB11567 DB00046 DB05229 DB03410 DB13136 DB00453 DB13347 DB04665 DB00013 DB00975 DB12329 DB00278 DB11598 DB06822 DB01225 DB00015 DB06543 DB13275 DB05115 DB06441 DB00686 DB08867 DB13616 DB00055 DB15880 DB14921 DB08794 DB00569 DB08496 DB06779 DB04932 DB05254 DB01418 DB00618 DB00256 DB01309 DB06209 DB01240 DB00560 DB12726 DB12831 DB00595 DB06404 DB05361 DB14094 DB01301 DB09260 DB11312 DB01026 DB13451 DB04925 DB09075 DB00086 DB00001 DB00030 DB11568 DB00931 DB12364 DB07767 DB00946 DB09228 DB00031 DB13646 DB06271 DB01017 DB01045 DB00498 DB00974 DB00054 DB01109 DB00029 DB09456 DB00006 DB09564 DB00071 DB00266 DB14726 DB11984 DB11166 DB13124","absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":448.261359639,"volume-of-distribution":null,"route-of-elimination":null,"name":"Algestone acetophenide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15775"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8007-70-3","sequences":null,"targets":null,"unii":"6Y89129C8H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anise oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15776"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":460.586,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"29205-06-9","sequences":null,"targets":null,"unii":"9J8AL6K50Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB00682 DB01208 DB16002 DB06272 DB09198 DB06737 DB00382 DB09217 DB11564 DB01078 DB00814 DB13446 DB00562 DB09273 DB00280 DB11397 DB01200 DB00232 DB13286 DB13432 DB01337 DB13947 DB00957 DB00605 DB01306 DB13691 DB00284 DB00368 DB08984 DB09022 DB01554 DB00732 DB01102 DB12781 DB04066 DB01067 DB13537 DB06814 DB01124 DB00046 DB00912 DB00388 DB00888 DB13136 DB01396 DB01339 DB00390 DB11201 DB00839 DB00222 DB00367 DB04846 DB01381 DB09082 DB04878 DB09067 DB00358 DB06117 DB01044 DB04891 DB11827 DB01320 DB00136 DB13981 DB00834 DB13928 DB13943 DB04828 DB11723 DB00487 DB11824 DB01432 DB00945 DB00901 DB13563 DB13954 DB01064 DB15861 DB01309 DB12610 DB00779 DB09080 DB00467 DB01274 DB01364 DB00731 DB09084 DB11412 DB13584 DB01165 DB00391 DB02901 DB05095 DB01035 DB00871 DB01471 DB00218 DB08619 DB00788 DB00939 DB00030 DB01541 DB13310 DB00685 DB01059 DB13167 DB06262 DB04892 DB00738 DB13058 DB00091 DB09045 DB05039 DB01122 DB11898 DB06725 DB00498 DB06292 DB00351 DB12545 DB01245 DB11950 DB00511 DB09265 DB05488 DB13169 DB00841 DB00749 DB00266 DB13612 DB08955 DB01397 DB01015 DB00983 DB14055 DB00169 DB00668 DB12100 DB00951 DB13467 DB04839 DB09220 DB00586 DB00784 DB00648 DB00414 DB00989 DB01120 DB00977 DB00468 DB00941 DB13097 DB02365 DB13823 DB02224 DB00823 DB01137 DB00582 DB13217 DB01277 DB12935 DB01283 DB00674 DB12268 DB00304 DB01536 DB06011 DB01435 DB09063 DB00294 DB14938 DB15171 DB06819 DB01325 DB08905 DB00606 DB01155 DB00416 DB09288 DB12025 DB00936 DB11567 DB06203 DB00999 DB01382 DB09269 DB08804 DB09218 DB13524 DB06736 DB13407 DB00146 DB00082 DB00816 DB03585 DB14678 DB11404 DB00783 DB13649 DB00469 DB13710 DB11094 DB04682 DB06410 DB14059 DB00624 DB00397 DB01251 DB01434 DB00861 DB13371 DB01199 DB08867 DB11892 DB08794 DB00153 DB00500 DB01357 DB01366 DB01418 DB01108 DB09200 DB05107 DB13668 DB09215 DB06789 DB00396 DB00545 DB11636 DB06713 DB13685 DB14035 DB00978 DB00812 DB16820 DB00585 DB00774 DB01278 DB13866 DB00717 DB08909 DB09043 DB09357 DB09295 DB01289 DB01250 DB00252 DB01524 DB13989 DB01016 DB13956 DB13953 DB13538 DB01268 DB01405 DB00603 DB00867 DB08972 DB13001 DB05804 DB16001 DB09199 DB11443 DB11156 DB13503 DB06266 DB00677 DB08439 DB06730 DB01407 DB13648 DB06655 DB13944 DB04876 DB01050 DB09201 DB00843 DB08981 DB00412 DB13958 DB01609 DB11780 DB01307 DB13261 DB00310 DB13657 DB12625 DB01363 DB05386 DB01456 DB16003 DB06250 DB01436 DB11507 DB01564 DB13544 DB13694 DB06774 DB07768 DB03410 DB00672 DB01009 DB12989 DB08907 DB00580 DB11473 DB00202 DB11943 DB04665 DB01700 DB00436 DB00357 DB01420 DB06600 DB00477 DB11491 DB08940 DB02845 DB06127 DB00565 DB00681 DB13275 DB05115 DB00573 DB12417 DB04576 DB05830 DB00554 DB06335 DB06692 DB11455 DB00461 DB11619 DB00508 DB01226 DB09212 DB00721 DB00808 DB04743 DB14031 DB11390 DB01481 DB00465 DB01408 DB03793 DB11466 DB08942 DB00805 DB01043 DB00984 DB12713 DB15217 DB00083 DB06756 DB11568 DB00711 DB11124 DB13401 DB13857 DB13527 DB13232 DB06160 DB13481 DB13946 DB05295 DB00944 DB00483 DB09216 DB01252 DB00817 DB11429 DB13295 DB00244 DB13430 DB00197 DB07402 DB12194 DB13139 DB13627 DB11774 DB09038 DB01221 DB01399 DB11992 DB00880 DB00537 DB01070 DB00392 DB00331 DB13675 DB01400 DB01132 DB00047 DB01001 DB11587 DB13629 DB01288 DB11518 DB01324 DB12482 DB12526 DB04834 DB13044 DB13783 DB09214 DB06194 DB04796 DB09389 DB00827 DB08882 DB12474 DB00482 DB01521 DB00359 DB04864 DB06710 DB01419 DB13860 DB11323 DB01395 DB13772 DB01014 DB00263 DB13347 DB11511 DB08976 DB04812 DB15317 DB00491 DB01276 DB00159 DB15614 DB00910 DB09213 DB08957 DB08496 DB00938 DB09285 DB13532 DB00728 DB00365 DB00991 DB12214 DB01401 DB00795 DB01485 DB09371 DB14027 DB13722 DB01010 DB01600 DB12412 DB16625 DB01261 DB13528 DB12445 DB04574 DB04830 DB00712 DB13314 DB01021 DB01424 DB04725 DB13451 DB11698 DB12399 DB01628 DB00946 DB13406 DB09123 DB14060 DB01336 DB11871 DB08382 DB01338 DB13587 DB00981 DB04572 DB04258 DB01135 DB00221 DB00821 DB01291 DB01233 DB00255 DB00515 DB08951 DB09456 DB13495 DB09564 DB08797 DB08991 DB00071 DB00914 DB00524 DB00533 DB08962 DB04552","absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":460.262502454,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluocortolone pivalate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15777"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":127.912,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"10034-85-2","sequences":null,"targets":null,"unii":"694C0EFT9Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":127.9123,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hydrogen iodide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15778"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":387.23,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"78266-06-5","sequences":null,"targets":null,"unii":"7PV0B6ED98","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":386.047735,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mebrofenin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15779"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":263.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"66516-09-4","sequences":null,"targets":null,"unii":"8NVY8268MY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":263.057591705,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mertiatide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15780"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Hu-rhEGF-rP64k\/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hu-rhEGF-rP64k\/Mont","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15781"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":480.862,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"540-10-3","sequences":null,"targets":null,"unii":"5ZA2S6B08X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":480.490631301,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cetyl palmitate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-21","drugbank-id":"DB15782"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":337.419,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"13479-13-5","sequences":null,"targets":null,"unii":"UC61HM8FX0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":337.167793605,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pargeverine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-17","drugbank-id":"DB15783"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":368.433,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"147568-66-9","sequences":null,"targets":null,"unii":"9810NUL4D1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":368.173607261,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carmoterol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15784"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":265.441,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7712-50-7","sequences":null,"targets":null,"unii":"9902116282","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":265.240564622,"volume-of-distribution":null,"route-of-elimination":null,"name":"Myrtecaine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15785"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"50JZ5Z98QY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB00682 DB00928 DB08953 DB13400 DB00656 DB09052 DB06679 DB06737 DB08814 DB12289 DB06251 DB11133 DB09217 DB00970 DB13875 DB13876 DB00034 DB00814 DB09253 DB01247 DB14006 DB00642 DB13510 DB00495 DB13286 DB13432 DB13199 DB00105 DB06228 DB00305 DB00605 DB06772 DB08984 DB01229 DB07615 DB01590 DB09030 DB00806 DB03619 DB00531 DB12814 DB00631 DB00888 DB13136 DB00853 DB11201 DB00278 DB01381 DB15119 DB00851 DB04017 DB00773 DB04828 DB09074 DB00008 DB00120 DB04818 DB02659 DB00945 DB00428 DB01033 DB12610 DB01240 DB00987 DB12726 DB09249 DB00276 DB08550 DB09084 DB01204 DB00758 DB05095 DB00086 DB04868 DB00788 DB00939 DB00552 DB00877 DB13233 DB12364 DB07767 DB00031 DB13167 DB00775 DB09251 DB06616 DB00033 DB01005 DB06271 DB14973 DB06725 DB00498 DB12545 DB09539 DB00614 DB00054 DB01109 DB01175 DB00749 DB00266 DB13612 DB08955 DB01397 DB13124 DB14055 DB00022 DB00476 DB06695 DB00715 DB00586 DB00784 DB00526 DB00601 DB01626 DB11095 DB00307 DB02224 DB06654 DB05099 DB02709 DB06635 DB08994 DB13217 DB06605 DB01283 DB13149 DB01435 DB04884 DB14938 DB01206 DB09154 DB09122 DB00069 DB09288 DB08813 DB00936 DB06807 DB09053 DB09218 DB13524 DB06736 DB13407 DB09068 DB03585 DB05109 DB13649 DB00469 DB01225 DB14059 DB00015 DB06543 DB00861 DB13371 DB13616 DB15880 DB00055 DB08910 DB09243 DB08794 DB00569 DB00176 DB01104 DB05015 DB00550 DB00500 DB09250 DB01008 DB01041 DB01418 DB09215 DB12749 DB01280 DB14094 DB01181 DB00780 DB00812 DB09543 DB01248 DB01099 DB01037 DB01207 DB00932 DB09295 DB01250 DB09245 DB00763 DB00619 DB13538 DB13001 DB00445 DB11984 DB13367 DB09259 DB14026 DB00322 DB02546 DB00188 DB00564 DB00398 DB08439 DB06294 DB06777 DB01105 DB09077 DB06406 DB01050 DB04896 DB04905 DB08857 DB09241 DB08981 DB15575 DB08834 DB00078 DB06081 DB04898 DB01166 DB00073 DB06287 DB01294 DB13657 DB00441 DB13509 DB00480 DB00215 DB00242 DB13544 DB02123 DB09211 DB03410 DB00291 DB08895 DB01009 DB00580 DB01254 DB01088 DB09283 DB00068 DB04665 DB11598 DB01169 DB06700 DB00208 DB08940 DB08887 DB00859 DB13275 DB12771 DB00573 DB06441 DB00374 DB00997 DB01138 DB00554 DB04845 DB13327 DB11455 DB06779 DB00461 DB09254 DB00694 DB00752 DB05472 DB04932 DB00864 DB01367 DB00446 DB09212 DB00721 DB04743 DB08833 DB00544 DB00261 DB01586 DB12693 DB09260 DB05767 DB09042 DB00465 DB11466 DB00805 DB08942 DB11312 DB09075 DB01262 DB04820 DB12321 DB04832 DB13527 DB13232 DB13646 DB13481 DB13929 DB09216 DB00244 DB00063 DB09073 DB07402 DB00029 DB01177 DB00488 DB00958 DB01399 DB11166 DB01149 DB09255 DB06754 DB11789 DB00407 DB00009 DB08871 DB13629 DB00380 DB11518 DB15434 DB13783 DB00309 DB00285 DB09258 DB09214 DB05266 DB01296 DB00444 DB12598 DB00482 DB01073 DB13036 DB08816 DB00570 DB00056 DB04348 DB09248 DB00041 DB08901 DB08889 DB01419 DB01030 DB13860 DB11323 DB05229 DB01014 DB13347 DB00563 DB00013 DB00975 DB08877 DB06822 DB00081 DB08976 DB00018 DB00352 DB04812 DB00087 DB00159 DB00011 DB12465 DB00686 DB12092 DB00233 DB09213 DB08496 DB09285 DB00991 DB01401 DB00795 DB09246 DB08935 DB05254 DB13722 DB12163 DB01600 DB09252 DB00293 DB06209 DB05990 DB12831 DB06731 DB05361 DB05258 DB12445 DB00361 DB00712 DB13314 DB01424 DB06769 DB04725 DB13451 DB04925 DB11622 DB00001 DB12399 DB09244 DB01171 DB01628 DB00946 DB08918 DB14060 DB05773 DB01101 DB04572 DB00762 DB02691 DB00974 DB00821 DB01168 DB00515 DB00262 DB08951 DB00472 DB01042 DB00006 DB08797 DB08991 DB14726 DB00533 DB04552","absorption":null,"created":"2020-08-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Maritime pine extract","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15786"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.[L15596]  It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-25","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD7442","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-26","drugbank-id":"DB15787"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the \"flu shot\", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or \"antigen\". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.\r\n\r\nThere are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from \"wild-type\" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"G1T4TD4PZC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-26","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza B virus B\/Phuket\/3073\/2013 BVR-1B antigen (formaldehyde inactivated)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-28","drugbank-id":"DB15788"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"8584IDD6OR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alpinia officinarum leaf","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-28","drugbank-id":"DB15789"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":317.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"5668-06-4","sequences":null,"targets":null,"unii":"U8V8239CRM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":317.1546421,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mecloxamine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15790"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":685.58,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"cell surface","enzymes":null,"type":"small molecule","cas-number":"865110-07-2","sequences":null,"targets":"BE0010014","unii":"S441P37178","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":684.1324593,"volume-of-distribution":null,"route-of-elimination":null,"name":"MK-0668","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-08-28","drugbank-id":"DB15791"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":411.7,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"127-82-2","sequences":null,"targets":null,"unii":"4O71YT5YB5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-28","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":409.910852,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc phenolsulfonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15793"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-28","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Solcoseryl","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15794"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":311.425,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"64-95-9","sequences":null,"targets":null,"unii":"YKG6OR043Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-08-31","groups":"approved withdrawn","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":311.188529049,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adiphenine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB15795"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":485.55,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GC-376 is a 3C-like protease (3CL<sup>pro<\/sup> or M<sup>pro<\/sup>) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells[A219036]. The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056]. In addition, GC-376 displays potent activity against various coronaviruses such as feline, ferret, and mink M<sup>pro<\/sup> coronavirus[A219026,A219031,A219036,A219041]. A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro<\/sup> _in vitro_, and results show potent inhibition of this target[A219036]. These results suggest that GC-376, and its metabolites may have therapeutic potential for Covid-19.","enzymes":null,"type":"small molecule","cas-number":"1417031-79-8","sequences":null,"targets":"BE0010016 BE0010017 BE0010018 BE0010020 BE0010019","unii":"O9H5KY11SV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":485.183186144,"volume-of-distribution":null,"route-of-elimination":null,"name":"GC-376 free acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-03","drugbank-id":"DB15796"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":403.479,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, [GC-376 free acid][A219031,A219036]. It is an inhibitor of M<sup>pro<\/sup> (otherwise known as 3CL<sup>pro<\/sup>), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription[A219036]. GC-373 has been shown to inhibit the M<sup>pro<\/sup> target in various coronavirus strains, including feline, mink, and ferret M<sup>pro<\/sup> [A219041]. Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov-2 M<sup>pro<\/sup> [A219036]. The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].","enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":"BE0010016 BE0010017 BE0010018 BE0010020 BE0010019","unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":403.210721046,"volume-of-distribution":null,"route-of-elimination":null,"name":"GC-373","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-03","drugbank-id":"DB15797"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis. Its use has shown clinical improvement, rapid bacterial clearance, and enhanced immune responses to Mycobacterium leprae antigens. \r\n\r\nM.w immunization activates macrophages and lymphocytes upon administration. It has protective efficacy against M. tuberculosis and M. leprae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Mycobacterium w. Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15798"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"LNP-nCoVsaRNA Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-20","drugbank-id":"DB15799"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C. \r\nThis vaccine causes induction of bactericidal antibodies with broad cross-reactivity. Novel antigens such as -glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study. This vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"VA-MENGOC-BC","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-13","drugbank-id":"DB15800"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The bacille Calmette-Gurin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization. Currently, this recombinant vaccine has been found to be more efficacious and safer than BCG in preclinical studies. \r\n\r\nVPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other BCG versions due to the lack of the RD2 genome segment. This vaccine\u20ACs urease C gene is replaced with the listeriolysin O encoding gene from Listeria monocytogenes. By reducing urease C, phagosome acidification can occur, promoting phagolysosome fusion while also providing the optimal low pH for listeriolysin O stability. \r\n\r\nVPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"VPM1002","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15801"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).\r\n\r\nThe vaccine is created from the receiving patients\u20AC isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration. \r\n\r\nThe vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252)  to test the vaccine.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AV-COVID-19","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15802"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation. \r\n\r\nAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dendritic cells vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-13","drugbank-id":"DB15803"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). \r\n\r\n\r\nAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"LV-SMENP Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15804"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. \r\n\r\nThe vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"SCB-2019","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15805"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation[A219758]. It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the rhesus macaque. The antibodies were found to neutralize 10 representative SARS-CoV-2 strains. As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety and immunogenicity.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"M1QXB372B8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CoronaVac","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-14","drugbank-id":"DB15806"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BBIBP-CorV vaccine contains a SARS-CoV-2 strain inactivated inside Vero Cells. Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques[A219763]. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BBIBP-CorV","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-13","drugbank-id":"DB15807"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CIGB 2020 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15808"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens (RPCEC00000313).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CIGB-258 peptide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15809"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Nuvaxovid contains a recombinant spike (S) protein and saponin-based Matrix-M adjuvant that induce strong cellular and humoral immune responses in humans and across several animal models against SARS-CoV-2;[A243789, A243794, A243799] a two-dose regimen results in vaccine efficacy rates of ~90%.[A243804, L39534] As with all vaccines, nuvaxovid carries a risk of hypersensitivity and other injection-related reactions; it should be given with caution to those receiving anticoagulant therapy, those with thrombocytopenia or a coagulation disorder, and in those suffering from an acute infection or febrile illness. Protection may not be complete until at least seven days following the second dose, and immunocompromised individuals may not benefit from the same level of protection as immunocompetent individuals. The duration of protection afforded by the recommended dosing schedule remains unknown.[L39534]","msds":null,"description":"SARS-CoV-2, the causative agent of COVID-19, relies on the interaction between its trimeric spike (S) glycoprotein and angiotensin-converting enzyme 2 (hACE2) expressed on host cells in order to establish a productive infection in humans.[A243789] Antibodies directed against the S protein are capable of blocking S-hACE2 interactions and neutralizing viral particles and are present in convalescent patients and those who have been inoculated against COVID-19. Nuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated expression in Sf9 cells derived from _Spodoptera frugiperda_ together with a Matrix-M adjuvant (Fractions A and C from _Quillaja saponaria_ extract).[A243789, L39534] The resulting stable perfusion S protein nanoparticles are thermostable and capable of inducing productive cellular and humoral immune responses in humans and across a wide range of animal models.[A243789, A243794, A243799]\r\n\r\nThe European Commission granted Novavax conditional marketing authorization for nuvaxovid for active immunization to prevent COVID-19 caused by SARS-CoV-2 on December 20, 2021.[L39534] On February 17, 2022, nuvaxovid was approved by Health Canada.[L40548,L40553] On July 13, 2022, nuvaxovid was granted an emergency use authorization by the FDA for the prevention of COVID-19 in adults, which was expanded to include patients \u203012 years of age in August 2022.[L42450,L42965]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"UK9AK2IN1P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":"Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G: SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038\/s41467-020-20653-8.","mechanism-of-action":"Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is associated with a spectrum of illness from asymptomatic infection to a severe disease requiring hospitalization and supplemental oxygen and can be fatal. The SARS-CoV-2 spike (S) protein is a class I fusion glycoprotein with an RRAR furin-like cleavage site that gives rise to the S2 stalk and S1 cap; non-covalent assembly of three S1\/S2 protomers gives rise to the functional S-trimer. Upon binding to its receptor, human angiotensin-converting enzyme 2 (hACE2), the S protein undergoes significant structural rearrangement to expose the hydrophobic fusion peptide that mediates membrane fusion and intracellular viral particle release. The S-hACE2 interaction, therefore, represents a critical step in SARS-CoV-2 infection.[A243789]\r\n\r\nGiven the important role of the S protein in infection, active immunization with S protein mRNA or protein variants remains an important strategy in controlling COVID-19. Nuvaxovid comprises a recombinant S protein, with a mutated furin-like cleavage site (682-QQAQ-685) and two proline substitutions (K986P and V987P), produced using Sf9 cells, together with a saponin-based Matrix-M adjuvant.[A243789, L39534] The recombinant S protein forms thermostable 27.2 nm nanoparticles that bind hACE2 with an IC<sub>50<\/sub> of 18 ng mL<sup>-1<\/sup>. Active immunization in mice with 0.1-10 g S protein\/5 g Matrix-M had significantly higher anti-S IgG titers, higher CD4<sup>+<\/sup>\/CD8<sup>+<\/sup> effector cells counts, higher germinal centre Tfh\/B cell counts, higher levels of type I (IFN-) and type II (IL-4 and IL-5) cytokines, and decreased viral load; these metrics were associated with improved lung histopathology.[A243789] Similar results were obtained in non-human primates and human volunteers during phase I\/II clinical trials.[A243789, A243794, A243799]\r\n\r\nOverall, nuvaxovid, given as a two-dose regimen with Matrix-M adjuvant, appears to induce mature antibody subclass (IgG\/IgA) production and a general trend towards a Th1 over a Th2 cellular immune response.[A243789, A243794, A243799]","drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB02806 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB00764 DB04845 DB11817 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB11569 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB00620 DB01013 DB01204 DB06603 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00588 DB00180 DB00262 DB00515 DB06589 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00687 DB00445 DB00005 DB08906 DB01410 DB03523","absorption":null,"created":"2020-09-05","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nuvaxovid","metabolism":null,"reactions":null,"indication":"Nuvaxovid is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in patients 12 years of age and older.[L39534,L44426] \r\n\r\nNuvaxovid is also available in the US under an emergency use authorization (EUA) for the prevention of COVID-19 in patients \u203012 years of age.[L42965]","ahfs-codes":null,"updated":"2022-12-23","drugbank-id":"DB15810"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020,  the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and immunogenicity of the vaccine.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BacTRL-spike","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15811"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"[COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. Immunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"V-SARS","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15812"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic \u20ACminigene\u20AC was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting cells (aAPC), and activate T-cells. \r\n\r\nAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-13","drugbank-id":"DB15813"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. \r\n\r\nDendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to both prime and boost cell responses; they are considered the most powerful antigen-presenting cells, and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells. DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. \r\n\r\nThis vaccine was developed and tested by Beijing TIL Therapeutics. As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-05","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"COVID19 s-vax loaded autologous dendritic cell vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-06","drugbank-id":"DB15814"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Boldo leaf extract allergenic extract is used in allergenic testing.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"Q4EWM09M3O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-07","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Boldo leaf extract","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15815"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":326.314,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"62008-22-4","sequences":null,"targets":null,"unii":"37SBE2S23Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":326.0314583,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium monoethylfumarate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-11","drugbank-id":"DB15816"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":310.541,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"83918-60-9","sequences":null,"targets":null,"unii":"D5767608S8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":310.05390911,"volume-of-distribution":null,"route-of-elimination":null,"name":"Magnesium monoethylfumarate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-11","drugbank-id":"DB15817"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":351.62,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"62008-21-3","sequences":null,"targets":null,"unii":"M1U6WWM55B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":349.998009,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc monoethylfumarate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-11","drugbank-id":"DB15818"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":360.402,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7259-25-8","sequences":null,"targets":null,"unii":"OC4598NZEQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-09","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":359.99734302,"volume-of-distribution":null,"route-of-elimination":null,"name":"Potassium aspartate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-01","drugbank-id":"DB15819"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"9025-56-3","sequences":null,"targets":null,"unii":"S2MZZ5DR1O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hemicellulase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-11","drugbank-id":"DB15820"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":474.613,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"303-40-2","sequences":null,"targets":null,"unii":"90893P8662","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB00682 DB01208 DB16002 DB06272 DB09198 DB06737 DB00382 DB09217 DB11564 DB01078 DB00814 DB13446 DB00562 DB09273 DB00280 DB11397 DB01200 DB00232 DB13286 DB13432 DB01337 DB13947 DB00957 DB00605 DB01306 DB13691 DB00284 DB00368 DB08984 DB09022 DB01554 DB00732 DB01102 DB12781 DB04066 DB01067 DB13537 DB06814 DB01124 DB00046 DB00912 DB00388 DB00888 DB13136 DB01396 DB01339 DB00390 DB11201 DB00839 DB00222 DB00367 DB04846 DB01381 DB09082 DB04878 DB09067 DB00358 DB06117 DB01044 DB04891 DB11827 DB01320 DB00136 DB13981 DB00834 DB13928 DB13943 DB04828 DB11723 DB00487 DB11824 DB01432 DB00945 DB00901 DB13563 DB13954 DB01064 DB15861 DB01309 DB12610 DB00779 DB09080 DB00467 DB01274 DB01364 DB00731 DB09084 DB11412 DB13584 DB01165 DB00391 DB02901 DB05095 DB01035 DB00871 DB01471 DB00218 DB08619 DB00788 DB00939 DB00030 DB01541 DB13310 DB00685 DB01059 DB13167 DB06262 DB04892 DB00738 DB13058 DB00091 DB09045 DB05039 DB01122 DB11898 DB06725 DB00498 DB06292 DB00351 DB12545 DB01245 DB11950 DB00511 DB09265 DB05488 DB13169 DB00841 DB00749 DB00266 DB13612 DB08955 DB01397 DB01015 DB00983 DB14055 DB00169 DB00668 DB12100 DB00951 DB13467 DB04839 DB09220 DB00586 DB00784 DB00648 DB00414 DB00989 DB01120 DB00977 DB00468 DB00941 DB13097 DB02365 DB13823 DB02224 DB00823 DB01137 DB00582 DB13217 DB01277 DB12935 DB01283 DB00674 DB12268 DB00304 DB01536 DB06011 DB01435 DB09063 DB00294 DB14938 DB15171 DB06819 DB01325 DB08905 DB00606 DB01155 DB00416 DB09288 DB12025 DB00936 DB11567 DB06203 DB00999 DB01382 DB09269 DB08804 DB09218 DB13524 DB06736 DB13407 DB00146 DB00082 DB00816 DB03585 DB14678 DB11404 DB00783 DB13649 DB00469 DB13710 DB11094 DB04682 DB06410 DB14059 DB00624 DB00397 DB01251 DB01434 DB00861 DB13371 DB01199 DB08867 DB11892 DB08794 DB00153 DB00500 DB01357 DB01366 DB01418 DB01108 DB09200 DB05107 DB13668 DB09215 DB06789 DB00396 DB00545 DB11636 DB06713 DB13685 DB14035 DB00978 DB00812 DB16820 DB00585 DB00774 DB01278 DB13866 DB00717 DB08909 DB09043 DB09357 DB09295 DB01289 DB01250 DB00252 DB01524 DB13989 DB01016 DB13956 DB13953 DB13538 DB01268 DB01405 DB00603 DB00867 DB08972 DB13001 DB05804 DB16001 DB09199 DB11443 DB11156 DB13503 DB06266 DB00677 DB08439 DB06730 DB01407 DB13648 DB06655 DB13944 DB04876 DB01050 DB09201 DB00843 DB08981 DB00412 DB13958 DB01609 DB11780 DB01307 DB13261 DB00310 DB13657 DB12625 DB01363 DB05386 DB01456 DB16003 DB06250 DB01436 DB11507 DB01564 DB13544 DB13694 DB06774 DB07768 DB03410 DB00672 DB01009 DB12989 DB08907 DB00580 DB11473 DB00202 DB11943 DB04665 DB01700 DB00436 DB00357 DB01420 DB06600 DB00477 DB11491 DB08940 DB02845 DB06127 DB00565 DB00681 DB13275 DB05115 DB00573 DB12417 DB04576 DB05830 DB00554 DB06335 DB06692 DB11455 DB00461 DB11619 DB00508 DB01226 DB09212 DB00721 DB00808 DB04743 DB14031 DB11390 DB01481 DB00465 DB01408 DB03793 DB11466 DB08942 DB00805 DB01043 DB00984 DB12713 DB15217 DB00083 DB06756 DB11568 DB00711 DB11124 DB13401 DB13857 DB13527 DB13232 DB06160 DB13481 DB13946 DB05295 DB00944 DB00483 DB09216 DB01252 DB00817 DB11429 DB13295 DB00244 DB13430 DB00197 DB07402 DB12194 DB13139 DB13627 DB11774 DB09038 DB01221 DB01399 DB11992 DB00880 DB00537 DB01070 DB00392 DB00331 DB13675 DB01400 DB01132 DB00047 DB01001 DB11587 DB13629 DB01288 DB11518 DB01324 DB12482 DB12526 DB04834 DB13044 DB13783 DB09214 DB06194 DB04796 DB09389 DB00827 DB08882 DB12474 DB00482 DB01521 DB00359 DB04864 DB06710 DB01419 DB13860 DB11323 DB01395 DB13772 DB01014 DB00263 DB13347 DB11511 DB08976 DB04812 DB15317 DB00491 DB01276 DB00159 DB15614 DB00910 DB09213 DB08957 DB08496 DB00938 DB09285 DB13532 DB00728 DB00365 DB00991 DB12214 DB01401 DB00795 DB01485 DB09371 DB14027 DB13722 DB01010 DB01600 DB12412 DB16625 DB01261 DB13528 DB12445 DB04574 DB04830 DB00712 DB13314 DB01021 DB01424 DB04725 DB13451 DB11698 DB12399 DB01628 DB00946 DB13406 DB09123 DB14060 DB01336 DB11871 DB08382 DB01338 DB13587 DB00981 DB04572 DB04258 DB01135 DB00221 DB00821 DB01291 DB01233 DB00255 DB00515 DB08951 DB09456 DB13495 DB09564 DB08797 DB08991 DB00071 DB00914 DB00524 DB00533 DB08962 DB04552","absorption":null,"created":"2020-09-09","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":474.278152519,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluocortolone caproate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15821"},{"toxicity":"Pralsetinib administered to rats at 20 mg\/kg (roughly 2.5-3.6 times the recommended human exposure) resulted in resorption of litters in pregnant female mice in 92% of pregnancies (82% complete resorption); resorption occurred at doses as low as 5 mg\/kg (0.3 times the recommended human exposure). Both male and female rats given 10 mg\/kg pralsetinib or more had observable degeneration within the testis\/ovaries. In 28-day rat and monkey studies, once-daily pralsetinib resulted in histological necrosis at doses 1.1 or more times the recommended human dose and myocardial hemorrhage at doses 2.6 or more times the recommended human dose. Also, pralsetinib induced hyperphosphatemia (rats only, dose 2.4-3.5 times the recommended human dose) and multi-organ mineralization (dose 0.11 or more times the recommended human dose).[L15986]","snp-adverse-drug-reactions":null,"average-mass":533.612,"transporters":"BE0000703 BE0003659 BE0001032 BE0003657 BE0001066 BE0001067 BE0001004 BE0004752","pharmacodynamics":"Pralsetinib exerts an anti-tumour effect through specific inhibition of the rearranged during transfection (RET) tyrosine kinase, including multiple distinct oncogenic RET fusions, mutated RET kinase domains harbouring gatekeeper mutations, and in RET kinases with a variety of activating single point mutations.[A202049, A202046, A202055, A219746, L15986] Due to pralsetinib's high selectivity for RET over other kinases, both _in vitro_ and _in vivo_,[A219751] pralsetinib has been described as having a better safety profile compared to previously used multi-kinase inhibitors.[A202049, A202046, A202055, A219746] Despite this, pralsetinib use may increase the risk of hypertension, hemorrhagic events, impaired wound healing, hepatotoxicity, interstitial lung disease\/pneumonitis, and embryo-fetal toxicity.[L15986]","msds":null,"description":"Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity.[A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, L15986]\r\n\r\nAlthough a phase 1\/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETO\u201E by Blueprint Medicines.[L15986]","enzymes":"BE0002887 BE0002363 BE0002362 BE0002638 BE0002793 BE0002433","type":"small molecule","cas-number":"2097132-94-8","sequences":null,"targets":"BE0002411 BE0009501 BE0001039 BE0000748 BE0000147 BE0002408 BE0000369 BE0002131 BE0000205 BE0004145 BE0001124","unii":"1WPE73O1WV","protein-binding":"Pralsetinib is 97.1% bound to plasma proteins regardless of concentration.[L15986]","fda-label":null,"clearance":"Pralsetinib has a mean apparent steady-state oral clearance of 9.1 L\/h (CV 60%).[L15986]","atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS Other protein kinase inhibitors PROTEIN KINASE INHIBITORS","pdb-entries":false,"food-interactions":"Take on an empty stomach. Food affects the absorption of pralsetinib. Patients should take pralsetinib either at least one hour before or at least two hours after a meal.","state":"solid","synthesis-reference":"Jason D. Brubaker, Joseph L.  Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro, \"Inhibitors of ret.\" U.S. Patent US20170121312A1, issued July 24, 2018.","mechanism-of-action":"Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development.[A202061, A202055] Constitutive RET activation is achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain leading to constitutive dimerization and subsequent autophosphorylation; the most common fusions are _KIF5B-RET_ and _CCDC6-RET_, although more than 35 genes have been reported to fuse with _RET_.[A202055, A202049, A202073] Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[A202046]\r\n\r\nPralsetinib (formerly referred to as BLU-667) was developed through screening more than 10,000 agnostically designed kinase inhibitors followed by extensive chemical modification to improve its properties. Pralsetinib displays _in vitro_ IC<sub>50<\/sub> values for both WT RET as well as several mutant forms, including CCDC6-RET, in the range of 0.3-0.4 nmol\/L, and is 100-fold more selective for RET kinase over 96% of 371 kinases tested.[A219751] It is this specific inhibition of RET kinase that is associated with anti-tumour activity and clinical benefit in patients.[A219751, A219756, L15986]\r\n\r\nDespite increased selectivity for RET over other kinases, pralsetinib has been reported to inhibit DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1-2 at clinically relevant concentrations. The significance of these findings remains uncertain.[L15986]","drug-interactions":"DB08880 DB00328 DB00682 DB08953 DB12095 DB14649 DB12457 DB00742 DB00656 DB09198 DB13259 DB06737 DB00916 DB09570 DB00540 DB00204 DB06712 DB01142 DB00970 DB00637 DB12130 DB15035 DB08828 DB04951 DB00814 DB00649 DB09185 DB12978 DB00338 DB12035 DB00845 DB00177 DB05232 DB00495 DB03756 DB13878 DB06228 DB01223 DB00957 DB01086 DB06772 DB13691 DB00962 DB00277 DB01327 DB00557 DB01229 DB08922 DB12235 DB00321 DB00503 DB07615 DB00973 DB00863 DB12781 DB01129 DB12952 DB00220 DB01256 DB01590 DB04066 DB09030 DB05316 DB01067 DB00490 DB13867 DB04908 DB00421 DB01124 DB04957 DB04690 DB00700 DB00531 DB01075 DB11855 DB00912 DB12825 DB00535 DB00631 DB09076 DB13136 DB11828 DB01127 DB01396 DB11901 DB00390 DB00741 DB08865 DB01039 DB00222 DB00367 DB00839 DB11823 DB00246 DB08735 DB00613 DB14541 DB00714 DB00787 DB00481 DB00358 DB00301 DB00238 DB02520 DB06739 DB11703 DB11827 DB00281 DB08820 DB01320 DB03553 DB13981 DB00834 DB00773 DB13943 DB01323 DB13578 DB01259 DB09074 DB01624 DB06717 DB01051 DB04938 DB02659 DB00945 DB03467 DB00440 DB00820 DB00799 DB09299 DB13563 DB01062 DB13954 DB06813 DB14009 DB13879 DB12332 DB09080 DB01274 DB01216 DB00731 DB11979 DB00012 DB11932 DB01204 DB11742 DB05521 DB11951 DB01165 DB09161 DB00758 DB11502 DB11739 DB01100 DB01035 DB09101 DB11641 DB04881 DB04868 DB14723 DB00788 DB08881 DB11575 DB00917 DB00549 DB06595 DB06119 DB00877 DB13310 DB01182 DB06290 DB14960 DB12364 DB09142 DB08930 DB01184 DB00402 DB00908 DB06616 DB00718 DB00738 DB00091 DB05039 DB09227 DB00584 DB11633 DB06725 DB06292 DB14973 DB00351 DB00612 DB02527 DB11689 DB08894 DB11613 DB14540 DB06589 DB00872 DB01201 DB00749 DB08870 DB01217 DB00266 DB06199 DB00420 DB00980 DB09046 DB01015 DB08906 DB00214 DB16390 DB05928 DB14055 DB00983 DB01583 DB00203 DB00213 DB06738 DB06695 DB00476 DB09107 DB00951 DB12001 DB04839 DB06448 DB12015 DB12319 DB00586 DB02703 DB00327 DB00784 DB00526 DB00175 DB11952 DB01156 DB14019 DB00648 DB00414 DB04851 DB01120 DB08873 DB00977 DB00468 DB01333 DB11936 DB00270 DB12712 DB12010 DB00641 DB15328 DB13955 DB00307 DB00823 DB06654 DB08502 DB11978 DB01137 DB01234 DB04856 DB12026 DB00582 DB06605 DB01283 DB00312 DB00304 DB01094 DB00363 DB11869 DB09183 DB09063 DB01435 DB00206 DB00294 DB00313 DB00297 DB00193 DB12147 DB12500 DB06237 DB09288 DB12025 DB08846 DB00936 DB00822 DB11757 DB09053 DB06721 DB00882 DB00568 DB13874 DB09068 DB15444 DB06510 DB14678 DB00705 DB00617 DB00783 DB05109 DB00432 DB01227 DB00734 DB01195 DB00469 DB12836 DB04682 DB00624 DB08896 DB00532 DB01097 DB00224 DB01251 DB00394 DB00604 DB05541 DB12532 DB01118 DB15133 DB12267 DB08867 DB08910 DB00559 DB11886 DB00471 DB16165 DB00454 DB00176 DB01104 DB01161 DB05015 DB09296 DB11712 DB01053 DB01095 DB01357 DB00401 DB01008 DB01041 DB11730 DB01092 DB00921 DB09345 DB01058 DB01418 DB11574 DB08884 DB06207 DB09200 DB00201 DB09009 DB00343 DB00622 DB06789 DB11560 DB00196 DB14068 DB00396 DB08840 DB11636 DB09342 DB00590 DB01181 DB06713 DB06603 DB00158 DB13685 DB11652 DB00833 DB00812 DB13345 DB01114 DB08893 DB06414 DB12582 DB00818 DB01355 DB01026 DB01248 DB08862 DB13866 DB00717 DB01037 DB00661 DB09118 DB13683 DB16222 DB00404 DB11697 DB00502 DB00932 DB01289 DB00486 DB11363 DB14881 DB00252 DB01045 DB11853 DB00763 DB01016 DB01054 DB13956 DB14011 DB01167 DB13953 DB00619 DB01268 DB01002 DB05239 DB13385 DB05804 DB00603 DB04847 DB06670 DB00520 DB09078 DB12799 DB00518 DB00745 DB11672 DB11800 DB00188 DB09199 DB05667 DB00398 DB00564 DB00572 DB06266 DB11581 DB08439 DB06730 DB08864 DB09065 DB08899 DB07348 DB00770 DB13944 DB09291 DB06191 DB11362 DB01050 DB04896 DB09201 DB00229 DB00843 DB09241 DB16098 DB00412 DB11614 DB08931 DB00295 DB01232 DB01263 DB14069 DB00911 DB14185 DB00755 DB14989 DB01166 DB04898 DB01211 DB08995 DB00879 DB12941 DB06287 DB09049 DB00675 DB00904 DB06403 DB00455 DB00528 DB01611 DB05889 DB00441 DB14542 DB01029 DB08836 DB15569 DB00709 DB01431 DB04946 DB14737 DB11732 DB06626 DB00248 DB00345 DB11507 DB01601 DB00242 DB02123 DB01072 DB00672 DB06774 DB06218 DB00625 DB09048 DB00645 DB08895 DB08907 DB01267 DB00943 DB00580 DB11943 DB01254 DB11760 DB01242 DB01154 DB09272 DB04665 DB00836 DB01656 DB01169 DB06700 DB00477 DB06480 DB06210 DB09330 DB01685 DB09085 DB00335 DB01023 DB09237 DB00859 DB12597 DB06234 DB09374 DB00349 DB00693 DB01394 DB00997 DB00374 DB00457 DB03496 DB04854 DB00296 DB05294 DB14921 DB06652 DB00796 DB12612 DB00250 DB11753 DB01138 DB05830 DB00554 DB01332 DB06335 DB14583 DB15233 DB11817 DB00698 DB08860 DB04845 DB00813 DB00461 DB00155 DB01220 DB11619 DB11779 DB00694 DB00300 DB09027 DB09239 DB03783 DB00864 DB04841 DB13328 DB11995 DB00721 DB14975 DB00688 DB14631 DB00750 DB00892 DB09289 DB00381 DB00544 DB01586 DB00317 DB00465 DB14126 DB06636 DB09143 DB11693 DB01131 DB01589 DB13179 DB12713 DB15685 DB09075 DB01110 DB08987 DB06176 DB13125 DB09054 DB00976 DB00969 DB04832 DB00972 DB00016 DB13401 DB11148 DB13857 DB14057 DB00900 DB00497 DB12466 DB00829 DB04540 DB01098 DB00966 DB00207 DB00244 DB00539 DB00567 DB11915 DB00408 DB00197 DB09073 DB00588 DB13139 DB00696 DB00333 DB01177 DB00369 DB00470 DB00286 DB01203 DB00458 DB01221 DB11586 DB12265 DB05154 DB01149 DB01076 DB00080 DB00537 DB01004 DB04216 DB00331 DB09008 DB00437 DB13675 DB11791 DB01132 DB09280 DB01224 DB13919 DB00360 DB06077 DB00536 DB00740 DB00802 DB00499 DB09071 DB00199 DB00907 DB01198 DB06697 DB00794 DB11986 DB00527 DB09079 DB08875 DB01036 DB01222 DB09298 DB14539 DB12161 DB00857 DB13044 DB02115 DB00309 DB00514 DB00285 DB11963 DB09137 DB01264 DB09389 DB12371 DB00950 DB12483 DB12455 DB00571 DB11642 DB08912 DB00608 DB00444 DB08882 DB00482 DB12474 DB09039 DB08816 DB00347 DB09297 DB08934 DB00570 DB04348 DB15762 DB01128 DB12151 DB00744 DB08901 DB08916 DB01028 DB09102 DB01406 DB00359 DB06240 DB08889 DB01030 DB00320 DB04855 DB01395 DB05229 DB15442 DB00530 DB13751 DB12377 DB00563 DB01174 DB00975 DB08877 DB11737 DB11796 DB00678 DB06268 DB09279 DB00216 DB14568 DB01414 DB11770 DB00346 DB13952 DB01544 DB12070 DB09256 DB00439 DB09213 DB12301 DB01218 DB11644 DB09231 DB08496 DB13941 DB12515 DB00279 DB00938 DB01079 DB00365 DB00961 DB01087 DB01126 DB00807 DB14754 DB04557 DB00795 DB09371 DB12245 DB16703 DB14840 DB06370 DB11967 DB06803 DB00275 DB00501 DB01103 DB06212 DB06209 DB01261 DB06419 DB13528 DB08883 DB00726 DB05990 DB00342 DB00896 DB06267 DB00897 DB06731 DB09061 DB15719 DB00227 DB00448 DB04574 DB00361 DB00862 DB00620 DB01190 DB16236 DB00673 DB00712 DB00909 DB01136 DB03255 DB00683 DB00575 DB01424 DB06770 DB00243 DB01645 DB06769 DB04725 DB01159 DB00669 DB12016 DB09034 DB00602 DB08827 DB01238 DB01628 DB00946 DB15149 DB13406 DB09123 DB08918 DB05773 DB04572 DB01101 DB00425 DB01183 DB01197 DB13055 DB12141 DB00762 DB00247 DB00918 DB00255 DB13007 DB01415 DB12887 DB08736 DB00472 DB00541 DB01115 DB01606 DB00533 DB08962 DB00701 DB15982 DB01068 DB01388 DB11273","absorption":"Pralsetinib given at 400 mg once daily resulted in a mean steady-state C<sub>max<\/sub> of 2830 ng\/mL (coefficient of variation, CV, 52.5%) and AUC<sub>0-24h<\/sub> of 43900 ng\\*h\/mL (CV 60.2%). The C<sub>max<\/sub> and AUC of pralsetinib increased inconsistently with increasing doses between 60 and 600 mg once daily, with a median T<sub>max<\/sub> across this range of between two and four hours. At 400 mg once daily, pralsetinib reached steady-state plasma concentration by three to five days.[L15986]\r\n\r\nPralsetinib absorption is affected by food. A single dose of 400 mg given with a high-fat meal (800 to 1000 calories with 50 to 60% of calories coming from fat) increased the mean C<sub>max<\/sub> by 104% (95% CI 65-153%), mean AUC<sub>0-<\/sub> by 122% (95% CI 96-152%), and the median T<sub>max<\/sub> from four to 8.5 hours.[L15986]","created":"2020-09-10","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Pralsetinib has a plasma elimination half-life of 14.7  6.5 hours following a single dose and 22.2  13.5 hours following multiple doses.[L15986]","monoisotopic-mass":533.266299469,"volume-of-distribution":"Pralsetinib has a mean apparent volume of distribution of 228 L (CV 75%).[L15986]","route-of-elimination":"Pralsetinib is primarily eliminated through the fecal route (73%, 66% unchanged) with a small amount found in the urine (6%, 4.8% unchanged).[L15986]","name":"Pralsetinib","metabolism":"Pralsetinib is metabolized _in vitro_ primarily by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Pralsetinib given as a single oral dose of 310 mg in healthy volunteers led to the detection of metabolites from both oxidation (M453, M531, and M549b) and glucuronidation (M709), although these constituted less than 5% of the detected material.[L15986]","reactions":null,"indication":"Pralsetinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA approved test.[L15986] It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic _RET_-mutant medullary thyroid cancer, and in this same population for the treatment of advanced or metastatic _RET_ fusion-positive thyroid cancer who require systemic therapy and for whom radioactive iodine is not appropriate.[L15986]\r\n\r\nPralsetinib is currently approved for this indication under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.[L15986]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15822"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"68333-16-4","sequences":null,"targets":null,"unii":"1PRR1V42V5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lactobacillus acidophilus","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-13","drugbank-id":"DB15823"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ferrimannitol-ovalbumin (FMOA) is an adduct between ovalbumin and the complex Fe(III)-mannitol.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ferrimannitol ovalbumin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15824"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":143.993,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"16482-55-6","sequences":null,"targets":null,"unii":"84H8Z9550J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB09139 DB11789 DB11622 DB04348 DB01218 DB14016 DB08930 DB06777 DB03619 DB02123 DB02659 DB08858 DB00252 DB08857 DB02691 DB08834 DB05990 DB11860 DB08833 DB04847 DB01586","absorption":null,"created":"2020-09-11","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":143.9615309,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dihydroxyaluminum sodium carbonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15825"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-11","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Oxerutins","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15826"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":408.424,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"29546-59-6","sequences":null,"targets":null,"unii":"72R7F44611","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-11","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":407.182378,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ciclonium bromide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15827"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":430.629,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"472-11-7","sequences":null,"targets":null,"unii":"BXI92R2VUJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":430.308309832,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ruscogenin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15830"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":130.143,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1460-34-0","sequences":null,"targets":null,"unii":"787T50HCIV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":130.062994182,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Keto-beta-methylvaleric acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-16","drugbank-id":"DB15831"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.19,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"583-91-5","sequences":null,"targets":null,"unii":"Z94465H1Y7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.035065356,"volume-of-distribution":null,"route-of-elimination":null,"name":"Desmeninol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15832"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":130.143,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"24809-08-3","sequences":null,"targets":null,"unii":"XQL9PAO004","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":130.062994182,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Keto-isoleucine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-13","drugbank-id":"DB15833"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.","enzymes":null,"type":"small molecule","cas-number":"8002-43-5","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Lecithin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-07-03","drugbank-id":"DB15834"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":540.456,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"94087-98-6","sequences":null,"targets":null,"unii":"36H4OGY275","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-15","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":540.15010814,"volume-of-distribution":null,"route-of-elimination":null,"name":"Desonide sodium phosphate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15835"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8007-20-3","sequences":null,"targets":null,"unii":"BJ169U4NLG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-15","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cedar leaf oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15836"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"DSS8V86H3Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-15","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Orthosiphon aristatus leaf","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-20","drugbank-id":"DB15838"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"6OM09RPY36","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hawthorn leaf with flower","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-16","drugbank-id":"DB15839"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8011-48-1","sequences":null,"targets":null,"unii":"YFH4WC535J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-16","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pine tar","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15840"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":222.31,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"16731-55-8","sequences":null,"targets":null,"unii":"65OE787Q7W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":221.84612843,"volume-of-distribution":null,"route-of-elimination":null,"name":"Potassium metabisulfite","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-16","drugbank-id":"DB15841"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":190.09,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7681-57-4","sequences":null,"targets":null,"unii":"4VON5FNS3C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-16","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":189.89825401,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sodium metabisulfite","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15842"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CVnCoV Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15843"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"5TP24STD1S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CVnCoV","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15844"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for \u20ACproof of concept.\u20AC The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15845"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Covax-19\u201E, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine\u20ACs adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19\u201E was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Covax-19\u201E","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15846"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7\/8 agonist adsorbed gel. The components of the vaccine include BBV152A, BBV152B, and BBV152C. Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations with both types of adjuvants. The formulation with the TLR7\/8 adjuvant specifically induced significant Th1 biased antibody responses and increased SARS-CoV-2 lymphocyte responses. Thus, as of July 2020, BBV152 is in Phase 1\/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"76JZE5DSN6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"BBV152","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15847"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. The vaccine candidate is a heterologous COVID-19 vaccine containing two components, recombinant adenovirus type 26 (rAd26) vector and recombinant adenovirus type 5 (rAd5) vector which both carry the SARS-CoV-2 spike glycoprotein. The vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo). Phase 1\/2 human trials with 76 participants evaluated the safety, tolerability, and immunogenicity of both frozen (Gam-COVID-Vac;NCT04436471) and freeze-dried (Gam-COVID-Vac Lyo;NCT04437875) vaccine candidates in June 2020, and were completed in early August 2020. Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gam-COVID-Vac","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15848"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ\u20ACs rapid response \u20ACmolecular clamp\u20AC vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established adjuvant technology, MF59, from Seqirus. The SARS-CoV-2 Sclamp Vaccine was developed within 3 weeks and moved immediately into preclinical testing through partnership with Dutch company, Viroclinics Xplore. Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response. As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). TetraQ, Australian National University (ANU), the University of Melbourne, and the Peter Doherty Institute for Infection and Immunity are also involved in the clinical component.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"SARS-CoV-2 Sclamp","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15849"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine\u20ACs ability to stimulate cancer patients\u20AC immune systems to help kill cancer cells. As of July 2020, researchers from the Ottawa Hospital and Queen\u20ACs University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over 1500 participants to evaluate the vaccine\u20ACs protective effects on cancer patients from severe COVID-19 infection (NCT04442048).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"IZT740JY57","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"IMM-101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15850"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine\u20ACs ability to stimulate cancer patients\u20AC immune systems to help kill cancer cells. As of July 2020, researchers from the Ottawa Hospital and Queen\u20ACs University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over 1500 participants to evaluate the vaccine\u20ACs protective effects on cancer patients from severe COVID-19 infection (NCT04442048).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"IMM101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15851"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and cellular responses. In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine. In addition, Medicago partnered with GlaxoSmithKline (GSK) to test its adjuvant, AS03. A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity of this vaccine candidate with or without either Cpg 1018 or AS03 (NCT04450004) in adults aged 18-55 years.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Coronavirus-Like Particle COVID-19 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15852"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The RUTI Vaccine contains fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli. The vaccine has demonstrated a reasonable safety profile and potent stimulation of the immune response against tuberculosis. Much like the BCG vaccine, the RUTI vaccine is also being tested as a prophylactic for SARS-CoV2. Sponsored by Fundaci Institut Germans Trias i Pujol, the RUTI Vaccine is being tested for prevention of COVID-19 infection in a controlled trial with 315 healthcare worker participants (NCT04453488).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"RUTI Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15853"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine. As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"MVC-COV1901","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15854"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SARS-CoV-2 mRNA vaccine (ARCoV)  is a novel mRNA coronavirus vaccine that consists of a lipid nanoparticle-encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2[A220048]. It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People\u20ACs Liberation Army (PLA) Academy of Military Sciences. Preclinical studies in mice and non-human primates has shown that intramuscular administration of ARCoV elicited a Th1-biased cellular response and robust antibodies against SARS-CoV-2[A220048]. Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"SARS-CoV-2 mRNA vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15855"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product. On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1\/2 clinical studies (NCT04463472).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"AG0301-COVID19","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15856"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson (J&J), Janssen Pharmaceutical, and the Beth Israel Deaconess Medical Center. A preclinical study in hamsters infected with SARS-COV-2 infection[A220053] showed a single immunization with the vaccine-elicited neutralizing responses and protected against SARS-CoV-2 induced pneumonia and mortality, providing protection against the disease progression. Follow-up preclinical studies in rhesus monkeys[A220058] showed that the Ad26 vaccine produced a robust response and provided near perfect protection in nasal swabs and bronchoalveolar lavage following SARS-COV-2 challenge. As of June 2020, a Phase 1\/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55 (NCT04436276). The Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"JT2NS6183B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"The Janssen COVID-19 Vaccine comprises a recombinant, replication-incompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 Spike (S) protein in a stabilized conformation.[L39180] Immunization with the vaccine results in the expression of SARS-CoV-2 spike proteins in the recipient, which stimulates antibody formation and cellular immune responses directed against the S antigen and ultimately conferring immunological protection to the SARS-CoV-2 virus.","drug-interactions":"DB08880 DB00328 DB00290 DB00022 DB00322 DB00928 DB02546 DB14762 DB00188 DB00564 DB09091 DB00398 DB13014 DB14919 DB15091 DB09052 DB05459 DB00526 DB14039 DB08868 DB09077 DB00092 DB00970 DB08871 DB13003 DB00601 DB04951 DB00034 DB00380 DB12902 DB00075 DB00993 DB14724 DB01222 DB00072 DB16694 DB13856 DB14539 DB00642 DB11988 DB12947 DB00078 DB13068 DB00307 DB15434 DB00309 DB00495 DB11921 DB01234 DB00755 DB04956 DB00105 DB12371 DB03451 DB00305 DB00073 DB06643 DB06772 DB16650 DB00444 DB14545 DB00635 DB11616 DB14681 DB00277 DB14066 DB06287 DB04630 DB01229 DB01073 DB06650 DB01423 DB01611 DB00570 DB00056 DB11834 DB00441 DB01206 DB15646 DB14783 DB15762 DB00480 DB01590 DB05259 DB00041 DB08901 DB13843 DB11803 DB09036 DB09378 DB13867 DB09122 DB00069 DB08889 DB00242 DB01030 DB12025 DB00531 DB00108 DB08970 DB12814 DB00631 DB00888 DB00291 DB08895 DB09053 DB00853 DB01254 DB00111 DB12617 DB00068 DB00563 DB00741 DB01380 DB08877 DB01169 DB13208 DB05109 DB00081 DB00432 DB15626 DB00018 DB00352 DB13491 DB12530 DB15119 DB00087 DB09082 DB09383 DB01097 DB12991 DB00011 DB01285 DB00859 DB00394 DB00065 DB00851 DB11487 DB00997 DB01816 DB05676 DB11767 DB00959 DB08904 DB02806 DB08059 DB08910 DB12612 DB00773 DB12917 DB09029 DB00443 DB05015 DB11708 DB00550 DB15628 DB00764 DB04845 DB11817 DB09074 DB00008 DB00120 DB00795 DB00547 DB01008 DB00694 DB01041 DB05260 DB08935 DB00663 DB05472 DB09033 DB00864 DB00428 DB00059 DB13241 DB16703 DB00446 DB06674 DB01108 DB06813 DB01024 DB11569 DB06273 DB01033 DB00293 DB00688 DB13223 DB06372 DB01280 DB00324 DB05258 DB01196 DB00276 DB00544 DB06681 DB01181 DB00361 DB00620 DB01013 DB01204 DB06603 DB00098 DB01281 DB11693 DB11466 DB08971 DB12692 DB01384 DB00591 DB06769 DB04868 DB06168 DB09095 DB01248 DB09054 DB11776 DB12016 DB14512 DB15253 DB00552 DB00877 DB01099 DB01262 DB00860 DB01257 DB12996 DB05773 DB00051 DB11976 DB01101 DB00033 DB04572 DB06616 DB01005 DB14219 DB00091 DB08908 DB14845 DB08879 DB00762 DB06343 DB00074 DB01047 DB00763 DB06662 DB06612 DB09073 DB01168 DB14540 DB00588 DB00180 DB00262 DB00515 DB06589 DB00541 DB00619 DB00095 DB01042 DB01177 DB01268 DB00026 DB08870 DB11529 DB11580 DB00488 DB00958 DB09312 DB00687 DB00445 DB00005 DB08906 DB01410 DB03523","absorption":null,"created":"2020-09-17","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Janssen COVID-19 Vaccine","metabolism":null,"reactions":null,"indication":"Janssen COVID-19 Vaccine is indicated for active immunization for the prevention of coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 virus in individuals 18 years of age and older.[L39180]\r\n\r\nIn the US, Janssen COVID-19 vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older for whom other FDA-authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older who elect to receive the Janssen COVID19 Vaccine because they would otherwise not receive a COVID-19 vaccine.[L41745]","ahfs-codes":null,"updated":"2022-06-03","drugbank-id":"DB15857"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The KBP-201 COVID-19 Vaccine was developed by British American Tobacco\u20ACs (BAT) U.S. biotech subsidiary, Kentucky BioProcessing (KBP). KBP cloned COVID-19\u20ACs genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction. Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals.  As of July 2020, KBP is conducting a Phase 1\/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"KBP-COVID-19","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15858"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NasoVAX contains replication-deficient adenovirus vectors in suspension.  It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313]. Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313]. As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"NasoVAX","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-18","drugbank-id":"DB15859"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"J65X53KM9E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-17","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cassia fistula fruit","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15860"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":353.84,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"2043-38-1","sequences":null,"targets":null,"unii":"W00SSD35VW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"DIURETICS CARDIOVASCULAR SYSTEM DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00682 DB00887 DB06196 DB09198 DB00178 DB00970 DB13875 DB00814 DB00562 DB14006 DB00232 DB13286 DB11921 DB13199 DB06228 DB09307 DB09257 DB13807 DB00305 DB00605 DB06772 DB00962 DB09195 DB01209 DB00321 DB06711 DB01129 DB14506 DB01140 DB01020 DB09026 DB00292 DB06767 DB13537 DB08822 DB01124 DB13341 DB00700 DB00888 DB01396 DB09050 DB01551 DB00873 DB00741 DB00222 DB13293 DB04846 DB15119 DB13604 DB00787 DB00543 DB13277 DB09462 DB00851 DB04017 DB05676 DB00230 DB00519 DB09363 DB00268 DB00136 DB11228 DB00869 DB01610 DB00120 DB11114 DB00428 DB00440 DB01555 DB06402 DB01466 DB00017 DB09224 DB00581 DB01364 DB09394 DB00438 DB00877 DB13240 DB00908 DB09368 DB09251 DB01005 DB00091 DB09045 DB06271 DB09227 DB09409 DB00498 DB09496 DB00614 DB00253 DB00841 DB00925 DB00266 DB13612 DB00420 DB13323 DB01410 DB13124 DB00022 DB09238 DB12080 DB06738 DB06695 DB00668 DB13467 DB00789 DB12319 DB00327 DB01120 DB00468 DB12010 DB00307 DB02224 DB15821 DB05099 DB01241 DB13217 DB12935 DB12268 DB00363 DB01638 DB00206 DB14938 DB15171 DB04930 DB09121 DB09154 DB06237 DB16629 DB08813 DB00936 DB00231 DB04890 DB09053 DB11090 DB09218 DB00831 DB00146 DB13384 DB00734 DB13649 DB00596 DB14059 DB01550 DB14544 DB00861 DB00852 DB09449 DB05541 DB00842 DB08904 DB15880 DB13378 DB00176 DB05015 DB01041 DB00921 DB00035 DB06706 DB01418 DB14007 DB00875 DB00343 DB01450 DB08996 DB13606 DB11113 DB00158 DB00449 DB00780 DB08893 DB00833 DB09095 DB00502 DB01213 DB14337 DB01244 DB11783 DB01011 DB00619 DB01268 DB01342 DB00445 DB13246 DB00660 DB00322 DB09199 DB13225 DB11156 DB00330 DB11750 DB13269 DB00854 DB01193 DB09163 DB11609 DB06445 DB08931 DB04581 DB11338 DB08890 DB00310 DB13657 DB12107 DB00441 DB11135 DB01029 DB08836 DB00480 DB01431 DB06781 DB13526 DB13664 DB03410 DB00291 DB01576 DB08907 DB01267 DB00580 DB00049 DB06786 DB14509 DB01242 DB01254 DB00068 DB08872 DB00375 DB00922 DB08940 DB13551 DB06190 DB06762 DB01023 DB06127 DB00859 DB00681 DB00573 DB06441 DB00349 DB09134 DB14643 DB14498 DB01151 DB00554 DB01138 DB00658 DB00264 DB01214 DB00190 DB00461 DB09129 DB09128 DB12007 DB09264 DB01048 DB00865 DB00688 DB00716 DB06815 DB01013 DB09260 DB01018 DB09165 DB11312 DB13170 DB15685 DB11691 DB13211 DB04895 DB13756 DB00860 DB06707 DB00288 DB00273 DB13166 DB00497 DB00966 DB15965 DB09472 DB00029 DB00588 DB00696 DB00616 DB11529 DB00488 DB00286 DB09287 DB00880 DB11166 DB09255 DB09262 DB00407 DB06623 DB13675 DB00009 DB01224 DB13919 DB00254 DB11145 DB00802 DB14232 DB00759 DB01433 DB01222 DB01403 DB12161 DB09282 DB09137 DB06194 DB00844 DB00608 DB11642 DB09329 DB14208 DB08934 DB13559 DB01205 DB00041 DB01028 DB06710 DB00393 DB04861 DB13545 DB00320 DB01529 DB11278 DB00657 DB12248 DB01454 DB00982 DB00314 DB00013 DB09202 DB01497 DB00081 DB00352 DB00087 DB01276 DB00159 DB06809 DB01285 DB01189 DB12361 DB08826 DB00910 DB01144 DB09213 DB14125 DB08957 DB00279 DB00764 DB01126 DB00663 DB05254 DB14503 DB00761 DB09268 DB06209 DB13223 DB06267 DB12831 DB00897 DB09061 DB05361 DB04574 DB04830 DB00862 DB00361 DB00620 DB00186 DB01159 DB00001 DB00413 DB09244 DB01238 DB00946 DB00225 DB00217 DB04572 DB00235 DB13478 DB00974 DB00221 DB09135 DB00262 DB00006 DB08991 DB00782 DB13185 DB01068 DB04552 DB01388 DB11273 DB01345 DB00328 DB00742 DB00656 DB09052 DB06737 DB08814 DB09570 DB00540 DB09205 DB01142 DB08841 DB11792 DB01078 DB00034 DB01612 DB15465 DB09273 DB00280 DB01200 DB00642 DB13510 DB06701 DB09484 DB00105 DB01306 DB09325 DB00284 DB00368 DB01229 DB06154 DB00863 DB09030 DB00490 DB14504 DB00535 DB00388 DB00853 DB01039 DB00278 DB09082 DB14541 DB04878 DB11057 DB00773 DB13928 DB13943 DB00181 DB09481 DB01249 DB01432 DB04818 DB00945 DB00901 DB00820 DB13954 DB01064 DB01309 DB13496 DB01622 DB00245 DB08925 DB12726 DB01216 DB00599 DB13180 DB08950 DB05095 DB04868 DB00788 DB12661 DB00030 DB01182 DB00846 DB07767 DB00031 DB13167 DB00775 DB00733 DB06262 DB06616 DB00723 DB06292 DB00351 DB12545 DB00511 DB01109 DB08894 DB00866 DB08955 DB01015 DB00983 DB09020 DB12100 DB00601 DB05018 DB01158 DB05395 DB01333 DB00270 DB00629 DB00165 DB00753 DB01234 DB09477 DB08994 DB01277 DB06605 DB00960 DB00312 DB00635 DB01435 DB01206 DB01459 DB11110 DB06203 DB00999 DB00633 DB13251 DB00937 DB13524 DB06736 DB00816 DB00432 DB01227 DB11094 DB01225 DB00397 DB00394 DB13371 DB04840 DB12930 DB00559 DB09502 DB00153 DB00500 DB06283 DB09200 DB09215 DB14502 DB00196 DB14068 DB13178 DB01280 DB14530 DB11189 DB15889 DB00350 DB00690 DB00812 DB13345 DB01384 DB13025 DB00838 DB01099 DB01037 DB00661 DB09043 DB01531 DB00830 DB09295 DB00651 DB09395 DB00692 DB01365 DB01116 DB01047 DB00763 DB13692 DB00353 DB00603 DB11984 DB09277 DB00290 DB02546 DB00572 DB00713 DB01407 DB09236 DB13944 DB01050 DB06406 DB00182 DB08981 DB01587 DB00704 DB00295 DB09292 DB01378 DB14185 DB06764 DB00755 DB00073 DB11780 DB01307 DB14681 DB09049 DB06282 DB09089 DB00699 DB13156 DB00785 DB00248 DB00242 DB01212 DB09106 DB01088 DB04665 DB00436 DB01380 DB01169 DB01420 DB06480 DB00198 DB11543 DB06702 DB00804 DB05115 DB01394 DB09167 DB00484 DB01022 DB13873 DB13514 DB04845 DB11817 DB11455 DB06779 DB00364 DB09254 DB09239 DB09016 DB14631 DB12278 DB00381 DB01049 DB00544 DB15456 DB08942 DB01043 DB09223 DB08971 DB12713 DB13728 DB13757 DB11568 DB12843 DB01262 DB14010 DB00561 DB13481 DB15972 DB09344 DB13946 DB05295 DB00829 DB13139 DB01177 DB14627 DB00958 DB01221 DB12783 DB03322 DB01149 DB00537 DB00331 DB00697 DB06678 DB09112 DB00499 DB11587 DB01288 DB01509 DB01036 DB12526 DB09276 DB00285 DB09214 DB09258 DB00226 DB11785 DB05266 DB04796 DB00512 DB11059 DB00444 DB09104 DB11755 DB00703 DB01073 DB13453 DB00570 DB09174 DB13191 DB09248 DB08901 DB13108 DB00542 DB00489 DB01349 DB11323 DB01260 DB04836 DB00263 DB00563 DB08911 DB06822 DB00548 DB04812 DB00018 DB00678 DB06268 DB04920 DB13996 DB00341 DB11770 DB01089 DB12465 DB00346 DB12092 DB14585 DB08496 DB00938 DB00991 DB12214 DB13160 DB01401 DB09246 DB08900 DB14027 DB00275 DB00501 DB09252 DB11699 DB00896 DB12445 DB01136 DB06769 DB04925 DB01171 DB06799 DB09286 DB13406 DB01090 DB14060 DB01183 DB05562 DB01135 DB13967 DB09281 DB01415 DB00515 DB08951 DB01042 DB09564 DB08797 DB00524 DB01297 DB04899 DB14652 DB13400 DB06272 DB00610 DB06679 DB06712 DB01215 DB11085 DB00223 DB13446 DB09185 DB12945 DB09253 DB00800 DB13691 DB01556 DB06796 DB09022 DB01102 DB06148 DB06705 DB00665 DB01590 DB13843 DB00806 DB04908 DB06814 DB00912 DB12814 DB01273 DB13136 DB01558 DB08932 DB00492 DB00390 DB11201 DB12551 DB13411 DB11738 DB01295 DB01577 DB00777 DB13398 DB09383 DB00714 DB04891 DB06690 DB00959 DB09480 DB11723 DB00684 DB09074 DB01624 DB00008 DB00547 DB11367 DB13452 DB01033 DB00708 DB01240 DB00987 DB00370 DB09249 DB01046 DB13787 DB15478 DB00731 DB00276 DB08550 DB09084 DB01204 DB01035 DB01082 DB00939 DB00402 DB00372 DB09210 DB00738 DB00033 DB00652 DB14217 DB00612 DB13158 DB11950 DB09265 DB00598 DB14540 DB00180 DB00872 DB00749 DB13595 DB14538 DB14207 DB08906 DB00214 DB14529 DB00203 DB00213 DB00476 DB00951 DB09220 DB00586 DB14213 DB01156 DB06694 DB01347 DB00993 DB13097 DB09242 DB06654 DB01137 DB11127 DB13624 DB01283 DB00695 DB09413 DB01359 DB00881 DB04871 DB13429 DB08810 DB00294 DB00628 DB08905 DB09378 DB00606 DB06763 DB00069 DB01452 DB11567 DB13782 DB00894 DB14963 DB09068 DB00469 DB00903 DB06410 DB08985 DB00624 DB11136 DB15593 DB00015 DB06543 DB00988 DB01118 DB00594 DB08960 DB08794 DB00454 DB14516 DB01161 DB01053 DB00401 DB01438 DB01366 DB01008 DB08824 DB01108 DB06207 DB13312 DB00622 DB13114 DB08840 DB14094 DB00590 DB14035 DB01130 DB00930 DB00377 DB12212 DB00774 DB09118 DB00422 DB13884 DB13779 DB04948 DB00486 DB04953 DB01054 DB00384 DB13385 DB14545 DB00956 DB09259 DB00188 DB08439 DB01105 DB08899 DB06655 DB04876 DB11362 DB04896 DB09241 DB01608 DB00911 DB01166 DB04898 DB09235 DB13374 DB01614 DB12625 DB01377 DB00373 DB00709 DB01060 DB01436 DB14527 DB06152 DB01180 DB00672 DB01009 DB08895 DB00679 DB00797 DB06700 DB00477 DB00014 DB00208 DB00335 DB13275 DB00457 DB11481 DB04854 DB12417 DB00443 DB09311 DB06335 DB11632 DB14499 DB11577 DB09204 DB00694 DB00300 DB09027 DB04932 DB00446 DB09212 DB01186 DB01467 DB00808 DB04743 DB09289 DB00465 DB14126 DB09075 DB14512 DB04820 DB13598 DB00653 DB13401 DB13646 DB09203 DB09216 DB01252 DB13435 DB13430 DB13777 DB09517 DB00197 DB09073 DB11251 DB09301 DB00369 DB11358 DB04816 DB01203 DB11373 DB00458 DB01119 DB00953 DB11992 DB11989 DB14644 DB09038 DB11556 DB01004 DB06754 DB00437 DB09091 DB11365 DB00047 DB08871 DB01001 DB00356 DB09071 DB00765 DB13856 DB00187 DB13783 DB00309 DB09324 DB12598 DB00482 DB09139 DB00056 DB13852 DB09066 DB00359 DB08808 DB01419 DB13860 DB04855 DB01014 DB04824 DB13347 DB00876 DB00318 DB13491 DB13987 DB00491 DB14231 DB00011 DB00315 DB06216 DB00435 DB09256 DB09285 DB00961 DB08935 DB05271 DB13722 DB01010 DB01261 DB06782 DB05258 DB00998 DB00712 DB00909 DB01348 DB00308 DB00683 DB13410 DB00243 DB13631 DB15777 DB04725 DB00968 DB13451 DB00415 DB11622 DB14482 DB00669 DB00790 DB13707 DB01253 DB01628 DB00184 DB15360 DB01101 DB11164 DB01197 DB11130 DB00762 DB00743 DB01081 DB09456 DB00760 DB00071 DB01472 DB08962 DB01580 DB11328 DB00928 DB14649 DB12289 DB07715 DB09217 DB06823 DB11564 DB06230 DB13876 DB08999 DB00558 DB09209 DB01247 DB14633 DB00177 DB00495 DB08941 DB13432 DB01409 DB13703 DB08984 DB15477 DB00583 DB12781 DB06211 DB01067 DB01235 DB01535 DB13867 DB00531 DB00046 DB08970 DB00631 DB01148 DB11901 DB00839 DB00246 DB13208 DB00905 DB09111 DB06117 DB09206 DB11827 DB00834 DB04828 DB11824 DB01579 DB14659 DB09546 DB09081 DB06813 DB00577 DB12610 DB09080 DB00240 DB01274 DB13145 DB06826 DB00324 DB04817 DB00553 DB00871 DB09132 DB00086 DB11873 DB00552 DB12364 DB08861 DB11898 DB05039 DB00691 DB00584 DB06725 DB13940 DB00054 DB09320 DB09194 DB00980 DB01397 DB14055 DB00169 DB13781 DB09136 DB11720 DB08952 DB00784 DB11102 DB00237 DB00526 DB00334 DB00414 DB11121 DB00899 DB01484 DB01626 DB09133 DB12054 DB11095 DB09208 DB00915 DB13955 DB09488 DB09149 DB01093 DB00007 DB00706 DB11364 DB06635 DB09103 DB06011 DB13149 DB00316 DB00355 DB00418 DB09414 DB00297 DB00193 DB09318 DB00722 DB13605 DB09122 DB09288 DB14543 DB01382 DB15226 DB13407 DB03585 DB12779 DB13454 DB13399 DB00450 DB00783 DB05109 DB01251 DB01143 DB13616 DB08910 DB00055 DB09243 DB00828 DB00569 DB00550 DB09250 DB01170 DB01092 DB01192 DB01157 DB11560 DB11477 DB13307 DB09407 DB01181 DB00212 DB00339 DB11098 DB00591 DB00818 DB01275 DB00952 DB00323 DB01248 DB01278 DB00811 DB00555 DB08909 DB00289 DB00404 DB09357 DB01289 DB01250 DB14881 DB09245 DB09483 DB12615 DB01133 DB01016 DB13956 DB00195 DB13801 DB13538 DB09317 DB01002 DB00867 DB13001 DB15566 DB00564 DB00398 DB06294 DB06684 DB09077 DB13486 DB13003 DB09201 DB00412 DB01392 DB00078 DB00597 DB09418 DB00589 DB06287 DB04630 DB00200 DB06403 DB00528 DB14546 DB01563 DB08815 DB01363 DB06016 DB04946 DB01591 DB11541 DB13544 DB11943 DB13917 DB09272 DB01700 DB14684 DB11598 DB01236 DB01656 DB09148 DB01685 DB00883 DB12942 DB09237 DB11487 DB04829 DB00997 DB00374 DB13520 DB00296 DB00796 DB00935 DB00698 DB00813 DB01255 DB12313 DB00752 DB05472 DB00864 DB01367 DB00886 DB01024 DB08897 DB00721 DB00185 DB00325 DB01442 DB00319 DB00934 DB01427 DB00191 DB00344 DB09042 DB01408 DB11466 DB12846 DB00805 DB15217 DB01565 DB01282 DB00115 DB00211 DB00287 DB11124 DB12766 DB06204 DB13803 DB13527 DB13232 DB00900 DB14507 DB08954 DB09156 DB04831 DB00521 DB00244 DB00567 DB11915 DB07402 DB00333 DB01399 DB00080 DB06637 DB01070 DB11089 DB00730 DB06186 DB01132 DB09219 DB12492 DB11428 DB01340 DB13629 DB00380 DB11518 DB01324 DB00303 DB01330 DB14539 DB00995 DB15434 DB14526 DB12371 DB14646 DB00571 DB08882 DB08816 DB09338 DB12093 DB11097 DB13909 DB13443 DB04823 DB08889 DB01030 DB13575 DB05229 DB00975 DB08877 DB08976 DB09279 DB00216 DB14513 DB00686 DB15614 DB13952 DB12927 DB01032 DB13532 DB01079 DB09232 DB06153 DB14754 DB00795 DB13508 DB00647 DB01600 DB01069 DB02032 DB12412 DB00293 DB11107 DB00726 DB06800 DB00575 DB13314 DB01424 DB01021 DB14528 DB14669 DB11698 DB11268 DB00271 DB12399 DB00727 DB01162 DB06824 DB09123 DB08918 DB13064 DB05773 DB11871 DB08382 DB14634 DB04258 DB00611 DB01113 DB00821 DB00247 DB00918 DB01233 DB01291 DB01168 DB01428 DB01115 DB00914 DB14726 DB00533 DB00687","absorption":null,"created":"2020-09-17","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":353.0270761,"volume-of-distribution":null,"route-of-elimination":null,"name":"Buthiazide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-14","drugbank-id":"DB15861"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone.[A220158] Double-blind, randomized, placebo-controlled phase 1 (96 participants) and phase 2 (224 participants) were carried out in healthy adults between 18-59 years.[A220158] Results from these trials showed low rates of adverse reactions and demonstrated immunogenicity.[A220158] Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).[A219758]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-18","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inactivated SARS-Cov-2 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB15862"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells[A219758]. This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-18","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-20","drugbank-id":"DB15863"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with the wild poliovirus[L16348]. The vaccine is created by weakening the wildtype before being placed into the oral vaccine. After administration, OPV strains extensively multiply in the intestinal tract, becoming widely spread in the community to immunize a sizable proportion of those unvaccinated in the population[A220163]. With administration, this vaccine prevents cases of paralytic poliomyelitis.\r\n\r\nThe polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are completed[A220168].","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The polio vaccine allows for the encounter of the polio virus by the immune system to be less threatening while still allowing for the body to mount a humoral response for protection against any future exposure of the virus[A220168]. For the OPV specifically, upon administration, the vaccine elicits a local immune response in the intestinal mucous membranes, a location at which the poliovirus multiplies[L16348]. Antibodies produced locally then will inhibit multiplication of following infections of the wildtype poliovirus[L16348].","drug-interactions":null,"absorption":null,"created":"2020-09-18","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Oral Polio Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-13","drugbank-id":"DB15864"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations.[A220173] It is comprised of [immunoglobulin G (IgG)](https:\/\/www.drugbank.ca\/drugs\/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]","enzymes":null,"type":"biotech","cas-number":"97794-27-9","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Pentaglobin has potential antibacterial and immunomodulatory properties where, compared to immunoglobulin treatments without IgM, pentaglobin may have an increased ability to eliminate infectious pathogens . The IgM in the preparation plays a role in complement activation and neutralization of bacterial endo- and exotoxins.[L16353] Pentaglobin is used as an adjuvant in treatment of severe bacterial infections while it is also investigated against peritonitis, sepsis, and COVID-19.[A220178]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pentaglobin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15865"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.[L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"H7DFT9JF6M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"T-Reg cells engage with antigen-presenting cells lining the alveolar epithelium. This likely results in disarmament and dampening of the cytokine storm \u20AC\u201D seen with a study where there was a rapid decline in peripheral biomarkers and decreased blood levels of inflammatory cytokines after treatment with CK0802. It is also a possibility that these cells can calm inflammation where it is most active and act discriminately, avoiding general immunosuppression. This therapy is currently being investigated against COVID-19 acute respiratory distress syndrome (ARDS), inflammatory diseases, and autoimmune disorders.[L16358]","drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CK0802","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15866"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Autologous non-hematopoietic peripheral blood stem cells have been created into a formulation for use in a clinical trial (NCT04473170) by the Abu Dhabi Stem Cells Center. The cells have the characterizations of CD90+, CD133+, Oct-4+, CD45-, and CD71-.[L16363]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Autologous Non-Hematopoietic Peripheral Blood Stem Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15867"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus.[A220183,T823] These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.[A220183]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Amniotic epithelial cells have immunosuppression properties, the likely reason why these cells seem to be resistant to rejection after allotransplantation. Further therapeutic effects of these cells include reported neuroprotection and neuroregeneration properties, attributed to the growth factor secretion by AECs. These cells are being investigated as a therapy against many different conditions, some of which include lung fibrosis, liver fibrosis, multiple sclerosis, congenital metabolic disorders, familial hypercholesterolemia, spinal cord injuries, ophthalmic diseases, and Parkinson\u20ACs disease.","drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amniotic Epithelial Cells","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15868"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.[A220188] It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"A2WX2UCW6F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Platelet lysate plays a role in regeneration through the growth factors it contains, resulting in an increase in cell proliferation and angiogenesis. Nebulized platelet lysate can be administered to the lungs and has applications in treatment of acute lung injuries, chronic obstructive pulmonary disease (COPD), and asthma. Because of the aforementioned diseases that the plasma lysate can treat and its ability to relegate severe inflammatory processes of the respiratory tract, it is currently also being investigated against COVID-19 infection-related acute respiratory syndrome (ARDS).","drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Platelet Lysate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15869"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.[L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Probiorinse","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15870"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Human amniotic fluid is the liquid surrounding the human embryo and fetus.[L16373] Physically, the fluid provides protection through cushioning. Chemically, the fluid provides protection through its inherent antibacterial properties. The fluid contains carbohydrates, proteins, lipids, electrolytes, urea, immunoglobulins, growth factors, and vitamins.[L16373,L16378]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"6SQ06FQ2GH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Human amniotic fluid was seen to reduce inflammation in lungs of COVID-19 patients through a decrease in C-reactive protein in a study.[L16378] However, the mechanisms of action of this therapy are unclear. Currently, human amniotic fluid is being investigated against COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Human Amniotic Fluid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-22","drugbank-id":"DB15871"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":215.142,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"33049-08-0","sequences":null,"targets":null,"unii":"O35QN01X8F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-21","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":215.055874173,"volume-of-distribution":null,"route-of-elimination":null,"name":"L-alpha-Glycerophosphorylethanolamine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-10","drugbank-id":"DB15872"},{"toxicity":"If radiation overdose occurs, patients should be advised to drink plenty of water and to void frequently to increase the rate of elimination of the radionuclide.[L16393] In certain cases, it may be appropriate to administer a diuretic.[L16393]","snp-adverse-drug-reactions":null,"average-mass":1497.55,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68<\/sup>Ga-labeled somatostatin analogs for positron emission tomography (PET).[A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.[A220348] Further studies should be performed to compare the two tracers. \r\n\r\nFurther, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide.[A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348]","enzymes":null,"type":"small molecule","cas-number":"1426155-87-4","sequences":null,"targets":"BE0003528","unii":"N3858377KC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":"Take with fluids. Patients should remain well hydrated before and after imaging with copper Cu 64 dotatate to limit radiation exposure.","state":null,"synthesis-reference":null,"mechanism-of-action":"The main target of the positron-emitting Copper Cu 64 dotatate is somatostatin receptor type 2 (SSTR2).[L16393] SSTR2 is frequently overexpressed in malignant neuroendocrine cells; therefore, accumulation of the radionuclide at the site permits PET imaging to occur.[L16393]","drug-interactions":"DB06663 DB06791 DB09099 DB00104 DB04894","absorption":"Radioactivity can be identified in the kidney, liver, adrenal glands, spleen, and pituitary glands 1-3 hours after copper Cu 64 dotatate is administered.[L16393]","created":"2020-09-22","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The half-life of Copper Cu 64 is 12.7 hours.[L16393]","monoisotopic-mass":1496.508926883,"volume-of-distribution":null,"route-of-elimination":"16% - 40% of the original radioactivity was detected in urine 6 hours after the intravenous administration of a single dose.[L16393]","name":"Copper oxodotreotide Cu-64","metabolism":null,"reactions":null,"indication":"Copper Cu 64 Dotatate is a radiopharmaceutical used with positron emission tomography(PET) to locate somatostatin receptor-positive neuroendocrine tumors.[L16393]","ahfs-codes":null,"updated":"2021-03-04","drugbank-id":"DB15873"},{"toxicity":"Data regarding overdoses of agalsidase alfa are not readily available.[L16398] Patients experiencing an overdose of agalsidase alfa may experience an increased incidence and severity of adverse effects. Overdose can be managed through the use of symptomatic and supportive measures.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":"BE0004494","pharmacodynamics":"Agalsidase alfa is a recombinant human -galactosidase A used as enzyme replacement therapy in the treatment of Fabry disease.[L16398] It has a long duration of action and a wide therapeutic index.[L16398] Patients should be counselled regarding the risk of infusion related reactions and hypersensitivity.[L16398]","msds":null,"description":"Agalsidase alfa is a recombinant human -galactosidase A similar to [agalsidase beta]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]\r\n\r\nAgalsidase alfa was granted EMA approval on 3 August 2001.[L16413]","enzymes":null,"type":"biotech","cas-number":null,"sequences":">Agalsidase alfa sequence\nLDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCI\nDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGY\nYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPF\nQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIG\nNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQL\nRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVK\nRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL","targets":"BE0004830","unii":"2HLC17MX9G","protein-binding":"Agalsidase alfa is not expected to be protein bound in circulation.[L16398]","fda-label":null,"clearance":"The clearance for doses of 0.007-0.2 mg\/kg were 2.66 mL\/min\/kg for males and 2.10 mL\/min\/kg for females.[L16398]","atc-codes":"OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS ALIMENTARY TRACT AND METABOLISM Enzymes","pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"-galactosidase A is uptaken by cells via the mannose 6 phosphate receptor.[A220323] Agalsidase alfa hydrolyzes globotriaosylceramide and other glycosphingolipids that would normally be hydrolyzed by endogenous -galactosidase A.[L16398] Preventing the accumulation of glycosphingolipids prevents or reduces the severity of manifestations of Fabry disease such as renal failure, cardiomyopathy, or cerebrovascular events.[L16398]","drug-interactions":"DB01118 DB00600 DB00103 DB00608 DB00798","absorption":"A dose of agalsidase alfa in non end stage renal disease patients reaches a C<sub>max<\/sub> of 3710  855 U\/mL with an AUC of 256,958  63,499 min\\*U\/mL.[A220338]","created":"2020-09-22","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The elimination half life was 108  17 minutes for males and 89  28 minutes for females.[L16398]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution at steady state in non end stage renal disease patients was approximately 17% of body weight regardless of sex.[A220338,L16398]","route-of-elimination":"After nonspecific proteolysis, the amino acids from protein drugs are reused for protein synthesis or further broken down and eliminated by the kidneys.[A182009]","name":"Agalsidase alfa","metabolism":"Data regarding the metabolism of agalsidase alfa is not readily available.[L16398] However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.[A182009]","reactions":null,"indication":"Agalsidase alfa is indicated in the treatment of Fabry disease.[L16398]","ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15874"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":168.192,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"621-23-8","sequences":null,"targets":null,"unii":"00VJI3VG3D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":168.078644246,"volume-of-distribution":null,"route-of-elimination":null,"name":"1,3,5-Trimethoxybenzene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-10","drugbank-id":"DB15875"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-23","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haemophilus influenzae b polysaccharide-tetanus conjugate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-24","drugbank-id":"DB15876"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":513.807,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"102580-74-5","sequences":null,"targets":null,"unii":"5333CM4X3G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":513.418194635,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cetyltrimethylammonium naproxenate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-10","drugbank-id":"DB15877"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":159.95,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"14259-85-9","sequences":null,"targets":null,"unii":"O0L10E6352","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":161.886161,"volume-of-distribution":null,"route-of-elimination":null,"name":"Molybdate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-24","drugbank-id":"DB15878"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"66455-30-9","sequences":null,"targets":null,"unii":"CEI2QJ2WAR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Polygeline","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15879"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":475.38,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"24967-94-0","sequences":null,"targets":null,"unii":"J3OC7JVS54","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Other antithrombotic agents BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB13821 DB00328 DB08953 DB00682 DB00928 DB09124 DB13400 DB09381 DB00656 DB09052 DB06679 DB06737 DB03374 DB08814 DB12289 DB06251 DB09217 DB11133 DB00970 DB01066 DB13875 DB13876 DB00034 DB00814 DB00562 DB00036 DB09253 DB01247 DB14006 DB01942 DB00642 DB13510 DB13286 DB00495 DB00232 DB13432 DB13199 DB00105 DB06228 DB13947 DB00305 DB00605 DB00957 DB06715 DB06772 DB01327 DB01543 DB08984 DB01229 DB12235 DB00583 DB07615 DB14473 DB00100 DB01140 DB01590 DB04066 DB09030 DB00806 DB03619 DB11330 DB00531 DB12814 DB00535 DB00631 DB00888 DB13136 DB00853 DB09050 DB11201 DB13266 DB00278 DB00367 DB01381 DB15119 DB00851 DB04017 DB00389 DB03404 DB13981 DB00834 DB00773 DB13943 DB04828 DB09062 DB14655 DB09074 DB00008 DB00120 DB04818 DB13201 DB11367 DB02659 DB00945 DB00428 DB13563 DB13954 DB00274 DB01033 DB15861 DB12610 DB01240 DB00987 DB12726 DB09249 DB13148 DB00276 DB09084 DB08550 DB01204 DB00758 DB02901 DB13192 DB05095 DB00438 DB00086 DB08619 DB04868 DB00788 DB00447 DB00939 DB00552 DB01541 DB00877 DB13310 DB13233 DB12364 DB07767 DB00031 DB00908 DB13167 DB00775 DB09251 DB06616 DB00033 DB01005 DB06206 DB06271 DB12909 DB13999 DB04865 DB06725 DB00498 DB00351 DB01331 DB12545 DB09539 DB00614 DB00054 DB01109 DB13533 DB01175 DB00749 DB01572 DB08955 DB13612 DB00266 DB01397 DB13461 DB13124 DB14055 DB00022 DB00203 DB00476 DB06695 DB01150 DB01139 DB04839 DB00586 DB00715 DB00784 DB13667 DB00526 DB00601 DB13504 DB09369 DB00977 DB00468 DB01626 DB01333 DB11095 DB13933 DB00307 DB02224 DB11674 DB00823 DB06654 DB01326 DB05099 DB02709 DB06635 DB08994 DB13217 DB06605 DB01283 DB00304 DB13149 DB01435 DB04884 DB14938 DB00294 DB01206 DB09154 DB09318 DB00606 DB09222 DB09122 DB00069 DB09288 DB08813 DB00936 DB12025 DB01416 DB00999 DB00456 DB06807 DB09422 DB09053 DB04918 DB09218 DB13524 DB06736 DB13407 DB03585 DB14678 DB00783 DB13649 DB05109 DB00469 DB04682 DB13133 DB00624 DB14059 DB01225 DB00015 DB06543 DB00861 DB13371 DB13386 DB01112 DB08867 DB13616 DB00055 DB08910 DB09243 DB14093 DB08794 DB00569 DB00176 DB01104 DB05015 DB00550 DB00500 DB14725 DB14679 DB09250 DB01357 DB11311 DB01008 DB01041 DB00923 DB01418 DB09215 DB06789 DB12749 DB02261 DB00396 DB11606 DB00430 DB01280 DB11636 DB14094 DB01181 DB06713 DB13685 DB00780 DB00812 DB00833 DB09543 DB00671 DB14570 DB00774 DB01248 DB01099 DB13866 DB00717 DB01037 DB13499 DB13884 DB01207 DB00932 DB09295 DB01250 DB11478 DB07637 DB00763 DB09245 DB00689 DB00493 DB13956 DB13953 DB13538 DB00619 DB09317 DB00603 DB13001 DB00445 DB11984 DB13367 DB04570 DB09259 DB14026 DB00322 DB02546 DB00188 DB00564 DB00398 DB06266 DB08439 DB06730 DB06294 DB06777 DB01105 DB09077 DB13944 DB06406 DB04896 DB04905 DB00229 DB08857 DB09241 DB08981 DB15575 DB08834 DB00078 DB06081 DB09418 DB13958 DB01166 DB04898 DB13470 DB01609 DB00073 DB06287 DB00675 DB01294 DB13151 DB13657 DB09109 DB00441 DB11935 DB13644 DB13509 DB00480 DB01431 DB00215 DB11507 DB01564 DB09070 DB00242 DB13544 DB02123 DB09211 DB13230 DB03410 DB01212 DB00291 DB01009 DB08895 DB00580 DB01254 DB01088 DB11372 DB09283 DB00068 DB04665 DB00267 DB00436 DB13418 DB11598 DB01169 DB01420 DB13778 DB06700 DB00208 DB08940 DB08887 DB00859 DB13275 DB12771 DB00573 DB06441 DB00374 DB00997 DB09567 DB13682 DB00554 DB05830 DB01138 DB01332 DB04845 DB13327 DB11455 DB06779 DB00461 DB01569 DB11619 DB09254 DB00694 DB00752 DB05472 DB04932 DB00864 DB01367 DB00446 DB09212 DB00721 DB13638 DB04743 DB08833 DB00544 DB01481 DB00261 DB01373 DB01586 DB15334 DB12693 DB00465 DB05767 DB09260 DB09042 DB11466 DB08942 DB15786 DB00805 DB11312 DB09075 DB04820 DB01262 DB14733 DB12321 DB13602 DB04832 DB13152 DB13857 DB13527 DB13232 DB13646 DB13481 DB13946 DB09216 DB13929 DB00163 DB11429 DB00244 DB00207 DB13430 DB00539 DB15775 DB00063 DB00567 DB07402 DB09073 DB00029 DB01177 DB00488 DB00958 DB00286 DB01399 DB01328 DB00880 DB11166 DB01149 DB09255 DB15335 DB06754 DB11789 DB00407 DB09008 DB00048 DB00009 DB14738 DB00254 DB08871 DB00199 DB13629 DB00380 DB11518 DB14700 DB09079 DB13143 DB01324 DB01330 DB15434 DB13044 DB13783 DB00285 DB00309 DB09214 DB09258 DB04573 DB00269 DB05266 DB09389 DB09329 DB00444 DB12598 DB00482 DB12474 DB01073 DB13036 DB08816 DB00570 DB00056 DB04348 DB09248 DB11668 DB00041 DB08901 DB01419 DB08889 DB13860 DB01030 DB11323 DB13923 DB01395 DB00378 DB05229 DB01014 DB06590 DB11051 DB13347 DB00563 DB00013 DB00975 DB08877 DB01413 DB06822 DB00081 DB08976 DB04812 DB00018 DB00352 DB00087 DB00159 DB00011 DB01414 DB12465 DB00686 DB12092 DB00233 DB13952 DB08496 DB09285 DB13532 DB00991 DB11079 DB01329 DB01783 DB01401 DB00795 DB01485 DB13804 DB09246 DB09371 DB08935 DB13951 DB05254 DB13150 DB13722 DB12163 DB01600 DB09252 DB00293 DB06209 DB05990 DB14577 DB13528 DB07447 DB12831 DB06731 DB05361 DB05258 DB16007 DB12445 DB04574 DB00361 DB00620 DB00712 DB07931 DB13314 DB01424 DB01021 DB12409 DB06769 DB11608 DB04725 DB13451 DB04925 DB11622 DB11268 DB00001 DB12399 DB09244 DB01171 DB09568 DB01628 DB00946 DB09123 DB14060 DB08918 DB05773 DB01101 DB04572 DB09310 DB00762 DB02691 DB01510 DB00974 DB00821 DB00255 DB01415 DB01168 DB00025 DB00262 DB08951 DB00515 DB00472 DB01042 DB00006 DB08797 DB08991 DB01606 DB14726 DB00533 DB04575 DB04552 DB14562 DB13197","absorption":null,"created":"2020-09-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":475.064287314,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dermatan sulfate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15880"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":244.72,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"17692-28-3","sequences":null,"targets":null,"unii":"YH9K692U9S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":244.0767261,"volume-of-distribution":null,"route-of-elimination":null,"name":"Clonazoline","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15881"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":269.34,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"515-59-3","sequences":null,"targets":null,"unii":"R12OZ3O07F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":269.029268954,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sulfamethylthiazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15882"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":461.49,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"87234-24-0","sequences":null,"targets":null,"unii":"7E8Q32N75N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":461.104541898,"volume-of-distribution":null,"route-of-elimination":null,"name":"Piroxicam cinnamate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15883"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":115.15,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"2682-20-4","sequences":null,"targets":null,"unii":"229D0E1QFA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":115.009184959,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methylisothiazolinone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-09-26","drugbank-id":"DB15884"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":166.184,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"72156-70-8","sequences":null,"targets":null,"unii":"6RR3G0X81D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":166.082333433,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methacetin methoxy-C-13","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15885"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":184.66,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"5665-94-1","sequences":null,"targets":null,"unii":"5EL163606Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":184.0654927,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carvasept","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15886"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":105.166,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"407582-13-2","sequences":null,"targets":null,"unii":"700YTQ6F2B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"DIAGNOSTIC RADIOPHARMACEUTICALS VARIOUS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":105.10518851,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fluorocholine F-18","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15887"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":339.435,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"4546-39-8","sequences":null,"targets":null,"unii":"P32MG14U83","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-28","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":339.183443669,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pipethanate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15888"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"AK7JF626KX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB00219 DB00887 DB00742 DB08980 DB00540 DB06712 DB00737 DB01142 DB07715 DB13695 DB00387 DB00562 DB15465 DB13505 DB00280 DB13252 DB00232 DB01409 DB09484 DB01337 DB13792 DB00424 DB01209 DB15477 DB00321 DB00810 DB07615 DB00732 DB13738 DB01535 DB00421 DB00463 DB14504 DB01075 DB00700 DB11855 DB09076 DB01148 DB01339 DB01551 DB00246 DB00777 DB00209 DB13636 DB09234 DB00543 DB11057 DB09462 DB11827 DB11228 DB09481 DB00332 DB13468 DB01062 DB01555 DB01466 DB15861 DB00708 DB00245 DB01046 DB13787 DB00581 DB00599 DB00835 DB13488 DB13584 DB00670 DB09015 DB14018 DB00908 DB00652 DB08861 DB09227 DB06292 DB14064 DB01175 DB00872 DB09125 DB00819 DB00420 DB13769 DB00214 DB09300 DB00967 DB09238 DB06738 DB13284 DB00715 DB00327 DB00237 DB00334 DB06694 DB13542 DB00899 DB00241 DB00270 DB00941 DB13835 DB00915 DB00753 DB00695 DB00312 DB09413 DB01412 DB00363 DB14066 DB08801 DB01638 DB08838 DB00418 DB01231 DB00809 DB01459 DB09414 DB04843 DB00193 DB01325 DB00606 DB13605 DB00416 DB01452 DB11110 DB00999 DB00979 DB00568 DB05246 DB01625 DB14963 DB00311 DB13454 DB01227 DB13617 DB00903 DB09449 DB14063 DB01118 DB00594 DB01199 DB08960 DB16165 DB00454 DB00505 DB14516 DB11315 DB11960 DB13678 DB00401 DB06283 DB11235 DB00921 DB01192 DB13725 DB00875 DB00343 DB00496 DB00622 DB14502 DB14068 DB04838 DB01450 DB06446 DB13766 DB13606 DB11189 DB11113 DB13913 DB01355 DB00774 DB00849 DB00555 DB00661 DB06787 DB01531 DB14881 DB00942 DB01116 DB01244 DB13989 DB01054 DB13801 DB00384 DB13254 DB14500 DB00956 DB13759 DB00572 DB01173 DB13961 DB08162 DB13648 DB09236 DB13486 DB00854 DB11609 DB01354 DB00704 DB00295 DB13950 DB01378 DB12670 DB00340 DB09235 DB08890 DB05710 DB00310 DB09049 DB13666 DB00528 DB14546 DB01377 DB09089 DB09230 DB01591 DB13526 DB00771 DB13791 DB06152 DB08907 DB00517 DB01483 DB12704 DB09272 DB00836 DB00436 DB14684 DB00477 DB06480 DB01239 DB00354 DB06702 DB13448 DB00804 DB01023 DB09237 DB12942 DB00565 DB12131 DB09167 DB01151 DB08961 DB13663 DB09311 DB00725 DB00813 DB00376 DB14499 DB00508 DB01226 DB09239 DB04841 DB08897 DB00721 DB13413 DB00808 DB04842 DB00934 DB14065 DB04743 DB12278 DB00381 DB08992 DB11181 DB08997 DB13170 DB01565 DB09229 DB00747 DB02925 DB00383 DB00653 DB12766 DB13803 DB00593 DB06204 DB00497 DB00483 DB00940 DB04831 DB13295 DB00986 DB13430 DB09472 DB00333 DB12221 DB14627 DB04816 DB09287 DB00458 DB00880 DB05885 DB09262 DB00392 DB09090 DB09007 DB12554 DB09219 DB01224 DB12492 DB11365 DB00802 DB14232 DB00907 DB01288 DB00794 DB01433 DB01036 DB01324 DB13844 DB01351 DB01403 DB04834 DB12526 DB00462 DB00514 DB00434 DB00844 DB11059 DB09104 DB12923 DB01352 DB00703 DB12086 DB09338 DB12093 DB01353 DB00347 DB09174 DB04823 DB00393 DB13619 DB01496 DB13380 DB01529 DB01395 DB00657 DB00767 DB13850 DB13405 DB01174 DB01497 DB00318 DB04920 DB14513 DB13351 DB12092 DB01144 DB14585 DB15959 DB09231 DB00728 DB13532 DB09232 DB01079 DB13708 DB06153 DB13160 DB00366 DB13720 DB00647 DB14503 DB06370 DB01069 DB11107 DB06212 DB09268 DB00342 DB09240 DB01136 DB00909 DB13500 DB01021 DB00306 DB11622 DB13581 DB14482 DB13369 DB01238 DB09023 DB13707 DB01090 DB01336 DB15360 DB01338 DB11130 DB00611 DB13478 DB01135 DB09281 DB04825 DB01081 DB01074 DB00472 DB09401 DB00782 DB13507 DB01115 DB00524 DB01388 DB05034","absorption":null,"created":"2020-09-29","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Senna leaf","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-12-01","drugbank-id":"DB15889"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The hybrid TREG and Th2 phenotype of these cells inhibits the inflammatory pathways of COVID-19 through modulation of cytokines and chemokines and cross-regulation of Th1 and Th17 populations. This therapy also has been seen to mediate protection on lung alveolar tissue. The immunomodulation that occurs is in a T-cell receptor independent manner. Currently, RAPA-501-ALLO is being investigated against COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-09-30","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"RAPA-501-Allo","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-01","drugbank-id":"DB15890"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-30","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"GX-19 Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-01","drugbank-id":"DB15891"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758]. The vaccine was developed using a DNA vaccine platform with a  non-replicating and non-integrating plasmid carrying the gene of interest[L16503]. Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503]. The DNA vaccine platform offers minimal biosafety requirements, more improved vaccine stability, and lower cold chain requirements[L16503]. Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and tolerance[A219758,L16493]. As of August, 2020 the candidate is in Phase II clinical trials[A219758].","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-30","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"ZYCOV-D","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-01","drugbank-id":"DB15892"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"This vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758]. The vaccine candidate is sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. and is undergoing phase I clinical trials to evaluate safety and tolerability.","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-09-30","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CHO Cells Recombinant Vaccine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-01","drugbank-id":"DB15893"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"42B5YD8F0K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-10-01","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Glycyrrhiza uralensis root","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-01","drugbank-id":"DB15894"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on [COVID-19 convalescent plasma]. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability to neutralize the virus, reduce inflammatory responses, and the absence of aggravating reactions following treatment[L16563]. Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558]. As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety and efficacy of XAV-19 (NCT04453384).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-10-03","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"XAV-19","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-04","drugbank-id":"DB15895"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.[L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]","enzymes":null,"type":"biotech","cas-number":"2423948-94-9","sequences":null,"targets":"BE0010022","unii":"N7Q9NLF11I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Etesevimab aims to neutralize SARS-CoV-2 by specifically binding to the virus' surface spike protein receptor binding domain. This high affinity binding then prevents SARS-CoV-2 from binding to the ACE2 host cell surface receptor. Etesevimab is currently being investigated against COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-10-07","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Etesevimab","metabolism":null,"reactions":null,"indication":"Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. This combination regimen is also used for post-exposure prophylaxis of COVID-19 in unvaccinated or immunocompromised adults and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death.[L40184]","ahfs-codes":null,"updated":"2022-04-01","drugbank-id":"DB15897"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Atoltivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the GP<sub>1,2<\/sub> glycoprotein that provides both neutralizing and Fc-dependent immune-mediated activity against _Zaire ebolavirus_. As a mAb, Atoltivimab exhibits low toxicity and is generally well tolerated but does include the risk of potentially life-threatening hypersensitivity reactions.[L17320]","msds":null,"description":"Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.[A222078] The chief surface target of EBOV particles is the GP<sub>1,2<\/sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.[A222078]\r\n\r\nINMAZEB\u201E, formerly referred to as REGN-EB3, combines the three humanized IgG1 mAbs Atoltivimab (REGN 3470), [Odesivimab] (REGN 3471), and [Maftivimab] (REGN 3479) in equimolar proportions. All three mAbs bind to a distinct portion of the GP<sub>1,2<\/sub> glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against EBOV infection _in vivo_. INMAZEB\u201E is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]","enzymes":null,"type":"biotech","cas-number":"2135632-29-8","sequences":null,"targets":"BE0010023","unii":"FJZ07Q63VY","protein-binding":null,"fda-label":null,"clearance":"Atoltivimab administered to healthy subjects at 50 mg\/kg has a mean clearance of 3.08  0.719 mL\/day\/kg.[L17320]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093\/infdis\/jiy285.","mechanism-of-action":"Ebola virus (EBOV) is one of several viruses within the _Ebolavirus_ genus known to infect humans with an average case fatality rate of 43.92%.[A221825] EBOV particles expose the GP<sub>1,2<\/sub> glycoprotein on their surface, which comprises a trimer of GP<sub>1<\/sub> and GP<sub>2<\/sub> subunit heterodimers, with the subunits connected by a disulfide bond. GP<sub>1,2<\/sub> plays an important role in both cell surface attachment\/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1\/Niemann-Pick C1 protein (NPC1). In this manner, GP<sub>1,2<\/sub> is integral to the pathogenic cycle of EBOV.[A221825, A221830]\r\n\r\nAtoltivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the EBOV GP<sub>1,2<\/sub> glycoprotein, which binds the GP<sub>1,2<\/sub> glycan cap parallel to the viral surface with a binding affinity (_K<sub>D<\/sub>_) of between 7.74 and 7.84 nM.[A221830, L17320] Atoltivimab exhibits strong (<90%) neutralization of chimeric lentiviral particles expressing EBOV GP<sub>1,2<\/sub> with a half-maximal inhibitory concentration (IC<sub>50<\/sub>) value of 0.27 nM. In addition, Atoltivimab is capable of dose-dependent activation of FcRIIIa signalling in effector cells in the presence of GP<sub>1,2<\/sub>-expressing cells with a half-maximal effective concentration (EC<sub>50<\/sub>) of 2.9 nM.[A221830] Combined with [Odesivimab] and [Maftivimab], Atoltivimab works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells.[A221825, A221830, A222078, L17320]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12386 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB14685 DB12520 DB10804 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB11003 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB10317 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB11050 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB10343 DB00078 DB16648 DB05136 DB04956 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB10318 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB10805 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB14409 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB12768 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"Atoltivimab administered to healthy subjects at 50 mg\/kg produced a mean C<sub>max<\/sub> of 1220  101 mg\/L and a mean AUC<sub>0-<\/sub> of 17,100  4480 mg\\*day\/L.[L17320]","created":"2020-10-16","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Atoltivimab administered to healthy subjects at 50 mg\/kg has a mean elimination half-life of 21.2  3.36 days.[L17320]","monoisotopic-mass":null,"volume-of-distribution":"Atoltivimab administered to healthy subjects at 50 mg\/kg produced a mean steady-state volume of distribution of 58.2  2.66 mL\/kg.[L17320]","route-of-elimination":null,"name":"Atoltivimab","metabolism":null,"reactions":null,"indication":"Atoltivimab is indicated in combination with [Odesivimab] and [Maftivimab] for the treatment of _Zaire ebolavirus_ infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for _Zaire ebolavirus_ infection. This combination has not been established as efficacious for any other species within either the _Ebolavirus_ or _Marburgvirus_ genera; special care should be taken to evaluate the susceptibility of circulating _Zaire ebolavirus_ strains before beginning treatment, and the possible emergence of resistance should be monitored.[L17320]","ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB15898"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Maftivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the GP<sub>1,2<\/sub> glycoprotein that provides strong neutralizing activity against _Zaire ebolavirus_. As a mAb, maftivimab exhibits low toxicity and is generally well tolerated but does include the risk of potentially life-threatening hypersensitivity reactions.[L17320]","msds":null,"description":"Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.[A222078] The chief surface target of EBOV particles is the GP<sub>1,2<\/sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.[A222078]\r\n\r\nINMAZEB\u201E, formerly referred to as REGN-EB3, combines the three humanized IgG1 mAbs Maftivimab (REGN 3479), [Odesivimab] (REGN 3471), and [Atoltivimab] (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP<sub>1,2<\/sub> glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against EBOV infection _in vivo_. INMAZEB\u201E is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]","enzymes":null,"type":"biotech","cas-number":"2135632-36-7","sequences":null,"targets":"BE0010023","unii":"KOP95331M4","protein-binding":null,"fda-label":null,"clearance":"Maftivimab administered to healthy subjects at 50 mg\/kg has a mean clearance of 2.78  0.558 mL\/day\/kg.[L17320]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093\/infdis\/jiy285.","mechanism-of-action":"Ebola virus (EBOV) is one of several viruses within the _Ebolavirus_ genus known to infect humans with an average case fatality rate of 43.92%.[A221825] EBOV particles expose the GP<sub>1,2<\/sub> glycoprotein on their surface, which comprises a trimer of GP<sub>1<\/sub> and GP<sub>2<\/sub> subunit heterodimers, with the subunits connected by a disulfide bond. GP<sub>1,2<\/sub> plays an important role in both cell surface attachment\/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1\/Niemann-Pick C1 protein (NPC1). In this manner, GP<sub>1,2<\/sub> is integral to the pathogenic cycle of EBOV.[A221825, A221830]\r\n\r\nMaftivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the EBOV GP<sub>1,2<\/sub> glycoprotein, which binds between GP1 and GP2 protomers at the base of the GP<sub>1,2<\/sub> protein with a binding affinity (_K<sub>D<\/sub>_) of between 2.97 and 3.34 nM.[A221830, L17320] Maftivimab exhibits strong neutralization of chimeric lentiviral particles expressing EBOV GP<sub>1,2<\/sub> with a half-maximal inhibitory concentration (IC<sub>50<\/sub>) value or 0.17 nM, but lacks the ability to induce FcRIIIa signalling in effector cells.[A221830]. Combined with [Odesivimab] and [Atoltivimab], Maftivimab works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells.[A221825, A221830, A222078, L17320]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12386 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB14685 DB12520 DB10804 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB11003 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB10317 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB11050 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB10343 DB00078 DB16648 DB05136 DB04956 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB10318 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB10805 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB14409 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB12768 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"Maftivimab administered to healthy subjects at 50 mg\/kg produced a mean C<sub>max<\/sub> of 1280  68.0 mg\/L and a mean AUC<sub>0-<\/sub> of 18,700  4100 mg\\*day\/L.[L17320]","created":"2020-10-16","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Maftivimab administered to healthy subjects at 50 mg\/kg has a mean elimination half-life of 22.3  3.09 days.[L17320]","monoisotopic-mass":null,"volume-of-distribution":"Maftivimab administered to healthy subjects at 50 mg\/kg produced a mean steady-state volume of distribution of 57.6  3.89 mL\/kg.[L17320]","route-of-elimination":null,"name":"Maftivimab","metabolism":null,"reactions":null,"indication":"Maftivimab is indicated in combination with [Odesivimab] and [Atoltivimab] for the treatment of _Zaire ebolavirus_ infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for _Zaire ebolavirus_ infection. This combination has not been established as efficacious for any other species within either the _Ebolavirus_ or _Marburgvirus_ genera; special care should be taken to evaluate the susceptibility of circulating _Zaire ebolavirus_ strains before beginning treatment, and the possible emergence of resistance should be monitored.[L17320]","ahfs-codes":null,"updated":"2022-01-27","drugbank-id":"DB15899"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Odesivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the GP<sub>1,2<\/sub> glycoprotein that provides both neutralizing and Fc-dependent immune-mediated activity against _Zaire ebolavirus_. As a mAb, Odesivimab exhibits low toxicity and is generally well tolerated but does include the risk of potentially life-threatening hypersensitivity reactions.[L17320]","msds":null,"description":"Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.[A222078] The chief surface target of EBOV particles is the GP<sub>1,2<\/sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.[A222078]\r\n\r\nINMAZEB\u201E, formerly referred to as REGN-EB3, combines the three humanized IgG1 mAbs Odesivimab (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions. All three mAbs bind to a distinct portion of the GP<sub>1,2<\/sub> glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against EBOV infection _in vivo_. INMAZEB\u201E is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]","enzymes":null,"type":"biotech","cas-number":"2135632-30-1","sequences":null,"targets":"BE0010023","unii":"UY9LQ8P6HW","protein-binding":null,"fda-label":null,"clearance":"Odesivimab administered to healthy subjects at 50 mg\/kg has a mean clearance of 2.02  0.374 mL\/day\/kg.[L17320]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":"Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093\/infdis\/jiy285.","mechanism-of-action":"Ebola virus (EBOV) is one of several viruses within the _Ebolavirus_ genus known to infect humans with an average case fatality rate of 43.92%.[A221825] EBOV particles expose the GP<sub>1,2<\/sub> glycoprotein on their surface, which comprises a trimer of GP<sub>1<\/sub> and GP<sub>2<\/sub> subunit heterodimers, with the subunits connected by a disulfide bond. GP<sub>1,2<\/sub> plays an important role in both cell surface attachment\/entry and eventual lysosomal escape through binding to the NPC intracellular cholesterol transporter 1\/Niemann-Pick C1 protein (NPC1). In this manner, GP<sub>1,2<\/sub> is integral to the pathogenic cycle of EBOV.[A221825, A221830]\r\n\r\nOdesivimab is a fully-humanized IgG1 monoclonal antibody (mAb) directed against the EBOV GP<sub>1,2<\/sub> glycoprotein, which binds within the \"chalice\" structure near the GP head in partial contact with the glycan cap with a binding affinity (_K<sub>D<\/sub>_) of between 8.26 and 8.42 nM.[A221830, L17320] Odesivimab exhibits weak (<50%) neutralization of chimeric lentiviral particles expressing EBOV GP<sub>1,2<\/sub> and is able to bind soluble GP<sub>1,2<\/sub>. In addition, Odesivimab is capable of dose-dependent activation of FcRIIIa signalling in effector cells in the presence of GP<sub>1,2<\/sub>-expressing cells with a half-maximal effective concentration (EC<sub>50<\/sub>) of 1.6 nM.[A221830] Combined with [Maftivimab] and [Atoltivimab], Odesivimab works to block EBOV cell infection and lysosomal escape, as well as the potential antibody-dependent cell-mediated killing of EBOV-infected cells.[A221825, A221830, A222078, L17320]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12386 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB14685 DB12520 DB10804 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB11003 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB09369 DB00977 DB12891 DB15415 DB05276 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB10317 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB11050 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB10343 DB00078 DB16648 DB05136 DB04956 DB06081 DB12159 DB14443 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB10318 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB10805 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB14409 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB12768 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":"Odesivimab administered to healthy subjects at 50 mg\/kg produced a mean C<sub>max<\/sub> of 1260  81.2 mg\/L and a mean AUC<sub>0-<\/sub> of 25,600  5040 mg\\*day\/L.[L17320]","created":"2020-10-16","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Odesivimab administered to healthy subjects at 50 mg\/kg has a mean elimination half-life of 25.3  3.86 days.[L17320]","monoisotopic-mass":null,"volume-of-distribution":"Odesivimab administered to healthy subjects at 50 mg\/kg produced a mean steady-state volume of distribution of 56.0  3.16 mL\/kg.[L17320]","route-of-elimination":null,"name":"Odesivimab","metabolism":null,"reactions":null,"indication":"Odesivimab is indicated in combination with [Maftivimab] and [Atoltivimab] for the treatment of _Zaire ebolavirus_ infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for _Zaire ebolavirus_ infection. This combination has not been established as efficacious for any other species within either the _Ebolavirus_ or _Marburgvirus_ genera; special care should be taken to evaluate the susceptibility of circulating _Zaire ebolavirus_ strains before beginning treatment, and the possible emergence of resistance should be monitored.[L17320]","ahfs-codes":null,"updated":"2022-01-27","drugbank-id":"DB15900"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.221,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"3228-02-2","sequences":null,"targets":null,"unii":"H41B6Q1I9L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-10-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.104465071,"volume-of-distribution":null,"route-of-elimination":null,"name":"o-Cymen-5-ol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-10-27","drugbank-id":"DB15901"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":209.289,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"36981-91-6","sequences":null,"targets":null,"unii":"860MHI4WBA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-12","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":209.141578856,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fepradinol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15902"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":404.93,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Chlormadinone acetate is a progesterone derivative first synthesized in 1961. In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens. However, the use of these drugs was associated with the development of mammary tumors in dogs. In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.[L43942,L42975] Chlormadinone acetate continues to be used in other countries due to its high contraceptive efficacy and tolerability.[A254422,L33974]","enzymes":null,"type":"small molecule","cas-number":"302-22-7","sequences":null,"targets":null,"unii":"0SY050L61N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB16019 DB09277 DB00089 DB14805","absorption":null,"created":"2020-11-19","groups":"experimental withdrawn","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":404.1754371,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chlormadinone acetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15903"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"24A0VB48CA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-19","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alnus glutinosa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-23","drugbank-id":"DB15904"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":107.112,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"500-22-1","sequences":null,"targets":null,"unii":"840R4IDQ1T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":107.037113785,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nicotinaldehyde","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-23","drugbank-id":"DB15905"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":26.038,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"74-86-2","sequences":null,"targets":null,"unii":"OC7TV75O83","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":26.015650064,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acetylene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15906"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2262.538,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"6805-41-0","sequences":null,"targets":null,"unii":"RUU8G67GQM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2261.101807298,"volume-of-distribution":null,"route-of-elimination":null,"name":"Escin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-13","drugbank-id":"DB15907"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":309.158,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"66813-51-2","sequences":null,"targets":null,"unii":"JDN69ZV6XV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":309.0372809,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alexitol sodium","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB15908"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":536.888,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7488-99-5","sequences":null,"targets":null,"unii":"45XWE1Z69V","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":536.438201803,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Carotene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-23","drugbank-id":"DB15909"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1344-00-9","sequences":null,"targets":null,"unii":"058TS43PSM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sodium aluminosilicate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15910"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":255.273,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"51579-82-9","sequences":null,"targets":null,"unii":"28O5C1J38A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":255.089543283,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amfenac","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15911"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":142.98,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7778-54-3","sequences":null,"targets":null,"unii":"11DXB629VZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":141.8901255,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium hypochlorite","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15912"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":552.887,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"472-70-8","sequences":null,"targets":null,"unii":"6ZIB13GI33","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-20","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":552.433116423,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cryptoxanthin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-23","drugbank-id":"DB15914"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":231.133,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"76-29-9","sequences":null,"targets":null,"unii":"NAY429URSN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":230.030628,"volume-of-distribution":null,"route-of-elimination":null,"name":"Camphor monobromide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-23","drugbank-id":"DB15915"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":148.205,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"4180-23-8","sequences":null,"targets":null,"unii":"Q3JEK5DO4K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":148.088815006,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anethole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15916"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":136.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"79-92-5","sequences":null,"targets":null,"unii":"G3VG94Z26E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":136.125200515,"volume-of-distribution":null,"route-of-elimination":null,"name":"Camphene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15917"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":152.237,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1195-79-5","sequences":null,"targets":null,"unii":"4Q6W8568TG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":152.120115135,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fenchone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15918"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":790.306,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"59985-21-6","sequences":null,"targets":null,"unii":"7828VC80FJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":789.993831105,"volume-of-distribution":null,"route-of-elimination":null,"name":"Diquafosol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15919"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":154.253,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"89-80-5","sequences":null,"targets":null,"unii":"9NH5J4V8FN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":154.1357652,"volume-of-distribution":null,"route-of-elimination":null,"name":"Menthone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15920"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":535.813,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"43119-47-7","sequences":null,"targets":null,"unii":"WI1J5UCY5C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":535.402544571,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tocopheryl nicotinate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15921"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8008-98-8","sequences":null,"targets":null,"unii":"J3TO6BUQ37","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cajuput oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15922"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":214.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7758-05-6","sequences":null,"targets":null,"unii":"I139E44NHL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":213.85292,"volume-of-distribution":null,"route-of-elimination":null,"name":"Potassium iodate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15923"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":143.95,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1313-27-5","sequences":null,"targets":null,"unii":"22FQ3F03YS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-23","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":145.890149,"volume-of-distribution":null,"route-of-elimination":null,"name":"Molybdenum trioxide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15924"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":79.055,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1066-33-7","sequences":null,"targets":null,"unii":"45JP4345C9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":79.026943025,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ammonium bicarbonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15925"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":96.086,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"506-87-6","sequences":null,"targets":null,"unii":"PDP691CN28","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":96.053492126,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ammonium carbonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15926"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":130.187,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"628-63-7","sequences":null,"targets":null,"unii":"92Q24NH7AS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":130.099379691,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amyl acetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15927"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"9000-04-8","sequences":null,"targets":null,"unii":"W9FZA51AS1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Asafoetida","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15928"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":465.958,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1304-76-3","sequences":null,"targets":null,"unii":"A6I4E79QF1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":465.94554,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bismuth oxide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15929"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":201.225,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"63-25-2","sequences":null,"targets":null,"unii":"R890C8J3N1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00975","absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":201.078978598,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carbaryl","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15930"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":184.282,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"529-05-5","sequences":null,"targets":null,"unii":"Z439UH6E5F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":184.125200515,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chamazulene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15931"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":325.84,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"442-52-4","sequences":null,"targets":null,"unii":"T97CB3796L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":325.1345754,"volume-of-distribution":null,"route-of-elimination":null,"name":"Clemizole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15932"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":179.6,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"130-16-5","sequences":null,"targets":null,"unii":"BPF36H1G6S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":179.0137915,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cloxyquin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15933"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":479.858,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1301-70-8","sequences":null,"targets":null,"unii":"MUL7ONL3Z6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-24","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":479.897222,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ferric glycerophosphate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-30","drugbank-id":"DB15934"},{"toxicity":"Data regarding overdoses of lumasiran are not readily available.[L23519] In the event of an overdose, patients should be monitored for signs of adverse reactions and be treated symptomatically.[L23519]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Lumasiran is a small interfering RNA that prevents the translation of glycolate oxidase, which reduces levels of glyoxylate, reducing metabolism of glyoxylate to oxalate.[L23404,L23519] The duration of action is long as it is given every 3 months.[L23519] Patients should be counselled regarding the risk of worsening metabolic acidosis in severe or end stage renal disease, as well as potentially decreased efficacy in moderate to severe hepatic impairment.[L23519]","msds":null,"description":"Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.[L23554] These patients experience frequent kidney stones, nephrocalcinosis, and renal failure.[L23554]\r\n\r\nOxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1.[L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.[L23554]\r\n\r\nLumasiran was granted FDA approval on 23 November 2020.[L23394]","enzymes":"BE0002887","type":"biotech","cas-number":"1834610-13-7","sequences":null,"targets":"BE0003766","unii":"RZT8C352O1","protein-binding":"Lumasiran is 77% to 85% bound to protein in plasma.[L23519]","fda-label":null,"clearance":"The apparent plasma clearance of lumasiran based on population estimate is 26.5 L\/h for an average 70 kg adult.[L23519] The mean renal clearance is 2.0-3.4 L\/h.[L23519]","atc-codes":"OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS ALIMENTARY TRACT AND METABOLISM Various alimentary tract and metabolism products","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Patients with primary hyperoxaluria type 1 produce an excess of oxalate due to a deficiency in the enzyme alanine-glyoxylate aminotransferase.[A224369,L23404]\r\n\r\nLumasiran is a small interfering RNA that silences the gene hydroxyacid oxidase 1 (HOA1).[L23404] Lumasiran targets HOA1 mRNA, preventing translation to the enzyme glycolate oxidase (GO).[L23519] Reduced levels of GO, reduce levels of glyoxylate, leaving less reactants available for metabolism to oxalate.[L23519] In the ILLUMINATE trials, lumasiran reduced oxalate levels in 84% of adults and children over 6 years to at or below 1.5 times the upper limits of normal.[L23404]","drug-interactions":null,"absorption":"In patients \u203020 kg; a 3 mg\/kg subcutaneous dose of lumasiran reacheas a C<sub>max<\/sub> of 529 ng\/mL, with a T<sub>max<\/sub> of 4.0 hours, and an AUC of 7400 ng\\*h\/mL.[L23519] In patients <20 kg; a 6 mg\/kg subcutaneous dose of lumasiran reaches a C<sub>max<\/sub> of 912 ng\/mL and an AUC of 7960 ng\\*h\/mL.[L23519]","created":"2020-11-24","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":"BE0000530","half-life":"The mean terminal half life of lumasiran is 5.2 hours.[L23519]","monoisotopic-mass":null,"volume-of-distribution":"The apparent central volume of distribution based on population estimate is 4.9 L.[L23519]","route-of-elimination":"7-26% of a dose of lumasiran is recovered in the urine as the unmetabolized parent compound.[L23519]\r\n\r\nA radiolabelled dose administered to rats was 19.5% recovered in urine and 33.9% recovered in feces.[L23554]","name":"Lumasiran","metabolism":"Lumasiran is metabolized to smaller oligonucleotides by endo- and exonucleases.[L23519] The sense strand is less prone to metabolism due to protection by the GalNac group at the 3' end.[L23554]\r\n\r\nLumasiran weakly inhibits CYP2C8 with an IC<sub>50<\/sub> of 461 M, 14000 times pharmacologically relevant concentrations.[L23554] It is not a substrate or inducer of any CYP450 enzymes.[L23554]","reactions":null,"indication":"Lumasiran is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients.[L23394,L23519,L43413]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB15935"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza virus type A (H1N1)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15936"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza virus type A (H3N2)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15937"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza virus type B (Victoria)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15938"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza virus type B (Yamagata)","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-25","drugbank-id":"DB15939"},{"toxicity":"There is limited information on overdose. Up to 4000 mg, which is approximately seven times the recommended dose of the drug, was administered in clinical trials. There is no known specific antidote for imdevimab overdose so treatment of overdose should involve general supportive measures.[L39135]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Casirivimab and imdevimab work to neutralize the spike protein of SARS-CoV-2.[L23524] In a clinical trial, casirivimab and imdevimab, when given together, reduced COVID-19-related hospitalization or emergency room visits in patients diagnosed with COVID-19 who were at high risk for disease progression within 28 days after treatment. No benefit has been shown in patients already hospitalized due to COVID-19 receiving this combination.[L23539]","msds":null,"description":"Imdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19.[L23539] This drug is a combination of antibodies derived from humanized VelocImmune  mice in addition to blood samples from patients who have recovered from COVID-19.[A224429]  These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.[A221495] \r\n\r\nOn November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.[L39130,L39135]\r\n\r\nFull safety and efficacy data on imdevimab are not yet available, and further evaluation of this investigational therapy will continue.[L23529,L23539,L14303]","enzymes":null,"type":"biotech","cas-number":"2415933-40-1","sequences":null,"targets":"BE0010022","unii":"2Z3DQD2JHM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":"Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010-1014. doi:10.1126\/science.abd0827","mechanism-of-action":"Imdevimab is a recombinant human IgG1 monoclonal antibody targeting the receptor binding domain of the spike protein of SARS-CoV-2; a protein playing an important role in viral attachment, fusion, and entry into the target cell by binding to the ACE2 receptor.[A224424,A224434,L23529] Together with casirivimab, imdevimab neutralizes the spike protein of SARS-CoV-2.[L23529]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-11-25","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Imdevimab","metabolism":null,"reactions":null,"indication":"According to the Emergency Use Authorization (EUA) by the FDA and EMA, indevimab is used only with casirivimab to prevent COVID-19 and treat mild to moderate COVID-19 from laboratory-confirmed SARS-CoV-2 infection in patients aged 12 years of age and older who weigh at least 40 kg. Treatment is reserved for patients who are at high risk for progressing to require hospitalization or severe COVID-19.[L23524,L23534,L39135]\r\n\r\nThis combination may only be administered by intravenous infusion in healthcare settings with immediate access to treatment for infusion reactions and anaphylaxis, and the ability to activate the emergency medical system (EMS), as required.[L23534,L23539]\r\n\r\n**Limitations of use**\r\n\r\nImdevimab and casirivimab are not for use in patients currently hospitalized due to COVID-19, patients requiring oxygen therapy due to COVID-19, patients requiring increases in baseline oxygen flow rate from COVID-19, or patients on oxygen therapy for non-COVID-19 related morbidity.[L23524,L23534]","ahfs-codes":null,"updated":"2021-12-04","drugbank-id":"DB15940"},{"toxicity":"There is limited information on overdose. Up to 4000 mg, which is approximately seven times the recommended dose of the drug, was administered in clinical trials. There is no known specific antidote for casirivimab overdose so treatment of overdose should involve general supportive measures.[L39135]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Casirivimab and imdevimab work to neutralize the spike protein of SARS-CoV-2.[L23524] In a clinical trial, casirivimab and imdevimab, when given together, reduced COVID-19-related hospitalization or emergency room visits in patients diagnosed with COVID-19 who were at high risk for disease progression within 28 days after treatment. No benefit has been shown in patients already hospitalized due to COVID-19 receiving this combination.[L23539]","msds":null,"description":"Casirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19.[L23539] This drug is a combination of antibodies derived from humanized VelocImmune  mice in addition to blood samples from patients who have recovered from COVID-19.[A224429]  These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape.[A221495] \r\n\r\nOn November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.[L39130,L39135]\r\n\r\nFull safety and efficacy data are not yet available, and further evaluation of this investigational therapy will continue.[L23539,L23529,L14303]","enzymes":null,"type":"biotech","cas-number":"2415933-42-3","sequences":null,"targets":"BE0010022","unii":"J0FI6WE1QN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":"Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010-1014. doi:10.1126\/science.abd0827","mechanism-of-action":"Casirivimab is a recombinant human IgG1 monoclonal antibody targeting the receptor binding domain of the spike protein of SARS-CoV-2; a protein playing an important role in viral attachment, fusion, and entry into the cell.[A224434,L23529] Together with imdevimab, casirivimab neutralizes the spike protein of SARS-CoV-2.[L23529]","drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB15258 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-11-25","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Casirivimab","metabolism":null,"reactions":null,"indication":"According to the Emergency Use Authorization (EUA) by the FDA and EMA, indevimab is used only with casirivimab to prevent COVID-19 and treat mild to moderate COVID-19 from laboratory-confirmed SARS-CoV-2 infection in patients aged 12 years of age and older who weigh at least 40 kg. Treatment is reserved for patients who are at high risk for progressing to require hospitalization or severe COVID-19.[L23524,L23534,L39135]\r\n\r\nThis combination may only be administered by intravenous infusion in healthcare settings with immediate access to treatment for infusion reactions and anaphylaxis, and the ability to activate the emergency medical system (EMS), as required.[L23539,L23534]\r\n\r\n**Limitations of use**\r\n\r\nImdevimab and casirivimab are not for use in patients currently hospitalized due to COVID-19, patients requiring oxygen therapy due to COVID-19, patients requiring increases in baseline oxygen flow rate from COVID-19, or patients on oxygen therapy for non-COVID-19 related morbidity.[L23524,L23534]","ahfs-codes":null,"updated":"2022-02-03","drugbank-id":"DB15941"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":360.9,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"15599-36-7","sequences":null,"targets":null,"unii":"U89MCO87LX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":360.1063122,"volume-of-distribution":null,"route-of-elimination":null,"name":"Haletazole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15942"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":624.592,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"24292-52-2","sequences":null,"targets":null,"unii":"4T2GVA922X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":624.205420459,"volume-of-distribution":null,"route-of-elimination":null,"name":"Hesperidin methylchalcone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15943"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":254.26,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"130-36-9","sequences":null,"targets":null,"unii":"I2BE1ZEN8I","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB12409 DB13192 DB13244 DB01083 DB11608 DB13151 DB14473 DB09109 DB06245 DB00100 DB00086 DB00058 DB06679 DB13729 DB11668 DB14738 DB00009 DB00170 DB09222 DB00302 DB13884 DB13152 DB00031 DB06692 DB11330 DB01783 DB13923 DB11311 DB13201 DB13646 DB09310 DB12909 DB11091 DB13150 DB13999 DB00036 DB14700 DB01942 DB13933 DB00013 DB14577 DB00025 DB02261 DB11606 DB00029 DB00755 DB13148 DB13133 DB16007 DB00513 DB01373 DB00015 DB09329 DB14562 DB13197 DB13149","absorption":null,"created":"2020-11-25","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":254.024894596,"volume-of-distribution":null,"route-of-elimination":null,"name":"Menadione bisulfite","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB15944"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":308.249,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1043-21-6","sequences":null,"targets":null,"unii":"27L0EP6IZK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":308.043321366,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pirenoxine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15945"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":237.343,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Piroctone olamine is used in combination with other substances as a part of shampoo effectively reduced the amount of dandruff and, at the same time, provided hair conditioning advantages. Recently was shown, that piroctone olamine could induce apoptosis and possessed a significant in vivo effect against myeloma.[L34189]","enzymes":null,"type":"small molecule","cas-number":"50650-76-5","sequences":null,"targets":null,"unii":"R49EFA73Q7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":237.172878985,"volume-of-distribution":null,"route-of-elimination":null,"name":"Piroctone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB15946"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":367.445,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"54063-52-4","sequences":null,"targets":null,"unii":"M09N8K7YJY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ALIMENTARY TRACT AND METABOLISM ANTISPASMODICS IN COMBINATION WITH ANALGESICS Synthetic anticholinergic agents in combination with analgesics DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":367.178358289,"volume-of-distribution":null,"route-of-elimination":null,"name":"Pitofenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15947"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":248.253,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1319-69-3","sequences":null,"targets":null,"unii":"6ZC849M884","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":247.92543792,"volume-of-distribution":null,"route-of-elimination":null,"name":"Potassium glycerophosphate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15948"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":352.434,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"483-04-5","sequences":null,"targets":null,"unii":"4QJL8OX71Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":352.178692641,"volume-of-distribution":null,"route-of-elimination":null,"name":"Raubasine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15949"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":254.28,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"21791-94-6","sequences":null,"targets":null,"unii":"CFN2D8XEIU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":254.05887442,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sodium camphorsulfonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-30","drugbank-id":"DB15950"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":488.4,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"3863-80-7","sequences":null,"targets":null,"unii":"58B6F1X64H","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":487.98371497,"volume-of-distribution":null,"route-of-elimination":null,"name":"Azapentacene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15951"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":84.994,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7631-99-4","sequences":null,"targets":null,"unii":"8M4L3H2ZVZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":84.97758714,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sodium nitrate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15952"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":270.501,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"112-92-5","sequences":null,"targets":null,"unii":"2KR89I4H1Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":270.292265844,"volume-of-distribution":null,"route-of-elimination":null,"name":"Stearyl alcohol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15953"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":334.419,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"57-24-9","sequences":null,"targets":null,"unii":"H9Y79VD43J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":334.168127956,"volume-of-distribution":null,"route-of-elimination":null,"name":"Strychnine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-13","drugbank-id":"DB15954"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":330.556,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"6809-52-5","sequences":null,"targets":null,"unii":"57B67OXM8F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Teprenone acts as an anti-ulcer and gastric mucoprotective agent used to treat gastric ulcers and gastritis. Currently, the full mechanisms of action are still unclear.","drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":330.292265844,"volume-of-distribution":null,"route-of-elimination":null,"name":"Teprenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15955"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":154.253,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"8000-41-7","sequences":null,"targets":null,"unii":"21334LVV8W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":154.1357652,"volume-of-distribution":null,"route-of-elimination":null,"name":"Terpineol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15956"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":196.29,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"8007-35-0","sequences":null,"targets":null,"unii":"9RXE0I9F2J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":196.146329884,"volume-of-distribution":null,"route-of-elimination":null,"name":"Terpinyl acetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15957"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":562.71,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"67-16-3","sequences":null,"targets":null,"unii":"UJV8K21YKL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":562.214443955,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thiamine disulfide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15958"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":369.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"73803-48-2","sequences":null,"targets":null,"unii":"G36A0E9CVT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB01345 DB00328 DB00682 DB14652 DB00928 DB14649 DB00887 DB00742 DB06196 DB06255 DB06737 DB00178 DB09570 DB00204 DB06251 DB09205 DB07715 DB09217 DB01142 DB06823 DB11564 DB06230 DB01078 DB06696 DB01215 DB11085 DB00814 DB09185 DB09273 DB00558 DB09209 DB15465 DB14633 DB14006 DB00280 DB00802 DB00642 DB08437 DB00800 DB13286 DB13432 DB11921 DB09484 DB01409 DB06228 DB01337 DB09257 DB12604 DB00605 DB01306 DB13691 DB00962 DB09325 DB00368 DB09195 DB06796 DB01209 DB08984 DB11520 DB06154 DB15477 DB00583 DB00321 DB00732 DB00863 DB01102 DB01129 DB14506 DB01140 DB06211 DB00665 DB13843 DB01020 DB06705 DB00292 DB06767 DB00490 DB00806 DB01067 DB13537 DB01535 DB06814 DB14504 DB01124 DB00798 DB08970 DB00046 DB00535 DB00631 DB01273 DB01558 DB08932 DB00853 DB01396 DB01148 DB01339 DB09050 DB11901 DB01551 DB00390 DB00492 DB11201 DB00741 DB00839 DB01039 DB01421 DB13208 DB01577 DB13293 DB04846 DB09082 DB09383 DB14541 DB09111 DB00787 DB11057 DB09462 DB00851 DB05676 DB00519 DB00230 DB00959 DB13943 DB04828 DB00181 DB11228 DB09481 DB00684 DB14659 DB01249 DB01610 DB00547 DB09546 DB11367 DB11114 DB00945 DB09081 DB00901 DB00440 DB00820 DB01555 DB06402 DB06813 DB13954 DB01466 DB01064 DB00017 DB00577 DB01309 DB00708 DB14210 DB12610 DB01240 DB09080 DB09224 DB00245 DB01274 DB01046 DB00581 DB13145 DB01364 DB13787 DB15478 DB00731 DB09084 DB13180 DB13584 DB00553 DB00630 DB05095 DB01035 DB01082 DB00871 DB09394 DB00438 DB09132 DB00788 DB00939 DB00030 DB00552 DB13240 DB14209 DB13167 DB00402 DB00775 DB00908 DB09368 DB00733 DB06262 DB00372 DB09210 DB00091 DB00652 DB03615 DB05039 DB00529 DB00691 DB14217 DB08861 DB00584 DB09409 DB06725 DB00351 DB09496 DB00612 DB12545 DB01245 DB00511 DB00598 DB09265 DB08894 DB00710 DB14540 DB09320 DB09194 DB00841 DB00749 DB13595 DB08955 DB13612 DB00980 DB14207 DB01397 DB01015 DB08906 DB01410 DB00983 DB14529 DB00213 DB09020 DB00476 DB00668 DB06695 DB09136 DB06738 DB13467 DB12100 DB00951 DB00789 DB09220 DB00586 DB00327 DB00784 DB14213 DB11102 DB00237 DB01156 DB00720 DB11121 DB05018 DB00899 DB01333 DB09133 DB11817 DB00270 DB00993 DB00915 DB13955 DB09488 DB09149 DB02224 DB00165 DB01093 DB01234 DB00007 DB09477 DB00706 DB01137 DB11127 DB11364 DB01241 DB13217 DB09103 DB01283 DB00695 DB00960 DB00452 DB00635 DB09413 DB00881 DB00312 DB00363 DB01359 DB01638 DB00316 DB04871 DB01435 DB00355 DB00206 DB14938 DB00294 DB00628 DB00418 DB01459 DB04930 DB09414 DB00884 DB09121 DB00193 DB09378 DB08905 DB09318 DB00722 DB13605 DB00416 DB09288 DB01452 DB00936 DB11567 DB00231 DB04890 DB11110 DB06203 DB00894 DB00633 DB06807 DB11090 DB09218 DB13524 DB14963 DB06736 DB13407 DB09068 DB00816 DB03585 DB13454 DB00734 DB13649 DB00432 DB00469 DB00955 DB00783 DB01227 DB00624 DB14059 DB11136 DB15593 DB00397 DB01550 DB00394 DB00479 DB00861 DB13371 DB09449 DB00988 DB05541 DB00842 DB01199 DB08904 DB08910 DB09502 DB00828 DB00454 DB00569 DB00176 DB14516 DB00500 DB01170 DB00401 DB01366 DB01438 DB06283 DB01092 DB00921 DB00035 DB08824 DB01192 DB01108 DB14007 DB13312 DB09215 DB01157 DB14502 DB00196 DB11560 DB01450 DB08996 DB13307 DB09407 DB13178 DB08840 DB14530 DB11189 DB13606 DB15889 DB00803 DB11113 DB01181 DB00158 DB00780 DB00690 DB00812 DB00339 DB00833 DB08893 DB11098 DB09543 DB01384 DB00591 DB00377 DB04729 DB01275 DB00323 DB11512 DB09095 DB13025 DB01099 DB00811 DB00555 DB00661 DB08909 DB09118 DB13884 DB00289 DB09083 DB00404 DB09357 DB01531 DB00502 DB01213 DB09295 DB00651 DB00692 DB04948 DB01250 DB09395 DB14881 DB01047 DB11783 DB12615 DB09483 DB00763 DB09245 DB01133 DB04953 DB13956 DB01011 DB13538 DB09317 DB01002 DB00603 DB00867 DB13001 DB14545 DB00956 DB09277 DB00290 DB14026 DB00322 DB00660 DB15566 DB00564 DB00398 DB11156 DB00330 DB08439 DB13269 DB00713 DB01407 DB01105 DB08899 DB13648 DB13003 DB13486 DB13944 DB01050 DB04896 DB00854 DB09163 DB00182 DB09241 DB11609 DB08981 DB01587 DB00412 DB00704 DB00597 DB00295 DB09292 DB01378 DB00911 DB11338 DB09418 DB01166 DB08890 DB01307 DB14681 DB04630 DB09049 DB01294 DB00200 DB13657 DB14546 DB01563 DB06282 DB12107 DB01363 DB01377 DB00441 DB08836 DB00373 DB00709 DB11135 DB13509 DB00480 DB09089 DB01431 DB01060 DB13156 DB13526 DB14527 DB13544 DB01180 DB00672 DB01212 DB01009 DB08907 DB12989 DB01267 DB00580 DB00202 DB14509 DB01242 DB09106 DB11943 DB13917 DB09272 DB01380 DB14684 DB01169 DB01656 DB08872 DB01420 DB11598 DB06700 DB00477 DB06480 DB00282 DB00014 DB09148 DB00198 DB08940 DB00208 DB01685 DB06702 DB12942 DB00804 DB00565 DB11487 DB05115 DB00573 DB00349 DB01394 DB09134 DB14643 DB00296 DB01022 DB14498 DB01151 DB13873 DB00554 DB00443 DB09311 DB06335 DB04626 DB00264 DB00190 DB11455 DB00698 DB00461 DB00364 DB00813 DB14499 DB09129 DB09204 DB11577 DB12007 DB00300 DB01226 DB01048 DB09027 DB09264 DB00886 DB01367 DB09212 DB01024 DB08897 DB14631 DB00688 DB00808 DB00185 DB00325 DB00319 DB00934 DB01427 DB04743 DB12278 DB01172 DB00716 DB06815 DB01013 DB00465 DB01018 DB01408 DB14126 DB11466 DB08942 DB08971 DB01043 DB09165 DB09223 DB13170 DB01565 DB09075 DB00115 DB00994 DB11691 DB14512 DB11568 DB12843 DB04895 DB00653 DB11124 DB13756 DB00860 DB13401 DB06707 DB06204 DB13527 DB13232 DB00273 DB13166 DB13481 DB15972 DB00900 DB09344 DB13946 DB00497 DB14507 DB00483 DB00829 DB09216 DB09156 DB13295 DB00244 DB09472 DB00567 DB11915 DB07402 DB00588 DB13139 DB11251 DB00333 DB09301 DB11529 DB14627 DB00369 DB00958 DB11358 DB04816 DB00286 DB09287 DB01203 DB00458 DB11989 DB01399 DB00953 DB01221 DB14644 DB12783 DB09038 DB01149 DB00080 DB00537 DB01004 DB11089 DB06637 DB09255 DB09262 DB00730 DB00331 DB06186 DB06623 DB00437 DB04808 DB09091 DB09219 DB15565 DB01224 DB12492 DB11365 DB00254 DB00047 DB13540 DB11145 DB01001 DB11587 DB14232 DB01340 DB00356 DB00499 DB13629 DB00399 DB01288 DB00759 DB09071 DB00380 DB11518 DB01433 DB01036 DB01222 DB00303 DB13856 DB01330 DB12161 DB00995 DB04834 DB12526 DB13783 DB00285 DB09276 DB09214 DB14526 DB09137 DB09324 DB00512 DB00844 DB14646 DB00571 DB11059 DB00608 DB11642 DB09329 DB14208 DB09104 DB00482 DB09139 DB09338 DB11097 DB08934 DB13909 DB09174 DB13191 DB01205 DB00041 DB09066 DB00542 DB04823 DB00359 DB06710 DB01419 DB13860 DB01030 DB01529 DB11323 DB01077 DB00657 DB11278 DB01014 DB00982 DB04824 DB00563 DB00314 DB01413 DB08877 DB08911 DB01497 DB00548 DB00081 DB08976 DB04812 DB13491 DB13987 DB00318 DB04920 DB13996 DB00159 DB14513 DB00341 DB06809 DB01285 DB08826 DB00233 DB00435 DB13952 DB12927 DB01032 DB09256 DB09213 DB14125 DB14585 DB08957 DB00938 DB00279 DB09285 DB00728 DB01079 DB00991 DB00961 DB14754 DB13160 DB01401 DB00795 DB08900 DB00663 DB00647 DB13722 DB14503 DB01010 DB01600 DB00501 DB01069 DB00761 DB09268 DB06209 DB01261 DB13223 DB11699 DB11107 DB00897 DB06782 DB06800 DB12445 DB00620 DB04574 DB00712 DB00909 DB01348 DB00308 DB13314 DB01424 DB00683 DB00243 DB04725 DB00968 DB04263 DB14669 DB00186 DB11622 DB00415 DB14528 DB14482 DB00271 DB00669 DB12399 DB00790 DB00413 DB09244 DB13707 DB01628 DB06824 DB00225 DB14060 DB01336 DB08918 DB09123 DB11871 DB15360 DB01338 DB01101 DB01183 DB11164 DB01197 DB11130 DB00611 DB00235 DB13478 DB01135 DB00221 DB09281 DB00743 DB00821 DB01291 DB00918 DB01233 DB13967 DB01081 DB01415 DB09135 DB00515 DB00262 DB08951 DB01428 DB09456 DB09564 DB08797 DB08991 DB00760 DB00782 DB01115 DB13185 DB00071 DB00524 DB00533 DB00687 DB01068 DB04552 DB11328","absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":369.0913904,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tripamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15959"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":197.96,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"2782-57-2","sequences":null,"targets":null,"unii":"PHR838Y52L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":196.9394963,"volume-of-distribution":null,"route-of-elimination":null,"name":"Troclosene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15960"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":319.19,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"10139-47-6","sequences":null,"targets":null,"unii":"762R7A0O0B","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":317.73808,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc iodide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15961"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":78.075,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7789-75-5","sequences":null,"targets":null,"unii":"O3B55K4YKI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":77.9593972,"volume-of-distribution":null,"route-of-elimination":null,"name":"Calcium fluoride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15962"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":205.33,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"940-69-2","sequences":null,"targets":null,"unii":"Q1GT04827L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-26","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":205.059506455,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thioctamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15963"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":322.32,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"304448-55-3","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-27","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":322.095356939,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dynasore","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-11-27","drugbank-id":"DB15964"},{"toxicity":"Data regarding overdose of naxitamab are unavailable. In the event of an overdose, patients should be treated with symptomatic and supportive measures.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"In targeting cell surface glycoproteins (GD2) that occur on the surface of neuroendocrine tumors, naxitamab directs the immune system towards these cancerous cells and induces the activation of both complement-dependent and antibody-dependent cytotoxicity.[L24454] \r\n\r\nNaxitamab can cause serious infusion reactions - including hypotension, hypoxia, anaphylaxis, and cardiac arrest - that necessitate careful monitoring during therapy. All patients should be pre-medicated with intravenous corticosteroids (e.g. [methylprednisolone]) as well as an antihistamine, H2 receptor antagonist, acetaminophen, and an antiemetic prior to therapy to mitigate the risk and severity of infusion-related reactions. Naxitamab may also cause severe neurotoxicity, including significant neuropathic pain, transverse myelitis, reversible posterior leukoencephalopathy syndrome (RPLS), and ocular toxicities. Pain management should be implemented prior to and during therapy - patients should take a 12-day course of neuropathic pain prophylaxis (e.g. gabapentin) starting 4 days prior to infusion, and should receive oral opioids 45-60 minutes prior to infusion and intravenous opioids and\/or ketamine as needed thereafter.[L24454]","msds":null,"description":"Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors),[A224609] and is rarely subject to antigen loss.[A224604]\r\n\r\nThe first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015.[A224474] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).[L24929]\r\n\r\nNaxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed\/refractory neuroblastoma of the bone or bone marrow.[L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making the administration of naxitamab therapy markedly simpler than that of its predecessor.","enzymes":null,"type":"biotech","cas-number":"1879925-92-4","sequences":null,"targets":"BE0008624","unii":"9K8GNJ2874","protein-binding":null,"fda-label":null,"clearance":"The clearance of naxitamab appears to be correlated inversely with body weight.[L24454]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":"liquid","synthesis-reference":null,"mechanism-of-action":"Neuroblastomas are neuroendocrine tumors occurring in immature and developing cells of the nervous system and are the most common malignancy diagnosed in children <1 year of age.[A224604] The GD2 disialoganglioside is a glycolipid found highly expressed on the surface of neuroectodermal tumors,[A224609] including neuroblastomas. GD2 exhibits high density and homogeneity across neuroblastomas and a rare occurrence of antigen loss,[A224604] making it a desirable target in the treatment of these cancers.\r\n\r\nNaxitamab is an IgG1 monoclonal antibody directed against GD2 disialogangliosides - it binds to GD2 on the surface of neuroblastoma cells and induces both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC),[L24454] the latter of which is enhanced by co-administration with GM-CSF.[A224604]","drug-interactions":"DB00328 DB09275 DB13400 DB12710 DB00656 DB00610 DB06737 DB00178 DB13841 DB06712 DB00540 DB09205 DB01142 DB09217 DB08841 DB13875 DB00814 DB00649 DB09273 DB12945 DB09253 DB01247 DB00177 DB01200 DB01618 DB00800 DB13286 DB13510 DB08941 DB13432 DB06701 DB11537 DB09307 DB13703 DB00605 DB00368 DB01556 DB08984 DB01229 DB08922 DB01598 DB00321 DB06711 DB01102 DB06148 DB01246 DB09026 DB00292 DB05316 DB00490 DB04908 DB08822 DB13341 DB00700 DB00531 DB00388 DB08932 DB00492 DB12551 DB11738 DB13411 DB01295 DB11823 DB00246 DB01577 DB04846 DB00777 DB09082 DB13398 DB13604 DB00543 DB08927 DB09206 DB13552 DB04017 DB00519 DB09363 DB06690 DB09480 DB13554 DB04828 DB01579 DB01624 DB04818 DB00945 DB13452 DB00901 DB00820 DB01064 DB15861 DB00708 DB12610 DB13496 DB01240 DB09080 DB09224 DB01622 DB00370 DB08925 DB01274 DB01216 DB09249 DB01364 DB09084 DB13584 DB08950 DB04817 DB00391 DB01100 DB05095 DB00871 DB00623 DB04888 DB00788 DB12661 DB00939 DB01182 DB07767 DB00908 DB13167 DB09251 DB06262 DB00372 DB00091 DB05039 DB00691 DB14217 DB00723 DB00584 DB09225 DB06725 DB00612 DB12545 DB01245 DB00614 DB00598 DB13940 DB00866 DB00841 DB00749 DB00925 DB08955 DB00420 DB13323 DB14207 DB01397 DB13612 DB00214 DB00983 DB09238 DB12080 DB13781 DB00668 DB11720 DB08952 DB12100 DB12958 DB09220 DB00586 DB14213 DB00784 DB06694 DB00601 DB01347 DB00899 DB01158 DB01484 DB01626 DB12054 DB05395 DB00924 DB00270 DB00629 DB02224 DB13209 DB09242 DB00753 DB06654 DB09477 DB00260 DB13217 DB13624 DB01283 DB00695 DB00960 DB01359 DB00781 DB00881 DB00363 DB13429 DB01435 DB08810 DB00206 DB09154 DB00606 DB00722 DB06763 DB16629 DB09288 DB00936 DB13782 DB00999 DB00633 DB13251 DB00937 DB15226 DB09218 DB13524 DB11540 DB00831 DB06736 DB09068 DB13407 DB00816 DB03585 DB12779 DB13384 DB13399 DB00450 DB00734 DB13649 DB00469 DB13784 DB08985 DB14059 DB00397 DB12273 DB00861 DB00852 DB00988 DB13371 DB04840 DB01199 DB11376 DB12930 DB00559 DB09243 DB08960 DB13378 DB14651 DB00500 DB09250 DB01170 DB00401 DB01366 DB00035 DB06706 DB00343 DB00875 DB13312 DB09215 DB00622 DB13114 DB14068 DB08996 DB11477 DB14094 DB00590 DB00350 DB00212 DB00780 DB00812 DB08893 DB13345 DB13213 DB00818 DB01275 DB00952 DB12212 DB00774 DB13025 DB01615 DB00422 DB01037 DB00289 DB13779 DB00502 DB00830 DB09295 DB00692 DB04948 DB01250 DB01365 DB01116 DB01244 DB11783 DB09245 DB13692 DB00353 DB12518 DB01063 DB01054 DB00195 DB13801 DB13538 DB13385 DB00867 DB13001 DB13246 DB13420 DB09000 DB00572 DB13225 DB08439 DB01407 DB06684 DB06144 DB09236 DB13256 DB11362 DB01050 DB01193 DB00182 DB09241 DB08981 DB06445 DB01608 DB01392 DB08931 DB04581 DB06764 DB14185 DB00589 DB09235 DB00310 DB13374 DB01614 DB06403 DB00528 DB13657 DB08815 DB01029 DB01363 DB00373 DB08836 DB06016 DB00699 DB04946 DB00785 DB00248 DB01591 DB11541 DB13544 DB13791 DB01180 DB06152 DB01009 DB01576 DB01267 DB00580 DB00202 DB01242 DB00679 DB13917 DB00436 DB01236 DB00797 DB00477 DB01627 DB01239 DB08940 DB11543 DB06190 DB00335 DB06762 DB01023 DB09237 DB05687 DB00573 DB00374 DB04829 DB13520 DB00457 DB11481 DB09167 DB01621 DB01151 DB00796 DB00554 DB00935 DB00264 DB11455 DB00461 DB00813 DB01255 DB00433 DB09128 DB12313 DB13273 DB09254 DB00508 DB09239 DB00752 DB00865 DB00886 DB01367 DB09212 DB09016 DB01186 DB01467 DB00808 DB00325 DB04842 DB01442 DB04743 DB09289 DB00381 DB00191 DB00344 DB12278 DB01049 DB12693 DB13403 DB00465 DB01018 DB01408 DB11466 DB00805 DB08942 DB12846 DB09223 DB15685 DB13757 DB00994 DB00211 DB13211 DB04820 DB13598 DB14010 DB11124 DB12766 DB00561 DB06707 DB13803 DB13527 DB13232 DB13166 DB13481 DB00900 DB13946 DB11281 DB08954 DB01623 DB09203 DB09216 DB09226 DB04831 DB00966 DB00244 DB13435 DB13777 DB00408 DB07402 DB00696 DB13139 DB00616 DB01203 DB11373 DB00458 DB01119 DB00953 DB01399 DB00880 DB03322 DB01149 DB11556 DB13523 DB01224 DB13919 DB06827 DB06678 DB11428 DB00802 DB01001 DB11587 DB01340 DB00765 DB13629 DB01288 DB01509 DB11518 DB00680 DB01324 DB01403 DB06288 DB00187 DB13783 DB09214 DB00226 DB11785 DB12371 DB00571 DB00444 DB14208 DB11755 DB00482 DB04872 DB12093 DB13453 DB12401 DB13852 DB13559 DB13665 DB13909 DB13443 DB09248 DB01028 DB13108 DB00542 DB00393 DB08808 DB04861 DB01419 DB13860 DB00320 DB04855 DB13575 DB00657 DB11278 DB12248 DB01454 DB04836 DB01014 DB00876 DB13910 DB09202 DB08976 DB04812 DB00678 DB06268 DB14231 DB00216 DB00159 DB00315 DB06216 DB11770 DB01089 DB12465 DB12092 DB01189 DB12361 DB12927 DB00933 DB09213 DB14125 DB08957 DB01356 DB00938 DB09285 DB13532 DB00409 DB00850 DB06153 DB00991 DB01126 DB14754 DB01401 DB00795 DB13508 DB09246 DB05271 DB13722 DB00275 DB01600 DB01069 DB02032 DB09252 DB13382 DB00726 DB09061 DB12445 DB13557 DB00998 DB00361 DB01190 DB01136 DB00712 DB01348 DB00575 DB13314 DB01021 DB13410 DB01424 DB13631 DB00968 DB01159 DB00669 DB00790 DB09244 DB01171 DB00727 DB01238 DB01253 DB01162 DB01628 DB09286 DB01090 DB14060 DB13064 DB11871 DB00217 DB01197 DB05562 DB12867 DB00221 DB00821 DB00247 DB00918 DB01291 DB13676 DB08951 DB00541 DB00898 DB08797 DB08991 DB00524 DB01472 DB00533 DB01580 DB04552 DB01388 DB11273 DB01297","absorption":"The mean plasma concentration of naxitamab following an intravenous infusion of 3 mg\/kg over 30 minutes was 57.4 g\/mL.[L24454] The AUC of naxitamab appears to correlate with body size.[A224474]","created":"2020-11-28","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean terminal half-life of naxitamab is 8.2 days.[L24454]","monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":"Monoclonal antibodies are typically eliminated via uptake into cells and subsequent catabolism via lysosomal degradation. Due to their large size, they are only eliminated renally under pathologic conditions.[A216712]","name":"Naxitamab","metabolism":"While the metabolism of naxitamab has not been studied directly,[L24454] monoclonal antibodies as a class are principally metabolized to smaller peptides via catabolic processes.[L24454,A216712]","reactions":null,"indication":"Naxitamab-gqgk is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of patients 1 year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.[L24454]","ahfs-codes":null,"updated":"2021-07-02","drugbank-id":"DB15965"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"1314JZ2X6W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-11-29","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Influenza virus type B","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15966"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":188.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"74-61-3","sequences":null,"targets":null,"unii":"086L82361J","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":187.96355764,"volume-of-distribution":null,"route-of-elimination":null,"name":"2,3-Dimercapto-1-propanesulfonic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-02","drugbank-id":"DB15967"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":452.614,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"107080-63-7","sequences":null,"targets":null,"unii":"7WSK03KXXW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":452.279535128,"volume-of-distribution":null,"route-of-elimination":null,"name":"Butropium","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15968"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":300.29,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"70063-04-6","sequences":null,"targets":null,"unii":"BMQ12812QR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":300.052840676,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carbazochrome sulfonic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15969"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":392.88,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"52080-57-6","sequences":null,"targets":null,"unii":"564IBO56IP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"OPHTHALMOLOGICALS SENSORY ORGANS Corticosteroids and antiinfectives in combination ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":392.1390516,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chloroprednisone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15970"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":344.9,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"13448-22-1","sequences":null,"targets":null,"unii":"E65W20MU7A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":344.1113976,"volume-of-distribution":null,"route-of-elimination":null,"name":"Clorotepine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15971"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"64-85-7","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN CORTICOSTEROIDS FOR SYSTEMIC USE SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS Mineralocorticoids","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00328 DB00682 DB01208 DB16002 DB06272 DB00887 DB09198 DB06737 DB00382 DB09217 DB11564 DB01078 DB00814 DB13446 DB00562 DB09273 DB13249 DB00280 DB11397 DB01200 DB00232 DB13286 DB13432 DB01337 DB13947 DB00957 DB00605 DB01306 DB13691 DB00284 DB00368 DB08984 DB09022 DB01554 DB00732 DB01102 DB12781 DB04066 DB00070 DB01067 DB13537 DB06814 DB01124 DB00046 DB00912 DB00388 DB00888 DB13136 DB01396 DB01339 DB00390 DB11201 DB00839 DB00222 DB00367 DB04846 DB01381 DB09082 DB04878 DB09067 DB00358 DB06117 DB01044 DB04891 DB11827 DB01320 DB00136 DB13981 DB00834 DB13928 DB13943 DB04828 DB11723 DB00487 DB11824 DB09481 DB01432 DB00945 DB00901 DB13563 DB13954 DB01064 DB15861 DB01309 DB12610 DB00779 DB09080 DB00467 DB01274 DB01364 DB00731 DB09084 DB11412 DB13584 DB01165 DB00391 DB02901 DB05095 DB01035 DB00871 DB01471 DB00218 DB08619 DB00788 DB00939 DB00030 DB01541 DB13310 DB00685 DB01059 DB13167 DB06262 DB04892 DB00738 DB13058 DB00091 DB09045 DB05039 DB01122 DB11898 DB06725 DB00498 DB06292 DB00351 DB12545 DB01245 DB06718 DB11950 DB00511 DB09265 DB05488 DB13169 DB00841 DB13280 DB00749 DB13595 DB00266 DB08955 DB13612 DB01397 DB01015 DB00214 DB00983 DB14055 DB00169 DB00668 DB12100 DB00951 DB13467 DB04839 DB09220 DB00586 DB00784 DB00648 DB00414 DB00989 DB01120 DB00977 DB00468 DB00941 DB13097 DB02365 DB13823 DB02224 DB00823 DB01137 DB00582 DB13217 DB01277 DB12935 DB01283 DB00695 DB00674 DB12268 DB00304 DB01536 DB06011 DB01435 DB09063 DB00621 DB01390 DB00294 DB14938 DB15171 DB06819 DB01325 DB08905 DB00606 DB01155 DB00416 DB09288 DB12025 DB00936 DB11567 DB06203 DB00999 DB01382 DB09269 DB08804 DB09218 DB13524 DB06736 DB13407 DB00146 DB00082 DB00816 DB03585 DB14678 DB11404 DB00783 DB13649 DB00469 DB13710 DB11094 DB00903 DB04682 DB06410 DB00624 DB14059 DB00397 DB01251 DB01434 DB00861 DB13371 DB01199 DB08867 DB11892 DB08794 DB00153 DB00500 DB01357 DB01366 DB01418 DB01108 DB09200 DB05107 DB13668 DB09215 DB06789 DB00396 DB00545 DB11636 DB06713 DB13685 DB14035 DB00978 DB00812 DB16820 DB01185 DB00585 DB00774 DB01278 DB13866 DB00717 DB08909 DB09043 DB09357 DB13829 DB09295 DB01289 DB01250 DB00252 DB01524 DB13322 DB13989 DB01016 DB13956 DB13953 DB13538 DB01268 DB01405 DB00603 DB00867 DB08972 DB13001 DB06412 DB05804 DB16001 DB09199 DB11443 DB11156 DB13503 DB06266 DB00677 DB08439 DB06730 DB01407 DB13648 DB06655 DB06205 DB13944 DB13486 DB04876 DB01050 DB09201 DB00843 DB08981 DB00412 DB13958 DB01609 DB11780 DB01307 DB13261 DB00310 DB13657 DB12625 DB01363 DB01377 DB05386 DB01456 DB16003 DB06250 DB01436 DB13650 DB11507 DB01564 DB13544 DB13694 DB06774 DB07768 DB03410 DB00672 DB01009 DB12461 DB12989 DB08907 DB00580 DB11473 DB00202 DB11943 DB04665 DB01700 DB00436 DB00357 DB01420 DB06600 DB11491 DB00477 DB08940 DB02845 DB06127 DB00565 DB00681 DB13275 DB05115 DB00573 DB12417 DB04576 DB08961 DB05830 DB00554 DB06335 DB06692 DB11455 DB00461 DB11619 DB00508 DB01226 DB13626 DB09212 DB00721 DB06709 DB00808 DB04743 DB14031 DB11390 DB01481 DB00465 DB01408 DB03793 DB11466 DB08942 DB00805 DB01043 DB00984 DB12713 DB15217 DB00083 DB06756 DB11568 DB00711 DB02925 DB11124 DB13401 DB13857 DB13527 DB13232 DB06160 DB13481 DB13946 DB05295 DB06724 DB00944 DB00483 DB09216 DB01252 DB00817 DB11429 DB13295 DB00244 DB13430 DB00197 DB07402 DB12194 DB13139 DB13627 DB11774 DB09038 DB01399 DB01221 DB11992 DB00880 DB00537 DB01070 DB00392 DB00331 DB13675 DB01400 DB01132 DB00047 DB01001 DB11587 DB13629 DB01288 DB00527 DB11518 DB01324 DB12482 DB12526 DB04834 DB13044 DB13783 DB09214 DB06194 DB04796 DB09389 DB00827 DB08882 DB09104 DB12474 DB00482 DB01521 DB01406 DB00359 DB04864 DB06710 DB14517 DB01419 DB13860 DB11323 DB01395 DB13772 DB01014 DB06723 DB00263 DB13347 DB11511 DB08976 DB04812 DB15317 DB00491 DB01276 DB00159 DB15614 DB14740 DB00910 DB08938 DB09213 DB08957 DB08496 DB15959 DB00938 DB09285 DB13532 DB00728 DB00365 DB00991 DB12214 DB01401 DB00795 DB01485 DB09371 DB14027 DB13722 DB01010 DB01600 DB12412 DB16625 DB01261 DB13528 DB12445 DB04574 DB04830 DB00712 DB13314 DB01021 DB01424 DB04725 DB13451 DB11698 DB12399 DB01628 DB00946 DB13406 DB09123 DB14060 DB01336 DB11871 DB08382 DB01338 DB13587 DB00981 DB04572 DB04258 DB01135 DB00221 DB09281 DB00821 DB01291 DB01233 DB00255 DB00515 DB08951 DB09456 DB13495 DB09564 DB08797 DB08991 DB00071 DB00914 DB00524 DB00533 DB08962 DB04552","absorption":null,"created":"2020-12-02","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Desoxycortone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-07","drugbank-id":"DB15972"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":594.68,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"75018-71-2","sequences":null,"targets":null,"unii":"H6630PU5ZJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":595.208196,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tauroselcholic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-04-07","drugbank-id":"DB15973"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":490.17,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"15283-45-1","sequences":null,"targets":null,"unii":"6GKU52ZCI0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":489.792004,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gold sodium thiosulfate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-04","drugbank-id":"DB15974"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":286.32,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"32909-92-5","sequences":null,"targets":null,"unii":"F5AK41IPQG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTIBACTERIALS FOR SYSTEMIC USE ANTIINFECTIVES FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB00331 DB09199 DB13675 DB01132 DB09198 DB00047 DB06655 DB00414 DB11564 DB04876 DB08999 DB01120 DB00468 DB13446 DB09201 DB00280 DB01200 DB00412 DB09214 DB01277 DB12935 DB01306 DB11780 DB01307 DB08882 DB12268 DB00284 DB06011 DB09022 DB12625 DB15171 DB12781 DB01067 DB00359 DB01124 DB11567 DB00657 DB00046 DB00912 DB06203 DB00672 DB01382 DB01009 DB08907 DB00263 DB00563 DB01700 DB00839 DB00222 DB00491 DB04878 DB01276 DB14513 DB06127 DB01251 DB05115 DB11827 DB12417 DB08960 DB00834 DB13928 DB11723 DB01161 DB06335 DB11824 DB12214 DB01053 DB14027 DB09200 DB12412 DB01309 DB01261 DB00731 DB04830 DB14035 DB12713 DB15217 DB11698 DB01278 DB00030 DB11568 DB09043 DB01090 DB00184 DB13406 DB08382 DB00738 DB01289 DB00091 DB09045 DB11898 DB01252 DB01116 DB06292 DB11950 DB09265 DB00197 DB01016 DB09456 DB01268 DB09564 DB00071 DB00914 DB08962 DB09038 DB01015 DB11992","absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":286.019432546,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sulfametrole","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15975"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":334.376,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"53808-87-0","sequences":null,"targets":null,"unii":"5R6712AY0K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTIBACTERIALS FOR SYSTEMIC USE ANTIINFECTIVES FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":334.164105204,"volume-of-distribution":null,"route-of-elimination":null,"name":"Tetroxoprim","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15976"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":150.221,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"80-57-9","sequences":null,"targets":null,"unii":"IFV46DXC6U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":150.104465071,"volume-of-distribution":null,"route-of-elimination":null,"name":"Verbenone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-04","drugbank-id":"DB15977"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":296.43,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"84-08-2","sequences":null,"targets":null,"unii":"2305SQ56Z2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":296.134719826,"volume-of-distribution":null,"route-of-elimination":null,"name":"Parathiazine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15978"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":314.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"848-53-3","sequences":null,"targets":null,"unii":"N5MVC31W2N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-03","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":314.1549764,"volume-of-distribution":null,"route-of-elimination":null,"name":"Homochlorcyclizine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15979"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":217.265,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"20064-19-1","sequences":null,"targets":null,"unii":"0HU2UI27HF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-07","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":217.131408096,"volume-of-distribution":null,"route-of-elimination":null,"name":"Levocarnitine propionate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15980"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":884.07,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"40922-77-8","sequences":null,"targets":null,"unii":"053VA4B06Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-07","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":883.492935275,"volume-of-distribution":null,"route-of-elimination":null,"name":"Josamycin propionate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15981"},{"toxicity":"There is no information on the LD<sub>50<\/sub> or overdose of berotralstat.","snp-adverse-drug-reactions":null,"average-mass":562.573,"transporters":"BE0001032 BE0001067","pharmacodynamics":"Berotralstat prevents angioedema attacks by inhibiting plasma kallikrein, thereby regulating excess bradykinin generation in patients with hereditary angioedema (HAE). It had a fast onset of action, long duration of action, and acceptable tolerance in clinical trials.[A225106] Berotralstat inhibits plasma kallikrein in a concentration-dependent.[L26661] In clinical trials, berotralstat reduced HAE attack rates at 24 weeks, and its effects sustained through 48 weeks.[L26656]\r\n\r\nIn clinical trials, doses of berotralstat higher than 150 mg once daily led to QT Prolongation in a concentration-dependent manner.[L26661]","msds":null,"description":"Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE).[L26661] It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656]\r\n\r\nDeveloped by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.[A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.[L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.[L41960]","enzymes":"BE0002363 BE0002638","type":"small molecule","cas-number":"1809010-50-1","sequences":null,"targets":"BE0002440","unii":"XZA0KB1BDQ","protein-binding":"Plasma protein binding is approximately 99%.[L26661]","fda-label":null,"clearance":"There is no information on the clearance rate.","atc-codes":"OTHER HEMATOLOGICAL AGENTS BLOOD AND BLOOD FORMING ORGANS Drugs used in hereditary angioedema","pdb-entries":false,"food-interactions":"Take with food. This is instructed by the prescribing information of berotralstat. A high-fat meal had no significant effects on the Cmax and AUC of berotralstat, but the Tmax was delayed by 3 hours.","state":"solid","synthesis-reference":null,"mechanism-of-action":"Hereditary angioedema (HAE) is a rare genetic disorder associated with severe swelling of the skin and upper airway.[A225106] It is caused by mutations in the regulatory or coding regions of the gene that encodes C1 inhibitor (SERPING1), which result in either a deficiency (type I) or dysfunction (type II) of C1 inhibitor (C1 esterase inhibitor, C1-INH). C1 inhibitor is a serine protease inhibitor that normally regulates bradykinin production by covalently binding to and inactivating plasma kallikrein.[A225121] \r\n\r\nPlasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK).[L26661] During HAE attacks, the levels of plasma kallikrein fall, leading to the cleavage of high-molecular-weight-kininogen and the release of bradykinin, a potent vasodilator that increases vascular permeability. Bradykinin plays a major role in promoting edema and pain associated with HAE.[A225166,L26661] Patients with HAE cannot properly regulate plasma kallikrein activity due to the deficiency or dysfunction of a serum inhibitor of C1 inhibitor, leading to uncontrolled increases in plasma kallikrein activity and recurrent angioedema attacks.[L26661] Berotralstat is a potent inhibitor of plasma kallikrein that works by binding to plasma kallikrein and blocking its proteolytic activity, thereby controlling excess bradykinin generation.[A225121,L26661]","drug-interactions":"DB08880 DB00682 DB00825 DB01208 DB08953 DB09124 DB14649 DB09381 DB13456 DB12457 DB00742 DB00656 DB15091 DB11891 DB09198 DB08980 DB00916 DB09570 DB06712 DB00737 DB00540 DB00204 DB01142 DB00637 DB00970 DB12130 DB15035 DB08828 DB04951 DB00814 DB01215 DB12978 DB00338 DB12035 DB00451 DB00845 DB00280 DB11397 DB01200 DB00495 DB11921 DB13878 DB01409 DB06228 DB01223 DB13652 DB00957 DB00424 DB01086 DB13691 DB06772 DB00962 DB00277 DB00557 DB09195 DB01595 DB08922 DB01229 DB12235 DB00321 DB00503 DB07615 DB11919 DB06148 DB01129 DB00220 DB12952 DB12781 DB01590 DB01246 DB09351 DB09026 DB09030 DB06506 DB05316 DB00490 DB04908 DB04652 DB04957 DB00700 DB06719 DB01075 DB11855 DB12645 DB06217 DB12825 DB09076 DB00531 DB00912 DB08970 DB00546 DB11828 DB08932 DB01396 DB11901 DB00640 DB01551 DB00390 DB08865 DB00741 DB01039 DB01295 DB00367 DB12329 DB11823 DB00246 DB13293 DB13208 DB01577 DB04846 DB09082 DB00613 DB09383 DB01117 DB00714 DB09234 DB00778 DB00592 DB15102 DB14541 DB00358 DB00543 DB00238 DB01044 DB08807 DB05676 DB06739 DB00230 DB00959 DB08820 DB00281 DB11827 DB11703 DB01320 DB00136 DB13981 DB00834 DB00773 DB13943 DB01323 DB01319 DB04828 DB00487 DB01259 DB09074 DB01624 DB06717 DB11408 DB01051 DB04938 DB03467 DB00440 DB00820 DB09299 DB01062 DB06402 DB13954 DB01466 DB00708 DB14009 DB13879 DB12332 DB00779 DB09224 DB09080 DB00467 DB00245 DB00370 DB01274 DB01216 DB07780 DB00731 DB11979 DB00835 DB11742 DB11412 DB13488 DB11951 DB01165 DB09161 DB05521 DB00758 DB05812 DB01191 DB00391 DB01100 DB01035 DB00871 DB00218 DB11641 DB09101 DB04881 DB04868 DB14723 DB08881 DB11575 DB06334 DB06595 DB06119 DB00877 DB01182 DB06290 DB00685 DB12364 DB01184 DB08930 DB01059 DB00906 DB00908 DB00402 DB00738 DB06616 DB00091 DB05039 DB00529 DB00691 DB09227 DB09225 DB11633 DB14973 DB06292 DB00351 DB00612 DB00598 DB05488 DB11689 DB01175 DB00710 DB00866 DB11613 DB14064 DB14540 DB00949 DB06589 DB00872 DB06480 DB01201 DB08870 DB00420 DB00980 DB01015 DB08906 DB01410 DB16390 DB00967 DB05928 DB00983 DB14055 DB01583 DB09238 DB00203 DB00169 DB00476 DB00213 DB06695 DB06738 DB11640 DB08952 DB14713 DB12001 DB04839 DB06448 DB12015 DB02703 DB00715 DB00586 DB12629 DB00526 DB00175 DB11952 DB00334 DB14019 DB04851 DB08873 DB00977 DB00468 DB01158 DB00924 DB00270 DB12712 DB12010 DB00641 DB00915 DB15328 DB13835 DB13955 DB09488 DB00307 DB13823 DB00753 DB00823 DB06654 DB01234 DB11978 DB00007 DB01137 DB08799 DB00706 DB12026 DB04856 DB06155 DB06200 DB00582 DB01241 DB06605 DB00960 DB00674 DB00635 DB01359 DB01094 DB00304 DB00363 DB01536 DB11869 DB14066 DB00316 DB05223 DB04871 DB01435 DB09183 DB09063 DB08838 DB04884 DB00206 DB00294 DB00628 DB00313 DB00297 DB00193 DB12147 DB12500 DB09378 DB09318 DB01155 DB06237 DB09288 DB04835 DB00822 DB06203 DB00999 DB11757 DB09053 DB05246 DB00568 DB00882 DB13874 DB09068 DB15444 DB14678 DB00705 DB13399 DB00450 DB00617 DB00734 DB00783 DB01195 DB05109 DB06663 DB01227 DB11094 DB12836 DB08896 DB00624 DB03701 DB09166 DB00532 DB00224 DB00394 DB00604 DB05541 DB14063 DB01118 DB04840 DB15133 DB12267 DB08936 DB11892 DB08867 DB08910 DB00559 DB11886 DB00471 DB16165 DB08794 DB00454 DB06700 DB00176 DB00985 DB01104 DB05015 DB11712 DB09296 DB11960 DB11718 DB01095 DB00401 DB01357 DB01008 DB11730 DB09555 DB11841 DB00921 DB01058 DB01192 DB11574 DB11637 DB13725 DB01418 DB09200 DB06207 DB00201 DB00343 DB12174 DB00875 DB11591 DB00496 DB00622 DB00196 DB14068 DB06789 DB06735 DB04838 DB00396 DB12376 DB13766 DB06446 DB11636 DB00590 DB11652 DB00719 DB06603 DB01181 DB06713 DB13685 DB00690 DB00978 DB08893 DB13345 DB00379 DB01114 DB06414 DB06608 DB01384 DB00591 DB00818 DB00377 DB04934 DB01026 DB12212 DB09095 DB14570 DB01248 DB00615 DB01615 DB01134 DB13866 DB00555 DB01037 DB00661 DB00717 DB09118 DB00289 DB16222 DB09083 DB13775 DB00404 DB13679 DB13358 DB11697 DB04889 DB00502 DB12543 DB00932 DB04948 DB06468 DB00486 DB14881 DB13744 DB11363 DB00252 DB01045 DB11853 DB01244 DB01047 DB14761 DB00353 DB00556 DB04953 DB05467 DB01054 DB01016 DB13956 DB14011 DB00195 DB01167 DB13953 DB00619 DB01268 DB01405 DB01071 DB09317 DB05239 DB13385 DB00603 DB08972 DB04847 DB06670 DB12286 DB09078 DB12799 DB06685 DB00518 DB00956 DB14545 DB00745 DB11672 DB00107 DB02546 DB15566 DB11800 DB12231 DB01411 DB05667 DB00188 DB00564 DB06788 DB00398 DB11443 DB00572 DB09199 DB01173 DB11581 DB13961 DB08439 DB04833 DB06730 DB08864 DB00234 DB09065 DB01105 DB06684 DB06144 DB08899 DB07348 DB06742 DB06777 DB12471 DB09236 DB13944 DB09291 DB06191 DB11362 DB01050 DB04896 DB01193 DB04905 DB01006 DB00843 DB00182 DB09241 DB09201 DB16098 DB03515 DB01587 DB00412 DB01392 DB11614 DB01232 DB00295 DB08931 DB13950 DB01263 DB14069 DB14185 DB00636 DB00755 DB00911 DB00589 DB14989 DB01166 DB00736 DB09235 DB01211 DB08995 DB13261 DB12941 DB06287 DB09049 DB07841 DB00675 DB00748 DB00904 DB04630 DB06403 DB00455 DB12537 DB00528 DB01611 DB06282 DB05889 DB08815 DB00441 DB14542 DB00373 DB15569 DB01456 DB09089 DB06016 DB01431 DB00699 DB04946 DB11732 DB09230 DB14737 DB00215 DB00248 DB06626 DB01591 DB01601 DB13651 DB13791 DB06152 DB01072 DB00625 DB06218 DB09048 DB08895 DB01576 DB00751 DB01267 DB08907 DB00580 DB11943 DB01254 DB01242 DB00679 DB11760 DB01154 DB00836 DB01380 DB01236 DB01169 DB01656 DB01420 DB06600 DB00477 DB11491 DB00922 DB00014 DB01620 DB00889 DB01239 DB00208 DB06210 DB00354 DB06702 DB01685 DB09330 DB00335 DB06762 DB01023 DB09237 DB12597 DB06234 DB01426 DB11487 DB00374 DB04829 DB00349 DB01394 DB00997 DB00427 DB12131 DB04854 DB01393 DB09167 DB05294 DB01621 DB04576 DB01151 DB06652 DB14921 DB00250 DB11753 DB01138 DB00443 DB11830 DB06335 DB13653 DB04845 DB00264 DB11817 DB09017 DB15233 DB13074 DB00813 DB04975 DB01255 DB00433 DB09128 DB13273 DB09204 DB11619 DB16691 DB00300 DB09027 DB09239 DB06691 DB03783 DB00864 DB00865 DB04841 DB11995 DB09016 DB01106 DB14975 DB14631 DB00688 DB05212 DB05351 DB00808 DB04842 DB00185 DB00934 DB14065 DB04743 DB09289 DB00381 DB00191 DB00344 DB12278 DB08833 DB01049 DB01196 DB00544 DB00757 DB11390 DB00261 DB01013 DB00104 DB08992 DB00317 DB14126 DB06636 DB09143 DB11693 DB01018 DB00805 DB08971 DB09223 DB01589 DB13179 DB12713 DB00990 DB15685 DB09075 DB09229 DB16732 DB06176 DB13757 DB13125 DB09054 DB00747 DB14512 DB00976 DB14010 DB00969 DB12766 DB00972 DB00860 DB13602 DB13555 DB00593 DB06726 DB12674 DB13857 DB06160 DB00497 DB12466 DB01623 DB00829 DB09216 DB11448 DB00163 DB00817 DB04540 DB01098 DB00966 DB00207 DB00539 DB01176 DB00567 DB11915 DB00408 DB15031 DB09073 DB00588 DB00696 DB13627 DB00333 DB11251 DB11774 DB01177 DB04844 DB00470 DB11529 DB00286 DB01203 DB00458 DB01221 DB11586 DB05885 DB12265 DB05154 DB01149 DB01076 DB00537 DB01429 DB00080 DB09262 DB04216 DB09090 DB11791 DB00697 DB01132 DB09280 DB01224 DB00360 DB06077 DB06678 DB15011 DB08871 DB01001 DB00356 DB00499 DB00199 DB00907 DB09071 DB08903 DB00759 DB06697 DB00802 DB01198 DB11986 DB00680 DB09079 DB08875 DB01036 DB01222 DB14539 DB01403 DB12161 DB06288 DB00187 DB00857 DB02115 DB00285 DB00514 DB11963 DB00309 DB11785 DB01264 DB12371 DB00434 DB00950 DB00827 DB12483 DB09389 DB12455 DB12877 DB00571 DB00608 DB11642 DB08882 DB08912 DB00444 DB12240 DB00574 DB12923 DB00482 DB12474 DB08816 DB09039 DB12093 DB00347 DB09297 DB08934 DB00570 DB04348 DB01228 DB13443 DB01128 DB02187 DB08901 DB00744 DB08916 DB01028 DB09102 DB06470 DB00359 DB06710 DB00393 DB08808 DB04861 DB06240 DB08889 DB00489 DB00320 DB04855 DB01030 DB01349 DB05465 DB13772 DB01395 DB00378 DB01454 DB00982 DB12523 DB00263 DB15442 DB00530 DB13347 DB12752 DB00563 DB06708 DB08877 DB11511 DB01599 DB11737 DB11796 DB00318 DB13546 DB00678 DB11274 DB00216 DB04920 DB14568 DB00341 DB06216 DB01285 DB11770 DB00405 DB00346 DB01189 DB12092 DB05482 DB13952 DB00910 DB01544 DB12070 DB00933 DB00439 DB12301 DB01218 DB11644 DB09231 DB08496 DB01356 DB12515 DB00938 DB13941 DB00850 DB01079 DB00365 DB00409 DB09232 DB11635 DB01087 DB00366 DB00795 DB13508 DB09371 DB12245 DB00283 DB00647 DB05271 DB00927 DB16703 DB09173 DB00663 DB01588 DB14840 DB11967 DB02789 DB01069 DB01103 DB11739 DB06212 DB01261 DB06419 DB13528 DB00342 DB00726 DB08883 DB06267 DB13530 DB00897 DB09061 DB15719 DB00448 DB00227 DB09240 DB00361 DB00620 DB00862 DB01190 DB04574 DB16236 DB01136 DB00909 DB00673 DB06780 DB11942 DB00308 DB13500 DB01424 DB06770 DB00575 DB00683 DB00243 DB06727 DB01645 DB06769 DB14669 DB00186 DB04695 DB11799 DB12016 DB13609 DB09034 DB01171 DB08827 DB00602 DB01238 DB01012 DB01253 DB00946 DB01628 DB15149 DB09123 DB08918 DB05773 DB01084 DB00425 DB04572 DB12565 DB11130 DB13055 DB12141 DB00762 DB01559 DB11837 DB00743 DB01113 DB00247 DB04825 DB00918 DB01233 DB00255 DB01074 DB13007 DB12887 DB15822 DB00472 DB00541 DB06699 DB00898 DB01115 DB02638 DB06825 DB00914 DB01472 DB00701 DB00533 DB01580 DB00687 DB01068 DB01388 DB11273 DB01297","absorption":"The steady-state of berotralstat is reached within 6 to 12 days following initial administration. After once-daily administration, the Cmax and AUC of berotralstat at steady-state is approximately five times that of the drug after a single dose. Following oral administration of berotralstat once-daily, the steady-state Cmax was 158 ng\/mL (range: 110 to 234 ng\/mL) at the dose of 150 mg and 97.8 ng\/mL (range: 63 to 235 ng\/mL) at the dose of 110 mg. The area under the curve over the dosing interval (AUCtau) was 2770 ng*hr\/mL (range: 1880 to 3790 ng*hr\/mL) and 1600 ng*hr\/mL (range: 950 to 4170 ng*hr\/mL) at the dose of 110 mg. The median Tmax is 2 hours in a fasted state and a high-fat meal delays the Tmax to 5 hours. The Tmax can range from 1 to 8 hours.[L26661]","created":"2020-12-08","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Following a single oral dose administration of 300 mg radiolabeled berotralstat, the median elimination half-life of berotralstat was approximately 93 hours, ranging from 39 to 152 hours.[L26661]","monoisotopic-mass":562.210422133,"volume-of-distribution":"The blood to plasma ratio was approximately 0.92 following a single 300 mg dose administration of radiolabeled berotralstat.[L26661]","route-of-elimination":"Following a single oral dose administration of 300 mg radiolabeled berotralstat, approximately 9% of the drug was excreted in the urine, where 1.8 to 4.7% of the total radiolabeled compound accounted for the unchanged parent drug. About 79% of the drug was excreted in feces.[L26661]","name":"Berotralstat","metabolism":"Berotralstat is metabolized by CYP2D6 and CYP3A4. The metabolic pathway and the metabolites of berotralstat have not yet been characterized. Following a single oral dose administration of 300 mg radiolabeled berotralstat, about 34% of the total plasma radioactivity accounted for the unchanged drug while about eight detectable metabolites accounted for 1.8 to 7.8% of the total radioactivity.[L26661]","reactions":null,"indication":"Berotralstat is indicated for prophylaxis of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. It is not used for the treatment of acute HAE attacks.[L26661,L41965,L41990]","ahfs-codes":null,"updated":"2022-06-10","drugbank-id":"DB15982"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":242.359,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"579-94-2","sequences":null,"targets":null,"unii":"C3B9R0E116","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":242.188194697,"volume-of-distribution":null,"route-of-elimination":null,"name":"Menglytate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15983"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":364.91,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"855-19-6","sequences":null,"targets":null,"unii":"780ZZX4P14","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":364.1805225,"volume-of-distribution":null,"route-of-elimination":null,"name":"Clostebol acetate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15984"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":119.12,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"924-49-2","sequences":null,"targets":null,"unii":"1ZHM019FLD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":119.058243154,"volume-of-distribution":null,"route-of-elimination":null,"name":"Gamma-amino-beta-hydroxybutyric acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-07","drugbank-id":"DB15985"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8007-80-5","sequences":null,"targets":null,"unii":"A4WO0626T5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cinnamon oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-21","drugbank-id":"DB15986"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":496.01,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"606-90-6","sequences":null,"targets":null,"unii":"SI78RFJ7XI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":495.2037175,"volume-of-distribution":null,"route-of-elimination":null,"name":"Piprinhydrinate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15987"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":263.337,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1082659-36-6","sequences":null,"targets":null,"unii":"T9S008S8JL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":263.15214354,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ephedrine levulinate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-06","drugbank-id":"DB15988"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8000-78-0","sequences":null,"targets":null,"unii":"4WG8U28833","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Garlic oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB15989"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":203.198,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"13115-71-4","sequences":null,"targets":null,"unii":"H7125Z98HT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":203.090605911,"volume-of-distribution":null,"route-of-elimination":null,"name":"Glycylglutamine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15990"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":238.243,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"658-79-7","sequences":null,"targets":null,"unii":"A226496H4O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":238.095356939,"volume-of-distribution":null,"route-of-elimination":null,"name":"Glycyltyrosine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15991"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":204.2,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7134-11-4","sequences":null,"targets":null,"unii":"6L00O0WHZR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":204.009244532,"volume-of-distribution":null,"route-of-elimination":null,"name":"Sulfogaiacol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB15992"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":307.307,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7675-83-4","sequences":null,"targets":null,"unii":"LZB1G2I725","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":307.149183416,"volume-of-distribution":null,"route-of-elimination":null,"name":"Arginine aspartate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15993"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":16.0425,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"74-82-8","sequences":null,"targets":null,"unii":"OP0UW79H66","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":"gas","synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":16.031300128,"volume-of-distribution":null,"route-of-elimination":null,"name":"Methane","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15994"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":63.012,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"7697-37-2","sequences":null,"targets":null,"unii":"411VRN1TV4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":62.995642896,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nitric acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB15995"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"8008-45-5","sequences":null,"targets":null,"unii":"Z1CLM48948","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nutmeg oil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB15996"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":438.059,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"307-34-6","sequences":null,"targets":null,"unii":"6P60ZBK0QL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":437.971256934,"volume-of-distribution":null,"route-of-elimination":null,"name":"Perfluorooctane","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB15997"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":171.193,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"923-09-1","sequences":null,"targets":null,"unii":"5UW00M8KR0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":170.99338917,"volume-of-distribution":null,"route-of-elimination":null,"name":"Potassium hydrogen DL-aspartate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15998"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":458.595,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"69164-69-8","sequences":null,"targets":null,"unii":"0PA7CJ4RFB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":458.266838944,"volume-of-distribution":null,"route-of-elimination":null,"name":"Prednisolone caproate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB15999"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":195.174,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"25395-22-6","sequences":null,"targets":null,"unii":"5LB8V0RHJV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":195.053157774,"volume-of-distribution":null,"route-of-elimination":null,"name":"Salicylamide O-acetic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16000"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":442.684,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"5721-91-5","sequences":null,"targets":null,"unii":"IJW60LAO6S","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB04630 DB08971 DB01384 DB00591 DB14652 DB14643 DB15777 DB15566 DB00959 DB14669 DB14649 DB09095 DB09091 DB14512 DB01285 DB13843 DB00443 DB09378 DB00860 DB13867 DB00764 DB14659 DB09368 DB13003 DB00547 DB15972 DB08970 DB00663 DB14545 DB01108 DB01222 DB01047 DB14633 DB13856 DB14539 DB00741 DB01380 DB14631 DB13223 DB15821 DB14540 DB00180 DB00588 DB11921 DB01234 DB13208 DB13491 DB00324 DB11529 DB09383 DB14541 DB14646 DB00620 DB00687 DB01013 DB01410 DB08906 DB00635 DB14644 DB14681 DB00394 DB11487","absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":442.344695341,"volume-of-distribution":null,"route-of-elimination":null,"name":"Testosterone decanoate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16001"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":386.576,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"15262-86-9","sequences":null,"targets":null,"unii":"X8ST05GYDM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB04630 DB08971 DB01384 DB00591 DB14652 DB14643 DB15777 DB15566 DB00959 DB14669 DB14649 DB09095 DB09091 DB14512 DB01285 DB13843 DB00443 DB09378 DB00860 DB13867 DB00764 DB14659 DB09368 DB13003 DB00547 DB15972 DB08970 DB00663 DB14545 DB01108 DB01222 DB01047 DB14633 DB13856 DB14539 DB00741 DB01380 DB14631 DB13223 DB15821 DB14540 DB00180 DB00588 DB11921 DB01234 DB13208 DB13491 DB00324 DB11529 DB09383 DB14541 DB14646 DB00620 DB00687 DB01013 DB01410 DB08906 DB00635 DB14644 DB14681 DB00394 DB11487","absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":386.282095084,"volume-of-distribution":null,"route-of-elimination":null,"name":"Testosterone isocaproate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16002"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":420.593,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1255-49-8","sequences":null,"targets":null,"unii":"8GN84GWX51","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB04630 DB08971 DB01384 DB00591 DB14652 DB14643 DB15777 DB15566 DB00959 DB14669 DB14649 DB09095 DB09091 DB14512 DB01285 DB13843 DB00443 DB09378 DB00860 DB13867 DB00764 DB14659 DB09368 DB13003 DB00547 DB15972 DB08970 DB00663 DB14545 DB01108 DB01222 DB01047 DB14633 DB13856 DB14539 DB00741 DB01380 DB14631 DB13223 DB15821 DB14540 DB00180 DB00588 DB11921 DB01234 DB13208 DB13491 DB00324 DB11529 DB09383 DB14541 DB14646 DB00620 DB00687 DB01013 DB01410 DB08906 DB00635 DB14644 DB14681 DB00394 DB11487","absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":420.266445019,"volume-of-distribution":null,"route-of-elimination":null,"name":"Testosterone phenylpropionate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-22","drugbank-id":"DB16003"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":292.073,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"51395-42-7","sequences":null,"targets":null,"unii":"26PB1U68YF","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":291.974920518,"volume-of-distribution":null,"route-of-elimination":null,"name":"Butedronic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16004"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":218.205,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"102-76-1","sequences":null,"targets":null,"unii":"XHX3C3X673","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":218.079038171,"volume-of-distribution":null,"route-of-elimination":null,"name":"Triacetin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16005"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":329.57,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"15281-32-0","sequences":null,"targets":null,"unii":"T967Q579KA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":327.988507,"volume-of-distribution":null,"route-of-elimination":null,"name":"Zinc DL-aspartate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16006"},{"toxicity":"There is no information on the LD<sub>50<\/sub> of rurioctocog alfa pegol. No symptoms of overdose with recombinant coagulation factor VIII have been reported.[L40099]","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Rurioctocog alfa pegol is a recombinant coagulation factor that promotes blood clotting. In clinical trials, personalized administration of rurioctocog alfa pegol based on each patient's clinical profile led to increased plasma levels of factor VIII and reduced bleeding episodes at six and 12 months of treatment.[A245134] Rurioctocog alfa pegol has a long duration of action compared to [octocog alfa]: it has an extended half-life of 1.4 to 1.5-fold compared to octocog alfa in adolescents and adults.[L40099]","msds":null,"description":"Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII or antihemophilic factor. Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous or secondary events like trauma or surgery.[A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII. Bleeding in joints is a common manifestation of hemophilia A, and bleeding episodes can be severe and life-threatening like intracranial hemorrhage.[A245139] Rurioctocog alfa pegol aims to restore functional levels of factor VIII in patients with hemophilia A to manage and prevent bleeding episodes. It was first approved by the European Commission in January 2018.[L40119]\r\n\r\nRurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line. The presence of the polyethylene glycol (PEG) moiety increases the plasma half-life of the drug, thereby increasing the drug's duration of action.[L40099]","enzymes":null,"type":"biotech","cas-number":"1417412-83-9","sequences":">Rurioctocog alfa pegol heavy chain\nATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN\nIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ\nREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSLYSHVDLVKDLNSGLIGALLVCR\nEGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR\nSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL\nMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF\nDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG\nRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI\nTDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME\nRDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG\nVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH\nKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE\nDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP\nKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ\nLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN\nTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW\nGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL\nLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK\nKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG\nQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK\nKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR\nTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL\nPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI\nPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK\nNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI\nYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK\nLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP\nEIEVTWAKQGRTERLCSQNPPVLKRHQR >Rurioctocog alfa pegol light chain\nEITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWD\nYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVE\nDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKD\nEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKS\nWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMG\nSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHA\nGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPF\nSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFG\nNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDA\nQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGV\nKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRI\nHPQSWVHQIALRMEVLGCEAQDLY","targets":"BE0001043 BE0000016","unii":"5X3GF74R79","protein-binding":"Once rurioctocog alfa pegol enters the circulation, it binds to von Willebrand factor, just like how an endogenous factor VIII would. There is limited information on the binding profile of rurioctocog alfa pegol to plasma proteins other than von Willebrand factor.[L40099]","fda-label":null,"clearance":"Following intravenous administration of rurioctocog alfa pegol, the mean  SD clearance was 2.58  0.84 mL\/(kgh) in adolescents and 2.16  0.75 mL\/(kgh) in adults.[L40099]","atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Factor VIII plays an essential role in the intrinsic pathway of the blood coagulation cascade: as a cofactor for activated factor IX (FIXa), factor VIII significantly facilitates the conversion of FIXa-mediated transformation of inactive factor X (FX) to its active form (FXa). FXa then promotes the conversion of prothrombin into thrombin, a key serine protease of the coagulation cascade. Proper blood clotting cannot be achieved with the deficient levels of factor VIII, leading to increased excessive bleeding spontaneously or as a result of accidental or surgical trauma.[A245149, L40099] Hemophilia A is an X-chromosomal linked hereditary disorder of blood coagulation due to defects in the F8C gene that encodes coagulation factor VIII, leading to decreased production of functional factor VIII.[A245139]\r\n\r\nRurioctocog alfa pegol is a pegylated recombinant human factor VIII that aims to restore the plasma levels and hemostatic activity of functional factor VIII. It can be used for both prophylactic or on-demand treatment of bleeding episodes associated with hemophilia A.[L40099]","drug-interactions":"DB14055 DB00682 DB09255 DB06754 DB09259 DB00022 DB00407 DB06695 DB09107 DB00019 DB14712 DB06679 DB00009 DB06294 DB08814 DB12289 DB06811 DB15944 DB06406 DB14700 DB11095 DB09208 DB13933 DB06325 DB09258 DB05099 DB13199 DB06228 DB12578 DB06635 DB03394 DB04898 DB08994 DB06605 DB09329 DB12598 DB13149 DB08816 DB00058 DB13729 DB09154 DB09030 DB09122 DB08813 DB11567 DB05229 DB12814 DB03410 DB06022 DB13136 DB11091 DB13347 DB04665 DB00013 DB00082 DB00975 DB00278 DB11598 DB06822 DB00061 DB01225 DB00015 DB05860 DB06543 DB13275 DB06441 DB00686 DB13616 DB15880 DB00055 DB08904 DB08794 DB00569 DB08496 DB12842 DB00302 DB06692 DB06779 DB00008 DB04932 DB05254 DB00059 DB01418 DB12839 DB06209 DB01240 DB06293 DB12726 DB12831 DB13200 DB05361 DB14094 DB05202 DB09260 DB13244 DB11312 DB13451 DB04925 DB09075 DB00086 DB00001 DB04895 DB00170 DB12364 DB07767 DB00946 DB11661 DB00031 DB13646 DB06611 DB06271 DB00498 DB00974 DB11707 DB00054 DB01109 DB08894 DB00029 DB12258 DB00006 DB00513 DB00266 DB14726 DB09287 DB05321 DB11984 DB01839 DB11166 DB13124","absorption":"Following intravenous administration of rurioctocog alfa pegol, the mean  SD C<sub>max<\/sub> was 117  28 IU\/dL in adolescents and 145  29 IU\/dL in adults.[L40099]","created":"2020-12-10","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Following intravenous administration of rurioctocog alfa pegol, the mean  SD terminal half-life was 13.80  4.01 hours in adolescents and 15.01  3.89 hours in adults.[L40099]","monoisotopic-mass":null,"volume-of-distribution":"Following intravenous administration, the mean  SD volume of distribution at steady-state was 0.54  0.22 dL\/kg in adolescents and 0.40  0.09 dL\/kg in adults.[L40099]","route-of-elimination":"There is limited information regarding the route of elimination of rurioctocog alfa pegol.","name":"Rurioctocog alfa pegol","metabolism":"There is limited information regarding the metabolism of rurioctocog alfa pegol; however, it is expected to undergo catabolism just like endogenous coagulation factor VIII. Metabolism pathways and CYP involvement are not known to exist regarding coagulation factors.[L40129]","reactions":null,"indication":"Rurioctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in patients 12 years and above with hemophilia A (congenital factor VIII deficiency).[L40099]","ahfs-codes":null,"updated":"2022-02-10","drugbank-id":"DB16007"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":405.455,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).","enzymes":null,"type":"small molecule","cas-number":"130636-43-0","sequences":null,"targets":null,"unii":"5VZ7GZM43E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":405.201218989,"volume-of-distribution":null,"route-of-elimination":null,"name":"Nifekalant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16008"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":451.531,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).","enzymes":null,"type":"small molecule","cas-number":"1192189-69-7","sequences":null,"targets":null,"unii":"74B3C4ZT96","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":451.233187822,"volume-of-distribution":null,"route-of-elimination":null,"name":"LX-7101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16009"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).","enzymes":null,"type":"biotech","cas-number":"257277-05-7","sequences":null,"targets":null,"unii":"Q9SAI36COS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iseganan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16010"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":357.494,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Levophencynonate is under investigation in clinical trial NCT02299804 (A Clinical Trial to Evaluate Efficacy and Safety of Levophencynonate Hydrochloride in Patient With Vertigo).","enzymes":null,"type":"small molecule","cas-number":"230313-75-4","sequences":null,"targets":null,"unii":"4TNV157KEQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":357.230393862,"volume-of-distribution":null,"route-of-elimination":null,"name":"Levophencynonate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16011"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":533.753,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Celivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation\/flutter).","enzymes":null,"type":"small molecule","cas-number":"401925-43-7","sequences":null,"targets":null,"unii":"K45001587E","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":533.350508997,"volume-of-distribution":null,"route-of-elimination":null,"name":"Celivarone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16012"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1781.237,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension).","enzymes":null,"type":"small molecule","cas-number":"383123-18-0","sequences":null,"targets":null,"unii":"VJ98TJ922K","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-10","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1780.110046948,"volume-of-distribution":null,"route-of-elimination":null,"name":"SER-100","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16013"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":390.344,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).","enzymes":null,"type":"small molecule","cas-number":"118159-48-1","sequences":null,"targets":null,"unii":"9734122TH2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":390.09508216,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bicyclol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16014"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":514.405,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).","enzymes":null,"type":"small molecule","cas-number":"403717-06-6","sequences":null,"targets":null,"unii":"8BK3483OW5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":514.148133854,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bisphosphocin Nu-3","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-11","drugbank-id":"DB16015"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":207.233,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Histamine glutarimide is under investigation in clinical trial NCT03450434 (XC8 in the Treatment of Patients With Bronchial Asthma).","enzymes":null,"type":"small molecule","cas-number":"1464897-15-1","sequences":null,"targets":null,"unii":"VOM9DP10M3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-11","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":207.100776671,"volume-of-distribution":null,"route-of-elimination":null,"name":"Histamine glutarimide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-12","drugbank-id":"DB16016"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed non-protein coding gene).","enzymes":null,"type":"biotech","cas-number":"2166100-08-7","sequences":null,"targets":null,"unii":"98YK326XZ6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-12","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Inodiftagene vixteplasmid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-03","drugbank-id":"DB16017"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"biotech","cas-number":"1905415-02-2","sequences":null,"targets":null,"unii":"M9N48CJY6T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-12","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Timrepigene emparvovec","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-05-11","drugbank-id":"DB16018"},{"toxicity":"There is limited information on the LD<sub>50<\/sub> value of Ga-68 PSMA-11. In the event of an overdose, it is recommended to enhance drug elimination by hydration, frequent bladder voiding, or the use of diuretics.[L26981]","snp-adverse-drug-reactions":null,"average-mass":1011.909,"transporters":null,"pharmacodynamics":"Ga-68 PSMA-11 works by binding to prostate-specific membrane antigen (PSMA) expressed on malignant prostate cancer cells. Gallium-68 (Ga-68) is a +-emitting radionuclide and Ga-68 PSMA-11 can be imaged by PET to indicate the presence of PSMA-positive prostate cancer lesions in the tissues of the body.[L26981] Ga-68 PMSA-11 has a high affinity to PSMA and was shown to be effective in imaging of both local prostate cancer tumours and distant metastatic lesions in clinical trials.[A36121,A225531] In a clinical trial comprising patients with relapsed prostate cancer, Ga-68 PSMA-11 PET detection rate was different depending on the clinical stage of biochemical recurrence.[A225541]","msds":null,"description":"Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET).[L26981] Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries and many patients treated with androgen-deprivation therapy relapse with castration-resistant prostate cancer.[A225396] In nearly all prostate cancers, malignant cells express a transmembrane protein called prostate-specific membrane antigen (PSMA).[A225396] Ga-68 PSMA-11 is an imaging agent that binds PSMA during positron emission tomography: it emits positrons to indicate the presence of PSMA-positive prostate cancer lesions in patients with suspected prostate cancer or in patients who may have recurrent prostate cancer.[L27006] \r\n\r\nOn December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.[L27006] It is administered intravenously. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Ga-68 gozetotide be granted marketing authorization for the diagnosis of prostate cancer.[L43542]","enzymes":null,"type":"small molecule","cas-number":"1906894-20-9","sequences":null,"targets":"BE0008983","unii":"ZJ0EKR6M10","protein-binding":"There is no information on plasma protein binding.","fda-label":null,"clearance":"There is limited information on the clearance rate, but Ga-68 PSMA-11 shows fast blood clearance.[A225541]","atc-codes":"DIAGNOSTIC RADIOPHARMACEUTICALS VARIOUS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein expressed throughout the body, such as in lacrimal and salivary glands, the kidneys, small intestine, liver and spleen.[A36121,A225536,A225401] It is highly associated with tumour-associated angiogenesis and has been described in various tumours, such as prostate cancer, glioblastoma, thyroid cancer, gastric cancer, breast cancer, renal cancer, and colorectal cancers.[A225541] The expression of PSMA has been linked to the degree of tumour differentiation, as it is overexpressed particularly in poorly differentiated and metastatic lesions.[A225396,A225536] PSMA has been extensively studied as a reliable target for imaging and therapy for prostate cancer, as it is overexpressed one-hundred to one thousand-fold in over 90 % of primary prostate cancers.[A225541] \r\n\r\nPositron emission tomography (PET) is a type of molecular imaging used to improve the accuracy of detecting prostate cancer at an earlier time and examine tumour characteristics. Ga-68 PSMA-11 is a PSMA-targeted imaging agent for PET that binds to PSMA via clathrin-coated pits, resulting in endosome accumulation and the internalization of the PSMA-drug complex.[A225541]","drug-interactions":"DB08899 DB11901 DB11853 DB00499 DB01128 DB04839 DB13528 DB00665 DB12941 DB15903","absorption":"Following intravenous injection, Ga-68 PSMA-11 uptake occurs in the adrenal and prostate glands, with high uptake in PSMA-expressing tissues.[A225541] Uptake of the drug is very minimal in the cerebral cortex, heart, and lungs.[L26981] Mean maximum standardized uptake value (SUV<sub>max<\/sub>) at later acquisition times is about 15.3.[A225531]","created":"2020-12-13","groups":"approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":"Gallium-68 (Ga-68) decays with a half-life of 68 minutes.[L26981]","monoisotopic-mass":1011.321652961,"volume-of-distribution":"Ga-68 PSMA-11 accumulates in the liver (15%), kidneys (7%), spleen (2%), and salivary glands (0.5%).[L26981] Ga-68 PSMA-11 accumulation increases at later acquisition times.[A225531]","route-of-elimination":"About 14% of the total injected dose is excreted in the urine within two hours following intravenous administration.[L26981]","name":"Gallium Ga-68 gozetotide","metabolism":"Ga-68 PSMA-11 decays to stable zinc-68.[L26981]","reactions":null,"indication":"Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in patients with suspected prostate cancer metastasis who are also candidates for initial surgical or radiation therapy. It is also indicated for patients with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.[L26981,L39553]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16019"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":291.435,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"1092-46-2","sequences":null,"targets":null,"unii":"WA1RT89G9X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":291.219829178,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ketocaine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16020"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":341.43,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"23672-07-3","sequences":null,"targets":null,"unii":"JTG7R315LK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"Benzamides ANTIPSYCHOTICS NERVOUS SYSTEM PSYCHOLEPTICS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08953 DB14028 DB14719 DB12710 DB08329 DB00219 DB00656 DB01560 DB13082 DB01545 DB13642 DB13841 DB11552 DB00540 DB00737 DB01142 DB06554 DB12184 DB11957 DB13875 DB13695 DB13876 DB01215 DB00387 DB09185 DB05542 DB12193 DB09253 DB01247 DB13505 DB00280 DB01200 DB05232 DB01618 DB13799 DB13252 DB06701 DB01409 DB01337 DB13703 DB09307 DB13522 DB00395 DB00424 DB01086 DB00962 DB00557 DB09195 DB01556 DB01209 DB01595 DB09184 DB08922 DB11859 DB13303 DB00321 DB00810 DB13354 DB00732 DB06148 DB13754 DB14506 DB13738 DB01246 DB12338 DB00292 DB00490 DB00475 DB01235 DB01535 DB04908 DB00463 DB01075 DB02234 DB11855 DB09076 DB13534 DB01065 DB00546 DB01558 DB01148 DB01339 DB01551 DB13948 DB13411 DB11823 DB00246 DB01577 DB00777 DB15119 DB00209 DB09190 DB13636 DB00714 DB00543 DB08927 DB13572 DB13552 DB04017 DB06690 DB00230 DB00281 DB00268 DB01320 DB09480 DB13554 DB01323 DB00181 DB13219 DB01579 DB01495 DB01624 DB04818 DB08839 DB00332 DB13468 DB01062 DB01555 DB12883 DB08811 DB12404 DB01466 DB06529 DB00708 DB13496 DB12229 DB09224 DB01622 DB00370 DB00245 DB09249 DB13787 DB00599 DB13541 DB08550 DB00835 DB13837 DB11951 DB13584 DB00670 DB00391 DB01100 DB13396 DB13253 DB00623 DB01445 DB04888 DB12661 DB11903 DB01202 DB13233 DB00906 DB00908 DB00402 DB09251 DB00372 DB00652 DB08861 DB11889 DB13805 DB01107 DB09225 DB06582 DB04917 DB01245 DB00614 DB13940 DB01175 DB00866 DB00949 DB09194 DB00819 DB00662 DB00420 DB00980 DB13323 DB13769 DB09300 DB00967 DB12576 DB04821 DB00996 DB12177 DB00476 DB12080 DB06738 DB11868 DB13014 DB12958 DB00715 DB00327 DB00237 DB00334 DB01156 DB12110 DB00601 DB13542 DB00899 DB00241 DB13414 DB00468 DB01484 DB00924 DB01626 DB00941 DB13662 DB13817 DB00753 DB06654 DB06155 DB11664 DB13402 DB13624 DB06512 DB05227 DB00960 DB00312 DB01359 DB00363 DB08801 DB04871 DB12590 DB08810 DB13687 DB04884 DB00206 DB01534 DB00628 DB00418 DB01231 DB01616 DB00313 DB06201 DB04843 DB00297 DB00193 DB13605 DB00416 DB01452 DB11555 DB13782 DB00231 DB01566 DB00633 DB00937 DB09097 DB05246 DB01625 DB13737 DB11540 DB00831 DB09068 DB12395 DB13384 DB13454 DB00450 DB00617 DB00734 DB01227 DB13784 DB09166 DB00532 DB11400 DB00754 DB12273 DB00604 DB00852 DB05541 DB11582 DB00842 DB12427 DB01199 DB11376 DB08986 DB00776 DB08059 DB08910 DB09243 DB12930 DB08960 DB14651 DB00454 DB00176 DB09117 DB01104 DB00505 DB00985 DB01161 DB11371 DB11315 DB09250 DB04819 DB13678 DB06283 DB01041 DB11235 DB00921 DB09345 DB09021 DB01192 DB05607 DB09009 DB00875 DB00496 DB00622 DB13114 DB01450 DB08996 DB06446 DB11477 DB13221 DB13588 DB13606 DB00474 DB13234 DB00780 DB00690 DB13913 DB01114 DB13213 DB00818 DB00377 DB01355 DB00952 DB00323 DB13025 DB00849 DB01615 DB13993 DB00555 DB00423 DB00422 DB01037 DB09118 DB11686 DB06787 DB00404 DB01531 DB13577 DB00502 DB13733 DB04948 DB00486 DB14881 DB01365 DB01017 DB00252 DB01511 DB05077 DB00942 DB09001 DB09245 DB00801 DB13550 DB12518 DB04953 DB01063 DB14011 DB13335 DB12649 DB01071 DB01002 DB13254 DB13246 DB00956 DB01954 DB13420 DB00660 DB13759 DB12308 DB15203 DB00564 DB09000 DB00572 DB01501 DB11156 DB01173 DB13225 DB13352 DB04833 DB00234 DB01105 DB06684 DB06144 DB01440 DB13648 DB13256 DB04896 DB00854 DB00843 DB00182 DB01354 DB09241 DB11609 DB13357 DB13437 DB01587 DB01608 DB01392 DB00295 DB13099 DB13950 DB14185 DB14043 DB00589 DB00340 DB05710 DB00748 DB00904 DB01614 DB12105 DB13666 DB06527 DB12537 DB01563 DB06282 DB08815 DB01547 DB09089 DB06016 DB04946 DB14737 DB13070 DB13770 DB11732 DB00215 DB00248 DB01591 DB01567 DB13745 DB09011 DB00771 DB13791 DB00625 DB00645 DB06218 DB01576 DB00751 DB01267 DB00202 DB12989 DB14509 DB00517 DB01242 DB00679 DB01154 DB01483 DB06109 DB13455 DB13457 DB06660 DB14715 DB08872 DB01236 DB06700 DB00477 DB00889 DB01239 DB11543 DB09085 DB00354 DB06702 DB13448 DB06753 DB00804 DB05687 DB13324 DB00189 DB00565 DB00349 DB04829 DB13520 DB00427 DB12131 DB00150 DB09167 DB00484 DB00296 DB01621 DB01151 DB12327 DB00725 DB13362 DB09017 DB09247 DB00813 DB00376 DB01255 DB00433 DB09128 DB13273 DB14672 DB09254 DB00508 DB01226 DB00752 DB01463 DB00865 DB06691 DB13331 DB01367 DB04841 DB04903 DB08897 DB00494 DB09016 DB00721 DB13413 DB00750 DB01467 DB01186 DB00892 DB04842 DB01442 DB00934 DB09289 DB12278 DB00191 DB00344 DB00042 DB00579 DB01049 DB09014 DB00757 DB12693 DB13403 DB08992 DB01018 DB06579 DB13623 DB00805 DB09223 DB01589 DB06797 DB14718 DB08997 DB01565 DB00083 DB00747 DB04820 DB13598 DB00383 DB00653 DB14010 DB00969 DB14575 DB04832 DB00972 DB04599 DB06204 DB00593 DB12111 DB00273 DB06716 DB00497 DB14507 DB01121 DB00483 DB01623 DB08954 DB00829 DB09226 DB00940 DB13295 DB00986 DB11549 DB01176 DB00408 DB15031 DB00588 DB00696 DB00333 DB00470 DB04844 DB00832 DB00458 DB00953 DB01221 DB01149 DB11556 DB09262 DB13523 DB00392 DB09007 DB00697 DB12554 DB01224 DB12492 DB06077 DB06678 DB11428 DB00740 DB00802 DB00356 DB14050 DB09071 DB00765 DB00907 DB01198 DB00794 DB01509 DB00527 DB00680 DB01433 DB01036 DB09119 DB13844 DB01351 DB01594 DB01403 DB06288 DB12161 DB04834 DB12526 DB13601 DB00285 DB00462 DB00514 DB04827 DB00434 DB00844 DB01219 DB00574 DB00371 DB01352 DB11755 DB12086 DB04872 DB12093 DB01353 DB02207 DB00347 DB13643 DB12401 DB01489 DB09174 DB00228 DB13665 DB09248 DB02852 DB06470 DB01028 DB13108 DB13619 DB00320 DB13380 DB01529 DB12725 DB03575 DB13690 DB01454 DB00767 DB13850 DB04836 DB13370 DB01174 DB01497 DB11675 DB00318 DB01488 DB00216 DB00341 DB00315 DB06216 DB13351 DB00405 DB12465 DB12951 DB01189 DB12361 DB01544 DB04165 DB00933 DB06264 DB13377 DB01356 DB00728 DB00850 DB00409 DB06153 DB00961 DB13160 DB14754 DB00366 DB13720 DB09187 DB09246 DB00283 DB05271 DB00647 DB01588 DB06624 DB12163 DB01069 DB09252 DB11699 DB08883 DB00342 DB00726 DB13382 DB06458 DB00897 DB01437 DB06731 DB13872 DB09061 DB13557 DB00998 DB00909 DB00683 DB13500 DB00306 DB06770 DB00575 DB12071 DB00186 DB13984 DB00837 DB01159 DB13581 DB00669 DB00413 DB09244 DB09034 DB01171 DB09186 DB13369 DB01238 DB09023 DB01253 DB09286 DB02959 DB08918 DB01336 DB04325 DB08892 DB15360 DB01338 DB00425 DB06594 DB04885 DB05562 DB11130 DB00611 DB13478 DB01559 DB12867 DB01135 DB00247 DB00918 DB01233 DB01081 DB01178 DB01553 DB01168 DB09290 DB13676 DB00472 DB09072 DB00898 DB00782 DB13507 DB01080 DB01472 DB12833 DB01580 DB01068","absorption":null,"created":"2020-12-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":341.140927407,"volume-of-distribution":null,"route-of-elimination":null,"name":"Levosulpiride","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16021"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":261.39,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"91-79-2","sequences":null,"targets":null,"unii":"E4U52363JE","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-14","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":261.129968798,"volume-of-distribution":null,"route-of-elimination":null,"name":"Thenyldiamine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16022"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":380.78,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"532-40-1","sequences":null,"targets":null,"unii":"P712T71Q3T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":380.0474909,"volume-of-distribution":null,"route-of-elimination":null,"name":"Monophosphothiamine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16023"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":774.97,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"3599-32-4","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"DIAGNOSTIC AGENTS VARIOUS Other diagnostic agents OTHER DIAGNOSTIC AGENTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-14","groups":"experimental approved","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":774.27732387,"volume-of-distribution":null,"route-of-elimination":null,"name":"Indocyanine green","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2023-01-03","drugbank-id":"DB16024"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":303.319,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"56265-06-6","sequences":null,"targets":null,"unii":"808T94CEU6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-14","groups":"experimental","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":303.154268796,"volume-of-distribution":null,"route-of-elimination":null,"name":"Arginine PCA","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-15","drugbank-id":"DB16025"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":685.855,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).","enzymes":null,"type":"small molecule","cas-number":"401519-96-8","sequences":null,"targets":null,"unii":"V9G7HR5L1Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":685.382596975,"volume-of-distribution":null,"route-of-elimination":null,"name":"NCX-1000","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16026"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":296.451,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).","enzymes":null,"type":"small molecule","cas-number":"57818-44-7","sequences":null,"targets":null,"unii":"0DE74TJ7EZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":296.23514489,"volume-of-distribution":null,"route-of-elimination":null,"name":"alpha-Hydroxylinoleic acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16027"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":371.41,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Azemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients).","enzymes":null,"type":"small molecule","cas-number":"1133819-87-0","sequences":null,"targets":null,"unii":"81MXZ6QOBM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":371.082743825,"volume-of-distribution":null,"route-of-elimination":null,"name":"Azemiglitazone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16028"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":205.216,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).","enzymes":null,"type":"small molecule","cas-number":"1236354-10-1","sequences":null,"targets":null,"unii":"AK3K0K6CM5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":205.09797163,"volume-of-distribution":null,"route-of-elimination":null,"name":"2-(5-fluoro-pentyl)-2-methyl-malonic-acid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16029"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":469.401,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VLX1570 is under investigation in clinical trial NCT02372240 (A Study of VLX1570 and Dexamethasone in Myeloma Patients).","enzymes":null,"type":"small molecule","cas-number":"1956378-23-6","sequences":null,"targets":null,"unii":"K6067N5M6N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":469.108541605,"volume-of-distribution":null,"route-of-elimination":null,"name":"VLX1570","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16030"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":405.667,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction).","enzymes":null,"type":"small molecule","cas-number":"14291-24-8","sequences":null,"targets":null,"unii":"3W389841RN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":405.360679757,"volume-of-distribution":null,"route-of-elimination":null,"name":"TRO40303","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16031"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":313.288,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).","enzymes":null,"type":"small molecule","cas-number":"280571-30-4","sequences":null,"targets":null,"unii":"W7KQU075CV","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":313.086269421,"volume-of-distribution":null,"route-of-elimination":null,"name":"GW810781","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16032"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":460.538,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).","enzymes":null,"type":"small molecule","cas-number":"1419609-94-1","sequences":null,"targets":null,"unii":"63FJ7LF55O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":460.222288786,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK2798745","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16033"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":229.66,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).","enzymes":null,"type":"small molecule","cas-number":"1353949-71-9","sequences":null,"targets":null,"unii":"D7NM51C3GU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":229.050571,"volume-of-distribution":null,"route-of-elimination":null,"name":"JBPOS0101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16034"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":439.394,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BFH772 is under investigation in clinical trial NCT01449591 (Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients).","enzymes":null,"type":"small molecule","cas-number":"890128-81-1","sequences":null,"targets":null,"unii":"T1IV236CVP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":439.114375876,"volume-of-distribution":null,"route-of-elimination":null,"name":"BFH772","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16035"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":507.401,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ABX-1431 is under investigation in clinical trial NCT03625453 (Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder).","enzymes":null,"type":"small molecule","cas-number":"1446817-84-0","sequences":null,"targets":null,"unii":"FB39E94UXK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":507.156830427,"volume-of-distribution":null,"route-of-elimination":null,"name":"ABX-1431","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16036"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":633.79,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).","enzymes":null,"type":"small molecule","cas-number":"866086-05-7","sequences":null,"targets":null,"unii":"7L3WOA232W","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":633.352634253,"volume-of-distribution":null,"route-of-elimination":null,"name":"BI 44370 TA","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16037"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":542.54,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PLX8394 is under investigation in clinical trial NCT02428712 (A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors).","enzymes":null,"type":"small molecule","cas-number":"1393466-87-9","sequences":null,"targets":null,"unii":"J2L7Z273SG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":542.134794223,"volume-of-distribution":null,"route-of-elimination":null,"name":"PLX8394","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16038"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":276.06,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AN2898 is under investigation in clinical trial NCT01301508 (Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-moderate Atopic Dermatitis).","enzymes":null,"type":"small molecule","cas-number":"906673-33-4","sequences":null,"targets":null,"unii":"6O60L94RMB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":276.070622,"volume-of-distribution":null,"route-of-elimination":null,"name":"AN2898","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16039"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":491.99,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"DU125530 is under investigation in clinical trial NCT01119430 (Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder).","enzymes":null,"type":"small molecule","cas-number":"161611-99-0","sequences":null,"targets":null,"unii":"ZB05V621UD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":491.1281698,"volume-of-distribution":null,"route-of-elimination":null,"name":"DU125530","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16040"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":265.309,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"EPI-589 is under investigation in clinical trial NCT02460679 (Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)).","enzymes":null,"type":"small molecule","cas-number":"1147883-03-1","sequences":null,"targets":null,"unii":"I4ZSB1Q2DU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":265.131408096,"volume-of-distribution":null,"route-of-elimination":null,"name":"EPI-589","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16041"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":472.0,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SB-773812 is under investigation in clinical trial NCT00259870 (SB-773812 Administered in Adults With Schizophrenia).","enzymes":null,"type":"small molecule","cas-number":"630407-66-8","sequences":null,"targets":null,"unii":"ZNP5SNF9FY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":471.1271072,"volume-of-distribution":null,"route-of-elimination":null,"name":"SB-773812","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16042"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":555.61,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).","enzymes":null,"type":"small molecule","cas-number":"2230198-02-2","sequences":null,"targets":null,"unii":"DN9IUI24GP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":555.228182629,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-06882961","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16043"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":356.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).","enzymes":null,"type":"small molecule","cas-number":"1226793-34-5","sequences":null,"targets":null,"unii":"4JEH3BL51N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":356.130697074,"volume-of-distribution":null,"route-of-elimination":null,"name":"PF-05212377","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16044"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":540.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).","enzymes":null,"type":"small molecule","cas-number":"1103500-20-4","sequences":null,"targets":null,"unii":"VVA2ZDV3LX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":539.1378618,"volume-of-distribution":null,"route-of-elimination":null,"name":"TERN-101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16045"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":328.412,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TRC150094 is under investigation in clinical trial NCT03254446 (Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension).","enzymes":null,"type":"small molecule","cas-number":"1092551-88-6","sequences":null,"targets":null,"unii":"B93608MTGW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":328.178692641,"volume-of-distribution":null,"route-of-elimination":null,"name":"TRC150094","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16046"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":404.353,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).","enzymes":null,"type":"small molecule","cas-number":"1034895-42-5","sequences":null,"targets":null,"unii":"ND1SOF0DLU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":404.08084969,"volume-of-distribution":null,"route-of-elimination":null,"name":"Elraglusib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16047"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":480.96,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BTRX-246040 is under investigation in clinical trial NCT03193398 (BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder).","enzymes":null,"type":"small molecule","cas-number":"1307245-86-8","sequences":null,"targets":null,"unii":"4I67US2V8Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":480.1198312,"volume-of-distribution":null,"route-of-elimination":null,"name":"BTRX-246040","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16048"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":356.329,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Farudodstat (ASLAN003) is under investigation in clinical trial NCT03451084 (A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1035688-66-4","sequences":null,"targets":null,"unii":"I58WE41H6X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":356.097248645,"volume-of-distribution":null,"route-of-elimination":null,"name":"Farudodstat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16049"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":530.677,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":"1472797-69-5","sequences":null,"targets":null,"unii":"7V7IHI0SYG","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":530.311772496,"volume-of-distribution":null,"route-of-elimination":null,"name":"FF-10101-01","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16050"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":382.261,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"MOL-4239 is under investigation in clinical trial NCT01826201 (Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis).","enzymes":null,"type":"small molecule","cas-number":"1204306-34-2","sequences":null,"targets":null,"unii":"PTN9LJL6PY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":381.047675,"volume-of-distribution":null,"route-of-elimination":null,"name":"MOL-4239","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16051"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":488.439,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).","enzymes":null,"type":"small molecule","cas-number":"41263-94-9","sequences":null,"targets":null,"unii":"XO2533XO8R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":488.17412033,"volume-of-distribution":null,"route-of-elimination":null,"name":"2'-Fucosyllactose","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16052"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":516.37,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).","enzymes":null,"type":"small molecule","cas-number":"1202891-16-4","sequences":null,"targets":null,"unii":"5LO1ZK1LCW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":515.0902429,"volume-of-distribution":null,"route-of-elimination":null,"name":"ARRY-502","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16053"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":415.46,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"INCB-057643 is under investigation in clinical trial NCT02959437 (Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)).","enzymes":null,"type":"small molecule","cas-number":"1820889-23-3","sequences":null,"targets":null,"unii":"87TZD0JEBS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":415.120191962,"volume-of-distribution":null,"route-of-elimination":null,"name":"INCB-057643","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16054"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":383.34,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).","enzymes":null,"type":"small molecule","cas-number":"1672665-49-4","sequences":null,"targets":null,"unii":"6O16716DXP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":383.043913533,"volume-of-distribution":null,"route-of-elimination":null,"name":"PT-2385","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16055"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":470.533,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).","enzymes":null,"type":"small molecule","cas-number":"1788906-96-6","sequences":null,"targets":null,"unii":"XX8E5WP7FS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":470.206638721,"volume-of-distribution":null,"route-of-elimination":null,"name":"GZ-389988","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16056"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":460.427,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed\/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)).","enzymes":null,"type":"small molecule","cas-number":"2097713-68-1","sequences":null,"targets":null,"unii":"X6SH5T8H76","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":460.151171539,"volume-of-distribution":null,"route-of-elimination":null,"name":"OBI-3424","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16057"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":427.504,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).","enzymes":null,"type":"small molecule","cas-number":"590416-75-4","sequences":null,"targets":null,"unii":"I2CST2BV1Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":427.189591677,"volume-of-distribution":null,"route-of-elimination":null,"name":"AK106-001616","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16058"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":472.476,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ\/11 Mutations or PRKC Fusions).","enzymes":null,"type":"small molecule","cas-number":"1874276-76-2","sequences":null,"targets":null,"unii":"E0YF0M8O09","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":472.194691882,"volume-of-distribution":null,"route-of-elimination":null,"name":"IDE-196","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16059"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":442.82,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"V116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).","enzymes":null,"type":"small molecule","cas-number":"1073616-61-1","sequences":null,"targets":null,"unii":"TBJ73RQT8F","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":442.1019526,"volume-of-distribution":null,"route-of-elimination":null,"name":"V116517","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16060"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":394.523,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).","enzymes":null,"type":"small molecule","cas-number":"1805833-75-3","sequences":null,"targets":null,"unii":"46D4HS9ODA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":394.24810961,"volume-of-distribution":null,"route-of-elimination":null,"name":"Samuraciclib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16061"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":272.74,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).","enzymes":null,"type":"small molecule","cas-number":"139339-45-0","sequences":null,"targets":null,"unii":"MLW2GKK8LI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":272.0828741,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ro 24-7429","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16062"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":317.352,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).","enzymes":null,"type":"small molecule","cas-number":"1140964-99-3","sequences":null,"targets":null,"unii":"9X5A2QIA7C","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":317.127660123,"volume-of-distribution":null,"route-of-elimination":null,"name":"2X-121","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16063"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":435.528,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).","enzymes":null,"type":"small molecule","cas-number":"1898283-02-7","sequences":null,"targets":null,"unii":"19HY34R6UN","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":435.227039814,"volume-of-distribution":null,"route-of-elimination":null,"name":"LY-3200882","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16064"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":517.5,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).","enzymes":null,"type":"small molecule","cas-number":"1398046-21-3","sequences":null,"targets":null,"unii":"QX6O64GP40","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Proxalutamide is an antagonist at the androgen receptor which leads to inhibition of androgen-induced receptor activation and results in formation of inactive complexes that are not able to translocate to the nucleus. It also induces androgen receptor downregulation, furthering adrogen-induced receptor activation. This drug is being investigated for its potential antineoplastic activity and is being investigated specifically against prostate cancer and COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":517.119558698,"volume-of-distribution":null,"route-of-elimination":null,"name":"Proxalutamide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-01-20","drugbank-id":"DB16065"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":495.86,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CCX-140 is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).","enzymes":null,"type":"small molecule","cas-number":"1100318-47-5","sequences":null,"targets":null,"unii":"380F68J5PH","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":495.0379727,"volume-of-distribution":null,"route-of-elimination":null,"name":"CCX-140","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16066"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":284.238,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TAK-831 is under investigation in clinical trial NCT03214588 (Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia).","enzymes":null,"type":"small molecule","cas-number":"1425511-32-5","sequences":null,"targets":null,"unii":"76IC00YRVR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":284.077262091,"volume-of-distribution":null,"route-of-elimination":null,"name":"TAK-831","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16067"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":453.562,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).","enzymes":null,"type":"small molecule","cas-number":"2244614-14-8","sequences":null,"targets":null,"unii":"XK5ILZ28KI","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":453.254003453,"volume-of-distribution":null,"route-of-elimination":null,"name":"BTRX-335140","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16068"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":355.41,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"SP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).","enzymes":null,"type":"small molecule","cas-number":"911714-45-9","sequences":null,"targets":null,"unii":"WBX54NZ436","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":355.108958574,"volume-of-distribution":null,"route-of-elimination":null,"name":"SP-420","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16069"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":586.686,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"KZR-616 is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).","enzymes":null,"type":"small molecule","cas-number":"1629677-75-3","sequences":null,"targets":null,"unii":"O4BT6C02M2","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":586.300264328,"volume-of-distribution":null,"route-of-elimination":null,"name":"KZR-616","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16070"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":261.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"4'-Thio-fac is under investigation in clinical trial NCT02661542 (Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas).","enzymes":null,"type":"small molecule","cas-number":"184302-49-6","sequences":null,"targets":null,"unii":"R5B1HX1HUY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":261.058340595,"volume-of-distribution":null,"route-of-elimination":null,"name":"4'-Thio-fac","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16071"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":961.338,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).","enzymes":null,"type":"small molecule","cas-number":"1820753-68-1","sequences":null,"targets":null,"unii":"SE6KE496VO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":960.622767673,"volume-of-distribution":null,"route-of-elimination":null,"name":"ORP-101","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16072"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":487.483,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"AZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients).","enzymes":null,"type":"small molecule","cas-number":"1092453-15-0","sequences":null,"targets":null,"unii":"6H81G454I7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":487.183124142,"volume-of-distribution":null,"route-of-elimination":null,"name":"AZD8529","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16073"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":426.95,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"LY2828360 is under investigation in clinical trial NCT01319929 (A Study of LY2828360 in Patients With Osteoarthritic Knee Pain).","enzymes":null,"type":"small molecule","cas-number":"1231220-79-3","sequences":null,"targets":null,"unii":"O12H7VFU6P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":426.1934872,"volume-of-distribution":null,"route-of-elimination":null,"name":"LY2828360","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16074"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":301.69,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"8-Chloroadenosine is under investigation in clinical trial NCT02509546 (8-chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia).","enzymes":null,"type":"small molecule","cas-number":"34408-14-5","sequences":null,"targets":null,"unii":"PA05MFH3I7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":301.0577816,"volume-of-distribution":null,"route-of-elimination":null,"name":"8-Chloroadenosine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16075"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":390.532,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK2245035 is under investigation in clinical trial NCT02833974 (Effect of the GSK2245035 on the Allergen-induced Asthmatic Response).","enzymes":null,"type":"small molecule","cas-number":"1207629-49-9","sequences":null,"targets":null,"unii":"5L3SX16QBQ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":390.274324359,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK2245035","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16076"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).","enzymes":null,"type":"biotech","cas-number":"792921-10-9","sequences":null,"targets":null,"unii":"3YK0326U7X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB13259 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB00814 DB11604 DB12344 DB13886 DB05232 DB14811 DB11884 DB11685 DB11746 DB15118 DB01086 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB01075 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB00281 DB14897 DB13578 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00012 DB00098 DB11502 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB08894 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB09107 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB00297 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12532 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB01161 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB09345 DB11826 DB14004 DB09009 DB06241 DB00057 DB00112 DB09342 DB05793 DB06049 DB06168 DB16659 DB13683 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB01002 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB06774 DB00645 DB15363 DB00111 DB01270 DB13418 DB14947 DB09085 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB00296 DB06162 DB12489 DB09264 DB13328 DB12773 DB12456 DB06273 DB12413 DB00721 DB12317 DB06317 DB14809 DB12807 DB00750 DB00892 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB08987 DB12202 DB13045 DB00016 DB11148 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB00907 DB00527 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB16151 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB00961 DB00807 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB03255 DB07931 DB15044 DB06770 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Abagovomab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16077"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":410.41,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Abeprazan is under investigation in clinical trial NCT04341454 (Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis).","enzymes":null,"type":"small molecule","cas-number":"1902954-60-2","sequences":null,"targets":null,"unii":"BE52S2C1QT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":410.091198078,"volume-of-distribution":null,"route-of-elimination":null,"name":"Abeprazan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16078"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":478.63,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).","enzymes":null,"type":"small molecule","cas-number":"2082752-83-6","sequences":null,"targets":null,"unii":"X150A3JK8R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":478.30428708,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aclimostat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16079"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":457.57,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).","enzymes":null,"type":"small molecule","cas-number":"182167-02-8","sequences":null,"targets":null,"unii":"815LJ9X0D1","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":457.225308482,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acolbifene","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16080"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":445.406,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).","enzymes":null,"type":"small molecule","cas-number":"1229453-99-9","sequences":null,"targets":null,"unii":"F2CB8801I3","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":445.147407337,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acrizanib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16081"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Adagloxad simolenin is under investigation in clinical trial NCT03562637 (Study of Adagloxad Simolenin (OBI-822)\/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC).","enzymes":null,"type":"biotech","cas-number":"1458687-85-8","sequences":null,"targets":null,"unii":"UCG949AA7Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adagloxad simolenin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16082"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":274.361,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Adelmidrol is under investigation in clinical trial NCT01420510 (Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis).","enzymes":null,"type":"small molecule","cas-number":"1675-66-7","sequences":null,"targets":null,"unii":"1BUC3685QU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":274.189257325,"volume-of-distribution":null,"route-of-elimination":null,"name":"Adelmidrol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16083"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":144.127,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"764-65-8","sequences":null,"targets":null,"unii":"U3YC62H084","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":144.043355897,"volume-of-distribution":null,"route-of-elimination":null,"name":"Iron (III) oxide adipate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16084"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":471.66,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension).","enzymes":null,"type":"small molecule","cas-number":"910562-20-8","sequences":null,"targets":null,"unii":"R096XE6760","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":471.244329849,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aganepag isopropyl","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16085"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Nonalcoholic Steatohepatitis and Stage 2\/3 Fibrosis (ALPINE 2\/3)).","enzymes":null,"type":"biotech","cas-number":"1616639-03-2","sequences":null,"targets":null,"unii":"IK9NYN31ZM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Aldafermin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16086"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":568.605,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).","enzymes":null,"type":"small molecule","cas-number":"1869057-83-9","sequences":null,"targets":null,"unii":"A49A7A5YN4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":568.252206759,"volume-of-distribution":null,"route-of-elimination":null,"name":"Alflutinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16087"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":314.341,"transporters":null,"pharmacodynamics":null,"msds":null,"description":null,"enzymes":null,"type":"small molecule","cas-number":"87344-05-6","sequences":null,"targets":null,"unii":"3RS348SV6U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":314.126657068,"volume-of-distribution":null,"route-of-elimination":null,"name":"Amtolmetin guacil","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16088"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Anivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).","enzymes":null,"type":"biotech","cas-number":"959716-29-1","sequences":null,"targets":null,"unii":"4OXU6KPQ3R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Anivamersen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16089"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"2145115-85-9","sequences":null,"targets":null,"unii":"RD2I59M9FC","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"CX-2009","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16090"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced\/metastatic Solid Tumors).","enzymes":null,"type":"biotech","cas-number":null,"sequences":null,"targets":null,"unii":"G86X5QQ7M5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"EMB-01","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16091"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"RO6874281 is under investigation in clinical trial NCT03193190 (A Study of Multiple Immunotherapy-based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-pancreatic Cancer)).","enzymes":null,"type":"biotech","cas-number":"1776942-10-9","sequences":null,"targets":null,"unii":"FL08SGO9XA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"RO6874281","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16092"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"PEGylated Recombinant Factor VIII is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).","enzymes":null,"type":"biotech","cas-number":"1417412-83-9","sequences":null,"targets":null,"unii":null,"protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"PEGylated Recombinant Factor VIII","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16093"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Antithrombin gamma is under investigation in clinical trial NCT04182373 (KW-3357 Study in Patients With Early Onset Severe Preeclampsia).","enzymes":null,"type":"biotech","cas-number":"1311281-25-0","sequences":null,"targets":null,"unii":"29Y3UO9LWK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Antithrombin gamma","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16094"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1157.42,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"APG-1387 is under investigation in clinical trial NCT04568265 (A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B).","enzymes":null,"type":"small molecule","cas-number":"1570231-89-8","sequences":null,"targets":null,"unii":"E53VN70K2X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1156.487430906,"volume-of-distribution":null,"route-of-elimination":null,"name":"APG-1387","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16095"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).","enzymes":null,"type":"biotech","cas-number":"2278276-46-1","sequences":null,"targets":null,"unii":"UZ54216N0Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Apitegromab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16096"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":401.52,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Artemisone is under investigation in clinical trial NCT00936767 (Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia).","enzymes":null,"type":"small molecule","cas-number":"255730-18-8","sequences":null,"targets":null,"unii":"796LMW5BUZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":401.187208896,"volume-of-distribution":null,"route-of-elimination":null,"name":"Artemisone","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16097"},{"toxicity":"There are no data regarding overdosage with atogepant. Symptoms of atogepant overdose are likely to be consistent with its adverse effect profile and may therefore include significant gastrointestinal effects, such as nausea and constipation, as well as fatigue and somnolence.[L38739] A single oral dose of 300mg (5x the maximum recommended dose) did not result in any serious adverse events and did not appear to impact cardiac function.[A239089]","snp-adverse-drug-reactions":null,"average-mass":603.525,"transporters":"BE0003659 BE0001032 BE0003657 BE0001066 BE0001067 BE0001004 BE0003648","pharmacodynamics":"Atogepant helps to prevent migraine headaches by antagonizing the activity of a pronociceptive molecule (CGRP) which has been implicated in migraine pathophysiology.[L38739] Intended for preventative use, rather than abortive migraine therapy, atogepant is administered once daily.[L38739]\r\n\r\nWhile no dose adjustments are required for patients with mild or moderate hepatic impairment, atogepant should be avoided in patients with severe hepatic impairment. Similarly, no dose adjustments are required for patients with mild or moderate renal impairment, but patients with severe renal impairment should be limited to a maximum daily dose of 10mg.[L38739]","msds":null,"description":"Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches.  It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.[L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.[L38814]\r\n\r\nIn patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g. [valproic acid] or [topiramate]) or beta-blockers (e.g. [propranolol]), all of which can be associated with significant adverse effects.[A239094] The \"gepants\" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions to other preventative therapies.","enzymes":"BE0002638","type":"small molecule","cas-number":"1374248-81-3","sequences":null,"targets":"BE0009009","unii":"7CRV8RR151","protein-binding":"Atogepant is extensively (~95.3%) protein-bound in plasma.[L38739]","fda-label":null,"clearance":"The mean apparent oral clearance of atogepant is approximately 19 L\/h.[L38739]","atc-codes":"ANTIMIGRAINE PREPARATIONS Calcitonin gene-related peptide (CGRP) antagonists ANALGESICS NERVOUS SYSTEM","pdb-entries":null,"food-interactions":"Take with or without food. Co-administration with food does not affect the pharmacokinetics of atogepant to a clinically significant extent.","state":"solid","synthesis-reference":null,"mechanism-of-action":"The currently accepted theory of migraine pathophysiology considers dysfunction of the central nervous system, in particular the trigeminal ganglion, to be the root cause behind the condition.[A189207] Activation of the trigeminal ganglion triggers the stimulation of trigeminal afferents that project to the spinal cord and synapse on various pain-sensing intra- and extracranial structures, such as the dura mater. Pain signals are then further transmitted via second-order ascending neurons to the brainstem, hypothalamus, and thalamic nuclei, and from there to several cortical regions (e.g. auditory, visual, motor cortices).[A189207] The trigeminal ganglion appears to amplify and perpetuate the migraine headache pain through the activation of perivascular fibers and the release of molecules involved in pain generation, such as calcitonin gene-related peptide (CGRP).[A189207]\r\n\r\nThe -isoform of CGRP, expressed in primary sensory neurons, is a potent vasodilator and has been implicated in migraine pathogenesis - CGRP levels are acutely elevated during migraine attacks, return to normal following treatment with triptan medications, and intravenous infusions of CGRP have been shown to trigger migraine-like headaches in migraine patients. In addition to its vasodilatory properties, CGRP appears to be a pronociceptive factor that modulates neuronal excitability to facilitate pain responses.[A189213]\r\n\r\nAtogepant is an antagonist of the calcitonin gene-related peptide receptor[L38739] - it competes with CGRP for occupancy at these receptors, preventing the actions of CGRP and its ability to induce and perpetuate migraine headache pain.","drug-interactions":"DB01149 DB01076 DB08880 DB11672 DB00328 DB00537 DB08953 DB04216 DB12095 DB00203 DB14649 DB00213 DB00564 DB05667 DB00398 DB00951 DB09198 DB11581 DB09280 DB06448 DB02703 DB00586 DB12319 DB13919 DB08864 DB06712 DB09065 DB08899 DB14019 DB00648 DB00199 DB00794 DB08873 DB04896 DB00468 DB09185 DB12978 DB11936 DB00451 DB00270 DB09298 DB00641 DB00177 DB00412 DB13955 DB01892 DB00307 DB01232 DB01263 DB09292 DB01234 DB13878 DB12026 DB01264 DB00582 DB01241 DB01211 DB06749 DB06772 DB08912 DB08882 DB11642 DB00312 DB12941 DB00363 DB11869 DB00583 DB00503 DB00206 DB00570 DB09297 DB04348 DB15569 DB15762 DB00220 DB01590 DB01406 DB09102 DB12500 DB06626 DB06237 DB01601 DB00345 DB13867 DB04855 DB01072 DB11757 DB00625 DB09048 DB00646 DB01127 DB11901 DB13874 DB00390 DB09272 DB15444 DB08865 DB01174 DB00975 DB00705 DB00655 DB00246 DB00783 DB11796 DB06700 DB06210 DB00778 DB14568 DB00224 DB00394 DB02520 DB01118 DB13952 DB01320 DB01393 DB00559 DB00439 DB14921 DB00834 DB09231 DB01323 DB11753 DB00176 DB01087 DB08860 DB01095 DB01051 DB06442 DB00795 DB11779 DB11730 DB01092 DB16703 DB02659 DB00864 DB13954 DB00343 DB00622 DB13879 DB00342 DB00196 DB00896 DB00396 DB06731 DB00227 DB14240 DB11652 DB11932 DB05521 DB11942 DB00673 DB06636 DB06414 DB06151 DB01645 DB13179 DB09101 DB01026 DB01110 DB00607 DB04868 DB09054 DB08862 DB06595 DB00976 DB06119 DB00877 DB06290 DB14960 DB09118 DB00602 DB00661 DB04832 DB00908 DB00502 DB00932 DB01183 DB00091 DB05016 DB09227 DB00252 DB01045 DB00762 DB11633 DB01098 DB00763 DB14761 DB00255 DB00197 DB11613 DB15822 DB13956 DB00588 DB01167 DB06589 DB00696 DB00872 DB00541 DB04850 DB13953 DB01201 DB14845 DB05239 DB04847 DB00286 DB00701 DB09046 DB00520 DB09078 DB15982 DB08906 DB11586 DB05928 DB00745","absorption":"The time to peak plasma concentration following oral administration is approximately 2-3 hours.[L38739] Atogepant displays dose-proportional pharmacokinetics up to approximately 3-fold its recommended maximum dosage, and its pharmacokinetics are not significantly influenced by co-administration with food.[L38739]","created":"2020-12-15","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The elimination half-life of atogepant following oral administration is approximately 11 hours.[L38739]","monoisotopic-mass":603.170508599,"volume-of-distribution":"The mean apparent volume of distribution of atogepant is 292 L.[L38739]","route-of-elimination":"The elimination of atogepant occurs primarily via metabolism by CYP3A4.[L38739] Following a single oral dose of radiolabeled atogepant to healthy male subjects, 42% of the administered dose was recovered as unchanged parent drug in the feces and 5% as unchanged parent drug in the urine.[L38739] In total, approximately 81% of the radioactivity was recovered in the feces, with only 8% recovered in the urine.[A239069]","name":"Atogepant","metabolism":"The metabolism of atogepant is mediated primarily via CYP3A4.[L38739] The most prevalent circulating compounds in plasma are atogepant itself and a glucuronide conjugate metabolite (M23),[L38739] comprising approximately 75% and 15% of the administered dose, respectively,[A239069] with at least 10 other metabolites detected in feces representing <10% of the administered dose.","reactions":null,"indication":"Atogepant is indicated for the prevention of episodic migraine in adults.[L38739]","ahfs-codes":null,"updated":"2021-10-23","drugbank-id":"DB16098"},{"toxicity":"There is limited information on the overdose profile and LD<sub>50<\/sub> values of avalglucosidase alfa.","snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":"Avalglucosidase alfa is a recombinant alpha-glucosidase (GAA) enzyme that catalyzes hydrolysis of glycogen. In clinical trials, avalglucosidase alfa reduced the levels of glycogen excreted in the urine of patients with Pompe disease, indicating that it effectively cleaved excess glycogen.[L35155] Avalglucosidase alfa has significantly higher binding affinity for cation-independent mannose-6-phosphate receptor (CI-MPR) for cellular uptake and better muscle targeting than [alglucosidase alfa]. In GAA-deficient mice, avalglucosidase alfa reduced glycogen with more efficacy than alglucosidase alfa at an equivalent dose.[A232960]","msds":null,"description":"Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the GAA enzyme is missing and patients are unable to properly break down glycogen, resulting in the accumulation of glycogen within lysosomes and progressive disruption of cellular function, especially in smooth, cardiac, and skeletal muscle cells. Pompe disease is characterized by progressive muscle weakness and loss of motor function, including respiratory muscle weakness, which leads to premature death and debilitating effects on people\u20ACs lives.[A232955] Avalglucosidase alfa is a recombinant form of GAA that restores deficient enzyme levels. First developed by Sanofi Genzyme, avalglucosidase alfa is a chemically modified version of [alglucosidase alfa], where synthetic bis-phosphorylated oligosaccharides were attached to the structure to improve cellular uptake of the drug and better muscle targeting.[A232960]\r\n\r\nOn August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.[L35160] Late-onset Pompe disease is associated with a range of debilitating physical symptoms, such as progressive muscle weakness, including respiratory muscle weakness, and loss of motor function.[A232955] In clinical trials, avalglucosidase alfa improved lung function in patients with Pompe disease.[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease.[L39205] The EMA approved the drug on June 24, 2022.[L42720]","enzymes":null,"type":"biotech","cas-number":"1802558-87-7","sequences":">Avalglucosidase alfa protein sequence\nQQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQG\nLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETE\nNRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTV\nAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHP\nFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLD\nVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTF\nNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPL\nIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNN\nELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPF\nVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEE\nLCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQA\nHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQ\nTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTES\nRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEG\nAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","targets":"BE0003623","unii":"EO144CP0X9","protein-binding":"There is limited information on drug protein binding.","fda-label":null,"clearance":"The mean avalglucosidase alfa-ngpt clearance was 0.9 L\/hour in patients with late-onset Pompe disease.[L35155]","atc-codes":"OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS ALIMENTARY TRACT AND METABOLISM Enzymes","pdb-entries":null,"food-interactions":null,"state":"solid","synthesis-reference":null,"mechanism-of-action":"Pompe disease is a genetic glycogen metabolism disorder that is also referred to as acid maltase deficiency or glycogen storage disease type II (GSD II). It is caused by mutations in the GAA gene, which encodes the lysosomal hydrolase acid -glucosidase (GAA), an enzyme that normally catalyzes hydrolysis of glycogen to release free glucose for absorption and use for cellular functions. GAA deficiency leads to accumulation of glycogen within lysosomes and progressive disruption of cellular function, especially in smooth, cardiac, and skeletal muscle cells.[A232955]\r\n\r\nEnzyme replacement therapy using avalglucosidase alfa aims to restore the missing GAA enzyme. Avalglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human GAA enzyme that is conjugated with multiple synthetic bis-mannose-6-phosphate (bis-M6P) tetra-mannose glycans for enhanced targeting to skeletal muscles. The M6P of avalglucosidase alfa binds to cation-independent mannose-6-phosphate receptor (CI-MPR) on the cell surface with high affinity, which allows drug uptake into cells. Avalglucosidase alfa is internalized and transported into lysosomes to undergo proteolytic cleavage. It then exerts GAA enzymatic activity to cleave glycogen.[A232955, L35155]","drug-interactions":null,"absorption":"The avalglucosidase alfa-ngpt exposure increases in an approximately proportional manner with increasing doses over a range from 5 to 20 mg\/kg. Following intravenous infusion of 20 mg\/kg every two weeks in patients with late-onset Pompe disease, the mean  SD plasma C<sub>max<\/sub> of avalglucosidase alfa-ngpt was 259  72 g\/mL at week one and 242  81 g\/mL at week 49. The mean  SD plasma AUC of avalglucosidase alfa-ngpt was 1,290  420 gh\/mL at week one and 1,250  433 gh\/mL at week 49.[L35155]","created":"2020-12-15","groups":"approved investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":"The mean avalglucosidase alfa-ngpt plasma elimination half-life was 1.6 hours in patients with late-onset Pompe disease.[L35155]","monoisotopic-mass":null,"volume-of-distribution":"The volume of distribution of avalglucosidase alfa-ngpt was 3.4 L in patients with late-onset Pompe disease. No accumulation was observed following every two\r\nweeks-dosing schedules.[L35155]","route-of-elimination":"There is limited information on drug elimination.","name":"Avalglucosidase alfa","metabolism":"The metabolic pathway of avalglucosidase alfa-ngpt has not been characterized. The protein portion of avalglucosidase alfa-ngpt is expected to be metabolized into small peptides and amino acids via catabolic pathways.[L35155]","reactions":null,"indication":"Avalglucosidase alfa is a hydrolytic lysosomal glycogen-specific enzyme indicated for the treatment of patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).[L35155,L39357,L42720] In the US, it is approved in patients one year of age and older. [L35155]","ahfs-codes":null,"updated":"2022-12-01","drugbank-id":"DB16099"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":279.38,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Axomadol is under investigation in clinical trial NCT01043263 (Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain).","enzymes":null,"type":"small molecule","cas-number":"187219-99-4","sequences":null,"targets":null,"unii":"9J92U4CVS0","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":279.183443669,"volume-of-distribution":null,"route-of-elimination":null,"name":"Axomadol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16100"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":270.24,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase \u2026A Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).","enzymes":null,"type":"small molecule","cas-number":"491-67-8","sequences":null,"targets":null,"unii":"49QAH60606","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":270.052823422,"volume-of-distribution":null,"route-of-elimination":null,"name":"Baicalein","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16101"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":256.389,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bakuchiol is under investigation in clinical trial NCT03112863 (Comparison of the Cosmetic Effects of Bakuchiol and Retinol).","enzymes":null,"type":"small molecule","cas-number":"10309-37-2","sequences":null,"targets":null,"unii":"OT12HJU3AR","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":256.182715393,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bakuchiol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16102"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":371.25,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Batabulin is under investigation in clinical trial NCT00057382 (T138067 Versus Doxorubicin in Chemotherapy-naive, Unresectable, Hepatocellular Carcinoma Patients).","enzymes":null,"type":"small molecule","cas-number":"195533-53-0","sequences":null,"targets":null,"unii":"T4NP8G3K6Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":371.005083241,"volume-of-distribution":null,"route-of-elimination":null,"name":"Batabulin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16103"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).","enzymes":null,"type":"biotech","cas-number":"2187430-05-1","sequences":null,"targets":null,"unii":"C98V9UMX3D","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Batoclimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16104"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric\/gastroesophageal Junction Cancer (FIGHT)).","enzymes":null,"type":"biotech","cas-number":"1952272-74-0","sequences":null,"targets":null,"unii":"RJW23BQ0KW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bemarituzumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16105"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":414.89,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).","enzymes":null,"type":"small molecule","cas-number":"1224887-10-8","sequences":null,"targets":null,"unii":"R7O0O4110G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":414.1571017,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK2256098","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16106"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":521.666,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).","enzymes":null,"type":"small molecule","cas-number":"755038-02-9","sequences":null,"targets":null,"unii":"4LJG22T9C6","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":521.311438144,"volume-of-distribution":null,"route-of-elimination":null,"name":"BI 2536","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16107"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":399.51,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TAK-715 is under investigation in clinical trial NCT00760864 (Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis).","enzymes":null,"type":"small molecule","cas-number":"303162-79-0","sequences":null,"targets":null,"unii":"WE92U03C5Z","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":399.140533482,"volume-of-distribution":null,"route-of-elimination":null,"name":"TAK-715","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16108"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":195.218,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).","enzymes":null,"type":"small molecule","cas-number":"921195-93-9","sequences":null,"targets":null,"unii":"Y4H78S56YZ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":195.089543283,"volume-of-distribution":null,"route-of-elimination":null,"name":"GED-0507-34-Levo","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16109"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":364.485,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"GSK232802 is under investigation in clinical trial NCT00604825 (Treatment of Hot Flashes\/flushes in Postmenopausal Women (WARM Study)).","enzymes":null,"type":"small molecule","cas-number":"843661-24-5","sequences":null,"targets":null,"unii":"AG92SGO434","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":364.203844762,"volume-of-distribution":null,"route-of-elimination":null,"name":"GSK232802","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16110"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":472.508,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"CR6086 is under investigation in clinical trial NCT03163966 (A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in Dmard-nave Patients With Early Rheumatoid Arthritis).","enzymes":null,"type":"small molecule","cas-number":"1417742-86-9","sequences":null,"targets":null,"unii":"SS2LQQ8094","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":472.197377226,"volume-of-distribution":null,"route-of-elimination":null,"name":"CR6086","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16111"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":492.569,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).","enzymes":null,"type":"small molecule","cas-number":"870809-51-1","sequences":null,"targets":null,"unii":"5WVS67PLAL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":492.247166127,"volume-of-distribution":null,"route-of-elimination":null,"name":"OT-730","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16112"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And\/or HPV-18 Related Anal or Anal\/peri-anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1\/2).","enzymes":null,"type":"biotech","cas-number":"1977488-08-6","sequences":null,"targets":null,"unii":"D8W2DVO5ZJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Bizalimogene ralaplasmid","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16113"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":410.42,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects).","enzymes":null,"type":"small molecule","cas-number":"729607-74-3","sequences":null,"targets":null,"unii":"7PR4P7YOKT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":410.106019065,"volume-of-distribution":null,"route-of-elimination":null,"name":"HIV Integrase Inhibitor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16114"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).","enzymes":null,"type":"biotech","cas-number":"1610353-18-8","sequences":null,"targets":null,"unii":"50EI9G8Q6U","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Brazikumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16115"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Brivoligide is under investigation in clinical trial NCT04104919 (Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores).","enzymes":null,"type":"biotech","cas-number":"1803075-42-4","sequences":null,"targets":null,"unii":"O32A9ET2M7","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Brivoligide","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16116"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":595.777,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Buprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex\/suboxone to RBP-6300).","enzymes":null,"type":"small molecule","cas-number":"951123-45-8","sequences":null,"targets":null,"unii":"968KUA5J54","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":595.350902922,"volume-of-distribution":null,"route-of-elimination":null,"name":"Buprenorphine hemiadipate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16117"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":520.02,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Capadenoson is under investigation in clinical trial NCT00518921 (Capadenoson in Angina Pectoris).","enzymes":null,"type":"small molecule","cas-number":"544417-40-5","sequences":null,"targets":null,"unii":"O519NVW73R","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":519.0590449,"volume-of-distribution":null,"route-of-elimination":null,"name":"Capadenoson","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16118"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":569.44,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Carotegrast methyl is under investigation in clinical trial NCT03531892 (A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis).","enzymes":null,"type":"small molecule","cas-number":"401905-67-7","sequences":null,"targets":null,"unii":"OYK17DYO9M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":568.1280254,"volume-of-distribution":null,"route-of-elimination":null,"name":"Carotegrast methyl","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16119"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":442.376,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Epigallo Catechin Gallate is under investigation in clinical trial NCT00799890 (Sunphenon in Progressive Forms of Multiple Sclerosis).","enzymes":null,"type":"small molecule","cas-number":"25615-05-8","sequences":null,"targets":null,"unii":"78OW2GLG8Q","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":442.08999678,"volume-of-distribution":null,"route-of-elimination":null,"name":"Epigallo Catechin Gallate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16120"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cemdisiran is under investigation in clinical trial NCT03841448 (A Study of Cemdisiran in Adults With Immunoglobulin a Nephropathy (Igan)).","enzymes":null,"type":"biotech","cas-number":"1639264-46-2","sequences":null,"targets":null,"unii":"S66Z65E10T","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cemdisiran","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16121"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":331.463,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).","enzymes":null,"type":"small molecule","cas-number":"57961-90-7","sequences":null,"targets":null,"unii":"QD4VI0J9T5","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":331.204847817,"volume-of-distribution":null,"route-of-elimination":null,"name":"Centhaquine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16122"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":435.564,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ceralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).","enzymes":null,"type":"small molecule","cas-number":"891859-12-4","sequences":null,"targets":null,"unii":"BZ2O8A84A4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":435.240958547,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ceralifimod","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16123"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":435.483,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed\/refractory Non-hodgkin's Lymphoma).","enzymes":null,"type":"small molecule","cas-number":"1256349-48-0","sequences":null,"targets":null,"unii":"F40IRN5981","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":435.158291548,"volume-of-distribution":null,"route-of-elimination":null,"name":"Chiauranib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16124"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":407.434,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit\/ Hyperactivity Disorder (ADHD)).","enzymes":null,"type":"small molecule","cas-number":"1202402-40-1","sequences":null,"targets":null,"unii":"8KFO2187CP","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":407.170587564,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ciforadenant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16125"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":565.71,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 G\/h, 10 G\/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).","enzymes":null,"type":"small molecule","cas-number":"329773-35-5","sequences":null,"targets":null,"unii":"59K0Y58UAD","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":565.28282336,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cinaciguat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16126"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).","enzymes":null,"type":"biotech","cas-number":"2094516-02-4","sequences":null,"targets":null,"unii":"W83JGQ40XX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Cinpanemab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16127"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Crovalimab is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).","enzymes":null,"type":"biotech","cas-number":"1917321-26-6","sequences":null,"targets":null,"unii":"H9KH1GP3UU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Crovalimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16128"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":500.684,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).","enzymes":null,"type":"small molecule","cas-number":"1008993-65-4","sequences":null,"targets":null,"unii":"9NFY3MS3SL","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":500.336255913,"volume-of-distribution":null,"route-of-elimination":null,"name":"TZP-102","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16129"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":133.17,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).","enzymes":null,"type":"small molecule","cas-number":"54863-37-5","sequences":null,"targets":null,"unii":"2Z03364G96","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Dapansutrile specifically inhibits the NLRP3 inflammasome and subsequent activation of IL-1. It is currently being investigated against gout flares, joint pain and COVID-19.[A226085]","drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":133.019749643,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dapansutrile","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16130"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).","enzymes":null,"type":"biotech","cas-number":"1416147-64-2","sequences":null,"targets":null,"unii":"N4606MB5HM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dapirolizumab pegol","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16131"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":253.27,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Deferitrin is under investigation in clinical trial NCT00069862 (Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-thalassemia).","enzymes":null,"type":"small molecule","cas-number":"239101-33-8","sequences":null,"targets":null,"unii":"T69Y9LDN44","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":253.040879012,"volume-of-distribution":null,"route-of-elimination":null,"name":"Deferitrin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16132"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":310.361,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg\/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).","enzymes":null,"type":"small molecule","cas-number":"1263774-59-9","sequences":null,"targets":null,"unii":"9L0Q8KK220","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":310.154209224,"volume-of-distribution":null,"route-of-elimination":null,"name":"Delgocitinib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16133"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":373.379,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Denagliptin is under investigation in clinical trial NCT00387972 (Study of Denagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM)).","enzymes":null,"type":"small molecule","cas-number":"483369-58-0","sequences":null,"targets":null,"unii":"DOS9ZOT21L","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":373.140196701,"volume-of-distribution":null,"route-of-elimination":null,"name":"Denagliptin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16134"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":332.312,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).","enzymes":null,"type":"small molecule","cas-number":"1616690-16-4","sequences":null,"targets":null,"unii":"Y962PQA4KS","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"The small molecule hypoxia-inducible factor, desidustat, inhibits the prolyl hydrozylase and stimulates erythropoiesis. It is currently being investigated against anemia of inflammation and COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":332.100836243,"volume-of-distribution":null,"route-of-elimination":null,"name":"Desidustat","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16135"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":141.258,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dexisometheptene mucate is under investigation in clinical trial NCT02423408 (Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-type Headache).","enzymes":null,"type":"small molecule","cas-number":"1620401-56-0","sequences":null,"targets":null,"unii":"GOO8ZCK7RT","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":141.151749616,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dexisometheptene mucate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16136"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":421.45,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed\/refractory Hodgkin Lymphoma).","enzymes":null,"type":"small molecule","cas-number":"1262440-25-4","sequences":null,"targets":null,"unii":"2K59L7G59M","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":421.1121075,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dezapelisib","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16137"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":398.366,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Diflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).","enzymes":null,"type":"small molecule","cas-number":"220997-97-7","sequences":null,"targets":null,"unii":"QKT1LC4J1P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":398.107813329,"volume-of-distribution":null,"route-of-elimination":null,"name":"Diflomotecan","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16138"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":267.328,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).","enzymes":null,"type":"small molecule","cas-number":"174691-84-0","sequences":null,"targets":null,"unii":"Q3PJ4B4D0X","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":267.125928791,"volume-of-distribution":null,"route-of-elimination":null,"name":"DAR-0100A","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16139"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab).","enzymes":null,"type":"biotech","cas-number":"1791420-09-1","sequences":null,"targets":null,"unii":"F27LAH6D5O","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dilpacimab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16140"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":470.738,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dimethandrolone Undecanoate is under investigation in clinical trial NCT03455075 (Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men).","enzymes":null,"type":"small molecule","cas-number":"366472-45-9","sequences":null,"targets":null,"unii":"VMT7Z23GLM","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":470.37599547,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dimethandrolone Undecanoate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16141"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":227.267,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Acetyldinaline is under investigation in clinical trial NCT00005624 (CI-994 in Treating Patients With Advanced Myeloma).","enzymes":null,"type":"small molecule","cas-number":"58338-59-3","sequences":null,"targets":null,"unii":"RG9G4Z82PY","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":227.105862051,"volume-of-distribution":null,"route-of-elimination":null,"name":"Acetyldinaline","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16142"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":424.647,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).","enzymes":null,"type":"small molecule","cas-number":"2137932-23-9","sequences":null,"targets":null,"unii":"2G3T6M1AS9","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":424.16384584,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dirocaftor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16143"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1694.21,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).","enzymes":null,"type":"small molecule","cas-number":"868562-36-1","sequences":null,"targets":null,"unii":"L32IM11DV4","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1692.784147935,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dopastatin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16144"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":358.19,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).","enzymes":null,"type":"small molecule","cas-number":"1285572-51-1","sequences":null,"targets":null,"unii":"305EB53128","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB08844","absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":356.9629343,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dotinurad","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16145"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":2147.523,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).","enzymes":null,"type":"small molecule","cas-number":"80448-90-4","sequences":null,"targets":null,"unii":"9M18T0TD14","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":2146.191210375,"volume-of-distribution":null,"route-of-elimination":null,"name":"Dynorphin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16146"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":599.74,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ebopiprant is under investigation in clinical trial NCT03369262 (Poc Study of OBE022 in Threatened Preterm Labour).","enzymes":null,"type":"small molecule","cas-number":"2005486-31-5","sequences":null,"targets":null,"unii":"Z1AVZ44TEJ","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":599.192391718,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ebopiprant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16147"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":480.686,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy\/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).","enzymes":null,"type":"small molecule","cas-number":"136892-64-3","sequences":null,"targets":null,"unii":"Q2XM6VR8DO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":480.345089266,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ecraprost","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16148"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Efavaleukin alfa is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).","enzymes":null,"type":"biotech","cas-number":"2049067-94-7","sequences":null,"targets":null,"unii":"YNH9K62UXU","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Efavaleukin alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16149"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).","enzymes":null,"type":"biotech","cas-number":"1800476-36-1","sequences":null,"targets":null,"unii":"SJ82PK3HWA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eftilagimod alfa","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16150"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).","enzymes":null,"type":"biotech","cas-number":"762260-74-2","sequences":null,"targets":null,"unii":"BM86P708HW","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":"DB05209 DB14905 DB06474 DB09381 DB06647 DB11959 DB09052 DB12034 DB11857 DB14039 DB12023 DB06305 DB15898 DB14877 DB11604 DB12344 DB13886 DB14811 DB11884 DB11685 DB11746 DB15118 DB14997 DB12815 DB12235 DB06602 DB12053 DB14012 DB09035 DB14891 DB13017 DB00108 DB06599 DB06310 DB14864 DB09105 DB12520 DB12396 DB05797 DB05656 DB06557 DB12274 DB11680 DB13140 DB06607 DB15443 DB14897 DB00028 DB12104 DB15001 DB12261 DB12849 DB13954 DB12826 DB12844 DB04962 DB11866 DB12205 DB12498 DB11715 DB00098 DB11621 DB16385 DB00113 DB12246 DB15627 DB00002 DB04949 DB13535 DB01257 DB12335 DB00890 DB04901 DB11976 DB12119 DB09045 DB14952 DB00054 DB05111 DB15626 DB16225 DB12698 DB13073 DB08870 DB11731 DB14776 DB11771 DB05304 DB12893 DB15090 DB16755 DB05437 DB14919 DB15135 DB05459 DB14211 DB12363 DB15865 DB12943 DB12584 DB15899 DB09369 DB00977 DB05276 DB12891 DB15415 DB11914 DB16170 DB00072 DB11988 DB06371 DB11674 DB15045 DB01269 DB06550 DB16355 DB06322 DB13976 DB15089 DB14967 DB13979 DB11834 DB05679 DB05006 DB09318 DB14843 DB12589 DB06606 DB11756 DB15160 DB14907 DB12734 DB15022 DB15277 DB15172 DB11597 DB00783 DB12530 DB16265 DB00065 DB15718 DB05892 DB13386 DB12089 DB09303 DB08904 DB12487 DB14959 DB12917 DB12845 DB06192 DB00043 DB15628 DB12976 DB09559 DB01357 DB09033 DB11826 DB14004 DB06241 DB00057 DB00112 DB05793 DB06049 DB06168 DB16659 DB14996 DB16222 DB06043 DB11945 DB08879 DB00076 DB06366 DB09037 DB11478 DB05550 DB12169 DB06612 DB15397 DB05595 DB13956 DB06318 DB11569 DB13953 DB14784 DB09317 DB14824 DB16376 DB15453 DB11580 DB12142 DB14580 DB05555 DB16195 DB12189 DB00110 DB09077 DB15428 DB00075 DB14724 DB05101 DB00078 DB05136 DB04956 DB06081 DB12159 DB11856 DB06101 DB00073 DB06643 DB12560 DB12797 DB05496 DB12157 DB12609 DB05916 DB05889 DB06467 DB12102 DB04958 DB12342 DB09070 DB14988 DB12090 DB15432 DB15363 DB00111 DB01270 DB13418 DB14947 DB15441 DB15383 DB14962 DB15349 DB05941 DB11930 DB06050 DB06162 DB12489 DB09264 DB12773 DB12456 DB06273 DB12413 DB12317 DB06317 DB14809 DB12807 DB15334 DB00089 DB05097 DB11840 DB13375 DB16732 DB12202 DB13045 DB06360 DB15595 DB00051 DB14908 DB12820 DB15941 DB15113 DB00095 DB05578 DB15101 DB00286 DB12701 DB14778 DB12331 DB15335 DB14762 DB06186 DB15559 DB11850 DB08902 DB15409 DB15014 DB12296 DB13143 DB16695 DB16394 DB15225 DB12250 DB15434 DB14042 DB04573 DB00269 DB12213 DB16077 DB12240 DB06650 DB16393 DB11646 DB15252 DB00056 DB11803 DB09036 DB14707 DB12683 DB13923 DB16421 DB09302 DB12118 DB05915 DB00655 DB14871 DB00081 DB00087 DB11657 DB12775 DB04988 DB05996 DB11767 DB13952 DB05139 DB06304 DB11595 DB09029 DB05545 DB08935 DB15076 DB11972 DB06116 DB14040 DB06674 DB15900 DB09331 DB14041 DB13127 DB15719 DB04574 DB07931 DB15044 DB11608 DB15104 DB11862 DB05336 DB11714 DB12152 DB11776 DB15253 DB06324 DB12534 DB04964 DB15336 DB11849 DB05773 DB14597 DB15940 DB09057 DB12718 DB00074 DB13037 DB06342 DB00255 DB05405 DB12077 DB09312 DB04575","absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Efungumab","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16151"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":1073.224,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1\/2)).","enzymes":null,"type":"small molecule","cas-number":"673478-49-4","sequences":null,"targets":null,"unii":"S68632MB2G","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":1072.577776571,"volume-of-distribution":null,"route-of-elimination":null,"name":"VEGFR2-169","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16152"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":428.298,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Eltanexor is under investigation in clinical trial NCT02649790 (Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed\/refractory Cancer Indications).","enzymes":null,"type":"small molecule","cas-number":"1642300-52-4","sequences":null,"targets":null,"unii":"Q59IQJ9NTK","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":428.082027944,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eltanexor","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16153"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous \u201DF508 Cystic Fibrosis Patients).","enzymes":null,"type":"biotech","cas-number":"2101868-82-8","sequences":null,"targets":null,"unii":"V30WFP6S2Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Eluforsen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16154"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).","enzymes":null,"type":"biotech","cas-number":"1192706-53-8","sequences":null,"targets":null,"unii":"F0B69ZZ07A","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Colony stimulating factors IMMUNOSTIMULANTS","pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Empegfilgrastim","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16155"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors).","enzymes":null,"type":"biotech","cas-number":"1912424-97-5","sequences":null,"targets":null,"unii":"43HH4XYH2N","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Enapotamab vedotin","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16156"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":477.565,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).","enzymes":null,"type":"small molecule","cas-number":"1884461-72-6","sequences":null,"targets":null,"unii":"3E3D8T1GIX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":"Ensifentrine is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR). This drug has bronchodilatory and anti-inflammatory properties due to the dual inhibition; it also has mucous viscosity reduction and improved mucociliary clearance effects due to the CFTR activation. Ensifentrine is currently being investigated against COPD, cystic fibrosis, asthma, other respiratory diseases, and COVID-19.","drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":477.237604498,"volume-of-distribution":null,"route-of-elimination":null,"name":"Ensifentrine","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16157"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Epafipase is under investigation in clinical trial NCT00037687 (Safety and Efficacy of Recombinant Human Platelet-activating Factor Acetylhydrolase for the Treatment of Severe Sepsis).","enzymes":null,"type":"biotech","cas-number":"208576-22-1","sequences":null,"targets":null,"unii":"369989188P","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Epafipase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16158"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":244.265,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Esflurbiprofen is under investigation in clinical trial NCT03434197 (Safety and Efficacy of SFPP in Knee Osteoarthritis).","enzymes":null,"type":"small molecule","cas-number":"51543-39-6","sequences":null,"targets":null,"unii":"J5ZZK9P7MX","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":"MUSCULO-SKELETAL SYSTEM Antiinflammatory preparations, non-steroids for topical use TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN","pdb-entries":false,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":244.089957822,"volume-of-distribution":null,"route-of-elimination":null,"name":"Esflurbiprofen","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-05-05","drugbank-id":"DB16159"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":539.696,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"ASTX660 is under investigation in clinical trial NCT02503423 (Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas).","enzymes":null,"type":"small molecule","cas-number":"1799328-86-1","sequences":null,"targets":null,"unii":"2LHZ9ZC3YO","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":539.327168395,"volume-of-distribution":null,"route-of-elimination":null,"name":"ASTX660","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16160"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":null,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).","enzymes":null,"type":"biotech","cas-number":"1404122-92-4","sequences":null,"targets":null,"unii":"67F0M5CY5Y","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":null,"volume-of-distribution":null,"route-of-elimination":null,"name":"Exebacase","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16161"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":589.57,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Exicorilant is under investigation in clinical trial NCT03437941 (Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With Mcrpc).","enzymes":null,"type":"small molecule","cas-number":"1781244-77-6","sequences":null,"targets":null,"unii":"GTB859B7K8","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":589.151921455,"volume-of-distribution":null,"route-of-elimination":null,"name":"Exicorilant","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16162"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":196.25,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).","enzymes":null,"type":"small molecule","cas-number":"110958-19-5","sequences":null,"targets":null,"unii":"42O8UF5CJB","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":196.121177763,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fasoracetam","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2021-02-21","drugbank-id":"DB16163"},{"toxicity":null,"snp-adverse-drug-reactions":null,"average-mass":421.497,"transporters":null,"pharmacodynamics":null,"msds":null,"description":"Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).","enzymes":null,"type":"small molecule","cas-number":"134098-61-6","sequences":null,"targets":null,"unii":"9W557V4RYA","protein-binding":null,"fda-label":null,"clearance":null,"atc-codes":null,"pdb-entries":null,"food-interactions":null,"state":null,"synthesis-reference":null,"mechanism-of-action":null,"drug-interactions":null,"absorption":null,"created":"2020-12-15","groups":"investigational","pathways":null,"snp-effects":null,"carriers":null,"half-life":null,"monoisotopic-mass":421.200156361,"volume-of-distribution":null,"route-of-elimination":null,"name":"Fenpyroximate","metabolism":null,"reactions":null,"indication":null,"ahfs-codes":null,"updated":"2020-12-20","drugbank-id":"DB16164"}]}